{"title": "PDF", "author": "PDF", "url": "https://www.leitlinien.de/themen/copd/leitlinienreport/copd-2aufl-vers1-llr.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \nTr\u00e4ger : \nBundes\u00e4rztekammer  \nKassen\u00e4rztliche Bundesvereinigung \nArbeitsgemeinschaft der W issenschaftlichen\nMedizinischen Fachgesellschaften  \n \u00a9 2021 \nNationale VersorgungsLeitlinie  \nCOPD  \nLeitlinienreport\n 2.A uflage, Version 1\nAWMF -Register -Nr. nvl -003 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  1\n Impressum \nHERAUSGEBER \nBundes\u00e4rztekammer (B\u00c4K)  \nArbeitsgemeinschaft der Deutschen \u00c4rztekammern  www.baek.de  \nKassen\u00e4rztliche Bundesvereinigung (KBV)  www.kbv.de  \nArbeitsgemeinschaft der Wissenschaftlichen \nMedizinischen Fachgesellschaften (AWMF)  www.awmf.org  \nAUTOR *INNEN \u2013 LEITLINIENREPORT NVL COPD , 2. AUFLAGE \nSabine Sch\u00fcler ; Corinna Schaefer   \n\u00c4rztliches Zentrum f\u00fcr Qualit\u00e4t in der Medizin (\u00c4ZQ)  \nDr. Monika Nothacker , MPH ; Dr. Susanne Bl\u00f6dt , MScPH  \nArbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)  \nREDAKTION UND PFLEGE  \n\u00c4rztliches Zentrum f\u00fcr Qualit\u00e4t in der Medizin  \n(Gemeinsame Einrichtung von Bundes\u00e4rztekammer \nund Kassen\u00e4rztlicher Bundesvereinigung)  \nim Auftrag von B\u00c4K, KBV, AWMF  \nKORRESPONDENZ  \n\u00c4ZQ \u2013 Redaktion Nationale VersorgungsLeitlinien  \nTiergartenTower , Stra\u00dfe des 17. Juni 106-108 , 10623 Berlin  \nTel.: 030-4005- 2508 - Fax: 030 -4005- 2555  \nE-Mail : nvl@azq.de\nIn\nternet: www.leitlinien.de\n\u2013K\nommentare und \u00c4nderungsvorschl\u00e4ge bitte nur an diese Adresse \u2013\nFASSUNGEN DER LEITLINIE  \nDie Nationale VersorgungLeitlinie COPD  wird mit folgenden Komponenten publiziert:  \n\uf0a1 Langfassung: Graduierte Empfehlungen und Darstellung der Evidenzgrundlage (Evidenz und weitere \nErw\u00e4gungen); \n\uf0a1 Kurzfassung: \u00dcbersicht der graduierten Empfehlungen; \n\uf0a1 Leitlinienreport  (das vorliegende Dokument) ; \n\uf0a1 Patientenl eitlinie ; \n\uf0a1 weitere Patientenmaterialien wie Patientenbl\u00e4tter und Kurzinformationen.  \nAlle Fassungen sind zug\u00e4nglich \u00fcber das Internetangebot des NVL-Programms www.leitlinien.de/copd. \nBITTE WIE FOLGT ZITIEREN  \nBundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftli-chen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie COPD  \u2013 Leitlinienreport , 2. Auf-\nlage.  Version 1. 2021 [cited: YYYY-MM-DD]. DOI: 10.6101/AZQ/000478. www.leitlinien.de/copd . \nInternet: www.leitlinien.de , www.awmf .org. \nNVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  2\n  Erg\u00e4nzungen u nd Modifikationen der Le itlinie si nd \u00fcber di e Webseite www.leitlinien.de/copd \nzug\u00e4nglich. \nBitte beachten Sie, dass  nur die unter www.leitlinien.de enthaltenen Dokumente des Pro-\ngramms f\u00fcr Nationale VersorgungsLeitlinien (NVL) durch die Tr\u00e4ger des NVL-P rogramms \nautorisiert und damit g\u00fcltig sind. Bei NVL-D okumenten, die Sie von anderen Webseiten \nbeziehen, \u00fcber-nehmen wir k eine Verantwortung f\u00fcr deren G\u00fcltigkeit. \nBesonderer Hinweis  \nDie Medizin unterliegt einem fortw\u00e4hrenden Entwicklungsprozess, sodass alle Angaben, ins-\nbesondere zu diagnostischen und therapeutischen Verfahren, immer nur dem Wissensstand \nzur Zeit der Drucklegung der VersorgungsLeitlinie entsprechen k\u00f6nnen. Hinsichtlich der an-gegebenen Empfehlungen zur Therapie und der Auswahl sowie Dosierung von Medikamen-ten wurde die gr\u00f6\u00dftm\u00f6gliche Sorgfalt beachtet. Gleichwohl werden die Nutzenden aufgefor-\ndert, die Beipackzettel und Fachinformationen der pharmazeutischen Unternehmen zur Kon-\ntrolle heranzuziehen und im Zweifelsfall entsprechende Fachleute zu konsultieren. Fragliche \nUnstimmigkeiten sollen bitte im allgemeinen Interesse der NVL- Redaktion mitgeteilt werden.  \nDie Nutzenden selbst bleiben verantwortlich f\u00fcr jede diagnostische und therapeutische Appli-kation, Medikation und Dosierung.  \nIn dieser VersorgungsLeitlinie sind eingetragene Warenzeichen (gesch\u00fctzte Warennamen) \nnicht besonders kenntlich gemacht. Es kann also aus dem Fehlen eines entsprechenden Hin-\nweises nicht geschlossen werden, dass es sich um einen freien Warennamen handelt.  \nDas Werk ist in allen seinen Teilen urheberrechtlich gesch\u00fctzt. Jede Verwertung au\u00dferhalb der Bestimmung des Urheberrechtsgesetzes ist ohne schriftliche Zustimmung des \u00c4ZQ un-zul\u00e4ssig und strafbar. Kein Teil des Werkes darf in irgendeiner Form ohne schriftliche Geneh-\nmigung des \u00c4ZQ reproduziert werden. Dies gilt insbesondere f\u00fcr Vervielf\u00e4ltigungen, \u00dcberset-\nzungen, Mikroverfilmungen und die Einspeicherung, Nutzung und Verwertung in elektroni-schen Systemen, Intranets und dem Internet.  \nAbweichend davon stimmen die Rechteinhaber*innen der uneingeschr\u00e4nkten Nutzung ihrer \nf\u00fcr diese Leitlinie erstellten Abbildungen und Tabellen durch Dritte ausdr\u00fccklich zu. Insbeson-\ndere ist dem Gemeinsamen Bundesausschuss die Nutzung gestattet, einschlie\u00dflich der voll-\nst\u00e4ndigen oder teilweisen Aufnahme von Abbildungen und Tabellen in ver\u00e4nderter oder un-ver\u00e4nderter Form in amtlichen Werken, wie den Richtlinien und Tragenden Gr\u00fcnden des Ge-meinsamen Bundesausschusses, und deren Ver\u00f6ffentlichung, unter anderem im Bundesan-\nzeiger und im Internet.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  3 \n  \n  \n Inhaltsverzeichnis  \nImpressum  .............................................................................................................................................. 1 \n1 Programm f\u00fcr Nationale VersorgungsLeitlinien  ......................................................................... 4 \n2 Zielsetzung  ................................................................................................................................... 5 \n3 Adressat*innen  ............................................................................................................................. 5 \n4 Zusammensetzung der Leitliniengruppe  .................................................................................... 6 \n5 Patient*innenbeteiligung ............................................................................................................ 11 \n6 Auswahl und Bewertung der Evidenz  ....................................................................................... 11 \n7 Formulierung von Empfehlungen .............................................................................................. 14 \n8 Entwicklung und Konsentierung  ............................................................................................... 15 \n9 Externe Begutachtung  ............................................................................................................... 17 \n10 Redaktionelle Unabh\u00e4ngigkeit  .................................................................................................. 17 \n11 G\u00fcltigkeit und Aktualisierung  ..................................................................................................... 18 \n12 Anwendung und Verbreitung  .................................................................................................... 18 \n12.1  Materialien und Formate  ................................................................................................... 18 \n12.2  Implementierung und \u00d6ffentlichkeitsarbeit  ....................................................................... 20 \n13 Evaluation  ................................................................................................................................... 21 \nTabellenverz eichnis  .............................................................................................................................. 22 \nAnhang  .................................................................................................................................................. 23 \nAnhang 1  Darstellung von Interessenkonflikten  ................................................................................ 23 \nAnhang 2  Endpunktgraduierung  ........................................................................................................ 64 \nAnhang 3  Recherchestrategien  ......................................................................................................... 64 \nAnhang 4  Evidenztabellen Definition und Epidemiologie  ................................................................ 123 \nAnhang 5  Evidenztabellen Diagnostik und Monitoring  .................................................................... 123 \nAnhang 6  Evidenztabellen  Tabakentw\u00f6hnung  ................................................................................ 151 \nAnhang 7  Evidenztabellen Nicht -medikament\u00f6se Therapie und Rehablitation  .............................. 174 \nAnhang 8  Evidenztabellen Medikament\u00f6se Therapie  ..................................................................... 225 \nAnhang 9  Evidenztabellen  Medizinische Re habilitation  .................................................................. 286 \nAnhang 10  Evidenztabellen  Versorgungskoordination  ..................................................................... 300 \nAnhang 11  Kommentare aus der \u00f6ffentlichen Konsultation  .............................................................. 310 \nLiteratur  ............................................................................................................................................... 345 \n \n  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  4 \n  \n  \n 1 Programm  f\u00fcr Nationale  VersorgungsLeitlinien  \nIm Rahmen des Programms f\u00fcr Nationale VersorgungsLeitlinien ( NVL)  von Bundes\u00e4rztekammer (B\u00c4K), Kassen-\n\u00e4rztlicher Bundesvereinigung (KBV) und Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesell-\nschaften (AWMF) haben die zust\u00e4ndigen Fachgesellschaften und Organisationen inhaltliche Eckpunkte f\u00fcr die 2. \nAuflage der NVL COPD konsentiert. Die B eteiligung von Patient*innen wird durch die Kooperation mit der Bundes-\narbeitsgemeinschaft Selbsthilfe (BAG SELBSTHILFE) gew\u00e4hrleistet.  \nDie \u00dcberarbeitung der NVL COPD erfolgt modular. Die 2. Auflage beinhaltet die Kapitel:  \n\uf0a1 \u201eDefinition und Epidemiologie\u201c ; \n\uf0a1 \u201eDiagnostik und Monitoring\u201c;  \n\uf0a1 \u201eTabakentw\u00f6hnung\u201c;  \n\uf0a1 \u201eNicht -medikament\u00f6se Therapie\u201c;  \n\uf0a1 \u201eMedikament\u00f6se Therapie\u201c;  \n\uf0a1 \u201eMedizinische Rehabilitation\u201c und \n\uf0a1 \u201eVersorgungskoordination\u201c.  \nSie ist Teil eines sp\u00e4teren Gesamtdokumentes. Weitere Themen werden im Rahmen der n\u00e4chsten Auflagen bear-beitet und ver\u00f6ffentlicht (siehe auch \u00dcbersicht ausstehender Themen in der NVL).  \nDas NVL -Programm zielt auf die Entwicklung und Implementierung versorgungsbereichs\u00fcbergreifender Leitlinien \nzu ausgesuchten Erkrankungen hoher Pr\u00e4valenz unter Ber\u00fccksichtigung der Methoden der Evidenzbasierten Me-\ndizin (EbM). Insbesondere sind NVL inhaltliche Grundlage f\u00fcr die Ausgestaltung von Konzepten der strukturierten und integrierten Versorgung [1]. \nZiele des NVL -Programms sind insbesondere:  \n\uf0a1 Empfehlungen zu versorgungsbereichs\u00fcbergreifenden Vorgehensweisen f\u00fcr pr\u00e4valente Erkrankungen entspre-chend dem besten Stand der medizinischen Erkenntnisse unter Ber\u00fccksichtigung der Kriterien der Evidenzba-\nsierten Medizin zu erarbeiten und formal zu konsentieren;  \n\uf0a1 Empfehlungen hinsichtlich der Abstimmung und Koordination der an der Versorgung beteiligten Fachdisziplinen \nund weiterer Fachberufe im Gesundheitswesen in den verschiedenen Versorgungsbereichen zu geben;  \n\uf0a1 durch Einbeziehung aller an der Versorgung beteiligten Disziplinen, Organisationen und Patient*innen eine effek-\ntive Verbreitung und Umsetzung der Empfehlungen zu erm\u00f6glichen;  \n\uf0a1 Ber\u00fccksichtigung von NVL- Empfehlungen in der \u00e4rztlichen Aus -, Fort-  und Weiterbildung und in Qualit\u00e4tsmana-\ngementsystemen sowie bei Vertr\u00e4gen zur Integrierten Versorgung oder strukturierten Behandlungsprogrammen;  \n\uf0a1 Unterst\u00fctzung der gemeinsamen Entscheidungsfindung zwischen \u00c4rzt*innen und Patient*innen  durch qualitativ \nhochwertige Patienteninformationen und Entscheidungshilfen.  \nAuf diesem Weg soll  die Qualit\u00e4t der Versorgung verbessert und die Stellung der Patient*in nen gest\u00e4rkt werden. \nZudem wird von der Ber\u00fccksichtigung der Empfehlungen eine Effizienzsteigerung im Gesundheitswesen erwartet.  \nDie Erarbeitung der NVL erfolgt unter wesentlicher Ber\u00fccksichtigung der Konzepte des Internationalen Leitlinien-Netzwerks GIN [2], der Leitlinien-Empfehlungen des Europarats [3], der Beurteilungskriterien f\u00fcr  Leitlinien von B\u00c4K \nund KBV [4] , des De utschen Leitlinienbewertungsinstruments DELBI von \u00c4ZQ und AWMF [5\n\u2060,6] sowie de s AWMF -\nRegelwerks Leitlinien [7].  \nDie grundlegende methodische Vorgehensweise ist im NVL- Methodenreport [8] beschrieben . Die spezifische me-\nthodische Vorgehensweise beschreibt das hier vorliegende Dokument, das einen essentiellen Bestandteil der Leit-\nlinie darstellt.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  5 \n  \n  \n Leitlinien als Entscheidungshilfen  \nBei einer NVL handelt es sich um  eine systematisch entwickelte Entscheidungshilfe \u00fcber die angemessene \u00e4rztli-\nche Vorgehensweise bei speziellen gesundheitlichen Problemen im Rahmen der strukturierten medizinischen Ver-\nsorgung und damit um eine Orientierungshilfe im Sinne von \u201eHandlungs - und Entscheidungsvorschl\u00e4gen\u201d, von de-\nnen in begr\u00fcndeten F\u00e4llen abgewichen werden kann oder sogar muss [4].  \nDie Entscheidung dar\u00fcber, ob einer bestimmten Empfehlung gefolgt werden soll, muss individuell unter Ber\u00fcck-\nsichtigung der bei der jeweiligen Patientin beziehungsweise dem jeweiligen Patienten vorliegenden Gegebenheiten \nund Pr\u00e4ferenzen sowie der verf\u00fcgbaren Ressourcen getroffen werden [3].  \nEine NVL wird erst dann wirksam, wenn ihre Empfehlungen bei der V ersorgung  von Patient*innen Ber\u00fccksichtigung \nfinden. Die Anwendbarkeit einer Leitlinie oder einzelner Leitlinienempfehlungen muss in der individuellen Situation \ngepr\u00fcft werden nach den Prinzipien der Indikationsstellung, Beratung, Pr\u00e4ferenzermittlung und partizipativen Ent-scheidungsfindung [7\n\u2060,9]. \nEbenso wie bei jeder anderen medizinischen Leitlinie handelt es sich bei einer NVL explizit nicht um eine Richtlinie im Sinne einer Regelung des Handelns oder Unterlassens, die von einer rechtlich legitimierten Institution konsen-\ntiert, schriftlich fixiert und ver\u00f6ffentlicht wurde, f\u00fcr den Rechtsraum dieser Institution verbindlich ist und deren Nicht-beachtung definierte Sanktionen nach sich zieht [4] . \n2 Zielsetzung  \nNationale VersorgungsLeitlinien sollen die Versorgung von Patient*innen in Deutschland verbessern durch aktuelle wissenschaftlich begr\u00fcndete Empfehlungen zu Diagnostik, Behandlung und Rehabilitation sowie f\u00fcr ein strukturier-tes und optimiertes Management der Erkrankung. Dazu geh\u00f6rt insbesondere auc h eine verbesserte Kommunika-\ntion zwischen den Behandelnden \u00fcber alle Sektoren- und F\u00e4chergrenzen hinaus sowie der Einbezug der Patient*in-\nnen in alle Behandlungsentscheidungen.  \nDar\u00fcber hinaus erhoffen sich die Autor*innen und die herausgebenden Organisationen  der Nationalen Versor-\ngungsLeitlinie COPD konkret:  \n\uf0a1 Eine Verbesserung der Diagnostik. Dies beinhaltet die m\u00f6glichst fr\u00fche Diagnose der Erkrankung, eine ange-messene Verlaufskontrolle aber auch die Vermeidung von \u00dcber - und Unterdiagnostik durch Verwendung an-\ngemessener Referenzwerte f\u00fcr die Spirometrie.  \n\uf0a1 Eine Optimierung des Therapiemanagements: insbesondere eine an die individuellen Voraussetzungen jedes  \nPatienten beziehungsweise jeder Patient in angepasste Therapie die auch das Potenzial nichtmedikament\u00f6ser \nVerfahren aussch\u00f6pft sowie wichtige Aspekte wie Multimorbidit\u00e4t angemessen ber\u00fccksichtigt.  \n\uf0a1 Eine Optimierung des Managements der Komorbidit\u00e4ten, insbesondere der Umgang mit Angst und Depres-sion, Osteoporose, Schmerz.  \n\uf0a1 Die St\u00e4rkung der Arzt -Patienten-Kommunikation mit dem Ziel, die Adh\u00e4renz zu gemeinsam vereinbarten The-\nrapiezielen zu f\u00f6rdern und die vorausschauende Planung der Behandlung zu f\u00f6rdern.  \n\uf0a1 Die F\u00f6rderung des Verst\u00e4ndnisses von COPD als eine chronische Erkrankung, die dauerhafter Betreuung insbesondere auch palliativmedizinischer Versorgung bedarf.  \n\uf0a1 Die F\u00f6rderung von Aufkl\u00e4rung \u00fcber und Motivation zu lebensstilbezogener Anpassung: Dies betrifft k\u00f6rperli-che Aktivit\u00e4t und Training sowie insbesondere die Beachtung des gro\u00dfen Stellenwerts der Tabakentw\u00f6hnung.  \n3 Adressat *innen  \nDie Empfehlungen der NVL COPD  richten sich an  \n\uf0a1 alle \u00c4rzt *innen, die in den von der NVL angesprochenen Versorgungsbereichen t\u00e4tig sind (z.  B. Allgemeinmedi-\nzin, Arbeitsmedizin, Innere Medizin, Pneumologie, Physikalische Medizin und Rehabilitation, Psychosomatik);  \n\uf0a1 die nicht -\u00e4rztlichen Fachberufe, die in den von einer NVL angesprochenen Versorgungsbereichen als Kooper ie-\nrende der \u00c4rzteschaft t\u00e4tig sind (z.  B. Apotheker *innen, Physiotherapeut *innen, Psychotherapeut *innen);  \n\uf0a1 betroffene Patient*innen sowie ihr pers\u00f6nliches Umfeld (z.  B. Partner *innen, Kinder) unter Nutzung von speziel-\nlen Patientenleitlinien und Patienteninformationen.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  6 \n  \n  \n Die NVL COPD richtet  sich weiterhin an  \n\uf0a1 die Vertragsverantwortlichen von \u201eStrukturierten Behandlungsprogrammen\u201c und \u201e Integrierten Versorgungsver-\ntr\u00e4gen\u201c;  \n\uf0a1 die medizinischen wissenschaftlichen Fachgesellschaften und andere Herausgeber von Leitlinien, deren Leitli-\nnien ihrerseits die Gru ndlage f\u00fcr die NVL bilden k\u00f6nnen;  \n\uf0a1 die Kostentr\u00e4ger im Gesundheitssystem;  \n\uf0a1 die \u00d6ffentlichkei t zur Information \u00fcber gute medizinische Vorgehensweise.  \n4 Zusammensetzung  der Leitliniengruppe  \nPrim\u00e4re Ansprechpartner*innen  bei der Benennung von Leitlinienautor *innen sind die Mitgliedsgesellschaften der \nAWMF sowie die Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4). Die an der Versorgung von Patient*in-\nnen mit COPD ma\u00dfgeblich beteiligten Fachgesellschaften wurden durch das \u00c4ZQ angesprochen und um Entsen-\ndung von Mandatstr\u00e4ger *innen in die Leitliniengruppe gebeten.  Die Nominierung liegt im Verantwortungsbereich \nder angesprochenen medizinischen wissenschaftlichen Fachgesellschaften. Die Leitliniengruppe wurde multidis-ziplin\u00e4r zusammengesetzt.  \nBei der Erstellung der 2. Auflage der NVL COPD vertretene Fachgesellschaft en/Organisationen:  \n\uf0a1 Akade mie f\u00fcr Ethik in der Medizin e. V. (AEM);  \n\uf0a1 Arzneimittelkommission der Deutschen Apotheker (AMK) ; \n\uf0a1 Arzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4) ; \n\uf0a1 Bundesarbeitsgemeinschaft SELBSTHILFE e. V. (BAG Selbsthilfe);  \n\uf0a1 Deutsche Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin e. V. (DEGAM);  \n\uf0a1 Deutsche Gesellschaft f\u00fcr Geriatrie e. V. (DGG) ; \n\uf0a1 Deutsche Gesellschaft f\u00fcr Gerontologie und Geriatrie e. V. (DGGG) ; \n\uf0a1 Deutsche Gesellschaft f\u00fcr Hals -Nasen -Ohren-Heilkunde, Kop f- und Hals -Chirurgie e. V. (DGHNOKHC) ; \n\uf0a1 Deutsche Ges ellschaft f\u00fcr Innere Medizin e. V. (DGIM) ; \n\uf0a1 Deutsche Gesel lschaft f\u00fcr Palliativmedizin e.  V. (DGP);  \n\uf0a1 Deutsche Gesells chaft f\u00fcr Pflegewissenschaft e. V. (DGP);  \n\uf0a1 Deutsche Gesellschaft f\u00fcr Physikalische und Rehabil itative Medizin e. V. (DGPRM) ; \n\uf0a1 Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin e. V. (DGP);  \n\uf0a1 Deutsche Gesellschaft f\u00fcr Psychosomatische Medizin und \u00c4rztliche Psychotherapie e.  V. (DGPM) ; \n\uf0a1 Deutsche Gesellschaft f\u00fcr R ehabilitationswissenschaften e. V. (DGRW) ; \n\uf0a1 Deutsche Gesellschaft f\u00fcr Schlafforschung und Schlafmedizin e.  V. (DGSM) ; \n\uf0a1 Deutsche R\u00f6ntgengesellschaft e.  V. (DRG) ; \n\uf0a1 Deutscher Verband f\u00fcr Physiotherapie e.  V. (ZVK);  \n\uf0a1 Deutsches Kollegium f\u00fcr Psychosomatische Medizin und Psychotherapie (DKPM) ; \n\uf0a1 Gesellschaf t f\u00fcr Phytotherapie e. V. (GPT).  \nIn der ersten Sitzung zur Aktualisierung der NVL COPD, 2. Auflage am 22.01.2018 wurde die Repr\u00e4sentativit\u00e4t der Gruppe zur \u00dcberarbeitung der NVL durch die Leitliniengruppe gepr\u00fcft. Folgende Fachgesellschaften/Organisatio-\nnen wurden neu aufgenommen:  \n\uf0a1 Deutsche Atemwegsliga e.  V.; \n\uf0a1 Deutsche Forschungsgruppe Pneumologie in der Prim\u00e4rversorgung e.  V. (DFPP);  \n\uf0a1 Deutsche Gesellschaft f\u00fcr Arbeitsmedizin und Umweltmedizin e.  V. (DGAUM);  \n\uf0a1 Deutsche Gesellschaft f\u00fcr Internistische Intensivmedizin und Notfallmedizin e. V. (DGIIN);  \n\uf0a1 Deutsche Gesellschaft f\u00fcr Kardiologie \u2013  Herz und Kreislaufforschung e. V. (DGK);  \n\uf0a1 Deutsche Gesellschaft f\u00fcr Nikotin- und Tabakforschung e.  V. (DGNTF);  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  7 \n  \n  \n \uf0a1 Deutsche Gesellschaft f\u00fcr Thoraxc hirurgie e. V. (DGT);  \n\uf0a1 Deutsche Interdisziplin\u00e4re Gesellschaft f\u00fcr Au\u00dferklinische Beatmung e.  V. (DIGAB).  \nIm Laufe der Aktualisierung wurden folgende Fachgesellschaften nachbenannt:  \n\uf0a1 Deutsche Gesellschaft f\u00fcr Psychologie e.  V. (DGPs);  \n\uf0a1 Deutsche Gesellschaft f\u00fcr Suchtforschung und Suchttherapie e.  V. (DG-Sucht) . \nB\u00c4K und KBV haben zur Begleitung des Ak tualisierungsprozesses der NVL COPD diskontinuierlich Referent *innen \naus den zust\u00e4ndigen Dezernaten in die Sitzungen der Leitliniengruppe als Beobach ter*innen  entsandt.  \nIn Tabelle 1 werden alle Vertreter *innen der Fachgesellschaften aufgef\u00fc hrt, die an der Erstellung der 2. Auflage \nder NVL COPD und dem formalen Konsensusverfahren beteiligt war en. Autor *innen, die an der vorherigen Auf-\nlage beteiligt waren, sind im jeweiligen Leitlinienreport dokumentiert  [10]. \nTabelle 1: Vertreter*innen der Fachgesellschaften/ Organisationen  \nFachgesellsch aft/ \nOrganisation  Funktion in der \nLeitliniengruppe  Experte/Expertin  Arbeitsgruppen zur \nAktualisierung  (2. Auflage)  \nAkademie f\u00fcr Ethik in der \nMedizin  (AEM)  Erstbenannte \nVertreterin  der Fach-\ngesellschaft  Dr. Elisabeth Heis-\nter Nicht -medikament\u00f6se Therapie, \nRehabilitation  \nRespiratorische Insuffizienz  \nAkademie f\u00fcr Ethik in der \nMedizin  (AEM)  Stellvertreter de r \nErstbenannten  Prof. Dr. Alfred Si-\nmon Nicht -medikament\u00f6se Therapie, \nRehabilitation  \nArzneimittelkommission \nder Deutschen Apotheker \n(AMK)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Martin \nSchulz  Medikament\u00f6se Therapie  \nVersorgungskoordination  \nArzneimittelkommission \nder Deutschen Apotheker \n(AMK)  Stellvertreter des \nErstbenannten  Dr. Eric Martin  Medikament\u00f6se Therapie  \nVersorgungskoordination  \nArzneimittelkommission \nder deutschen \u00c4rzteschaft \n(Akd\u00c4)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Harald \nSch\u00e4fer  Diagnostik  \nMedikament\u00f6se Therapie  \nArzneimittelkommission \nder deutschen \u00c4rzteschaft \n(Akd\u00c4)  Stellvertreter des \nErstbenannten  Prof. Dr. Klaus Dal-\nhoff - \nDeutsche Atemwegsliga  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Carl -Peter \nCri\u00e9e  Diagnostik  \nNicht -medikament\u00f6se Therapie, \nRehabilitation  \nRespiratorische Insuffizienz  \nMedikament\u00f6se Therapie  \nAktualisierung Definition  \nDeutsche Atemwegsliga   Stellvertreterin  des \nErstbenannten  Prof. Dr. Andrea \nKoch (bis M\u00e4rz \n2019)1 - \nDeutsche Forschungs-\ngruppe Pneumologie in der \nPrim\u00e4rversorgung (DFPP)  Erstbenannter \nVertreter der \nFachgesellschaft  Dr. Michael Weber  \n Diagnostik  \nNicht -medikament\u00f6se Therapie, \nRehabilitation  \nMedikament\u00f6se Therapie  \nDeutsche Forschungs-\ngruppe Pneumologie in der \nPrim\u00e4rversorgung (DFPP)  Stellvertreter des \nErstbenannten  Dr. Andreas \nHellmann  \n Diagnostik  \nTabakentw\u00f6hnung  \nRespiratorische Insuffizienz  \nVersorgungskoordination  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  8 \n  \n  \n Fachgesellsch aft/ \nOrganisation  Funktion in der \nLeitliniengruppe  Experte/Expertin  Arbeitsgruppen zur \nAktualisierung  (2. Auflage)  \nDeutsche Forschungs-\ngruppe Pneumologie in der \nPrim\u00e4rversorgung (DFPP)  2. Stellvertreter des \nErstb enannten  Dr. Thomas Hering \n(ab Oktober 2019)  Tabakentw\u00f6hnung  \nDeutsche Gesellschaft f\u00fcr \nAllgemeinmedizin  und Fa-\nmilienmedizin  (DEGAM ) Erstbenannter \nVertreter der \nFachgesellschaft  Univ. -Prof. Dr. \nAntonius  Schneider  - \nDeutsche Gesellschaft f\u00fcr \nAllgemeinmedizin  und Fa-\nmilienmedizin  (DEGAM)  Stellvertreter des \nErstbenannten  Prof. Dr. Michael \nFreitag , MPH  Diagnostik  \nMedikament\u00f6se Therapie  \nVersorgungskoordination  \nDeutsche Gesellschaft f\u00fcr \nAllgemeinmedizin  und Fa-\nmilienmedizin  (DEGAM)  2. Stellvertreter des \nErstbenannten  Univ. -Prof. Dr. \nDaniel  Kotz, PhD, \nMPH (ab August \n2019)  Tabakentw\u00f6hnung  \nDeutsche Gesellschaft f\u00fcr \nArbeitsmedizin und Um-\nweltmedizin  (DGAUM)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Dennis \nNowak  Tabakentw\u00f6hnung  \nDeutsche Gesellschaft f\u00fcr \nArbeitsmedizin und Um-\nweltmedizin  (DGAUM)  Stellvertreter des \nErstbenannten  Univ. -Prof. Dr. \nThomas Kraus  -  \nDeutsche Gesellschaft f\u00fcr \nGeriatrie  (DGG)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Hans \nJ\u00fcrgen Heppner  -  \nDeutsche Gesellschaft f\u00fcr \nGeriatrie  (DGG)  Stellvertreter des \nErstbenannten  PD Dr. Helmut \nFrohnhofen  Diagnostik  \nDeutsche Gesellschaft f\u00fcr \nGerontologie und Geriatrie \n(DGGG)  Erstbenannte \nVertreterin  der \nFachgesellschaft  Dr. Katrin Knoll  - \nDeutsche Gesellschaft f\u00fcr \nGerontologie und Geriatrie \n(DGGG)  Stellvertreter der \nErstbenannten  Dr. Manfred Gogol  - \nDeutsche Gesellschaft f\u00fcr \nHals-Nasen -Ohren -Heil-\nkunde, Kopf - und Hals -Chi-\nrurgie  (DGHNOKHC)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Andreas \nNeumann  - \nDeutsche Gesellschaft f\u00fcr \nInnere Medizin  (DGIM)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Stefan \nAndreas  Tabakentw\u00f6hnung  \nMedikament\u00f6se Therapie  \nDeutsche Gesellschaft f\u00fcr \nInternistische Intensivmedi-\nzin und Notfallmedizin \n(DGIIN)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Tobias \nWelte  - \nDeutsche Gesellschaft f\u00fcr \nInternistische Intensivmedi-\nzin und Notfallmedizin \n(DGIIN)  Stellvertreter des \nErstbenannten  Prof. Dr. Claus F. \nVogelmeier  Aktualisierung Definition  \nDeutsche Gesellschaft f\u00fcr \nKardiologie \u2013 Herz und \nKreislaufforschung (DGK) Erstbenannter \nVertreter der \nFachgesellschaft  PD Dr. Tobias J. \nLange  Diagnostik  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  9\n Fachgesellsch aft/ \nOrganisation  Funktion in der \nLeitliniengruppe  Experte/Expertin  Arbeitsgruppen zur \nAktualisierung  (2. Auflage)  \nDeutsche Gesellschaft f\u00fcr \nNikotin - und Tabakfor-\nschung (DGNTF)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. David \nGroneberg  Tabakentw\u00f6hnung  \nDeutsche Gesellschaft f\u00fcr \nNikotin - und Tabakfor-\nschung (DGNTF)  Stellvertreter des \nErstbenannten  Dr. Ulf Ratje (bis \nJuni 2018)1 - \nDeutsche Gesellschaft f\u00fcr \nPalliativmedizin  (DGP) Erstbenannte \nVertreterin der Fach-\ngesellschaft  Prof. Dr. Claudia \nBausewein, PhD  Nicht -medikament\u00f6se Therapie , \nRehabilitation  \nRespiratorische Insuffizienz  \nDeutsche Gesellschaft f\u00fcr \nPalliativmedizin  (DGP) Stellvertreterin der \nErstbenannten  Dr. Wiebke Nehls  Nicht -medikament\u00f6se Therapie , \nRehabilitation  \nDeutsche Gesellschaft f\u00fcr \nPflegewissenschaft  (DGP) Erstbenannte \nVertreterin der \nFachgesellschaft  Christiane Freitag, \nB.A. Tabakentw\u00f6hnung  \nNicht -medikament\u00f6se Therapie , \nRehabilitation  \nDeutsche Gesellschaft f\u00fcr \nPhysikalische und Rehabi-\nlitative Medizin  (DGPRM)  Erstbenannter \nVertreter der \nFachgesellschaft  Dr. Konrad Schultz  Tabakentw\u00f6hnung  \nNicht -medikam ent\u00f6se Therapie, \nRehabilitation  \nDeutsche Gesellschaft f\u00fcr \nPneumologie und Beat-\nmungsmedizin  (DGP) Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Heinrich \nWorth  Diagnostik  \nTabakentw\u00f6hnung  \nNicht -medikament\u00f6se Therapie, \nRehabilitation  \nRespiratorische Insuffizienz  \nAktualisierung Definition  \nDeutsche Gesellschaft f\u00fcr \nPneumologie und Beat-\nmungsmedizin  (DGP) Stellvertreter des \nErstbenannten  PD Dr. Henrik Watz  Diagnostik  \nMedikament\u00f6se Therapie  \nDeutsche Gesellschaft f\u00fcr \nPneumologie und Beat-\nmungsmedizin  (DGP) 2. Stellvertreter des\nErstbenanntenDr. Andr\u00e9s de Roux \n(ab M\u00e4rz 2018)  Diagnostik  \nMedikament\u00f6se Therapie  \nVersorgungskoordination  \nDeutsche Gesellschaft f\u00fcr \nPsychologie (DGPs) Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Stephan \nM\u00fchlig (ab August \n2019)  Tabakentw\u00f6hnung  \nDeutsche Gesellschaft f\u00fcr \nPsychosomatische Medizin \nund \u00c4rztliche Psychothera-\npie (DGPM) Erstbenannte \nVertreterin der \nFachgesellschaft  PD Dr. Cora Weber \n(ab April 2018)  Diagnostik  \nNicht -medikament\u00f6se Therapie, \nRehabilitation  \nVersorgungskoordination  \nDeutsche Gesellschaft f\u00fcr \nPsychosomatische Medizin \nund \u00c4rztliche Psychothera-\npie (DGPM) Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Hans \nChristian Deter (bis \nM\u00e4rz 2018)1 - \nDeutsche Gesellschaft f\u00fcr \nRehabilitationswissenschaf\nten (DGRW)  Erstbenannter \nVertreter der \nFachgesellschaft  Dr. Konrad Schultz  Tabakentw\u00f6hnung  \nNicht -medikam ent\u00f6se Therapie, \nRehabilitation  \nDeutsche Gesellschaft f\u00fcr \nSchlafforschung und \nSchlafmedizin  (DGSM) Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Georg \nNilius  Diagnostik  \nNicht -medikament\u00f6se Therapie, \nRehabilitation  \nRespiratorische Insuffizienz  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  10 \n  \n  \n Fachgesellsch aft/ \nOrganisation  Funktion in der \nLeitliniengruppe  Experte/Expertin  Arbeitsgruppen zur \nAktualisierung  (2. Auflage)  \nDeutsche Gesellschaft f\u00fcr \nSuchtforschung und Sucht-\ntherapie (DG-Sucht)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Anil Batra \n(ab August 2019)  Tabakentw\u00f6hnung  \nDeutsche Gesellschaft f\u00fcr \nThoraxchirurgie  (DGT)  Erstbenannter \nVertreter der \nFachgesellschaft  Dr. Stephan \nEggeling  - \nDeutsche Gesellschaft f\u00fcr \nThoraxchirurgie (DGT)  Stellvertreter des \nErstbenannten  PD Dr. Stefan \nWelter  - \nDeutsche Interdisziplin\u00e4re \nGesellschaft  f\u00fcr Au\u00dferklini-\nsche Beatmung (DIGAB)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Jan H. \nStorre  Nicht -medikament\u00f6se Therapie, \nRehabilitation  \nRespiratorische Insuffizienz  \nDeutsche Interdisziplin\u00e4re \nGesellschaft  f\u00fcr Au\u00dferklini-\nsche Beatmung (DIGAB)  Stellvertreter des \nErstbenannten  Prof. Dr. Michael \nDreher  Nicht -medikament\u00f6se Therapie, \nRehabilitation  \nRespiratorische Insuffizienz  \nAktualisierung Definition  \nDeutsche R\u00f6ntgengesell-\nschaft (DRG)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Claus \nPeter  Heu\u00dfel  Tabakentw\u00f6hnung  \nNicht -medikament\u00f6se Therapie, \nRehabilitation  \nDeutsche R\u00f6ntgengesell-\nschaft  (DRG)  Stellvertreter des \nErstbenannten  Prof. Dr. Hans -Ul-\nrich Kauczor  Diagnostik  \nDeutscher Verband f\u00fcr \nPhysiotherapie (ZVK)  Erstbenannter \nVertreter der \nFachgesellschaft  Jan Kaufmann  Nicht -medikament\u00f6se Therapie, \nRehabilitation  \nVersorgungskoordination  \nDeutsches Kollegium f\u00fcr \nPsychosomatische  Medizin \nund Psychotherapie \n(DKPM) Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Thomas \nRitz (ab April 2018)  Diagnostik  \nNicht -medikament\u00f6se Therapie, \nRehabilitation  \nDeutsches Kollegium f\u00fcr \nPsychosomatische  Medizin \nund Psychotherapie \n(DKPM) Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Hans \nChristian Deter (bis \nM\u00e4rz 2018)1 - \nGesellschaft f\u00fcr Phytothe-\nrapie (GPT)  Erstbenannter \nVertreter der \nFachgesellschaft  Prof. Dr. Jost \nLanghorst  - \nGesellschaft f\u00fcr \nPhytotherapie (GPT)  Stellvertreterin des \nErstbenannten  Dr. Petra Klose  Nicht -medikament\u00f6se Therapie, \nRehabilitation  \nMedikament\u00f6se Therapie  \nDeutsche PatientenLiga \nAtemwegserkrankungen \n(DPLA) Erstbenannter \nVertreter  Dr. Michael K\u00f6hler  Tabakentw\u00f6hnung  \nNicht -medikament\u00f6se Therapie, \nRehabilitation  \nMedikament\u00f6se Therapie  \n1 Die aufgef\u00fchrten Expert*innen wurden f\u00fcr die NVL COPD benannt, waren jedoch nicht an der Erstellung beteiligt.  \nFrau Claudia Meiling vom Deutschen Verband der Ergotherapeuten unterst\u00fctzte die Arbeitsgruppe Nicht -medika-\nment\u00f6se Therapie als externe Expertin bei der Erarbeitung des  Kapitel s Ergotherapie.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  11 \n  \n  \n Tabelle 2: Methodik, Redaktion und Moderation  \nRedaktion und Moderation  \nSabine Sch\u00fcler  \u00c4rztliches Zentrum f\u00fcr Qualit\u00e4t \nin der Medizin (\u00c4ZQ)  Literaturrecherche, Evidenzaufbereitung, \nMethodische Begleitung, Redaktion, \nModeration  \nCorinna Schaefer  \u00c4rztliches Zentrum f\u00fcr Qualit\u00e4t \nin der Medizin (\u00c4ZQ)  Methodische Begleitung, Redaktion, \nModeration, Redaktion \nPatientenmaterialien  \nIsabell Vader, MPH   \n(bis 01/2021)  \u00c4rztliches Zentrum f\u00fcr Qualit\u00e4t \nin der Medizin (\u00c4ZQ)  Literaturrecherche, Evidenzaufbereitung , \nModeration  \nDr. Susanne Bl\u00f6dt,  MScPH  Arbeitsgemeinschaft der Wis-\nsenschaftlichen Medizinischen \nFachgesellschaften (AWMF)  Methodische Begleitung  \nDr. Monika Nothacker, MPH  Arbeitsgemeinschaft der Wis-\nsenschaftlichen Medizinischen \nFachgesellschaften (AWMF)  Moderation  \n5 Patient *innenbeteiligung  \nNeben der wissenschaftlichen Evidenz und den \u00e4rztlichen Erfahrungen stellen die Erfahrungen und L\u00f6sungsvor-\nschl\u00e4ge von Patient *innen(-organisationen) im Hinblick auf die Versorgungssituation bei der betreffenden Erkran-\nkung eine wertvolle Informationsquelle f\u00fcr Leitlinien dar [11] . Vor diesem Hintergrund haben B\u00c4K, KBV und AWMF \ndie konsequente Beteiligung von Patient *innen am NVL-Programm beschlossen. Patient *innen sind regelhaft be-\nteiligt an der NVL-Erstellung, am externen Begutachtungsverfahren und an der Erstellung von Patientenleitlinien (siehe  Kapitel 12.1 Materialien und Formate) zur entsprechenden NVL. Die Benennung von Patientenvertreter *in-\nnen erfolgt nach einem transparenten, standardisierten Verfahren (siehe Handb uch Patientenbeteiligung [12]) \u00fcber \ndie Dachverb\u00e4nde der Selbsthilfeorganisationen:  \n\uf0a1 Bundesarbeitsgemeinschaft Selbsthilfe (BAG SELBSTHILFE);  \n\uf0a1 Deutsche Arbeitsgemeinschaft Selbsthilfegruppen (DAG SHG);  \n\uf0a1 Forum chronisch kranker und behinderter Menschen im Parit\u00e4tischen Gesamtverband).  \nDie Interessenvertretung der an COPD  erkrankten Patient *innen \u00fcbernahm Herr Dr. Michael K\u00f6hler von der Deut-\nschen PatientenLiga Atemwegserkrankungen (DPLA) .  \n6 Auswahl  und Bewertung der Evidenz  \nQuell - und Referenzleitlinien  \nDie strukturierte S uche nach Leitlinien zum Thema COPD  bei fach\u00fcbergreifenden und fachspezifischen Leitlinien-\ndatenbanken und -anbietern  erbrachte 18 Treffer , welche als potentielle Grundlage f\u00fcr eine Leitlinie nsynopse ge-\neignet waren. Bei n\u00e4herer Betrachtung ergab sich jedoch, dass die Qualit\u00e4t der Leitlinien \u2013 insbesondere in den \nBereichen \u201emethodische Exaktheit\u201c und \u201eredaktionelle Unabh\u00e4ngigkeit\u201c zumeist unzureichend war . \nAufgrund dieser \u00dcberlegungen wurde auf eine Leitlinienadaptation verzichtet und stattdessen f\u00fcr die gesamte NVL eine strukturierte Recherche nach aggregierter Evidenz durchgef\u00fchrt. F\u00fcr einzelne Fragestellungen wurde auf Re-\nferenzleitlinien Bezug genommen. Die Bewertung und Auswahl der internationalen Quell - und Referen zleitlinien \nwird strukturiert im  Anhang 3.1  dargestellt.  Aus dem deutschen Versorgungskontext stammende Leitlinien (AWMF -\nLeitlinienregister, www.awmf.org/leitlinien.html ) wurden, da sie bereits seitens der AWMF  umfassend begutachtet  \nwurden, nicht zus\u00e4tzlich bewertet.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  12 \n  \n  \n Strukturierte Recherche  \nF\u00fcr die gesamte NVL COPD wurde a ggregierte Evidenz zum Thema COPD in der Cochrane-Datenbank recher-\nchiert. Die gefundenen Publikationen wurden zweistufig, als Titel/Abstract und im Volltext gesichtet. Die einge-\nschlossenen systematischen Reviews wurden bewertet und die Ergebnisse extrahiert. In den Evidenztabellen \nwurde die empfehlungsrelevante Evidenz ausf\u00fchrlich dargestellt. Eine \u00dcbersicht der Literatursichtung sowie Evi-\ndenztabellen befinden sich im Anhang.  \nF\u00fcr weitere Fragestellungen erfolgte in einem zweistufigen Vorgehen zun\u00e4chst eine strukturierte Suche nach HTA -\nBerichten oder systematischen \u00dcbersichtsarbeiten, die durch das IQWiG (Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen), das National Institute for Health and Care Excellence (NICE), die Agency for Healthcare \nResearch and Quality (AHRQ) oder die Cochrane Collaboration erstellt wurden. Diese Institutionen wurden auf Grund ihrer evidenzbasierten Vorgehensweise, ihrer hohen Berichtsqualit\u00e4t, ihrer wissenschaftlichen Unabh\u00e4ngig-keit und \u2013 im Falle des IQWiG und NICE \u2013 ihres Bezugs zum deutschen bzw. europ\u00e4ischen Versorgungskontext \nals prim\u00e4re Quellen systematischer \u00dcbersichtsarbeiten ausgew\u00e4hlt.  \nZu folgender Fragestellung wurde eine strukturierte Recherche auf Basis aggregierter Evidenz durchgef\u00fchrt:  \n\uf0a1 H\u00e4usliche Trainingstherapie bei Patient*innen mit COPD, Anhang 3.12  \nSystematische Evidenzrecherche  \nEine zus\u00e4tzliche systematische Recherche erfolgte bei Fehlen thematisch passender \u00dcbersichtsarbeiten von Cochrane. Systematische Recherchen wurden in Medline via Pubmed und der Cochrane-Datenbank durchgef\u00fchrt . \nDie gefundenen Publikationen wurden zweis tufig, als Titel/Abstract und im Volltext gesichtet. Die eingeschlossenen \nsystematischen \u00dcbersichtsarbeiten und Prim\u00e4rstudien wurden bewertet und die Ergebnisse extrahiert. In den Evi-denztabellen wurde die empfehlungsrelevante Evidenz ausf\u00fchrlich dargestel lt.  \nZu folgenden  Themen wurden systematische Recherchen durchgef\u00fchrt:  \n\uf0a1 Diagnostische Verfahren, Anhang 3.4;  \n\uf0a1 \u00dcber -/Unterdiagnose, Anhang 3.5;  \n\uf0a1 Ph\u00e4notypisierung mittels Computertomographie, Anhang 3.6 ; \n\uf0a1 Cut-Off Symptomerfassung , Anhang 3.7;  \n\uf0a1 Angst/Depression, Anhang 3.8 ; \n\uf0a1 Ganzk\u00f6rpervibration, Anhang 3.11;  \n\uf0a1 Atemtechniken, Anhang 3.13;  \n\uf0a1 Patientenschulung, Anhang 3.14;  \n\uf0a1 Ern\u00e4hrung, Anhang 3.15;  \n\uf0a1 Ger\u00e4tebasiertes Training, Anhang 3.16;  \n\uf0a1 Telemedizin , Anhang 3.17;  \n\uf0a1 Triple -Therapie , Anhang 3.18;  \n\uf0a1 kardiale Nebenwirkungen bei inhalativer Dauertherapie m it einem LAMA oder LABA , Anhang 3.19 ; \n\uf0a1 Eosinophile, Anhang 3.20;  \n\uf0a1 Roflumilast , Anhang 3.21;  \n\uf0a1 Mukolytika , Anhang 3.23; \n\uf0a1 Wechsel des Inhalationssystems ohne erneute Instruktion, Anhang 3.24.  \nF\u00fcr fol gende Fragestellungen wurden aufgrund ihrer  \u00dcbertragbarkeit auf Patient*innen mit COPD systematische Re-\ncherchen der NVL Asthma [13] herangezogen:  \n\uf0a1 Asthma COPD Overlap , Anhang 5.1 ; \n\uf0a1 Wirksamkeit von Instruktionen in Inhalationssysteme, Anhang 3.22;  \n\uf0a1 Auswirkungen des Wechsels von Inhalationssystemen ohne erneute Instruktion, Anhang 3.24.  \nDie Recherchedokumentationen zu den jeweiligen systematischen Recherchen sind i m Leitlinienreport der NVL \nAsthma  [14] (www.leitlinien.de/asthma ) einzusehen.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  13 \n  \n  \n In Zusammenarbeit mit der Cochrane Airways Group wurde eine systematische Update- Recherche eines Cochrane \nReviews zur Wirksamkeit verhaltensbezogener und/oder pharmakologischer Ma\u00dfnahmen zur Raucherentw\u00f6hnung \nbei rauchenden Patient*innen mit COPD [15]  durchgef\u00fchrt . F\u00fcr ein Suchupdate wurde die damals verwendete Such-\nstrategie seitens der Cochrane Airways Group erneut umgesetzt. Die Ergebnisse dieser Update- Suche wurden dem  \n\u00c4ZQ zur Verf\u00fcgung gestellt. Die  Sichtung im Titel/Abstract und im Volltext,  sowie die Bewertung und Extraktion erfolgte \ndurch das \u00c4ZQ ( Anhang 3.9).  \nIm Rahmen der Aktualisierung der S3-Leitlinie \u201e Rauchen und Tabakabh\u00e4ngigkeit: Screening, Diagnostik und Be-\nhandlung\u201c [16] wurde eine systematische Update-Recherche bez\u00fcglich der Nutzung v on E-Zigaretten durchgef\u00fchrt. \nDie identifizierten Volltexte  wurden dem \u00c4ZQ zur Verf\u00fcgung gestellt  (Anhang 3.10).  \nDer Leitlinienkoordinator der  S3-Leitlinie  \u201eTabakentw\u00f6hnung bei COPD \u201c [17], welcher auch Mitglied der Leitlinien-\ngruppe der NVL COPD ist, stellte die Evidenz zu m\u00f6glichen motivierenden Effekten der Besprechung von Lungen-funktion oder CO -Werten mit den Patient*innen zur Verf\u00fcgung (Anhang 6.3) . Weitere Informationen zu dieser sys-\ntematischen Recherche finden sich unter www.awmf.org/leitlinien/detail/ll/020-005.html . \nSelektiv recherchierte Arbeiten wurden in Ausnahmen erg\u00e4nzend f\u00fcr den Hintergrundtext herangezogen, wenn sie aus Sicht der Leitliniengruppe im medizinischen Diskurs von besonderer Bedeutung waren (z. B.  RCT zum Effekt von \nMetoprolol hinsichtlich des Exazerbationsrisikos bei Patient*innen mit moderater bis schwerer COPD)  oder auf ein-\nzelne praxisrelevante Aspekte eingingen.  \nWeitere Quellen  \nZur Aktualisierung d es Kapitels Epidemiologie wurde gezielt  nach epidem iologischen Daten aus dem deutsc hen \nVersorgungskontext gesucht.  Als aktuellste verf\u00fcgbare Daten wurden die Ergebnisse der Querschnittstudie GEDA \n2014/2015-EHIS  [18] sowie Auswertungen des Zi (Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in Deutsch-\nland)  von bundesweiten vertrags\u00e4rztlichen Abrechnungsdaten [19] herangezogen.  \nF\u00fcr ausgew\u00e4hlte Fragestellungen wurden Ver\u00f6ffentlichungen der European Medicines Agency (EMA) und des Ge-\nmeinsamen Bundesausschusses (G -BA) gezielt durchsucht.  \nEvidenzbewertung  \nDie methodische Bewertung der recherchierten \u00dcbersichtsarbeiten erfolgte zun\u00e4chst  mit dem AMSTAR -Tool [20]. \nBewertet wurden elf Fragen zur methodischen Qualit\u00e4t der systematischen \u00dcbersichtsarbeit mit den Kategorien ja, nein, nicht anwendbar und nicht beantwortbar. Gez\u00e4hlt wurden die Ja-Antworten. Von den Entwicklern wurde kein Cut-off-Wert f\u00fcr methodisch gute Arbeiten festge legt. Innerhalb der Leitliniengruppe wurde ein Cut -off-Wert von 6 \nf\u00fcr den Einschluss einer Arbeit festgelegt. Zudem musste das Kriterium 7 \u201eQualit\u00e4tsbewertung der eingeschlosse-nen Prim\u00e4rstudien\u201c erf\u00fcllt sein, um in die Evidenzsynthese eingeschlossen zu wer den.  \nIm Verlauf der Arbeiten an der NVL COPD wurde die Bewertung systematischer \u00dcbersichten dann mit der aktuali-\nsierten Version \u2013 AMSTAR -2-Tool [21] \u2013 entsprechend durchgef\u00fchrt . Bewerte t wurden nun sechzehn Fragen zur \nmethodischen Qualit\u00e4t der systematischen \u00dcbersichtsarbeit mit den Kategorien \u201eja\u201c, \u201epartiell ja\u201c, \u201enein\u201c oder \u201enicht \nanwendbar\u201c. Bewertet wurden die als kritische Dom\u00e4nen bezeichneten Fragen sowie die nicht -kritischen Dom\u00e4n en \nnach den vorgeschlagenen Bewertungskategorien \u201eHigh\u201c, \u201eModerate\u201c, \u201eLow\u201c und \u201eCritically low\u201c. Dabei durften f\u00fcr \ndie Kategorie \u201eHigh\u201c keine kritische Dom\u00e4ne oder eine nicht -kritische Dom\u00e4ne verletzt sein, f\u00fcr die Kategorie \u201eMo-\nderate\u201c mehr als eine nicht -kritische Dom\u00e4ne, f\u00fcr die Kategorie \u201eLow\u201c eine kritische Dom\u00e4ne und f\u00fcr die Kategorie \n\u201eCritically low\u201c mehr als eine kritische Dom\u00e4ne. Wird eine systematische \u00dcbersichtsarbeit mit \u201eCritically low\u201c bewer-\ntet, f\u00fchrt dies nicht automatisch zum Ausschluss. Gege bene nfalls werden im Einzelfall die nicht erf\u00fcllten Kriterien \nindividuell kritisch gepr\u00fcft.  \nDie methodische Bewertung der randomisierten kontrollierten Studien erfolgte in Anlehnung an das Cochrane Risk \nof Bias Tool, wobei die Dom\u00e4nen \u201eSelection bias\u201c, \u201ePerformance bias\u201c, \u201eDetection bias\u201c, \u201eAttrition bias\u201c, \u201eReporting \nbias\u201c sowie \u201eandere Bias -Ursachen\u201c jeweils mit \u201e hoch\u201c, \u201eniedrig\u201c oder \u201eunklar\u201c bewertet wurden [22]. Die Bewertung \nvon nicht randomisierten Studien erfolgte entsprechend den Empfehlungen zur \u201eBewertung des Biasrisikos (Ri siko \nsystematischer Fehler) in klinischen Studien: ein Manual f\u00fcr die Leitlinienerstellung\u201c [23]; diagnostische Studien \nwurden mit dem QUADAS -2-Tool  bewertet  [24]. NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  14 \n  \n  \n Evidenzqualit\u00e4t  \nF\u00fcr den Fall, dass eine Bewertung nach GRADE bereits durch die Autor *innen der systematischen \u00dcbersichtsarbeit \nerfolgt war, wurde diese \u00fcbernommen. Wenn e ine Bewertung nach GRADE nicht zur Verf\u00fcgung stand, oder Pri-\nm\u00e4rstudien aus systematisch durchgef\u00fchrten Recherchen f\u00fcr die Formulierung von Empfehlungen herangezogen \nwurden, wurde die Pr\u00e4zision, Direktheit und Konsistenz der Evidenz , sowie endpunktbezogene Studienqualit\u00e4t  be-\ntrachtet und narrativ beschrieben. Daraus ergab sich eine Bewertung der Evidenzqualit\u00e4t in Anlehnung an G RADE \nvon hoch bis sehr gering. Eigene GRADE -Bewertungen wurden nicht vorgenommen, da auch keine eigenen Me-\ntaanalysen durchgef\u00fchrt wurden.  \nEndpunktgraduierung  \nIn der Auftaktsitzung zur NVL COPD , 2. Auflage wurden klinisch relevante Endpunkte gesammelt ( Anhang 2) und \nin einer elektronischen Abstimmung in Anlehnung an die Empfehlungen von GRADE priorisiert [25]. Die Endpunkte \n\u201ekrankheitsspezifische Mortalit\u00e4t\u201c, \u201eSymptomatik: Atemnot, Husten und Auswurf\u201c, \u201eMobilit\u00e4t/Funktionalit\u00e4t\u201c, \u201esoziale \nTeilhabe\u201c, \u201eExazerbationen\u201c, \u201eReduktion des zuk\u00fcnftigen Krankheitsr isikos: COPD -bedingte Hospitalisierung\u201c und \n\u201eLebensqualit\u00e4t\u201c wurden am h\u00e4ufigsten als \u201ekritisch\u201c bewertet. F\u00fcr diese sowie f\u00fcr die Angaben zur Sicherheit fand \neine Extraktion der Ergebnisse statt.  \n7 Formulierung von Empfehlungen  \nDie Empfehlungsgrade wurden durch die Leitlinienautor*innen im Rahmen eines formalen Konsensverfahrens ver-geben ( siehe Kapitel 8 Entwicklung und Konsentierung ). Dabei wurden die folgenden Kriterien f\u00fcr die klinische \nBeurteilung vorgegeben [7\n\u2060,9 \u2060,26]: \n\uf0a1 die klinische Relevanz der Studienendpunkte (Outcome), Pr\u00e4zision des Effektsch\u00e4tzers und Effektst\u00e4rken;  \n\uf0a1 die Konsistenz der Studienergebnisse;  \n\uf0a1 die Abw\u00e4gung von potentiellem Nutz en und Schaden (Verh\u00e4ltnis von erw\u00fcnschten und unerw\u00fcnschten Effek-\nten); \n\uf0a1 die Anwendbarkeit der Evidenz auf die Patientenzielgruppen der NVL (Direktheit);  \n\uf0a1 die Angemessenheit der Vergleichsintervention;  \n\uf0a1 das Risiko f\u00fcr Publikationsbias;  \n\uf0a1 die Pr\u00e4ferenzen der Patient*innen;  \n\uf0a1 die Umsetzbarkeit im klinischen Alltag und in verschiedenen Versorgungssettings/Sektoren;  \n\uf0a1 ethische, rechtliche sowie \u00f6konomische Erw\u00e4gungen.  \nDie Graduierung der Empfehlungen im NVL-Verfahren entspricht den in Tabelle 3  dargestellten Symbolen. Zu-\nn\u00e4chst bestimmt die Qualit\u00e4t der Evidenz den Empfehlungsgrad. Eine mittlere Evidenzst\u00e4rke f\u00fchrt demnach zu einem mittleren Empfehlungsgrad. Aufgrund der oben genannten Kriterien, insbesondere der Relevanz der End-punkte und Effektst\u00e4rken f\u00fcr die Patient*innen, kann es jedoch zu einem begr\u00fcndeten Auf - oder Abwerten der \nEmpfehlungs st\u00e4rke  gegen\u00fcber dem Evidenzgrad kommen. Die Gr\u00fcnde f\u00fcr ein Auf - oder Abwer ten werden im Hin-\ntergrundtext dargelegt. Empfehlungen sollten m\u00f6glichst klar und eindeutig, handlungsorientiert und leicht verst\u00e4nd-\nlich formuliert sein. Vereinfacht dr\u00fccken im Ergebnis die Empfehlungsgrade folgende Gesamteinsch\u00e4tzung aus:  \n\uf0a1 Bei starken Empfehlungen (soll) sind sich die Leitlinienautor*innen in ihrer Einsch\u00e4tzung sicher. Starke Emp-\nfehlungen dr\u00fccken aus, dass die w\u00fcnschenswerten Folgen mit hoher Wahrscheinlichkeit m\u00f6gliche uner-\nw\u00fcnschte Effekte in Bezug auf patientenrelevante Endpunkte \u00fcberwiegen.  \n\uf0a1 Bei abgeschw\u00e4chten Empfehlungen (sollte) sind sich die Leitlinienautor*innen in ihrer Einsch\u00e4tzung weniger sicher.  \n\uf0a1 Bei offenen Empfehlungen (kann) sind sich die Leitlinienautor*innen nicht sicher. Offene Empfehlungen dr\u00fc-cken eine Handlungsoption in Uns icherheit aus.  \nEmpfehlungen f\u00fcr Versorgungsabl\u00e4ufe und Entscheidungsprozesse mit verschiedenen Handlungsoptionen werden als klinische Algorithmen dargestellt [27] . NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  15 \n  \n  \n Tabelle 3: Schema zur Graduierung von NVL- Empfehlungen, modifiziert nach  [7 \u2060,9]  \nEmpfehlungsgrad  Beschreibung  Formulierung  Symbol  \nA Starke Positiv -Empfehlung  Soll \u21d1\u21d1 \nB Abgeschw\u00e4chte Positiv -Empfehlung  Sollte  \u21d1 \n0 Offene Empfehlung  Kann  \u21d4 \nB Abgeschw\u00e4chte Negativ -Empfehlung  Sollte nicht  \u21d3 \nA Starke Negativ -Empfehlung  Soll nicht  \u21d3\u21d3 \n8 Entwicklung  und Konsentierung  \nEntwicklung  \nDer Entwicklungsprozess der 2. Auflage der NVL COPD  wurde durch das \u00c4ZQ seit M\u00e4rz 2017 organisiert. Nach \nDurchf\u00fchrung der strukturierten Recherche in der Cochrane- Datenbank  (siehe Kapitel 6 Auswahl und Bewertung \nder Evidenz ) wurde die  identifizierte aggregierte Evidenz bewertet , extrahiert  und den jeweiligen Kapiteln der NVL \nCOPD  zugeordnet.  \nFolgende Kapitel wurden in den Arbeitsgruppen diskutiert und komplett \u00fcberarbeitet:  \n\uf0a1 Definition und Epidemiologie;  \n\uf0a1 Diagnostik und Monitorin g; \n\uf0a1 Taba kentw\u00f6hnung;  \n\uf0a1 Nicht -medikament\u00f6se Therapie;  \n\uf0a1 Medikament\u00f6se Therapie;  \n\uf0a1 Medizinische Rehabilitation;  \n\uf0a1 Versorgungskoordination.  \nZwischen April 2018 und J anuar 2020 wurden die Empfehlungen und Hintergrundtexte der NVL in mehreren Tele-\nfonkonferenzen der Arbeitsgruppen (siehe Tabelle 4) diskutiert und erarbeitet. Die in den Arbeitsgruppen vorberei-\nteten Empfehlungen und Algorithmen wurden in der Konsensuskonferenz im Februar 2020 formal konsentiert. Im  \nM\u00e4rz und April 2020 wurde im Nachgang zur Konsensuskonferenz  das Kapitel \u201eAtmungsunter st\u00fctzende Ma\u00dfnah-\nmen bei chronisch respiratorischer Insuffizienz\u201c in zwei weiteren Telefonkonferenzen (siehe Tabelle 4) erarbeitet \nund im elektronischen Abstimmungsverfahren konsentiert.  Die Hintergrundtexte zu den Kapiteln wurden im schrift-\nlichen Umlaufverfahren abgestimmt.  \nTabelle 4: Verfahren der Arbeitsgruppen, 2 . Auflage  \nArbeitsgruppe  Diskussion der Empfehlungen und Hintergrundtexte  \nDiagnostik (inklusive Definition und Epidemiologie)  6 Telefonkonferenzen  \nUnterarbeitsgruppe: Aktualisierung Definition  1 Telefonkonferenz  \nTabakentw\u00f6hnung  3 Telefonkonferenzen  \nNicht -medikament\u00f6se Therapie ; Rehabilitation  4 Telefonkonferenzen  \nUnterarbeitsgruppe: Respiratorische Insuffizienz  2 Telefonkonferenzen  \nMedikament\u00f6se Therapie  5 Telefonkonferenzen  \nUnterarbeitsgruppe: Darstellung Deeskalation  1 Telefonkonferenz  \nVersorgungskoordination  1 Telefonkonferenz  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  16 \n  \n  \n Konsentierung  \nDie Empfehlungen und Abbildungen wurden in der Konsensuskonferenz ( 17.02.2020) sowie in einem formalisier-\nten, schriftlichen Abstimmungsverfahren unter Anwendung der Delphi -Technik formal konsentiert. An den Abstim-\nmungsprozessen nahmen die benannten Vertreter *innen der an der Erstellung der NVL beteiligten Fachgesell-\nschaften teil. J eder Fachgesellschaft stand im Abstimmungsverfahren jeweils eine Stimme zur Verf\u00fcgung.  \nBei der Konsensuskonferenz wurden die Empfehlungen mit Hilfe eines nominalen Gruppenprozesses von Frau \nSchaefer und Frau Vader  moderiert. Enthaltungen aufgrund eines In teressenkonfliktes sind im Anhang 1.4 doku-\nmentiert. Der Ablauf des nominalen Gruppenprozesses gestaltete sich wie folgt:  \n\uf0a1 Pr\u00e4sentation der zu konsentierenden Inhalte;  \n\uf0a1 Gelegenheit zu R\u00fcckfragen zum methodischen Vorgehen/inhaltlichen Verst\u00e4ndnis;  \n\uf0a1 Notiz von Stellungnahmen (jeder Teilnehmer f\u00fcr sich);  \n\uf0a1 Registrierung der Stellungnahmen im Einzel -/Umlaufverfahren;  \n\uf0a1 Klarstellung und Begr\u00fcndung alternativer Vorschl\u00e4ge;  \n\uf0a1 Abstimmung \u00fcber Erstentwurf und alle Alternativen.  \nWenn notwendig:  \n\uf0a1 Feststellung von Diskussionspunkten und Dissens;  \n\uf0a1 Debattieren und Diskutieren;  \n\uf0a1 endg\u00fcltige Abstimmung.  \nDas elektronisch basierte, formalisierte, schriftliche Abstimmung sverfahren unter Anwendung der Delphi -Technik \nwurde wie folgt durchgef\u00fchrt:  \n\uf0a1 Pr\u00e4sentation der zu konsentierenden Empfehlungen und Abbildungen  in einer schriftlichen Umfrage;  \n\uf0a1 schriftliche Abstimmung der Empfehlungen/Abbildungen . \nNach der Konsensuskonferenz w urde eine zus\u00e4tzliche schriftliche Abstimmung durchgef\u00fchrt. Es wurden die neu \nerarbeiteten Empfehlungen des Kapitels \u201eAtmungsunterst\u00fctzende Ma\u00dfnahmen bei chronisch respiratorischer In-\nsuffizienz\u201c schriftlich abgestimmt. Au\u00dferdem wurde eine neue Empfehlung zum Diagnostik-Algorithmus  (aus Kon-\nsistenzgr\u00fcnden) sowie die Darstellung der medikament\u00f6sen Deeskalation im Algorithmus \u201eMedikament\u00f6se Lang-\nzeitbehandlung\u201c und als neue Empfehlung abgestimmt.  \nMit den oben beschriebenen Vorgehensweisen wurde zur Formulierung aller Empfehlungen ein Konsens erreicht. \nGem\u00e4\u00df dem Methodenreport NVL [8] stehen den Mitgliedern der Leitliniengruppe bei Nichterreichen eines Kon-\nsenses verschiedene Optionen, wie z.  B. das Einbringen eines Sondervotums zur Verf\u00fcgung.  \nTabelle 5: Feststellung der Konse nsst\u00e4rke \nKlassifikation der Konsensst\u00e4rke  \nstarker Konsens  Zustimmung von > 95% der Teilnehmer *innen  \nKonsens  Zustimmung von > 75 -95% der Teilnehmer *innen  \nmehrheitliche Zustimmung  Zustimmung von > 50 -75% der Teilnehmer *innen  \nkein Konsens  Zustimmung von < 50% der Teilnehmer *innen  \nAlle Texte, Tabellen, Abbildungen und Patientenbl\u00e4tter wurden w\u00e4hrend der Erstellung der Leitlinie in der Leitlini-engruppe abgestimmt. Die Vorst\u00e4nde aller beteiligten Fachges ellschaften und Organisationen werden  vor der Ver-\n\u00f6ffentlichung der NVL um Zustimmung gebeten und im Impressum als Mitherausgeber aufgef\u00fchrt.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  17 \n 9 Externe  Begutachtung \nNach Fertigstellung der inhaltlichen Arbeiten an der 2. Auflage der NVL wurde die Konsultationsfassung auf der \nInternetseite des NVL -Programms (www.leitlinien.de ) \u00f6ffentlich zug\u00e4nglich f\u00fcr sechs Wochen  (vom 08.10.2020 bis \n19.11.2020)  zur Kommentierung bereitgestellt. Der Beginn dieses externen Begutachtungsverfahrens w urde auf \nden Internetseiten des \u00c4ZQ und \u00fcber eine Pressemitteilung an Presseverteiler bekanntgegeben.  \nEingehende Kommentare wurden durch das \u00c4ZQ gesammelt, aufbereitet und an die Leitliniengruppe weitergeleitet. In einer Telefonkonferenz  am 18.01.2021 und im schriftlichen Umlauf wu rden die eingegangenen Komment are \ndiskutiert und daraus resultierende \u00c4nderungen beraten. Inhaltliche \u00c4nderungen an den Empfehlungen ergaben sich nicht. Eingegangene Kommentare und entsprechende Beschl\u00fcsse mit ihren jeweiligen Begr\u00fcndungen sind im Anhang zu finden. Literatur, die daraufhin erg\u00e4nzend in die Leitlinie aufgenommen w urde,  ist bei der Recherchestra-\ntegie bzw. in den Evidenztabellen der jeweiligen Kapitel zu finden.  \n10 Redaktionelle  Unabh\u00e4ngigkeit  \nDie Erstellung der NVL COPD  erfolgt in redaktioneller Unabh\u00e4ngigkeit von den finanzierenden Tr\u00e4gern des NVL -\nProgramms. Diese finanzieren die Koordination und methodische Unterst\u00fctzung der Entwicklung der NVL. Die im Rahmen der Treffen anfallenden Reisekosten werden von den beteiligten Fachgesellschaften/Organisationen ge-tragen, die Leitlinienautor *innen arbeiten ehrenamtlich und ohne Honorar.  \nBei der Erstellung der NVL COPD  kommen folgende sch\u00fctzende Faktoren zur Anwendung, die den Einfluss m\u00f6g-\nlicher Interessenkonflikte reduzieren:  \n\uf0a1 unabh\u00e4ngige Koordination der  Leitlinie (\u00c4ZQ);  \n\uf0a1 unabh\u00e4ngige Moderation (AWMF, \u00c4ZQ);  \n\uf0a1 unabh\u00e4ngige Leitung von Arbeitsgruppen (\u00c4ZQ);  \n\uf0a1 Evidenzaufbereitung durch Methodiker innen  (\u00c4ZQ); \n\uf0a1 Diskussion der Interessenerkl\u00e4rung und des Umgangs mit Interessenkonflikten in der Auftaktsitzung und Kon-\nsensuskonferenz;  \n\uf0a1 multidisziplin\u00e4re Leitliniengruppe, bei Abstimmungen hat jede Fachgesellschaft/Organisation eine Stimme;  \n\uf0a1 strukturierter Konsensprozess;  \n\uf0a1 festgeschriebene Leitlinienmethodik (von der Evidenz zur Empfehlung bzw. ein stru kturiertes Vorgehen bei \nrein konsensbasierten Empfehlungen). \nUmgang mit Interessenkonflikten  \nDie Mitglieder der Leitliniengruppe haben etwaige Interessen im Zusammenhang mit der Erstellung der NVL COPD  \nzu Beginn schriftlich erkl\u00e4rt und vor der Konsensuskonferenz aktualisiert (Formular siehe Anhang 1.1). Diese sind \nim Anhang 1.2 tabellarisch zusammengefasst. Die vollst\u00e4ndigen Erkl\u00e4rungen sind im \u00c4ZQ hinterlegt. Interessen-\nkonflikte (IK) wurden im Rahmen der Diskussion der Leitliniengruppe sowohl in der Auftaktsitzung als auch in der Konsensuskonferenz offen thematisiert. Dabei fand die von der AWMF empfohlene Vorgehensweise zum Umgang mit Interessenkonflikten Anwendung [7\n\u2060,9 \u2060,28]. Vor der Konsensuskonferenz wurden die IK von einem Gremium \nbewertet (CS/\u00c4ZQ und MN/AWMF). Den Teilnehmenden der Konsensuskonferenz lagen w\u00e4hrend der Konferenz \nListen vor, auf denen vermerkt war , wie die Interessenkonflikte der einzelnen Teilnehmer durch AWMF und \u00c4ZQ \nbewert et wurden, siehe auch Anhang 1.3. Ausschl\u00fcsse aus der Leitlini engruppe wurden als nicht erforderlich an-\ngesehen.  \nHatte ein e Expert in beziehungsweise ein Experte im aktuellen oder in einem der drei vorausgegangenen Jahre \nHonorare von der Industrie f\u00fcr Vortr\u00e4ge, Berater - oder Gutachtert\u00e4tigkeit oder Forschungsvorhaben angegeben, \nauch wenn diese keinen Themenbezug zur Leitlinie haben, jedoch insbesondere b ei Verbindungen zu Herstellern \noder Firmen, die Medikamente zur Tabakentw\u00f6hnung bzw. Bronchodilatatoren und/oder Inhalationsger\u00e4te herstel-\nlen, wurden die Interessen als \u201emoderat\u201c eingesch\u00e4tzt mit der Folge der Enthaltung bei themenbezogenen Abstim-\nmungen.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  18 \n  \n  \n Enthaltungen bei empfehlungsrelevanten Interessenkonflikten bei nicht -finanziellen Kategorien wurden nahegelegt. \nWenn bezahlte Vortragst\u00e4tigkeit einen geringen Finanzrahmen von 1 000 \u20ac insgesamt nicht \u00fcberschritt und keine \nweiteren finanziellen Verbindungen vorlagen,  wurde dies als geringer IK bewertet. In diesem Falle wurden gem\u00e4\u00df \nAWMF -Regel Enthaltungen nicht als erforderlich angesehen.   \nLag bei dem  oder der Erstbenannten der Fachgesellschaft ein Interessenkonflikt vor, wurde die Empfehlung vom \njeweiligen Vertreter \u2013  sofern anwesend und ohne Interessenkonflikte \u2013  abgestimmt.  \nEnthaltungen aufgrund eines Interessenkonfliktes in der Konsensuskonferenz  und in der elektronischen Abstim-\nmung  sind im  Anhang 1.4  dokumentiert.  \n11 G\u00fcltigkeit  und Aktualisierung  \nG\u00fcltigkeitsdauer und Fortschreibung  \nDie 2. Auflage der NVL COPD wurde am 25. Juni 2 021 durch die Tr\u00e4ger des NVL-Programms verabschiedet . Die \nG\u00fcltigkeit der NVL ist in der aktuellen Fassung der Leitlinie festgelegt. Eine f\u00fcnfj\u00e4hrliche \u00dcberarbeitung und Her-\nausgabe \u2013 gemessen ab dem Zeitraum der schriftlichen Publikation \u2013 wird angestrebt.  \nVerantwortlichkeit f\u00fcr die Aktualisierung  \nF\u00fcr die Aktualisierung ist die NVL-Redakti on im \u00c4ZQ verantwortlich. Im Falle neuer relevanter Erkenntnisse, welche \ndie \u00dcberarbeitung der NVL erforderlich machen, erfolgt eine kurzfristige Aktualisierung und Information der \u00d6ffent-\nlichkeit \u00fcber die Internetseite des Programms f\u00fcr Nationale VersorgungsLeitlinien ( www.leitlinien.de/copd) und die \nInternetseite des Leitlinienregisters der AWMF ( www.awmf.org/leitlinien/detail/ll/nvl -003.html ). \n\u00c4nderungsprotokoll  \nNotwendige Korrekturen, \u00c4nderungen oder redaktionelle \u00dcberarbeitungen an den konsentierten und im Internet ver\u00f6ffentlichten Texten werden im Impressum der Langfassung protokolliert. Um \u00c4nderungen transparent und nachvollziehbar zu ma chen, stehen im Archiv auf der Internetseite alle Versionen der NVL zur Verf\u00fcgung:  \nwww.leitlinien.de/nvl/copd/archiv . \n12 Anwendung  und Verbreitung  \n12.1 Materialien und Formate  \nLangfassung  \nDie Langfassung wi rd als Druckversion (PDF -Format) herausgegeben und kann auf den Internetseiten des NVL-\nProgramms kostenlos heruntergeladen werden. Zus\u00e4tzlich steht sie dort auch im html -Format zur Verf\u00fcgung. Hier-\ndurch ist die NVL auf mobilen Endger\u00e4ten sehr gut lesbar. Di e Empfehlungen werden als \u00dcbersicht dargestellt, so \ndass der Nutzer von der Empfehlung zum Hintergrundtext und weiter zur Evidenz navigieren kann. Technisch be-\ndingt kann die Darstellung der html -Version von der PDF -Version abweichen \u2013  die Inhalte bleiben d ie gleichen.  \nKurzfassung  \nDie Kurzfassung besteht aus den Empfehlungen, wichtigen Tabellen und den Algorithmen der Langfassung. Nach \nder Ver\u00f6ffentlichung der Langfassung wird sie redaktionell im \u00c4ZQ erstellt und ist als Druckversion auf den Inter-\nnetseiten des NVL -Programms frei verf\u00fcgbar.  \nFlyer und Foliensatz  \nZur besseren Verbreitung und Information von \u00c4rzten wurde ein DIN -A5-Flyer mit den wichtigsten \u00c4nderungen und \nKernbotschaften der NVL erstellt. Der Flyer kann kosteng\u00fcnstig in gro\u00dfem Umfang gedruckt und z.  B. bei Kongres-\nsen oder Aktionstagen der Fachgesellschaften verteilt werden. Erg\u00e4nzend wurde ein Foliensatz erstellt. Dieser \nkann f\u00fcr Vortr\u00e4ge und Pr\u00e4sentationen der Leitlinienautor *innen auf Kongressen und/oder Veranstaltungen adaptiert \nund genutzt bzw. kostenlos von den Internetseiten heruntergeladen werden.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  19 \n  \n  \n Patientenbl\u00e4tter  \nZur Implementierung der Empfehlungen der NVL bei spezifischen Entscheidungs - oder Informationssituationen \nwurden Patientenbl\u00e4tter erstellt . Diese sollen behandelnde \u00c4r zt*innen bei der Beratung der Patient *innen unterst\u00fct-\nzen und zur gemeinsamen Entscheidungsfindung ( Shared-Decision -Making) beitragen.  \nThemen f\u00fcr spezifische Entscheidungs - oder Informationssituationen wurden w\u00e4hrend des gesamten Leitlinienpro-\nzess gesammelt . Dabei wurden folgende Kriterien (modifiziert nach GKE -Manual der AWMF [29] ) angewendet:  \n\uf0a1 Hinweise auf ein Versorgungsproblem;  \n\uf0a1 Umsetzbarkeit in der Praxis, M\u00f6glichkeit der Beeinflussung in der Praxis;  \n\uf0a1 geringes Risiko f\u00fcr Fehlsteuerung;  \n\uf0a1 erh\u00f6hter Kommunikationsbedarf mit Patient*innen.  \nZu diesen Themen wurden passende Patientenbl\u00e4tter gem\u00e4\u00df den Anforderungen der \u201eGuten Praxis Gesundheitsin-\nformation\u201c [30] entwickelt. Die Patientenbl\u00e4tter wurden mit der Leitliniengruppe abgestimmt und werden als integ-\nraler Bestandteil der NVL COPD ver\u00f6ffentlicht. Evidenzgrundlage ist die Evidenzaufbereitung der NVL COPD (siehe Tabelle 6: Evidenzgrundlage der Patientenbl\u00e4tter ). \nTabelle 6: Evidenzgrundlage der Patientenbl\u00e4tter  \nCOPD: Information f\u00fcr Angeh\u00f6rige  Literatur  \nTabelle 5: Risikofaktoren f\u00fcr die Entwicklung einer COPD  [31] \nEmpfehlung 3-1  [32 \u2060,33] \nEmpfehlung 5-1 und Abbildung 4: Medikament\u00f6se Langzeitbehandlung  [34 \u2060\u201351] \nEmpfehlungen 5-4 - 5-7 [52 \u2060\u201355], Expert *innenkonsens  \nEmpfehlungen 4-1 - 4-9; 6-3 [56 \u2060\u201388] \nEmpfehlungen 4-15; 4-18 Expert *innenkonsens  \nCOPD: Meine wichtigsten Medikamente  Literatur  \nEmpfehlung 5-1 und Abbildung 4: Medikament\u00f6se Langzeitbehandlung  [34 \u2060\u201351] \nEmpfehlungen 5-4 - 5-7 [52 \u2060\u201355] \nEmpfehlung 5-8  [89 \u2060\u201391] \nCOPD: Warum Bewegung wichtig ist  Literatur  \nEmpfehlungen 4-1 - 4-5; 6-3 [56 \u2060\u201368] \nCOPD: Brauche ich besondere Impfungen?  Literatur  \nEmpfehlung 5-9  [92 \u2060\u201394] \nCOPD: Spray, Pulver oder Vernebler \u2013  Welche Unterschiede gibt es?  Literatur  \nEmpfehlungen 5-4; 5 -7; 7-11 Expert *innenkonsens  \nCOPD: Was tun  bei unbekanntem Inhalier -Ger\u00e4t  Literatur  \nEmpfehlungen 5-6; 7-9 - 7-11 [53 \u2060\u201355]; Expert *innenkonsens  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  20 \n  \n  \n COPD: Brauche ich Kortison?  Literatur  \nEmpfehlung 5-1 und Abbildung 4: Medikament\u00f6se Langzeitbehandlung  [39 \u2060\u201350 \u2060,95 \u2060\u201399] \nCOPD: Warum allt\u00e4gliche und seelische Belastungen wichtig werden \nk\u00f6nnen  Literatur  \nPunkt 2.5.2 Angst und Depression  [100 \u2060\u2013103] \nPunkt 4.7.1 Psychosomatische Einsch\u00e4tzung  [104 \u2060\u2013106] \nCOPD: Warum Rauchstopp  wichtig ist  Literatur  \nTabelle 5: Risikofaktoren f\u00fcr die Entwicklung einer COPD  [31] [31] \nEmpfehlung 3-1 [17 \u2060,32 \u2060,33 \u2060,107 \u2060,108] ; \nExpert *innenkonsens  \nEmpfehlungen 3-3;  3-4 [15 \u2060,109] ; Expert *innenkonsens  \nCOPD: Soll ich an einer Schulung teilnehmen?  Literatur  \nEmpfehlung 4-10 [110 \u2060,111]  \nEmpfehlung 4-11 [13]; Expert*innenkonsens  \nPatientenleitl inie \nIm Anschluss an die Ver\u00f6ffentlichung der Langfassung wird die Patientenleitlinie COPD  aktualisiert. Die Patienten-\nleitlinie \u00fcbersetzt die \u00e4rztliche Leitlinie in eine allgemeinverst\u00e4ndliche Sprache und stellt umfassend alles Wesent-\nliche zum Krankheitsbi ld COPD  dar. Die Patientenleitlinie wird vom \u00c4ZQ mit dem Patientenvertreter und Mitgliedern \nder Leitliniengruppe gem\u00e4\u00df einer festgeschriebenen Methodik (siehe www.patienten -information.de/medien/me-\nthodik/erstellung-pll -mr-nvl-ol-2aufl -vers1.pdf ) erstellt und auf den Seiten des \u00c4ZQ ver\u00f6ffentlicht ( www.leitli-\nnien.de/copd  bzw. www.patienten-information.de/uebersicht/copd).  \nKurzinformationen  \nIm Anschluss an die Ver\u00f6ffentlichung der Langfassung w ird die Kurzinformation f\u00fcr Patient *innen aktualisiert. In \nder Kurzinformation werden die wichtigsten Informationen zum Krankheitsbild \u00fcbersichtlich auf zwei DIN -A4-Seiten \nzusammengefasst. Die Kurzinformationen werden im \u00c4ZQ nach einer festgeschriebenen Methodik (siehe www.pa-\ntienten-information.de/medien/methodik/aezq- kip-patienten- methodik -aufl3.pdf ) erstellt und in den Sprachen \nDeutsch, Englisch, Franz\u00f6sisch, Spanisch, Russisch, T\u00fcrkisch und Arabisch herausgegeben (www.leitli-\nnien.de/copd  bzw. www.patienten-information.de/uebersicht/copd) . \n12.2 Implementierung und \u00d6ffentlichkeitsarbeit  \nZur Verbreitung und Implementierung gibt es folgende Ma\u00dfnahmen:  \n\uf0a1 Verbreitung \u00fcber die Publikationsorgane und Kongressveranstaltungen der kooperierenden Fachgesellschaf-\nten und Organisationen (z.  B. Verteilung der Flyer bei Kongressen);  \n\uf0a1 Informationen an Einrichtungen der gemeinsamen Selbstverwaltung und an Berufsorganisationen;  \n\uf0a1 Integration der NVL-Inhalte in bestehende Qualit\u00e4tsmanagementsysteme, z. B. QEP\u00ae ( www.kbv.de/qep) oder \nKTQ\u00ae ( www.ktq.de ); \n\uf0a1 Unterst\u00fctzung d er Verbreitung der Patientenleitlinie durch die Patient *innenorganisationen ( www.patienten-\ninformation.de/ueber -uns/wie -wir-arbeiten#selbsthilfe).  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  21 \n  \n  \n 13 Evaluation  \nEine Evaluation der NVL  soll im Hinblick auf die Ziele des NVL-Programms erfolgen:  \n\uf0a1 Verbreitung von evidenzbasierten und formal konsentierten \u00e4rztlichen Empfehlungen zu versorgungsbereichs-\n\u00fcbergreifenden Vorgehensweisen f\u00fcr spezielle Erkrankungen;  \n\uf0a1 Verbreitung von NVL-basierten Qualit\u00e4tsindikatoren, Patientenleitlinien und weiteren Patientenmaterialien;  \n\uf0a1 m\u00f6glichst fl\u00e4chendeckende Implementierung der NVL-Empfehlungen;  \n\uf0a1 Ber\u00fccksichtigung von NVL-Empfehlungen durch insbesondere strukturierte  Behandlungsprogramme (DMP) \nsowie durch Vertr\u00e4ge zur Integrierten Versorgung (IV);  \n\uf0a1 Ber\u00fccksichtigung von NVL-Empfehlungen in der \u00e4rztlichen Aus -, Fort - und Weiterbildung und in Qualit\u00e4tsma-\nnagementsystemen.  \n  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  22 \n  \n  \n Tabellenverzeichnis  \nTabelle 1:  Vertreter*innen der Fachgesellschaften/Organisationen ............................................. 7 \nTabelle 2:  Methodik, Redaktion und Moderation  ........................................................................ 11 \nTabelle 3:  Schema zur Graduierung von NVL- Empfehlungen, modifiziert nach [7,9]  ................ 15 \nTabelle 4:  Verfahren der Arbeitsgruppen, 2. Auflage  .................................................................  15 \nTabelle 5:  Feststellung der Konsensst\u00e4rke ................................................................................. 16 \nTabelle 6:  Evidenzgrundlage der Patientenbl\u00e4tter  ...................................................................... 19 \n \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  23 \n  \n  \n Anhang  \nAnhang 1  Darstellung von Interessenkonflikten  \nAnhang 1.1  Formular zur Darlegung von Interessenkonflikten  \n \n \nNVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  24 \n  \n  \n  \nNVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  25 \n  \n  \n  \nNVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  26 \n  \n  \n  \nNVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  27 \n  \n  \n  \nNVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  28 \n  \n  \n  \nNVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  29 \n  \n  \n Anhang 1.2  \u00dcbersicht Interessenkonflikterkl\u00e4rungen  \nNr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n Berater -/Gut-\nachtert\u00e4tigkeit  Mitarbeit in ei-\nnem Wissen-\nschaftlichen \nBeirat (advi-\nsory board)  Vortrags -/ \noder Schu-\nlungst\u00e4tigkeit  Forschungs -\nvorha-\nben/Durchf\u00fch-\nrung klini-\nscher Studien  Eigent\u00fcmerin-\nteressen (Pa-\ntent, Urheber-\nrecht, Aktien-\nbesitz)  Mitglied-\nschaft/Funk-\ntion in Interes-\nsenverb\u00e4nden  Schwerpunkte \nwissenschaft-\nlicher T\u00e4tigkei-\nten, Publikati-\nonen  Schwerpunkte \nklinischer T\u00e4-\ntigkeiten  Federf\u00fchrende \nBeteiligung an \nFortbildungen \n/Ausbildungs -\ninstituten  Enge pers\u00f6nli-\nche Beziehun-\ngen zu einem \nVertre tungs-\nberechtigten \neines Unter-\nnehmens der \nGesundheits-\nwirtschaft  Sehen Sie an-\ndere Aspekte \noder Um-\nst\u00e4nde, die \nvon Dritten als \neinschr\u00e4nkend \nin Bezug auf \nIhre Obje ktivi-\nt\u00e4t oder Unab-\nh\u00e4ngigkeit \nwahrgenom-\nmen werden \nk\u00f6nnten?  Gegenw\u00e4rtiger \nArbeitgeber \nund Funktion   Fr\u00fchere Arbeit-\ngeber und \nFunktion (im \nZeitraum der \nErkl\u00e4rung)  \nAndreas, Prof. \nDr. med. \nStefan  Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Deutsche For-\nschungsge-\nmeinschaft  \n Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Boehringer; \nkontinuierlich; \nHonorar; per-\ns\u00f6nlich  \n- GSK; kontinu-\nierlich; Honorar; \npers\u00f6nlich  \n- Novartis; kon-\ntinuierlich; Ho-\nnorar; pers\u00f6n-\nlich \n Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- AstraZeneca; \n2017; Honorar; \npers\u00f6nlich  \n- Boehringer \nIngelheim; kon-\ntinuierlich; Ho-\nnorar ; pers\u00f6n-\nlich \n- Chiesi; 2017; \nHonorar; per-\ns\u00f6nlich  \n- GSK; kontinu-\nierlich; Honorar; \npers\u00f6nlich  \n- Novartis; kon-\ntinuierlich; Ho-\nnorar; pers\u00f6n-\nlich \n- Roche; ko nti-\nnuierlich; Hono-\nrar; pers\u00f6nlich  Keine Keine Themenbezug \nzur Leitlinie:  \n- Deutsche Ge-\nsellschaft \nPneumologie; \nkontinuierlich  \n- Lungenstif-\ntung; kontinu-\nierlich  \n- Deut. Gesell \nSchlafmed.; \nkontinuierlich  \n- Hess. Onkolo-\ngiegesellschaft; \nkontinuierlich  \n- Aktionsb \u00fcnd-\nnis Nichtrau-\ncherschutz; \nkontinuierlich  \n \nMarburger \nBund; kontinu-\nierlich  \n- Fellow DZL \n(Deutsches \nZentrum Lun-\ngenforschung)  Themenbezug \nzur Leitlinie:  \n- COPD; konti-\nnuierlich  \n- Kardiopulmo-\nnale Interak-\ntion; kontinuier-\nlich \n- Tabakentw\u00f6h-\nnung; kontinu-\nierlich  - Pneumologie  \n- COPD  \n- Kardiopulmo-\nnale Interaktion  - Vorlesungen \nUniversit\u00e4tsme-\ndizin G\u00f6ttingen  Keine Keine Lungenfachkli-\nnik Immenhau-\nsen und Uni-\nversit\u00e4tsmedi-\nzin G\u00f6ttingen; \n\u00c4rztlicher Leiter   \nBatra, Prof. Dr. \nAnil  Keine Keine Themenbezug \nzur Leitlinie \n(Tabakentw\u00f6h-\nnung):  \n- Forum f. Med. \nFortbildungen; \n2016- 2019; Ho-\nnorar; pers\u00f6n-\nlich \n \nThemenbezug \nzur Leitlinie Themenbezug \nzur Leitlinie \n(Studie zur Ta-\nbakentw\u00f6h-\nnung):  \n- Deutsche \nKrebs-\nhilfe;2016-\n2019; Drittmit-\ntel; Institution  \n \n Keine Themenbezug \nzur Leitlinie:  \n- Wissenschaft-\nliche Aktions-\nkreis Tabakent-\nw\u00f6hnung(WAT) \ne. V.; schon vor \n2016  \n- DG-Sucht; \nschon vor 2016  \n- DG-Suchtme-\ndizin; schon vor Themenbezug \nzur Leitlinie:  \n-Tabakentw\u00f6h-\nnung; schon \nvor 2016  \n- Grundlage der \nTabakabh\u00e4n-\ngigkeit; schon \nvor 2016  \n- Ganz allge-\nmein: Suchtfor-\nschung und Themenbezug \nzur Leitlinie:  \n- Leitung der \nSektion Sucht-\nmedizin und \nSuchtfor-\nschung; seit \n2008  Themenbezug \nzur Leitlinie:  \n- Curriculum \nTabakabh\u00e4n-\ngigkeit der Bun-\ndes\u00e4rztekam-\nmer; schon vor \n2016  \n- Curriculum \nVerhaltensthe-\nrapie; schon \nvor 2016  Keine \"Klageinit iative \nTabakentw\u00f6h-\nnung\": Finan-\nzierung der Ta-\nbakentw\u00f6h-\nnung soll von \nKassen \u00fcber-\nnommen wer-\nden; \nEigenes Rau-\ncherentw\u00f6h-Universit\u00e4tskli-\nnik T\u00fcbingen; \nStellvertreten-\nder \u00c4rztlicher \nDirektor    NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  30 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n(Curriculum \nTabak):  \n- \u00c4rztekam-\nmern; 2016-\n2019; Honorar;  \npers\u00f6nlich  \n- Wissenstrans-\nfer; 2016- 2018; \nHonorar;  per-\ns\u00f6nlich  \n- Deutsche \nPsycholo gen \nAkademie; \n2016- 2019; Ho-\nnorar;  pers\u00f6n-\nlich Themenbezug \nzur Leitlinie \n(Entwicklung \nIRIS Bera-\ntungsplattform \nTabak):  \n- BZgA; 2016 -\n2019; Drit tmit-\ntel; Institution  \n \nThemenbezug \nzur Leitlinie \n(Entwicklung \nCSI Bera-\ntungsplattform \nTabak):  \n- BMBF; 2016 -\n2019; Drittmit-\ntel; Institution  2016  \n- DGPPN; \nschon vor 2016  Suchttherapie; \nschon vor 2016  nungspro-\ngramm \"Nicht-\nraucherin 6 \nWochen\" mit \nSchulungen \nvon Teilneh-\nmern und eige-\nnem Manual  \nBausewein, \nProf. Dr. med. \nClaudia, PhD, \nMSc Themenbezug \nzur Leitlinie \n(S3 LL Pallia-\ntivmedizin):  \n- Deutsche \nKrebshilfe; seit \n2012; Drittmit-\ntel; institutionell  Keine  Themenbezug \nzur Leitlinie:  \n- Thema: Atem-\nnot; Bayer \nHealthcare; \n10/2015; Hono-\nrar; pers\u00f6nlich  \n- Thema: Fort-\nbildungen zu \nS3 LL Palliativ-\nmedizin; Natio-\nnale Gesund-\nheitsakademie; \nseit 2015; Ho-\nnorar; pers\u00f6n-\nlich \n- diverse The-\nmen; diverse \nHospizvereine, \nKrankenh\u00e4u-\nser; seit 2012; \nHonorar; per-\ns\u00f6nlich  \n- Thema: Pallia-\ntivmedizin bei \nLungenerkran-\nkungen; Med \nUpdate GmbH; \n2016; Honorar; \npers\u00f6nlich  Themenbezug \nzur Leitlinie:  \n- Thema:  \nAtemnot; BMBF \n(2x); seit 2014; \nForschungsf\u00f6r-\nderung; institu-\ntionell  \n- Thema: Arz-\nneimittelinfor-\nmation; Dr. Au-\ngust und Anni -\nLesm\u00fcllerstif-\ntung; For-\nschungsf\u00f6rde-\nrung; institutio-\nnell \n- Thema: Kom-\nplexit\u00e4t in der \nPalliativmedi-\nzin; Dt. Stifter-\nverband; seit \n2014; For-\nschungsf\u00f6rde-\nrung; institutio-\nnell \n-  Mitwirkung an \neiner EU -gef\u00f6r-\nderten Arznei-\nmittelstudie zur \nTestung von \nMirtazapin bei \nAtemnot (F\u00f6r-\nderung von \n2019 -2022)  Keine  Themenbezug \nzur Leitlinie:  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPalliativmedi-\nzin, Co -Leitung \nder S3 LL Palli-\nativmedizin f\u00fcr \nPatienten mit \nnicht heilbaren \nKrebserkran-\nkungen; seit \n2012  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPalliativmedi-\nzin, Sprecherin \nder AG LL; seit \n2006  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPalliativmedi-\nzin, Sprecherin \nder Landesver-\ntretung Bayern; \nseit 2014; \nSchriftf\u00fchrerin, \nseit 2018  Themenbezug \nzur Leitlinie:  \n- Palliativmedi-\nzin f\u00fcr Patien-\nten mit nicht -\nonkologischen \nErkrankungen; \nseit 2005  \n- Management \nvon Atemnot \nbei Patienten \nmit fortgeschrit-\ntenen Erkran-\nkungen; seit \n2005  Themenbezug \nzur Leitlinie:  \n- Palliativmedi-\nzinische Ver-\nsorgung von \nPatienten mit \nfortgeschritte-\nnen malignen \nund nicht -ma-\nlignen Erkran-\nkungen; seit 20 \nJahren  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Leiterin der \nChristophorus \nAkademie f\u00fcr \nPalliativmedi-\nzin, Palliativ-\npflege und \nHospizarbeit \nder Klinik f\u00fcr \nPalliativmedi-\nzin; seit 2012  \n- Leitung von \nKursen zum Er-\nwerb der Zu-\nsatzbezeich-\nnung Palliativ-\nmedizin und \nanderen Fort-\nbildungen zu \nPalliativmedi-\nzin; seit 2012  Keine  Keine  Klinikum der \nUniversit\u00e4t \nM\u00fcnchen; Kli-\nnikdirektorin, \nLehrstuhlinha-\nberin  Keine  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  31 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nCri\u00e9e, Prof. Dr. \nmed. C. -P. Keine Themenbezug \nzur Leitlinie  \n(Arzneimittel):  \n- Chiesi; seit \n2015; Honorar; \npers\u00f6nlich  \n- B\u00f6hringer; \nseit 2015; Ho-\nnorar; pers\u00f6n-\nlich \n- Novartis; seit \n2015; Honorar; \npers\u00f6nlich  Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Berlin -Che-\nmie; seit 2015; \nHonorar; per-\ns\u00f6nlich  \n- B\u00f6hringer; \nseit 2015; Ho-\nnorar; pers\u00f6n-\nlich \n- Novartis; seit \n2015; H onorar; \npers\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Diagnostik):   \n- Chiesi; 2017; \nHonorar; per-\ns\u00f6nlich  \n- TEVA; 2016 -\n2017; Honorar; \npers\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Beatmung):  \n- Res-Med; \n2015- 2017; Ho-\nnorar; pers\u00f6n-\nlich Keine  Keine  Themenbezug \nzur Leitlinie:  \n- Deutsche \nAtemwegsliga; \nVorsitzender  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPneumologie + \nBeatmungsme-\ndizin; Mitglied  \n- Deutsche in-\nterdisziplin\u00e4re \nGesellschaft f\u00fcr \nau\u00dferklinische \nBeatmung; Mit-\nglied  Themenbezug \nzur Leitlinie:  \n- Mitglied der \nLeitlinien-\ngruppe der \nAtemw egsliga \nund DGB zu \nden Leitlinien \nAsthma und \nCOPD  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Chefarzt einer \npneumolog. \nAbteilung Keine  Keine  Keine  Evangelisches \nKrankenhaus \nG\u00f6ttinen -We-\nende; \u00e4rztliche \nT\u00e4tigkeiten  Keine  \nDalhoff, Prof. \nDr. med. Klaus  Keine Keine  Themenbezug \nzur Leitlinie:  \n- Thema: Anti-\nbiotika; Bayer -\nVital; 10/2017; \nHonorar; per-\ns\u00f6nlich  \n- Thema: Aller-\ngische Alveoli-\ntis; Gilead; \n12/2015; Hono-\nrar; institutionell  \n \nThemenbezug \nzur Leitlinie \n(Impfungen):  \n- Novart is; \n11/2014; Hono-\nrar; pers\u00f6nlich  \n- Pfizer; \n05/2014; Hono-\nrar; pers\u00f6nlich  Themenbezug \nzur Leitlinie:  \n- Thema: \nPneumol. On-\nkologie/Infektio-\nlogie; Multicen-\nterstudien als \nLeiter des Stu-\ndienzentrums \nder eigenen Kli-\nnik; Keine per-\ns\u00f6nliche Zu-\nwendung  Keine  Themenbezu g \nzur Leitlinie:  \n- DGP  \n- Akd\u00c4 \n- ERS (Eur Re-\nspir Society)  \n- ATS (Am Tho-\nraeie Society)  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- DGIM  \n- DGI Kein Themen-\nbezug zur Leit-\nlinie:  \n- Pneumonie  \n- Deutsches \nZentrum f\u00fcr \nLungenfor-\nschung (DZL)  - Pneumologie  \n- Infektiologie  Keine  Keine  Keine  UKSH; Stv. Kli-\nnikdirektor    NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  32 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nde Roux, Dr. \nmed. Andr\u00e9s    Themenbezug \nzur Leitlinie:  \n- Boehringer; \n2016; COPD; \nHonorar; per-\ns\u00f6nlich  Themenbezug \nzur Leitlinie:  \n- Mundipharma; \n2016; Produkte \nPneumologie; \nHonorar; per-\ns\u00f6nlich  \n- Astra; 2016; \nCOPD ; Hono-\nrar; pers\u00f6nlich  \n- Novartis; \n2015; COPD; \nHonorar; per-\ns\u00f6nlich  \n- Berlin Che-\nmie; \n2015+2016; \nAsthma, \nCOPD; Hono-\nrar; pers\u00f6nlich  \n- Bayer; 2016; \nBronchiekas-\nten; Honorar; \npers\u00f6nlich  Themenbezug \nzur Leitlinie:   \n- Bayer; seit \n2010; Finanzie-\nrung des Prog-\nnosisregisters; \nDrittmittel; \nPrognosis, \nBronchiekas-\nten, Register ( \nich bin Mitglied \nder Steue-\nrungsgruppe, \nAntr\u00e4ge wur-\nden \u00fcber die \nMHH Hannover \ngestellt)  Keine  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Vorstandmit-\nglied im BdP; \n2017- 2018  \n- Vorsitzender \ndes LvBB (Ber-\nlin-Branden-\nburg); seit 2/18  \n-Berufs -ver-\nbandsvorsit-\nzender der Ber-\nlin-Brandenbur-\nger Pneumolo-\ngen e. V.; seit \n2016  \nKV - Berlin; Mit-\nglied der Ver-\ntreterversamm-\nlung, seit 2018  Themenbezug \nzur Leitlinie:  \n- Schutzimpfun-\ngen, COPD; \nseit 1999  \n- Brochiektasen \n(PROG NOSIS \nREGISTER); \n2017- 2020  Themenbezug \nzur Leitlinie:  \n-Lungenfach-\narzt in der Nie-\nderlassung; seit \n2008  Themenbezug \nzur Leitlinie:  \n- Qualit\u00e4tszirkel \nder Berliner \nPneumologen; \nseit 2016   Keine   Keine  Praxisinhaber; \nChef  Keine  \nDreher, Mi-\nchael Prof. Dr. \nmed.  Keine Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- B\u00f6hringer; \nseit 2014; Ho-\nnorar; pers\u00f6n-\nlich \n- Novartis; seit \n2016; Honorar; \npers\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Beatmung):   \n- Res-Med; seit \n2013; Honorar; \npers\u00f6nlich  \n- Respironics; \nseit 2013; Ho-\nnorar; pers\u00f6n-\nlich Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- B\u00f6hringer; \nseit 2013; Ho-\nnorar; pers\u00f6n-\nlich \n- Novartis; seit \n2013; Honorar; \npers\u00f6nlich  \n Chiesi; seit \n2017; Honorar; \npers\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Beatmung):   \n- Res-Med; seit \n2010; Honor ar;  \npers\u00f6nlich  \n- Respironics; \nseit 2010; per-\ns\u00f6nlich  Themenbezug \nzur Leitlinie \n(Beatmung):  \n- Res-Med; \n2015- 2017; \nDrittmittel; insti-\ntutionell  Keine Themenbezug \nzur Leitlinie:  \n- DGP, Vertre-\nter der DGp in \nder FERS; seit \n2015  \n- Vorstandsmit-\nglied der \nDIGAB; 20 13-\n2017  \n- Secretary der \nGroup 2.02 der \nERS \n- Chair der \nGroup 2.02 der \nERS Themenbezug \nzur Leitlinie:  \n- Nichtinvasive \nBeatmung; seit \n2005  \n- Pathophysio-\nlogie der \nCOPD; seit \n2005  \n- Inhalations-\ntechnik bei \nCOPD; seit \n2017  Keine Keine Keine Keine Uniklinik RWTH \nAachen; Leiter \nder Sektion \nPneumologie  Universit\u00e4tsklini-\nkum Freiburg;  \nAssistenz- , \nFach - und Ober-\narzt der  \nAbteilung f\u00fcr \nPneumologie  \nEggeling, Dr. \nmed. Stephan  Keine Keine  Keine  Keine  Keine  Keine  Keine  Keine  Kein Themen-\nbezug zur Leit-\nlinie:   \n- Leitlinie \nPneumothorax \nD6 TH; 2016 -  \n2018  Keine  Keine  Vivantes \nGmbH; Chef-\narzt Klinik F\u00fcr \nThoraxchirurgie  Keine  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  33 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nFreitag, Chris-\ntiane, B.A.  Keine Keine  Keine  Keine  Keine  Themenbezug \nzur Leitlinie:  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPflegewissen-\nschaft, Mitglied; \n08.2017 bis auf \nweiteres  \nKein Themen-\nbezug zur Leit-\nlinie:  \n- DRK Hamm \nOV Bockum - \nH\u00f6vel, Gemein-\nschaft Bockum - \nH\u00f6vel; 09.1989 \nbis auf weiteres  \n- Ausbilder Sa-\nnit\u00e4tsdienst/ \nErste Hilfe im \nDRK KV \nHamm; \n04.2014 bis auf \nweiteres  \n- Medi zinpro-\nduktbeauf-\ntragte/ Hygie-\nnebeauftragte \nim DRK OV \nBockum H\u00f6vel; \n10.2011 bis auf \nweiteres  \n- Rettungssani-\nt\u00e4terin im DRK; \n07.2007 bis auf \nweiteres  Keine  Themenbezug \nzur Leitlinie:  \n- Gesundheits - \nu. Krankenpfle-\ngerin im UKM \nHerz -u. Thora-\nxchirurgie; \n05.2001 - bis \nauf weiteres  \n- QMB Pflege \nHerz -Thora-\nxchirurgie \nUKM; 03.2012 \nbis auf weiteres  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- Medizinpro-\nduktbeauftragte \nPflege Herz -u. \nThoraxchirurgie  \nUKM; 01.2002 \nbis auf weiteres  \n  Keine  Keine  Keine  Universit\u00e4tskli-\nnikum M\u00fcnster, \nDepartment f\u00fcr \nHerz - Thora-\nxchirurgie; \nStellv. Stations-\nleitung    \nFreitag, Prof. \nDr. med. Mi-\nchael, MPH  Keine Themenbezug \nzur Leitlinie \n(Krankenversi-\ncherung):  \n- DAK Gesund-\nheit; 2007 -aktu-\nell; Honorar; \npers\u00f6nlich  Themenbezug \nzur Leitlinie \n(Fortbildung):  \n- \u00c4rztekammer \nNiedersachsen; \n2015- aktuell; \nHonorar; per-\ns\u00f6nlich  Kein Themen-\nbezug zur Leit-\nlinie:  \n- G-BA (Innova-\ntionsfonds); \n07/2017 -aktu-\nell; Drittmittel; \ninstitutionell  Keine Themenbezug \nzur Leitlinie:  \n- Mitglied der \nSt\u00e4ndigen Leit-\nlinienkommis-\nsion der DE-\nGAM; seit 2007  \n \n- Mitglied beim \nDeutschen \nHaus\u00e4rztever-\nband  - Borreliose, Di-\nabetes, Multi-\nmorbidit\u00e4t  - Allgemeinme-\ndizin/Prim\u00e4rver-\nsorgung  Keine Keine Keine Carl von Os-\nsietzky- Univer-\nsit\u00e4t Oldenburg \n(seit 02/2015); \nUniversit\u00e4tspro-\nfessur f\u00fcr Allge-\nmein medizin  Universit\u00e4tsklini-\nkum Jena (bis \n01/2015); Wiss. \nMitarbeiter  \nFrohnhofen, \nPD Dr. med. \nHelmut  Keine Themenbezug \nzur Leitlinie \n(Osteopo-\nrose):  \n- Amgen; seit \n2012; Honorar; Themenbezug \nzur Leitlinie \n(Osteopo-\nrose):  \n- Amgen; seit \n2012; Honorar; Keine  Bayer AG; per-\ns\u00f6nlich  Keine  Themenbezug \nzur Leitlinie:  \n- Schlafst\u00f6run-\ngen; Schlafap-\nnoe; Demenz; Themenbezug \nzur Leitlinie:  \n- Leitender \nKrankenhaus-\narzt; 1999  Keine  Keine  Keine  Alfried -Krupp -\nKrankenhaus, \nEssen; Abtei-\nlungsarzt Al-\ntersmedizin  Kliniken Essen \nMitte; Direktor \nZentrum f\u00fcr Al-\ntersmedizin  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  34 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \npers\u00f6nlich  \n- Heel; 2017; \nHonorar; per-\ns\u00f6nlich  pers\u00f6nlich  \n- Lilly; 2017; \nHonorar; per-\ns\u00f6nlich  COPD im Alter; \nseit 2007  \nGogol, Dr. \nmed. Manfred  Kein Themen-\nbezug zur Leit-\nlinie:  \n- 7. Altenbe-\nrichtskommis-\nsion; 2015 -16; \nHonorar; per-\ns\u00f6nlich  \n- AOK Baden -\nW\u00fcrttemberg; \n2014- 16; Hono-\nrar; pers\u00f6nlich  \n- IQTiQ; 2017; \nHonorar; per-\ns\u00f6nlich  \n- IQWiG; 2014 -\n16; Honorar; \npers\u00f6nlich  \n- Common-\nwealth Fund; \n2017; Honorar; \npers\u00f6nlich  Keine Themenbezug \nzur Leitlinie:  \n- Novartis 3 x; \n2015- 16; Hono-\nrar; pers\u00f6nlich  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- Pfizer 5 x; \n2014- 17; Hono-\nrar; pers\u00f6nlich  \n- Astellas 1 x; \n2016; Honorar; \npers\u00f6nlich  \n- Osuka 1 x; \n2015;  Honorar; \npers\u00f6nlich  \n- BMS; 2017; \nHonorar; per-\ns\u00f6nlich  Themenbezug \nzur Leitlinie:  \n- COSYCO-\nNET; 2014- 17; \nDrittmittel; insti-\ntutionell  Keine Themenbezug \nzur Leitlinie:  \n- Mitglied DGP \nund ERS; fort-\nlaufend  \n- Mitglied DGG, \nDGGG, DGIM, \nBDI, AGS, \nBGS, GSA, \nAAA, AAAS; \nfortlaufend  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- Schatzmeister \nAWMF; 05/17  \n- Ich war Dele-\ngierter f\u00fcr die \nGeriatrie in der \nS3-LL Demen-\nzen sowie Teil-\nnehmer der \nGr\u00fcndungssit-\nzung des Steu-\nerkreises der \ngeplanten LL \nEingeschr\u00e4nkte \nEinwilligungsf\u00e4-\nhigkeit 2016; \n2014- 16 \n- Ich bin Trea-\nsurer in der \nFachgesell-\nschaft Geriatric \nMedicines \nSociety (GMS).  \n-Ich bin Vice \nchair der Spe-\ncial Interest \nGroup WE -\nSHARE (The \nWorld Explores \nSpace Health \nand Aging Re-\nsearch) der Ge-\nrontological \nSociety of Ame-\nrica (GSA); fort-\nlaufend  \n- Ich bin Fellow Themenbezug \nzur Leitlinie:  \n- Geriatrie und \nGerontologie; \nfortlaufend  \n- COPD; fort-\nlaufend  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- Gemeinsam \nKlug Entschei-\nden; fortlaufend  \n- Kognition; \nfortlaufend  Themenbezug \nzur Leitlinie:  \n- Chefarzt; bis \n30.06.2017 (s. \n\"Fr\u00fcherer Ar-\nbeitgeber\")  Keine Keine Keine Seit 01.07.2017 \nfreiberufliche \nT\u00e4tigkeit in \nForm von Gut-\nachtert\u00e4tigkeit \nf\u00fcr Gerichte \nund Schlich-\ntungsstelle f\u00fcr \nArzthaftpflicht-\nfragen.  Bis 30.06.2017 \nChefarzt der Kli-\nnik f\u00fcr Geriatrie \nam Krankenhaus \nLindenbrunn, \n31863 Coppen-\nbr\u00fcgge; Chefarzt  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  35 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nder GSA seit \n2016.  \n- Ich  bin  Mit-\nglied  der  Spe-\ncial Interast  \nGroup  Ge-\nroscience  der  \nGerontological  \nSociety  of  \nAmerica (GSA); \nseit 2015  \n- Ich bin Mit-\nglied der  Spe-\ncial Interast  \nGroup Ge-\nroscience  der \nAmerican Geri-\natrics  Society  \n(AGS); seit \n2016.  \n- Ich bin Mit-\nglied der Spe-\ncialinterast \nGroup Healthy \nAging der AGS; \nseit 2017.  \n- Ich bin Mit-\nglied des Her-\nausgebergremi-\nums  der Zeit-\nschrift f\u00fcr Ge-\nrontologie und \nGeriatrie (Z Ge-\nrontol Geriatr); \nseit 2010/11.  \n- Ich bin Mit-\nglied des Her-\nausgebergremi-\nums der Zeit-\nschrift Euro-\npean Geriatrie \nMedicine (Eur  \nGeriatr Med).  \n- Ich war Pr\u00e4si-\ndent  der Deut-\nschen Gesell-\nschaft f\u00fcr Ge-\nrontologie  und \nGeriatrie \n(DGGG); bis  \n09/2014  \n- Ich bin Dele-\ngierter der \nDeutschen Ge-\nsellschaft f\u00fcr \nGerontologie  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  36 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nund Geriatrie \n(DGGG) f\u00fcr die \nAWMF; seit \nca.2004  \n- Ich  bin  Stell-\nvertretender  \nVorsitzender  \nder  Alzheimer -\nGesellschaft   \nHameln -Pyr-\nmont  und  \nNiedersachsen.  \n- Ich war Man-\ndatstr\u00e4ger f\u00fcr \ndie Deutsche \nGesellschaft f\u00fcr \nGeriatrie \n(OGG) und die \nDeutsche Ge-\nsellschaft f\u00fcr \nGerontologie  \nund  Geriatrie \n(OGGG) bei \nder B\u00c4K f\u00fcr die \nNovellierung \nder GO\u00c4.  \n- Ich bin Mit-\nglied der Kom-\nmission Ge-\nmeinsam Klug \nEntscheiden \nder AWMF.  \nIch bin Mitglied \nder Kommis-\nsion Klug Ent-\nscheiden der \nDGIM f\u00fcr die \nGeriatrie.  \n- Ich Mitglied im \nInternational \nChoosing Wi-\nsely Roundable \nseit 2014 und \nvertrete dort mit \nD. Klemperer \nDeutschland.  \n- Ich bin Mi t-\nglied des Medi-\nkamenten -Be-\nwertungs -\nBoard  FORTA \n(Fit fOR The A-\nged).  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  37 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nGroneberg, \nProf. Dr. David  Keine Themenbezug \nzur Leitlinie \n(Editor):  \n- Springer Ver-\nlag; 2015 -2018; \nHonorar; \nGroneberg  \n- Journal of Oc-\ncupational Me-\ndicine; 2016 -\n2018; Honorar; \nGroneberg  \n \nThemenbezug \nzur Leitlinie \n(Beirat):  \n- Europ\u00e4ische \nForschungsver-\neinigung; 2015-\n2018; Auf-\nwandsentsch\u00e4-\ndigung; Grone-\nberg Kein Themen-\nbezug zur Leit-\nlinie:  \n- Landes\u00e4rzte-\nkammer Hes-\nsen; 2015 -\n2018; Grone-\nberg Kein Themen-\nbezug zur Leit-\nlinie:  \n- UBS Optimus \nFoundation; \n2016; Drittmit-\ntel; Goethe -\nUniversit\u00e4t  \n- Bundesminis-\nterium f\u00fcr Bil-\ndung und For-\nschung; 2017; \nDrittmittel; Goe-\nthe-Universit\u00e4t  \n- Berufsgenos-\nsenschaft Ge-\nsundheit; 2015-\n2018; Drittmit-\ntel; Goethe -\nUniversit\u00e4t  Kein Themen-\nbezug zur Lei t-\nlinie:  \n- Europ\u00e4ischer \nSozialfond; \n2015; Drittmit-\ntel; Goethe -\nUniversit\u00e4t  \n-  Europ\u00e4ische \nForschungsver-\neinigung; 2015-\n2017; Drittmit-\ntel; Goethe -\nUniversit\u00e4t  Themenbezug \nzur Leitlinie:  \n- Deutsche Ge-\nsellschaft f\u00fcr \nArbeitsmedizin \nund Umweltme-\ndizin; 2015-\n2018  \n- Deutsche Ge-\nsellschaft f\u00fcr \nNikotin und Ta-\nbakforschung; \n2014- 2018  Themenbezug \nzur Leitlinie:  \n- Arbeitsmedi-\nzin, Umweltme-\ndizin, Pneumo-\nlogie, Allergolo-\ngie; 2015 -2018  \n- Versorgungs-\nforschung, \nPublic Health; \n2014- 2018  Keine  Themenbezug \nzur Leitlinie:  \n- Landes\u00e4rzte-\nkammer Hes-\nsen - Weiterbil-\ndung Arbeits-\nmedizin  Keine  Keine  Goethe -Univer-\nsit\u00e4t Frankfurt \nam Main, Insti-\ntut f\u00fcr Arbeits-\nmedizin, Sozial-\nmedizin, Um-\nweltmedizin; Di-\nrektor    \nHellmann, Dr. \nAndreas  Themenbezug \nzur Leitlinie \n(Mitglied VV, \nAussch\u00fcsse):  \n- KBV; perma-\nnent; Entsch\u00e4-\ndigungen; per-\ns\u00f6nlich  \n- KVB; perma-\nnent; Entsch\u00e4-\ndigungen; per-\ns\u00f6nlich  \n \n- Thema: Dele-\ngierter \u00c4rzte-\ntag; BL\u00c4K; per-\nmanent; Ent-\nsch\u00e4digungen; \npers\u00f6nlich  \n- Thema: Vor-\nstand Akade-\nmie, Delegierter \n\u00c4rztetag; B\u00c4K; \npermanent; \nEntsch\u00e4digun-\ngen; pers\u00f6nlich  \n- Thema: ...; \nmedInfo; per-\nmanent; Hono-\nrar; pers\u00f6nlich  Themenbezug \nzur Leitlinie:  \n- Thema: Ver-\nsorgungsfor-\nschung; WIN-\nPNEU; perma-\nnent; Entsch\u00e4-\ndigung, Praxis-\nausfall; pers\u00f6n-\nlich \n- Thema: advi-\nsory board; D\u00e4-\nnisches Konsu-\nlat; 25.2.2015; \nHonorar  Themenbezug \nzur Leitlinie \n(Schulung von \nMFA bez. Al-\nlergologe):  \n- Allergo-\npharma; \n25.02.2017; \nHonorar; per-\ns\u00f6nlich  \n-  Allergo-\npharma;10.06.2\n017 Honorar; \npers\u00f6nlich  \n-  Allergo-\npharma; \n15.07.2017; \nHonorar; per-\ns\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Vortrag):  \n- Novartis; \n01.02.2015; \npers\u00f6nlich  Themenbezug \nzur Leitlinie \n(Daccord Stu-\ndie):  \n- Institut f\u00fcr \nLungenfor-\nschung; 2017; \nHonorar; Praxis  Keine  Themenbezug \nzur Leitlinie:  \n- Berufsver-\nband der \nPneumologen \nBayern, Ehren-\nvorsitz; perma-\nnent \n- Deutsche Ge-\nsellschaft f\u00fcr \nPneumologie, \nMitglied; per-\nmanent  \n- DFFP, stellv. \nVorsitzender; \npermanent  \n- Pneumomed \ne.G., Vorstand; \npermanent  \nKein Themen-\nbezug zur Leit-\nlinie: \n- BD Internis-\nten, Mitglied; \npermanent  \n- Bundesver-\nband der Be-\nleg\u00e4rzte, stellv. \nVorsitz; perma-\nnent Themenbezug \nzur Leitlinie:  \n- Versorgungs-\nforschung; per-\nmanent  Themenbezug \nzur Leitlinie:  \n- Praxis; per-\nmanent  Themenbezug \nzur Leitlinie:  \n- Pneumologi-\nsche Schlag-\nlichter; 2015-\n2017  \n- Pneumologi-\nsche Praxis-\ntage; 2015-\n2017  Keine  Keine  selbstst\u00e4ndig, \nPraxis; Praxis-\nleiter    NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  38 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nHeister, Dr. \nmed. Elisabeth  keine, aber an-\ngestellt bei \nDRV - RLP; seit \n01.12.2017; \nGutachter -\u00c4rz-\ntin Keine  Themenbezug \nzur Leitlinie:  \n(Innere Medi-\nzin; Ergothera-\npieschule):   \n- Lehrt\u00e4tigkeit; \nseit 2000; Do-\nzentenhonorar;  \npers\u00f6nlich  \n \n  Keine  Keine  - Akademie f\u00fcr \nEthik in der Me-\ndizin; Mitglied  \n- DGNR Deut-\nsche Gesell-\nschaft f\u00fcr \nNeuro. Reha.; \nMitglied  \n- DGG Deut-\nsche Gesell-\nschaft f\u00fcr Geri-\natrie; Mitglied  \n- BDI Bund \nDeutscher In-\nternisten; Mit-\nglied  \n- Berufsver-\nband der \u00c4rzte \nf\u00fcr Physikali-\nsche u. Rehabi-\nlitative Medizin; \nMitglied  Keine  -Neurologische \nFr\u00fchrehabilita-\ntion; seit 1998 \nbis 11/2017  \n-Stat. Reha, \nNeurlogie, In-\nnere Medizin, \nOrthop\u00e4die, \n1990- 1998  - Klinisches \nEthik Komitee / \nAK Ethik, W est-\npfalz -Klinikum \nGmbH; 2000 \nbis 11/2017  Keine  Keine  Westpfalz -Klini-\nkum GmbH bis \n30.11.2017; \nFach\u00e4rztin  \nab 01.12.2017 \nDRV Rheinland \nPfalz; Gut-\nachter\u00e4rztin  -Univ. Freiburg, \nInstitut f\u00fcr Ge-\nschichte der Me-\ndizin; 1987- 1990; \nwissenschaftli-\nche Angestellte  \n- LVA Baden; \nStations\u00e4rztin; \n1990- 1998  \nHeppner, Prof. \nDr. med. Hans \nJ\u00fcrgen  Keine Kein Themen-\nbezug zur Leit-\nlinie:  \n- Pfizer \nPharma; 07.16-\n01.17; Honorar; \ninstitutionell  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Pfizer \nPharma; 2014-\n2017; Honorar; \ninstitutionell  \n- Bayer \nHealthcare; \n2014- 2017; Ho-\nnorar; institutio-\nnell \n- Sanofi \nPharma; 2014-\n2017; Honorar; \ninstitutionell  \n- Omnicell; \n05.2015; Hono-\nrar; institutionell  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Robert -Bosch -\nStiftung; 08.15 -\n02.17; Studien-\ngeld; instit utio-\nnell Keine  Themenbezug \nzur Leitlinie:  \n- Deutsche Ge-\nsellschaft f\u00fcr \nGeriatrie; 01.07 \nbis heute  Themenbezug \nzur Leitlinie:  \n- Infektion, \nSepsis, Beat-\nmung, in der \nGeriatrie; bis \nheute  Themenbezug \nzur Leitlinie:  \n- Geriatrie; bis \nheute  Keine  Keine  Keine  Helio s Klinikum \nSchwelm; Chef-\narzt \nUniversit\u00e4t Wit-\nten/Herdecke; \nLehrstuhlinha-\nber Geriatrie    \nHering, Dr. \nmed. Thomas  Themenbezug \nzur Leitlinie \n(COPD/Asthm\na): \n- Berlin -Che-\nmie; laufend; \nHonorar; per-\ns\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Asthma):  \n- GSK; 2019; Themenbezug \nzur Leitlinie \n(Asthma):  \n- Sanofi; 2018-\n2019; Honorar; \npers\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(COPD) : \n- GSK; 2019; \nHonorar; per-\ns\u00f6nlich  Themenbezug \nzur Leitlinie \n(COPD/Asthm\na): \n- Berlin -Che-\nmie; laufend; \nHonorar; per-\ns\u00f6nlich  Keine  Keine  Themenbezug \nzur Leitlinie:  \n- Bundesver-\nband der \nPneumologen \n(BdP); Beauf-\ntragter f\u00fcr die \nTabak -Entw\u00f6h-\nnung; laufend  \n- WAT (Wi ssen-\nschaftlicher Ak-\ntionskreis Ta-Themenbezug \nzur Leitlinie:  \n- Tabak -Risiken \nund Tabakent-\nw\u00f6hnung  \n- Asthma und \nCOPD  Themenbezug \nzur Leitlinie:  \n- Lungenfach-\narzt in eigener \nPraxis  Keine  Keine  Keine  eigene Praxis; \nLeitung Keine  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  39 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nHonorar; per-\ns\u00f6nlich  \n- Sanofi; lau-\nfend; Honorar; \npers\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Tabakabh\u00e4n-\ngigkeit):  \n- Pfizer; lau-\nfend; Honorar; \npers\u00f6nlich  bakentw\u00f6h-\nnung); Dele-\ngierter des \nBdP; laufend  \nHeu\u00dfel, Prof. \nDr. med. Claus \nPeter  - Pfizer; 2008-\n2014  \n- Boehringer \nIngelheim; \n2010- 2014  \n- Novartis; \n2010, 2012, \n2014  \n- Gilead; 2011-\n2015  \n- Intermune; \n2013- 2014  \n- Fresenius; \n2013, 2014  Keine  - Gilead; 2008 -\n2014  \n- MSD; 2009 -\n2014  \n- Pfizer; 2010-\n2014  \n- Intermune; \n2011- 2014  \n- Novartis; \n2013- 2016  \n- Basilea: 2015, \n2016  \n- Bayer; 2016  - Siemens; \n2012- 2014  \n- Pfizer; 2012-\n2014  \n- Boehringer \nIngelheim; \n2014  \n- Deutsches \nLungenfor-\nschungszent-\nrum - Aktienbesitz \nin der \nMedizinindus-\ntrie: GSK  \nPatent:  Method \nand Device For \nRepresenting \nthe Microstruc-\nture of the \nLungs. IPC8 \nClass: \nAA61B5055FI, \nPAN: \n20080208038, \nInventors: W \nSchreiber, U \nWolf, AW \nScholz, CP \nHeussel  - Mitglied im \nDeutschen \nLungenfor-\nschungszent-\nrum \n- Mitglied  in \nder Arbeitsge-\nmeinschaft \nThoraxdiagnos-\ntik in der deut-\nschen \nR\u00f6ntgengesell-\nschaft:  \n- Leitlinien: \nLungenkarzi-\nnom, Mesothe-\nliom, COPD, \nScreening Lun-\ngenkarzinom, \nCT und MR -\nBildgebung des \nThorax, Pneu-\nmonie, HAP  \n- Berater f\u00fcr E-\nCIL-3, \nECCMID, E-\nORTC/MSG  \n- Guideline for \ndiagnosis of in-\nfections in im-\nmunocompro-\nmized hosts  \n- Gr\u00fcndungs-\nmitglied der Ar-\nbeitsgemein-\nschaft Infektio-\nnen der H\u00e4ma-\ntologie/ Onkolo-\ngie der DGHO  \n- Guideline for \ndiagnosis of in-Mitherausgeber \n\u201eMedizinische \nKlinik, Intensiv-\nmedizin und \nNotfallmedizin\u201c, \nDr. Dietrich \nSteinkopff \n(Springer Ver-\nlag) Keine  Keine  Keine  Keine Thoraxklinik am \nUniversit\u00e4tskli-\nnikum Heidel-\nberg \nR\u00f6ntgenstra\u00dfe \n1 \n69126 Heidel-\nberg; Chefarzt \nder  Diagnosti-\nschen und In-\nterventionellen \nRadiologie mit \nNuklearmedizin    NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  40 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nfections in im-\nmunocompro-\nmized hosts  \n- Fakult\u00e4tsmit-\nglied der Euro-\npean Society of \nThoracic Radio-\nlogy (ESTI)  \n- Fakult\u00e4tsmit-\nglied der Euro-\npean Respira-\ntory Society \n(ERS)  \n- Mitglied der \nEIBALL (Euro-\npean Imaging \nBiomarkers Alli-\nance)  \nKauczor, Prof. \nDr. med. Hans -\nUlrich  Keine Keine  Themenbezug \nzur Leitlinie \n(Technologie):  \n- Siemens, Phi-\nlips; 2014-\n2017; Honorar; \npers\u00f6nlich  \n- Boehringer \nlngelheim; \n2014- 2017; Ho-\nnorar; pers\u00f6n-\nlich \n- Glaxo Smit-\nhKline; 2014-\n2017; Honorar; \npers\u00f6nlich  \n- Novartis; \n2014- 2017; Ho-\nnorar; pers\u00f6n-\nlich \n- AstraZeneca; \n2014- 2017; Ho-\nnorar; pers\u00f6n-\nlich \n \nThemenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Bracco; 2016; \nHonorar; per-\ns\u00f6nlich  Themenbezug \nzur Leitlinie:   \n- Thema: Tech-\nnologie; Sie-\nmens; 2014-\n2017; Drittmit-\ntel, geldwerte \nVorteile; institu-\ntionell  \n- Thema: Arz-\nneimittel; \nBayer; 2014 -\n2017; geld-\nwerte Vor teile; \ninstitutionell  Keine  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Deutsche \nR\u00f6ntgengesell-\nschaft; 2014-\n2017  \n- Europ\u00e4ische \nR\u00f6ntgengesell-\nschaft; 2014-\n2017  Themenbezug \nzur Leitlinie:  \n- Thoraxradiolo-\ngie; 2014 -2017  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Onkoradiolo-\ngie; 2014 -2017  Keine  Keine  Keine  Universit\u00e4tskli-\nnik Heidelberg, \nLand  \nBaden- W\u00fcrt-\ntemberg; \u00c4rztli-\ncher Direktor    \nKaufmann, \nJan  Keine Keine  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Hochschule \nFresenius; Keine  Keine  Themenbezug \nzur Leitlinie:  \n- AG-Atemphy-\nsiotherapie/ Themenbezug \nzur Leitlinie:  \n- K\u00f6rperliches \nTraining und Themenbezug \nzur Leitlinie:  \n- Rehabilitation \nbei pneumolo-Themenbezug \nzur Leitlinie:  \n- Fortbildungs-\nreihe \"Atem-\nphysiotherapie\" Keine  Keine  Therapie - und \nRehabilitations -\nzentrum Baum -\ngarten am Och-\nsenzoll GmbH,  Atem -Reha \nGmbH, Junge-\nstr.10, 20535 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  41 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n01/2014 -heute; \nHonorar; per-\ns\u00f6nlich  Deutscher Ver-\nband f\u00fcr Physi-\notherapie \n(ZVK) e. V.; \n01/2010 -heute  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPneumologie \nund Beat-\nmungsmedizin \ne. V.; 01/2006-\nheute  \n- Beisitz im Vor-\nstand der \"AG \nLungensport in \nDeutschland \ne. V.\" \n \nKein Them en-\nbezug zur Leit-\nlinie: \n- Buteyko \nDeutschland - \nArbeitsgemein-\nschaft von \nAtemlehrerIn-\nnen und F\u00f6rde-\nrern e. V.; \n04/2011 -heute  Atemphysiothe-\nrapie bei \npneumologi-\nschen Erkran-\nkungen  gischen Erkran-\nkungen; \n01/2003 -heute  der AG -Atem-\nphysiotherapie; \n01/2015 -heute  Langen horner \nChaussee 623, \n22419 Ham-\nburg Hamburg; Lei-\ntender Physio-\ntherapeut  \n \nRehaCentrum \nHamburg, Marti-\nnistr. 66, 20251 \nHamburg  \nKlose, Dr. \nPetra, M.A. Keine Keine  Keine  Keine  Keine  evtl. Themen-\nbezug zur Leit-\nlinie:  \n- Gesellschaft \nf\u00fcr. Phytothera-\npie Kein Themen-\nbezug zur Leit-\nlinie:  \n- Naturheil-\nkundliche For-\nschung  Keine  Keine  Keine  Keine  Kliniken Essen -\nMitte    \nKnoll, Dr. med. \nKatrin  Keine Keine Kein Themen-\nbezug zur Leit-\nlinie:  \n- Akademie des \nEGZB; Vortrag \nund Tutorent\u00e4-\ntigkeit; Honorar \nf\u00fcr Vortrag; per-\ns\u00f6nlich  \nTeilweise The-\nmenbezug zur \nLeitlinie:  \n- Berlin Chemie \n2019 (1x); Vor-\ntrag \"Diabetes \nim Alter\"; Hono-\nrar; pers\u00f6nlich  \n Keine Keine Kein Themen-\nbezug zur Leit-\nlinie:  \n- Mitglied im \nMarburger \nBund (passiv ); \nseit 2004  \n- Mitglied der \nDGGG (pas-\nsiv); seit 2017  \n- Mitglied im \nBerufsverband \nDeutscher In-\nternisten (BDI), \npassiv; seit \n2016  Keine teilweise The-\nmenbezug zur \nLeitlinie:  \n- geriatrische, \nfr\u00fchrehabilita-\ntive Komplex-\nbehandlung; \nseit 2016  Keine Keine Keine Vivantes Hum-\nboldt Klinikum; \nInnere Medizin \n- Geriatrie; \nChef\u00e4rztin  Ev. Geriatrie-\nzentrum Berlin; \nOber\u00e4rztin  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  42 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nK\u00f6hler, Dr. \nmed. Michael  Keine Keine  Keine  Keine  Keine  Themenbezug \nzur Leitlinie:  \n- Deutsche Pa-\ntientenliga \nAtemwegser-\nkrankungen \ne. V.  \n- DPLA; seit \n2010 Vorsitzen-\nder \n- Deutsche Ge-\nsellschaft f\u00fcr \nPneumologie \nund Beat-\nmungsmedizin \ne. V.; seit ca. \n25 Jahren Mit-\nglied  \n- Deutsche \nAtemwegsliga \ne. V.; seit ca. \n30 Jahren Mit-\nglied  \n- Deutsche \nLungenstiftung \ne. V.; \nseit ca. 25 Jah-\nren Mitglied  \n- AG Lungen-\nsport in \nDeutschland \ne. V.; seit ca. \n30 Jahren Mit-\nglied  \n- Deutscher \nLungentag \ne. V.; seit ca. \n20 Jahren Mit-\nglied  Themenbezug \nzur Leitlinie:  \n- Deutsche \nSauerstoffliga \nund Beat-\nmungsmedizin \nLOT e. V.; seit \nc.. 10 Jahren \nMitglied und \nseit 2017 Besit-\nzer \n  \n- Redaktionslei-\nter der Patien-\ntenzeitschrift \n\"Luftpost\"; seit \nEnde 2014  Keine  Keine  Keine  Keine  Sascha Piprek, \nSP Medienser-\nvice, K\u00f6ln; Re-\ndaktionsleiter \nder \"Luftpost\"    \nKotz, Univ. -\nProf. Dr. Da-\nniel, PhD, \nMSc, MPH  Keine Keine  Keine  Themenbezug \nzur Leitlinie:  \n-  Bundesminis-\nterium f\u00fcr Ge-\nsundheit; \n03.2019 -\n02.2022; \nThema: \nDERBA- II Stu-\ndie: Repr\u00e4sen-\ntative Befra-\ngung der deut-\nschen Bev\u00f6lke-\nrung zum Kon-\nsum von Tabak Keine  Themenbezug \nzur Leitlinie:  \n- Society for \nResearch on \nNicotine and \nTobacco \n(SRNT); Vor-\nstandsmitglied \nund aktueller \nPr\u00e4sident; seit \n09.2017  \n- WAT; Mit-\nglied; seit \n03.2019  Themenbezug \nzur Leitlinie:  \n- Leiter des \nSchwerpunkts \nSuchtforschung \nund kli nische \nEpidemiologie \nam Institut f\u00fcr \nAllgemeinmedi-\nzin, Medizini-\nsche Fakult\u00e4t \nder Heinrich -\nHeine -Universi-\nt\u00e4t D\u00fcsseldorf; \nseit 12.2014  \n- Senior Editor Keine  Keine  Keine  Keine  Heinrich -Heine -\nUniversit\u00e4t \nD\u00fcsseldorf; \nProfessor f\u00fcr \nAllgemeinmedi-\nzin mit Schwer-\npunkt Suchtfor-\nschung und kli-\nnische Epide-\nmiologie  Keine  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  43 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nund E -Inhalati-\nonsprodukten \n(DRKS0001132\n2); Drit tmittel; \ninstitutionell  \n- Bundesminis-\nterium f\u00fcr Ge-\nsundheit; \n03.2017 -\n02.2020: Dritt-\nmittel; Thema: \nABC-II Studie: \nRandomisierter \nkontrollierter \nTrial zum Trai-\nning von Haus-\n\u00e4rzten in der \nleitliniengerech-\nten Kurzbera-\ntung zur Tabak-\nentw\u00f6hnung \n(DRKS0001278\n6);  ins titutionell  \n- European \nUnion Horizon \n2020 (HCO -06-\n2015); \n11.2015 -\n11.2019; \nThema: To-\nbacco cessa-\ntion within tu-\nberculosis pro-\ngrammes: a \n\"real world\" so-\nlution for count-\nries with dual \nburden of dise-\nases (IS -\nRCTN4381146\n7); Drittmittel; \ninstitutionell  \n- Ministerium \nf\u00fcr Innovation, \nWissenschaft \nund Forschung \ndes Landes \nNordrhein \nWestfalen; \n12.2014 -\n12.2019; \nThema: For-\nschungspro-\ngramm mit ver-\nschiedenen \nProjekten zu der Fachzeit-\nschrift Addic-\ntion; seit 2016  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  44 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nTabakrauchen, \nTabakentw\u00f6h-\nnung und Nut-\nzung von E -Zi-\ngaretten (NRW \nR\u00fcckkehrpro-\ngramm); Dritt-\nmittel; institutio-\nnell \nKraus, Prof. \nDr. med. \nThomas  Themenbezug \nzur Leitlinie \n(Berufskrank-\nheit): \n- Sozialgerichte \nBG`n`; 03/15 - \na.w.; Honorar ; \npers\u00f6nlich  Keine  Themenbezug \nzur Leitlinie \n(COPD als Be-\nrufskrankheit):  \n- DGUV; 03/15 \n- a.w.; Hono-\nrar/Reisekos-\nten; pers\u00f6nlich  Keine  Keine  Themenbezug \nzur Leitlinie:  \n- DGAUM / \nWissen. Fach-\ngesellschaft; \n03/15 - a.w. Themenbezug \nzur Leitlinie:  \n- berufsbe-\ndingte Atem-\nwegserkran-\nkung; 03/15 -  \na.w. Themenbezug \nzur Leitlinie:  \n- berufsbe-\ndingte Atem-\nwegserkran-\nkung; - a.w. Keine  Keine  Keine  Uniklinikum \nRWTH Aachen; \nDirektor des In-\nstituts f\u00fcr Ar-\nbeits -, Sozial - \nund Umweltme-\ndizin   \nLange, PD Dr. \nmed. Tobias J.  Themenbezug \nzur Leitlinie:   \n- Actelion; \nWiss -Kommitee \neiner klin. S tu-\ndie; seit \n03.2018; Hono-\nrar; institutionell  Themenbezug \nzur  \nLeitlinie (Arz-\nneimittel):  \n- GSK; \n12.2015; Hono-\nrar; pers\u00f6nlich  \n- Actelion; \n03.2015 - \n02.2020; Hono-\nrar; pers\u00f6nlich  \n- Acceleron; \n07.19; Honorar; \npers\u00f6nlich  \n Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Actelion; \n03.2015 - \n02.2020; Hono-\nrar; pers\u00f6nlich  \n- Bayer; \n03.2015 - \n03.2018; Hono-\nrar; pers\u00f6nlich  \n- MSD; \n03.2015 - \n02.2020; Hono-\nrar; pers\u00f6nlich  \n- Pfizer; \n03.2015 - \n10.2017; Hono-\nrar; pers\u00f6nlich  \n- OMT; \n11.2018; Hono-\nrar; pers\u00f6nlich  \nThemenbezug \nzur Leitlinie \n(Antikoagulan-\nzien):  \n- BMS; 07.2019 \n; Honorar; per-\ns\u00f6nlich  Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Actelion; \n03.2015 -\n02.2020; Dritt-\nmittel; institutio-\nnell \n- Bayer; \n03.2015 -\n03.2018; Dritt-\nmittel; institutio-\nnell \n- Pfizer ; \n03.2015 -01.20 \nDrittmittel; insti-\ntutionell  \n- Acceleron; \n06.18- 06.21; \nDrittmittel; insti-\ntutionell  Keine  Themenbezug \nzur Leitlinie:  \n- Mitglied der \nDeutschen Ge-\nsellschaft f\u00fcr \nKardiologie,  ak-\ntuell Sprecher \nAG25;  seit \n03.2015  \n- Mitglied der \nDeutschen Ge-\nsellsch aft f\u00fcr \nPneumologie \nund Beat-\nmungsmedizin; \nseit 03.2015  \n- Mitglied der \nEuropean Re-\nspiratory \nSociety (ERS); \nseit 03.2015  \nkein Themen-\nbezug zur Leit-\nlinie:  \n-Mitglied im \nHERMES exa-\nmination com-\nmittee der ERS; \nseit 03.2015  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Publika tionen \nzur Diagnostik \nund Therapie \nder pulmonalen \nHypertonie; seit \n03.2015  Themenbezug \nzur Leitlinie:  \n- Leitung Spezi-\nalambulanz f\u00fcr \nPulmonale Hy-\npertonie am \nUKR; 03.2015-\n02.2020  \n- Internistische \nIntensivmedi-\nzin; 10.2018-\n03.2020  Themenbezug \nzur Leitlinie:  \n- Mitgestaltung \nvon Fortbildun-\ngen im Rah-\nmen der Kon-\ngresse von \nDGK und DGP; \nseit 03.2015  Keine  nein Universit\u00e4tskli-\nnikum Regens-\nburg Klinik f\u00fcr \nInnere Medizin \nII; Oberarzt Be-\nreich Pneumo-\nlogie  nein  \nLanghorst, \nProf. Dr. med. \nJost  Themenbezug \nzur Leitlinie \n(Experten-\nroundtable):  \n- Steigerwald \nArzneimittel; Keine  Themenbezug \nzur Leitlinie \n(Integrative \nTherapien bei \nCED):  \n- Falk Founda-\ntion; 1 -2015 - Themenbezug \nzur Leitlinie:  \n- Thema: Lite-\nraturrecher che \nf\u00fcr Metaanaly-\nsen und Leitlini-\nenvorbereitung; Keine  Themenbezug \nzur Leitlinie:  \n- Leitlinienbe-\nauftragter der \nGesellschaft f\u00fcr \nPhytotherapie; \n1-2015 - 12-Themenb ezug \nzur Leitlinie:  \n- Phytotherapie  \n- Naturheil-\nkunde und \nkomplement\u00e4re \nMedizin  Themenbezug \nzur Leitlinie:  \n- Lehrstuhl f\u00fcr \nNaturheilkunde  \n- Integrative \nMedizin  \n- Integrative Themenbezug \nzur Leitlinie:  \n- Naturheilver-\nfahren  Keine  Keine  Prof. Dr. med. \nJost Langhorst  \nLeitender Arzt  \nIntegrative \nGastroenterolo-\ngie \nNaturheilkunde   NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  45 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n07-2016; Hono-\nrar; pers\u00f6nlich  \n- Repha GmbH; \n01-2015 - \n6.2017; Hono-\nrar; pers\u00f6nlich  \n- Ferring Arz-\nneimittel; 02 -\n2017-  06-2017; \nHonorar; per-\ns\u00f6nlich  \n \nThem enbezug \nzur Leitlinie \n(Schriftleitung \nZPT):  \n- Medizinver-\nlage Stuttgart; \n01-2015 -\n12.2017; Hono-\nrar; pers\u00f6nlich  12-2017; Hono-\nrar; pers\u00f6nlich  \n- MSD \nShap&Dohme; \n8-2016;  Hono-\nrar; pers\u00f6nlich  \n \nThemenbezug \nzur Leitlinie:  \n(Phytotherapie \nbei CED und \nRDS)  \n- Repha GmbH; \n1-2015 - 12-\n2017; Honorar ; \npers\u00f6nlich  \nThemenbezug \nzur Leitlinie \n(Integrative \nTherapie des \nRDS):  \n- Ardeypharm; \n2015; Honorar; \npers\u00f6nlich  \n \nThemenbezug \nzur Leitlin ie \n(Integrative \nTherapie des \nPankreas- Ca): \n- Celgene \nGmbH; 5 -2017; \nHonorar; per-\ns\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Phytotherapie \nbei Husten):  \n- Dr. Wilmar \nSchwabe Arz-\nneimittel; 9 -\n2017; Honorar; \npers\u00f6nlich  Rut-und Klaus \nBahlsen- Stif-\ntung; 1- 2015 - \n12-2017; For-\nschungsgrant; \ninstitutionell  \n- Thema: \nPET/MRT bei \nCED; Eli and \nEdythe L. \nBroad Founda-\ntion Medical \nResearch Pro-\ngram und die \nCrohn\u00b4s Colitis \nFoundation of \nAmerica \n(CCFA); 1 -2016 \n- 12-2017; For-\nschungsgrant; \ninstitutionell  \n- Thema: Le-\nbensstil und \nKrankheitsakti-\nvit\u00e4t bei Colitis \nulcerosa \u2013 eine \nrandomisiert \nkontrollierte \nStudie zum \nEinfluss von \nStressreduktion \nund Lebensstil-\nmodifikation \nund Kurzketti-\ngen Fetts\u00e4ur en \nbei Colitis ulce-\nrosa - Einfluss \neines pflanzli-\nchen Kombina-\ntionspr\u00e4parats \naus Myrrhe, \nKaffeekohle \nund Kamillen-\nbl\u00fctenextrakt \nim Vergleich \nzum Goldstan-\ndard Mesalazin \nauf den Verlauf \nvon kurzketti-\ngen Fetts\u00e4uren  \nin Remission \nund akutem \nSchub; Karl \nund Veronica \nCarstens -Stif-\ntung; 1 -2016 - 2017  \n- Leitlinienbe-\nauftragter der \nDeutschen Ge-\nsellschaft f\u00fcr \nNaturheilkunde; \n1-2015 - 12-\n2017  \n- Deutsche \nSchmerzgesell-\nschaft; 1 -2015 - \n12-2017  \n- Deutsches \nKollegium f\u00fcr \nPsychosomati-\nsche Medizin; \n1-2015 - 12-\n2017  \nKein Themen-\nbezug zur Leit-\nlinie: \n- Sprecher der \nAG Psychoso-\nmatik in der \nGastroenterolo-\ngie der Deut-\nsche Gesell-\nschaft f\u00fcr Gast-\nroenterologie; \n9-2017 - 12-\n2017  \n- Deutsche Ge-\nsellschaft f\u00fcr \nNeurogastro-\nenterologie und \nMotilit\u00e4t; 1 -\n2015 - 12-2017  - Mind -Body -\nVerfahren  \nKein Themen-\nbezug zur Leit-\nlinie: \n- Gastroentero-\nlogie  Gastroenterolo-\ngie und Integrative \nMedizin  \nKliniken Essen-\nMitte  \nKnappschafts \nKrankenhaus  \nAm Deimels-\nberg 34 a  \n45276 Essen; \nLeitender Arzt  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  46 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n12-2017; For-\nschungsgrant; \ninstitutionell  \n \nKein Themen-\nbezug zur Leit-\nlinie:   \n- Thema: TSST \nbei Colitis ulce-\nrosa; Ra\u00dffeld-\nStiftung; 2016; \nForschungs-\ngrant;  instituti-\nonell  \n- Thema: Le-\nbensstil bei Co-\nlitis ulcerosa; \nDr. Heinz Hors t \nDeichmann \nStiftung; 2015; \nForschungs-\ngrant; institutio-\nnell \n- Thema: Phy-\ntotherapie Coli-\ntis ulcerosa; \nSteigerwald \nArzneimittel-\nwerke GmbH; \n2015; For-\nschungsgrant; \ninstitutionell  \n-  Thema: Leci-\nthin Colitis ulce-\nrosa; Falk \nFoundation; \n01/2015 -\n12/2017; For-\nschungs grant; \ninstitutionell  \n- Thema: f\u00e4kale \nBiomarker; \nTechLab; \n01/2015 -\n12/2017; For-\nschungsgrant; \ninstitutionell  \n- Thema: Phy-\ntotherapie \nRDS); Dr. \nWilmar \nSchwabe; \n01/2016 -NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  47 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n12/2017; For-\nschungsgrant; \ninstitutionell  \nMartin, Dr. \nphil. nat. Eric  Themenbezug \nzur Leitlinie:  \n- Astra Zeneca; \nExperten- Work-\nshop zu \n\"Asthma Zero\"; \n2019  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- Sanofi Aven-\ntis; Thema: Ein-\nsatz von \nLaxanzien in \nder Selbstmedi-\nkation; seit \n09/19  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Bundesapo-\nthekerkammer; \nseit 1999 fort-\nlaufend; Auf-\nwandsentsch\u00e4-\ndigung; pers\u00f6n-\nlich \n- F\u00f6rderinitia-\ntive pharm. Be-\ntreuung; 2007 -\n2016; Keine; \npers\u00f6nlich  \n- Bayer. Akad. \nF. Klin. Phar-\nmazie; 2007-\n2016; R eise-\nkosten; pers\u00f6n-\nlich Themenbezug \nzur Leitlinie:  \n- Thema: \nAsthma im Kin-\ndesalter ge-\nmeinsam mit \nKinderpneumo-\nlogen, Keine \nMitsprache des \nAuftraggebers \nbei Inhalen..; \nConsilium -In-\nfectopharm; \n11/2014 -\n04/2017; Hono-\nrar; pers\u00f6nlich  \n- Vortr\u00e4ge f\u00fcr \nKammern, \nHochsch ulen, \nFachgesell-\nschaften  \n- Berlin Che-\nmie; drei Vor-\ntr\u00e4ge: \"Pharma-\nkodynamische \nund pharmako-\nkinetische Un-\nterschiede in-\nhalativer Gluko-\nkortikoide\", In-\nhalative Thera-\npie (2019/20)  Keine  Aktien der \nStada AG (von \nbisheriger Inha-\nberin der Apo-\ntheke im Zuge \ndes Erwerbs \nder Apotheke \n\u00fcbernommen); \nDie Stada AG \n(Standard -Arz-\nneimittel Deut-\nscher Apothe-\nker) war fr\u00fcher \neine Genos-\nsenschaft und \nder Erwerb von \nGenossen-\nschaftsanlei-\nhen, sp\u00e4ter Ak-\ntien, Vorausset-\nzung f\u00fcr die \nKonfektionieren \nvon Eigenspe-\nzialit\u00e4ten (= \nkein Interes-\nsenkonflikt).  Themenbezug \nzur Leitlinie:  \n- Mitglied der \nArzneimittel-\nkommission der \nDt. Apotheker \nAMK; seit 2007  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- Mitglied des \nwissenschaftli-\nchen Beir ats \nder Bun-\ndesapotheker-\nkammer (T\u00e4tig-\nkeitsschwer-\npunkt Planung \nund Konzeptio-\nnierung der \nproduktneutra-\nlen Pharma-\ncon-Kongresse \nder BAK); \n1999- 2019  \n- Mitglied des \nwissenschaftli-\nchen Beirats \nder F\u00f6rderinitia-\ntive Pharmaz. \nBetreuung; \n2007- 2016  \n- Mitglied des \nwisse nschaftli-\nchen Beirats \nder Bayer. Aka-\ndemie f\u00fcr Klin. \nPharmazie; \n2007- 2016  Themenbezug \nzur Leitlinie:  \n- Pharmazeuti-\nsche Betreuung \nvon Patienten \nmit Asthma \nbronchiale bzw. \nCOPD  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- Pharmazeuti-\nsche  Betreu-\nung von Patien-\nten mit Ty p-2-\nDiabetes  Keine  \n(im Berichts-\nzeitraum ledig-\nlich eine Stu-\ndienteilnahme \nals Interventi-\nonsapotheke \n(Typ-2-Diabe-\ntes); 07/2017 ff  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Als Mitglied \ndes Wissen-\nschaftlichen \nBeirats der \nBundesapothe-\nkerkammer mit-\nverantwortlich \nf\u00fcr di e inhaltli-\nche Gestaltung \nder j\u00e4hrlichen \nPharmacon -  \nKongresse in \nSchladming / \nMeran (pro-\nduktneutral, \nkein Fir-\nmensponso-\nring); laufend  Keine  Keine  Selbstst\u00e4ndig; \nLeiter der Hu-\nbertus -Apo-\ntheke, Luitpold-\nstra\u00dfe 31,  \n97828 \nMarktheiden-\nfeld   \nM\u00fchlig, Prof. \nDr. Step han  Keine Keine Themenbezug \nzur Leitlinie \n(Tabakentw\u00f6h-\nnung):  \nPfizer; 2017 -\n2019;  Vortrag \n+ Tagung; per-\ns\u00f6nlich  Themenbezug \nzur Leitlinie \n(Tabak+ \nCOPD):  \n- AOKPLUS; \n2015- 2020; \nDrittmittel; insti-\ntutionell  \n \nThemenbezug \nzur Leitlinie Keine Themenbezug \nzur Leitlinie:  \n- Wissenschaft-\nlicher Aktions-\nkreis Tabak \n(WAT); seit \n2015  \n- Deutsche Ge-\nsellschaft f\u00fcr \nSuchtforschung \nund -therapie Themenbezug \nzur Leitlinie:  \n- Tabakfor-\nschung; seit \n2002  \n- Publikationen \nzum Rauchen + \nCOPD; seit \n2002  Themenbezug \nzur Leitlinie:  \n- Tabakentw\u00f6h-\nnung; seit 2004  \n- Raucheram-\nbulanz Chem-\nnitz; seit 2007  \n \nKein Themen-\nbezug zur Leit-\nlinie:  Themenbezug \nzur Leitlinie:  \n- Train -the-Trai-\nner-Seminar e \nu.a. von Kam-\nmern; seit 2012  \n \nKein Themen-\nbezug zur Leit-\nlinie:  Keine Keine TU Chemnitz; \nPHA- TUC; Pro-\nfessur f\u00fcr Klini-\nsche Psycholo-\ngie und Psy-\nchotherapie; \nKlinischer Di-\nrektor, Ge-\nsch\u00e4ftsf\u00fchrer  vor 2007  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  48 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n(Tabakentw\u00f6h-\nnung):  \nDeutsche; \n2018- 2020; \nDrittmittel; insti-\ntutionell  (DGS); seit \n2010  \n- Editor Zeit-\nschrift SUCHT; \nseit 2018  \n- Psych. Psy-\nchotherapeut \nmit Fachkunde \nVerhaltensthe-\nrapie; seit 2014  \n -Fortbildungen \nf\u00fcr PT - und \n\u00c4rztekammer; \nseit 2014  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPsychologie; \nseit 2000  - Psychothera-\npie; seit 2014  - TUCed; seit \n2007  \nNehls, Dr. \nmed. Wiebke  Keine  Keine  Themenbezug \nzur Leitlinie \n(Palliativver-\nsorgung):  \n- mission le-\nbenshaus \ngGmbH; 01/15-\n10/17; Honorar; \ninstitutionell  \n- Wannsee \nAkademie; \n01/15 - 12/16; \nHonorar; insti-\ntutionell  \n- Thema: Pallia-\ntivversorgung \nCOPD; \nPneumo  Up-\ndate; 11/16; \nHonorar; insti-\ntutionell  Keine Keine  Themenbezug \nzur Leitlinie:  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPalliativversor-\ngung; Vor-\nstandst\u00e4tigkeit; \nab 07/14 bis \naktuell  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPneumologie; \nseit 2009  Themenbezug \nzur Leitlinie:  \n- Kommunika-\ntion; 2014 -2016  \n- Palliativver-\nsorgung; 2014 -\n2017  Themenbezug \nzur Leitlinie:  \n- Palliativmedi-\nzin in der \nPneumologie; \nseit 2008  Keine  Keine  Keine  HELlOS Klini-\nkum Emil von \nBehring, Klinik \nf\u00fcr \nPneumologie; \nOber\u00e4rztin, Be-\nreichsleitung \nPalliativmedizin    \nNeumann, \nProf. Dr. med. \nAndreas  Keine Keine Keine Keine Keine Themenbezug \nzur Leitlinie:  \n- Deutsche Ge-\nsellschaft f\u00fcr \nHNO Heil-\nkunde, KHC  \n \nKein Themen-\nbezug zur Leit-\nlinie:  Themenbezug \nzur Leitlinie:  \n- Septum- Ne-\nbenh\u00f6hlenchi-\nrurgie  \n \nimplantierbare \nH\u00f6rsysteme  Themenbezug \nzur Leitlinie:  \n- Nebenh\u00f6hlen-\nchirurgie  \n- Septumde-\nfektverschluss  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- rekonstruktive Kein Themen-\nbezug zur Leit-\nlinie:  \n- Neusser \nHNO -Kollo-\nquium  \n- Pr\u00e4sident  \nwestdeutscher \nHNO -Kongess \n2019  Keine Keine St\u00e4dtische Kli-\nniken Neuss  \nKlinik f\u00fcr Hals -\nNasen- Ohren-\nheilkunde; seit \n9 Jahren Chef-\narzt   NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  49 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n- Deutsch -Spa-\nnische HNO -\nGesellschaft; > \n20 Jahre  \n- Deutsche Ge-\nsellschaft f\u00fcr \nBiomaterialien  Mittelohrchirur-\ngie \nNilius, Prof.  \nDr. med. \nGeorg  Themenbezug \nzur Leitlinie \n(Kontrolle von \nKrankenhaus-\nbehandlun-\ngen):  \n- Qualit\u00e4tssi-\ncherung, Pneu-\nmonie Landes-\n\u00e4rztekammer; \nfortlaufend; \nReisekosten; \npers\u00f6nlich  Keine Themenbezug \nzur Leitlinie \n(\u00c4rztliche Wei-\nterbildung):  \n- Akademie f\u00fcr \n\u00e4rztliche Fort-\nbildung; fortlau-\nfend; Honorar; \npers\u00f6nlich  \n- Boehringer; \n05/2017; Hono-\nrar; Klinik  Themenbezug \nzur Leitlinie:  \n- Thema: Beat-\nmung/Nasale \nHigh flow The-\nrapie; Studie \nCOPO und Hy-\nperkapnie; fort-\nlaufend; Dritt-\nmittel; Klinik  \n- Thema: \nGrundlagenfor-\nschung; Bio-\nmarker bei \nCOPD/Bayer; \nseit 3/2017; \nDrittmitte; Klinik  \n- Thema: Ger\u00e4-\nteentwicklung; \nCPAP/Algorith-\nmen zur Thera-\npiesteue-\nrung/L\u00f6wen-\nstein; fortlau-\nfend; Drittmittel; \nKlinik  Keine Themenbezug \nzur Leitlinie:  \n- DGP; fortlau-\nfend \n- DGSM; fort-\nlaufend  \n- ERS; fortlau-\nfend \n- ATS; fortlau-\nfend Themenbezug \nzur Leitlinie:  \n- Beatmungs-\nthera-\npie/Atmungsun-\nterst\u00fctzun g bei \nrespiratorischer \nInsuffizienz und \nSchlaf -Apnoe; \nfortlaufend  Themenbezug \nzur Leitlinie:  \n- Chefarzt HEL-\nlOS Klinik Ha-\ngen-Ambrock; \nFachgruppen-\nleiter der HEL-\nlOS  Kliniken \nf\u00fcr Pneumolo-\ngie /Thoraxchi-\nrurgie; fortlau-\nfend Themenbezug \nzur Leitlinie:  \n- Akademie f\u00fcr \n\u00e4rztliche Wei-\nterbildung \nWestfalen-\nLippe; fortlau-\nfend \n  Keine Keine HELlOS -Klinik \nHagen-\nAmbrock \nGmbH; Chef-\narzt   \nNothacker, Dr. \nmed. Monika  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Thema: Medi-\nzinisch Fachli-\nche Beratung \nFr\u00fche Nutzen-\nbewertung \nPertuzumab; \nIQWiG; Okto-\nber 2015; Ho-\nnorar; pers\u00f6n-\nlich \n- Thema: Me-\nthodische Bera-\ntung planungs -\nrelevante Indi-\nkatoren; IQTIG; \nJanuar -Juni \n2016; Honorar; \npers\u00f6nlich  Keine Themenbezug \nzur Leitlinie:  \n- Thema: Maxi-\nmale Medizin \u2013  \nOptimal?; 4. \nVortrag Berliner \nUG \n2017; Honorar; \npers\u00f6nlich  \nKein Themen-\nbezug zur Leit-\nlinie: - Thema: \nEbM und Leitli-\nnien; 1. Dozen-\ntin: QM -Kurs \n\u00c4rztekammer \nNiedersachsen; \n2/2016 2/2017; \nHonorar; per-\ns\u00f6nlich  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Thema: Dritt-\nmittel im Rah-\nmen des Leitli-\nnienprogramms \nOnkologie; \nDeutsche \nKrebshilfe; Ge-\nsamter Zeit-\nraum; Drittmit-\ntel; institutionell  \n- Thema: For-\nschungsprojek t \nleitlinienba-\nsierte QI; DFG; \n7/2016- 6/2018; \nDrittmittel; insti-\ntutionell  Keine - Deutsches \nNetzwerk Evi-\ndenzbasierte \nMedizin: Spre-\ncherin Fachbe-\nreich Leitlinien; \nGesamter Zeit-\nraum  \n- Deutsche \nKrebsgesell-\nschaft: einfache \nMitgliedschaft  - Publikationen \nzu Leit linien \nund zu Ge-\nmeinsam Klug \nEntscheiden; \nGesamter Zeit-\nraum  Keine Keine Keine Keine Arbeitsgemein-\nschaft der Wis-\nsenschaftlichen \nMedizinischen \nFachgesell-\nschaften e. V. \n(AWMF); Wiss. \nMitarbeiterin, \nStellvertr. Leitli-\nnien des \nAMWF -Instituts \nf\u00fcr Medizini-\nsches W issens-\nmanagement  s.o. NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  50 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n- Thema: Wahl-\npflichtfach: \nEbM und Leitli-\nnien; 2.Dozen-\ntin: Berlin \nSchool of  \nPublic Health; \n2013- 2016 je-\nweils 4 Ter-\nmine; Honorar; \npers\u00f6nlich  \nNowak, Prof. \nDr. med. Den-\nnis Themenbezug \nzur Leitlinie \n(Aspekt Be-\nrufskrankhei-\nten): \n- Gutachtert\u00e4-\ntigkeit f\u00fcr Un-\nfallversiche-\nrungstr\u00e4ger \nund Sozialge-\nrichte; laufend; \nHonorare; per-\ns\u00f6nlich, Mitar-\nbeiterbeteili-\ngung und Ab-\nf\u00fchrung an Kli-\nnikum  Themenbezug \nzur Leitlinie \n(Rauchent-\nw\u00f6hnung):  \n- Pfizer; lau-\nfend; Honorare, \nReisekosten; \npers\u00f6nlich  Themenbezug \nzur Leitlinie \n(Begutach-\ntung, Medika-\ntion):  \n- Berlin Che-\nmie, Pfizer, \nMundipharma, \nBoehringer, \nMedUpdate; \nlaufend; Hono-\nrare, Reisekos-\nten; pers\u00f6nlich  Themenbezug \nzur Leitlinie \n(Forschung \n\u00fcber Berufs-\nkrankheiten):  \n- DGUV; lau-\nfend; Drittmittel; \ninstitutionell  - nur Misch-\nfonds  Themenbezug \nzur Leitlinie:  \n- DGAUM; lau-\nfend \n- DGP; laufend  Themenbezug \nzur Leitlinie:  \n- Arbeits - und \numweltbedingte \nAtemwegs-  und \nLungenkrank-\nheiten; laufend  Themenbezug \nzur Leitlinie:  \n- Berufskrank-\nheiten, Pr\u00e4ven-\ntion, Asthma, \nCOPD; laufend  Themenbezug \nzur Leitlinie:  \n- zahlreiche \nFortbildungs-\nveranstaltun-\ngen zu o.g. \nThemen; lau-\nfend Keine  Keine  Klinikum der \nUniversit\u00e4t \nM\u00fcnchen, Insti-\ntut und Polikli-\nnik f\u00fcr Arbeits -, \nSozial - und \nUmweltmedizin; \nDirektor    \nRitz, Prof. Dr. \nThomas  Themenbezug \nzur Leitlinie:  \n- 11/16 -12/16; \nBreathing trai-\nning for \nasthma; Hono-\nrar; pers\u00f6nlich  \n- Editor -in-\nChief, Biologi-\ncal Psychology \n(Elsevier)  Themenbezug \nzur Leitlinie:  \n- Mitglied des \nKommittees  \nfuer die S2k -\nLeitlinie zur Di-\nagnostik und \nTherapie von \nPatienten mit \nAsthma, 2015 -  \n2021  Keine  Themenbezug \nzur Leitlinie:   \n- National Insti-\ntutes of Health; \n9/15- 8/18; A \nWearable \nAsthma Trigger \nMonitorin g Sys-\ntem with inte-\ngrated physio-\nlogical monitor; \nGehalt; \npers\u00f6nlich, in-\nstitutionell  \n- National Insti-\ntutes of Health; \n7/18- 8/18; The \nDallas Asthma \nBrain an Cogni-\ntion Study; \npers\u00f6nlich, in-\nstitutionell  \n- National Insti-\ntutes of Health; \n7/18- 8/18; Re-\nward Sesiv ity Themenbezug \nzur Leitlinie:  \n- U.S. \n10,942,174 B2 \n(approved \n03/09/21); Title: \n\u201cCalcium Bind-\ning Protein, \nSpermatid Spe-\ncific 1, as a Bi-\nomarker for Di-\nagnosis or \nTreatment of \nStress\u201d; A nteile; \npers\u00f6nlich  Kein \nThemenbezug \nzur Leitlinie:  \n- America Psy-\nchosomatic So-\nciety; 2001 -\n2008  \n- International \nSociety for the \nAdvancement \nof Respiratory \nPsychophysiol-\nogy; 1996 -2008  \n- Society for \nPsychophysio-\nlogical Re-\nsearch; 1993-\n2008  Themenbezug \nzur Leitl inie: \n- Psychophysi-\nologie und Ver-\nhaltensmedizin \nvon Atemweg-\nserkrankungen; \n2015- 2021  Keine  Keine  Keine  Keine  Southern Me-\nthodist Univer-\nsity (SMU), De-\npartment of \nPsychology; \nProfessor, For-\nschung und \nLehre  Keine  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  51 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nas a Mecha-\nnism of Positive \nAffect Treat-\nment; \npers\u00f6nlich, in-\nstitutionell  \nSchaefer, Co-\nrinna , M.A.  Keine Keine Keine Keine Keine Kein Themen-\nbezug zur Leit-\nlinie:  \n- DNEbM; \nFachbereiche \nLeitlinien und \nPatienteninfor-\nmation  Keine Keine Keine Keine Keine \u00c4rztliches Zent-\nrum f\u00fcr Qualit\u00e4t \nin der Medizin; \nStv. Leitung; \nAbteilungslei-\ntung EbM/Leitli-\nnien und Pati-\nenteninforma-\ntion   \nSch\u00e4fer, Prof. \nDr. med. Ha-\nrald  Keine Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Boehringer \nlngelheim; \n5/2015-\n10/2017; Hono-\nrar; pers\u00f6nlich  Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Novartis; \n2/2015-\n10/2017; Hono-\nrar; pers\u00f6nlich  \n- AstraZeneca; \n4/2015; Hono-\nrar; pers\u00f6nlich  \n- Boehringer; \n5/2015-\n10/2017; Hono-\nrar; pers\u00f6nlich  \n- Berlin Che-\nmie; 07-\n09/2014; Hono-\nrar; pers\u00f6nlich  Keine Keine Keine Keine Themenbezug \nzur Leitlinie:  \n- Pneumologie; \nseit 1995  Themenbezug \nzur Leitlinie:  \n- Veranstaltung \nvon Fortbil-\ndungsveran-\nstaltungen zum \nThema \nPneumologie; \nseit 1996  Keine Keine SHG Kliniken \nV\u00f6lklingen; \nChefarzt und \n\u00c4rztlicher Di-\nrektor    \nSchneider, \nUniv. -Prof. Dr. \nmed. Antonius  Themenbezug \nzur Leitlinie:  \n- Thema: Lun-\ngenfunktionsdi-\nagnost ik; medi-\nnfo GmbH; \n01/17 - bis \njetzt; Honorar; \npers\u00f6nlich  \n- Thema: Quali-\nt\u00e4tsindikatoren \nQISA; AOK \nBundesver-\nband; 2016-\n2017; Honorar; \npers\u00f6nlich  \n- Thema: DMP \nAsthma/COPD; \nG-BA; 2004- bis \njetzt; Honorar Keine  Themenbezug \nzur Leitlinie \n(DMP \nAsthma/COPD\n): \n- Kassen\u00e4rztli-\nche Vereini-\ngung Bayerns; \n2012- 12/15; \nHonorar; per-\ns\u00f6nlich  Ganshorn (Her-\nsteller von Spi-\nrometern und \nBo-\ndyplethysmo-\ngraphen); \n01.02.2018; \nDrittmittel;  \nMit dem Projekt \nsoll ein neuarti-\nges Spirometer \nevaluiert wer-\nden, das in der \nLage ist, mitar-\nbeitsunabh\u00e4n-\ngig Atem-\nwegsobstruktio-\nnen zu detek-Keine  Themenbezug \nzur Leitlinie:  \n- Deutsche Ge-\nsellschaft f\u00fcr \nAllgemeinmedi-\nzin (DEGAM); \n2003 bis jetzt  \n- Sprecher der \nSelektion For-\nschung, st\u00e4n-\ndige Leitl inien-\nkommission \n(SKL); jetzt  Themenbezug \nzur Leitlinie:  \n- Zahlreiche; \nsiehe \nwww.am.med.t\num.de (TU \nM\u00fcnchen); bis \njetzt Themenbezug \nzur Leitlinie:  \n- Allgemeinme-\ndizin/Hausarzt-\npraxis; bis jetzt  Keine  Keine  Keine  Kliniken rechts \nder Isar / TU \nM\u00fcnchen; Di-\nrektion Institut \nf\u00fcr Allgemein-\nmedizin    NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  52 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n(Aufwandsent-\nsch\u00e4digung); \npers\u00f6nlich  tieren (Diag-\nnostische Stu-\ndie).  \nSch\u00fcler, Sa-\nbine Keine  Keine  Keine  Keine  Keine  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Berlin -Bran-\ndenburgische \nGesellschaft f\u00fcr \nHerz - und \nKreislauferkran-\nkungen e. V. \n(BBGK e. V.) Themenbezug \nzur Leitlinie:  \n- methodische \nund Berichts-\nqualit\u00e4t diag-\nnostischer Ge-\nnauigkeitsstu-\ndien im Rah-\nmen der Pro-\nmotion; seit \n2011  Keine  Keine  Keine  Keine  \u00c4rztliches Zent-\nrum f\u00fcr Qualit\u00e4t \nin der Medizin \n(\u00c4ZQ)  \nStra\u00dfe des 17. \nJuni 106- 108 \n10623 Berlin; \nWissenschaftli-\nche Mitarbeite-\nrin 01/2016 - \n12/2016: Bezirk-\nsamt Neuk\u00f6lln; \nGesundheitsamt; \nAssistenz\u00e4rztin \nim Bereich Hygi-\nene und Umwelt-\nmedizin  \n11/2012 - \n04/2014: Medical \nPark Berlin Hum-\nboldtm\u00fchle; As-\nsistenz\u00e4rztin in \nder Abteilung Or-\nthop\u00e4die und Un-\nfallchirurgie  \nSchultz, \nDr.med. Kon-\nrad  Keine  Themenb ezug \nzur Leitlinie \n(allg. Pneumo-\nlogie inklusive \nArzneimittel):  \n- Boehringer; \n2014- 2015; Ho-\nnorar; pers\u00f6n-\nlich \n- Berlin Che-\nmie; seit 2014; \nHonorar; per-\ns\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Alpha -1-AT-\nCenter):  \n- Grifols 2014-\n2015; Honorar; \npers\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Rehabilita-\ntion):  \n- Novartis; \n2014; Honorar; \npers\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Mundipharma; Themenbezug \nzur Leitlinie \n(Rehabilitation \n+ Arzneimit-\ntel): \n- Berlin Che-\nmie, seit 2014; \nHonorar; per-\ns\u00f6nlich  \n- Novartis; seit \n2014; Honorar; \npers\u00f6nlich  \n- AstraZeneca; \n2014 und 2016; \nHonorar; per-\ns\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(Rehabilita-\ntion):  \n- Mundipharma; \n2014- 2015; Ho-\nnorar; pers\u00f6n-\nlich \n- Boehringer; \nseit 2014; Ho-\nnorar; pers\u00f6n-\nlich \n \nThemenbe zug \nzur Leitlinie \n(Pneum. Diag-\nnostik):  \n- BdP; seit Themenbezug \nzur Leitlinie \n(Asthma, \nCOPD):  \n- DRV Bayern \nS\u00fcd; seit 2014; \nDrittmittel; insti-\ntutionell  Keine  Themenbezug \nzur Leitlinie:  \nFachgesell-\nschaften  \n- DGP; >20 \nJahre  \n- ERS; >15 \nJahre  \n- DGPMR; >20 \nJahre  \n- DGRW; seit \n2014  \n- DGAKI; seit \n2014  \nBerufsver-\nb\u00e4nde  \n- BdP; seit \n2008  \n- BDI; > 20 \nJahre  \n- BV der Reha-\nbilitations\u00e4rzte \nDeutschlands; \nseit 2008  Themenbezug \nzur Leitlinie:  \n- Asthma, \nCOPD, nicht -\nmedikamen-\nt\u00f6se Therapie, \nRehabilitation; \nseit 2014  - Allgemeine \nPneumologie  \n- Innere Medi-\nzin \n- Rehabilitation  \n- Sozialmedizin  Themenbezug \nzur Leitlinie:  \n- Durchf\u00fchrung \nvon DMP -Kur-\nsen zu \nAsthma/COPD  Keine  Keine  Klinik Bad Rei-\nchenhall der \nDRV Bayern \nS\u00fcd; Medizini-\nscher Direktor    NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  53 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n2014; Honorar; \npers\u00f6nlich  2014; Honorar; \npers\u00f6nlich  \nSchulz, Prof. \nDr. rer. nat. \nMartin  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Gerichtsgut-\nachten; \n09/2015 -\n09/2019; Gut-\nachten MASGF \nBrandenburg; \nAufwandsent-\nsch\u00e4digung; \npers\u00f6nlich  \n Keine  Themenbezug \nzur Leitlinie \n(Arzneimit-\ntel*):  \n- LAKs/LAVs; \n09/2015 -\n08/2017; Hono-\nrar; pers\u00f6nlich  \n- BVKA; 2016; \nHonorar; per-\ns\u00f6nlich  \n- MSD; \n10/2017; Hono-\nrar; pers\u00f6nlich  \n*nicht im Be-\nreich COPD \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- Schwabe; \n10/2017; Vor-\ntragshonorar; \npers\u00f6nlich  \n- Novartis; \n10/2017; Pos-\nterhonorar; per-\ns\u00f6nlich  \n- DGK; \n05/2019; Vor-\ntragshonorar  \n- DHKT; \n01/2020; Vor-\ntragshonorar  \n- Sanofi; \n01/2020; Vor-\ntragshonorar  Themenbezug \nzur Leitlinie \n(Medikations-\nplan):  \n- BMG; 2015 -\n2017; Drittmit-\ntel; institutionell  Keine  Kein Themen-\nbezug zur Leit-\nlinie:  \n-Vorsitzender \nder Arzneimit-\ntelkommission \nder Deutschen \nApotheker \n(AMK); 2009  \n- Mitglied \nDNEbM; konti-\nnuierlich  \n-DPhG; konti-\nnuierlich  \n-DGPT; konti-\nnuierlich  \n- ESCP; konti-\nnuierlich  \n- ASCPT; konti-\nnuierlich  \n- ACCPharm; \nkontinuierlich  \n- ACCPharma-\ncol; kontinuier-\nlich \n- ISPE; kontinu-\nierlich  \n- ISOP; konti-\nnuierlich  \n- APhA; konti-\nnuierlich  \n- ESC/DGK; \nkontinuierlich  \n- DDG; kontinu-\nierlich  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Evidenzba-\nsierte Medizin \nund Pharmazie \n(= Schule); > \n10 Jahre  \n- Therapie-\ntreue; > 10 \nJahre  \n- AM-Versor-\ngung; > 10 \nJahre  \n- AMTS; > 10 \nJahre  \n- Pharmakoepi-\ndemiologie; > \n10 Jahre  Keine  Keine  Keine  Keine  ABDA -Bundes-\nvereinigung \nDeutscher Apo-\nthekerverb\u00e4nde \ne. V., BAK, \nDAV; Ge-\nsch\u00e4ftsf\u00fchrer \nArzneimittel    \nSimon, Prof. \nDr. phil. Alfred  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Nds. Ministe-\nrium f\u00fcr Wis-\nsenschaft und \nKultur; j\u00e4hrlich \n(seit 1996); In-\nstitutionelle \nF\u00f6rderung der \nGesch\u00e4ftsstelle \nder Akademie \nf\u00fcr Ethik in der \nMedizin; institu-\ntionell  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Mitglied des \nAusschusses \nf\u00fcr ethische \nund medizi-\nnisch -juristi-\nsche Grund-\nsatzfragen der \nBundes\u00e4rzte-\nkammer*  \n- Sprecher der \nArbeitsgruppe Kein Themen-\nbezug zur Leit-\nlinie: \nDozentent\u00e4tig-\nkeit* im Rah-\nmen von Wei-\nterbildungskur-\nsen zu Palliativ-\nmedizin / Pallia-\ntiv Care f\u00fcr \n\u00c4rzte, Pfle-\ngende und Ver-\ntreter anderer \nGesundheits-\nberufe, u.a. f\u00fcr  Keine  Keine  Themenbezug \nzur Leitlinie:  \n- Mitglied der \nAkademie f\u00fcr \nEthik in der Me-\ndizin (AEM); \nkontinuierlich  \n- Mitglied der \nDeutschen Ge-\nsellschaft f\u00fcr \nPalliativmedi-\nzin; kontinuier-\nlich Themenbezug \nzur Leitlinie:  \n- Ethische As-\npekte medizini-\nscher Entschei-\ndungen am Le-\nbensende; kon-\ntinuierlich  \n- Patientenau-\ntonomie, Pati-\nentenverf\u00fc-\ngung, Gesund-\nheitliche Vo-\nrausplanung; \nkontinuierlich  Keine  Kein Themen-\nbezug zur Leit-\nlinie:   \n- Mitveranstal-\nter des Fern-\nlehrgang \u201eBera-\nter/in f\u00fcr Ethik \nim Gesund-\nheitswesen\u201c am \ncekib, Klinikum \nN\u00fcrnberg; kon-\ntinuierlich  \n- Mitveranstal-\nter des Qualifi-Keine  Keine  Akademie f\u00fcr \nEthik in der Me-\ndizin; Ge-\nsch\u00e4ftsf\u00fchrer  Universit\u00e4tsklini-\nkum M\u00fcnster (je-\nweils im Winter-\nsemester); Lehr-\nstuhlvertretung  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  54 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nEthik der Deut-\nschen Gesell-\nschaft f\u00fcr Palli-\nativmedizin \n(DGP)*  \n- Mitglied der \nAG Verfahrens-\ngrund-\ns\u00e4tze/Ethik der \nSt\u00e4ndigen \nKommission \nOrgantrans-\nplantation der \nBundes\u00e4rzte-\nkammer*  \n-Mitglied im \nVorstand des \nZentrums f\u00fcr \nMedizinrecht \nder Universit\u00e4t \nG\u00f6ttingen*  \n- Sprecher der \nArbeitsgruppe \nEthik der Deut-\nschen Gesell-\nschaft f\u00fcr Palli-\nativmedizin*  \n- Koordinator \nder Arbeits-\ngruppe Ethik-\nberatung im \nGesundheits-\nwesen in der \nAkademie f\u00fcr \nEthik in der Me-\ndizin (AEM)*  \n- Mitglied des \nWissenschaftli-\nchen Beirats \ndes Fernlehr-\ngangs \u201eBera-\nter/in f\u00fcr Ethik \nim Gesund-\nheitswesen\u201c \n(CeKIB, Klini-\nkum N\u00fcrnberg)*  \n-Mitglied des \nWissenschaftli-\nchen Beirats \nder Zeitschrift \nf\u00fcr Palliativme-\ndizin (Thieme \nVerlag)*  \n- Mitglied der \nProjektgruppe - APPH Nord-\nhessen; Hono-\nrar*; pers\u00f6nlich  \n- \u00c4rztekammer \nHessen; Hono-\nrar*; pers\u00f6nlich  \n- \u00c4rztekammer \nWestfalen-\nLippe; Hono-\nrar*; pers\u00f6nlich  \n- Mildred \nScheel Akade-\nmie G\u00f6ttingen; \nHonorar*; per-\ns\u00f6nlich  \nInhouse- Schu-\nlungen* zu \nEthik und Ethik-\nberatung im \nKrankenhaus \nbzw. im Ge-\nsundheitswe-\nsen, u.a. f\u00fcr  \n- BG Kliniken; \nHonorar*; per-\ns\u00f6nlich  \n- Ev. Kranken-\nhaus Hamm; \nHonorar*; per-\ns\u00f6nlich  \n- Gem ein-\nschaftskran-\nkenhaus Herd-\necke; Honorar*; \npers\u00f6nlich  \n- GPR Klinikum \nR\u00fcsselsheim; \nHonorar*; per-\ns\u00f6nlich  \n- HELIOS Klini-\nkum Bad \nSaarow; Hono-\nrar*; pers\u00f6nlich  \n- HELIOS Klini-\nkum Duisburg; \nHonorar*; per-\ns\u00f6nlich  \n- Johannes \nHospiz M\u00fcns-\nter; Honorar*; \npers\u00f6nlich  \n- Klinikum Kas-\nsel; Honorar*; \npers\u00f6nlich  \n- Klinikum Re-\ngion Hannover; - Klinische \nEthikberatung; \nkontinuierlich  zierungspro-\ngramm \u201eEthik-\nberatung im \nKrankenhaus\u201c \nam Zentrum f\u00fcr \nGe-sund-\nheitsethik, Han-\nnover; kontinu-\nierlich  \n- Kursleiter des \nQualifizierungs-\nprogramm \n\u201eEthikberater/in \nim Ge sund-\nheitswesen\u201c an \nder Mildred \nScheel Akade-\nmie, G\u00f6ttingen; \nseit 2015  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  55 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nEthik des Deut-\nschen Verban-\ndes f\u00fcr Ergo-\ntherapie*  \n* T\u00e4tigkeit er-\nfolgt ehrenamt-\nlich bzw. im \nRahmen mei-\nner beruflichen \nT\u00e4tigkeit als \nGesch\u00e4ftsf\u00fch-\nrer der Akade-\nmie f\u00fcr Ethik in \nder Medizin  Honorar*; per-\ns\u00f6nlich  \n- PalliativNetz \nPein; Honorar*; \npers\u00f6nlich  \n- Palliativnetz \nWolfsburg; Ho-\nnorar*; pers\u00f6n-\nlich \n- St\u00e4dtisches \nKlinikum Braun-\nschweig; Hono-\nrar*; pers\u00f6nlich  \n- Universit\u00e4ts-\nklinikum M \u00fcns-\nter; Honorar*; \npers\u00f6nlich  \n- Vitos Akade-\nmie Gie\u00dfen; \nHonorar*; per-\ns\u00f6nlich  \n- Vitos Rhein-\ngau; Honorar*; \npers\u00f6nlich  \n* Dozentenho-\nnorare entspre-\nchend den Ho-\nnorarordnun-\ngen der Lan-\ndes\u00e4rztekam-\nmer f\u00fcr Weiter-\nbildungen (bzw. \norientieren sich \ndaran)  \nStorre, Jan \nProf. Dr. med.  Themenbezug \nzur L eitlinie \n(Arzneimittel):  \n- B\u00f6hringer \nIngelheim; \n01.2014 -\n04.2018; Hono-\nrar; pers\u00f6nlich  \n \nThemenbezug \nzur Leitlinie \n(technischen \nHilfsmittel):  \n- Breas Medical \nAB; 01.2014-\n12.2019; Hono-\nrar; pers\u00f6nlich  Keine Themenbezug \nzur Leitlinie \n(techn. Hilfs-\nmittel):  \n- Fischer & \nPaykel \nHealthcare; \n01.2014 -\n03.2018; Hono-\nrar; pers\u00f6nlich  \n- Heinen & L\u00f6-\nwenstein und \nWeinmann; \n01.2014 -\n03.2018; Hono-\nrar; pers\u00f6nlich  \n- SenTec AG \nund Keller Me-\ndical; 01.2014-\n03.2018; Hono-\nrar; pers\u00f6nlich  Themenbezug \nzur Leitlinie  \n(techn. Hilfs-\nmittel):  \n- Weinmann \nGmbH und Vivi-\nsol Deutsch-\nland; 2013 -\n2015; Drittmit-\ntel; institutionell \n(K\u00f6ln)  \n- VitalAire \nGmbH; 2015-\n2017; institutio-\nnell (K\u00f6ln)  \n- Heinen & L\u00f6-\nwenstein und \nVivisol; 2015-\n2017; institutio-\nnell (K\u00f6ln)  Keine Themenbezug \nzur Leitlinie:  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPneumologie \nund Beat-\nmungsmedizin; \n>10 Jahre  \n- European Pe-\nspiratory \nSociety; >10 \nJahre  \n- Deutsche in-\nterdisziplin\u00e4re \nGesellschaft f\u00fcr \nau\u00dferklinische \nBeatmung;  \n>10 Jahre  \n- Deutsche Ge-\nsellschaft f\u00fcr Themenbezug \nzur Leitlinie:  \n- Forschungst\u00e4-\ntigkeiten Beat-\nmungsmedizin, \nLebensqualit\u00e4t \nbei respiratori-\nsche r Insuffizi-\nenz, Monitoring \ndes Gasaus-\ntausches u.a.; \n>10 Jahre  Themenbezug \nzur Leitlinie:  \n- siehe unten \nInstitutionen, \nLungenklinik/  \n- Fachklinik; \nseit 2011  Themenbezug \nzur Leitlinie:   \n- Lehrauftrag \nan der Albert -\nLudwigsuniver-\nsit\u00e4t Freiburg i. \nBr., Schwer-\npunkt Pneumo-\nlogie; seit 2011  \n- Ausbildung \nals leitender \nArzt in den u.g. \nPositionen, \nSchwerpunkt \nPneumologie; \nseit 2011  Keine Keine Pneumologie \nSolln  \nPraxis f\u00fcr Lun-\ngen- und Bron-\nchialheilkunde, \nInnere Medizin \nund Schlafme-\ndizin; eigene \nPraxis  \n Lungenkl inik \nK\u00f6ln-Merheim, \nKliniken der \nStadt K\u00f6ln  \ngGmbH, K\u00f6ln;  \nAsklepios Fach-\nklinik Abteilung \nf\u00fcr Intensiv -, \nSchlaf - und Be-\natmungsmedizin  \nGauting GmbH  \nRobert -Koch -Al-\nlee 2  \n82131 Gauting \nbis 09/2019  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  56 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n- VitalAire, Vivi-\nsol; 01.2014-\n03.2018; Hono-\nrar; pers \u00f6nlich  \n- ResMed; \n01.2014 -\n03.2018; Hono-\nrar; pers\u00f6nlich  \n- Linde und \nWKM; 01.2014 -\n03.2018; Hono-\nrar; pers\u00f6nlich  Schlaffor-\nschung und \nSchlafmedizin; \n>10 Jahre  \nVader, Isabell \nMPH   \n(ausgeschieden \n01/2021,  \nStand \n01/2021)  Keine Keine  Keine  Keine  Keine  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Mitglied Mar-\nburger Bund; \nseit 12/2012  Keine  Keine  Keine  Keine  Keine  \u00c4ZQ; wissen-\nschaftliche Mit-\narbeiterin  05/2015 -\n10/2015: Techni-\nsche Universit\u00e4t \nBerlin, Fachge-\nbiet Manage-\nment im Gesund-\nheitswesen (dritt-\nmittelfinanziert \ndurch BMBF);  \n \n09/2013 -\n09/2014: Evan-\ngelisches Kran-\nkenhaus K\u00f6nigin \nElisabeth Herz-\nberge Berlin  \nVogelmeier, \nProf. Dr. C.  Keine  Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Almirall; 2015; \nHonorar; per-\ns\u00f6nlich  \n- AstraZeneca; \naktuell; Hono-\nrar; pers\u00f6nlich  \n- Boehringer \nIngelheim; ak-\ntuell; Honorar; \npers\u00f6nlich  \n- Chiesi; aktu-\nell; Honorar; \npers\u00f6nlich  \n- Grifols; aktu-\nell; Honorar; \npers\u00f6nlich  \n- Novartis; aktu-\nell; Honorar; \npers\u00f6nl ich  \n- CSL Behring; \naktuell; Hono-\nrar; pers\u00f6nlich  Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Almirall; 2015; \nHonorar; per-\ns\u00f6nlich  \n- AstraZeneca; \naktuell; Hono-\nrar; pers\u00f6nlich  \n- Boehringer \nIngelheim; ak-\ntuell; Honorar;  \npers\u00f6nlich  \n- Chiesi; aktu-\nell; Honorar; \npers\u00f6nlich  \n- Grifols; aktu-\nell; Honorar; \npers\u00f6nlich  \n- Mundipharma; \n12.2016; Hono-\nrar; pers\u00f6nlich  \n- Novartis; aktu-\nell; Honorar; \npers\u00f6nlich  \n- Takeda; 2015; Kein Themen-\nbezug zur Leit-\nlinie:   \n- AstraZeneca; \naktuell; Drittmit-\ntel; institutionell  \n- Boehringer; \naktuell; Drittmit-\ntel; institutionell  \n- Grifols; aktu-\nell; Drittmittel; \ninstitutionell  \n- GlaxoSmit-\nhKline; aktuell;  \nDrittmittel; insti-\ntutionell  \n- Novartis; aktu-\nell; Drittmittel;  \ninstitutionell  \n- Teva; aktuell; \nDrittmittel; insti-\ntutionell  \n- Bundesminis-\nterium f\u00fcr Bil-\ndung und For-\nschung; aktuell; Keine  Themenbezug \nzur Leitlinie:  \n- Pr\u00e4sident der  \nDGP; 2009-\n2011  \n- Mitglied/Spre-\ncher des Sci-\nence Com-\nmiettee der \nGOLD; seit \n2009  \n \nKein Themen-\nbezug zur Leit-\nlinie:  \n- Vorsitzender \nder Deutschen \nLungenstiftung; \nseit 2015  Themenbezug \nzur Leitlinie:  \n- COPD; aktuell  Themenbezug \nzur Leitlinie:  \n- COPD; aktuell  Keine  nicht vorhan-\nden Nein!  Philips -Univer-\nsit\u00e4t Marburg \nund UKGM, \nStandort Mar-\nburg; Professor \nf\u00fcr Innere Me-\ndizin und Direk-\ntor der Klinik f\u00fcr \nInnere Medizin \nmit Schwer-\npunkt Pneumo-\nlogie, Intensiv - \nund Schlafme-\ndizin, UKGM, \nStandort Mar-\nburg Keine  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  57 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n- Berlin Chemie \n/ Menarini; per-\ns\u00f6nlich  Honorar; per-\ns\u00f6nlich  \n- Berlin Che-\nmie/ Menarini; \nHonorar; per-\ns\u00f6nlich  \n- CSL Behring; \nHonorar; per-\ns\u00f6nlich  Drittmittel; insti-\ntutionell  \nWatz , PD Dr. \nmed. Henrik  Themenbezug \nzur Leitlinie:  \n- GSK; seit \n2016; Honorar; \npers\u00f6nlich  \n- AstraZeneca; \nseit 2013; Ho-\nnorar; pers\u00f6n-\nlich  \n-Boehr. Ingel-\nheim; seit \n2013; Honorar; \npers\u00f6nlich  \n- Novartis; seit \n2017; Honorar; \npers\u00f6nlich  \n- BerlinChemie; \nseit 2017; Ho-\nnorar; pers\u00f6n-\nlich \n-CHIESI; seit \n2017; Honorar; \npers\u00f6nlich  Themenbezug \nzur Leitlinie:  \n- GSK; seit \n2014; Honorar; \npers\u00f6nlich  \n- AstraZeneca; \nseit 2014; Ho-\nnorar; pers\u00f6n-\nlich  \n-Boehr. Ingel-\nheim; seit \n2016; Honorar; \npers\u00f6nlich  \n-CHIESI; seit \n2019; Honorar; \npers\u00f6nl ich Themenbezug \nzur Leitlinie:  \n-Boehr. Ingel-\nheim; seit \n2013; Honorar; \npers\u00f6nlich  \n- Chiesi; seit \n2016; Honorar; \npers\u00f6nlich  \n- AstraZeneca; \nseit 2013; Ho-\nnorar; pers\u00f6n-\nlich \n- Novartis; seit \n2013; Honorar; \npers\u00f6nlich  \n- Berlin Che-\nmie; seit 2014; \nHonorar; per-\ns\u00f6nlich  Themenbezug \nzur Leitlinie:  \n- AstraZeneca; \nseit 2013; Ho-\nnorar; institutio-\nnell \n- Chiesi; seit \n2013; Honorar; \ninstitutionell  \n- GSK; seit \n2013; Honorar; \ninstitutionell  Themenbezug \nzur Leitlinie:  \n-Boehr. Ingel-\nheim; seit \n2013; Honorar; \ninstitutionell  \n- Novar tis; seit \n2013; Honorar; \ninstitutionell  \n- Takeda; seit \n2013; Honorar; \npers\u00f6nlich  Themenbezug \nzur Leitlinie:  \n- Co-Autor der \nCOPD -Leitlinie \nder DGP und \nAtemwegsliga; \nseit Dez 2015  \nKein Themen-\nbezug zur Leit-\nlinie: \n- Mitglied wis-\nsenschaftlicher \nFachgesell-\nschaften (DGP, \nATS, ERS); seit \n2008  \n- Mitglied \nDGIM; seit \n2003  Themenbezug \nzur Leitlinie:  \n- COPD und \nAsthma; > 100 \nPublikationen; \nseit 2005  Themenbezug \nzur Leitlinie:  \n- Internist und \nPneumologe; \nseit 2008  Themenbezug \nzur Leitli nie: \n- diverse Fort-\nbildungsveran-\nstaltungen f\u00fcr \nAllgemeinmedi-\nziner; seit 2008  \n- diverse Fort-\nbildungsveran-\nstaltungen f\u00fcr \nPneumologen; \nseit 2008  \n- Herausgeber \nCOPD Buch; \n2017  \n- ERS task \nforce chair K\u00f6r-\nperliche Aktivi-\nt\u00e4t COPD; \n2014  Keine  Keine  Pneumologi-\nsches For-\nschungsinstitut \nan der Lungen-\nClinic Gro\u00df-\nhansdorf; Arzt \nund Gesch\u00e4fts-\nf\u00fchrer    \nWeber, PD Dr. \nCora  Kein Themen-\nbezug zur Leit-\nlinie:  \n- Bayer; \n02/2017 -\n02/2019; Pain \nEndometriosis; \nHonorar; insti-\ntutionell  Keine Kein Themen-\nbezug zur Leit-\nlinie:  \n- Bayer; \n17.06.2017; \nPsychokardio-\nlogie; Honorar; \ninstitutionell \n(Klinik Konto)  \n- 38. BNK Jah-\nrestagung; Vor-\ntrag  \n- Servier Tele-\nfonh\u00f6rer -Aktion \n15.03.2018; \nDepression Te-\nlefonberatung; \nHonorar; per-\ns\u00f6nlich  Keine Keine Themenbezug \nzur Leitlinie:  \n- American \nPsychosomatic \nSociety; seit \n2004  \n- Deutsches \nKollegium f\u00fcr \nPsychosomati-\nsche Medizin \nDKPM e. V.; \nseit 2002  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPsychosomati-\nsche Medizin \nund \u00c4rztliche \nPsychotherapie \ne. V.; seit 2002  \n- Bundesver-\nband der Fach-\n\u00e4rzte f\u00fcr Psy-\nchosomatische Psychokardio-\nlogie, Herzra-\ntenvariabilit\u00e4t, \nSalzsensivit\u00e4t, \nBluthochdruck-\nregulation, \nSchmerz, inter-\nnistische Psy-\nchosomati k Themenbezug \nzur Leitlinie:  \n- Psychosoma-\ntische Medizin \nund Psychothe-\nrapie, Chef\u00e4rz-\ntin der Fachab-\nteilung innere \nMedizin (Fach-\n\u00e4rztin/ i.R. psy-\nchosomat. Me-\ndizin); seit \n1.1.18  Themenbezug \nzur Leitlinie:  \n- Psychokardio-\nlogie, Dozentin \nDt. Gesellschaft \nf\u00fcr Kardiologie, \nCurriculum \nPsychosomati-\nsche Grundver-\nsorgung  \n- Akademie f\u00fcr \npsychosom. \nMedizin und \nPsychothera-\npie, Berlin Do-\nzentin; seit \n2012  Keine nein Medizin und \nPsychotherapie  \nOberhavelklini-\nken Hennings-\ndorf; Chef\u00e4rztin \nseit 1.1.2018  Park-Klinik So-\nphie Charlot te, \nAbt. Psychoso-\nmatik; Chef\u00e4rztin \nv. 1.8.2014-\n31.12.2017  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  58 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nMedizin und \nPsychotherapie \ne. V., Wiss. \nBeirat; seit \n2014  \n- Dt. Gesell-\nschaft f\u00fcr Kardi-\nologie- Herz -u. \nKreislauffor-\nschung e. V.; \nseit 2017  \nWeber, Dr. Mi-\nchael   Keine  Themenbezug \nzur Leitlinie \n(Allergie):  \n- Bencard Aller-\ngie GmbH; \n2015; Honorar; \npers\u00f6nlich  Themenbezug \nzur Leitlinie \n(Medika-\nmente):  \n- Novartis; \n2015- 209; Ho-\nnorar; pers\u00f6n-\nlich \n- Boehringer; \n2015- 2019; Ho-\nnorar; pers\u00f6n-\nlich \n- Glaxo; 2015-\n2019; Honorar;  \npers\u00f6nlich  \n- Astra; 2015-\n2016; Honorar;  \npers\u00f6nlich  \n- Medlnfo; \n2015- 2019; Ho-\nnorar; pers\u00f6n-\nlich Kein Themen-\nbezug zur Leit-\nlinie (MS -Medi-\nkament):  \n- Novartis; \n2015- 2018  Keine  Themenbezug \nzur Leitlinie:  \n- Berufsver-\nband der \nPneumologen \nBundesver-\nband; -2017  \n- Berufsver-\nband der \nPneumologen \nBayern; -2018  \n- Deutsche Ge-\nsellschaft f\u00fcr \nPneumologie \nund Beat-\nmungsmedizin; \n-2018  \n- Deutsche For-\nschungsgruppe \nPneumologie in \nder Prim\u00e4rver-\nsorgung e. V. \n(DFPP); -2018  Keine  Themenbezug \nzur Leitlinie:  \n- Niedergelas-\nsener  \nPneumaloge in \neigener Praxis; \n1992- 2018  Keine  Keine  Keine  Keine  Keine  \nWelte, Prof. \nDr. med. \nTobias  Keine Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Boehringer; \n2017- 2020;  \npers\u00f6nlich  \n- AstraZeneca; \n2017- 2020; \npers\u00f6nlich  \n- GSK; 2017-\n2020;  \n- Novartis; \n2017- 2020; \npers\u00f6nlich  \n Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- AstraZeneca; \n2017- 2020; \npers\u00f6nlich  \n- Berlin -Che-\nmie; 2019; per-\ns\u00f6nlich  \n- Boehringer ; \n2017- 2020; \npers\u00f6nlich  \n- GSK; 2017-\n2020; pers\u00f6n-\nlich \n- Novartis; \n2017- 2020; \npers\u00f6nlich  \n- Chiesi; 2019; \npers\u00f6nlich  Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Novartis; \n2017- 2019; in-\nstitutionell  \n- GSK; 2018-\n2020; institutio-\nnell \n- AstraZeneca; \n2017- 2020; in-\nstitutionell  \n Keine  Themenbezug \nzur Leitlinie:  \n- President of \nthe European \nRespiratory \nSociety; \n2018/19  \n- President of \nthe Forum of \nInternal Respi-\nratory Society; \n2019  \n- Pr\u00e4sident der \nDeutschen Ge-\nsellschaft f\u00fcr \nPneumologie; \n2013- 2015  \n \nThemenbezug \nzur Leitl inie Themenbezug \nzur Leitlinie:  \n- Lungentrans-\nplant ation; seit \n1990  \n- Asthma + \nCOPD; seit \n1985  \n \nThemenbezug \nzur Leitlinie \n(bedingt):  \n- pulmonale In-\nfektionen ein-\nschlie\u00dflich \nPneumonie und \nSepsis; seit \n1985  \n- Intensivmedi-\nzin, vor allem Themenbezug \nzur Leitlinie:  \n- akute und \nchronische In-\nfektionen; seit \n1985  \n- Lungen-  und \nBronchialer-\nkrankungen; \nseit 1985  \n Themenbezug \nzur Leitlinie:  \n-Hannover Bio-\nmedical Rese-\narch School; \nseit 2004  \n Keine  Keine  Medizinische \nHochschule \nHannover; Kli-\nnikdirektor \nPneumologie  \nSenatsmitglied  \n   NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  59 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n (bedingt):  \n- Pr\u00e4sident der \nPaul Ehrlich \nGesellschaft; \n2018- 2020  \n- Pr\u00e4sident der \nDeutschen \nSepsis Gesell-\nschaft; 2009-\n2013  \n- Pr\u00e4sident der \nDeutschen Ge-\nsellschaft f\u00fcr in-\nternistische In-\ntensivmedizin; \n2008- 2010  Beatmung; seit \n1985  \n  \nWelt er, PD Dr. \nmed. Stefan  Keine Keine Themenbezug \nzur Leitlinie \n(Technologie):   \n- KLS- Martin; \n01.2014 -\n12.2017; Hono-\nrar und Reise-\nkostenerstat-\ntung; pers\u00f6n-\nlich \n- Johnson u. \nJohnson; \n01.2016 -\n03.2018; Rei-\nsekostenerstat-\ntung und Fort-\nbildungshospi-\ntation; pers\u00f6n-\nlich \n- MedExpert; \n01.2015 -\n10.2017; Hono-\nrar und Reise-\nkostenerstat-\ntung; pers\u00f6n-\nlich \n- Gore; \n01.2015 -\n03.2018; Hono-\nrar und Reise-\nkostenerstat-\ntung;  pers\u00f6n-\nlich Keine Keine Themenbezug \nzur Leitlinie:  \n- DGT; seit ca. \n2006  \n- DGP; seit \n2017  \n- ESTS; seit \n2008  \n \nKein Themen-\nbezug zur Leit-\nlinie:   \n- BDC; seit ca. \n2001  \n-DHV; seit \n2015  Themenbezug \nzur Leitlinie:   \n- Lungenmeta-\nstasenchirurgie  \n- Management \nvon Komplikati-\nonen  Themenbezug \nzur Leitlinie:   \n-operative Lun-\ngenreduktion; \n01.2008 -\n03.2018  \nKein Themen-\nbezug zur Leit-\nlinie:  \n- onkologische \nChirurgie der \nLunge  \n- septische Chi-\nrurgie  Keine Keine Keine Lungenklinik \nHeuer, Theo-\nFunccius -Str.1, \n58675 Heuer; \nChefarzt der \nThoraxchirurgie  Ruhrlandklinik, \nT\u00fcscheuer Weg \n40, 45239 Es-\nsen; Ltd. OA \nThoraxchir urgie  \nWorth, Prof. \nDr. med. Hein-\nrich  Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- AstraZeneca; \n07/2017 -jetzt; Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- AstraZeneca; \n2016; Honorar ; Themenbezug \nzur Leitlinie \n(Arzneimittel):  \n- Novartis; ca. 5 \nJahre; Honorar; Themenbezug \nzur Leitlinie \n(DACCORD-\nStudie):  \n- Novartis; ca. 5 Keine  Themenbezug \nzur Leitlinie:  \n- Deutsche \nAtemwegsliga; \nca. 30 Jahre  Themenbezug \nzur Leitlinie:  \n- Kardi orespira-\ntorische Inter-\naktionen, Themenbezug \nzur Leitlinie : \n- Pneumologie; \nca 25 Jahre  \n- Asthma, Themenbezug \nzur Leitlinie:  \n- Patienten-\nschulung \nAsthma, Keine  Keine Praxis -Koope-\nration Dr. \nBily/Keller-\nmann/F\u00fcrth; Chefarzt, Med. \nKlinik 1, Klinikum \nF\u00fcrth; bis \n31.12.2014  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  60 \n  \n  \n Nr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \nHonorar ; per-\ns\u00f6nlich  \n- Klosterfrau; \nca. 2008 -jetzt; \nHonorar ; per-\ns\u00f6nlich  \n- Chiesi; Hono-\nrar; pers\u00f6nlich;  \n- GSK; Hono-\nrar; pers\u00f6nlich;  \n- Novartis; Ho-\nnorar; pers\u00f6n-\nlich; \n- Omron; Hono-\nrar; pers\u00f6nlich;  \n \n- DMP \nAsthma/COPD; \nReisekosten  pers\u00f6nlich  \n- Klosterfrau; \nca. 5 Jahre; \nHonorar ; per-\ns\u00f6nlich  \n- BerlinChemie; \nca. 5 Jahre; \nHonorar ; per-\ns\u00f6nlich  \n- Chiesi; Hono-\nrar; pers\u00f6nlich  \n \n \nThemenbezug \nzur Leitlinie \n(COPD):  \n- Novartis; ca. 5 \nJahre; Honorar; \npers\u00f6nlich  pers\u00f6nlich  \n- BerlinChemie; \nca. 5 Jahre; \nHonorar; per-\ns\u00f6nlich  \n- Klosterfrau; \nca. 5 Jahre; \nHonorar; per-\ns\u00f6nlich  \n- AstraZeneca; \nca. 2 Jahre; \nHonorar; per-\ns\u00f6nlich  \n- Almirall; ca. 2 \nJahre; Honorar; \npers\u00f6nlich  Jahre; Honorar; \npers\u00f6nlich  - Deutsche Ge-\nsellschaft f\u00fcr \nPneumologie; \nca. 30 Jahre  \n- AG Lungen-\nsport in \nDeutschland; \nca. 15 Jahre  \n- Deutsche Ge-\nsellschaft f\u00fcr In-\nnere Medizin; \nca. 30 Jahre  COPD, \nAsthma, Pati-\nentenschulung, \nLungensport; \nca. 35 Jahre  COPD, Lun-\ngenembolie  COPD; ca. 20 \nJahre  Kooperations-\npartner  \n \n  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  61 \n  \n  \n Externe Expertin ohne Stimmberechtigung, 2. Auflage  \nNr. 1 2 3 4 5 6 7 8 9 10 11 12 13 \nArt Direkt  Indirekt  \n Berater -/Gut-\nachter -t\u00e4tigkeit  Mitarbeit in ei-\nnem Wissen-\nschaftlichen \nBeirat (advi-\nsory board)  Vortrags -/oder \nSchulungst\u00e4tig-\nkeit Forschungs -\nvorhaben/  \nDurchf\u00fchrung \nklinischer Stu-\ndien Eigent\u00fcmerin-\nteressen (Pa-\ntent, Urheber-\nrecht, Aktienbe-\nsitz) Mitglied-\nschaft/Funkt ion \nin Interessen-\nverb\u00e4nden  Schwerpunkte \nwissenschaftli-\ncher T\u00e4tigkei-\nten, Publikatio-\nnen Schwerpunkte \nklinischer T\u00e4-\ntigkeiten  Federf\u00fchrende \nBeteiligung an \nFortbildungen \n/Ausbildungs -\ninstituten  Enge pers\u00f6nli-\nche Beziehun-\ngen zu einem \nVertre tungs be-\nrech tigten ei-\nnes Unterneh-\nmens der Ge-\nsundheitswirt-\nschaft  Sehen Sie an-\ndere Aspekte \noder Umst\u00e4nde, \ndie von Dritten \nals einschr\u00e4n-\nkend in Bezug \nauf Ihre Objek-\ntivit\u00e4t oder Un-\nabh\u00e4ngigkeit \nwahrgenom-\nmen werden \nk\u00f6nnten?  Gegenw\u00e4rtiger \nArbeitgeber \nund Funktion  Fr\u00fchere Arbeit-\ngeber und \nFunktion (im \nZeitraum der \nErkl\u00e4rung)  \nMeiling, Clau-\ndia  Keine  Keine  Keine  Keine  Keine  Keine  Keine  Keine  Keine  Keine  Keine  Deutscher Ver-\nband der Ergo-\ntherapeuten \n(DVE); seit \n2011; Referentin \nf\u00fcr Standards \nund Qualit\u00e4t  Keine  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  62 \n  \n  \n Anhang 1.3  Stimmenthaltungen bei der Konsensuskonferenz, 2. Auflage  \nVor der Konsensuskonferenz waren die Interessenkonflikte der Teilnehmer *innen  durch AWMF und \u00c4ZQ (Frau Dr. \nNothacker und Frau Schaefer) bewertet worden. Enthaltungen waren bei moderaten IK unabh\u00e4ngig vom Themen-\nzug zur Leitlinie beschlossen worden. Jede Fachgesellschaft hatte eine Stimme. Waren mehrere Expert*innen f\u00fcr \neine Fachgesellschaft benannt und hatte nur einer /eine  einen IK angegeben, so konnte eine andere Vertreter in/ ein \nanderer Vertreter  das Stimmrecht f\u00fcr die Fachgesellschaft wahrnehmen. Folgende Liste lag bei der Konsensuskon-\nferenz  als Tischvorlage aus:  \n \nNVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  63 \n  \n  \n  \nNVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  64 \n  \n  \n Anhang 1.4  \u00dcbersicht: Stimmenthaltungen aufgrund Interessenkonflikt  \nStimmenthaltungen bei der Konsensuskonferenz aufgrund IK  \nEmpfehlung/Statement  \n(Nummerierung siehe Konsultationsfassung)  Anzahl Enthaltungen  aufgrund von \nInteressenkonflikten  \n3-2 + Abbildung 3 (Algorithmus Tabakentw\u00f6hnung)  3 \n3-4 2 \n5-1 + Abbildung 4 (Medikament\u00f6se Langzeitbehandlung)  8 \nStimmenthaltungen:  elektronische Abstimmung nach der Konsensuskonferenz  \nEmpfehlung/Statement  \n(Nummerierung siehe Konsultationsfassung)  Anzahl Enthaltungen  aufgrund von \nInteressenkonflikten  \n4-18 1 \n4-19 1 \nAnhang 2  Endpunktgraduierung  \nSammlung der Endpunkte in der Auftaktsitzung  \n\uf0a1 Gesamtmortalit\u00e4t  \n\uf0a1 krankheitsspezifische Mortalit\u00e4t  \n\uf0a1 Morbidit\u00e4t  \n\uf0fa Symptomatik: Atemnot, Husten und Auswurf  \n\uf0fa Mobilit\u00e4t/Funktionalit\u00e4t  \n\uf0fa soziale Teilhabe  \n\uf0fa Erwerbsf\u00e4higkeit  \n\uf0fa Exazerbationen  \n\uf0fa Reduktion des zuk\u00fcnftigen Krankheitsrisikos  \n- Lungenfunktion  \n- Gesamt -Hospitalisierung  \n- COPD -bedingte Hospitalisierung  \n\uf0fa therapiebedingte Morbidit\u00e4t  \n\uf0a1 Lebensqualit\u00e4t  \n\uf0a1 Krankheitsbew\u00e4lt igung  \nAnhang 3  Recherchestrategien  \nAnhang 3.1  Leitlinien  \nRecherchestrategie  \nDie strukturierte Leitlinienrecherche wurde vom 22.02.2017 bis 22.03.2017 durchgef\u00fchrt. Es wurden Leitlinien zu \nCOPD gesucht. Recherchestrategie und - vokabular richteten sich nach den M\u00f6glichkeiten der jeweiligen Recher-\nchequelle, wurden entsprechend modifiziert und sind nachfolgend dargelegt. Die Suche umfasst e Dokumente in \ndeutscher und englischer Sprache.  \nLeitliniendatenbanken  \nArbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaft en (AWMF)  \nLeitliniensuche unter  www.awmf.org/leitlinien/leitlinien -suche.html, keine weiteren Filter.  \nSuche nach \u201eCOPD\u201c, \u201eChronisch obstruktive Lungenerkrankung\", \u201eChronisch obstruktive A temwegserkrankung\", \n\u201eChronische Atemwegserkrankung\", \u201eChronisch obstruktive Bronchitis\", \u201eChronische Bronchitis\" .  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  65 \n  \n  \n Guidelines International Network (G -I-N) \nLeitliniensuche unter www.g -i-n.net/library/international -guidelines -library . \nSuche  nach: \u201eCOPD\", \u201e chronic obstructive pulmonary disease\", \u201echronic obstructive lung disease\", \u201echronic ob-\nstructive airway  disease\", \u201echronic bronchitis\", \u201eCOLD\".  \nNational Guideline Clearinghouse (NGC)  \nLeitliniensuche unter www.guideline.gov .  \nSuche nach: \u201e chronic  obstructive pulmonary disease\" (die Suche nach \u201e chronic  obstructive lung  disease\" und \u201e chro-\nnic obstructive airway disease\" war zus\u00e4tzlich nicht notwendig, da in der Suche nur Einzelw\u00f6rter gesucht werden \nund die Ergebnisse somit bereits in der oberen Suche \u201cchronic obstructive pulmonary disease\" gefunden wurden) , \n\u201echronic bronc hitis\", \u201e COAD\",  \u201eCOPD\", \u201eCOLD\".  \nNational Institute for Health and Clinical Excellence (NICE)  \nLeitliniensuche unter  www.nice.org.uk , \u00fcber \u201e guidance\u201d, filter by type: NICE guidelines; clinical guidelines, public \nguidelines.  \nSuch e nach: \u201eCOPD\u201d, \u201eCOLD\u201d,  \u201eCOAD\u201d,  \u201echronic obs tructive pulmonary disease\u201d, \u201e chronic obstructive lung dis-\nease\u201d, \u201ec hronic obstructive airway disease\u201d, \u201echronic bronchitis\u201d.  \nScottish Intercollegiate Guidelines Network (SIGN)  \nSichtung der List e \u201eGuidelines\u201d published by topic \u201crespiratory medicine\" unter www.sign.ac.uk  \nInstitute for Clinical Systems Improvement (ICSI)  \nLeitliniensuche unter www.icsi.org  \u00fcber \u201e guidelines and  more\", \u201eSearch by keywords\u201c  \nSuche nach: \u201eCOPD\u201c, \u201eCOAD\u201c, \u201eCOLD\u201c, \u201e chronic obstructive pulmonary disease\u201c, \u201e chronic obstructive lung dis-\nease\u201c, \u201e chronic obstructive airway disease\u201c, \u201e chronic bronchitis\u201c.  \nDeutsche Gesellschaft f\u00fcr Allgemeinmedizin (DEGAM), DE  \nSichtung der Leitlinien unter www.degam.de/degam -leitlinien -379.html  \nArzneimittelkommission der deutschen \u00c4rzteschaft (Akd\u00c4), DE  \nLeitliniensuche unter www.a kdae.de  \u00fcber die Suchfunktion mit  Eingrenzung: Arzneimitteltherapie/Therapieempfeh-\nlungen.  \nSuche nach: \u201eCOPD\", \u201e Chronisch obstruktive Lungenerkrankung\", \u201e Chronisch obstruktive Atemwegserkrankung\", \n\u201eChronische Atemwegserkrankung\", \u201e Chronisch obstruktive Bronchitis\", \u201eChronische Bronchitis\".  \nNational Health and Medical Research Council (NHMRC), AUS  \nGesucht wurde unter \u201e Guidelines & Publication\" auf der Seite des NHMRC ( www.nhmrc.gov.au/ ) und im Australia n \nClinical Practice Guidelines Portal ( www.clinicalguidelines.gov.au/ ).  \nLeitliniensuche unter www.nhmrc.gov.au/ , \u201efilter by keyword\u201c.  \nSuche nach: \u201eCOPD\u201c, \u201eCOAD\u201c, \u201eCOLD\u201c, \u201e chronic obstructive pulmonary disease\u201c, \u201e chronic obstructive lung dis-\nease\u201c, \u201e chronic obstructive airway disease\u201c, \u201e chronic bronchitis\u201c.  \nLeitliniensuche im \u201e guidelin e portal search\u201c \u00fcber \u201e Free text search\u201c unter www.clinicalguidelines.gov.au/  \nSuche nach: \u201eCOPD\u201c, \u201eCOAD\u201c, \u201eCOLD\u201c, \u201echronic obstructive pulmonary disease\u201c, \u201echronic obstructive lung dis-ease\u201c, \u201echronic obstructive airway disease\u201c, \u201eobstructive\u201c.  \nTripdatabase (UK)  \nLeitliniensuche unter www.tripdatabase.com/ , Filter: \u201e guidelines\u201c  \nSuche nach: \u201e COPD\u201c, \u201e chronic obstructive pulmonary disease\u201c, \u201e chronic obstructive pulmonary chronic obstructive \nlung copd\u201d.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  66 \n  \n  \n World Health Organization (WHO) (International)  \nLeitniniensuche unter www.euro.who.int/de  \u00fcber den Pfad: \u201ehealth topic\": \u201e chronic respiratory diseases\": \u201epublica-\ntions\".  \nDynaMed Pl us (USA)  \nLeitliniensuche unter www.dynamed.com/home, Eingrenzung: \u201e Guidelines a nd Resources\" und \u201e Keine Reviews\".  \nSuche nach: \u201e COPD\".  \nDie Suchbegriffe \"chronic obstructive pulmonary disease\", chronic obstructi ve lu ng disease\", \"chronic obstructi ve \nairway disease\" und \"COAD\" sind innerhalb der Dynamed- Suchfunktion auf das Suchwort \"COPD\" verlinkt und \nf\u00fchrten zu simultanen Suchergebnissen w ie bei o.g. Strategie (\u201e COPD\u201c).  \nSuche nach: \u201eCOLD\".  \nFachspezifische Anbiet erorganisationen  \nEuropean Respiratory Society (ERS) (EU) \nSichtung der Leitlinien auf www.ersnet.org/research/published-guidelines . Sortiert nach Topic: COPD;  \nSuche ohne Einschr\u00e4nkungen nach \u201eCOPD\u201d.  \nDeutsche Atemwegsliga ( DE)  \nLeitliniensuche auf www.atemwegsliga.de/empfehlungen-positionspapiere.html , keine weiteren Einschr\u00e4nkungen \nm\u00f6glich.  \nDeutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin (DGP) (DE)  \nLeitliniensuche auf www.pneumologie.de/publikationen/leitlinien/ , keine we iteren Einschr\u00e4nkungen m\u00f6glich.  \nSchweizerische Gesel lschaft f\u00fcr Pneumologie, CH  \nLeitliniensuche auf www.pneumo.ch/ , \u00fcber \u201e Informationen f\u00fcr Fachpersonen\u201c.  \nAmerican Association for Respiratory Care (AARC) (US)  \nLeitliniensuche auf www.aarc.org/resources/clinical -resources/clinical -practice -guidelines , keine we iteren Ein-\nschr\u00e4nkungen m\u00f6glich.  \nAmerican College of Chest Physicians (ACCP) (US)  \nLeitliniensuche auf www.chestnet.org/Guidelines -and-Resources/CHEST -Guideline-Topic -Areas/Airway -Disor-\nders, keine we iteren Einschr\u00e4nkungen m\u00f6glich.  \nNational Heart, Lung, and Blood Institut e (NHLBI) (US)  \nLeitliniensuche auf www.nhlbi.nih.gov/health-pro/guidelines/current  und https://www.nhlbi.nih.gov/ health-pro/gui-\ndelines/archive, keine weiteren Einschr\u00e4nkung en m\u00f6glich.  \nAustralian Lung Foundation (AUS)  \nLeitliniensuche auf lungfoundation.com.au/health-professionals/guidelines /. \nBritish Thoracic Society (BTS), UK  \nLeitliniensuche auf www.brit -thoracic.org.uk/standards -of-care/guidelines  \u00fcber \u201e Disease/Condition: COPD\u201c  \nCanadian Thoracic Society (CTS) (CA)  \nLeitliniensuche auf www.respiratoryguidelines.org/  \u00fcber \u201e COPD: Guidelines and Standards\u201c  \nThoracic Society of Australia & New Zealand (TSANZ) (AUS, NZ)  \nLeitliniensuche auf www.thoracic.org.au/journal/search.  \nSuche nach \u201e keyw ord: guideline, category: COPD\u201d.  \nSuche nach \u201e keyw ords: COPD, sort by relevance\u201d,  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  67 \n  \n  \n Global Initiative for chronic obstructive lung disease (GOLD) (US, WHO) (INT)  \nLeitliniensuche auf  goldcopd.org  \u00fcber GOLD Reports.  \nIdentifizierte Leitlinien  \nEingeschlossenen Leitlinien  \nTitel Suchergebnis  Land  Kommentar  DELBI \nDom\u00e4ne  3 DELBI \nDom\u00e4ne  6 \nNICE: Chronic obstructive pulmonary dis-\nease in over 16s: di agnosis and manage-\nment (update)  2010  UK Quellleitlinie  85% 50% \nNICE: Chronic obstructive pulmonary dis-\nease in over 16s: diagnosis and manage-\nment \u2013 NICE guideline 2018  UK Quellleitlinie  85% 75% \nGlobal Initiative for Chronic Obstructive Lung \nDisease (GOLD) global strategy for the diag-\nnosis, management, and prevention of \nchronic obstructive pulmonary disease (Re-\nport 2018)  INT Quellleitlinie, interna-\ntional  38% 50% \nGlobal Initiative for Chronic Obstructive Lung \nDisease (GOLD) gl obal strategy for the diag-\nnosis, management, and prevention of \nchronic obstructive pulmonary disease (Re-\nport 2020)  INT Quellleitlinie, interna-\ntional  40% 42% \nS2k-Leitlinie zur Diagnostik und Therapie \nvon Patienten mit chronisch obstruktiver \nBronchitis und Lungenemphysem (COPD)  DE Referenzleitlinie  S2k  \nSpirometrie  DE Referenzleitlinie  S2k  \nTabakentw\u00f6hnung bei COPD  DE Referenzleitlinie  S3  \nHusten  DE Referenzleitlinie  S3  \nTabakkonsum (Rauchen), abh\u00e4ngiger und \nsch\u00e4dlicher: Screening, Diagnostik und Be-\nhandlung  DE Referenzleitlinie  S3  \nNichtinvasive und invasive Beatmung als \nTherapie der chronischen respiratorischen \nInsuffizienz  DE Referenzleitlinie  S2k  \nLangzeit -Sauerstofftherapie  DE Referenzleitlinie, ak-\ntuell in Revision; se-\nlektiv eingebracht  S2k  \nNicht erholsamer Schlaf /Schlafst\u00f6rungen - \nSchlafbezogene Atmungsst\u00f6rungen  DE Referenzleitlinie  S3  \nHaus\u00e4rztliche Leitlinie  \nMultimedikation  DE Referenzleitlinie  S2e  \nProlongiertes Weaning  DE Referenzleitlinie  S2k  \nAkuter und chronischer Husten, Diagnostik \nund Therapie von erwachsenen Patienten  DE Referenzleitlinie  S2k  \nPalliativmedizin f\u00fcr Patienten mit einer nicht \nheilbaren Krebserkrankung  DE zur\u00fcckgestellte Refe-\nrenzleitlinie; f\u00fcr Kapi-\ntel Palliativmedizin, \n3. Auflage NVL \nCOPD    NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  68 \n  \n  \n Titel Suchergebnis  Land  Kommentar  DELBI \nDom\u00e4ne  3 DELBI \nDom\u00e4ne  6 \nNichtinvasive Beatmung als Therapie der \nakuten respiratorischen Insuffizienz  DE zur\u00fcckgestellte Re-\nfenzleitlinie; f\u00fcr Kapi-\ntel Exazerbation, 3. \nAuflage NVL COPD  S3  \nVA/DoD clinical practice guideline for the \nmanagement of chronic obstructive pulmo-\nnary disease.  USA Suche max. bis \n2015, E f\u00fcr Diagnos-\ntik-Kapitel 65% 25% \nManagement of COPD exacerbations: a Eu-\nropean Respiratory Society/American Tho-\nracic Society guideline EU/ \nUSA zur\u00fcckgestellt; evtl. \nf\u00fcr Kapitel E xazerba-\ntionen, 3. Auflage \nNVL COPD 67% 25% \nPrevention of COPD exacerbations: a Euro-\npean Respiratory Society/American Thoracic \nSociety guideline EU/ \nUSA zur\u00fcckgestellt; evtl. \nf\u00fcr Kapitel Exazerba-\ntionen, 3. Auflage \nNVL COPD 63% 25% \nAusgeschlossene Leitlinien  \nTitel Suchergebnis  Land  A Kommentar  \nPrevention of Acute Exacerbations of COPD: \nAmerican College of Chest Physicians and \nCanadian Thoracic Society Guideline  USA/ \nCA A4 Literaturrecherche bis 2013 durchgef\u00fchrt.  \nGlobal Initiative for Chronic Obstructive Lung \nDisease (GOLD) global strategy on diagnosis, \nmanagement, and prevention of COPD (Re-\nport 2017)  INT A4 Aktualisierte Version verf\u00fcgbar.  \nInstitute for Clinical Systems Improvement \n(ICSI) Health Care Guideline: Diagnosis and \nManagement of Chronic Obstructive Pulmo-\nnary Disease (COPD)  USA A3 keine LL; behandelt andere Forschungsfragen.  \nNational Institute for Health and Clinical Ex-\ncellence (NICE) guideline on management of \nCOPD in adults in primary and s econdary \ncare; Update 2012  UK A4 Aktualisierte Version verf\u00fcgbar.  \nDiagnosis and Pharmacotherapy of Stable \nChronic Obstructive Pulmonary Disease: The \nFinnish Guidelines  FIN A2 Methodische Bewertung nicht m\u00f6glich; nur \nAuszug in Englisch verf\u00fcgbar (MiniReview); \nLangfassung der Leitlinie nur in Finnisch.  \nThe COPD X Plan: Australian and New Zea-\nland Guidelines for the management of \nChronic Obstructive Pulmonary Disease 2016  AUS A7 Methodische Qualit\u00e4t AGREE II, Dom\u00e4ne 3: \n10%.  \nChronic Obstructive Pulm onary Disease \n(COPD): Diagnosis and Management  CA A7 Methodische Qualit\u00e4t AGREE II, Dom\u00e4ne 3: \n8%. \nClinical practice guideline for the treatment of \npatients with chronic obstructive pulmonary \ndisease (COPD)  ESP A3 Kein Diagnostik -Kapitel; methodische Begleit-\ndokumente nur in Spanisch.  \nDiagnosis and Management of Chronic Ob-\nstructive Pulmonary Disease: The Swiss \nGuidelines  CHE  A7 Methodische Qualit\u00e4t Dom\u00e4ne 3: 8%; Dom\u00e4ne \n6: 0%.  \nLagerungstherapie und Fr\u00fchmobilisation zur \nProphylaxe oder Therapie von pulmonalen \nFunktionsst\u00f6rungen  DE A3 zu speziell f\u00fcr NVL.  \nPneumonie, ambulant erworben, Behandlung \nund Pr\u00e4vention von erwachsenen Patienten  DE A3 nicht COPD -relevant.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  69 \n  \n  \n Titel Suchergebnis  Land  A Kommentar  \nEpidemiologie, Diagnostik und Therapie er-\nwachsener Patienten mit nosokomialer Pneu-\nmonie  DE A3 zu speziell f\u00fcr NVL  \nTherapieempfehlungen der Arzneimittelkom-\nmission der deutschen \u00c4rzteschaft 3. Auflage \n2013 Atemwegsinfektionen  DE A5 keine Leitlinie  \nLungenszintigraphie  DE A3 zu speziell f\u00fcr NVL  \nLegende der Ausschlussgr\u00fcnde: A1: Dopplung, A2: Sprache, A3: thematisch nicht passend, A4: G\u00fcltigkeit/ Ver\u00f6ffentli-\nchungsdatum, A5: keine Leitlinie, A6: nicht erh\u00e4ltlich; A7: Qualit\u00e4t  \nAnhang 3.2  Cochrane Reviews  bis 2017 \nPICO -Fragestellung  \nPopulation: COPD  \nIntervention: keine Einschr\u00e4nkung  \nVergleich: keine Einschr\u00e4nkung \nEndpunkte: keine Einschr\u00e4nkung  \nStudientyp: Cochrane Reviews (Systematische \u00dcbersichtsarbeiten und Metaanalysen) und Protokolle  \nBegr\u00fcndung f\u00fcr die Recherche \nZiel war es, qualitativ hochwertige  systematische \u00dcbersichtsarbeiten f\u00fcr die Aktualisierung der NVL COPD, 2. Auf-\nlage zu identifizieren.  \nRecherchestrategien  \nDatenbanken der Cochrane Library (4. September 2017)  \nNr. Suchfrage  Anzahl  \n#5 #1 or #2 or #3 or #4 in Cochrane Reviews (Reviews and Protocols)  174 \n#4 (obstruct*) near/3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*):ti  \n(Word variations have been searched)  6172  \n#3 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  3428  \n#2 COAD:ti,ab,kw  (Word variations have been searched)  48 \n#1 COPD:ti,ab,kw  (Word variations have been searched)  10352  \n \nCochrane Reviews  \n\u2022 Review  \n\u2022 Protocol   \n146 \n28 \nAnzahl der Treffer: 174  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  70 \n  \n  \n Flussdiagramm:  \n \nLegende:  \nA3: andere Fragestellung  \nA4: abgelaufene G\u00fcltigkeit, neuere Version des Reviews bereits ver\u00f6ffentlicht  \nA5: Publikationstyp: Protokolle (vorl\u00e4ufig), Netzwerk -Metaanalyse  \nIn der Literaturrecherche identifizierte und thematisch passende Protokolle wurden nach dem Volltext -Screening \nvorerst wieder als ausgeschlossen gekennzeichnet (n=21). Sobald diese als Reviews publiziert werden, wird erneut \nder Volltext gepr\u00fcft, die AMSTAR -Bewertung durchgef\u00fchrt und dementsprechend \u00fcber Ein - bzw. Ausschluss ent-\nschieden.  \nCochrane Reviews, welche sich inhaltlich mit Patient*innen mit Bronchiektasen befassen, wurden A3 ausgeschlos -\nsen (n=13).  \nCochrane Reviews 08/2018 \nF\u00fcr die Arbeiten an den Kapiteln nichtmedikament\u00f6se Therapie sowie Rehabi litation wurde der Publikationsstatus \nder zu diesen Themen passenden Protokolle (n=9) \u00fcberpr\u00fcft. 2 Reviews wurden mittlerweile ver\u00f6ffentlicht. Einer dieser Review [59] behandelt speziell Patient*innen mit  COPD, so dass ein bis dato vorl\u00e4ufig eingeschlossener \nReview [112] , welcher COPD als Subgruppe untersuchte, nun ausgeschlossen werden konnte.  \nFlussdiagramm:  \n \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 174 \nEingeschlossene Titel/Abstracts:  \nn = 120 \nEingeschlossene Volltexte  \nn = 80 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 54 \nAusgeschlossene  \nVolltexte: n  = 40 \nA3: n = 14  \nA4: n = 4 \nA5: n = 22 \n \nLiteratur von Experten  \nn = 0 \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 174 \nEingeschlossene Titel/Abstracts:  \nn = 120 \nEingeschlossene Volltexte  \nn = 81 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 54 \nAusgeschlossene  \nVolltexte: n  = 40 \nA3: n = 15 \nA4: n = 4 \nA5: n  = 20 \n \nLiteratur von Experten  \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  71 \n  \n  \n Anhang 3.3  Cochrane Reviews 2017 \u2013  2019  \nPICO -Fragestellung  \nPopulation:  COPD  \nIntervention:  keine Einschr\u00e4nkung  \nVergleich:  keine Einschr\u00e4nkung  \nEndpunkte:  keine Einschr\u00e4nkung  \nStudientyp : Cochrane Reviews (Systematische \u00dcbersichtsarbeiten und Metaanalysen) und Protokolle  \nBegr\u00fcndung f\u00fcr die Recherche \nDie im September 2017 durchgef\u00fchrte Recherche zum Thema COPD in der Cochrane Library wurde wiederholt; \neine Einschr\u00e4nkung des Suchzeitraumes von 09/2017 \u2013  01/2019 wurde angewendet.  \nRecherchestrategie  \nDatenbanken der Cochrane Library (11. Januar 2019)  \nKomplettrecherche Update (Suchzeitraum 09/2017 \u2013  01/2019):  \nNr. Suchfrage  Anzahl  \n#5 #1 or #2 or #3 or #4 with Cochrane Library publication date Between Sep 2017 and \nJan 2019, in Cochrane Reviews, Cochrane Protocols  23 \n#4 (obstruct*) near/3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*):ti \n(Word variations have been searched)  6074  \n#3 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4634  \n#2 (COAD):ti,ab,kw  63 \n#1 (COPD):ti,ab,kw  12057  \n \nCochrane Reviews  \n\u2022 Review  \n\u2022 Protocol   \n13 \n10 \nF\u00fcr die n=13 identifizierten Reviews:  \n\uf0a1 1/13 wurde neu gefunden, behandelt das Selbstmanagement bei Bronchiektasen und wird somit A3 ausge-\nschlossen.  \n\uf0a1 7/13 sind publizierte Reviews, deren Protokolle in der 1. Recherche identifiziert wurden.  \n\uf0a1 5/13 sind Update-Reviews, deren Vorg\u00e4ngerversionen ebenfalls bereits gefunden werden konnten.  \nFlussdiagramm:  \n \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 174 + 23  \nEingeschlossene Titel/Abstracts:  \nn = 120 + 23  \nEingeschlossene Volltexte  \nn = 88 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 54 \nAusgeschlossene  \nVolltexte: n=  \nA3: n = 16 \nA4: n = 9 \nA5: n = 23 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  72 \n  \n  \n Anhang 3.4  Stellenwert der diagnostischen  Verfahren  \nPICO -Fragestellung  \nPopulation: Patient*innen mit (Verdacht auf) COPD  \nIntervention: Spirometrie, DLCO, Bodyplethysmographie, Computertomographie  \nVergleich: jegliche  \nEndpunkte: Testg\u00fcte; diagnostische Genauigkeit  \nStudientyp: Diagnostische Studien, systematische \u00dcbersichtsarbeiten  \nRecherchestrategien  \nDer McMaster (2) \u2013 Filter f\u00fcr diagnostische Studien wurde in dieser Recherche angewendet.  \nMedline via Pubmed (www.pubmed.gov) (08.06.2018)  \nNr. Suchfrage  Anzahl  \n#21 Search  ((#17 AND #19) NOT #20)  2057  \n#20 Search  (#17 AND #18)  285 \n#19 Search  (sensitiv*[Title/Abstract] OR sensitivity and specificity[MeSH Terms] OR \n(predictive[Title/Abstract] AND value*[Title/Abstract]) OR predictive value of tests[MeSH \nTerm] OR accuracy*[Title/Abstract])  1830262  \n#18 Search  systematic[sb]  365593  \n#17 Search  (#7 AND #16)  15134  \n#16 Search  (#8 OR #9 OR #11 OR #12 OR #13 OR #14 OR #15)  673350  \n#15 Search  ((Computed OR Computerized OR \"Computer Assisted\" OR x -ray OR xray) AND \ntomography[tiab]) OR CT[tiab] OR CT -scan OR \"CAT scan\" OR CAT -scan OR \"Electron \nBeam Tomography\" OR MDCT OR MSCT OR multi -detector OR \u201cmulti detector\u201d OR \nmultidetector OR multi -slice OR \u201cmulti slice\u201d OR multislice  634520  \n#14 Search  \"Tomography, X -Ray Computed\"[Mesh]  381065  \n#13 Search  \u201cBody plethysmogra phy\u201d[tiab] OR \u201cBodyplethysmography\u201d[tiab]  1726  \n#12 Search  \"Plethysmography, Whole Body\"[Mesh]  1800  \n#11 Search  \u201clung diffusion\u201d[tiab] OR \u201cdiffusion capacity\u201d [tiab] OR \u201cdiffusing capacity\u201d[tiab] OR \n\u201cdiffusion lung capacity\u201d [tiab] OR \u201ctransfer factor\u201d [ti ab] OR \u201cDLCO\u201d[tiab] OR \u201cTLCO\u201d[tiab]  9206  \n#10 Search  \"Pulmonary Diffusing Capacity\"[Mesh]  3675  \n#9 Search  spirometr*[tiab]  19399  \n#8 Search  \"spirometry\"[Mesh]  20552  \n#7 Search  (#1 OR #2 OR #3 OR #4 OR #5 OR #6)  96369  \n#6 Search  \u201cAir trapping\u201d[tiab] OR airtrapping[tiab]  1210  \n#5 Search  COAD [tiab]  260 \n#4 Search  COPD[tiab]  38713  \n#3 Search  Emphysem*[tiab]  25581  \n#2 Search  \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  48371  \n#1 Search  ((chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or \nairway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab])))  53298  \nAnzahl der Treffer: Aggregierte Evidenz: 285; Diagnostische Studien: 2057  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  73 \n  \n  \n Datenbanken der Cochrane Library (08.06.2018)  \nNr. Suchfrage  Anzahl  \n#43 #36 and #42 in Cochrane Reviews (Reviews and Protocols), Other Reviews, Trials \nand Technology Assessments  259 \n#42 #37 or #38 or #39 or #40 or #41  85211  \n#41 (predictive and value*):ti,ab,kw  (Word variations have been searched)  16587  \n#40 MeSH descriptor: [Predictive Value of Tests] explode all trees  7863  \n#39 accuracy*:ti,ab,kw  (Word variations have been searched)  20958  \n#38 sensitiv*:ti,ab,kw  (Word variations have been searched)  62756  \n#37 MeSH descriptor: [Sensitivity and Specificity] explode all trees  19485  \n#36 #9 and #35  2581  \n#35 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 \nor #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 #33 or #34  98092  \n#34 (MDCT or MSCT):ti,ab,kw  464 \n#33 (multi -detector or \"multi detector\" or multidetector or multi -slice or \"multi slice\" or \nmultislice):ti,ab,kw  (Word variations have been searched)  1159  \n#32 \"Electron Beam Tomography\":ti,ab,kw  (Word variations have been searched)  34 \n#31 \"CAT scan\":ti,ab,kw  (Word variations have been searched)  18 \n#30 CT-scan:ti,ab,kw  (Word variations have been searched)  3444  \n#29 CT:ti,ab,kw  86283  \n#28 \"Xray tomography\":ti,ab,kw  (Word variations have been searched)  0 \n#27 \"x-ray tomography\":ti,ab,kw  (Word variations have been searched)  12 \n#26 \"Computer Assisted tomography\":ti,ab,kw  (Word variations have been searched)  4897  \n#25 \"Computerized tomography\":ti ,ab,kw  (Word variations have been searched)  657 \n#24 \"Computed tomography\":ti,ab,kw  (Word variations have been searched)  9682  \n#23 MeSH descriptor: [Tomography, X -Ray Computed] explode all trees  5664  \n#22 \"Bodyplethysmography\":ti,ab,kw  (Word variations have been searched)  24 \n#21 \"Body plethysmography\":ti,ab,kw  (Word variations have been searched)  229 \n#20 MeSH descriptor: [Plethysmography, Whole Body] explode all trees  95 \n#19 TLCO:ti,ab,kw  38 \n#18 DLCO:ti,ab,kw  376 \n#17 \"transfer factor\":ti,ab,kw  (Word variations have been searched)  196 \n#16 \"diffusion lung capacity\":ti,ab,kw  (Word variations have been searched)  6 \n#15 \"diffusing capacity\":ti,ab,kw  (Word variations have been searched)  382 \n#14 \"diffusion capacity\":ti,ab,kw  (Word variations have been searched)  360 \n#13 \"lung diffusion\":ti,ab,kw  (Word variations have been searched)  289 \n#12 MeSH descriptor: [Pulmonary Diffusing Capacity] explode all trees  121 \n#11 spirometry:ti,ab,kw  (Word variations have been searched)  4504  \n#10 MeSH descriptor: [Spirometry] explode all trees  1625  \n#9 #1 or #2 or #3 or #4 or #7 or #8  17799  \n#8 (\"air trapping\" or airtrapping):ti,ab,kw  (Word variations have been searched)  99 \n#7 (#6 and chronic*):ti,ab,kw  12332  \n#6 (#5 and obstruct*):ti,ab,kw  18192  \n#5 (pulmonary or lung* or airway* or airflow* or bronchi* or respirat*):ti,ab,kw  (Word \nvariations have been searched)  121055  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  74 \n  \n  \n Nr. Suchfrage  Anzahl  \n#4 Emphysem*:ti,ab,kw  (Word variations have been searc hed) 1228  \n#3 COAD:ti,ab,kw  51 \n#2 COPD:ti,ab,kw  12534  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  5044  \n \nCochrane Reviews  \n\u2022 Review  \n\u2022 Protocol   \n0 \n0 \nOther Reviews  1 \nTrials  258 \nMethods Studies   Nicht gesucht  \nTechnology Assessment  0 \nEconomic Evaluations  Nicht gesucht  \nCochrane Groups  Nicht gesucht  \nAnzahl der Treffer: 259  \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  285 1 286 \nDiagnostische Studien/  \nTrials  2057  258 2315  \nGesamt    2601  \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 137  \nA2 (nicht englisch/deutsch): 145  \nA3 (Conference Abstracts): 43  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 2276  \nFlussdiagramm:  \n \nAa: andere Fragestellung; Ap: Pu blikationstyp nicht passend  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 2276  \nEingeschlossene Titel/Abstracts:  \nn = 155 \nEingeschlossene Volltexte  \nn = 16 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 2121  \nAusgeschlossene  \nVolltexte: n=  \nAa: n = 103   \nAp: n = 36 \nLiteratur von Experten  \noder durch Handsuche \nn =  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  75 \n  \n  \n Anhang 3.5  \u00dcber -/Unterdiagnose  \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD bzw. mit Verdacht auf COPD  \nIntervention: jegliche  \nVergleich: jegliche \nEndpunkte: \u00dcber - und Unterdiagnose  \nStudientyp: Kohortenstudien, systematische \u00dcbersichtsarbeiten, keine Eingrenzung des Suchzeitraumes  \nRecherchestrategien  \nGesucht wurde nach m\u00f6glicher \u00dcber - bzw. Unterdiagnose einer COPD im Rahmen der verschiedenen diagnosti-\nschen Verfahren. Insbesondere die Nutzung verschiedener Referenzwerte soll n\u00e4her beleuchtet werden. Der SIGN \n\u2013Filter f\u00fcr Kohortenstudien wurde in dieser Recherche angewendet.  \nMedline via Pubmed (www.pubmed.gov) (06.06.2018)  \nNr. Suchfrage  Anzahl  \n#30 Search (((#23 AND #27) NOT (#28 OR #29))) - Beobachtungsstudien  927 \n#29 Search ((#23 AND #25) NOT #28) - RCTs  239 \n#28 Search (#23 AND #24) \u2013 aggregierte Evidenz  144 \n#27 Search (((((((((\"Case -Control Studies\"[Mesh] OR \"Cohort Studies\"[Mesh]))) OR \"Cross -\nSectional Studies\"[Mesh]) OR ((\"Follow -Up Studies\"[Mesh] OR ((\"follow -up\" OR \"follow \nup\") AND (studies OR study))))) OR ((longitudinal[tw] OR retrospective[tw] OR \"cross -sec-\ntional \"[tw] OR \"cross sectional\"[tw]))) OR (\"case control\"[tw] OR (cohort[tw] AND \nanaly*[tw]))) OR \"Observational Study\"[pt])))  2767403  \n#25 Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized \n[tiab] OR placebo [tiab] OR \"cli nical trials as topic\" [MeSH Terms:noexp] OR randomly \n[tiab] OR trial [ti])  1160741  \n#24 Search systematic[sb]  365316  \n#23 Search (#7 AND #22)  3149  \n#22 Search (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR \n#18 OR #19 OR #20 OR #21)  500488  \n#21 Search ((Accuracy[tiab] OR Inaccuracy[tiab] OR Inadequate[tiab] OR Improper[tiab] OR \nIncorrect[tiab] OR Imprecise[tiab] OR Erroneous[tiab]) AND diagnos*[tiab])  113990  \n#20 Search Validit*[tiab]  150189  \n#19 Search \u201cFalse negative\u201d [tiab]  25493  \n#18 Search Under -diagnos*[tiab]  2929  \n#17 Search Underdiagnos*[tiab]  7921  \n#16 Search \u201cFalse positive\u201d [tiab]  43517  \n#15 Search Overdetection[tiab]  95 \n#14 Search Mis -diagnos*[tiab]  183 \n#13 Search Misdiagnos*[tiab]  27986  \n#12 Search Overdiagnos*[tiab]  3431  \n#11 Search \u201cdiagnostic error\u201d[tiab]  1239  \n#10 Search \"Diagnostic Errors\"[Mesh]  109206  \n#9 Search Overestimat*[tiab]  33606  \n#8 Search Underestimat*[tiab]  56642  \n#7 Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6)  96331  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  76 \n  \n  \n Nr. Suchfrage  Anzahl  \n#6 Search \u201cAir trapping\u201d[tiab] OR airtrapping[tiab]  1210  \n#5 Search COAD[tiab]  260 \n#4 Search COPD[tiab]  38687  \n#3 Search Emphysem*[tiab]  25576  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  48354  \n#1 Search ((chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab])))  53267  \nAnzahl der Treffer: aggregierte Evidenz: 144; RCTs 239; Beobachtungsstudien: 927  \nDatenbanken der Cochrane Library (06.0 6.2018)  \nNr. Suchfrage  Anzahl  \n#26 (#9 and #25) not \"conference abstract\":pt in Cochrane Reviews (Reviews and Proto-\ncols), Other Reviews, Trials, Methods Studies and Technology Assessments  357 \n#25 #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 \nor #23 or #24  46333  \n#24 Overestimat*:ti,ab,kw  (Word variations have been searched)  1797  \n#23 Underestimat*:ti,ab,kw  (Word variations have been searched)  2268  \n#22 (#21 and diagnos*):ti,ab,kw  (Word variations have been searched)  12801  \n#21 (Accuracy or Inaccuracy or Inadequate or Improper or Incorrect or Imprecise or Errone-\nous):ti,ab,kw  (Word variations have been searched)  31255  \n#20 Validit*:ti,ab,kw  (Word variations have been searched)  8866  \n#19 \"False negative\":ti,ab,kw  (Word variations have been searched)  1554  \n#18 Under -diagnos*:ti,ab,kw  (Word variations have been searched)  123 \n#17 Underdiagnos*:ti,ab,kw  (Word variations have  been searched)  196 \n#16 \"False positive\":ti,ab,kw  (Word variations have been searched)  2414  \n#15 Overdetection:ti,ab,kw  (Word variations have been searched)  20 \n#14 Mis-diagnos*:ti,ab,kw  (Word variations have been searched)  3 \n#13 Misdiagnos*:ti,ab,kw  (Word variations have been searched)  375 \n#12 Overdiagnos*:ti,ab,kw  (Word variations have been searched)  221 \n#11 \"diagnostic error*\":ti,ab,kw  (Word variations have been searched)  648 \n#10 MeSH descriptor: [Diagnostic Errors] explode all trees  3093  \n#9 #1 or #2 or #3 or #4 or #7 or #8  17788  \n#8 (\"air trapp*\" or airtrapp*):ti,ab,kw  (Word variations have been searched)  88 \n#7 (#6 and chronic*):ti,ab,kw  12332  \n#6 (#5 and obstruct*):ti,ab,kw  18192  \n#5 (pulmonary or lung* or airway* or airflow* or bronchi* or respirat*):ti,ab,kw  (Word varia-\ntions have been searched)  121055  \n#4 Emphysem*:ti,ab,kw  (Word variations have been searched)  1228  \n#3 COAD:ti,ab,kw  51 \n#2 COPD:ti,ab,kw  12534  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  5044  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  77 \n  \n  \n Cochrane Reviews  \n\u2022 Review  \n\u2022 Protocol   \n14 \n1 \nOther Reviews  0 \nTrials  337 \nMethods Studies   4 \nTechnology Assessment  1 \nEconomic Evaluations  Nicht gesucht  \nCochrane Groups  Nicht gesucht  \nAnzahl der Treffer: 357  \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  144 16 160 \nRCTs  239 341 1507  \nBeaobachtungsstudien  927 \nSumme    1667  \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 168  \nA2 (nicht englisch/deutsch): 84 \nA3 (Conference Abstracts/Poster): 13  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 1402  \nKriterien f\u00fcr Ein-  und Ausschluss  \nEinschluss: Fragestellung passend; Systematic Review; Randomisierte kontrollierte Studien (RCT)  \nEz: zur\u00fcckgestellt. mit Experten diskutieren \nAusschluss  \nAa: thematisch nicht passend: andere Erkrankung, andere Fragestellung, anderes Thema Verwendung anderer \nEquations als GLI -Referenzwerte (Bsp: NHANRS I I reference equation)  \nAp: Publikationstyp nicht passend: nicht -systematischer (narrativer) Review, Prim\u00e4rstudien (RCT, Kohorten etc.), \nEditorials, Kommentare, Letter etc., Guidelines  \nAq: schwache methodische Qualit\u00e4t  \nCross -over -Studien wurden in die Ergebn isse mit einbezogen. Vergleichsstudien, welche andere Referenzwerte \nals die GLI -Werte von 2012 f\u00fcr die spiro metrische Beurteilung nutzen, wurden Aa ausgeschlossen. Ebenso wurden \nStudien, welche ausschlie\u00dflich prebronchodilatatorische Werte betrachten Aa au sgeschlossen.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  78 \n  \n  \n Flussdiagramm  \n \nAnhang 3.6  Ph\u00e4notypisierung mittels Computertomographie \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: Computertomographie  \nVergleich: jegliche \nEndpunkte: Ph\u00e4notypisierung der COPD  \nStudientyp: diagnostische Studien, aggregierte Evidenz, ggf. Beobachtungsstudien  \nRecherchestrategien  \nDie Spirometrie als Comparator wurde nicht mit einbezogen, da sich diese zu restriktiv in der Recherche auswirkte. \nDer McMaster (2) \u2013 Filter f\u00fcr diagnostische Studien wurde in dieser Recherche angewendet.  \nMedline via Pubmed (www.pubmed.gov) (18.06.2018)  \nNr. Suchfrage  Anzahl  \n#19 Search  (#15 AND #17) NOT #18  145 \n#18 Search  #15 AND #16  6 \n#17 Search  sensitiv*[Title/Abstract] OR sensitivity and specificity[MeSH Terms] OR \n(predictive[Title/Abstract] AND value*[Title/Abstract]) OR predictive value of tests[MeSH \nTerm] OR accuracy*[Title/Abstract]  1832919  \n#16 Search  systematic[sb]  366468  \n#15 Searc h (#6 AND #14)  724 \n#14 Search  (#9 AND #13)  28332  \n#13 Search  ((#10 AND #11) OR #12)  1158158  \n#12 Search  (morpholog*[tiab] OR phenotyp*[tiab] OR subtyp*[tiab])  1157574  \n#11 Search  (focal[tiab] OR panacin*[tiab] OR panlobul*[tiab] OR centriacin*[tiab] OR \ncentrilobul* OR parasept*[tiab])  142051  \n#10 Search  (Emphysem*[tiab] OR \"Pulmonary Emphysema\"[Mesh])  30207  \n#9 Search  (#7 OR #8)  635548  \n#8 Search  ((Computed OR Computerized OR \"Computer Assisted\" OR x -ray OR xray) AND \ntomography[tiab]) OR CT[tiab] OR CT -scan OR \"CAT scan\" OR CAT -scan OR \"Electron \nBeam Tomography\" OR MDCT OR MSCT OR multi -detector OR \u201cmulti detector\u201d OR \nmultidetector OR multi -slice OR \u201cmulti slice\u201d OR multislice  635548  \n#7 Search  \"Tomography, X -Ray Compu ted\"[Mesh]  381691  \n#6 Search  #1 OR #2 OR #3 OR #4 OR #5  84586  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 1402  \nEingeschlossene Ti-\ntel/Abstracts: 142 \n   \nEingeschlossene Volltexte  \nn = 5 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 1260  \nAusgeschlossene  \nVolltexte: n=  \nAa: n = 108 \nAp: n = 8 \nAq: n = 3 \nEz: n = 18 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  79 \n  \n  \n Nr. Suchfrage  Anzahl  \n#5 Search  \u201cAir trapping\u201d[tiab] OR airtrapping[tiab]  1210  \n#4 Search  COAD[tiab]  260 \n#3 Search  COPD[tiab]  38797  \n#2 Search  \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  48477  \n#1 Search  (chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or \nairway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab]))  53390  \nAnzahl der Treffer: Aggregierte Evidenz: 6; Diagnostische Studien: 145  \nDatenbanken der Cochrane Library (18.06.2018)  \nNr. Suchfrage  Anzahl  \n#34 (#29 and #33) not \"conference abstract\":pt in Cochrane Reviews (Reviews and \nProtocols), Other Reviews, Trials and Technology Assessments  8 \n#33 #30 or #31 or #32  85212  \n#32 ((predictive and value*) or accuracy* or sensitiv*):ti,ab,kw  (Word variations have been \nsearched)  84708  \n#31 MeSH descriptor: [Predictive Value of Tests] explode all trees  7863  \n#30 MeSH descriptor: [Sensitivity and Specificity] explode all trees  19485  \n#29 #8 and #28  70 \n#28 #21 and #27  1953  \n#27 (#24 and #25) or #26  16944  \n#26 (subtyp* or phenotyp* or morpholog*):ti,ab,kw  (Word variations have been searched)  16940  \n#25 (parasep* or centrilobu* or centriacin* or panlobul* or panacin* or focal):ti,ab,kw  (Word \nvariations have been searched)  3581  \n#24 #22 or #23  1228  \n#23 MeSH descriptor: [Pulmonary Emphysema] explode all trees  292 \n#22 Emphysem*:ti,ab,kw  1228  \n#21 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20  93346  \n#20 (MDCT or MSCT):ti,ab,kw  464 \n#19 (multi -detector or \"multi detector\" or multidetector or multi -slice or \"multi slice\" or \nmultislice):ti,ab,kw  (Word variations hav e been searched)  1159  \n#18 \"Electron Beam Tomography\":ti,ab,kw  (Word variations have been searched)  34 \n#17 \"CAT scan\":ti,ab,kw  (Word variations have been searched)  18 \n#16 CT-scan:ti,ab,kw  (Word variations have been searched)  3444  \n#15 CT:ti,ab,kw  86283  \n#14 \"Xray tomography\":ti,ab,kw  (Word variations have been searched)  0 \n#13 \"x-ray tomography\":ti,ab,kw  (Word variations have been searched)  12 \n#12 \"Computer Assisted tomography\":ti,ab,kw  (Word variations have been searched)  4897  \n#11 \"Computerized tomography\":ti,ab,kw  (Word variations have been searched)  657 \n#10 \"Computed tomography\":ti,ab,kw  (Word variations have been searched)  9683  \n#9 MeSH descriptor: [Tomography, X -Ray Computed] explode all trees  5664  \n#8 #1 or #2 or #3 or #6 or #7  17253  \n#7 (\"air trapping\" or airtrapping):ti,ab,kw  (Word variations have been searched)  99 \n#6 (#5 and chronic*):ti,ab,kw  12332  \n#5 (#4 and obstruct*):ti,ab,kw  18193  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  80 \n  \n  \n Nr. Suchfrage  Anzahl  \n#4 (pulmonary or lung* or airway* or airflow* or bronchi* or respirat*):ti,ab,kw  (Word \nvariations have been searched)  121058  \n#3 COAD:ti,ab,kw  51 \n#2 COPD:ti,ab,kw  12534  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  5044  \n \nCochrane Reviews  \n\u2022 Review  \n\u2022 Protocol   \n0 \n0 \nOther Reviews  0 \nTrials  8 \nMethods Studies   Nicht gesucht  \nTechnology Assessment  0 \nEconomic Evaluations  Nicht gesucht  \nCochrane Groups  Nicht gesucht  \nAnzahl der Treffer: 8 Trials  \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  6 0 6 \nDiagnostische Studien/Trials  145 8 153 \nGesamt  159 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 7  \nA2 (nicht englisch/deutsch): 5  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 147  \nFlussdiagramm:  \n \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 147 \nEingeschlossene Titel/Abstracts:  \nn = 32 \nEingeschlossene Volltexte  \nn = 7 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 115 \nAusgeschlossene  \nVolltexte:  \nAa: n = 24 \nAp: n = 1 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  81 \n  \n  \n Anhang 3.7  Cut-Off Symptomerfassung \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD oder Verdacht auf COPD  \nIntervention: mMRC, CAT, CCQ, SGRQ  \nVergleich: jegliche  \nEndpunkte: Cut Off f\u00fcr die Einsch\u00e4tzung: schwere vs. mittlere/geringe Symptomatik  \nStudientyp: Aggregierte Evidenz, RCTs, sonstige Prim\u00e4rpublikationen  \nRecherchestrategien  \nMedline via Pubmed (www.pubmed.gov) (14.06.2018)  \nNr. Suchfrage  Anzahl  \n#15 Search  (#10 NOT (#13 OR #14)) \u2013 Sonstige Prim\u00e4rpublikationen  168 \n#14 Search  ((#10 AND #12) NOT #13) \u2013 RCT 33 \n#13 Search  (#10 AND #11) \u2013 Aggregierte Evidenz  14 \n#12 Search  (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized \n[tiab] OR placebo [tiab] OR \"clinical trials as topic\" [MeSH Terms:noexp] OR randomly \n[tiab] OR trial [ti])  1162149  \n#11 Search  systematic[sb]  366144  \n#10 Search  (#7 AND #8 AND #9)  215 \n#9 Search  (Cutoff[tiab] OR \u201ccut off\u201d [tiab] OR cut -off[tiab] OR cut -score[tiab] OR cut-\nscores[tiab] OR \u201ccut score\u201d [tiab] OR \u201ccut scores\u201d [tiab] OR cut -point[tiab] OR cut -\npoints[tiab] OR cutpoint[tiab] OR cutpoints[tiab] OR \u201ccut point\u201d [tiab] OR \u201ccut points\u201d [tiab] \nOR threshold[tiab] OR thresholds[tiab])  309594  \n#8 Search  ((Symptom*[tiab ] AND (test[tiab] OR Questionnaire*[tiab])) OR mMRC[tiab] OR \n\u201cmodified Medical Research Council\u201d [tiab] OR (COPD[tiab] AND Clinical[tiab] AND Ques-\ntionnaire[tiab]) OR CCQ[tiab] OR \u201cRespiratory Questionnaire\u201d [tiab] OR SGRQ[tiab] OR \n\u201cCOPD assessment test\u201d [tiab] OR CAT[tiab])  255882  \n#7 Search  #1 OR #2 OR #3 OR #4 OR #5 OR #6  96456  \n#6 Search  \u201cAir trapping\u201d[tiab] OR airtrapping[tiab]  1210  \n#5 Search  COAD [tiab]  260 \n#4 Search  COPD[tiab]  38765  \n#3 Search  Emphysem*[tiab]  25595  \n#2 Search  \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  48448  \n#1 Search  ((chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or \nairway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab])))  53348  \nAnzahl der Treffer: Sonstige Prim\u00e4rpublikationen: 168; RCT: 33; Aggregierte Evidenz: 14  \nDatenbanken der Cochrane Library (14.06.2018)  \nNr. Suchfrage  Anzahl  \n#15 (#9 and #13 and #14) not \"conference abstract\":pt in Cochrane Reviews (Reviews \nand Protocols), Other Reviews, Trials and Technology Assessments  65 \n#14 (Cutoff or \"cut off\" or cut -off or cut -score or cut -scores or \"cut score\" or \"cut scores\" or cut -\npoint or cut -points or cutpoint or cutpoints or \"cut point\" or \"cut points\" or threshold or \nthresholds):ti,ab,kw  (Word variations have been searched)  25680  \n#13 #10 or #11 or #12  50207  \n#12 (symptom* and (test or questionnaire)):ti,ab,kw  (Word variations have been searched)  47674  \n#11 (COPD and Clinical and Questionnaire):ti,ab,kw  (Word variations have been searched)  940 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  82 \n  \n  \n Nr. Suchfrage  Anzahl  \n#10 (mMRC or \"modified Medical Research Council\" or CCQ or \"Respiratory Questionnaire\" or \nSGRQ or \"COPD assessment test\" or CAT):ti,ab,kw  (Word variations have been \nsearched)  3095  \n#9 #1 or #2 or #3 or #4 or #7 or #8  17799  \n#8 (\"air t rapping\" or airtrapping):ti,ab,kw  (Word variations have been searched)  99 \n#7 (#6 and chronic*):ti,ab,kw  12332  \n#6 (#5 and obstruct*):ti,ab,kw  18193  \n#5 (pulmonary or lung* or airway* or airflow* or bronchi* or respirat*):ti,ab,kw  (Word \nvariations have been searched)  121057  \n#4 Emphysem*:ti,ab,kw  (Word variations have been searched)  1228  \n#3 COAD:ti,ab,kw  51 \n#2 COPD:ti,ab,kw  12534  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  5044  \n \nCochrane Reviews  \n\u2022 Review  \n\u2022 Protocol   \n2 \n0 \nOther Reviews  0 \nTrials  63 \nMethods Studies   Nicht gesucht  \nTechnology Assessment  0 \nEconomic Evaluations  Nicht gesucht  \nCochrane Groups  Nicht gesucht  \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  14 2 16 \nRCTs  33 63 96 \nSonstige Prim\u00e4r  168  168 \nGesamt    280 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 41  \nA2 (nicht englisch/deutsch): 19 \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 220  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  83 \n  \n  \n Flussdiagramm:  \n \nAnhang 3.8  Angst/Depression \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: jegliche  \nVergleich: jegliche  \nEndpunkte: Pr\u00e4valenz/Koinzidenz von Angst und/oder Depression oder anderer psychischer Erkrankungen  \nStudientyp: systematische \u00dcbersichtsarbeiten, Beobachtungsstudien  \nRecherchestrategien  \nDer SIGN \u2013 Filter f\u00fcr Kohortenstudien wurde in dieser Recherche angewendet.  \nMedline via Pubmed (www.pubmed.gov) (29.08.2018)  \nNr. Suchfrage  Anzahl  \n#22 Search (#18 AND #20) NOT #21  353 \n#21 Search #18 AND #19  36 \n#20 Search (((((((((\"Case -Control Studies\"[Mesh] OR \"Cohort Studies\"[Mesh]))) OR \"Cross -\nSectional Studies\"[Mesh]) OR ((\"Follow -Up Studies\"[Mesh] OR ((\"follow -up\" OR \"follow \nup\") AND (studies OR study))))) OR ((longitudinal[tw] OR retrospective[tw] OR \"cross -sec-\ntional\"[tw] OR \"cross sectional\"[tw]))) OR (\"case control\"[tw] OR (cohort[tw] AND \nanaly*[tw]) )) OR \"Observational Study\"[pt])))  2815319  \n#19 Search systematic[sb]  374475  \n#18 Search #7 AND #14 AND #17  693 \n#17 Search #15 OR #16  618401  \n#16 Search \"Prevalence\"[Mesh]  256347  \n#15 Search Prevalence[tiab]  540197  \n#14 Search #8 OR #9 OR #10 OR #11 OR #12 OR #13  1392228  \n#13 Search Depressi*[tiab]  343143  \n#12 Search Anxiety[tiab]  163685  \n#11 Search \u201cpsychic disorder*\u201d[tiab]  60 \n#10 Search \u201cPsychiatric disorder*\u201d[tiab]  8503  \n#9 Search \"Mental Disorder*\u201d[tiab]  7535  \n#8 Search \"Mental Disorders\"[Mesh]  1132505  \n#7 Search #1 OR #2 OR #3 OR #4 OR #5 OR #6  97641  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 220 \nEingeschlossene Titel/Abstracts:  \nn = 21 \nEingeschlossene Volltexte  \nn = 12 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 199 \nAusgeschlossene  \nVolltexte:  \nAa: n = 9 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  84 \n  \n  \n Nr. Suchfrage  Anzahl  \n#6 Search \u201cAir trapping\u201d[tiab] OR airtrapping[tiab]  1219  \n#5 Search COAD[tiab]  265 \n#4 Search COPD[tiab]  39462  \n#3 Search Emphysem*[tiab]  25766  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  49141  \n#1 Search ((chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab])))  54152  \nAnzahl der Treffer: aggregierte Evidenz: 36; Beobachtungsstudien: 353  \nDatenbanken der Cochrane Library (29.08.2018)  \nNr. Suchfrage  Anzahl  \n#19 (#8 and #15 and #18) not \"conference abstract\":pt in Cochrane Reviews, Trials  56 \n#18 #16 or #17  34633  \n#17 MeSH descriptor: [Prevalence] explode all trees  4617  \n#16 (Prevalence):ti,ab,kw (Word variations have been searched)  34633  \n#15 #9 or #10 or #11 or #12 or #13 or #14  117770  \n#14 (Depressi*):ti,ab,kw (Word variations have been searched)  57699  \n#13 (Anxiety):ti,ab,kw (Word variations have been searched)  34392  \n#12 (\"Psychiatric disorder*\"):ti,ab,kw (Word variations have been searched)  1770  \n#11 (\"Psychic disorder*\"):ti,ab,kw (Word variations have been searched)  9 \n#10 (\"Mental Disorder*\"):ti,ab,kw (Word variations have been searched)  6488  \n#9 MeSH descriptor: [Mental Disorders] explode all trees  61453  \n#8 #1 or #2 or #3 or #4 or #6 or #7  17528  \n#7 (\"air trapping\" or airtrapping):ti,ab,kw (Word variations have been searched)  112 \n#6 (((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*):ti,ab,kw (Word variations have been searched)  12022  \n#5 (pulmonary or lung* or airway* or airflow* or bronchi* or respirat*):ti,ab,kw (Wor d varia-\ntions have been searched)  119726  \n#4 (Emphysem*):ti,ab,kw (Word variations have been searched)  1214  \n#3 (COAD):ti,ab,kw  60 \n#2 (COPD):ti,ab,kw  12512  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4562  \n \nCochrane Reviews  3 \nTrials  53 \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  36 3 39 \nRCTs   53 53 \nSonstige Prim\u00e4r  353  353 \nGesamt    445 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  85 \n  \n  \n A1 (Dubletten): 12  \nA2 (nicht englisch/deutsch): 12 \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 421  \n\uf0a1 aggregierte Evidenz: n=35  \n\uf0a1 Prim\u00e4rstudien: n=386  \nFlussdiagramm aggregierte Evidenz  \nEs wurden zun\u00e4chst im Rahmen eines iterativen Vor gehens die Publikationen der aggregierten Evidenz gescreent. \nDer folgende Flowchart bezieht sich auf n=35 identifizierte aggregierte Evidenzen:  \n \n \nAnhang 3.9  Rauchentw\u00f6hnung bei COPD: Update- Recherche  \nFragestellung des Cochrane- Reviews  [15] \nTo evaluate the effectiveness of beh avioural or pharmacological smoking cessation interventions, or both, in smok-\ners with COPD.  \nRecherchestrategien  \nProfessor Kotz (Mitglied der NVL COPD -Leitliniengruppe und Letztautor des 2016 aktualisierten Cochrane Re-\nviews: van Eerd 2016; Smoking cessation for people with chronic obstructive pulmonary disease. {van Eerd 2016: \n27017}) nahm Kontakt mit der Cochrane Airways Group auf, um die zuletzt im M\u00e4rz 2016 durchgef\u00fchrte Suche f\u00fcr \ndiesen Review erneut durchf\u00fchren zu lassen.  \nF\u00fcr ein Suchupdate wurde die damals verwendete Suchstrategie seitens der Cochrane Airways Group erneut um-\ngesetzt. Die Ergebnisse dieser Update-Suche (durchgef\u00fchrt am 17.09.2019; n=143 Treffer) wurden dem \u00c4ZQ im \nRIS-Format zur Verf\u00fcgung gestellt. Das Titel/Abstract -Screening zur Update-Recherche wurde durch das \u00c4ZQ \ndurchgef\u00fchrt werden.  \nMedline search strategy used to identify trials for the CAGR (17.September 2019)  \nNr. Suchfrage  \n1 Lung Diseases, Obstructive/  \n2 exp Pulmonary Disease, Chronic Obstructive/  \n3 emphysema$.mp.  \n4 (chronic$ adj3 bronchiti$).mp.  \n5 (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 35 \nEingeschlossene Titel/Abstracts:  \nn = 11 \nEingeschlossene Volltexte  \nn = 2 \nAusgeschlossene  \nTitel/Abstracts:  n = 24 \nAa: n = 23  \nAp: n = 1 \nAusgeschlossene  \nVolltexte:  \nAa: n = 3 \nAp: n = 2 \nAq: n = 4 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  86 \n  \n  \n Nr. Suchfrage  \n6 COPD.mp.  \n7 COAD.mp.  \n8 COBD.mp.  \n9 AECB.mp.  \n10 or/1-9 \n\u00dcbernommen aus [15] . \nFilter to identify RCTs  \nNr. Suchfra ge \n1 exp \u201cclinical trial [publication type]\u201d/  \n2 (randomised or randomised).ab,ti.  \n3 placebo.ab,ti.  \n4 dt.fs.  \n5 randomly.ab,ti.  \n6 trial.ab,ti.  \n7 groups.ab,ti.  \n8 or/1-7 \n9 Animals/  \n10 Humans/  \n11 9 not (9 and 10)  \n12 8 not 11  \n\u00dcbernommen aus [15] . \nSearch strategy fo r the Cochrane Airways Group Register (17.September 2019)  \nNr. Suchfrage  \n1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All  \n2 MeSH DESCRIPTOR Bronchitis, Chronic  \n3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)  \n4 COPD:MISC1  \n5 (COPD OR COAD OR COBD):TI,AB,KW  \n6 #1 OR #2 OR #3 OR #4 OR #5  \n7 MeSH DESCRIPTOR Smoking  \n8 MeSH DESCRIPTOR Smoking Cessation  \n9 MeSH DESCRIPTOR Tobacco  \n10 MeSH DESCRIPTOR Tobacco Use Disorder  \n11 MeSH DESCRIPTOR Tobacco Use Cessation  \n12 MeSH DESCRIPTOR Nicotine  \n13 ((nicotin* or tobacco or smok* or cigarette*) NEAR5 (replac* or cessat* or ceas* or control* or quit* or \nstop* or abstin* or abstain*  \nor self -help* or \u201cself help*\u201d or behaviour* or behavior* or educat* or counsel* or support* or advice or \ntreatment* or intervention*)):  \nti,ab,kw  \n14 \u201cnicotine replacement therapy\u201d or NRT  \n15 (nicotin*) NEAR3 (gum or patch or inhal* or nasal* or spray or lozenge* or polacrilex or agonist* or \nvaccin*)  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  87 \n  \n  \n Nr. Suchfrage  \n16 Varenicline  \n17 Champix  \n18 Chantix  \n19 Bupropion  \n20 Zyban  \n21 Nortriptyline  \n22 Nortrilen  \n23 (nicotin* or tobacco or smok* or cigarette*) NEAR5 (antidepressant*)  \n24 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or \n#22 or #23  \n25 #6 and #24  \nNOTE: The Airways Register is maintained in specialist software developed for The Cochrane Collaboration; the \nCRS (Cochrane Register of Studies). Line #4 in the strategy denotes the field in the CRS reference record in which \nthe record has been coded for condition, in this case, COPD.  \n\u00dcbernommen aus [15] . \n\u00dcbersicht der eingeschlossenen Tref fer \n Cochrane Airways Group  \nAggregierte Evidenz  - \nRCTs  143 \nSonstige Prim\u00e4r  - \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 3  \nA2 (nicht englisch/deutsch): 8  \nA3 (Conference Abstracts/Poster): 35  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 97  \nFlussdiagramm Update (03/2016 \u2013  09/2019)  \n \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 97 \nEingeschlossene Titel/Abstracts:  \nn = 7 \nEingeschlossene Volltexte  \nn = 2 \nAusgeschlossene  \nTitel/A bstracts:  \nn = 90 \nAusgeschlossene  \nVolltexte:  \nAa: n = 2 \nEz: n = 3 (Post hoc Ana-\nlysen, differente Ein-\nschlusskriterien)  \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  88 \n  \n  \n Anhang 3.10  E-Zigaretten Schadenspotential  \nPICO -Fragestellung  \nPopulation: Alle  \nIntervention: E -Zigarette  \nVergleich: Alle  \nEndpunkte: Alle  \nStudientyp: Systematishce \u00dcbersichtsarbeiten, RCT  \nRecherchestrategien  \nIm Rahmen der Aktualisierung der S3-Leitlinie \u201eScreening, Diagnostik und Behandlung abh\u00e4ngiger Tabakkonsum \n(Rauchen)\u201c [113]  wurde eine systematische Update- Recherche bez\u00fcglich der Nutzung von E -Zigaretten durchge-\nf\u00fchrt.  \nMedline via Pubmed ( www.pubmed.gov ) (10.10.2019)  \nFolgende Suchstrategie wurde verwendet: ((((vaporizer[Title/Abstract]) OR e-cigarette[Title/Abstract]) OR elec-\ntronic nicotine delivery system[Title/Abstract]) OR ENDS[Title/Abstract]) OR electronic cigarette[Title/Abstract] Fil-\nters: Systematic Reviews; Ran domized Controlled Trial; Publication date from 2015/01/01 to 2019/10/10. Es konn-\nten insgesamt 194 Publikationen identifiziert werden; 50 Artikel wurden in das Volltext -Screening einges chlossen \nund der AG Tabakentw\u00f6h nung der N VL COPD zur Verf\u00fcgung gestellt . \nDiese 50 Publikationen wurden seitens des \u00c4ZQ auf den Einschluss von Patient *innen mit COPD untersucht; es \nkonnten keine Studie n f\u00fcr diese Population identifi ziert werden.  \nFlussdiagramm:  \n \nUm ein m\u00f6gliches Schadenspotential von E -Zigaretten darstellen zu k\u00f6nnen, wurden diese Publikationen erneut \nbegutachtet und diesbez\u00fcglich extrahiert. Ziel war es, eine Aussage zu m\u00f6glichen Sch\u00e4den bei Nutzung von E -\nZigaretten zu erfassen und diese auf Patient *innen mit COPD zu extrapolieren.  N=21 Studien berichteten \u00fcber \nm\u00f6gliche Sch\u00e4den.  \nAnhang 3.11  Ganzk\u00f6rpervibration  \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: Ganzk\u00f6rpervibrationstraining  \nVergleich: jegliche  \nEndpunkte:  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 194 \nEingeschlossene Titel/Abstracts:  \nn = 50 \nEingeschlossene Volltexte  \nn = 0 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 144 \nAusgeschlossene  \nVolltexte:  \nAa: n = 50 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  89 \n  \n  \n \uf0a1 krankheitsspezifische Mortalit\u00e4t  \n\uf0a1 Morbidit\u00e4t  \n\uf0fa Symptomatik: Atemnot, Husten und Auswurf  \n\uf0fa Mobilit\u00e4t/Funktionalit\u00e4t  \n\uf0fa soziale Teilhabe  \n\uf0fa Exazerbationen  \n\uf0fa Reduktion des zuk\u00fcnftigen Krankheitsrisikos: COPD -bedingte Hospitalisierung  \n\uf0a1 Lebensqualit\u00e4t  \nStudientyp: Systematisc he \u00dcbersichtsarbeiten  \nRecherchestrategien  \nMedline via Pubmed (www.pubmed.gov) (15. Januar 2019)  \nNr. Suchfrage  Anzahl  \n#16 Search  ((#12 and #14) NOT #15)  21 \n#15 Search  (#12 and #13)  13 \n#14 Search  (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized \n[tiab] OR placebo [tiab] OR \u201cclinical trials as topic\u201d [MeSH Terms:noexp] OR randomly \n[tiab] OR trial [ti])  1200343  \n#13 Search  (systematic review [ti] OR meta -analysis [pt] OR meta -analysis [ti] OR systematic \nliterature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic \nreview [tiab] AND review [pt]) OR meta synthesis [ti] OR meta -analy*[ti] OR integrative re-\nview [tw] OR integrative research review [tw] OR rapid review [tw] OR umb rella review [tw] \nOR consensus development conference [pt] OR practice guideline [pt] OR drug class re-\nviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol \nassess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement \nrep [ta]) OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR ev-\nidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (re-\nview [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR \ntherapeutics [mh] OR evaluation studies[pt] OR validation studies[pt] OR guideline [pt] OR \npmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selec-\ntion [tw]) OR (predetermined [tw] OR inclusion [tw] AND cr iteri* [tw]) OR exclusion criteri* \n[tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) \nAND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] \nOR search* [tw] OR handsearch [tw] OR analys is [ti] OR critique [tiab] OR appraisal [tw] \nOR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (litera-\nture [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography \n[tiab] OR bibliographies [tiab] O R published [tiab] OR pooled data [tw] OR unpublished \n[tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks \n[tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] \nOR meta -analy* [tw] O R (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR \ntreatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt])  390425  \n#12 Search  (#7 and #11)  61 \n#11 Search  (#8 OR #9 OR #10)  5473  \n#10 Search  (vibrat*[tiab] AND (train* [tiab] OR therap*[tiab]))  3430  \n#9 Search  whole[tiab] AND body[tiab] AND vibrat*[tiab]  2076  \n#8 Search  Galileo[tiab] OR WBV[tiab]  1649  \n#7 Search  #1 OR #2 OR #3 OR #4 OR #5 OR #6  99965  \n#6 Search  \u201cAir trapping\u201d[tiab] OR airtrapping[tiab]  1244  \n#5 Search  COAD[tiab]  277 \n#4 Search  COPD[tiab]  40766  \n#3 Search  Emphysem*[tiab]  26172  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  90 \n  \n  \n Nr. Suchfrage  Anzahl  \n#2 Search  \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  50399  \n#1 Search  (chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab]))  55742  \nAnzahl der Treffer: 13 aggregierte Evidenz, 21 RCTs  \nDatenbanken der Cochrane Library (15. Januar 2019)  \nNr. Suchfrage  Anzahl  \n#13 (#7 and #12) not \"conference abstract\":pt in Cochrane Reviews, Cochrane Proto-\ncols, Trials  55 \n#12 #8 or #9 or #10 or #11  1768  \n#11 (Galileo):ti,ab,kw  45 \n#10 ((vibrat* and (train* or therap*))):ti,ab,kw (Word variations have been searched)  1552  \n#9 (wbv):ti,ab,kw  469 \n#8 ((whole and body and vibrat*)):ti,ab,kw (Word variations have been searched)  786 \n#7 #1 or #2 or #3 or #4 or #5 or #6  17318  \n#6 ((\"air trapping\" or airtrapping)):ti,ab,kw (Word variations have been searched)  112 \n#5 ((((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*)):ti,ab,kw (Word variations have been searched)  12103  \n#4 (Emphysem*):ti,ab,kw (Word variations have been searched)  1185  \n#3 (COAD):ti,ab,kw  63 \n#2 (COPD):ti,ab,kw  12057  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4634  \n \nCochrane Reviews  \n\u2022 Review  \n\u2022 Protocol   \n1 \n0 \nTrials  54 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  91 \n  \n  \n \u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  13 1 14 \nRCTs  21 54 75 \nGesamt    89 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 21  \nA2 (nicht englisch/deutsch): 4  \nA2 (Conference Abstract): 3  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 61  \nFlussdiagramm:  \n \nEs wurden der neueste Review mit den meisten Studien eingeschlossen (Zhou 2018  [63]); zus\u00e4tzlich ein zweiter \nReview (Glo eckl 2015 [62]), welche noch zwei ander e Prim\u00e4rstudien (Furness 2013 + Furness 2014; WBV vs. \nSham -WBV) betrachtet hat. Vier Reviews wurden f\u00fcr eine Evidenzbegr\u00fcndung zur\u00fcckgestellt, da sie entweder we-\nniger (n=4) Prim\u00e4rstudien eingeschlossen haben bzw. in der methodischen Bewertung schlechter ab schnitten.  \nAnhang 3.12  H\u00e4usliche Trainingstherapie \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: h\u00e4usliche Trainingstherapie  \nVergleich: ambulantes Training \nEndpunkte:  \n\uf0a1 krankheitsspezifische Mortalit\u00e4t  \n\uf0a1 Morbidit\u00e4t  \n\uf0fa Symptomatik: Atemnot, Husten und Auswurf  \n\uf0fa Mobilit\u00e4t/Funktionalit\u00e4t  \n\uf0fa soziale Teilhabe  \n\uf0fa Exazerbationen  \n\uf0fa Reduktion des zuk\u00fcnftigen Krankheitsrisikos: COPD -bedingte Hospitalisierung  \n\uf0a1 Lebensqualit\u00e4t  \nStudientyp: Systematische \u00dcbersichtsarbeiten  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 61 \nEingeschlossene Titel/Abstracts:  \nn = 6 \nEingeschlossene Volltexte  \nn = 2 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 55 \nAusgeschlossene  \nVolltexte:  \nEz: n = 4 \n \nLiteratur von Experten  \noder durch Handsuche \nn =  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  92 \n  \n  \n Recherchestrategien  \nStrukturiertes Vorgehen  \nStruktu rierte Suche nach HTA -Berichten oder \u00dcbersichtsarbeiten bei ausgew\u00e4hlten Institutionen. Aufgrund ihrer \nevidenzbasierten Vorgehensweise, ihrer hohen Berichtsqualit\u00e4t, ihrer wissenschaftlichen Unabh\u00e4ngigkeit, eines \nweitergehenden Einblicks in Studiendossiers  und ihres Bezugs zum deutschen bzw. europ\u00e4ischen Versorgungs-\nkontext sind diese (s.u.) besonders geeignet.  \nIQWiG (06.12.2019)  \nThemencheck ( https://www.themencheck -medizin.iqwig.de/ ):  \n\uf0a1 \u201dh\u00e4uslich\u201d: n= 0 \n\uf0a1 \u201dTraining\u201d: n=0  \n\uf0a1 \u201dCOPD\u201d: n=0  \nIQWiG ( www.iqwig.de ): \n\uf0a1 \u201dCOPD\u201d/alle Berichtsdokumente: n=110 Treffer; davon n=0 Publikationen zum Thema h\u00e4usliche Trainingsthe-\nrapie  \nNICE (06.12.2019) (National Institute for Health and Care Excellence)  \nNICE guidance ( https://www.nice.org.uk/guidance):  \n\uf0a1 \u201dCOPD\u201d/Document Type: Guidance: n=44 Treffer; davon n=0 \u00dcbersichtsarbeiten zum Thema h\u00e4usliche Trai-\nningstherapie  \n\uf0a1 \u201dchronic obstructive\u201d/ Document Type: Guidance: n=63 Treffer; davon n=0 \u00dcbersichtsarbeiten zum Thema \nh\u00e4usliche Trainingstherapie  \n\uf0a1 \u201dhome based\u201d/ Document Type: Guidance:  n=304 Treffer; davon n=0 \u00dcbersichtsarbeiten zum Thema h\u00e4usli-\nche Trainingstherapie  \nCochrane Collaboration (06.12.201 9) \nwww.cochranelibrary.com/search  \n\uf0a1 \u201eHome based\u201c: n=244 Treffer, n=2 im VT -Screening  \n\uf0fa Home versus center based physical activity programs in older adults  \nCochrane Systematic Review - Intervention Version published: 24 January 2005  \nhttps://doi.org/10.1002/14651858.CD004017.pub2  \n>> auch Patient *innen mit COPD eingeschlossen  \n>> bereits in Cochrane-Recherche identifiziert --> E  \n\uf0fa Pulmonary rehabilitation for chronic obstructive pulmonary disease  \nCochrane Systematic Review - Intervention Versi on published: 24 February 2015 see what's new \nhttps://doi.org/10.1002/14651858.CD003793.pub3  \n>> bereits in Cochrane-Recherche identifiziert  --> E  \n\uf0a1 \u201cCOPD\u201d/last year: n=9 Treffer; n=0 Publikationen zum Thema h\u00e4usliche Trainingstherapie bei Pati ent*innen \nmit COPD  \nJBI Database of Systematic Reviews and Implementation Reports (06.12.2019)  \njournals.lww.com/jbisrir/pages/advancedsearch.aspx  \n\uf0a1 \u201eCOPD\u201c/Content: Article/ Publication Date: all Dates: n=48 Treffer; davon n=1 Duplikat; n=0 Publikationen \nzum Thema h\u00e4usliche Trainingstherapie bei Patient *innen mit COPD  \n\uf0a1 \u201dchronic obstructive\u201d: n=90 Treffer; davon n=2 Duplikate; n=0 Publikationen zum Thema h\u00e4usliche Trainings-therapie bei Pat ient*innen mit COPD  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  93 \n  \n  \n AHRQ (06.12.2019)  \nwww.ahrq.gov/research/findings/evidence-based-reports/search.html  \n\uf0a1 \u201dCOPD\u201d: n=2 Treffer, n=1 im VT -Screening:  \n\uf0fa Comparative Effective ness Review; Number 221: Pharmacologic and Nonpharmacologic Therapies in \nAdult Patients With Exacerbation of COPD: A Systematic Review 10/2019--> keine systematische \u00dcber-\nsicht zur PICO -Frage: home- based vs. ambulantes Traning-- > Aa \n\uf0a1 \u201dhome based\u201d/ Topic Lung  conditions: n=18 Treffer; n=1 f\u00fcr VT -Screening: Aa (Comparative Effectiveness Re-\nview; Number 221 s.o.); n=0 Publikationen zum Thema h\u00e4usliche Trainingstherapie bei Patient *innen mit \nCOPD  \n\uf0a1 \u201dchronic obstructive\u201d / Topic Lung conditions: n=2; n=0 Publikationen zum Thema h\u00e4usliche Trainingstherapie bei Patient *innen mit COPD  \n\u00dcbersicht der eingeschlossenen Treffer  \n IQWiG  NICE  Cochrane  JBI AHRQ  Summe  \nAggregierte \nEvidenz  0 0 2 0 0 2 \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 2 \nAnhang 3.13  Atemtechniken  \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD; evtl. mit Exazerbation  \nIntervention: Atemtechniken (l\u00e4ngerfristige und Notfalltechniken)  \nVergleich: Jegliche  \nEndpunkte:  \n\uf0a1 krankheitsspezifische Mortalit\u00e4t  \n\uf0a1 Morbidit\u00e4t  \n\uf0fa Symptomatik: Atemnot, Husten und Auswurf  \n\uf0fa Mobilit\u00e4t/Funktionalit\u00e4t (K\u00f6rperliche Belastbarkeit, F\u00e4higkeit Treppen zu steigen, Exercise Tolerance)  \n\uf0fa soziale Teilhabe  \n\uf0fa Exazerbationen  \n\uf0fa Reduktion des zuk\u00fcnftigen Krankheitsrisikos: COPD -bedingte Hospitalisierung  \n\uf0a1 Lebensqualit\u00e4t  \nStudientyp:  Systematische \u00dcbersichtsarbeiten, RCTs  \nRecherchestrategien  \nF\u00fcr diese Recherche wurde ein Suchupdate des Cochrane- Reviews von Holland 2012 [88] durchgef\u00fchrt.  \nEin weiterer Teil der Suchbegriffe wurde dem Cochrane-Review von Osadnik (2012)  [80] entnommen. Diese \u00dcber-\nsichtsarbeit besch\u00e4ftigt sich mit Airway Clearance Techniken, welche ebenfalls in die Recherche aufgenommen \nwurden.  \nDa auch nach Notfalltechniken gesucht werden sollte, wurden die Suchbegriffe f\u00fcr COPD um die \u201eExazerbation\u201c \nbzw. \u201eVerschlechterung des klinischen Zustands\u201c erweitert.  \nMedline via Pubmed (www.pubmed.gov) (28.02.2019)  \nNr. Suchfrage  Anzahl  \n#16 Search ((#12 AND #14) NOT #15) Filters: Publication date from 2011/10/01  455 \n#15 Search (#12 AND #13) Filters: Publication date from 2011/10/01  154 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  94 \n  \n  \n Nr. Suchfrage  Anzahl  \n#14 Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized \n[tiab] OR placebo [tiab] OR \"clinical trials as topic\" [MeSH Terms:noexp] OR randomly \n[tiab] OR trial [ti])  1209550  \n#13 Search ((systematic review [ti] OR meta -analysis [pt] OR meta -analysis [ti] OR systematic \nliterature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic \nreview [tiab] AND review [pt]) OR meta synthesis [ti] OR meta -analy*[ti] OR integrative re-\nview [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] \nOR consensus development conference [pt] OR practice guideline [pt] OR drug class re-\nviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol \nassess [ta] OR evid rep technol assess summ [ta] OR jb i database system rev implement \nrep [ta]) OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR ev-\nidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (re-\nview [pt] OR diseases category[mh] OR behavior an d behavior mechanisms [mh] OR \ntherapeutics [mh] OR evaluation studies[pt] OR validation studies[pt] OR guideline [pt] OR \npmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selec-\ntion [tw]) OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* \n[tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) \nAND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] \nOR search* [tw] OR handsearch [tw ] OR analysis [ti] OR critique [tiab] OR appraisal [tw] \nOR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (litera-\nture [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography \n[tiab] OR bibliographi es [tiab] OR published [tiab] OR pooled data [tw] OR unpublished \n[tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks \n[tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] \nOR meta -analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR \ntreatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt]))  396094  \n#12 Search (#10 AND #11)  8113  \n#11 Search (breath*[tiab] OR \u201cventilation -feedback traini ng\u201d[tiab] OR \u201cyoga\u201d[tiab] OR \u201cchest \nphysiotherapy\u201d[tiab] OR \u201cchest physical therapy\u201d[tiab] OR \u201cbreath control\u201d[tiab] OR \n\"breathing control\"[tiab] OR \u201cbreathing technique\u201d[tiab] OR \u201cforced expiratory technique\u201d \n[tiab] OR \u201cdeep breath*\u201d[tiab] OR \u201cthoracic ex pansion\u201c[tiab] OR \u201csustained maximal in-\nspirat*\u201c[tiab] OR \u201cresistance breath*\u201d[tiab] OR \u201cbreathing retraining\u201d[tiab] OR \u201cdiaphrag-\nmatic breathing\u201d[tiab] OR \u201cpursed-lip breathing\u201d[tiab] OR \u201cpursed-lips breathing\u201d[tiab] OR \n\u201cpositive expiratory pressure\u201d[tiab] OR \u201ccontrolled breathing\u201d[tiab] OR \u201cmanual ther-\napy\u201d[tiab] OR \u201cairway clearance\u201d[tiab] OR \u201ctracheobronchial clearance\u201d[tiab] OR \u201cairway* \nclearance\u201d[tiab] OR \u201cchest clearance\u201d[tiab] OR \u201clung clearance\u201d[tiab] OR \u201csputum clear-\nance\u201d[tiab] OR \u201cmucus clearance\u201d[t iab] OR \u201chigh frequency chest wall oscillat*\u201d[tiab] OR \n\u201cELTGOL\u201d[tiab] OR \u201cactive cycle of breathing technique\u201d[tiab] OR ACBT[tiab] OR \u201cactive \ncycle of breathing techniques\u201d[tiab] OR \u201cpositioning\u201d[tiab] OR \u201clip brake assist\u201d[tiab] OR \noscillat*[tiab] OR OPEP [tiab] OR PEP[tiab])  270123  \n#10 Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)  148526  \n#9 Search (Worse*[tiab] AND respiratory[tiab] AND symptom*[tiab])  1910  \n#8 Search (exacerbate*[tiab] OR AECOPD[tiab])  47681  \n#7 Search \"Clinical Deterioration\"[Mesh]  98 \n#6 Search (\"Air trapping\" [tiab] OR airtrapping[tiab])  1253  \n#5 Search COAD[tiab]  291 \n#4 Search COPD[tiab]  41285  \n#3 Search Emphysem*[tiab]  26313  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  50844  \n#1 Search (chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab]))  56307  \nAnzahl der Treffer: 154 SR, 455 RCTs  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  95 \n  \n  \n Datenbanken der Cochrane Library (01.03.2019)  \nNr. Suchfrage  Anzahl  \n#13 (#10 and #11) not \"conference abstract\":pt with Publication Year from 2011 to pre-\nsent, in Trials  963 \n#12 (#10 and #11) not \"conference abstract\":pt with Publication Year from Oct 2011 to \npresent in Cochrane Reviews, Cochrane Protocols  99 \n#11 (breath* or \u201cventilation -feedback training\u201d or \u201cyoga\u201d or \u201cchest physiotherapy\u201d or \u201cchest \nphysical therapy\u201d or \u201cbreath control\u201d or \u201cbreathing control\u201d or \u201cbreathing technique\u201d or \n\u201cforced expiratory technique\u201d or \u201cdeep breath*\u201d or \u201cthoracic  expansion\u201c or \u201csustained maxi-\nmal inspirat*\u201c or  \u201cresistance breath*\u201d or \u201cbreathing retraining\u201d or \u201cdiaphragmatic breathing\u201d \nor \u201cpursed- lip breathing\u201d or \u201cpursed-lips breathing\u201d or \u201cpositive expiratory pressure\u201d or \n\u201ccontrolled breathing\u201d or \u201cmanual therapy \u201d or \u201cairway clearance\u201d or \u201ctracheobronchial \nclearance\u201d or \u201cairway* clearance\u201d or \u201cchest clearance\u201d or \u201clung clearance\u201d or \u201csputum \nclearance\u201d or \u201cmucus clearance\u201d or \u201chigh frequency chest wall oscillat*\u201d or \u201cELTGOL\u201d or \n\u201cactive cycle of breathing technique\u201d  or ACBT or \u201cactive cycle of breathing techniques\u201d or \n\u201cpositioning\u201d or \u201clip brake assist\u201d or oscillat* or OPEP or PEP):ti,ab,kw  29983  \n#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9  19488  \n#9 (Worse* and respiratory and symptom*):ti,ab,kw (Word var iations have been searched)  470 \n#8 (exacerbate* or AECOPD):ti,ab,kw (Word variations have been searched)  2078  \n#7 MeSH descriptor: [Clinical Deterioration] explode all trees  5 \n#6 (\u201cair trapping\u201d or airtrapping):ti,ab,kw (Word variations have been searched)  107 \n#5 (((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*):ti,ab,kw (Word variations have been searched)  12283  \n#4 (Emphysem*):ti,ab,kw (Word variations have been searched)  1191  \n#3 (COAD):ti,ab,kw  63 \n#2 (COPD):ti,ab,kw  11687  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4684  \nAnzahl der Treffer: 99 SR, 963 RCTs  \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  154 99 253 \nRCTs  455 963 1418  \nGesamt    1671  \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 416  \nA2 (nicht englisch/deutsch): 32 \nA3 (Conference Abstracts): 52  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 1171  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  96 \n  \n  \n Flussdiagramm:\n \nCrossover -Studien mit sehr geringer Teilnehmerzahl (<20) wurden Ez gestellt; Ausnahme: Ubolsaka Jones(einzige \nPublikation zum Thema).  \nLegende: Az: bereits in strukturierter Recherche identifiziert, Aq: methodische Qualit\u00e4t, Ap: Publikationstyp; Ad: In \nCochrane Review inkludiert, Aa: thematisch nicht passend  \nAnhang 3.14  Patientenschulung  \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: Patientenschulung; Setting: Ambulant, station\u00e4r (Reha-, Fach - und Akutkliniken)  \nVergleich: Jegliche \nEndpunkte:  \n\uf0a1 krankheitsspezifische Mortalit\u00e4t  \n\uf0a1 Morbidit\u00e4t  \n\uf0fa Symptomatik: Atemnot, Husten und Auswurf  \n\uf0fa Mobilit\u00e4t/Funktionalit\u00e4t  \n\uf0fa soziale Teilhabe  \n\uf0fa Exazerbationen  \n\uf0fa Reduktion des zuk\u00fcnftigen Krankheitsrisikos: COPD -bedingte Hospitalisierung  \n\uf0a1 Lebensqualit\u00e4t  \nStudientyp:  RCTs  \nRecherchestrategien  \nDie Suche wurde sowohl auf das ambulante als auch das station\u00e4re Setting ausgerichtet. Gesucht wurde im deut-\nschen Kontext. Device-Instruktionen werden gesondert im Kapitel Medikament\u00f6se Therapie betrachtet.  \nMedline via Pubmed (www .pubmed.gov) (04.03.2019)  \nNr. Suchfrage  Anzahl  \n#17 Search (#15 AND #16)  29 \n#16 Search (German OR Germany)  1813743  \n#15 Search (#13 AND #14)  578 \n#14 Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized \n[tiab] OR placebo [tiab] OR \"clinical trials as topic\" [MeSH Terms:noexp] OR randomly \n[tiab] OR trial [ti])  1210271  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 1171  \nEingeschlossene Titel/Abstracts:  \nn = 61 \nEingeschlossene Volltexte  \nn = 33 \nAusgeschlossene  \nTitel/Abstracts:  \nn = (bisher) 1097  \nAusgeschlossene  \nVolltexte:  \nAq: n = 2 \nAz: n = 3 \nAp : 3  \nAa: 5  \nAd: 1  \nEz: n = 24 \nLiteratur von Experten  \noder durch Handsuche \nn = 5 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  97 \n  \n  \n Nr. Suchfrage  Anzahl  \n#13 Search (#7 AND #12)  3922  \n#12 Search (#8 OR #9 OR #10 OR #11)  1087059  \n#11 Search Educat*[tiab]  554688  \n#10 Search \"Health Education\"[Mesh]  230604  \n#9 Search \"Patient Education as Topic\"[Mesh]  81576  \n#8 Search \"Education\"[Mesh]  761751  \n#7 Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6)  100880  \n#6 Search (\"Air trapping\" [tiab] OR airtrapping[tiab])  1253  \n#5 Search COAD[tiab]  292 \n#4 Search COPD[tiab]  41313  \n#3 Search Emphysem*[tiab]  26325  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  50858  \n#1 Search ((chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow* [tiab] or bronchi*[tiab] or respirat*[tiab])))  56364  \nAnzahl der Treffer: 29 RCTs  \nDatenbanken der Cochrane Library (04.03.2019)  \nNr. Suchfrage  Anzahl  \n#14 (#7 and #12 and #13) not \"conference abstract\":pt in Trials  12 \n#13 (German or Germany):ti,ab,kw (Word variations have been searched)  13100  \n#12 #8 or #9 or #10 or #11  64538  \n#11 (Educat*):ti,ab,kw (Word variations have been searched)  56730  \n#10 MeSH descriptor: [Health Education] explode all trees  17947  \n#9 MeSH descriptor: [Patient Education as Topic] explode all trees  8176  \n#8 MeSH descriptor: [Education] explode all trees  29567  \n#7 #1 or #2 or #3 or #4 or #5 or #6  17417  \n#6 (\"air trapping\" or airtrapping):ti,ab,kw (Word variations have been searched)  107 \n#5 ((((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*)):ti,ab,kw (Word variations have been searched)  12284  \n#4 (Emphysem*):ti,ab,kw (Word variations have been searched)  1191  \n#3 (COAD):ti,ab,kw  63 \n#2 (COPD):ti,ab,kw  11688  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4684  \nAnzahl der Treffer: 12 RCTs  \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Gesamt  \nRCTs  29 12 41 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 8  \nA2 (Conference Abstract): 1  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 32  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  98 \n  \n  \n Flussdiagramm:  \n \nLegende: Aa: andere Fragestellung, Ap: Publikationstyp (kein RCT).  \nAnhang 3.15  Ern\u00e4hrung  \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: Gewichtsmanagement -Strategien (bei \u00dcber - und Untergewicht, ggf. auch Normalgewicht)  \nVergleich: Jegliche \nEndpunkte:  \n\uf0a1 krankheitsspezifische Mortalit\u00e4t  \n\uf0a1 Morbidit\u00e4t  \n\uf0fa Symptomatik: Atemnot, Husten und Auswurf  \n\uf0fa Mobilit\u00e4t/Funktionalit\u00e4t  \n\uf0fa soziale Teilhabe  \n\uf0fa Exazerbationen  \n\uf0fa Reduktion des zuk\u00fcnftigen Krankheitsrisikos: COPD -bedingte Hospitalisierung  \n\uf0a1 Lebensqualit\u00e4t  \nStudientyp: Systematisc he \u00dcbersichtsarbeiten, RCTs  \nRecherchestrategien  \nMedline via Pubmed (www.pubmed.gov) (16. Januar 2019)  \nNr. Suchfrage  Anzahl  \n#23 Search (#19 AND #21) NOT #22  339 \n#22 Search #19 AND #20  154 \n#21 Search randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] \nOR placebo [tiab] OR \u201cclinical trials as topic\u201d [MeSH Terms:noexp] OR randomly [tiab] OR \ntrial [ti]  1200958  \n#20 Search (systematic review [ti] OR meta -analysis [pt] OR meta -analysis [ti] OR systematic \nliterature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic \nreview [tiab] AND review [pt]) OR meta synthesis [ti] OR meta -analy*[ti] OR integrative re-\nview [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] \nOR consensus development conference [pt] OR practice guideline [pt] OR drug class re-\nviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol \nassess [ta] OR evid rep technol assess summ [ta] OR jb i database system rev implement \nrep [ta]) OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR ev-\nidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (re-\nview [pt] OR diseases category[mh] OR behavior an d behavior mechanisms [mh] OR 390764  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 32 \nEingeschlossene Titel/Abstracts:  \nn = 8 \nEingeschlossene Volltexte  \nn = 2 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 24 \nAusgeschlossene  \nVolltexte:  \nAa: n = 1 \nAp: n = 5 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  99 \n  \n  \n Nr. Suchfrage  Anzahl  \ntherapeutics [mh] OR evaluation studies[pt] OR validation studies[pt] OR guideline [pt] OR \npmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selec-\ntion [tw]) OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* \n[tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) \nAND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] \nOR search* [tw] OR handsearch [tw ] OR analysis [ti] OR critique [tiab] OR appraisal [tw] \nOR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (litera-\nture [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography \n[tiab] OR bibliographi es [tiab] OR published [tiab] OR pooled data [tw] OR unpublished \n[tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks \n[tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] \nOR meta -analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR \ntreatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt])  \n#19 Search #7 AND #18  2865  \n#18 Search (#8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #1 5 OR #16 OR #17)  788335  \n#17 Search (\"Exercise\"[Mesh] OR exercise*[tiab] OR train*[tiab]) AND (\"Body Weight\"[Mesh] \nOR weight*[tiab] OR BMI[tiab])  73931  \n#16 Search Diet[tiab] OR dietary[tiab] OR nutrion*[tiab]  437028  \n#15 Search (Change[tiab] OR reduction[tiab] OR reducing[tiab] OR loss[tiab]) AND \n(weight[tiab] OR BMI[tiab])  222869  \n#14 Search Management[tiab] AND (obesity[tiab] OR overweight[tiab] OR underweight[tiab] \nOR thinness[tiab] OR leanness[tiab] OR weight[tiab] OR \"Body Weight\"[Mesh])  46166 \n#13 Search \"Nutrition Therapy\"[Mesh]  95021  \n#12 Search \"Thinness/therapy\"[Mesh]  274 \n#11 Search \"Obesity Management\"[Mesh]  22748  \n#10 Search \"Diet, Reducing\"[Mesh]  10787  \n#9 Search \"Body Weight Changes\"[Mesh]  65550  \n#8 Search \"Weight Reduction Programs\"[Mesh]  1681  \n#7 Search #1 OR #2 OR #3 OR #4 OR #5 OR #6  100017  \n#6 Search \u201cAir trapping\u201d[tiab] OR airtrapping[tiab]  1246  \n#5 Search COAD[tiab]  278 \n#4 Search COPD[tiab]  40792  \n#3 Search Emphysem*[tiab]  26181  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  50450  \n#1 Search (chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab]))  55771  \nAnzahl der Treffer: 154 aggregierte; 339 RCTs  \nDatenbanken der Cochrane Library (16. Januar 2019)  \nNr. Suchfrage  Anzahl  \n#27 (#7 and #26) not \"conference abstract\":p t in Cochrane Reviews, Cochrane Proto-\ncols and Trials  631 \n#26 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #17 or #18 or #19 or #25  116898  \n#25 #23 and #24  17087  \n#24 #22 or #16  100817  \n#23 #20 or #21  119869  \n#22 (Weight* or BMI):ti,ab,kw (Word variations have been searched)  96946  \n#21 (Exercise* or train*):ti,ab,kw (Word variations have been searched)  118258  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  100 \n  \n  \n Nr. Suchfrage  Anzahl  \n#20 MeSH descriptor: [Exercise] explode all trees  21034  \n#19 (Diet or dietary or nutrion*):ti,ab,kw (Word variations have been searched)  65425  \n#18 ((Change or reduction or reducing or loss) and (weight or BMI)):ti,ab,kw (Word variations \nhave been searched)  58879  \n#17 #15 and #16  2201  \n#16 MeSH descriptor: [Body Weight] explode all trees  23944  \n#15 (Management):ti,ab,kw (Word variations have been searched)  96722  \n#14 (Management and (obesity or overweight or underweight or thinness or leanness or \nweight)):ti,ab,kw (Word variations have been searched)  9527  \n#13 MeSH descriptor: [Nutrition Therapy] explode all trees  8481  \n#12 MeSH descriptor: [Thinness] explode all trees  266 \n#11 MeSH descriptor: [Obesity Management] explode all trees  789 \n#10 MeSH descriptor: [Diet, Reducing] explode all trees  1936  \n#9 MeSH descriptor: [Body Weight Changes] explode all trees  7440  \n#8 MeSH descriptor: [Weight Reduction Programs] explode all trees  538 \n#7 #1 or #2 or #3 or #4 or #5 or #6  17318  \n#6 ((\"air trapping \" or airtrapping)):ti,ab,kw (Word variations have been searched)  112 \n#5 ((((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*)):ti,ab,kw (Word variations have been searched)  12103  \n#4 (Emphysem*):ti,ab,kw  1185  \n#3 (COAD):ti,ab,kw  63 \n#2 (COPD):ti,ab,kw  12056  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4634  \n \nCochrane Reviews  \n\u2022 Review  \n\u2022 Protocol   \n28 \n0 \nTrials  603 \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  154 28 182 \nRCTs  339 603 942 \nGesamt    1124  \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 250  \nA2 (nicht englisch/deutsch): 49 \nA2 (Conference Abstract): 18  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 807  \nAlle Title/Abstracts, die sich mit dem Einfluss von Nahrungserg\u00e4nzungsmitteln oder anderen Supplements auf \nbspw. Dyspnoe oder Exercise \u2013Kapazit\u00e4t besch\u00e4ftigen, im Abstract jedoch nicht den Einfluss auf das Gewicht bei \nPatient*innen mit COPD beschreiben, wurden Aa ausgeschlossen, da sie die Fragestellung (Gewichtsmanage-ment) nicht beantworten. Studienprotokolle von thematisch passenden Prim\u00e4rstudien wurden nicht mit eingeschlos-sen. NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  101 \n  \n  \n Entsprechend einer sukzessiven Vorgehensweise wurden zun\u00e4chst systematische \u00dcbersichtsarbeiten betrachtet.  \nFlussdiagramm:  \n \nLegende: Ez: keine klinische Relevanz (Bsp. Wachstumshormone; Progesteron; Kr\u00e4uter) ; Aa: andere Fragestel-\nlung.  \nAnhang 3.16  Ger\u00e4tebasiertes Training \nPICO -Fragestellung  \nPopulation:  Patient*innen mit COPD  \nIntervention: ger\u00e4tebasiertes Training  \nVergleich: Training ohne Ger\u00e4te \nEndpunkte:  \n\uf0a1 krankheitsspezifische Mortalit\u00e4t  \n\uf0a1 Morbidit\u00e4t  \n\uf0fa Symptomatik: Atemnot, Husten und Auswurf  \n\uf0fa Mobilit\u00e4t/Funktionalit\u00e4t  \n\uf0fa soziale Teilhabe  \n\uf0fa Exazerbationen  \n\uf0fa Reduktion des zuk\u00fcnftigen Krankheitsrisikos: COPD -bedingte Hospitalisierung  \n\uf0a1 Lebensqualit\u00e4t  \nStudientyp: Systematisc he \u00dcbersichtsarbeiten, RCTs  \nRecherchestrategien  \nIn dieser Recherche wurden Interventionen im ambulanten und auch im station\u00e4ren Bereich betrachtet.  \nMedline via Pubmed (www.pubmed.gov) (05.03.2019)  \nNr. Suchfrage  Anzahl  \n#16 Search ((#12 AND #14) NOT #15) 26 \n#15 Search (#12 AND #13)  7 \n#14 Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized \n[tiab] OR placebo [tiab] OR \"clinical trials as topic\" [MeSH Terms:noexp] OR randomly \n[tiab] OR trial [ti])  1210507  \n#13 Search ((systematic review [ti] OR meta -analysis [pt] OR meta -analysis [ti] OR systematic \nliterature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic \nreview [tiab] AND review [pt]) OR meta synthesis [ti] OR meta -analy*[ti] OR integrative re-\nview [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] 396735  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 807 \nEingeschlossene Titel/Abstracts:  \nn = 22 \nEingeschlossene Volltexte  \nn = 1 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 785 \nAusgeschlossene  \nVolltexte: n=  \nEz: n = 19 \nAa: n = 2 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  102 \n  \n  \n Nr. Suchfrage  Anzahl  \nOR consensus development conference [pt] OR practice guideline [pt] OR drug class re-\nviews [ti] OR cochrane database syst rev [ta] OR acp journal clu b [ta] OR health technol \nassess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement \nrep [ta]) OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR ev-\nidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (re-\nview [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR \ntherapeutics [mh] OR evaluation studies[pt] OR validation studies[pt] OR guideline [pt] OR \npmcbook)) OR ((systematic [tw] OR systematically [tw] OR  critical [tiab] OR (study selec-\ntion [tw]) OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* \n[tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) \nAND (survey [tiab] OR surveys [tiab] OR over view* [tw] OR review [tiab] OR reviews [tiab] \nOR search* [tw] OR handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] \nOR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (litera-\nture [tiab] OR articles [tiab] OR p ublications [tiab] OR publication [tiab] OR bibliography \n[tiab] OR bibliographies [tiab] OR published [tiab] OR pooled data [tw] OR unpublished \n[tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks \n[tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] \nOR meta -analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR \ntreatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt]))  \n#12 Searc h (#7 AND #10 AND #11)  128 \n#11 Search (gym -based[tiab] OR gym[tiab] OR apparatus[tiab] OR equipment[tiab] OR equip-\nment - based[tiab] OR calisthenics -based[tiab] OR callisthenics -based[tiab] OR callis-\nthenic[tiab] OR calisthenic[tiab])  175111  \n#10 Search (#8 OR #9)  826022  \n#9 Search (Train*[tiab] OR \"physical activity\u201d [tiab] OR \u201cphysical activities\u201d [tiab] OR exer-\ncise*[tiab] OR \u201cexercise training\u201c[tiab] OR \u201cpulmonary rehabilitation\u201d[tiab])  769062  \n#8 Search \"Exercise\"[Mesh]  175314  \n#7 Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6)  100898  \n#6 Search (\"Air trapping\" [tiab] OR airtrapping[tiab])  1253  \n#5 Search COAD[tiab]  292 \n#4 Search COPD[tiab]  41325  \n#3 Search Emphysem*[tiab]  26329  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  50876  \n#1 Search ((chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab])))  56375  \nAnzahl der Treffer: 7 SR, 26 RCT  \nDatenbanken der Cochrane Library (05.03.2019)  \nNr. Suchfrage  Anzahl  \n#14 (#7 AND #11 AND #12) not \"conference abstract\":pt in Trials  99 \n#13 (#7 AND #11 AND #12) not \"conference abstract\":pt in Cochrane Reviews, \nCochrane Protocols  3 \n#12 (gym -based or gym or apparatus or equipment or equipment -based or calisthenics -based \nor callisthenics -based or callisthenic or calisthenic):ti,ab,kw (Word variations have been \nsearched)  15333  \n#11 #8 or #9 or #10  134454  \n#10 (physical and (activity or activities)):ti,ab,kw (Wo rd variations have been searched)  33606  \n#9 (Train* or exercise* or \u201cexercise training\u201c or \u201cpulmonary rehabilitation\u201d):ti,ab,kw (Word var-\niations have been searched)  117199  \n#8 MeSH descriptor: [Exercise] explode all trees  21453  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  103 \n  \n  \n Nr. Suchfrage  Anzahl  \n#7 #1 or #2 or #3 or #4 or #5 or #6 17417  \n#6 ((\"air trapping\" or airtrapping)):ti,ab,kw (Word variations have been searched)  107 \n#5 ((((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*)):ti,ab,kw (Word variations have been searched)  12284  \n#4 (Emphysem*):ti,ab,kw (Word variations have been searched)  1191  \n#3 (COAD):ti,ab,kw  63 \n#2 (COPD):ti,ab,kw  11688  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4684  \nAnzahl der Treffer: 3 SR, 99 RCT  \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  7 3 10 \nRCTs  26 99 125 \nGesamt    135 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 27  \nA2 (nicht englisch/deutsch): 3  \nA3 (Conference Abstracts): 3  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 102  \nFlussdiagramm:  \n \nAnhang 3.17  Telemedizin \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: Telemonitoring/Telemedizin in der Rehabilitation \nVergleich: Jegliche  \nEndpunkte:  \n\uf0a1 krankheitsspezifische Mortalit\u00e4t  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 102 \nEingeschlossene Titel/Abstracts:  \nn = 10 \nEingeschlossene Volltexte  \nE: n = 4 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 92 \nAusgeschlossene  \nVolltexte: n=  \nAa: n=3  \nAp: n = 1 \nA2: n = 1  \nEz = 1  \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  104 \n  \n  \n \uf0a1 Morbidit\u00e4t  \n\uf0fa Symptomatik: Atemnot, Husten und Auswurf  \n\uf0fa Mobilit\u00e4t/Funktionalit\u00e4t  \n\uf0fa soziale Teilhabe  \n\uf0fa Exazerbationen  \n\uf0fa Reduktion des zuk\u00fcnftigen Krankheitsrisikos: COPD -bedingte Hospitalisierung  \n\uf0a1 Lebensqualit\u00e4t  \nStudientyp: Systematische \u00dcbersichtsarbeiten, ggf. RCTs  \nRecherchestrategien  \nVor dieser Recherche wurde zun\u00e4chst der vorhandene Cochrane-Review gepr\u00fcft (McLean S. Telehealthcare for \nchronic obstructive pulmonary disease. [114] ). Dieser \u00e4ltere Review von 2011 besch\u00e4ftigt sich im Allgemeinen mit \nTelehealthcare bei Patient*innen mit COPD, beleuchtet jedoch nicht im Speziellen das Telemonitoring im Rahmen einer Rehabilitation.  \nDie Suchstrategie wurde in einem weiteren Schri tt auf \u201eTelemedizin\u201c ausgeweitet.  \nMedline via Pubmed (www.pubmed.gov) (27.02.2019)  \nNr. Suchfrage  Anzahl  \n#21 Search ((#17 AND #19) NOT #20)  57 \n#20 Search (#17 AND #18)  21 \n#19 Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized \n[tiab] OR placebo [tiab] OR \"clinical trials as topic\" [MeSH Terms:noexp] OR randomly \n[tiab] OR trial [ti])  1209364  \n#18 Search ((systematic review [ti] OR meta -analysis [pt] OR meta -analysis [ti] OR systematic \nliterature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic \nreview [tiab] AND review [pt]) OR meta synthesis [ti] OR meta -analy*[ti] OR integrative re-\nview [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] \nOR consensus development conference [pt] OR practice guideline [pt] OR drug class re-\nviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol \nassess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement \nrep [ta]) OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR ev-\nidence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (re-\nview [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR \ntherapeutics  [mh] OR evaluation studies[pt] OR validation studies[pt] OR guideline [pt] OR \npmcbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selec-\ntion [tw]) OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* \n[tw] OR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) \nAND (survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] \nOR search* [tw] OR handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] \nOR (reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (litera-\nture [tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography \n[tiab] OR bibliographies [tiab] OR published [tiab] OR pooled data [tw] OR unpublished \n[tw] OR citation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks \n[tiab] OR references [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] \nOR meta -analy* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR \ntreatment outcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt]))  395947  \n#17 Search (#7 AND #16)  198 \n#16 Search (#14 OR #15)  6358  \n#15 Search (Telerehabilitations[tiab] OR telerehabilitation[tiab] OR tele -rehabilitations[tiab] OR \ntele-rehabilitation[tiab])  722 \n#14 Search (#10 AND #13)  6162  \n#13 Search (#11 OR #12)  148994  \n#12 Search \"Telemedicine\"[Mesh]  24365  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  105 \n  \n  \n Nr. Suchfrage  Anzahl  \n#11 Search (Virtual[tiab] OR remote[tiab] OR tele[tiab] OR \u201cRemote physiological Monitor-\ning\u201c[tiab] OR digihealth*[tiab] OR digi -health*[tiab] OR \u201cdigital health*\u201d[tiab] OR \u201cdigital \ntherap*\u201d[tiab] OR \u201cdigital treat*\u201d[tiab] OR ehealth[tiab] OR e-health[tiab] OR etherap*[tiab] \nOR e -therap*[tiab] OR etreat*[tiab] OR e-treat*[tiab] OR mhealth[tiab] OR m -health[tiab] \nOR \u201cmobile health*\u201d[tiab] OR telehealth*[tiab] OR tele- health*[tiab] OR telemedic*[tiab] OR \ntele-medic*[tiab] OR telecommunicat*[tiab] OR tele -communicat*[tiab] OR tele -\nhomecare[tiab] OR teleho mecare[tiab] OR tele -monitor*[tiab] OR telemonitor*[tiab] OR te-\nlemanage*[tiab] OR tele-manage*[tiab] OR teleconsult*[tiab] OR tele-consult*[tiab] OR tel-\necare*[tiab] OR tele- care*[tiab] OR telepharmac*[tiab] OR tele-pharmac*[tiab] OR \ntelenurs*[tiab] OR tele- nurs*[tiab] OR tele-support[tiab] OR telesupport[tiab])  140370  \n#10 Search (#8 OR #9)  386292  \n#9 Search (rehabilitation[tiab] OR rehabilitations[tiab])  151046  \n#8 Search \"Rehabilitation\"[Mesh]  283220  \n#7 Search (#1 OR #2 OR #3 OR #4 OR #5 OR #6)  100794  \n#6 Search (\"Air trapping\"[tiab] OR airtrapping[tiab])  1253  \n#5 Search COAD[tiab]  289 \n#4 Search COPD[tiab]  41274  \n#3 Search Emphysem*[tiab]  26309  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  50839  \n#1 Search (chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab]))  56293  \nAnzahl der Treffer: 21 SR; 57 RCT  \nNr. Suchfrage  Anzahl  \n#17 (#7 AND #16) not \"conference abstract\":pt in Cochrane Reviews, Cochrane Proto-\ncols, Trials  92 \n#16 #14 OR #15  2547  \n#15 (Telerehabilitations or telerehabilitation or Tele -rehabilitations or tele -rehabilita-\ntion):ti,ab,kw (Word variations have been searched)  368 \n#14 #10 AND #13  2421  \n#13 #11 or #12  21299  \n#12 MeSH descriptor: [Telemedicine] explode all trees  1982  \n#11 (Virtual or remote or tele or digihealth* or digi -health* or digital health* or digital therap* or \ndigital treat* or ehealth or e- health or etherap* or e-therap* or etreat* or e-treat* or \nmhealth or m -health or mobile health*or telehealth* or tele-health* or telemedic* or tele-\nmedic* or telecommunicat* or tele-communicat* or tele -homecare or telehomecare or tele-\nmonitor* or telemonitor* or telemanage* or tele- manage* or teleconsult* or tele-consult* or \ntelecare* or tele-care* or telepharmac* or tele- pharmac* or telenurs* or tele-nurs* or tele-\nsupport or telesupport):ti,ab,kw (Word variations have been searched)  21260  \n#10 #8 OR #9  57303  \n#9 (Rehabilitation or rehabilitations):ti,ab,kw (Word variations have been searched)  36849  \n#8 MeSH descriptor: [Rehabilitation] explode all trees  30953  \n#7 #1 or #2 or #3 or #4 or #5 or #6  17309  \n#6 ((\"air trapping\" or airtrapping)):ti,ab,kw (Word variations have been searched)  104 \n#5 ((((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*)):ti,ab,kw (Word variations have been searched)  12195  \n#4 (Emphysem*):ti,ab,kw (Word var iations have been searched)  1183  \n#3 (COAD):ti,ab,kw  61 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  106 \n  \n  \n Nr. Suchfrage  Anzahl  \n#2 (COPD):ti,ab,kw  11603  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4622  \nAnzahl der Treffer: 2 SR; 89 RCT  \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  21 3 24 \nRCTs  57 89 146 \nGesamt    170 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 58  \nA2 (nicht englisch/deutsch): 1  \nA3 (Conference Abstracts): 6  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 105  \nFlussdiagramm f\u00fcr aggregierte Evidenz  \n(iteratives Vorgehen)  \n \nAnhang 3.18  Triple -Therapie \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: Triple Therapie  \nVergleich: alle anderen bronchodilatatorischen Mono- oder Dualtherapien  \nEndpunkte:  \n\uf0a1 krankheitsspezifische Mortalit\u00e4t  \n\uf0a1 Morbidit\u00e4t  \n\uf0fa Symptomatik: Atemnot, Husten und Auswurf  \n\uf0fa Mobilit\u00e4t/Funktionalit\u00e4t  \n\uf0fa soziale Teilhabe  \n\uf0fa Exazerbationen  \n\uf0fa Reduktion des zuk\u00fcnftigen Krankheitsrisikos: COPD -bedingte Hospitalisierung  \n\uf0a1 Lebensqualit\u00e4t  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 22 \nEingeschlossene Titel/Abstracts:  \nn = 4 \nEingeschlossene Volltexte  \nn = 2 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 18 \nAusgeschlossene  \nVolltexte:  \nEz: n = 2 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  107 \n  \n  \n Studientyp: RCTs  \nRecherchestrategien  \nGrundlage f\u00fcr die Entwicklung dieser Recherche ist die Suchstrategie des Cochrane-Reviews \u201eInhaled corticoster-\noids with combination inhaled lo ng-acting beta2-agonists and long-acting muscarinic antagonists for chronic ob-\nstructive pulmonary disease.\u201c(Tan 2016 [39]), welche um weitere Begriffe erg\u00e4nzt wurde. Ziel ist es, alle Prim\u00e4rstu-\ndien (RCTs) zum Thema \u201eTriple -Therapie\u201c, welche nach dem Ende des Suchzeitraums des Cochrane-Reviews \npubliziert wurden, zu identifizieren.  \nMedline via Pubmed (www.pubmed.gov) (21.02.2019)  \nNr. Suchfrage  Anzahl  \n#18 Search (#15 AND #16) Filters: Publication date from 2015/12/15  98 \n#17 Search (#15 AND #16)  232 \n#16 Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] \nOR placebo [tiab] OR \"clinical trials as topic\" [MeSH Terms:noexp] OR randomly [tiab] OR \ntrial [ti])  1208195  \n#15 Search (#7 and #14)  584 \n#14 Search ((#12 AND #13) OR #8)  5915  \n#13 Search (Mometa sone[tiab] OR Flunisolide[tiab] OR (Triamcinolone[tiab] OR \"Triamcino-\nlone\"[Mesh]) OR (Beclomethasone[tiab] OR \"Beclomethasone\"[Mesh]) OR (Budesonide[tiab] \nOR \"Budesonide\"[Mesh]) OR (Fluticasone[tiab] OR \"Fluticasone\"[Mesh]) OR (\u201cinhaled corti-\ncosteroid*\u201d[ti ab] OR \u201cinhaled steroid*\u201d[tiab] OR \u201cinhaled glucocorticoid*\u201d[tiab]) OR ICS[tiab])  32355  \n#12 Search ((#9 AND #10) OR #11)  1303  \n#11 Search QVA149[tiab]  44 \n#10 Search (PF -610355[tiab]) OR (abediterol[tiab] OR LAS100977[tiab]) OR (Clenbuterol[tiab] \nOR \"Clenbuterol\"[Mesh]) OR carmoterol[tiab] OR olodaterol[tiab] OR indacaterol[tiab] OR vi-\nlanterol[tiab] OR bambuterol[tiab] OR Arfomoterol[tiab] OR (Formoterol[tiab] OR \"Formoterol \nFumarate\"[Mesh]) OR (Salmeterol[tiab] OR \"Salmeterol Xi nafoate\"[Mesh]) OR (\u201cAdrenergic \nbeta-2 Receptor Agonists\u201d[Mesh]) OR ((long-acting[tiab] OR \u201clongacting\u201d[tiab]) AND adrener-\ngic*[tiab] AND (\u201cbeta 2 Receptor Agonists\u201d[tiab] OR \u201cbeta2-Agonists\u201d[tiab] OR \u201cbeta-2 Ago-\nnists\u201d[tiab])) OR LABA[tiab]  9323  \n#9 Search (darotropium[tiab] OR GSK233705[tiab]) OR (umeclidinium[tiab] OR \nGSK573719[tiab]) OR Glycopyrronium[tiab] OR Aclidinium[tiab] OR (tiotropium[tiab] OR \"Tio-\ntropium Bromide\"[Mesh]) OR (\"Muscarinic Antagonists\"[Mesh]) OR ((Long- acting[tiab] OR \nlongacting[tiab] ) AND (anticholinergic*[tiab] OR anti -cholinergic*[tiab] OR antimusca-\nrinic*[tiab] OR (Muscarinic*[tiab] AND Antagonist*[tiab]))) OR LAMA[tiab]  11340  \n#8 Search \"triple therapy\"[tiab]  5426  \n#7 Search #1 OR #2 OR #3 OR #4 OR #5 OR #6  100701  \n#6 Search \"Air trapping\" [tiab] OR airtrapping[tiab]  1253  \n#5 Search COAD[tiab]  289 \n#4 Search COPD[tiab]  41218  \n#3 Search Emphysem*[tiab]  26294  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  50786  \n#1 Search (chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab]))  56229  \nAnzahl der Treffer: 98 RCTs  \nDatenbanken der Cochrane Library (22.02.2019)  \nNr. Suchfrage  Anzahl  \n#32 (#7 and #31) not \"conference abstract\":pt with Publication Year from 2015 to present, \nin Trials  164 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  108 \n  \n  \n Nr. Suchfrage  Anzahl  \n#31 (#23 and #30) or #8  2978  \n#30 #24 or #25 or #26 or #27 or #28 or #29  14485  \n#29 ((Mometasone or Flunisolide:ti,ab,kw or Triamcinolone:ti,ab,kw or Beclomethasone or \nBudesonide or Fluticasone or ICS)):ti,ab,kw  12912  \n#28 MeSH descriptor: [Fluticasone] explode all trees  1532  \n#27 MeSH descriptor: [Budesonide] explode all trees  1655  \n#26 MeSH descriptor: [Beclomethasone] explode all trees  1070  \n#25 MeSH descriptor: [Triamcinolone Acetonide] explode all trees  937 \n#24 ((\u201cinhaled corticosteroid*\u201d or \u201cinhaled steroid*\u201d or \u201cinhaled glucocorticoid*\u201d)):ti,ab,kw (Word \nvariations have been searched)  4425  \n#23 #21 or #22  1467  \n#22 #13 and #20  1387  \n#21 (\u201cQVA149\u201d):ti,ab,kw  206 \n#20 #14 or #15 or #16 or #17 or #18 or #19  6335  \n#19 ((PF-610355 or (abediterol or LAS100977) or clenbuterol or carmoterol or olodaterol or in-\ndacaterol or vilanterol or bambuterol or arfomoterol or Formoterol or Salmeterol or \nLABA)):ti,ab,kw  6182  \n#18 MeSH descriptor: [Adrenergic beta -2 Receptor Agonists] explode all trees  385 \n#17 MeSH descriptor: [Salmeterol Xinafoate] explode all trees  992 \n#16 MeSH descriptor: [Formoterol Fumarate] explode all trees  945 \n#15 MeSH descriptor: [Clenbuterol] explode all trees  43 \n#14 (((\u201cbeta 2 Receptor Agonists\u201d or \u201cbeta 2 Agonists\u201d or \u201cbeta -2 Agonists\u201d) and (adrenergic*) \nand (long- acting or \u201clongacting\u201d))):ti,ab,kw (Word variations have been searched)  400 \n#13 #9 or #10 or #11 or #12  3732  \n#12 ((darotropium or GSK233705 or umeclidinium or GSK573719 or Glycopyrronium or \nAclidinium or Tiotropium or LAMA)):ti,ab,kw  2973  \n#11 ((Long -acting or longacting) and ((anticholinergic* or anti -cholinergic* or antimuscarinic*) or \n((Ant agonist* AND Muscarinic*)))):ti,ab,kw (Word variations have been searched)  696 \n#10 MeSH descriptor: [Muscarinic Antagonists] explode all trees  824 \n#9 MeSH descriptor: [Tiotropium Bromide] explode all trees  527 \n#8 (\"triple therapy\"):ti,ab,kw (Word variations have been searched)  2425  \n#7 #1 or #2 or #3 or #4 or #5 or #6  17309  \n#6 ((\"air trapping\" or airtrapping)):ti,ab,kw (Word variations have been searched)  104 \n#5 ((((pulmonary or lung* or airway* or airflow* or bronchi* or  respirat*) and obstruct*) and \nchronic*)):ti,ab,kw (Word variations have been searched)  12195  \n#4 (Emphysem*):ti,ab,kw (Word variations have been searched)  1183  \n#3 (COAD):ti,ab,kw  61 \n#2 (COPD):ti,ab,kw  11603  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4622  \nAnzahl der Treffer: 164 RCTs NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  109 \n  \n  \n \u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nRCTs  98 164 262 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 77  \nA2 (nicht englisch/deutsch): 4  \nA3 (Conference Abstracts): 19  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 162  \nFlussdiagramm:  \n \nAnhang 3.19  Kardiale Nebenwirkungen bei inhalativer Dauertherapie mit einem LAMA oder \nLABA \nPICO -Fragestellung  \nPopulation: therapienaive Patient*innen mit COPD  \nIntervention: inhalative Dauertherapie mit einem LAMA als Ersttherapie  \nVergleich: inhalative Dauertherapie mit einem LABA als Ersttherapie  \nEndpunkte: kardiale Nebenwirkungen  \nStudientyp: SR, RCTs, ggf. Kohortenstudien  \nRecherchestrategien  \nDer SIGN \u2013 Filter f\u00fcr Kohortenstudien wurde in dieser Recherche angewendet. Zus\u00e4tzlich wurde dieser um den \nBegriff \u201e(cohort AND( study OR studies))\u201c erweitert.  \nMedline via Pubmed (www.pubmed.gov) (29. April 2019)  \nNr. Suchfrage  Anzahl  \n#27 Search (#21 AND #24) NOT (#25 OR #26) - Beobachtungsstudien  21 \n#26 Search (#21 AND #23) NOT #25 - RCTs  78 \n#25 Search (#21 AND #22) \u2013 Aggregierte Evidenz  26 \n#24 Search ((((((((((\"Case -Control Studies\"[Mesh] OR \"Cohort Studies\"[Mesh]))) OR \"Cross -\nSectional Studies\"[Mesh]) OR ((\"Follow -Up Studies\"[Mesh] OR ((\"follow -up\" OR \"follow up\") \nAND (studies OR study))))) OR ((longitudinal[tw] OR retrospective[tw] OR \"cross -sec-\ntional\"[tw] OR \"cross sectional\"[tw]))) OR (\"case control\"[tw] OR (cohort[tw] AND \nanaly*[tw]))) OR \"Observational Study\"[pt])) OR (cohort AND( study OR studies)))  3001991  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 162 \nEingeschlossene Titel/Abstracts:  \nn = 18 \nEingeschlossene Volltexte  \nn = 8 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 144 \nAusgeschlossene  \nVolltexte: n=  \nAa: n = 1 \nAp: n = 1 \nEz: n = 8 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  110 \n  \n  \n Nr. Suchfrage  Anzahl  \n#23 Search ((randomized control led trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] \nOR placebo [tiab] OR \"clinical trials as topic\" [MeSH Terms:noexp] OR randomly [tiab] OR \ntrial [ti]))  1221076  \n#22 Search (systematic review [ti] OR meta -analysis [pt] OR meta -analysis [ ti] OR systematic \nliterature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic \nreview [tiab] AND review [pt]) OR meta synthesis [ti] OR meta -analy*[ti] OR integrative re-\nview [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] \nOR consensus development conference [pt] OR practice guideline [pt] OR drug class re-\nviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol as-\nsess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement rep \n[ta]) OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR evi-\ndence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (re-\nview [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR thera-\npeutics [mh] OR evaluation studies[pt] OR validation studies[pt] OR guideline [pt] OR pmc-\nbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selection \n[tw]) OR (predetermined [tw] OR inc lusion [tw] AND criteri* [tw]) OR exclusion criteri* [tw] \nOR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) AND \n(survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] OR \nsearch* [tw] OR handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] OR \n(reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recurrence))) AND (literature \n[tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography [tiab] \nOR bibli ographies [tiab] OR published [tiab] OR pooled data [tw] OR unpublished [tw] OR \ncitation [tw] OR citations [tw] OR database [tiab] OR internet [tiab] OR textbooks [tiab] OR \nreferences [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] OR meta -\nanaly* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment \noutcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt])  403566  \n#21 Search #7 AND #8 AND #9 AND #20  156 \n#20 Search #10 OR #11 OR #12 OR #13 OR #1 4 OR #15 OR #16 OR #17 OR #18 OR #19  874936  \n#19 Search \u201cAdverse event*\u201d[tiab] OR \u201cAdverse effect*\u201d[tiab]  51725  \n#18 Search \"Heart Failure\"[Mesh]  112878  \n#17 Search \u201cCardiac failure\u201d [tiab] OR \u201cmyocardial failure\u201d [tiab] OR \u201cheart decompensation\u201d \n[tiab]  12444  \n#16 Search \"Acute Coronary Syndrome\"[Mesh]  13709  \n#15 Search \"Acute Coronary Syndrome\"[tiab]  20286  \n#14 Search \"Myocardial Infarction\"[Mesh]  168159  \n#13 Search \u201cMyocardial infarct*\u201d[tiab] OR \u201cheart attack*\u201d[tiab] OR \u201ccardiovascular stroke\u201d[tiab]  23769  \n#12 Search \"Arrhythmias, Cardiac\"[Mesh]  198655  \n#11 Search Cardiac[tiab] AND (arrhythmia*[tiab] OR dysrhythmia*[tiab])  44342  \n#10 Search (cardiovascular[tiab] OR cardiac[tiab]) AND (events[tiab] OR safety[tiab] OR \nrisk[tiab] OR outcome[tiab] OR effect[tiab])  417460  \n#9 Search (PF -610355[tiab]) OR (abediterol[tiab] OR LAS100977[tiab]) OR (Clenbuterol[tiab] \nOR \"Clenbuterol\"[Mesh]) OR carmoterol[tiab] OR olodaterol[tiab] OR indacaterol[tiab] OR \nvilanterol[tiab] OR bambutero l[tiab] OR Arfomoterol[tiab] OR (Formoterol[tiab] OR \"For-\nmoterol Fumarate\"[Mesh]) OR (Salmeterol[tiab] OR \"Salmeterol Xinafoate\"[Mesh]) OR \n(\u201cAdrenergic beta -2 Receptor Agonists\u201d[Mesh]) OR ((long- acting[tiab] OR \u201clongacting\u201d[tiab]) \nAND (\u201cbeta 2 Receptor Agonists\u201d[tiab] OR \u201cbeta2 -Agonists\u201d[tiab] OR \u201cbeta-2 Agonists\u201d[tiab] \nOR \u03b2 -agonists[tiab])) OR LABA[tiab]  10178  \n#8 Search (darotropium[tiab] OR GSK233705[tiab]) OR (umeclidinium[tiab] OR \nGSK573719[tiab]) OR Glycopyrronium[tiab] OR Aclidinium[tiab] OR (tiotropium[tiab] OR \n\"Tiotropium Bromide\"[Mesh]) OR (\"Muscarinic Antagonists\"[Mesh]) OR ((Long-acting[tiab] \nOR longacting[tiab]) AND (anticholinergic*[tiab] OR anti -cholinergic*[tiab] OR antimusca-\nrinic*[tiab] OR (Muscarinic*[tiab] AND A ntagonist*[tiab]))) OR LAMA[tiab]  11447  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  111 \n  \n  \n Nr. Suchfrage  Anzahl  \n#7 Search #1 OR #2 OR #3 OR #4 OR #5 OR #6  101733  \n#6 Search \"Air trapping\" [tiab] OR airtrapping[tiab]  1265  \n#5 Search COAD[tiab]  295 \n#4 Search COPD[tiab]  41800  \n#3 Search Emphysem*[tiab]  26477  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  51410  \n#1 Search (chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab]))  56958  \nAnzahl der Treffer: 26 SR / 78 RCTs  / 21 Beobachtungsstudien  \nDatenbanken der Cochrane Library (29. April 2019)  \nNr. Suchfrage  Anzahl  \n#32 (#7 and #12 and #19 and #30) not \"conference abstract\":pt in Trials  281 \n#31 (#7 and #12 and #19 and #30) not \"conference abstract\":pt in Cochrane Reviews, \nCochrane Protocols  16 \n#30 #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29  315384  \n#29 (\u201cAdverse event*\u201d or \u201cAdverse effect*\u201d):ti,ab,kw (Word variations have been searched)  216745  \n#28 MeSH descriptor: [Heart Failure] explode al l trees  8158  \n#27 (\u201cCardiac failure\u201d or \u201cmyocardial failure\u201d or \u201cheart decompensation\u201d):ti,ab,kw (Word varia-\ntions have been searched)  869 \n#26 MeSH descriptor: [Acute Coronary Syndrome] explode all trees  1588  \n#25 (\"Acute Coronary Syndrome\"):ti,ab,kw (Word variations have been searched)  6152  \n#24 MeSH descriptor: [Myocardial Infarction] explode all trees  10241  \n#23 (\u201cMyocardial infarct*\u201d or \u201cheart attack*\u201d or \u201ccardiovascular stroke\u201d):ti,ab,kw (Word variations \nhave been searched)  28459 \n#22 MeSH descriptor: [Arrhythmias, Cardiac] explode all trees  8644  \n#21 (cardiac and (arrhythmia* or dysrhythmia*)):ti,ab,kw (Word variations have been searched)  5990  \n#20 ((cardiovascular or cardiac) and (events or safety or risk or outcome or effect)):ti,ab,kw \n(Word variations have been searched)  98781  \n#19 #13 or #14 or #15 or #16 or #17 or #18  7625  \n#18 (((PF -610355 or (abediterol or LAS100977) or clenbuterol or carmoterol or olodaterol or in-\ndacaterol or vilanterol or bambuterol or arfomotero l or Formoterol or Salmeterol or \nLABA))):ti,ab,kw  7390  \n#17 MeSH descriptor: [Adrenergic beta -2 Receptor Agonists] explode all trees  401 \n#16 MeSH descriptor: [Salmeterol Xinafoate] explode all trees  1003  \n#15 MeSH descriptor: [Formoterol Fumarate] explode all trees  962 \n#14 MeSH descriptor: [Clenbuterol] explode all trees  44 \n#13 ((((\u201cbeta 2 Receptor Agonists\u201d or \u201cbeta 2 Agonists\u201d or \u201cbeta -2 Agonists\u201d or \u03b2 -agonists) and \n(long- acting or \u201clongacting\u201d)))):ti,ab,kw (Word variations have been s earched)  716 \n#12 #8 or #9 or #10 or #11  4365  \n#11 (((darotropium or GSK233705 or umeclidinium or GSK573719 or Glycopyrronium or \nAclidinium or Tiotropium or LAMA))):ti,ab,kw  3548  \n#10 (((Long -acting or longacting) and ((anticholinergic* or anti-cholinergic* or antimuscarinic*) \nor ((Antagonist* AND Muscarinic*))))):ti,ab,kw (Word variations have been searched)  858 \n#9 MeSH descriptor: [Muscarinic Antagonists] explode all trees  840 \n#8 MeSH descriptor: [Tiotropium Bromide] explode all trees  542 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  112 \n  \n  \n Nr. Suchfrage  Anzahl  \n#7 #1 or #2 or #3 or #4 or #5 or #6  20406  \n#6 (((\"air trapping\" or airtrapping))):ti,ab,kw (Word variations have been searched)  134 \n#5 (((((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*))):ti,ab ,kw (Word variations have been searched)  14636  \n#4 (Emphysem*):ti,ab,kw (Word variations have been searched)  1411  \n#3 (COAD):ti,ab,kw  80 \n#2 (COPD):ti,ab,kw  14342  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4722  \n \nCochrane Reviews  16 \nCochrane Protocols  - \nTrials  281 \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  26 16 42 \nRCTs  78 281 359 \nKohortenstudien  21  21 \nGesamt    422 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 74  \nA2 (nicht englisch/deutsch): 3  \nA3 (Conference Abstracts): 3  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 342  \nFlussdiagramm:  \n \nAnhang 3.20  Eosinophile  \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: Eosinophile im Blut oder Sputum  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 342 \nEingeschlossene Titel/Abstracts:  \nn = 57 \nEingeschlossene Volltexte  \nn = 6 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 285 \nAusgeschlossene  \nVolltexte:  \nAa: n = 50 \nEz: n = 1 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 1 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  113 \n  \n  \n Vergleich: Jegliche \nEndpunkte:  \n\uf0a1 Cut-Off f\u00fcr Eosinophilie bez\u00fcglich dem Einsatz von Steroiden (Initiierung oder Absetzen von ICS bzw. der \nLangzeittherapie) sowie Morbidit\u00e4t  \n\uf0a1 dem Einsatz von Antibiotika im Rahmen einer Pneumonie.  \nStudientyp: aggregierte Evidenz, RCT, ggf. Beobachtungsstudien, diagnostische Studien  \nRecherchestrategien  \nDer SIGN -Filter f\u00fcr Kohortenstudien und der McMaster (2) Filter f\u00fcr diagnostische Studien wurden in dieser Re-\ncherche angewendet. Es konnten keine diagnostischen Studien identifiziert werden.  \nMedline via Pubmed (www.pubmed.gov) (14.08.2018)  \nNr. Suchfrage  Anzahl  \n#17 Search (#9 AND #13) NOT (#14 OR #15 OR #16) - diagnostische Studien  89 \n#16 Search (#9 AND #12) NOT (#14 OR #15) - Beobachtungsstudien  271 \n#15 Search (#9 AND #11) NOT #14 - RCTs  132 \n#14 Search (#9 AND #10) \u2013 aggregierte Evidenz  23 \n#13 Search ((sensitiv*[Title/Abstract] OR sensitivity and specificity[MeSH Terms] OR \n(predictive[Title/Abstract] AND value*[Title/Abstract]) OR predictive value of tests[MeSH \nTerm] OR accuracy*[Title/A bstract]))  1849988  \n#12 Search (((((((((((\"Case -Control Studies\"[Mesh] OR \"Cohort Studies\"[Mesh]))) OR \"Cross -\nSectional Studies\"[Mesh]) OR ((\"Follow -Up Studies\"[Mesh] OR ((\"follow -up\" OR \"follow \nup\") AND (studies OR study))))) OR ((longitudinal[tw] OR retrospective[tw] OR \"cross -\nsectional\"[tw] OR \"cross sectional\"[tw]))) OR (\"case control\"[tw] OR (cohort[tw] AND \nanaly*[tw]))) OR \"Observational Study\"[pt]))))  2807057  \n#11 Search randomized controlled trial [pt] OR controlled clinica l trial [pt] OR randomized [tiab] \nOR placebo [tiab] OR \"clinical trials as topic\" [MeSH Terms:noexp] OR randomly [tiab] OR \ntrial [ti]  1173322  \n#10 Search systematic[sb]  372798  \n#9 Search #7 AND #8  1512  \n#8 Search \"Eosinophils\"[Mesh] OR Eosinophil*[tiab]  74531  \n#7 Search #1 OR #2 OR #3 OR #4 OR #5 OR #6  97414  \n#6 Search \u201cAir trapping\u201d[tiab] OR airtrapping[tiab]  1218  \n#5 Search COAD[tiab]  264 \n#4 Search COPD[tiab]  39326  \n#3 Search Emphysem*[tiab]  25740  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  49021  \n#1 Search (chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or \nairway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab]))  53999  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  114 \n  \n  \n Datenbanken der Cochrane Library (14.08.2018)  \nNr. Suchfrage  Anzahl  \n#13 (#9 AND #12) not \"conference abstract\":pt  172 \n#12 #10 or #11  3763  \n#11 MeSH descriptor: [Eosinophils] explode all trees  742 \n#10 (Eosinophil*):ti,ab,kw (Word variations have been searched)  3763  \n#9 #1 or #2 or #3 or #4 or #7 or #8 17528  \n#8 (\"air trapping\" or airtrapping):ti,ab,kw (Word variations have been searched)  112 \n#7 (((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*):ti,ab,kw  12022  \n#6 ((pulmonary or lung* or airway* or air flow* or bronchi* or respirat*) and obstruct*):ti,ab,kw  17831  \n#5 (pulmonary or lung* or airway* or airflow* or bronchi* or respirat*):ti,ab,kw (Word varia-\ntions have been searched)  119721  \n#4 (Emphysem*):ti,ab,kw (Word variations have been searched)  1213  \n#3 (COAD):ti,ab,kw  60 \n#2 (COPD):ti,ab,kw  12511  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4562  \n \nCochrane  \n\u2022 Reviews  \n\u2022 Protocols   \n0 \n0 \nTrials  172 \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  23  23 \nRCTs  132 172 304 \nSonstige Prim\u00e4r  360  360 \nGesamt    687 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 112  \nA2 (nicht englisch/deutsch): 43 \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 532  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  115 \n  \n  \n Flussdiagramm:  \n \nAnhang 3.21  Roflumilast  \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: LAMA/LABA + Roflumilast als Add on \nVergleich: Jegliche \nEndpunkte:  \n\uf0a1 krankheitsspezifische Mortalit\u00e4t  \n\uf0a1 Morbidit\u00e4t  \n\uf0fa Symptomatik: Atemnot, Husten und Auswurf  \n\uf0fa Mobilit\u00e4t/Funktionalit\u00e4t  \n\uf0fa soziale Teilhabe  \n\uf0fa Exazerbationen  \n\uf0fa Reduktion des zuk\u00fcnftigen Krankheitsrisikos: COPD -bedingte Hospitalisierung  \n\uf0a1 Lebensqualit\u00e4t  \n\uf0a1 Sicherheit  \nStudientyp: Systematische \u00dcbersichtsarbeiten, RCTs  \nRecherchestrategie  \nSukzessives Vorgehen. Zun\u00e4chst wurden alle systematischen \u00dcbersichtsarbeiten gepr\u00fcft. Anschlie\u00dfend wurden \nalle Prim\u00e4rstudien hinsichtlich der Fragestellung betrachtet, insbesondere jene, welche nach dem Suchzeitraum \ndes Cochrane-Reviews zum Thema (Chong 2017 [51] ) ver\u00f6ffentlicht wurden.  \nMedline via Pubmed (www.pubmed.gov) (06.12.2019)  \nNr. Suchfrage  Anzahl  \n#16 Search (#12 AND #14) NOT #15  131 \n#15 Search (#12 AND #13)  37 \n#14 Search randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized \n[tiab] OR placebo [tiab] OR \"clinical trials as topic\" [MeSH Terms:noexp] OR randomly \n[tiab] OR trial [ti]  1262909  \n#13 Search (systematic review [ti] OR meta -analysis [pt] OR meta -analysis [ti] OR system-\natic literature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (sys-\ntematic review [tiab] AND review [pt]) OR meta synthesis [ti] OR meta -analy*[ti] OR in-\ntegrative review [tw] OR integrative research review  [tw] OR rapid review [tw] OR um-\nbrella review [tw] OR consensus development conference [pt] OR practice guideline [pt] \nOR drug class reviews [ti] OR cochrane database syst rev [ta] OR acp journal club [ta] 431687  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 532 \nEingeschlossene Titel/Abstracts:  \nn = 22 \nEingeschlossene Volltexte  \nn = 3 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 510 \nAusgeschlossene  \nVolltexte:  \nAa: n = 4 \nAp: n = 2 \nEz: n = 13 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  116 \n  \n  \n Nr. Suchfrage  Anzahl  \nOR health technol assess [ta] OR evid rep technol assess summ [ta] OR jbi database \nsystem rev implement rep [ta]) OR (clinical guideline [tw] AND management [tw]) OR \n((evidence based[ti] OR evidence-based medicine [mh] OR best practice* [ti] OR evi-\ndence synthesis [tiab]) AND (review [pt] OR diseases category[mh] OR behavior and \nbehavior mechanisms [mh] OR therapeutics [mh] OR evaluation studies[pt] OR valida-\ntion studies[pt] OR guideline [pt] OR pmcbook)) OR ((systematic [tw] OR systematically \n[tw] OR critical [tiab] OR (study selection [tw]) OR (predetermi ned [tw] OR inclusion [tw] \nAND criteri* [tw]) OR exclusion criteri* [tw] OR main outcome measures [tw] OR stand-\nard of care [tw] OR standards of care [tw]) AND (survey [tiab] OR surveys [tiab] OR \noverview* [tw] OR review [tiab] OR reviews [tiab] OR search* [tw] OR handsearch [tw] \nOR analysis [ti] OR critique [tiab] OR appraisal [tw] OR (reduction [tw]AND (risk [mh] \nOR risk [tw]) AND (death OR recurrence))) AND (literature [tiab] OR articles [tiab] OR \npublications [tiab] OR publication [tiab] OR bibliography [tiab] OR bibliographies [tiab] \nOR published [tiab] OR pooled data [tw] OR unpublished [tw] OR citation [tw] OR cita-\ntions [tw] OR database [tiab] OR internet [tiab] OR textbooks [tiab] OR references [tw] \nOR scales [tw] OR papers [tw] OR datasets [tw] OR tr ials [tiab] OR meta -analy* [tw] OR \n(clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment outcome \n[tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt])  \n#12 Search #7 AND #11  842 \n#11 Search #8 OR #9 OR #10  31459  \n#10 Search \"Phosphodiesterase 4 Inhibitors\"[Mesh]  1056  \n#9 Search PDE4*[tiab] OR Phosphodiesterase*[tiab]  31205  \n#8 Search \"Roflumilast\"[tiab]  546 \n#7 Search #1 OR #2 OR #3 OR #4 OR #5 OR #6  105447  \n#6 Search \"Air trapping\" [tiab] OR airtrapping[tiab]  1294  \n#5 Search COAD[tiab]  333 \n#4 Search COPD[tiab]  43945  \n#3 Search Emphysem*[tiab]  27028  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  53480  \n#1 Search ((chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab])))  59493  \nAnzahl der Treffer: 37 Aggregierte Evidenz; 131 RCTs  \nDatenbanken der Cochrane Library (06.12.2019)  \nNr. Suchfrage  Anzahl  \n#12 (#7 and #11) not \"conference abstract\":pt in Cochrane Reviews, Cochrane Protocols, \nTrials  257 \n#11 #8 or #9 or #10  2989  \n#10 MeSH descriptor: [Phosphodiesterase 4 Inhibitors] explode all trees  91 \n#9 ((PDE4* or Phosphodiesterase*)):ti,ab,kw (Word variations have been searched)  2823  \n#8 (Roflumilast):ti,ab,kw  354 \n#7 #1 or #2 or #3 or #4 or #5 or #6  21323  \n#6 (((\"air trapping\" or airtrapping))):ti,ab,kw (Word variations have been searched)  141 \n#5 (((((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*))):ti,ab,kw (Word variations have been searched)  15454  \n#4 (Emphysem*):ti,ab,kw (Word variations have been searched)  1457  \n#3 (COAD):ti,ab,kw  82 \n#2 (COPD):ti,ab,kw  15008  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4944  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  117 \n  \n  \n Treffer  \nCochrane Reviews  2 \nTrials  255 \nDatenbank: Epistemonikos (06.12.2019)  \nNr. Suchfrage  Anzahl  \n#3 #1 Filters: Publication type: Primary study  30 \n#2 #1 Filters: Publication type: Systematic review  26 \n#1 (title:((title:(COPD OR COAD OR Emphysem OR \"chronic obstructive pulmonary disease\") \nOR abstract:(COPD OR COAD OR Emphysem OR \"chronic obstructive pulmonary dis-\nease\"))) OR abstract:((title:(COPD OR COAD OR Emphysem OR \"chronic obst ructive pul-\nmonary disease\") OR abstract:(COPD OR COAD OR Emphysem OR \"chronic obstructive \npulmonary disease\"))))  \nAND  \n(title:(Roflumilast OR PDE4 OR Phosphodiesterase) OR abstract:(Roflumilast OR PDE4 OR \nPhosphodiesterase))  65 \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Epistemonikos  Summe  \nAggregierte Evidenz  37 2 26 65 \nRCTs/Sonstige  131 255 30 416 \nGesamt     481 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 132  \nA2 (nicht englisch/deutsch): 2  \nA3 (Conference Abstracts): 85  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 262  \nFlussdiagramm:  \n \nAnhang 3.22  Wirksamkeit von Instruktionen in Inhalationssysteme  \nRecherchestrategie  \nDie systematischen Recherchen der NVL Asthma wurden herangezogen und f\u00fcr Patient*innen mit COPD extrapo-\nliert. \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 262 \nEingeschlossene Titel/Abstracts:  \nn = 5 \nEingeschlossene Volltexte  \nn = 1 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 257 \nAusgeschlossene  \nVolltexte:  \nAa: n  =2 \nEz: n  = 2 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  118 \n  \n  \n In einer systematischen Recherche der NVL Asthma, 3. Auflage (Leitlinienreport  S. 56/ Evidenztabelle S. 221) [115]  \nwurde unter anderem eine systemat ische \u00dcbersichtsarbeit identifi ziert, die die Wirksamkeit von Instruktionen in \nInhalationssysteme untersuchte [52]  \nDie Evidenztabelle  aus der NVL Asthma, 3. Auflage ( www.leitlinien.de/nvl/asthma ) wurde adaptiert . Alle dargestell-\nten Ergebnisse wurden gepr\u00fcft und nur diejenigen dargestellt, die ausschlie\u00dflich f\u00fcr Erwachsene berechnet wurden.  \nAnhang 3.23  Mukolytika  \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: Mukopharmaka  \nVergleich: jegliche  \nEndpunkte:  \n\uf0a1 krankheitsspezifische Mortalit\u00e4t  \n\uf0a1 Morbidit\u00e4t  \n\uf0fa Symptomatik: Atemnot, Husten und Auswurf  \n\uf0fa Mobilit\u00e4t/Funktionalit\u00e4t  \n\uf0fa soziale Teilhabe  \n\uf0fa Exazerbationen  \n\uf0fa Reduktion des zuk\u00fcnftigen Krankheitsrisikos: COPD -bedingte Hospitalisierung  \n\uf0a1 Lebensqualit\u00e4t  \nStudientyp: SR, (ggf. RCTs)  \nRecherchestrategien  \nDie Suchbegriffe des Cochrane Reviews: Poole P. Mucolytic agents versus placebo for chronic bronchitis or chronic \nobstructive pulmonary disease (Update 05/2019) wurden f\u00fcr diese Recherche herangezogen und um weitere Be-\ngriffe erg\u00e4nzt. Da dieser Cochrane-Review Studien scheinbar ausschloss, welche Mukolytika mit Bronchodilatato-ren kombinieren, diese Patientengruppe aber im deutschen Versorgungsalltag nicht ausgeschlossen werden kann, \nwurde die Recherche nochmals durchgef\u00fchrt. Es wurde iterativ vorgegangen; zun\u00e4chst wurden systematische \u00dcbersichtsarbeiten gesichtet.  \nMedline via Pubmed (www.pubmed.gov) (30.07.2019)  \nNr. Suchfra ge Anzahl  \n#16 Search (#12 AND #14) NOT #15  189 \n#15 Search #12 AND #13  62 \n#14 Search ((randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] \nOR pla cebo [tiab] OR \"clinical trials as topic\" [MeSH Terms:noexp] OR randomly [tiab] OR \ntrial [ti]))  1238751  \n#13 Search (systematic review [ti] OR meta -analysis [pt] OR meta -analysis [ti] OR systematic \nliterature review [ti] OR this systematic review [tw] OR pooling project [tw] OR (systematic \nreview [tiab] AND review [pt]) OR meta synthesis [ti] OR meta -analy*[ti] OR integrative re-\nview [tw] OR integrative research review [tw] OR rapid review [tw] OR umbrella review [tw] \nOR consensus development conference [pt] OR practice guideline [pt] OR drug class re-\nviews [ti ] OR cochrane database syst rev [ta] OR acp journal club [ta] OR health technol as-\nsess [ta] OR evid rep technol assess summ [ta] OR jbi database system rev implement rep \n[ta]) OR (clinical guideline [tw] AND management [tw]) OR ((evidence based[ti] OR evi-\ndence-based medicine [mh] OR best practice* [ti] OR evidence synthesis [tiab]) AND (re-\nview [pt] OR diseases category[mh] OR behavior and behavior mechanisms [mh] OR thera-\npeutics [mh] OR evaluation studies[pt] OR validation studies[pt] OR guideline [pt] OR p mc-\nbook)) OR ((systematic [tw] OR systematically [tw] OR critical [tiab] OR (study selection \n[tw]) OR (predetermined [tw] OR inclusion [tw] AND criteri* [tw]) OR exclusion criteri* [tw] \nOR main outcome measures [tw] OR standard of care [tw] OR standards of care [tw]) AND 415190  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  119 \n  \n  \n Nr. Suchfra ge Anzahl  \n(survey [tiab] OR surveys [tiab] OR overview* [tw] OR review [tiab] OR reviews [tiab] OR \nsearch* [tw] OR handsearch [tw] OR analysis [ti] OR critique [tiab] OR appraisal [tw] OR \n(reduction [tw]AND (risk [mh] OR risk [tw]) AND (death OR recur rence))) AND (literature \n[tiab] OR articles [tiab] OR publications [tiab] OR publication [tiab] OR bibliography [tiab] \nOR bibliographies [tiab] OR published [tiab] OR pooled data [tw] OR unpublished [tw] OR \ncitation [tw] OR citations [tw] OR database [tiab ] OR internet [tiab] OR textbooks [tiab] OR \nreferences [tw] OR scales [tw] OR papers [tw] OR datasets [tw] OR trials [tiab] OR meta -\nanaly* [tw] OR (clinical [tiab] AND studies [tiab]) OR treatment outcome [mh] OR treatment \noutcome [tw] OR pmcbook)) NOT (letter [pt] OR newspaper article [pt])  \n#12 Search #7 AND #11  831 \n#11 Search #8 OR #9 OR #10  43723  \n#10 Search mucolytic*[tiab] OR mucoactiv*[tiab]  1692  \n#9 Search Acetylcysteine[tiab] OR bromhexine[tiab] OR carboxymethylcysteine[tiab] OR am-\nbroxol[ti ab] OR sobrerol[tiab] OR \u201ciodinated glycerol\u201d[tiab] OR isobutyrylcysteine[tiab] OR \nmyrtol[tiab] OR NAC[tiab] OR methylcysteine[tiab] OR carbocysteine[tiab] OR erdoste-\nine[tiab] OR stepronin[tiab] OR gelsolin[tiab] OR mesna*[tiab] OR cineole[tiab] OR nelten-\nexine[tiab] OR eucalyptus[tiab] OR eprazinone[tiab] OR guacetisal[tiab] OR Guai-\nfenesin[tiab] OR letosteine[tiab] OR mecysteine[tiab] OR \u201cPotassium Citrate\u201d[tiab] OR rosa-\nprostol[tiab] OR terpin[tiab]  35801  \n#8 Search \"Expectorants\" [Pharmacological Action]  17056  \n#7 Search #1 OR #2 OR #3 OR #4 OR #5 OR #6  103250  \n#6 Search \"Air trapping\" [tiab] OR airtrapping[tiab]  1284  \n#5 Search COAD[tiab]  306 \n#4 Search COPD[tiab]  42668  \n#3 Search Emphysem*[tiab]  26713  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  52203  \n#1 Search (chronic*[tiab]) AND (obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab])  58023  \nAnzahl der Treffer: 62 SR / 189 RCTs  \nDatenbanken der Cochrane Library (30.07.2019)  \nNr. Suchfrage  Anzahl  \n#13 (#7 and #11) not \"conference abstract\":pt in Trials  342 \n#12 (#7 and #11) not \"conference abstract\":pt in Cochrane Reviews, Cochrane Protocols  2 \n#11 #8 or #9 or #10  4476  \n#10 ((mucolytic* or mucoactiv*)):ti,ab,kw (Word variations have been searched)  463 \n#9 ((Acetylcysteine OR bromhexine OR carboxymethylcysteine OR ambroxol OR sobrerol OR \n\u201ciodinated glycerol\u201d OR isobutyrylcysteine OR myrtol OR NAC OR methylcysteine OR car-\nbocyst eine OR erdosteine OR stepronin OR gelsolin OR mesna* OR cineole OR neltenex-\nine OR eucalyptus OR eprazinone OR guacetisal OR Guaifenesin OR letosteine OR \nmecysteine OR \u201cPotassium Citrate\u201d OR rosaprostol OR terpin)):ti,ab,kw (Word variations \nhave been searc hed) 4194  \n#8 MeSH descriptor: [Expectorants] explode all trees  285 \n#7 #1 or #2 or #3 or #4 or #5 or #6 20835  \n#6 ((\"air trapping\" or airtrapping)):ti,ab,kw (Word variations have been searched)  136 \n#5 ((((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*)):ti,ab,kw (Word variations have been searched)  15013  \n#4 (Emphysem*):ti,ab,kw (Word variations have been searched)  1435  \n#3 (COAD):ti,ab,kw  81 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  120 \n  \n  \n Nr. Suchfrage  Anzahl  \n#2 (COPD):ti,ab,kw  14661  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4813  \n \nCochrane Reviews  2 \nCochrane Protocols  0 \nTrials  342 \n\u00dcbersicht der eingeschlossenen Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz  62 2 64 \nRCTs  189 342 531 \nGesamt    595 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 139  \nA2 (nicht englisch/deutsch): 62 \nA3 (Conference Abstracts): 55  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 339 (62 SR; 277 RCTs)  \nFlussdiagramm aggregierte Evidenz  \n \nAnhang 3.24  Wechsel des Inhalationssystems  \nPICO -Fragestellung  \nPopulation: Patient*innen mit COPD  \nIntervention: Wechsel des Inhalationssystems ohne erneute Instruktion  \nVergleich: Wechsel des Inhalationssystem s mit erneuter Instruktion  \nEndpunkte: Schaden  \nStudientyp: Prim\u00e4rstudien  \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 62 \nEingeschlossene Titel/Abstracts:  \nn = 12 \nEingeschlossene Volltexte  \nn = 7 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 49 \nAusgeschlossene  \nVolltexte:  \nAa: n = 1 \nAd: n = 1 \nEz: n = 3 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  121 \n  \n  \n Recherchestrategie  \nMedline via Pubmed (www.pubmed.gov) (23.10.2019)  \nNr. Suchfrage  Anzahl  \n#11 Search (#7 AND #8 AND #9) Filters: Publication date from 2009/01/01  471 \n#10 Search (#7 AND #8 AND #9)  813 \n#9 Search change*[tiab] OR changing*[tiab] OR switch*[tiab] OR replac*[tiab]  3432247  \n#8 Search \"Nebulizers and Vaporizers\"[Mesh] OR Vaporizer*[tiab] OR Vaporiser*[tiab] OR \nNebuliser*[tiab] OR Nebulizer*[tiab] OR Atomizer*[tiab] OR Atomiser*[tiab] OR In-\nhaler*[tiab] OR Inhalator*[tiab] OR Device*[tiab]  409013  \n#7 Search #1 OR #2 OR #3 OR #4 OR #5 OR #6  104604  \n#6 Search \"Air trapping\" [tiab] OR airtrapping[tiab]  1290  \n#5 Search COAD[tiab]  326 \n#4 Search COPD[tiab]  43454  \n#3 Search Emphysem*[tiab]  26912  \n#2 Search \"Pulmonary Disease, Chronic Obstructive\"[Mesh]  53079  \n#1 Search ((chronic*[tiab]) AND ((obstruct*[tiab]) AND (pulmonary[tiab] or lung*[tiab] or air-\nway*[tiab] or airflow*[tiab] or bronchi*[tiab] or respirat*[tiab])))  58918  \nDatenbanken der Cochrane Library (24.10.2019)  \nNr. Suchfrage  Anzahl  \n#20 #18 - Trials ab 2009  434 \n#19 #18 - Cochrane Reviews ab 2009 -01-01 16 \n#18 (#17) NOT (conference abstract):pt  693 \n#17 #7 and  #15 and #16 893 \n#16 (change* or changing* or switch* or replace*):ti,ab,kw (Word variations have been \nsearched)  316516  \n#15 #8 or #9 or #10 or #11 or #12 or #13 or #14  57079  \n#14 (device*):ti,ab,kw (Word variations have been searched)  49747  \n#13 (inhalator*):ti,ab,kw (Word variations have been searched)  167 \n#12 (inhaler*):ti,ab,kw (Word variations have been searched)  6170  \n#11 (atomizer* or atomiser*):ti,ab,kw (Word variations have been searched)  90 \n#10 (nebulizer* or nebuliser*):ti,ab,kw (Word variations have been searched)  3410  \n#9 (vaporizer* or vaporiser*):ti,ab,kw  1982  \n#8 MeSH descriptor: [Nebulizers and Vaporizers] explode all trees  2259  \n#7 #1 or #2 or #3 or #4 or #5 or #6  21117  \n#6 ((\"air trapping\" or airtrapping)):ti,ab,kw (Word variations have been searched)  139 \n#5 ((((pulmonary or lung* or airway* or airflow* or bronchi* or respirat*) and obstruct*) and \nchronic*)):ti,ab,kw (Word variations have been searched)  15271  \n#4 (Emphysem*):ti,ab,kw (Word variations have been searched)  1437  \n#3 (COAD):ti,ab,kw  82 \n#2 (COPD):ti,ab,kw  14860  \n#1 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees  4893  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n  \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  122 \n  \n  \n \u00dcbersicht eingeschlossene Treffer  \n Medline  Cochrane Datenbanken  Summe  \nAggregierte Evidenz   16 16 \nRCTs   434 434 \nAlle 471  471 \nGesamt    921 \nAnzahl der ausgeschlossenen Publikationen nach Ausschlussgrund:  \nA1 (Dubletten): 207  \nA2 (nicht englisch/deutsch): 20  \nA3 (Conference Abstracts): 6  \nEingeschlossene Treffer insgesamt nach Ausschl\u00fcssen: 688  \nFlussdiagramm  \n \nEs konnten keine Prim\u00e4rstudien zur Fragestellung identifiziert werden.  \nIn einer analogen systematischen Recherche der NVL Asthma, 3. Auflage (Leitlinienreport S. 70/ Evidenztabelle \nS.223)  [115]  konnten eine qualitative Studie  [53] und zwei A uswertungen von Regi sterdaten [54 \u2060,55] identifiziert \nwerden. Eine \u00dcbertragung und Ex trapolation dieser E rgebnisse auf Patient*innen mit COPD ist nach Einsch\u00e4tzung \nder Leitliniengruppe m\u00f6glich.  \n \nErgebnis der systematischen  \nLiteraturrecherche  \nn = 688 \nEingeschlossene Titel/Abstracts:  \nn = 11 \nEingeschlossene Volltexte  \nn = 0 \nAusgeschlossene  \nTitel/Abstracts:  \nn = 677 \nAusgeschlossene  \nVolltexte: n=  \nAa: n = 7  \nAp: n = 4 \n \nLiteratur von Experten  \noder durch Handsuche \nn = 0 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  123 \n      \n \nAnhang 4  Evidenztabellen Definition und Epidemiologie  \nGezielte Suche: Epidemiologische Daten  \nZitat \nAkmatov MK; Steffen A; Holstiege J; B\u00e4tzing J (2019): Die chronisch obstruktive Lungenerkrankung (COPD) in der ambulanten Ver sorgung in Deutschland \u2013 Zeitliche Trends und kleinr\u00e4umige Unter-\nschiede (Versorgungsatlas -Bericht, Nr. 19/06). Online verf\u00fcgbar unt er https://www.versorgungsatlas.de/fileadmin/ziva_docs/99/VA_19- 06_Bericht_COPD_2019- 08-20_V2.pdf , zuletzt gepr\u00fcft am \n02.09.2019. ) \nSteppuhn H, K uhnert R, Scheidt -Nave C (2017): 12 -Monats -Pr\u00e4valenz der bekannten chronisch obstruktiven Lungenerkrankung (COPD) in Deutschland. In: Journal of health monitoring 2 (3) , S. 46 \u201354. \nDOI: 10.17886/RKI -GBE -2017- 053. \nAnhang 5  Evidenztabellen Diagnostik  und Monitoring  \nAnhang 5.1  NVL Asthma // ACO  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nAlshabanat A. \nAsthma and COPD \nOverlap Syndrome \n(ACOS): A System-\natic Review and \nMeta Analysis. \nPLoS One \n2015;10(9):e01360\n65 Suchzeitraum: 2015/02  - gepoolte Pr\u00e4valenz des ACOS bei COPD -Patienten: 27% in Populationsbasierten Studien (95% CI: \n0.16\u2013 0.38, p<0.0001) und 28% in Krankenhausbasierten Studien (95% CI: 0.09\u2013 0.47, p = 0.0032)  \n- Alter: 7 studies;  ACOS subjects were younger than patients with only COPD, significant in five studies. \n2 studies reported that ACOS patients were significantly older than patients with asthma alone with a \nmean (SD) age (in years) of 60.4 (11.3) and 61 (7) Vs. 54.9 (10.9) and 53 (13) (p <0.001).  \n- Geschlecht von ACOS -Patienten: Difference in prevalence of ACOS among COPD patients for males \nversus females was -0.085 (95% CI: -0.178\u2013 0.008, p = 0.073)  \n- Inanspruchnahme: 5 studies reported that patients with ACOS had more frequent exacerbations, hospi-\ntalizations, and emergency department visits in comparison to patients with COPD alone  \n-LQ: quality of life of ACOS subjects was lower than COPD  \n-weitere EP: Medikationsbedarf, Raucherstatus, LuFu  nur 5/11 Punkten im AMSTAR  \n- wegen Relevanz und Alleinstellung \nEinschluss  \n- 12 Quer schnitts -, 5 Kohortenstudien NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  124 \n      \n \nSelektive eingebrachte Literatur: Epidemiologische Daten ACO  \nZitat  \nAkmatov MK, Ermakova T, Holstiege J, Kohring C, Ng F, V\u00f6lker S, B\u00e4tzing J. \u00dcberlappung von Asthma und COPD in der ambulanten Versorgung \u2013 Analyse anhand vertrags\u00e4rztlicher  Abrechnungsda-\nten. 2020 (Versor gungsatlas -Bericht; Nr. 20/06) [cited: 2021- 02-08]. DOI: 10.20364/VA -20.06. https://www.versorgungsatlas.de/fileadmin/ziva_docs/113/VA_20- 06_Bericht_ACO_2020- 11-10.pdf , \nzuletzt gepr\u00fcft am 08.04.2021. ) \nAnhang 5.2  Diagnostische Verfahren  \nIndextest CT  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nLi J-s. Diagnostic \nvalue of computed \ntomography in \nchronic obstructive \npulmonary disease: \nA systematic review \nand meta- analysis. \nCOPD 2012; \n9(5):563\u2013 70. \n \nhttps://www.ncbi.nl\nm.nih.gov/pub-\nmed/22708710  \n \n \n\u2022 Nicht zitiert.  \n \u2022 China  \n\u2022  Ziel: to evaluate the accuracy of CT in diagnosing COPD  \n\u2022  n=8 diagnostische Genauigkeitsstudien (3926 subjects)  \n\u2022  Suchzeitraum: Inception - 10/2010 (Cochrane:2011)  \n \n\u2022  Interventionen:  \n- CT (HRCT (n=1), LDCT (n=3), MSCT (n=3)) \n- PFT (Spirometry)  \n \n\u2022  Einschlusskriterien:  \n1) The type of research was a diagnostic test that assessed the diagnostic \naccuracy of CT, HRCT, LDCT or MSCT for COPD  \n2) sens and spec were reported or 2x2 table could be constructed  \n3) diagnsotic method  for evaluation of test was CT imaging diagnosis, and \nreference standard was PFT  \n4)publication was full reported \n All included studies (95% CI):  \nSens 0.83 (0.73- 0.89)  \nSpec 0.87 (0.70- 0.90)  \nPLR 6.2 (2.5- 15.5)  \nNLR 0.20 (0.12- 0.34)  \nDOR 31 (8 -116) \n \nSubgroup \"using lung density index\"  (n=4)  \nSens 0.80 (0.74- 0.84)  \nSpec 0.77 (0.58- 0.89)  \nPLR 3.5 (1.8- 6.9) \nNLR 0.26 (0.20- 0.34)  \nDOR 13 (6 -32) \n \nSubgroup \"other index\"  (emphysema index in inspiration, pixel \nindex in max expiratory, blood flow, diagnostic model)  (n=4)  \nSens 0.87 (0.64- 0.96)  \nSpec 0.95 (0.66- 0.99)  \nPLR 17.5 (1.8- 171.5)  \nNLR 0.14 (0.04- 0.45)  \nDOR 127 (5- 2982)  \n \nLDCT (95%CI)  \nSens 0.66 (0.61- 0.70)  \nSpec 0.88 (0.86- 0.89)  \nPLR 5.89 (4.57- 7.59)  \nNLR 0.25 (0.12- 0.53)  \nDOR 21.27 (8.47- 53.41)  \n \n \nNo metaanalysis for M SCT studies because of heterogeneity  AMSTAR: 7/11  \n \nn-y-y-n-n-y-y-y-y-y-n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  125 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \nauthors conclusion:  Our results suggest that quantitative \nmeasures in CT scans can be useful to identify suspected sub-\njects with COPD, although there was heterogeneity among the \nstudies. Because the early stages of COP D are substantially \nunder diagnosed, early detection of airflow limitation with chest \nCT and early intervention can improve outcomes for patients \nwith COPD.  \n \nIndextest Ganzk\u00f6rperbodyplethysmographie  \nZitat Studiencharak teristika  Studienergebnisse  Methodische Qualit\u00e4t  \nTang Y. The meas-\nurement of lung vol-\numes using body ple-\nthysmography and \nhelium dilution meth-\nods in COPD pa-\ntients: A correlation \nand diagnosis analy-\nsis. Sci Rep 2016; \n6:37550.  \n \nhttps://www.ncbi.nlm .\nnih.gov/pub-\nmed/27876834  \n \n \n\u2022 Nicht zitiert.  \u2022 China  \n\u2022 January 2014 to March 2015 \n\u2022 prospective correlation and diagnosis analysis  \n\u2022 n= 170 patients with stable COPD  \n\u2022 Ziel: to assess lung volumes stratified by airflow \nlimitation severity  \n \n\u2022 Interventionen/Measurements:  \n- Multi -breath Helium dilution method (MBHD)  \nand  \n- whole -body plethysmography (WBP ), Master-\nScreen PFT System (Jaeger Corp, Germany)  \nvs. \n- COPD defined by GOLD  classification of air-\nflow limitation (we combined mild and moderate \nCOPD patients, defined by GOLD classification of \nairflow limitation, as \u2018non- severe\u2019 group; while the \nsevere and very severe COPD patients were \ncombined as \u2018severe\u2019 group.)  \n \n\u2022 Einschlussk riterien: FEV1 /FVC ratio < 0.7 after \nbronchodilation; (b) no acute exacerbation during \nprevious 4 weeks; (c) stop the medications, which \nmay influence pulmonary function testing for at \nleast 3 days  \n\u2022 Ausschlusskriterien: coexisting medical condi-\ntions that  would interfere with pulmonary function \ntesting  \u2022 The discrepancies between these two methods (WBP + \nMBHD) were recorded as \u0394RV%pred, \u0394TLC%pred, and \n\u0394RV/ TLC.  \n \nThe \u0394 TLC%pred value of 34.2 would have a sensitivity of \n93.1% and specificity of 79.6%, with the positive and nega-\ntive likelihood ratio of 4.56 and 0.09, respectively. \n\u0394RV%pred, and \u0394 RV/TLC also had a relatively high sensi-\ntivity and specificity to differentiate COPD severity.  \n \n\u2022 value of \u0394RV%pred, \u0394TLC%pred, and \u0394 RV/TLC in dis-\ncriminating between mild/moderate and severe/very se-\nvere COPD patients:  \n \n- \u0394RV%pred cutoff Point 63.4:  \nSens 0.875, Spec 0.724, LR+ 3.17 , LR - 0.17 \n \n- \u0394TLC%pred cutoff Point 34.2:  \nSens 0.931, Spec 0.796, LR+ 4.56 , LR - 0.09 \n \n- \u0394RV/TLC cutoff Point 10.3:  \nSens 0.861, Spec 0.663, LR+ 2.55 , LR - 0.21 \n \n\u2022 authors conclusion: The differences of lung volume param-\neters measured by body plethysmography and helium dilu-\ntion methods were associated with airflow limitation and can \neffectively differentiate COPD severity, which may be a sup-\nportive method to assess the lung function of stable COPD QUADAS II (schwierig anzuwenden, da keine direkte diagnosti-\nsche Genauigkeitsstudie)  \n \nDomain 1: Patient Sele ction  \n \nCould the selection of patients have introduced bias? LOW  \n \nDomain 2: Index Test  \n \nCould the conduct or interpretation of the index test have intro-\nduced bias? NOT APPLICABLE  \n \nDomain 3: Reference Standard  \n \nCould the reference standard, its conduct, or its interpretation \nhave introduced bias? UNCLEAR  \n \nDomain 4: Flow and Timing  \n \nCould the patient flow have introduced bias? LOW  \n \nConcerns regarding applicability: UNCLEAR (Fragestellung \npassend?)  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  126 \n      \n \nZitat Studiencharak teristika  Studienergebnisse  Methodische Qualit\u00e4t  \n patients.  \n \n>> Unterscheidung zwischen milder/moderater und \nschwerer/sehr schwerer COPD  \nIndextest Spirometrie  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nLutchmedial SM. How \nCommon Is Airflow \nLimitation in Patients \nWith Emphysema on \nCT Scan of the Chest? \nChest 2015; \n148(1):176\u2013 84. \n \nhttps://www.ncbi.nlm.ni\nh.gov/pub-\nmed/25539080  \n \n \n\u2022 Nicht zitiert.  \u2022 USA  \n\u2022 01/2011 -  12/2011  \n\u2022 n=274 \n\u2022 retrospektive Analyse: assessed the preva-\nlence of obstruction by GOLD and LLN criteria \nin patients with emphysema on CT scan and \ndetermine which radiographic criteria were as-\nsociated with a clinical diagnosis of COPD  \n \n\u2022 Interventionen/Measurements:  \n- Spirometrie  \n- CT (16-, 40-, 64-, 128- , and 256- slice scan-\nners; Brilliance and iCT)  \n- klinische Daten  \n \n\u2022 Einschlusskriterien: to define COPD clinically, \nall of which had to be fulfilled: symptoms includ-\ning cough, sputum production, wheezing, and \ndyspnea; a smoking history; a physician diag-\nnosis of COPD; medication use including the \nneed for a long- acting b   agonist, a long- acting \nmuscarinic antagonist, and/or inhaled cortico-\nsteroids; and no other diagnosis or reason to \nsuspect another disease besides COPD  \n \n\u2022 Ausschlusskriterien: lack of visible emphy-\nsema on CT imaging (when reviewed by the ra-\ndiologist), concomitant fibrosis of any cause, \nsignificant bronchiectasis  (requiring airway \nclearance therapy), extensive infiltrate or lung \nmass, moderate or large pleural effusions, or \nprevious surgical resection  \n \u2022 mean age was 66.9 \u00b1 10.4 years, and 55% were men  \n \n\u2022 GOLD criteria detected obstruction in 228 patients (83%), \nand LLN detected obstruction in 206 patients (75%). How-\never, GOLD failed to correctly identify 19 patients (6.9%) \nand LLN failed to identify 38 patients (13.9%) (average \n10.4%) who had radiographic emphysema and a clinical di-\nagnosis of COPD.  \n \nIdentification of patients with clinical COPD by:  \n- GOLD: Sens 92%, Spec 77%  \n- LLN: Sens 84%, Spec 91%  \n \n \n\u2022 authors conclusion: Spirometry missed 10.4% of patients \nwith clinical COPD who have significant emphysema on \nchest CT scan.  \n QUADAS II  \n \nDomain 1: Patient Selection  \n \nCould the selection of patients have introduced bias? LOW  \n \nDomain 2: Index Test  \n \nCould the conduct or interpretation of the index test have intro-\nduced bias? UNCLEAR  \n \nDomain 3: Reference Standard  \n \nCould the reference standard, its conduct, or its interpretation \nhave introduced bias? LOW  \n \nDomain 4: Flow and Timing  \n \nCould the patient flow have introduced bias? HIGH  \n \nConcerns regarding applicabil ity \nLOW  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  127 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nBhatt SP. Comparison \nof spirometric thresh-\nolds in diagnosing \nsmoking -related airflow \nobstruction. Thorax \n2014; 69(5):409\u2013 14. \nhttps://www.ncbi.nlm.ni\nh.gov/pub-\nmed/23525095  \n \n \n\u2022 Nicht zitiert.  \u2022 USA  \n\u2022 Zeitraum nicht angegeben \n\u2022 retrospektive Datenanalyse; large multicenter \nstudy (COPDGene)  \n\u2022 n= 7743 Smokers and former smokers with \nand without airflow obstruction  \n\u2022 Ziel:  compared the accuracy and discrimina-\ntion of GOLD recommended Fixed ratio of \nFEV1/FVC<0.70 with LLN in diagnosing smok-\ning related airflow obstruction using computed \ntomography defined emphysema and gas trap-\nping as the disease gold standard \n \n\u2022Interventionen:  \n- spiromet ry (fixed ratio  of FEV1/FVC<0.70) \n& LLN (NHANES III);  post-bronchodilator val-\nues were used \nvs. \n- quantitative CT  \n \n\u2022 Einschlusskriterien: ages of 45 and 80 years \nwith at least 10 packyears of cigarette smokin  \n\u2022 Ausschlusskriterien: Subjects with lung dis-\neases other than asthma and COPD;  further \npatients with physician diagnosed asthma  \n  \n\u2022 Follow up: every 6 months by telephone; using \na questionnaire  \u2022 age range 45 to 80 years  \n\u2022 There was very good agreement between the two spiro-\nmetric cutoffs (kappa=0.85; 95% CI 0.83 to 0.86, p<0.001). \n7.3% were discordant.  \n \n\u2022 accuracy of FEV1/FVC cut offs in detecting emphy-\nsema and gas trapping:  \nEmphysema at least 10% (Prevalence = 18%):  \n- Fixed: Sens 94 ( 95% CI 92.6\u2013 95.2), Spec 69.6 (95% CI \n68.4\u2013 70.8)  \n- LLN: Sens 89.9 ( 95% CI88.2 \u201391.4), Spec 77.1 (95% \nCI76.0\u2013 78.1)  \n \nGas Trapping at least 15% (Prevalence = 48%):  \n- Fixed: Sens 70.2 (95% CI68.7\u2013 71.8), Spec 84.2 (95% \nCI83.0\u2013 85.4)  \n- LLN: Sens 61.2 (95% CI59.6\u2013 62.9), Spec 89.0 (95% \nCI87.9\u2013 90.0)  \n \n\u2022 authors conclusions: We have s hown a high degree of dis-\ncordance between CT and both spirometric thresholds. \nOverall, LLN appears to be marginally more specific for dis-\nease in older age groups, but will not identify a large number \nof older patients who have significant respiratory sympt oms \nand CT emphysema  \n QUADAS II  \n \nDomain 1: Patient Selection  \n \nCould the selection of patients have introduced bias? UN-\nCLEAR \n \nDomain 2: Index Test  \n \nCould the conduct or interpretation of the index test have intro-\nduced bias? UNCLEAR  \n \nDomain 3: Reference Standard  \n \nCould the reference standard, its conduct, or its interpretation \nhave introduced bias? UNCLEAR  \n \nDomain 4: Flow and Timing  \n \nCould the patient flow have introduced bias? LOW  \n \nConcerns regarding applicability LOW  \n \nSchneider A. Diagnos-\ntic accuracy of spirome-\ntry in primary care. \nBMC Pulm Med 2009; \n9:31.  \n \nhttps://www.ncbi.nlm.ni\nh.gov/pub-\nmed/19591673  \n \n \n\u2022 Nicht zitiert.  \u2022 Deutschland/Niederlande  \n\u2022 01/2006 -  12/2007  \n\u2022 Cross sectional diagnostic study; primary care  \n\u2022 n=219 patients suspected of having obstruc-\ntive airway disease (OAD)  \n\u2022 Endpunkte: evaluate the sensitivity, specificity \nand predictive values of spirometry for the diag-\nnosis of chronic obstructive pulmonary disease \n(COPD) and asthma  \n \n\u2022 Interventionen:  \n- Spirometrie ( Medikro SpiroStar USB\u00ae)  \u2022 n=50 with COPD, mean age 56.9 (SD 11.5); female 26 \n(54.1%)  \n\u2022 Obstructive airway disease was diagnosed if FEV1/VC \u2264 \n70% and/or FEV1 < 80%  \n \n\u2022 diagnosing airway obstruction in COPD  \n- sensitivity 92% (95%CI 80- 97) \n- specificity  84% (95%CI 77- 89) \n- PPV 63% (95%CI 51- 73) \n- NPV 97% (95%CI 93- 99) \n QUADAS II  \n \nDomain 1: Patient Selection  \n \nCould the selection of patients have introduced bias? LOW  \n \nDomain 2: Index Test  \n \nCould the conduct or interpretation of the index test have intro-\nduced bias? LOW  \n \nDomain 3: Reference Standard  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  128 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n- Ganzk\u00f6rperbodyplethysmographie  + bron-\nchiale Provokation (If there was no bronchial \nobstruction, bronchial provocation was per-\nformed to determine bronchial hyper -respon-\nsiveness (BHR))  \n \n\u2022 Einschlusskriterien: symptoms such as dysp-\nnea, coughing or expectorat ion; no previous di-\nagnosis for obstructive ariway disease  \n\u2022 Ausschlusskriterien: contra- indications for \nbronchodilator  \nreversibility testing or bronchial provocation (un-\ntreated hyperthyreosis, unstable coronary artery \ndisease,  \nand cardiac arrhythmia); Pregnancy also led to \nexclusion.  \n \u2022 authors conclusion: OPD can be estimated with high diag-\nnostic accuracy using spirometry.[...]  \n  \nCould the reference standard, its conduct, or its interpretation \nhave introduced bias? LOW  \n \nDomain 4: Flow and Timing  \n \nCould the patient flow have introduced bias? LOW  \n \nConcerns regarding applicability  \nLOW  \n \nIndextest Spirometrie inklusive DLCO (n=3)  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nHesselbacher SE. Cross -\nsectional analysis of the \nutility of pulmonary func-\ntion tests in predicting \nemphysema in ever -\nsmokers. Int J Environ \nRes Public Health 2011; \n8(5):1324\u2013 40. \n \nhttps: //www.ncbi.nlm.nih.\ngov/pubmed/21655122  \n \n \n \n\u2022 Nicht zitiert.  \u2022 USA  \n\u2022 Cross -Sectional Analysis, Sens und Spez \ngegeben  \n\u2022 n=224 ever -smokers (current or former), > \n40 years of age; part of the Longitudinal Ex-\nacerbation Study of COPD (LES -COPD)  \n \n\u2022 Ziel: to deter mine the sensitivity and speci-\nficity of pulmonary function tests (PFTs) in as-\nsessing emphysema using quantitative CT \nscans as the reference standard  \n \n\u2022 Einschlusskriterien: age over 40, no history \nof concurrent lung cancer, chest surgery, or \nchronic lung diseases other than COPD (e.g., \nsarcoidosis, fibrosis, etc.)  \n \n\u2022 Interventionen:  \n- PFT ( Spirometrie inklusive DLCO ) \nvs. \u2022 Significant emphysema (>7%) was detected in 122 (54%) \nsubjects. Twenty six (21%) emphysema subjects had no evi-\ndence of airflow obstruction (FEV1/FVC ratio <70%), while \nall subjects with >23% emphysema showed airflow obstruc-\ntion. \n  \n\u2022 Spirometry for detecting radiographic emphysema:  \n\u2022 FEV1/FVC < 70% :  \nSens 79 (95%CI 71\u2013 85), Spec 75 (95%CI 65\u2013 82), PPV \n79%, NPV 75%  \n\u2022 FEV1/FVC < LLN (NHANES):  \nSens 73 (95%CI 65\u2013 80), Spec 74 (95%C I 64\u2013 81), PPV \n77%, NPV 68%  \n\u2022 FEV1 < LLN:  \nSens 67 (95%CI 59\u2013 75), Spec 74 (95%CI 64\u2013 81), PPV \n75%, NPV 65%  \n \n\u2022 DLCO  for detecting emphysema:  \n- Sens 91 % (95%CI 84- 95), Spec 23 (95%CI 16\u2013 33), PPV \n59%, NPV 68%  QUADAS II  \n \nDomain 1: Patient Selection  \n \nCould the selection of patients have introduced bias? LOW  \n \nDomain 2: Index Test  \n \nCould the conduct or interpretation of the index test have in-\ntroduced bias? LOW  \n \nDomain 3: Reference Standard  \n \nCould the reference standard, its conduct, or its interpretation \nhave introduced bias? UNCLEAR  \n \nDomain 4: Flow and Timing  \n \nCould the patient flow have introduced bias? HIGH  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  129 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n- CT (Siemens Cardiac Sensation Cardiac \nscanner (Siemens Medical Solutions))  \n  \n\u2022 authors conclusion: [...] A proposed strategy in the evalua-\ntion of ever smokers may be to measure full pulmonary func-\ntion tests, including spirometry and lung volumes, and diffu-\nsion capacity; if spirometry is normal but hyperinflation, air \ntrapping, or reduced gas exchange are noted, a CT should \nbe cons idered to evaluate for isolated emphysema. Detec-\ntion of emphysema without airflow obstruction may also pro-\nvide an explanation of symptoms such as dyspnea or exer-\ncise intolerance in ever smokers with normal spirometry, \nwho might otherwise be identified as normal.[...]  \n Concerns regarding applicability  \nUNCLEAR (Fragestellung?)  \n \nLee JS. Validation of the \nlower limit of normal dif-\nfusing capacity for detect-\ning emphysema. Respira-\ntion 2011; 81(4):287\u2013 93. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/20110663  \n \n \n\u2022 Nicht zitiert.  \n \u2022 Korea  \n\u2022 08/2005 -  04/2008  \n\u2022 Diagnostische Genauigkeitsstudie \n- n=197 COPD -Patient*innen aus der Korean \nObstructive Lung Disease (KOLD) cohort +  \n- n=103 gesunde Erwachsene \n\u2022Ziel: to validate the LLN  (Pellegrino 2005)  \nfor DLco and to determine the optimum LLN \ncutoff value for detecting emphysema in pa-\ntients with COPD  \n \n\u2022 Interventionen:  \n- Spirometrie (Vmax22 instrument (Sen-\nsorMedics, Yorba Linda, Calif., USA) \ninklusive DLCO (measured by the single-\nbreath method using a Vmax229D instrument \n(SensorMedics) or a Masterlab Body (Jaeger, \nW\u00fcrzb urg, Germany)  \nvs. \n- CT (16- slice multidetector CT scanners in-\ncluding the Somatom Sensation 16 (Siemens \nMedical Systems, Erlangen, Germany), the \nGE Lightspeed Ultra (General Electric \nHealthcare, Milwaukee, Wisc., USA), and the \nPhilips Brilliance 16 (Philip s Medical Systems, \nBest, The Netherlands)  \n \n\u2022 COPD was diagnosed based on smoking \nhistory (more than 10 pack -years) and the \u2022 COPD -Patienten: Age: 66.1 \u00b1 7.2 years;  FEV 1 48.0 \u00b1 \n15.9% predicted  \n\u2022 male/female: 190/7  \n \n\u2022 ROC curve analysis: lower 5th percentile used as the \nLLN for DLco  \n- sensitivity of 68.3% ; specificity of 84.5%, PPV 88.7%, NPV \n60.0% to differentiate COPD patients with emphysema from \nCOPD patients without emphysema \n- sensitivity of 68.3% and a specificity of 98.1%, PPV 97.7%, \nNPV 71.6%  to differentiate COPD patients with emphysema \nfrom healthy subjects  \n \n\u2022 ROC curve analysis: lower 9th percentile   \n- sens 79.4%, spec 77.5%, PPV 86.2%, NPV 67.5% for dif-\nferentiating COPD patients with emphysema from COPD pa-\ntients without emphysema  \n- sens 79.4%, spec 94.2%, PPV 94.2%, NPV 77.0% for dif-\nferentiating COPD patients with emphysema from healthy \nsubjects was 87.2%.  \n \n\u2022 conclusions:  \n- lower 9th pe rcentile was the best LLN cutoff value for DLco \nto differentiate COPD patients with emphysema from COPD \npatients without emphysema and from healthy subjects  \n- our findings indicate that the lower 5th percentile of the ref-\nerence population may not be the best LLN cutoff value for \nD Lco because this value had a low sensitivity for detecting \nCOPD patients with emphysema.  QUADAS II  \n \nDomain 1: Patient Selection  \n \nCould the selection of patients have introduced bias? UN-\nCLEAR \n \nDomain 2: Index Test  \n \nCould the conduct or interpretation of the index test have in-\ntroduced bias? UNCLEAR  \n \nDomain 3: Reference Standard  \n \nCould the reference standard, its conduct, or its interpretation \nhave introduced bias? UNCLEAR  \n \nDomain 4: Flow and Timing  \n \nCould the patient flow have introduced bias? UNCLEAR  \n \nConcerns regarding applicability  \nHIGH (Fragestellung passend?)  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  130 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \npresence of airflow limitation that was not fully \nreversible [post -bronchodilator forced expira-\ntory volume in 1 s (FEV 1 )/forced vit al capac-\nity (FVC) < 70%]  \n\u2022 COPD patients with emphysema were de-\nfined as COPD patients in whom volumetric \nCT showed that the volume fraction of the \nlung at less than \u2013 950 Hounsfield units (HU) \nat full inspiration was more than 15%  \n  \nvan der Lee I. Nitric oxide \ndiffusing capacity versus \nspirometry in the early di-\nagnosis of emphysema in \nsmokers. Respir Med \n2009; 103(12):1892\u2013 7. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/19586765  \n \n \n\u2022 Nicht zitiert.  \n \u2022 Niederlande  \n\u2022 n=263 randomly selected heavy smokers \n(participating in the NELSON -project, a \nDutch -Belgian multi -centre lung cancer \nscreening trial)  \n\u2022 Diagnostische Genauigkeitsstudie \n \n\u2022 Ziele:  \n- whether the DLNO is more sensitive in diag-\nnosing emphysema in a large group of heavy \nsmokers than the DLCO  \n- whether the DLNO/DLCO ratio differs in \nsubjects with emphysema compared to \nhealthy individuals  \n \n\u2022 Interventionen  \n- Spirometrie via pneumotachography (flow -\nvolumes curves, DLNO, DLCO, the tr ansfer \ncoefficients KNO (DLNO/VA) and KCO \n(DLCO/VA))  \nvs. \n- CT 16 detector -row scanner (Mx8000 IDT or \nBrilliance 16P, Philips Medical Systems, \nCleveland, OH)  \n \u2022 all male, 50 -75 years of age with a smoking history of at \nleast 20 pack years  \n \n\u2022 Detection of em physema:  \n- DLCO: Sens 58.3%, Spec 81.5%, PPV 33.3%, NPV 92.5%  \n- DLNO: Sens 50.0%, Spec 81.9%, PPV 30.5%, NPV 91.2%  \n- KCO: Sens 88.9%, Spec 57.3%, PPV 24.8%, NPV 97.0%  \n- KNO: Sens 91.7%, Spec 72.7%, PPV 34.7%, NPV 98.2%  \n- FEV1/FVC: Sens 77.8%, Spec 70.1%, P PV 29.5%, NPV \n95.2%  \n \n\u2022 authors conclusion: spirometry is very important for the di-\nagnosis of emphysema, but it only measures airway obstruc-\ntion. The KNO is a very sensitive measure for the detection \nof CT -based emphysema. The DLNO/DLCO ratio is in-\ncreased i n (ex)smokers, which could be explained by the hy-\npothesis that pulmonary endothelial dysfunction precedes \nextensive parenchymal loss ultimately leading to airway ob-\nstruction. Further studies are needed to explore this con-\ncept, in which the DLNO/DLCO ratio could be used as a \nsensitive tool to detect microvascular malfunctioning.  \n QUADAS II  \n \nDomain 1: Patient Selection  \n \nCould the selection of patients have introduced bias? LOW  \n \nDomain 2: Index Test  \n \nCould the conduct or interpretation of the index test have i n-\ntroduced bias? UNCLEAR  \n \nDomain 3: Reference Standard  \n \nCould the reference standard, its conduct, or its interpretation \nhave introduced bias? UNCLEAR  \n \nDomain 4: Flow and Timing  \n \nCould the patient flow have introduced bias? LOW  \n \nConcerns regarding applicabi lity \nLOW  \n \nIndextests Spirometrie und Bodyplethysmographie  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nTashkin DP. The UCLA \npopulation studies of \u2022 USA  \n\u2022 1972 - 1974  \u2022 Reference \"Test\": physician defined diagnosis: taking into \nconsideration the results of all lung function tests, responses QUADAS II schwer anzuwenden, da Studie > 40 Jahre alt ist  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  131 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nchronic obstructive respir-\natory disease. II. Determi-\nnation of reliability and es-\ntimation of sensitivity and \nspecificity. Environ Res \n1979; 20(2):403\u2013 24. \n \nhttps://www.ncbi.nlm.nih.g\nov/pubmed/546647  \n \n\u2022 Nicht zitiert.  \n \n  \n\u2022 n=218 adults (2 Kohorten: one exposed to \nhigh levels of photochemical/oxidant -type pol-\nlutants; other: low levels of chemical pollu-\ntants); tested in mobile lung function (field) la-\nboratory vs. retesting in UCLA reference la-\nboratory  \n \n\u2022 Interventionen:  \n- Spirometry, Bodyplethysmography,  sin-\ngle-breath nitrogen test and modified NHLBI \nquestionnaire  \n- physician def ined diagnosis  (to judge the \npresence or absence of chronic obstructive \nrespiratory disease/CORD)  \n to the respiratory questionnaire , and reported findings on \nphysical exmination.  \n- physicians were not coached with regard to the relative \nweights to assign to the different kinds of subject data (symp-\ntoms, physical findings, pulmonary function test results) pre-\nsented to them.  \n \n\u2022 Sens Sp irometrie 58%  \n\u2022 Sens Plethysmography: 58%  \n \n\u2022 Spezifit\u00e4ten nicht angegeben: FEV1, FVC and plethysmog-\nraphy were estimated to be specific but relatively insensitive.  \n Domain 1: Patient Selection  \n \nCould the selection of patients have introduced bias? UN-\nCLEAR \n \nDomain 2: Index Tests  \n \nCould the conduct or interpretation of the index test have intro-\nduced bias? UNCLEAR  \n \nDomain 3: Reference Standard  \n \nCould the reference standard, its conduct, or its interpret ation \nhave introduced bias? UNCLEAR  \n \nDomain 4: Flow and Timing  \n \nCould the patient flow have introduced bias? LOW  \n \nConcerns regarding applicability  \nUNCLEAR  (Aktualit\u00e4t?)  \nAnhang 5.3  \u00dcber -/ Unterdiagnose  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nQuanjer PH. Implications of \nadopting the Global Lungs \nInitiative 2012 all -age refer-\nence equations for spirome-\ntry. Eur Respir J 2013; \n42(4):1046\u2013 54. \n \nhttps://www.ncbi.nlm.nih.gov\n/pubmed/23520323  \n \u2022 Vergleich der predictive equations \nvon GLI 2012, NHANES III und \nESCS/ERS; GOLD  \n\u2022 Australien, Polen, multicenter  \n \n\u2022 Studientyp: retrospective analy-\nsis of routinely obtained spirometric \ndata \n \n\u2022 Studienstart/Studienende:   \nData were collected between Au-\ngust 2008 and June 2012 (John \nHunter Hospital), January 2011 and \nMay 2012 (Austin Hospital) and \nApril 2009 and June 2012 (National \u2022 All spirometry data used were baseline or pre -bronchodilator status  \n\u2022 Mean predicted values and Z -scores were derived using prediction equa-\ntions from the European Community for Steel and Coal (ECSC)/ERS, Na-\ntional Health and Nutrition Examination Survey (NHANES) III and GLI 2012  \n \n\u2022 spirometric records from 17 572 subjects (49.5% females), aged 18\u2013 85 \nyears  \n \n\u2022 GLI 2012 vs. GOLD:  ( Figure 4 (S. 5); geschlechtsabh\u00e4ngig)  \nweiblich: GOLD --> Unterdiagnose bei j\u00fcngeren Patientinnen  \nm\u00e4nnlich: GOLD --> Unterdiagnose bei j\u00fcngeren Patienten und \u00dcberdiag-\nnose in \u00e4lteren Patienten \n \nIn conclusion, the transition from NHANES III to GLI 2012 spirometry refer-\nence data will lead to limited changes in the predicted values of FEV1 and Bias-Bewertung f\u00fcr nicht -vergleichende Studien (AWMF \n2016) --> Vertrauen in Studienergebnisse:  \n \n(i) prospektive Planung mit Protokoll , in dem Ein-\nschlusskriterien und Interventionen sowie interessie-\nrende Endpunkte hinterlegt sind: nicht eindeutig be-\nschrieben  \n \n \n(ii) konsekutiver Patienteneinschluss: ja  \n \n \n(iii) transparentes, nicht -selektives Berichten  in Be-\nzug auf Patientencharakteristika, Intervention und Er-\ngebnis: ja  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  132 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nTuberculosis and Lung Dis eases \nResearch Institute)  \n \n\u2022 Einschlusskriterien : limited to \nCaucasians, patients aged between \n18 - 85 years  \n \n \n FVC for adults. In contrast, users of ECSC/ERS prediction equations should \nbe aware that predicted values for FEV1 and FVC will increase by a few \nhundred millilitres on transition to GLI 2012 data. This will lead to a substan-\ntial increase in the prevalence rate of low FVC when changing from \nECSC/ERS, or a moderate decrease if changing from NHANES III. There \nare substantial differences in the predicted levels of FEV1/FVC rati o but not \nin their LLN, so that adopting the GLI 2012 prediction equations will have \nsmall effects on the rates of detection of obstructive ventilator defects. Our \nanalysis confirms previous findings in clinical populations that GOLD defini-\ntions for stage 2 and higher lead to .20% underdiagnosis of airway obstruc-\ntion in those aged f55 years, and to 16\u2013 23% overdiagnosis in older subjects.  \n  \nLlordes M. Prevalence, Risk \nFactors and Diagnostic Ac-\ncuracy of COPD Among \nSmokers in Primary Care. \nCOPD 2015; 12(4):404\u2013 12. \n \nhttps://www.ncbi.nlm.nih.gov\n/pubmed/25474184  \n \u2022 Pr\u00e4valenz der COPD in Katalon-\nien/Spanien,  single- center  \n\u2022 Einschlusskriterien:  subjects \nolder than 45 years with a history of \nsmoking  \n \n\u2022 Interventionen:  clinical question-\nnaire and spirometry  \nwith bronchodilator test (400 mcg of \nsalbutamol)  \n\u2022 participants with newly diagnosed \nCOPD, defined as postbronchodila-\ntor FEV1/FVC<0.7, underwent 4-\nweek treatment with formoterol (12 \nmcg/12 hours) and budesonide \n(200 m cg/12 hours) to rule out re-\nversible airflow obstruction \n \n\u2022 Studientyp:  population- based, \nepidemiological study ( cross -sec-\ntional)  \n \n\u2022 prim\u00e4rer Endpunkt:  prevalence \nof COPD among smokers  \n\u2022 sekund\u00e4rer Endpunkt:  accuracy \nof diagnosis of COPD in primary \ncare \n To investigate the possible overdiagnosis of COPD by fixed ratio, we also \ncalculated the frequency of airflow obstruction by the lower limit of normal \n(LLN) of the FEV1/FVC ratio using the GLI 2012 equations to calculate the \nLLN \n \n\u2022 n=1738 (valid spirometry ) \n\u2022 post -bronchodilator (salbutamol):   \nfixed ratio FEV1/FVC < 0.7:  n=422 (24.3%;95% CI: 22.3% -26.4%) (27.8 % \nfor men, 5.1 % for women)  \nFEV1/FVC below LLN: n=287 (15.5%, 95%CI: 13.8% \u201317.1%)  \n--> n= 135 (7.7%) discordant subjects (obstructive by fixed ratio but normal \nby LLN)  \n--> n=0 individuals obstructed by LLN with FEV1/FVC > 0.7  \n \n\u2022 new diagnosis of COPD: undergo treatment for 4 weeks with inhaled for-\nmoterol and budesonide  \nfixed ratio FEV1/FVC < 0.7 : n=239; n=199 (83.3%) undergo treatment --> \nn=32 (16%) showed a non- obstructive spirometry and were considered false \npositive cases of COPD.  \nFEV1/FVC below LLN: n=124 undergo treatment --> n=31 (25%) were no \nlonger obstructive by LLN after 4 weeks of treatment.  \n \nOn the other hand, 217 (12.5%) individuals from the target population of \n1,738 had a diagnosis of COPD in their medical records, and 90.2% were \nreceiving regular inhaled treatment for COPD, despite 34 (15.6%) not ful-\nfilling the spirometric criteria for COPD.  \n Bias-Bewertung f\u00fcr nicht -vergleichende Studien (AWMF \n2016) --> Vertrauen in Studienergebnisse:  \n \n(i) prospektive Planung mit Protokoll:  ja  \n \n \n(ii) konsekutiver Patienteneinschluss: nicht eindeutig \nbeschrieben  \n \n(iii) transparentes, nicht -selektives Berichten  in Be-\nzug auf Patientencharakteristika, Intervention und Er-\ngebnis: teilweise Daten nicht abgebildet  \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  133 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nGuerriero M. COPD preva-\nlence in a north- eastern Ital-\nian general population. \nRespir Med 2015; \n109(8):1040\u2013 7. \n \nhttps://www.ncbi.nlm.nih.gov\n/pubmed/26052037  \n \u2022 Pr\u00e4valenz der COPD in Nord- Ost-\nItalien  \n\u2022 gemessen nach GOLD -Kriterien \nvs. LLN nach GLI 2012 (ERS/ATS)  \n \n\u2022 Patienten:  subjects aged be-\ntween 18 and 79 years, municipal \nregistry was used as the data \nsource.  \n \n\u2022 Studienstart: Novemver 2011  \n\u2022 Studienende : Februar 2012  \n \n\u2022 Interventionen : Questionnaire, \nspirometry  \n \n\u2022 Studientyp:  observational cross -\nsectional study  \n \n\u2022 Ein - und Ausschlusskriterien : \nnicht beschrieben \n \n\u2022 prim\u00e4re Endpunkte:  prevalence \nand clinical features of COPD, as \ndefined by GOLD and ERS/ATS \nrecommendations  \n \n \n n=1275 completed questionnaire  \nn=1236 were able to correctly perform the spirometric tests  \n \npre-broncho dilator:  \nFEV1/FVC ratio <0.70:  airway obstruction in n=288 subjects (23.3%; 95%CI: \n20.9% - 25.7%).  \nLLN 5% (z -score -1.64):  airway obstruction in n=204 subjects (16.5%; \n95%CI: 14.4% -  18.6%).  \n \npost -bronchodilator (salbutamol):   \nFEV1/FVC ratio <0.70:  airway  obstruction in n= 145 subjects (11.7% -  \n95%CI: 9.9% -13.5%)  \nLLN 5% (z -score -1.64):  airway obstruction in n=109 subjects (9.1%; 95%CI: \n7.5%10.7%)  \n \n\u2022 multivariate logistic regression:  association between categorical varia-\nbles and LLN and GOLD defined COPD respectively. According to both LLN \nand GOLD criterion, a statistically significant association can be detected \nbetween COPD and  \n\u2022 male gender: LLN OR 1.69 (95% Ci 1.08 -  2.66; p 0.022); GOLD OR 1.84 \n(95% CI1.21 -  2.79; p 0.004)  \n\u2022 decade of pack -years (borderline): LLN OR 1.12 (95%CI 0.99 -  1.27 p \n0.083); GOLD OR  1.11 (95% CI 0.99 -  1.25; p 0.080)  \n\u2022 current smoking: LLN OR 1.98 (95% CI 1.06 -  3.68; p 0.032); GOLD OR \n2.10 (95%CI 1.15 - 3.84; p 0.016)  \n\u2022 history of respiratory disease during childhood: LLN O R 1.74 (95% CI 1.07 \n- 2.83; p 0.025); GOLD OR 2.08 (95%CI 1.33 -  3.26; p 0.001)  \n \nMoreover in the case of GOLD -based COPD diagnosis only, Odds ratio esti-\nmation suggests a statistically significant association with  \n\u2022 age: GOLD OR 1.76 (95%CI 1.4- 2.11; p <0. 001) \n\u2022 age: LLN OR 1.12 (95% CI 0.95 - 1.32; p 0.192)  \n Bias-Bewertung f\u00fcr nicht -vergleichende Studien (AWMF \n2016) --> Vertrauen in Studienergebnisse:  \n \n(i) prospektive Planung mit Protokoll , in dem Ein-\nschlusskriterien und Interventionen sowie interessie-\nrende Endpunkte hinterlegt sind: nicht eindeutig be-\nschrieben  \n \n(ii) konsekutiver Patienteneinschluss:  nicht eindeutig \nbeschrieben  \n \n(iii) transparentes, nicht -selektives Berichten  in Be-\nzug auf Patientencharakteristika, Intervention und Er-\ngebnis: ja  \n \nBorlee F. Spirometry, ques-\ntionnaire and electronic \nmedical record based COPD \nin a population survey: Com-\nparing prevalence, level of \nagreement and associations \nwith potential risk factors. \nPLoS One 2017; \u2022 Pr\u00e4valenz der COPD in Holland  \n\u2022 general population (aged 18- 70 \nyears) in the south of the Nether-\nlands  \n\u2022 Studienstart: 2012: Screening \nquestionnaire; 03/2014- Februar \n2015: Extended questionnaire, lung \nfunction, serum  Pr\u00e4valenz der COPD je nach genutzter Definition:  \n\u2022 Self -reported data \n\u2022 Electronic Medical Records  \n\u2022 Spirometry   \n1) post -BD measurement of FEV1/FVC below the LLN (GLI 2012)  \n2) a post -BD measurement of FEV1/FVC <0.70 (GOLD)  \n \n\u2022 n=1793 Bias-Bewertung f\u00fcr nicht -vergle ichende Studien (AWMF \n2016) --> Vertrauen in Studienergebnisse:  \n \n(i) prospektive Planung mit Protokoll , in dem Ein-\nschlusskriterien und Interventionen sowie interessie-\nrende Endpunkte hinterlegt sind: ja  \n \n(ii) konsekutiver Patienteneinschluss:  nicht eindeut ig NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  134 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n12(3):e0171494.  \n \nhttps://www.ncbi.nlm.nih.gov\n/pubmed/28273094  \n \u2022 Interventionen:  Self-reported \ndata, Electronic Medical Records, \nSpirometry  (GOLD and LLN GLI \n2012)  \n \n\u2022 Studientyp:  cross -sectional \nstudy; Follow -Up Studie  \n \n\u2022 inclusion criteria: 1) living in the \neastern part of Noord- Brabant or \nthe northern part of Limburg; 2) in-\nhabitant of a municipality with \n<30\u200a000 residents; and 3) aged 18\u2013\n70 years  \n\u2022 exclusion: farmers  (those who \nreported to be living or working on a \nfarm) (entnommen aus Ref. 16 des \nArtikels)  \n \n\u2022Endpunkt:  COPD- prevalence \nbased on four different operational \ndefinitions  \n \n \u2022 The highest COPD -prevalence was found based on spirometry using the \nGOLD -definition  \n(10.9%; n=196), followed by LLN -definition (5.9%,  n=105), self -report (4.6%, \nn=82) and EMR (2.9%, n=52)  \n \n\u2022 Associations of patients' characteristics (Tabelle 4; Auswahl; ohne Werte \nf\u00fcr EMR und SRD)  \nAge (per 10 years), mean (SD)  \nSpirometry GOLD: OR 1.81 (1.47- 2.22)  \nSpirometry LLN: OR 1.10 (0.87- 1.39)  \nFemale gender  \nSpirometry GOLD: OR 0.49 (0.35- 0.68)  \nSpirometry LLN: OR 0.74 (0.48- 1.13)  \nEver smoker  \nSpirometry GOLD: OR 3.50 (2.35- 5.22)  \nSpirometry LLN: OR 4.10 (2.35- 7.17)  \nPack years (per 10 years),Mean* (SD))  \nSpirometry GOLD: OR 1.23 (1.13- 1.35)  \nSpirometry LLN: OR 1.31 (1.19- 1.44)  \nBMI < 20 (ref = BMI 20- 25) \nSpirometry GOLD: OR 2.91 (1.04- 8.11)  \nSpirometry LLN: OR 6.44 (2.43- 17.11)  \nBMI > 25 (ref = BMI 20- 25) \nSpirometry GOLD: OR 0.57 (0.40- 0.82)  \nSpirometry LLN: OR 0.57 (0.36- 0.90)  \n beschrieben  \n \n(iii) transparentes, nicht -selektives Berichten  in Be-\nzug auf Patientencharakteristika, Intervention und Er-\ngebnis: ja  \n \nFisher AJ. Respiratory \nhealth and disease in a U.K. \npopulation- based cohort of \n85 year olds: The Newcastle \n85+ Study. Thorax 2016; \n71(3):255\u2013 66. \n \nhttps://www.ncbi.nlm.nih.gov\n/pubmed/26732736  \n \n \u2022 UK; North -East England  \n\u2022 population- based single year \nbirth-cohort of 85 year olds  \n \n\u2022 Studienstart/Studienende : 17 -  \nmonth- period spanning 2006 and \n2007 \n \n\u2022 Interventionen : self -reporting of \nsymptoms and measurement of spi-\nrometry  \n \n\u2022 Studientyp:  Pr\u00e4valenzstudie \n(Fall-Kontroll -Studie)  \n \u2022 healthy reference group aged 8 5 (HRG): with no respiratory symptoms, no \nrespiratory diagnoses, no current use of respiratory medications and no non-\nrespiratory diagnosis which might influence lung function (eg, Parkinson\u2019s \ndisease, kyphoscoliosis, heart failure, ankylosing spondylitis) in their GPRR. \nThose with a BMI >30 were also excluded from HRG.  \n \n\u2022 Spirometry: n=737 (HRG comprised 20.5% (151/737) of the spirometry co-\nhort) \nnormal FEV1/FVC ratio:  31.2% (230/737)  \nrestrictive pattern: 15.2% (112/737)  \nobstructive spirometry: men: 58.4%, 171/293; women: 50.5%, 224/444 --> \nbut with no gender difference in the spread of severity  \n \n\u2022 COPD group (physician diagnosed) (n=123 mit auswertbarer Spirometrie)  \nobstructive spi rometry by GOLD criteria: 75.6% (93/123) ; 76.9% (40/52) Bewertung des Biasrisikos nach der Newcastle Ottawa \nSkala (NOS)  \nI. Selektion der Studienteilnehmer  \n1) Wurden die \u201aF\u00e4lle\u2018 ad\u00e4quat definiert?: ja  \n2) Sind die \u201aF\u00e4lle\u2018 repr\u00e4sentativ?: ja \n3) Sind die \u201aKontrollen\u2018 repr\u00e4sentativ, erfolgte eine ad\u00e4-\nquate Auswahl der \u201aKontrollen\u2018?: ja  \n(\u201aKontrollen\u2018 stammen aus einer vergleichbaren Popula-\ntion wie die \u201aF\u00e4lle\u2018  \n4) Wurden die Kontrollen ad\u00e4quat definiert?: ja  \n \nII. Vergleichbarkeit  \n1) Ist die Vergleichbarkeit der \u201aF\u00e4lle\u2018 und \u201aKontrollen\u2018 ge-\ngeben?: ja  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  135 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n\u2022 Einschlusskriterien : people liv-\ning at home or in institutional care \nand regardless of their current \nhealth status  \n\u2022 Ausschlusskriterien:  have end-\nstage terminal illness or whose be-\nhaviour might prove a threat to a re-\nsearch nurse visiting alone  \n \n\u2022 prim\u00e4re Endpunkte : respiratory \nhealth, prevalence of respiratory \ndisease and use of spirometry in  \nrespiratory diagnosis  \n men and 74.7% (53/71)  woman  \nobstructive spirometry by GLI prediction model s: 49.6% (61); 48.1% (25/52) \nmen and 50.7% (36/71) women  \n \nApproximately half of the HRG (men: 47.4%, 27/57; women: 42.6%, 40/94) \nhad a spirometry definition of airflow obstruction by GOLD criteria yet did not \nfulfil the requirements for a diagnosis of COPD through lack of symptoms.  \n(All: 44.4% (67/151))  \nWhen applying the GLI criteria to HRG only 17.5% (10/57) men and 16% \n(15/94) women fulfilled criteria for airflow obstruction suggesting that GLI of-\nfered superiority to GOLD in spirometry interpretation in this age group. (All: \n16.6% (25/151)  \n \nConclusion : Current definitions of COPD based on spirometry may lead to \noverdiagnosi s in a group with transient symptoms and \u2018normal\u2019 lung ageing, \nwhereas at the same time failure to use spirometry to assess symptoms in \nthis age group may lead to mislabelling those with breathlessness or cough \nas having COPD when there are other explanati ons. \n III. Expositionserfassung  \n1) Erfolgte eine valide Erfassung der Exposition?: ja  \n2) Erfolgte die Erfassung der \u201aF\u00e4lle\u2018 und \u201aKontrollen\u2018 \nidentisch?: ja  \n3) Kann die \u201aNon- Response- Rate\u2018 als valide betrach tet \nwerden?: ja \n \nAnhang 5.4  Ph\u00e4notypisierung mittels Computertomographie \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nOcchipinti M. Emphysem-\natous and Nonemphy-\nsematous Gas Trapping \nin Chronic Obstructive \nPulmonary Disease: \nQuantitative CT Findings \nand Pulmonary Function. \nRadiology 2018; \n287(2):683\u2013 92. \n \nhttps://ww w.ncbi.nlm.nih.\ngov/pubmed/29361243  \n \n\u2022 Nicht zitiert.  \n \u25cfTwo -Center study; Italien  \n\u25cf Retrospektive Interpretation einer prospektiven, kon-\nsekutiven Korrelationsstudie  \n \n\u25cf Ziel: To identify a prevalent computed tomography \n(CT) subtype in patients with chronic obstructive pulmo-\nnary disease (COPD) by separating emphysematous \nfrom nonemphysematous contributions to total gas trap-\nping and to attempt to predict and grade the emphy-\nsematous gas trapping by using clinical and functional \ndata.  \n \n\u25cf Patienten mit COPD (GOLD stages I -  IV) \n \n\u25cf Interventionen:  \n- Pulmonary function testing: pre-  and postbronchodila-n=224; n=202 included in analysis (159 men; 43 women; \nmean age 71 years range 41 -  85 / 67 years range 46 -  84) \n \nPatients with similar values of %LAA -950insp had different \nvalues in %LAA -856exp  \n \n\u25cf prevalent emphysema group: n=29 (14,4%) (%LAA -\n950isnp higher than the mean value and and percantage of \nfunctional gas trapping lower than the mean value)  \n\u25cf prevalent functional gas trapping group: n= 46 (22,8%)  \n(%LAA -950isnp lower than the mean value and and percan-\ntage of functional gas trapping higher than the mean value)  \n\u25cf greater degree of both components: n=57 (28,2%)  \n\u25cf lower degree of both components: n=70 (34,6%)  \n \n\u25cf aut hors conclusion (Auszug): In conclusion, our study Beurteilung mit QUADAS II  (jedoch eingeschr\u00e4nkte \nBeurteilbarkeit, da dies keine explizite diagnostische \nGenauigkeitsstudie ist)  \n \nDomain 1: patient Selection  \n \nCould the selection of patients have i ntroduced bias? \nLOW \n \nDomain 2: Index Test(s)  \n \nCould the conduct or interpretation of the index test \nhave introduced bias? UNCLEAR  \n \nDomain 3: Reference Standard  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  136 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \ntor Spirometry, static lung volumes, single breath diffus-\ning capacity for carbon monoxide  \n- Chest -CT at full inspiration and expiration: Somatom \nSensation 64/ Somatom D efinition Flash 128; 120 kPv; \n200 mAs; rotation time 0.5 sec; pitch 1:1; section thick-\nness 0.75mm  \nTresholds at - 950 HU (inspiration) and - 856 HU (expira-\ntion) were chosen as densitometric cut -off values con-\nsistent with emphysema and total gas trapping --> p ost-\nprocessing image analysis of lung parenchyma and air-\nways  \n+ \nanalysis with deformable coregistration of paired inspir-\natory and expiratory CT scans, to obtain voxel -by-voxel \nattenuation maps (pulmonary parametric response \nmaps)  \n \n\u25cfEinschlusskriterien:  age 40- 85 years, smoking his-\ntory of >10 pack -years, with nonreversible postbroncho-\ndilator airway obstruction, underwent Chest CT within \n48 h of pulmonary function evaluation  \n\u25cfAusschlusskriterien:  exacerbation within 1 month, \nasthma, diffuse bronchiectasi s, interstitial lung disease, \nacute heart failure, chemotherapy and/or radiation ther-\napy, lung cancer, lung surgery, metal objects in chest  \n demonstrated that standard imaging metrics obtained at in-\nspiratory and expiratory thoracic CT scans can be used to \nidentify and quantify the relative contribution of emphysema-\ntous and nonemphysematous gas trapping, permitting a bet-\nter definition of COPD subtypes.  \n Could the reference standard, its conduct, or its inter-\npretation have introduced bias? UNCLEAR  \n \nDomain 4: Flow and Timing  \n \n \nCould the patient flow have introduced bias?: LOW  \n \n\u25cfpossible concerns regarding applicability: Matching \nour review question?  \n \nHong Y. Sex differences \nof COPD phenotypes in \nnonsmoking patients. Int \nJ Chron Obstruct Pulm on \nDis 2016; 11:1657\u2013 62. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/27524891  \n \n\u2022 Nicht zitiert.  \n \n \u25cfKorea  \n\u25cf nonsmoking patients with COPD  from a Korean \nCOPD cohort  \n\u25cf Subgruppenanalyse einer Kohortenstudie (n=445; \nn=335 with COPD -->97 patients were selected for this \nstudy if they had a cigarette smoking history of <1 pack -\nyear)  \n \n\u25cfEin- und Ausschlusskriterien Prim\u00e4rstudie:  aged \n>45 years and had a postbronchodilator forced expira-\ntory volume in 1 second (FEV )/forced vital capacity \n<0.7.  >>Geschlechtsunterschiede untersucht (Emphysemindex \nper CT)  \nn=97 (62 female, 35 male)  \n\u25cf sex-related phenotypes of COPD  \nEmphysema index was significantly lower (3.5\u00b14.2 vs \n6.2\u00b15.7, P<0.01) and mean WA% on computed tomography \nwas significantly higher (71.8%\u00b15% vs 69.4%\u00b15%, P<0.01) \nin females than in males  \n \n\u25cfMMRC, CAT, history of exacerbation, and FEV (% of pre-\ndicted) did not differ significantly between males and fe-\nmales  \n \n\u25cf \"authors conclusion\": WA% was higher and emphysema AWMF -Manual Bias -Bewertung nic htvergleichende \nStudien:  \n \n1.prospektive Planung mit Protokoll:  keine definitive \nBeurteilung m\u00f6glich  \n \n2. konsekutiver Patienteneinschluss:  unklar  \n \n3.  transparentes, nicht -selektives Berichten: ja \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  137 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n\u25cfInterventionen:  All patients were evaluated at the en-\nrollment visit by a medical interview, a physical exami-\nnation, spirometry, laboratory tests, and a CT scan \n(first-generation dual source).  \n\u25cfprim\u00e4rer Endpunk t: sex-related phenotypes of \nCOPD extent was lower in nonsmoking females with COPD than in \nnonsmoking males with COPD. These findings suggest that \nmales may be predisposed to an emphysema phenotype \nand females may be predisposed to an airway phenotype of \nCOPD.  \nMohamed Hoesein FA. \nDiscriminating dominant \ncomputed tomography \nphenotypes in smokers \nwithout or with mild \nCOPD. Respir Med 2014; \n108(1):136\u2013 43. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/24035313  \n \n \n\u2022 Nicht zitiert.  \n \u25cf1140 male smokers without or with mild COPD   \n\u25cfZiel: to discriminate emphysematous, large airway \nwall thickening and small airways disease dominant \nphenotypes  \n\u25cfsub -study of the Dutch and Belgium Lung Cancer \nScreening Trial (NELSON trial; RCT)  \n \n\u25cfErgebnisse des Screening- Armes wurden in dieser \nSubgruppenanalyse ausgewertet  \n\u25cfInterventionen:   1. Screen arm:  \na. 16- detector multi -slice comp uted tomography of the \nchest in year 1, 2 and 4 of the study;  \nb. Pulmonory function test;  \nc. Blood sampling;  \nd. Questionnaires;  \ne. Smoking cessation advice for current smokers.  \n \n\u25cfEinschlusskriterien Prim\u00e4rstudie:  \n1. Born between 1928 and 1956;  \n2a. Smoked >  15 cigarettes/day during > 25 years or;  \n2b. Smoked > 10 cigarettes/day during > 30 years;  \n3. Current or former smokers who quit smoking =< 10 \nyears ago.  \n \n\u25cfAusschlusskriterien Prim\u00e4rstudie:   \n Subjects  \n1. With a moderate or bad self -reported health who \nwere  unable to climb two flights of stairs;  \n2. With a body weight >= 140 kilogram;  \n3. With current or past renal cancer, melanoma or \nbreast cancer;  \n4. With lung cancer diagnosed less than 5 years ago or \n5 years or more ago but still under treatment;  \n5. Who had a chest CT examination less than one year \nbefore they filled in the first NELSON questionnaire.  >>3 verschiedene COPD -Ph\u00e4notypen: Detektion durch CT  \n\u25cfCOPD subjects (86%) were in GOLD stage 1, 14% had \nGOLD stage 2 or 3  \n \n\u25cf573 subjects had any of the three CT measures in the up-\nper quartile. Of these  \n\u25cfn=367 (64%) were in a single dominant group and n=206 \n(36%) were in a mixed group.  \n\u25cfOf all included subjects 143 (13%) subjects were emphy-\nsema dominant, 91 (8%) air trapping dominant and 133 \n(12%) AWT dom inant.  \n\u25cfAirway wall thickening dominance was associated with \nyounger age (p < 0.001), higher body mass index (p < \n0.001), more wheezing (p < 0.05) and lower FEV %pre-\ndicted (p < 0.001).  \n\u25cfEmphysema dominant subjects had lower FEV1/FVC (p < \n0.05) and Kco %predicted (p < 0.05).  \n\u25cfThere was no signi \ufb01cant difference in respiratory related \nhospitalizations (p = 0.09).  \n \n \n \n\"authors conclusion\": CT measures can discriminate three \ndifferent CT dominant groups of disease in male smokers \nwithout or with mild COPD.  \n \n AWMF -Manual Bias -Bewertung nichtvergleichende \nStudien:  \n \n1.prospektive Planung mit Protokoll: ja (online verf\u00fcg-\nbar) \n \n2. konsekutiver Patienteneinschluss:  unklar  \n \n3.  transparentes, nicht -selektives Berichten:  ja \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  138 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \nBafadhel M. The role of \nCT scanning in multidi-\nmensional phenotyping of \nCOPD. Chest 2011; \n140(3):634\u2013 42. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/21454400  \n \n \n\u2022 Nicht zitiert.  \n \u25cfEngland  \n\u25cfconsecutive stu dy (longitudinal Biomarkers in COPD \nExacerbation study)  \n\u25cfn=75  \n \n\u25cfEinschlusskriterien:  Patients with a physician diag-\nnosis of COPD (GOLD); obstructive spirometry with a \npostbronchodilator FEV1/FVC ratio of  <0.7  \n- patients with COPD who demonstrated bronchodilator \nreversibility were not excluded  \n\u25cfAusschlusskriterien:  Patients with a diagnosis of \nasthma, current active pulmonary TB, or any other clini-\ncally relevant lung disease  \n \n\u25cfMeasurements:  \n- Full lung function, including reversibility testing with \n400  mg inhaled albuterol  \n- SGRQ, Chronic Respiratory Disease Interviewer -Ad-\nministered Questionnaire BMI, Spontaneous or induced \nsputum analysis (PCR), Venous blood was collected for \nassessment of peripheral blood  differential cell counts \nand serum C -reactive protein  \n- CT Imaging: Sensation 16- slice scanner  \n n=58 men; n=17 women  \n \n\u25cfradiologic COPD disease groups  \nseen in clinical practice: emphysema (EM; included the \npresence of centrilobular, panlobular, and paraseptal EM), \nbronchial wall thickening (BWT), and bronchiectasis (BE)  \n \n\u25cfThe presence of emphysema (EM), bronchiectasis (BE), \nand bronchial wall thickening (BWT) was found in 67%, \n27%, and 27% of subjects, respectively. The presence of \nEM was associated with lower lung function (mean differ-\nence % FEV1 -20%; 95% CI, - 28 to -11;  P< .001).  \n \n\"authors conclusion\"  \nCT imaging provides additional value to clinical and physio-\nlogic parameters in the multidimensional phenotyping of \nCOPD \n AWMF -Manual Bias -Bewertung nichtvergleichende \nStudien:  \n \n1.prospektive Planung mi t Protokoll:  unklar  \n \n2. konsekutiver Patienteneinschluss : ja \n \n3. transparentes, nicht -selektives Berichten:  ja \n \nHan MK. Clinical signifi-\ncance of radiologic char-\nacterizations in COPD. \nCOPD 2009; 6(6):459\u2013\n67. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/19938970  \n \n \n\u2022 Nicht zitiert.  \n \u25cfUSA  \n\u25cfKorrelationsstudie, subset of the multicenter Lung Tis-\nsue Research Consortium LTRC  \n\u25cfn=156 (von n=1400 der Hauptstudie)  \n \n\u25cfEinsc hlusskriterien  \n- >10 pack -years smoking history  \n- airflow obstruction FEV1/FVC <0.70 \n- clinical diagnosis of COPD  \n\u25cfAusschlusskriterien:  \n-additional pathological or imaging chronical lung dis-\nease other than malignancy  \n \n\u25cfMeasurements:  \n- HRCT (8 detector or g reater)  We hypothesized HRCT phenotype would strongly influence \nclinical outcomes including health status, exacerbation fre-\nquency, and BODE  \n \n\u25cfemphysema percent is significantly correlated with both \nFEV1 and systemic components of BODE, with the strong-\nest correlation between emphysema percent and total \nBODE score  \n\u25cfFEV1 and HRCT features (emphysema percent and VBT) \nare both significantly related to health status, even when ac-\ncounting for FEV1  \n\u25cfthe airway thickness VBT, but not emphysema, predicts \nself-reported exacerbation frequency among patients who \nexperienced an exacerbation in the prior year, but with an \nattenuated effect for older ages, due to a n age -bronchial AWMF -Manual Bias -Bewertung nichtvergleichende \nStudien:  \n \n1.prospektive Planung mit Protokoll:  unklar  \n \n2. konsekutiver Patienteneinschluss:  unklar  \n \n3.  transparentes, nicht -selektives Berichten: ja \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  139 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n-SGRQ, BODE Index, self -reported exacerbation fre-\nquency, mMRC  \n- Spirometry (before and after albuterol) + DLCO  thickness interaction  \n \nKim WJ. CT metrics of \nairway disease and em-\nphysema in severe \nCOPD. Chest 2009; \n136(2):396\u2013 404. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/19411295  \n \n\u2022 Nicht zitiert.  \n \n \u25cfInternational  \n\u25cfSubgruppenanalyse von n=338 in the National Em-\nphysema Treatment Trial (NETT) Genetics Ancillary \nStudy  \n \n\u25cfpatients with severe COPD  \n \n\u25cfEinschlusskriterien:  FEV1< 45% predicted; CT scan \nevidence of severe emphysematous destruction  \n\u25cfMeasurements:  \n- CT \n- Spirometry, questionnaires, BODE Index  \n \u25cfMale subjects exhibited significantly thicker airway wall \nphenotypes (p = 0.007 for WT and p = 0.0006 for SRWA).  \n \nwall thickness (WT):  \nmale: 1,56 \u00b1 0,23 mm  \nfemale: 1,48 \u00b1 0,27 mm  \n \nsquare root of wall area (SRWA)   \nmale: 4,66 \u00b1 4,47 mm\u00b2  \nfemal e: 4,47 \u00b1 0,54 mm\u00b2  \n \n%LAA -950 \nmale: 0,17 \u00b1 0,10  \nfemale: 01,6 \u00b1 0,12  \np=0,81 \n \n\"authors conclusion\" : Airway disease and emphysema de-\ntected by CT scanning are inversely related in patients with \nsevere COPD. Airway wall phenotypes were influenced by \ngender and associated with lung function in subjects with se-\nvere emphysema.  AWMF -Manual Bias -Bewertung nichtvergleichende \nStudien:  \n \n1.prospektive Planung mit Protokoll: unklar  \n \n2. konsekutiver Patienteneinschluss:  unklar  \n \n3. transparentes, nicht -selektives Berichten:  ja \n \nCopley SJ. Thin -section \nCT in obstructive pulmo-\nnary disease: Discrimina-\ntory value. Radiology \n2002; 223(3):812\u2013 9. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/12034954  \n \n \n\u2022 Nicht zitiert.  \n \u25cfUK/Canada  \n\u25cfThin- section CT of n=105 patients with obstructive \npulmonary disease (asthma n=35; centrilobular emphy-\nsema n=30; panlobular emphysema n=21; obliterative \nbronchiolitis n=19) and healthy subjects  \n\u25cfDiagnostic accuracy for first -choice diagnosis by two \nobservers were calculated \n \nInterventionen \n\u25cfelectron- beam CT scanner or HiSpeed Advantage CT \nScanner  \n\u25cfpulmonary function test within 3 month of CT scanning  \n \u25cfA correct first -choice diag nosis was made [...] in 53 of 60 \n(88%) observations in patients with centrilobular emphy-\nsema, [\u2026] and in 20 of 42 (48%) observations in patients \nwith panlobular emphysema.  \n\u25cfOne major sources of diagnostic inaccuracy were differen-\ntiation between panlobular and centrilobular emphysema [...]  \n \nCentrilobular emphysema (n=60)  \nSensitivity(%) 88 (53/60)  \nSpecificity (%) 90 (194/216)  \nAccuracy (%) 89 (247/276)  \n \nPanlobular emphysema (n=42)  \nSensitivity(%) 48 (20/42)  \nSpecificity (%) 97 (227/234)  \nAccuracy (%) 89 (247/276)  Beurt eilung mit QUADAS II   \n \nDomain 1: patient Selection  \n \nCould the selection of patients have introduced bias? \nLOW \n \nDomain 2: Index Test(s)  \n  \nCould the conduct or interpretation of the index test \nhave introduced bias? UNCLEAR  \n \nDomain 3: Reference Standard  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  140 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \nThe prevalence of CT features in patients with centrilobular \nvs. panlobular emphysema was also assessed. The only \nsignificant difference in favor of panlobular emphysema was \nthe presence of long lines (adjoining visible interlobular \nsepta, not linear ate lectasis) (p=0.02.) Likewise, there was \nno significant difference between the extent of CT features, \napart from long lines (median extent for centrilobular emphy-\nsema: 0.5; range 0- 4.5; median extent for panlobular em-\nphysema: 2.5; range 0- 5-5; p<0.05)  Could the reference standard, its conduct, or its inter-\npretation have introduced bias? UNCLEAR  \n \nDomain 4: Flow and Timing  \n  \n>>Could the patient flow have introduced bias?: LOW  \n \n\u25cfpossible concerns regarding applicability: Matching \nour review question?  \n \nAnhang 5.5  Cut-Off Symptomerfassung \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nKarloh M. The COPD As-\nsessment Test: What Do \nWe Know So Far?: A \nSystematic Review and \nMeta- Analysis About \nClinical Outcomes Pre-\ndiction and Classification \nof Patients Into GOLD \nStages. Chest 2016; \n149(2):413\u2013 25.  \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/26513112  \n \n \u2022 Ziel des Reviews:  \n-review the determinants of the CAT \nscore  \n-its ability to predict clinical ou tcome  \n-agreement between CAT (\u2265 10) and \nmMC (\u22652)  \n \n\u2022 Suchzeitraum:  01/2009 - 06/2015 \n \n\u2022 untersuchte Tests: CAT, mMRC  \nMetaanalyse CAT und mMRC agree-\nment: n=8 Studien  \n \n\u2022 Population: patients with COPD or \nsuspected of COPD  \n\u2022 Einsschlusskriterien: English, \nSpanish and Portuguese language, \npublished in peer -reviewed journals  \n\u2022 Ausschluss : meeting abstracts, case \nreports, editorials, comments, reviews  \n\u2022 eingeschlossenen Studientypen:  \nCross -sectional, prospective observa-\ntional c ohort, retrospective cohort,  \ncross -sectional surveys  Ten studies have evaluated the distribution of patients in each stage of the new GOLD  grad-\ning clasification according to the tool used to assess symptoms. All studies found a different \nproportion of patients in each category using CAT \u2265 10 or mMC \u22652. There was a misclassifica-\ntion of 13% in all GOLD categories. Eight of them reported agreement analysis comparing the \nfrequencies of patients classified according to CAT or mMRC. The agreement between CAT \nand mMRC ranged from poor to substantial. The pooled k is not presented due to heterogene-\nity across studies (I\u00b2=99,3). Based on the discrepancy with respect to the of CAT or mMRC, \nJones et al . [Ref ID 28142] suggested the cut point of \u22651 for the mMRC showing greater k co-\nefficients  \n \nThe results also showed that CAT and mMRC are not equivalent for the purpose of assessing \na patients\u00b4symptoms,  \n \n \n \n>> systematischer Review  \n>> vergleicht Cut off von mMRC vs. CAT ein mMRC \u2265 1 (anstatt  \u2265 2) entspricht eher \ndem CAT \u2265 10  \n>> Verteilung der Patient*innen mit COPD auf das GOLD -System --> Unterschiede, je \nnachdem welcher Test genutzt wird  AMSTAR: 6/11  \n \nn-y-y-n-n-y-y-y-y-n-ca \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  141 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nHering T. COPD Classifi-\ncation GOLD I -IV vs. \nGOLD A -D in Real Life: \nComparing Impact on Ap-\nplication, Advantages and \nDisadvantages. Pneumol-\nogie 2015; 69(11):645\u2013\n53. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/26458126  \n \n \u202218 pneumologischen Facharztpraxen: \nschriftliche Befragung von  erwach-\nsene Patient*innen mit COPD  \n \n\u2022 Patienten:   mit COPD  \n \n\u2022 Studienstart/ Studienende:  4. Quar-\ntal 2014  \n \n\u2022 Einsschlusskriterien: erwachsene \nPatient*innen (mindestens 18 Jahre \nalt) mit COPD, die Diagnose muss \nvom Pneumologen best\u00e4tigt sein, der \nPatient muss  nicht \u201eneu\u201c sein, und der \nPatient/die Patientin wurde vom Haus-\narzt \u00fcberwiesen bzw. wird gemeinsam \nmit dem Hausarzt betreut.  \n \n\u2022 Endpunkte: Erhebung von CAT, \nExazerbationen+ Ermittlung der \nGOLD -Gruppenzugeh\u00f6rigkeit  \n \n n=1274   \n \nMit den Angaben zu CAT, Exazer bationen und Schweregrad wurde die Gruppenzugeh\u00f6rigkeit \nnach GOLD A \u2013D ermittelt. \n\u2022 Es zeigte sich, dass der Schweregrad nach GOLD nicht unbedingt einen R\u00fcckschluss auf die \nBeeintr\u00e4chtigung durch die COPD zul\u00e4sst.  \n\u2022 Wesentlich beeinflusst werden die Anteile der Patient*innen an den jeweiligen Gruppen auch \ndurch das Ergebnis des CAT mit 10 Punkten als Schwellenwert der Beeintr\u00e4chtigung. Ver-\nschiebt man diesen Wert auf 15 oder 20 Punkte, hat das einen erheblichen Einfluss auf die \nPatientenverteilung nach Gruppen. Bei einem Schwellenwert von 15 Punkten erh\u00f6hen sich die \nAnteile der Gruppen A und C mit geringer Beeintr\u00e4chtigung bereits um mehr als das Doppelte \nvon 12% auf 25% und von 6 % auf 14 %. Die Gruppe D mit hohem Risiko und hoher Beein-\ntr\u00e4chtigung sinkt von 46% auf 39 %. Bei einem Schwellenwert von 20 Punkten sinkt die \nGruppe D auf 28 %.  \n>> untersuchen Verteilung der Patient*innen mit COPD  auf das 2015er GOLD -System I -\nIV und A -D in deutscher Versorgung  \n>> hypothetische Verteilung, wenn der Cut -Off beim CAT f\u00fc r die Ensch\u00e4tzung ge-\nringe/starke Symptome bei >15 oder > 20 Punkten liegt  \n>> m\u00f6gliche \u00fcber - und Untertherapie  \n>> bei 15 Punkten anscheinend homogenere Verteilung der Patient*innen in die Grup-\npen \"Bias -Bewertung f\u00fcr nicht -verglei-\nchende Studien; AWMF 2016:  \n \n(I) prospektive Planung mit Proto-\nkoll: keine Angaben  \n \n(II) konsekutiver Patientenein-\nschluss: nicht eindeutig beschrie-\nben  \n \n(II) transparentes, nicht -selekti-\nves Berichten in Bezug auf Pati-\nentencharakteristika, Intervention \nund Ergebnis:  detaillierte Angab en \nzu den eingeschlossenen Patienten \nfehlen \n \nZhou Z. A comparison of \nthe assessment of health \nstatus between CCQ and \nCAT in a Chinese COPD \nclinical population: A \ncross -sectional analysis. \nInt J Chron Obstruct \nPulmon Dis 2018; \n13:1675\u2013 82. \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/29872285  \n \u2022 Chinesische Population  \n\u2022 Patient*innen: outpatients with sta-\nble COPD  \n \n\u2022 Studienstart: 11/2015 to 12/2016 \n(Enrollment)  \n \n\u2022 untersuchte Tests: CAT, CCQ  \n \n\u2022 Studientyp: observational, cross -\nsectional, cohort study  \n \n\u2022 Einschlusskriterien: Patients > 40 \nyears of age  \n\u2022 Ausschlusskriterien: Patients who \nrefused to complete questionnaires, n=372 \n \nThe CCQ cutoff point of 1.0 classified 97.3% of patients into the high symptom group (groups \nB and D), which was statistically higher than that of the C AT (82.3%) and CCQ with a cutoff \npoint of 1.5 (78.0%). No significant difference was observed in the proportion of subjects who \nhad more symptoms between the CAT and CCQ with the cutoff point of 1.5. The kappa of \nagreement for the symptom groups by CAT and  CCQ (cutoff point 1.5) was 0.495, suggesting \nmoderate agreement (Table 2), but slight agreement (0.144) was found between the CAT and \nCCQ with the cutoff point of 1.0.  \n \nmain findings: 1) compared with the CAT, the CCQ was more likely to classify the patients into \nmore severe categories, and it seemed that 1.5 rather than 1.0 might be a better cutoff point \nfor the CCQ and 2) both the CAT and the overall CCQ with its 3 domains could discriminate \nbetween groups of patients who differ in COPD severity.  \n \nThe CA T and CCQ results can be categorized into 4 levels: scores of 0\u2013 10, 11\u2013 20, 21\u2013 30, and \n31\u201340 represent low, medium, high, and very high impact level by CAT. Correspondingly, \"Bias -Bewertung f\u00fcr nicht -verglei-\nchende Studien; AWMF 2016:  \n \n(I) prospektive Planung mit Proto-\nkoll: ja  \n \n(II) konsekutiver Patientenein-\nschluss: nicht eindeutig beschrie-\nben  \n \n(II) transparentes, nicht -selekti-\nves Berichten in Bezug auf Pati-\nentencharakteristika, Intervention \nund Ergebnis: ja \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  142 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nasthma, lung cancer or other lung dis-\nease under active treatment (eg tuber-\nculosis or pneumonia)  \n \n\u2022 prim\u00e4rer Endpunkt: compare the \nevaluation of symptom severity be-\ntween the CAT and the CCQ and to \nfind a cutoff value of the CCQ for the \nChinese clinical population  \n\u2022 sekund\u00e4re Endpunkte: correlation \nbetween the CAT, the CCQ, the m odi-\nfied Medical Research Council \n(mMRC) questionnaire, lung function, \nand exacerbation history.  \n scores of the CCQ can be considered as acceptable (CCQ<1), acceptable for moderate dis-\nease (1\u2264CCQ<2), instable- severe limited (2\u2264CCQ<3), and very instable- very severe limited \n(CCQ\u22653).  \n \n>> CCQ cut -off von 1,5 Punkten (anstatt 1,0) entspricht eher dem CAT cut -off von 10 \nPunkten  \nJo YS. The cutoff point of \nclinical chronic obstruc-\ntive pulmonary disease \nquestionnaire for more \nsymptomatic patients. \nBMC Pulm Med 2018; \n18(1):38.  \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/29482616  \n \u2022 South Korea  \n\u2022 Patient*innen:  COPD patients  \n \n\u2022 Diagnosis of COPD:  4/2013 - \n12/2015 + 3/2014 -   \n12/2015; multicenter  \n \n\u2022 untersuchte Tests: SGRQ, CCQ, \n(CAT, mMRC)  \n \n\u2022 Studientyp: Registerstudie; Date-\nnanalyse aus:  prospective observa-\ntional cohort study that enrolls patients \nwith chronic airway disease, including \nCOPD \n \n\u2022 Einschlusskriterien:  aged > 40 \nyears who smoked/had smoked \u226510 \npacks/year  \n\u2022 Ausschlusskriterien: Participants \nwho were not assessed either by \nSGRQ, the CAT, or the CCQ at the \nbaseline visit  \n \n\u2022 prim\u00e4r e Endpunkte:  \n- assess wether the CCQ correlates n=126  \n \nThe CCQ significantly correlated well with SGRQ, the CAT, and the mMRC (r = 0.76, 0.69, and \n0.53, respectively) (Fig 2). The CCQ showed a significant negative correlation with FEV1 and \n6-min walk distance (r = \u2212 0.40 and \u2212 0.42, respectively).  \n \nA cutoff point of 1 .4 showed the highest AUROC for identifying more symptomatic patients with \nSGRQ \u226525 (AUROC = 0.605, 0.633, 0.681, 0.762, and 0.711 for the CCQ cutoff points of 0.7, \n1.0, 1.2, 1.4, and 1.6, respectively). The categorization based on the CCQ cutoff point of 1.4 \nshowed the highest agreement with the SGRQ 25- based categorization (CCQ cutoff point = \n0.7: agreement rate = 75.61% and \u03ba value = 0.27; CCQ cutoff point = 1: agreement rate = \n76.42% and \u03ba value = 0.33; CCQ cutoff point = 1.4: agreement rate = 82.11% and \u03ba value = \n0.56) (Table 2). Even when adjusting for age, sex, body mass index, and FEV1, a CCQ score \n\u2265 1.4 was the good determinant of an SGRQ score \u2265 25 in the CART analysis (relative hazard \nrisk, 1.23).  \n \n>> CCQ cut -off von 1,4 entspricht eher SGRQ von \u2264 25 (f\u00fcr mehr symptomatische Pati-\nent*innen)  \"Bias -Bewertung f\u00fcr nicht -verglei-\nchende Studien; AWMF 2016:  \n \n(I) prospektive Planung mit Proto-\nkoll: retrospektiv angemeldete Stu-\ndie; daher unklar  \n \n(II) konsekutiver Patientenein-\nschluss: nicht eindeutig beschrie-\nben  \n \n(II) transparentes, nicht -selekti-\nves Berichten in Bezug auf Pati-\nentencharakteristika, Intervention \nund Ergebnis: ja \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  143 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nwell with other health status measures, \nlung function, and exercise capacity in \nKorean COPD patients,  \n- determine CCQ cutoff point that cor-\nresponds well with the SGRQ cutoff \npoint of 25  \n \nSmid DE. How to deter-\nmine an impaired health \nstatus in COPD: Results \nfrom a population- based \nstudy. Neth J Med 2017; \n75(4):151\u2013 7. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/28522771  \n \n \u2022 Niederlande  \n\u2022 Patient*innen: mit und ohne COPD  \n \n\u2022 untersuchte Tests:  CAT, Spi-\nrometrie  \n \n\u2022 Studientyp: subsample of  \"the Lon-\ngitudinal  Aging Study Amsterdam \n(LASA)\",Dutch population- based study, \nmulticenter  \n \n\u2022 Einschlusskriterien: subjects aged \nbetween 55- 65 years; no inclusion or \nexclusion criteria were outlined in the \nLASA study.  \n \n\u2022 prim\u00e4rer Endpunkt: which cut -off \nvalue represents an abnormal CAT \nscore for non- COPD subjects in a \nDutch population  \n\u2022 sekund\u00e4re Endpunkte: measure the \nimpact of COPD on health status in a \nDutch population, after stratification for \nwork status  \n n=810  \n \nWhen applying the CAT \u2265 10 cut -point, 50.0% of COPD subjects had an impaired health status \nand when using a CAT > 18 cut -point 7.6% of COPD subjects had an impaired health status  \n \nSubjects with CAT \u2265 10 points, n (%): 165 (22.8)  \nSubjects with CAT > 18 points, n (%): 28 (3.9)  \n>> CAT >18 entspricht besserem cut -off f\u00fcr Einsch\u00e4tzung: impaired health status  \"Bias -Bewertung f\u00fcr nicht -verglei-\nchende Studien; AWMF 2016:  \n \n(I) prospektive Planung mit Proto-\nkoll: nicht eindeutig beschrieben  \n(II) konsekutiver Patientenein-\nschluss:  (ja)  \n \n(II) transparentes, nicht -selektives \nBerichten in Bezug auf Patien-\ntencharakteristika, Intervention und \nErgebnis: ja  \n \nTsiligianni IG. Investigat-\ning sensitivity, specificity, \nand area under the curve \nof the Clinical COPD \nQuestionnaire, COPD As-\nsessment Test, and Mod-\nified Medical Research \nCouncil scale according \nto GOLD using St \u2022 Deutschland, Niederlande  \n\u2022 Patient*innen:  mit COPD und Rau-\ncher (mind. 10 Jahre)  \n \n\u2022 untersuchte Tests: SGRQ, CAT, \nCCQ, mMRC \n \n\u2022 Studientyp:  Analyse zweier \nDatensets: study A, 238 patients from n=238 + n= 101  \n \nROC analysis: In study A, the proportions of sensitivity, specificity, and AUC for the cutoff point \nSGRQ \u2265 25 were (r espectively) 0.99, 0.43, and 0.96 for CCQ \u2265 1; 0.92, 0.48, and 0.89 for CAT \n\u2265 10; and 0.68, 0.91, and 0.91 for mMRC \u2265 2.  \n \nIn study B, these results were for the cutoff point SGRQ \u2265 25, and were (respectively) 0.87, \n0.77, and 0.9 for CCQ \u2265 1; 0.76, 0.73, a nd 0.82 for CAT \u2265 10; and 0.21, 1, and 0.81 for mMRC \n\u2265 2 (Table 3). The maximal difference of high versus low CCQ or CAT scores based on the \"Bias -Bewertung f\u00fcr nicht -verglei-\nchende Studien; AWMF 2016:  \n \n(I) prospektive Planung mit Proto-\nkoll: ja  \n \n(II) konsekutiver Patientenein-\nschluss: nicht beurteilbar  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  144 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nGeorge's Respiratory \nQuestionnaire cutoff 25 \n(and 20) as reference. Int \nJ Chron Obstruct Pulmon \nDis 2016; 11:1045\u2013 52. \n \nhttps://www.ncbi.nlm.nih .\ngov/pubmed/27274226  \n a pulmonary rehabilitation program; \nand study B, 101 patients from primary \ncare.  \n \n\u2022 Einschlusskriterien:  \nStudie A: Participants with spirometry -\nconfirmed COPD GOLD category II \u2013IV \nStudie B: Patients 45 years of age and \nolder with a smoking history of at least \n10 years  \n \n\u2022 Ausschlusskriterien:  \nStudie A: Patients with a relevant hy-\npercapnic respiratory failure (CO2 par-\ntial pressure \u2265 50 mmHg in rest or indi-\ncation for noninvasive breathing), lin-\nguistic and cognitive limitations, and \nlack of motivation  \nStudie B: concomitant asthma, unsta-\nble cardiovascular disease, or any res-\npiratory disease other than COPD  \n \n\u2022 prim\u00e4rer Endpunkt: investigate the \ncriterion validity of the CCQ, CAT, and \nmMRC scale cutoff points i n differenti-\nating between high-  and low -symptom \ngroups using the suggested cutoff \npoint of the SGRQ as the gold stand-\nard, \n changing SGRQ cutoff of 15 \u201330 was 2.01 for the CCQ and 11.5 for the CAT, both at the \nSGRQ cutoff point of 20.  \n \nWhen the SGRQ cutoff point was adjusted to \u226520, the proportions of sensitivity, specificity, and \nAUC were (respectively) 0.99, 0.73, and 0.99 for CCQ \u22651; 0.91, 0.73, and 0.94 for CAT \u226510; \nand 0.66, 0.95 and 0.94 for mMRC \u22652.  \nIn study B, these results were 0.8 , 0.89, and 0.89 for CCQ \u22651; 0.69, 0.78, and 0.8 for CAT \u226510; \nand 0.18, 1, and 0.81 for mMRC \u22652.  \n \n>> vergleicht Kompatibilit\u00e4t zwischen den Cut -offs von CAT, mMRC, CCQ im Vergleich \nzu SGRQ  \n>> ein Cut -off des SGRQ von \u2265 20 stimmt besser mit den anderen Cut -offs der Tests \n\u00fcberein, als der von \u2265 25  \n>> Beweis:verschiedene Cut -offs der 4 Tests sind nicht 1:1 \u00fcbertragbar  (II) transparentes, nicht -selekti-\nves Berichten in Bezug auf Pati-\nentencharakteristika, Intervention \nund Ergebnis: ja \n \nHuang W -C. Features of \nCOPD patients  by com-\nparing CAT with mMRC: \nA retrospective, cross -\nsectional study. NPJ Prim \nCare Respir Med 2015; \n25:15063.  \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/26538368  \n \u2022 Taiwan  \n\u2022 Patient*innen mit COPD  \n \n\u2022 Studienstart: 11/2012 \n\u2022 Studienende: 8/2013 \n \n\u2022 untersuchte Tests: CAT, mMRC  \n \n\u2022 Studientyp: Datenanalyse einer \nlarge- scale, cross sectional, multi -cen-\ntre, observational, retrospective study n=757 subjects included in analysis  \n \nBased on the cut -points CAT score  \u2265  10 and mMRC scale  \u2265 2 recommended by the GOLD \n2011, classifying patients by CAT resulted in 30.6, 17.3, 22.2 and 29.6% of participants in  \ngroups A, B, C and D, whereas by mMRC resulted in 22.2, 26.0, 1.9 and 35.9%, respectively.  \n \nThe best agreement of group assignment emerged when the cut -point CAT score  \u2265  10 corre-\nsponded to the cut -point mMRC  \u2265 3 (kappa = 0.55, P = 0.000), whereas the w orst agreement \nemerged when the cut -point CAT score  \u2265  10 corresponded to the cut -point mMRC  \u2265  1 \n(kappa = 0.36, P = 0.000)  \n \"Bias -Bewertung f\u00fcr nicht -verglei-\nchende Studien; AWMF 2016:  \n \n(I) prospektive Planung mit Proto-\nkoll: nicht eindeutig beschrieben  \n \n(II) konsekutiver Patientenein-\nschluss: nicht eindeutig beschrie-\nben  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  145 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nof the TOLD consortium  \n \n\u2022 Einschlusskriterien:  patients aged \n\u2a7e40 years with a confirmed diagnosis \nof COPD based on the GOLD 2011 \nrecommendation and a spirometry \nwithin the previous 1 year before en-\nrollment  \n\u2022 Ausschlusskriterien: participated in \ninterventional clinical trials in the previ-\nous 1 year, had a history of asthma or, \nfor the purpose of this study, did not \ncomplete both the CAT and mMRC  \n \n\u2022 prim\u00e4re Endpunkte: clarify how dif-\nferent patient characteristics influence \nthe differences, to determine the rela-\ntionships between CAT and mMRC \nand to charac terise COPD patients by \nboth CAT and mMRC  \n In contrast to the GOLD 2011 recommendation, COPD patients with a lower CAT score, less \nsevere airway obstruction and less severe airflow limitation were associated with discordant \ngroup assignments and should evaluate their symptoms with both CAT and mMRC simultane-\nously. We did not find any optimal cut -point for mMRC to correspond to the cut -point CAT \nscore \u2265  10.  \n \n>> We did not fi nd any optimal cut -point for mMRC to correspond to the cut -point CAT \nscore \u2265 10  \n--> jedoch kein Vorschlag f\u00fcr neue Cut -Offs (II) transparentes, nicht -selekti-\nves Berichten in Bezug auf Pati-\nentencharakteristika, Intervention \nund Ergebnis:  ja \n \nRhee CK. Discrepancies \nbetween modified Medi-\ncal Research Council \ndyspnea score and \nCOPD assessment test \nscore in patients with \nCOPD. Int J Chron Ob-\nstruct Pulmon Dis 2015; \n10:1623\u2013 31. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/26316736  \n \u2022 Korea  \n\u2022 Patient*innen: mit COPD  \n \n\u2022 Studienstart: initiated in April 2012 \n \n\u2022 untersuchte Tests: CAT, mMRC  \n \n\u2022 Studientyp: Datenanalyse: data ob-\ntained from the Korean COPD Sub-\ngroup Study cohort (KOCOSS), mul ti-\ncenter  \n \n\u2022 Einschlusskriterien: n.a.  \n\u2022 Ausschlusskriterien: n.a. \n \n\u2022 prim\u00e4re Endpunkte:  \n- examine the discrepancy between \nthe mMRC and CAT scores in patients \nwith COPD,  n=790 \n \nThere was a significant correlation between the CAT and mMRC scores (P<0.01). How ever, \nthe correlation was not strong (R=0.49).  \n \nAn ROC curve was used to identify the CAT score that was best correlated with the mMRC \nscore. For an mMRC score of 2, a CAT score of 15 showed the maximum value of Youden\u2019s \nindex with a sensitivity and specif icity of 0.70 and 0.66, respectively (area under the ROC \ncurve [AUC] 0.74; 95% confidence interval [CI], 0.70\u2013 0.77; P,0.01).  \nFor an mMRC score of 1, a CAT score of 10 showed the maximum value of Youden\u2019s index \nwith a sensitivity and specificity of 0.77 and 0.65, respectively (AUC 0.77; 95% CI, 0.72\u2013 0.83; \nP,0.01; Figure 3).  \n \nCAT score of 15 was the best cutoff point for an mMRC score of 2, and a CAT score of 10 was \nthe best cutoff point for an mMRC score of 1. Among four different combinations of CAT and \nmMR C scores, a CAT score of 10 was most concordant with an mMRC score of 1 when classi-\nfying patients with COPD into GOLD groups A \u2013D. However, a discrepancy remains between \nthe CAT and mMRC scores. The results of the present study suggest that the GOLD commit-\ntee needs to consider whether to lower the mMRC cutoff point to 1 or even to discard mMRC.  \n \"Bias -Bewertung f\u00fcr nicht -verglei-\nchende Studien; AWMF 2016:  \n \n(I) prospektive Planung mit Proto-\nkoll: nicht eindeutig beschrieben  \n \n(II) konsekutiver Patientenein-\nschluss:  nicht eindeutig beschrie-\nben \n \n(II) transparentes, nicht -selekti-\nves Berichten in Bezug auf Pati-\nentencharakteristika, Interven tion \nund Ergebnis: ja \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  146 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n- identify the ideal CAT score that ex-\nhibits minimal discrepancy with the \nmMRC score,  \n- extent of agreement between the \nmMRC and the CAT scores in different \nsettings  \n >> h\u00f6herer cut -off beim CAT von >15 entspricht eher dem vom mMRC von>2 zur Klassi-\nfizierung  h\u00f6her symptomatischer Patient*innen  \nXie G. New disease se-\nverity classification of pa-\ntients with stable chronic \nobstructive pulmonary \ndisease in Shanghai. \nChin Med J (Engl) 2014; \n127(17):3046\u2013 50. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/25189943  \n \u2022 Shanghai  \n\u2022 Patient*innen mit stabiler COPD  \n \n\u2022 Studienstart/Studienende:  1/2013\u2013\n6/2013 \n \n\u2022 untersuchte Tests: CAT, mMRC \n(assessment of symptom level)  \n \n\u2022 Studientyp : clinical study, multicen-\nter \n \n\u2022 Einschlusskriterien: met the diag-\nnostic criteria for COPD and had re-\ncovered for at least 12 weeks since the \nlast exacerbation  \n\u2022 Ausschlusskriterien: (1) patients \nwith reading and communication disor-\nders; and (2) patients unable to com-\nplete lung function tests  \n \n\u2022 prim\u00e4rer Endpunkt: To evaluate the \nclinical value of GOLD 2011 classifica-\ntion, a multicenter clinical study was \nconducted in patients with stable \nCOPD \n n=848  \n \nResults of Kappa test showed that using mMRC  grade=1 and CAT score=10 as cutoff points, \nthe coincidence rate of COPD symptom assessment was 86.6% (734/848, \u03ba=0.706), whereas \nusing mMRC grade=2 and CAT score=10 as cutoff points, the coincidence rate of COPD \nsymptom assessment was 77.9% (661/848, \u03ba=0.60). The above results indicate that the as-\nsessment of COPD symptom level with mMRC grade=1 and CAT score=10 as cutoff points \nwas more consistent compared with MRC grade=2 as cutoff point.  \n \n>> mMRC=1 korrespondiert besser mit CAT = 10  bei der Symptomschwereabsch\u00e4tzung \nvon Patienten mit COPD  \"Bias -Bewertung f\u00fcr nicht -verglei-\nchende Studien; AWMF 2016:  \n \n(I) prospektive Planung mit Proto-\nkoll: nicht eindeutig beschrieben  \n \n(II) konsekutiver Patientenein-\nschluss: nein \n \n(II) transparentes, nicht -selekti-\nves Berichten in Bezug auf Pati-\nentencharakteristika, Intervention \nund Ergebnis:  ja \n \nPrice DB. Real -world \ncharacterization and dif-\nferentiation of the Global \nInitiative for Chronic Ob-\nstructive Lung Disease \nstrategy classification. Int \u2022 multicenter: Patients were recruited \nin France (254, 15.3%), Germany \n(454, 27.3%), Italy (209, 12.6%), Spain \n(302, 18.2%), UK (52, 3.13%), and the \nUS (388, 23.39%).  \n\u2022 Patient*innen: mit COPD  \n n=1659  \n \nGOLD -recommended cut point  \nOut of the total 1,659 patients, there were 890 (53.65%) movers under the GOLD recom-\nmended cut points (GOLD -recommended mMRC cut point \u22652 versus the GOLD -recommended \nCAT cut point of \u226510), three (0.34%) patients moved left, from mMRC higher symptomatic \"Bias -Bewertung f\u00fcr nicht -verglei-\nchende Studien; AWMF 2016:  \n \n(I) prospektive Planung mit Proto-\nkoll: nicht beschrieben  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  147 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nJ Chron O bstruct Pulmon \nDis 2014; 9:551\u2013 61. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/24920893  \n \u2022 Studiendauer: 9/2012 - 12/2012  \n \n\u2022 untersuchte Tests: CAT, mMRC  \n \n\u2022 Studientyp: retrospektive Date-\nnanalyse: of COPD patient data from \nthe 2012 Adelphi Respiratory Dise ase \nSpecific Program (cross -sectional sur-\nveys)  \n \n\u2022 Einschlusskriterien f\u00fcr die \nGrundstudie:  the next six consulting \npatients of 40 years of age and older, \nwith a history of smoking and with a \nconfirmed diagnosis of COPD (COPD -\nonly or with mixed COPD and ast hma).  \n\u2022 Ausschlusskriterien f\u00fcr diese Ana-\nlyse:  with a mixed asthma diagnosis  \n \n\u2022 prim\u00e4rer Endpunkt: the degree of \nCAT and mMRC alignment given the \ncut points recommended by GOLD  \n\u2022 sekund\u00e4re Endpunkte: characterize \nthe patients who have a different \nGOLD classification depending on \nwhich instrument is used \u2013  the movers \n\u2013 and to determine a CAT cut point \nthat would more closely align the two \npopulations  \n GOLD groups B and D to the lower CAT -defined symptomatic GOLD groups of  A and C. Con-\nversely, 887 (99.66%) patients moved right from mMRC lower symptomatic GOLD groups A \nand C to the higher CAT defined symptomatic GOLD groups of B and D  \n \nROC- recommended cut point  \nOf the total number of patients who moved under the ROC -recommended cut point of \u226524 \n(429), 170 (39.63%) moved left from mMRC higher symptomatic groups B and D to the newly \ndefined CAT A and C lower symptomatic groups. The majority of patients, 259 (60.37%), still \nmoved to the right from mMRC lower symptomatic groups A  and C to the higher symptomatic \nROC CAT -defined groups B and D, albeit to a lesser degree \n \nKappa statistic- recommended cut point  \nOf the total number of patients who moved under the kappa statistic -recommended cut point of \n\u226526 (403), 230 (57.07%) patients moved left from mMRC higher symptomatic groups B and D \nto the newly defined CAT lower symptomatic groups A and C. Fewer patients 173 (42.92%) \nmoved to the right from mMRC lower symptomatic groups A and C to the higher symptomatic \ngroups of B and D defined by kappa statistic  \n \n>> CAT von \u226524 oder \u226526 entspricht mMRC \u22652  (II) konsekutiver Patientenein-\nschluss: ja  \n \n(II) transparentes, nicht -selekti-\nves Berichten in Bezug auf Pati-\nentencharakteristika, Intervention \nund Ergebnis:  ja \n \nJones PW. Characteris-\ntics of a COPD popula-\ntion categorised using the \nGOLD framework by \nhealth status and exacer-\nbations. Respir Med \n2014; 108(1):129\u2013 35. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/24041746  \n \u2022 France, Germany, Italy, Spain and \nthe UK \n\u2022 Patient*innen mit COPD  \n \n\u2022 Studiendauer: 6/2011- 9/2011 \n \n\u2022 untersuchte Tests: CAT, mMRC  \n \n\u2022 Studientyp. Datenanalyse: origi-\nnated from the Adelphi Respiratory \nDisease Specific Programme (DSP), n=1041  \n \nOur data show a very similar picture, with an mMRC score of 2 being approximately equal to a \nCAT score of 22. The mMRC \u2265 2 cut -point (On level ground, I walk slower than people of the \nsame age because of breathlessness, or have to stop for breath when walking at my own \npace) classified more patients as having low symptoms than using a CAT score \u2265 10. With the \nlatter, only 10% of patients were placed in the low symptom groups (GOLD groups A and C), \ncompared to using the mMRC \u2265  2 which placed 51% of patients in these groups.  \n \n>> CAT\u2265 22 entspricht mMRC \u22652  \n \"Bias -Bewertung f\u00fcr nicht -verglei-\nchende Studien; AWMF 2016:  \n \n(I) prospektive Planung mit Proto-\nkoll: keine Angaben  \n \n(II) konsekutiver Patientenein-\nschluss: ja  \n \n(II) transparentes, nicht -selekti-NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  148 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nan international, cross -sectional survey  \n \n\u2022 Einschlusskriterien: patients with a \nspirometric assessment, and com-\npleted exacerbation history, CAT and \nmMRC in the last year  \n \n\u2022 prim\u00e4rer Endpunkt:  examine the \ndistribution and clinical characteristics \nof COPD patients categorised accord-\ning to the 2011 GOLD assessment \nframework using data from a combined \nEuropean primary and secondary care \nroutine clinical practi ce patient popula-\ntion. \n >> keine \u00fcberschneidende Patientenkohorte mit Ref. 28139, da anderer Studienzeitraum \nanalysiert wurde  ves Berichten in Bezug auf Pati-\nentencharakteristika, Intervention \nund Ergebnis: ja \n \nJones PW. Comparisons \nof health status scores \nwith MRC grades in \nCOPD: Implications for \nthe GOLD 2011 classifi-\ncation. Eur Respir J \n2013; 42(3):647\u2013 54. \n \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/23258783  \n \u2022 Europe  \n\u2022 Patient*innen mit COPD  \n \n\u2022 Studiendauer: n.a. \n \n\u2022 untersuchte Tests: CAT, mMRC, \nSGRQ, SF -12, FACIT  \n \n\u2022 Studientyp: Datenalayse der Health-\nRelated Quality of Life in COPD in Eu-\nrope Study (HEED) database (large, \ncross -sectional, observational study)  \n \n\u2022 Einschlusskriterien: aged 40\u2013 80 \nyears; post bronchodilator FEV1/forced \nvital capacity (FVC) ratio of ,70%; \nsmoking pack history of o10 pack -\nyears  \n \n\u2022 prim\u00e4rer Endpunkt: test the equiva-\nlence, assumed by GOLD, between \nthese two symptom cut -points, by ex-\namining the relationship between \nhealth status scores and mMRC \ngrades  n=1817  \n \nPatients in all four groups, as categorised by the mMRC \u2265 2 cut -point, had worse health status \nscores and more fatigue (encompassing tiredness, weakness and difficulty in conducting usual \nactivities), compared with the equivalent group categorised by a CAT score \u2265 10.  \n \nProportion of patients in each GOLD group using CAT score  \u226510 and mMRC grade  \u22652 symp-\ntom cutpoints (GOLD recommendation):  \nThe proportion of patients categor ised into groups A to D differed according to the use of a \nGOLD symptom cut -point of mMRC grade \u2265 2 or CAT score \u2265 10.  The mMRC classified \n57.2% patients as having low symptoms (groups A and C), compared with 17.2% with the \nCAT. Concordance analysis comparing the frequencies of patients categorised by these two \nvariables, the mMRC grade \u2265 2 and CAT score \u2265 10 cut -points, resulted in a weighted k -coeffi-\ncient of 0.626.  \n \nProportion of patients in each GOLD group using CAT score  \u226510 and mMRC grade  \u22651 symp-\ntom cutpoints (amended criteria):  \nAs an exploratory exercise, health status scores were investigated when patients were catego-\nrised using a mMRC cut -point of grade \u22651. Using this cut -point, patients categorised by mMRC \ngrade \u22651 had similar mean health status and fatigue scores to those found with a CAT score \ncut-point of \u226510.  \nUsing this cut -point, the proportion of patients categorised in to groups A to D was similar to \nthat with the CAT. mMRC grade \u22651 classified 18.9% of patients as having low symptoms \n(grou ps A and C) compared with 17.2% with the CAT. Concordance analysis comparing the \nfrequencies of patients categorised by these two variables, the mMRC grade \u22651 and CAT \"Bias -Bewertung f\u00fcr nicht -verglei-\nchende Studien; AWMF 2016:  \n \n(I) prospek tive Planung mit Proto-\nkoll: nicht beschrieben  \n \n(II) konsekutiver Patientenein-\nschluss: nicht beschrieben  \n \n(II) transparentes, nicht -selekti-\nves Berichten in Bezug auf Pati-\nentencharakteristika, Intervention \nund Ergebnis: ja \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  149 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n\u2022sekund\u00e4re Endpunkte:  to compare \nthe demographic and clinical charac-\nteristics and  \nhealth status scores of patients \ngrouped using the new GOLD com-\nbined assessment framework  \n score \u226510 cut -points, resulted in a weighted kcoefficient of 0.792; indicating that there  was a \nhigher degree of agreement between these variables and their respective cut -points than be-\ntween the classification applying CAT \u226510 and mMRC \u22652.  \n \n>> CAT  \u226510 entspricht mMRC \u22651 \nAnhang 5.6  Angst/Depression \nDepression  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nMatte DL. Prevalence of \ndepression in COPD: A \nsystematic review and \nmeta- analysis of con-\ntrolled studies. Respir Med \n2016; 117:154\u2013 61. \n \nhttps://www.ncbi.nlm.nih.g\nov/pubmed/27492526  \n \u2022 Brasilien  \n\u2022 Metaanalyse, n=8 controlled studies (Cross -sectional studies)  \n \n\u2022 Ziel: this study aimed to perform a systematic review and meta- anal-\nysis of the literature on depression prevalence in COPD using stricter \ninclusion criteria for article selection than those described in previous \nmetanalysis. We also sought to explore remaining causes of inter -\nstudy variability in the reported prevalence.  \n \n\u2022 Suchzeitraum: inception - 01/01/2015 \n \n\u2022 Population:  Patient*innen mit stabiler COPD  \n \n\u2022 Einschlusskriterien:  \n- controlled studies with a sample size >100, outpatients with COPD \ndiagnosed by spirometry (post -bronchodilator FEV1/FVC \u2264 0.7) and, \nuse of a validated depression screening instrument  \n\u2022 depression determined by standardized and widely used criteria \n(e.g., SCID - DSM) or by a validated depression questionnaire (e.g., \nCES-D, GDS, HADS -D,SDS (Zung), HRSD)  \n \n\u2022 Ausschlusskriterien:  \n- Studies focused on  subpopulations, such as patients on continuous \noxygen therapy, included COPD patients recovering from an exacer-\nbation and/or hospital admission at the time of evaluation, comprising \nconvenience samples, focusing on pre- existing conditions that poten-\u2022 Using stricter criteria for study selection reduced the variability \nof the depression prevalence in COPD and controls, which was \n27.1% [25.9- 28.3] in COPD subjects  and 10.0% [9.2- 10.8] in the \ncontrol group. The pooled odds ratio and 95% CI was 3.74 [2.4-\n5.9] \n \n\u2022 high heterogeneity across studies:  Possible explanatory factor \nincluded sample s izes, COPD/controls ratio, smoker\u2019s/nonsmok-\ners ratio and qualitative differences (source of subjects, instru-\nments to screen depression, COPD severity, smoking status, and \ncomorbidities)  \n \n\u2022 Subgroup analysis comparing the prevalence of depression in \nCOPD su bjects according to disease severity was described in all \nincluded studies.  After adjustment for confounders disease se-\nverity was associated with higher prevalence of depression in five \nstudies  \n \n\u2022 \"authors conclusion\": The current systematic review of the lit-\nerature, based on controlled well conducted studies, provides evi-\ndence suggesting that the use of stricter criteria reduces the vari-\nability of the estimates of depression prevalence in COPD sub-\njects and controls. However, the observed lack in matching clini-\ncal variables that might increase the prevalence of depression \nand the absence of uniformity in choosing the instruments used to \nscreen depression in COPD subjects indicate that standardization \nis critical to improve the accuracy of the estimates and to allow \ncomparisons among studies.  ca-y-y-n-n-y-y-y-y-n-n \n \n \nAMSTAR- Score: 6/11  \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  150 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \ntially could increase the risk for depression (such as living alone, hav-\ning cancer)  \n \n\u2022 Body of Evidence :  n=8 controlled studies (n=5.552 COPD subjects \nand n=5.211 controls)   \nAngst  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nWillgoss TG. Anxiety dis-\norders in patients with \nCOPD: A systematic re-\nview. Respir Care 2013; \n58(5):858\u2013 66. \n \nhttps://www.ncbi.nlm.nih.g\nov/pubmed/22906542  \n \u2022 United Kingdom  \n\u2022 keine Metaanalyse, prospective studies  \n \n\u2022 Ziel: The aim of this systematic review is to synthesize the available \nliterature in order to estimate the prevalence of clinical anxiety and \nspecific anxiety disorders in patients with COPD.  \n \n\u2022 Suchzeitraum:  1966 - 31/01/2012 \n \n\u2022 Population: Patient*innen mit COPD (im -patient & out -patient)  \n \n\u2022 Einschlusskriterien: prospective studies, had diagnosed anxiety \ndisorders from a clinical interview using a recognized psychiatric for-\nmat (eg, Diagnostic and Statistical Manual of Mental Disorders -IV or \nprevious versions of DSM, or International Classification of Diseases, \n10th Revision), published in English \n \n\u2022 Body of Evidence: n=10 studies (prospective studies = inclusion cri-\nterion)),  n=691 subjects  \n \n\u2022 Herkunft der Stud ien: Nigeria, Turkey, New Zealand, US, Germany, \nCanada, Australia, UK  \u2022 Clinical Anxiety Disorder  \n- The prevalence of clinical anxiety ranged from 10\u2013 55% (median \n17%; n=8 studies)  \n- clinical anxiety in in-patients  varied from 10\u2013 55% (n=4 studies)  \n- preval ence of clinical anxiety in out -patient  ranged from 13\u2013 46% \n(n=4 studies)  \n n-y-y-n-n-y-n-n-na-n-n \n \n \nAMSTAR- Score: 3/10  \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  151 \n      \n \nAnhang 6  Evidenztabellen Tabakentw\u00f6hnung  \nAnhang 6.1  Cochrane Review  Tabakentw\u00f6hnung \nQuelle  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nvan-Eerd -Eva AM. \nSmoking cessation \nfor people with \nchronic obstructive \npulmonary disease. \nCochrane Data-\nbase of Systematic \nReviews 2016;(8).  \n \u2022 Fragestellung:  To evaluate the effectiveness \nof behavioural or pharmacological smoking ces-\nsation interventions, or both, in smokers with \nCOPD \n \n\u2022 Body of Evidence:   \n- n= 16 eingeschlossene RCTs (n=13.123 \neingeschlossene Teilnehmer);  \n- n=4 RCTs (n=1.540 Teilnehmer)  f\u00fcr \nMetaanalyse  \n \n\u2022 Suchzeitraum:  03/2016 \n \n\u2022 Population: smokers with C OPD  \n \n\u2022 Einschlusskriterien:  \n- RCTs reporting at least 6 months of follow -up \nabstinence rates  \n- trials assessing the effectiveness of any behav-\nioural or pharmacological treatment, or both, in \nsmokers with COPD  \n \n\u2022 Interventionen:   \n>> categorised behavioural treatment as \u2019high\u2019 if \nmore than one prescheduled counselling ses-\nsion of greater than 10 minutes was offered with \nat least one face- to-face counselling session;  \nOtherwise we categorised the behavioural treat-\nment as \u2019low\u2019.  \n \n\u2022 Behavioural treatment vs. no treatment or \nusual care.  \n\u2022 One form of behavioural treatment vs. a differ-\nent form of behavioural treatment.  \n\u2022 Pharmacological treatment vs. placebo.  \n\u2022 Pharmacological treatment vs. a different phar-\nmacological treatment.  \u2022 Baseline -Charakteristika  \n- age: ranged from 48 to 66 years  \n \nBehavioural treatment vs. no treatment or usual care  \n- Prolonged abstinence at longest follow -up (6 month):  RR 25.38 (95% CI \n8.03, 80.22; n=3562 participants; 1 study; 44/1000 vs. 2/1000, GRADE: \nmoderate)  \n>> high- intensity behavioural treatment increased abstinence rates when \ncompared with usual care  \n>> high- intensity behavioural treatment increased abstinence rates when \ncompared to l ow-intensity behavioural treatment (17/42 vs. 8/43; RR 2.18 \n(95% CI 1.05 to 4.49)), 1 RCT, n=85 participants  \n \n \nOne form of behavioural treatment vs. a different form of behavioural \ntreatment  \n- Prolonged abstinence at longest follow -up (6- 12 month):  Not est imable \n(n=739 participants; 4 studies) >> No pooling due to clinical and statistical \nheterogeneity. Individual RR were 2.18 (1.05, 4.49), RR 0.97 (0.47, 1.99),RR \n1.09 (0.59, 2.04) , and RR not estimable. 3 of the 4 studies had a low risk of \nbias. 1 study had a high risk of bias due to poor adherence to the study proto-\ncol \n \nPharmacological treatment  + behavioural treatment  vs. placebo  + be-\nhavioural treatment  \n\u2022 Gesamt  \n- Prolonged abstinence at longest follow -up (6- 12 month): RR 2.53 (95%CI \n1.83, 3.50; n=1429 participants; 4 studies; 168/1000 vs. 66/1000, GRADE: \nhigh)  \n \n\u2022 nicotine replacement therapy  \n- Prolonged abstinence at longest follow -up (12 month): RR 2.60 (95%CI \n1.29, 5.24; n=370 participants; 1 study; GRADE: high ) \n \n\u2022 bupropion  \n- Prolonged abstinence at longest follow -up (6 month): RR 2.03 (95%CI 1.26, \n3.28; n=503 participants; 2 studies; GRADE: moderate ) \n AMSTAR -Score gesamt: \n11/11 \n \ny-y-y-y-y-y-y-y-y-y-y \n Als sekund\u00e4rer End-\npunkt wurde bei ei-\nnigen Vergleichen \nauch die Point pre-\nvalence abstinence \nat longest follow -  up \ndargestellt  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  152 \n      \n \nQuelle  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n\u2022 Comparison of different combinati ons of be-\nhavioural and pharmacological treatments.  \n \n\u2022 Prim\u00e4rer Endpunkt:  \n- Percentage of participants with continuous or \nprolonged abstinence over a period of six \nmonths or longer.  \n \n\u2022 Sekund\u00e4rer Endpunkt:  \n- Percentage of participants with point preva-\nlence abstinence over a period of six months or \nlonger.  \n \u2022 varenicline  \n- Prolonged abstinence at longest follow -up (12 month): RR 3.34 (95%CI \n1.88, 5.92; n=504 participants; 1 study; GRADE: high ) \n \n\u2022 nortripty line \n- Prolonged abstinence at longest follow -up (6 month): RR 2.54 (95%CI 0.87, \n7.44; n=100 participants; 1 study: GRADE: low ) \n \nPharmacological treatment vs. a different pharmacological treatment  \n- Prolonged abstinence at longest follow -up (6- 12 month): N ot estimable \n(n=166 participants; 2 studies) >> No pooling due to clinical and statistical \nheterogeneity.  \n- NRT vs bupropion RR 0.74 (95% CI 0.27, 2.05),  \n- bupropion vs nortriptyline RR 1.29 (95% CI 0.63, 2. 63).  \n1 study had a high risk of bias due to poor adherence to the study protocol. 1 \nstudy had an unclear risk of bias  \n \nCombination interventions vs. different (combination) interventions or \nusual care  \n- Prolonged abstinence at longest follow -up (6- 60 month): Not estimable \n(n=6431 participants; 4 stud ies) >> No pooling due to clinical and statistical \nheterogeneity. Individual RR 4.10 (3.36, 5.00) , RR 2.22 (1.06, 4.68) , RR \n1.91 (0.65, 5.61), and RR not estimable. 3 studies had a low risk of bias, 1 \nstudy had a high risk of bias due to poor adherence t o the study protocol  \n \nAnhang 6.2  Suchupdate Cochrane Review Tabakentw\u00f6hnung  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nEllerbeck EF, Nollen \nN, Hutcheson TD, et \nal. Effect of Long-\nterm Nicotine Re-\nplacement Therapy \nvs Standard Smoking \nCessation for Smok-\ners With Chronic \nLung Disease: A \nRandomized Clinical \nTrial. JAMA network \u2022 Ziel:  To compare the effect of LT -NRT vs \nstandard smoking cessation (SSC) on expo-\nsure to cigarette smoke, harm related to \nsmoking, and cessation among smokers \nwith COPD  \n \n\u2022 Studiendesign: unblinded RCT  \n \n\u2022 Population:  Smokers with COPD (n=398)  \n\u2022 Intervention:  \n- Longterm nicotine replacement therapy \u2022 Baseline -Patientencharakteristika:  hinsichtlich Alter, Geschlecht, Faktoren zur \nEinsch\u00e4tzung des Rauchverhaltens weitestgehend ausgeglichen  \n \n- 59.8% female; mean [SD] age, 56.0 [9.3] years  \n- mean (SD) CPD was 23.1 (12.3)  \n- Participants completed assessments at baseline and 3, 6, and 12 months [...] re-\nceived $50 for each visit.  \n \nAt 12 months,  CO-verified 7- day point prevalence abstinence occurred in \nSSC:  23 of 197 participants (11.7%)  \nLT-NRT:  in 24 of 197 paticipants(12.2%) (risk difference, 0.5%; 95% CI, \u22125.9% to Selection bias  \nRandomisierung:  gering   \nAllocation concealment: gering   \nPerformance bias \nVerblindung von Teilnehmern und Personal:  \nhoch  \nDetection bias  \nVerblindung der Ergebnisevaluation: unklar   \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Da-\nten: gering  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  153 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nopen 2018; \n1(5):e181843. DOI: \n10.1001/jamanetwork\npen.2018.1843.  \n \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/30646142 . \n \n (LT-NRT)  \n=12 months of NRT and 6 follow -up \ncounseling sessions regardless of initial will-\ningness to quit  \n- Participants who set a quit date received a \npersonalized quit plan, incorporating the use \nof NRT  \n- Regardless of whether participants set a \nquit date , follow -up telephone counseling \nwas provided at 1, 3, and 6 weeks and 9 \nmonths after baseline and in per son at \nmonths 3 and 6.  \n \n\u2022 Vergleich:   \n- standard smoking cessation (SSC)  \n= 10 weeks of NRT and 4 follow -up counsel-\ning sessions for those willing to make a quit \nattempt  \n- baseline session: motivational strategies to \nincrease readiness to quit.  \n- Participants who set a quit date received a \npersonalized quit plan, incorporating the use \nof NRT  \n- Participants who set a quit date  were pro-\nactively contacted for telephone counseling \n1, 3, 6, and 10 weeks after the baseline visit  \n \n\u2022 Beide Gruppen: Combination NRT  \n- nicotine patches (14- 42 mg)  plus 2 mg of \nnicotine gum and/or lozenges.  \n \n\u2022 Follow -up: 12-month (completed \n6.12.2016)  \n\u2022 Studienzeitraum:  23.5.2014 - 30.11.2015 \n\u2022 USA  \n\u2022 Definitionen:  \n- cigarettes smoked per day (CPD)  6.9%).  \n \nSelf-reported smoki ng cessation at 3, 6, and 12 months and 6- month sustained \nabstinence were not significantly different across treatment arms. In multivariate \nanalyses, only increased age was associated with higher rates of cessation (odds \nratio, 4.30; 95% CI, 2.25- 8.19; P < .001)  \n \n12 months: among the participants who continued to smoke, both groups reported \nsimilar reductions relative to baseline in  \n- self-reported CPD (LT -NRT group, \u221214.5; SSC group, \u221212.4 CPD)  \n- expired CO level (LT -NRT group, \u22127.8 ppm; SSC group, \u22125.5 ppm)  \n- NNAL excretion (LT -NRT group, \u221223.0%; SSC group, \u221221.7%).  \n>> During the 12- month follow -up, these changes were significantly different from \nbaseline, but did not differ significantly between groups.  \n \nSecondary Outcomes  \nCAT-Score  \n- both groups experienced similar improvements in respiratory symptoms over \ntime, with the mean COPD Assessment Test score improving by 4.6 points in the \nLT-NRT arm and 3.6 points in the SSC arm.  \n \nEmergency department visits /hospitalizations  \n- Similar numbers of parti cipants in the 2 treatment arms had 1 or more respira-\ntory-associated emergency department visits or hospitalizations during the 12 \nmonths of follow -up. Both groups reported similar frequency of quit attempts.  \n \n\u2022 Sicherheit: The frequency of major adverse c ardiac events was similar in both \ngroups. During the course of the study, 17 major adverse cardiac events occurred, \nincluding 1 death. Nine events occurred in the SSC group and 8 in the LT -NRT \ngroup. Six events occurred while participants were receiving NR T and 11 occurred \nwhile not receiving NRT. Three noncardiac deaths were attributed to COPD com-\nplications, lung cancer, and pulmonary aspiration.  ITT-Analyse: durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: gering   \nAndere Biasursachen  \nBaseline imbalance: gering  \nInteressenkonflikte/ Sponsoring:   grants \nfrom Patient -Centered Outcomes Research In-\nstitute (PCORI) and National Institutes of \nHealth (NIH); investigator -initiated trial  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  154 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nZarghami M, Taghi-\nzadeh F, Sharifpour \nA, et al. Efficacy of \nSmoking Cessation \non Stress, Anxiety, \nand Depression in \nSmokers with \nChronic Obstructive \nPulmonary Disease: \nA Randomized Con-\ntrolled Clinical Trial. \nAddiction & health \n2018; 10(3):137\u2013 47. \nDOI: \n10.22122/ahj.v10i3.6\n00. \n \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/31105911 . \u2022 Ziel: This study was aimed to investigate \nthe effectiveness of smoking cessation on \nstress, anxiety, and depression in smokers \nwith COPD.  \n \n\u2022 Studiendesign:  3 block -RCT \n\u2022 Population: elderly adult  Smokers with \nCOPD \n\u2022 Interventionen:  \n- guided self -change (GSC)  (n = 19)  \n-- 5 sessions: screening and assessment, \ndeciding to change, discussing risky situa-\ntions, identifying different solutions to action, \nand steps to the future.  \n-- 5 one- hour sessions over 5 weeks  \n \n- nicotine replacement therapy (NRT ) (n = \n19) \n-- Nicotine (Nicolife\u00ae) blisters (labeled 30 \ngums) included 2 mg nicotine in each gum  \n \n- combined GSC -NRT (n = 19)  \n \n\u2022 Follow -up: 29 weeks  \n \n\u2022 Iran  \n\u2022 Messmetho den:  \n- Transtheoretical Model (TTM) question-\nnaire,  \n- Fagerstrom Test for Nicotine Dependence \n(FTND),  \n- Depression Anxiety Stress Scale (DASS),  \n- the Beck Depression Inventory -II (BDI -II), \n- Hospital Anxiety and Depression Scale \n(HADS)  \n- exhaled carbon monoxide (CO  \u2022 Baseline -Patientencharakteristika:  hinsichtlich Alter, sozialen Faktoren, t\u00e4gli-\nchem Zigarettenkonsum, Angst und Depressions -Einsch\u00e4tzungen keine signifi-\nkanten Unterschiede \n \n- mean of 23 daily cigarette (range of 5- 60) \n- Mean duration of smok ing: 32.9 years (range of 9- 59) \n- 57 men (mean age of 53.60 \u00b1 8.43)  \n \nSmoking cessation  \nGSC: A total of 9 (47.4%) participants in the GSC, 9 (47.4%) participants in com-\nbined groups, and 4 (21.1%) participants in the NRT group stated complete absti-\nnence from  smoking by the end of 29 weeks.  \n \n--> keine OR je Gruppe angegeben \n--> gesamt: the mean exhaled CO reduced from 22.6 \u00b1 1.5 to 12.8 \u00b1 0.9 and 8.6 \u00b1 \n0.7 ppm (P = 0.001) during the baseline, 12, and 29 weeks.  \n \n>>OR of smoking cessation in GSC and GSC -NRT grou ps decreased more than \nNRT group. In addition, DASS, FTND, and the exhaled CO in GSC and GSC -NRT \ngroups showed a better performance compared with the NRT group.  \n \n>> \u00c4nderung zum Protokoll  \n- laut IRCT Register: prim\u00e4rer Endpunkt: Smoking Cessatio Rate; alle anderen \nEndpunkte als sekund\u00e4r deklariert  \n- in Publikation: depression, anxiety, and stress changes, smoking cessation rate \nals prim\u00e4re Endpunkte beschrieben \n Selection bias  \nRandomisierung: gering   \nAllocation concealment: gering   \nPerformance bias \nVerblindung von Teilnehmern und Personal:  \nhoch  \nDetection bias  \nVerblindung der Ergebnisevaluation:  unklar  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Da-\nten: unklar   \nITT-Analyse: durchgef\u00fchrt; Studie gepowert  \nReporting bias  \nselektive Ergebnisdarstellung: hoch  \nAndere Biasursachen  \nBaseline imbalance:  gering  \nInteressenkonflikte/ Sponsoring: no CoI  \nweiteres: \u00c4nderung im Protokoll vs. Publika-\ntion (siehe Kommentar)  \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  155 \n      \n \nAnhang 6.3  Besprechung von Lungenfunktion oder CO -Werten  (aus [17]) \nErster  \nAutor  Titel (gek\u00fcrzt)  EG Studientyp  Intervention  N Effekt AE Qualit\u00e4t  Finanzie-\nrung  Kommentar  \nKotz D, 2011  \n Smoking cessa-\ntion and develo-\npment of respi-\nratory health in \nsmokers scree-\nned with normal \nspirometry  3b \n L\u00e4ngsschnittun-\ntersuchung, \nNachbeobach-\ntung 2,4 Jahre  \n Bei Rauchern mit normaler Lun-\ngenfunktion wurde eine Lufu \ndurchgef\u00fchrt  \n 255 \n Bei normaler Lufu keine Reduk-\ntion der Quit -Rate  nein Keine Inter-\nvention, le-\ndiglich Be-\nobachtung  \u00f6ffentlich  Non-smoking was validated \nby carbon monoxide. Long \nfollow up. Allerdings keine \nIntervention daher auch \nkeine Randomisierung  \n \nToljamo T, \n2010  \n Early detection \nof COPD combi-\nned with indivi-\ndualized coun-\nselling for smo-\nking cessation: a \ntwo-year pros-\npective study.  3b \n Bei Rauchern \nwurde TE (moti-\nvational Intervie-\nwing) und Lufu \ndurchgef\u00fchrt. \nLufu wurde aller-\ndings nicht er-\nl\u00e4utert  bei \"gesunden\" rauchern mit > \n20 PY wurde eine Lufu durchge-\nf\u00fchrt \n 584 \n in multivariater Analyse war Ob-\nstruktion in Lufu nicht pr\u00e4diktiv \nf\u00fcr quitting, Pharmakotherapie \nsehr nein \n m\u00e4\u00dfig, da \nLufu nicht \nals Interven-\ntion \n \u00f6ffentlich  \n Lufu nicht besprochen. Kein \nRCT \n \nSundblad \nBM, 2010  \n Lung function \ntesting in-\nfluences the atti-\ntude toward \nsmoking cessa-\ntion. 2b \n L\u00e4ngschnittun-\ntersuchung , 3 \nMonate. Fragen \nzum Aufh\u00f6r-\nwunsch vor und \nnach Lufu  smokers, of whom 77 had \nCOPD, answered a question-\nnaire before, shortly after, and 3 \nmonths after performing a lufu  \n 513 \n Nach Lufu mehr Aufh\u00f6rwillige \n(52% vs 9%; p<0.0001). Quit \nrate nach 3 Monaten 30 vs 14%; \np=0,02)  \n nein \n gut, random \nsample, \naber nicht \nrandomisiert  \u00f6ffentlich  \n Prospektiv, Vergleichs-\ngruppe, allerdings keine \nRandomisation, und keine \n(kaum) COPD Patienten  \n \nKotz D, 2009  Efficacy of con-\nfronting smokers \nwith airflow limi-\ntation for smok-\ning cessation.  1b \n RCT, Effekt der \nIntervention \nnach 1 Jahr un-\ntersucht  Raucher mit Obstruktion in Lufu \nwurde randomisiert in control \noder confronting with Lufu  \nNumber randomised: n= 296  \n \nBehavioural treatment  \nA. Experimental Individual coun-\nselling, lung minimal intervention \nstrategy (L -MIS), by respiratory \nnurse, C ONFRONTATION with \nspirometry. FC1: day 1 (40 \nminutes) ; FC2: day 8 (40 \nminutes); TQD: day 14; FC3: \nday 15 (40 minutes); FC4: day 296 \n OR f\u00fcr biochemisch -validierte \nLangzeitabstinenz (12 Monate) \nder Gruppen mit vs. ohne Lufu \nKonfrontation war 0.96 (0.43\u2013\n2.18), p=0.961  \nOnly the experimental group \nwas confronted with their abnor-\nmal spirometry (mean forced ex-\npiratory volume in one second \n(FEV1) post -bronchodilator \n80.5% predicted, mean \nFEV1/forced vital capacity post \nbronchodilator 62.5%).  \n nein gut aber \nsample size \nm\u00e4\u00dfig. RCT.  \n \u00f6ffentlich  \n RCT mit guter Methodik. \nDurch follow up von 1 Jahr \nErgebnisse klinisch relevant. \nJedoch Verlust von power.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  156 \n      \n \nErster  \nAutor  Titel (gek\u00fcrzt)  EG Studientyp  Intervention  N Effekt AE Qualit\u00e4t  Finanzie-\nrung  Kommentar  \n22 (40 minutes). Telephone \ncounselling day 15 (5 to 15 \nminutes)  \nB. Control 1 Individual counsel-\nling, L- MIS, by respiratory nurse, \nNOCONFRONTATION with spi-\nrometry. FC1: day 1 (40 \nminutes); FC2: day 8 (40 \nminutes); TQD: day 14; FC3: \nday 15 (40 minutes); FC4: day \n22 (40 minutes). Telephone \ncounselling day 15 (5 to 15 \nminutes)  \nC. Control 2 Referral to GP for \nusual care, NO CONFRONTA-\nTION with spirometry  \n \nPharmacological treatment  \nA. Experimental Nortriptyline, 25 \nmg day 1 to 3; 50 mg day 4 to 7, \n75 mg day 8 to end of treatment \nperiod \nB. Control 1 Nortriptyline, 25 mg \nday 1 to 3; 50 mg day 4 to 7, 75 \nmg day 8 to end of tr eatment pe-\nriod \nC. Control 2 Nortriptyline, 25 mg \nday 1 to 3; 50 mg day 4 to 7, 75 \nmg day 8 to end of treatment pe-\nriod >> no diffe rence in cotinine -vali-\ndated prolonged abstinence rate \nbetween the experimental group \n(11.2%) and control group 1 \n(11.6%) from week 5\u2013 52 (OR \n(95% CI) 0.96, 0.43\u2013 2.18.  \n \n>> conclusion: The present \nstudy did not provide evidence \nthat the confrontational ap-\nproach increases the rate of \nlong- term abstinence from \nsmoking compared with an \nequally intensive treatment in \nwhich smokers were not con-\nfronted with spirometry. The \nhigh failure rates (o88%) high-\nlight the need for treating to-\nbacco addiction as a chronic re-\nlapsing disorder.  \nvan der Aalst \nCM, 2010  \n Lung cancer \nscreening and \nsmoking absti-\nnence: 2 year \nfollow -up data \nfrom the Dutch-\nBelgian random-\nised controll ed 2b \n historischer Ver-\ngleich, RCT  \n CT screening  \n 1284  \n 16,6% der Studienteilnehmer \nhaben aufgeh\u00f6rt zu rauchen \n(historischer Vergleich 3- 7%) \n kein \n gut, gro\u00dfer \nRCT \n \u00f6ffentlich  \n CT-screening wird in der \no.g. Empfehlung nicht \n(mehr) abgebildet. Nur histo-\nrischer Vergleich der Rauch-\nstopp- Raten.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  157 \n      \n \nErster  \nAutor  Titel (gek\u00fcrzt)  EG Studientyp  Intervention  N Effekt AE Qualit\u00e4t  Finanzie-\nrung  Kommentar  \nlung cancer \nscreening trial.  \nSchook RM, \n2010  \n The finding of \npremalignant le-\nsions is not as-\nsociated with \nsmoking cessa-\ntion in chemo-\nprevention study \nvolunteers.  2b \n Retrospective \nAuswertung \neiner Chemo-\npreven-\ntionsstudie   188 \ncur-\nrent \nsmo-\nker \n Univariate regression demon-\nstrated that smoking cessation \nwas only associated with male \ngender.  \n nein \n Lediglich \nRegression-\nsanalyse    \nParkes G, \n2008 Effect on smok-\ning quit rate of \ntelling patients \ntheir lung age: \nthe Step2quit \nrandomised con-\ntrolled trial.  1b RCT with 5 GP \nin UK  \n Lung age vs FEV1  561 13.6% and 6.4% (difference \n7.2%, P=0.005, 95% confidence \ninterval 2.2% to 12.1%; number \nneeded to tr  nein Sehr gut, 12 \nMonate Na-\nchbeobach-\ntung \u00f6ffentlich  Exzellenter britisher RCT. \nObjektiv verifizierter End-\npunkt. Intervention war be-\nsonders effektiv bei denen \nmit schlechter Lufu. Aller-\ndings wurde eine Patienten-\ngruppe aus Hausarztpraxen \nin die Studie eingeschlos-\nsen, die relativ jung war und \n\u00fcberwiegend eine normale \nLungenfunktion hatte (FEV1 \n89-90%, FEV1/FVC 73-\n75%), also keine COPD -Pa-\ntientengruppe.  \nZudem spielt Selektionsbias \neine Rolle, weil nur Patien-\nten an der Studie teigenom-\nmen hatten, mit Interesse an \neiner Lungenfunktionsmes-\nsung.  \nBize R, 2007  Effecti veness of \nbiomedical risk \nassessment as \nan aid for smok-\ning cessation: a \nsystematic re-\nview.  3a Metaanalyse \nvon 2007 mit Lit. \nbis 2004   8 \nStu-\ndien \nzT \nschl\nech-\nter f\u00fcr einzelne Interventionen wie \nCO Bestimmung oder Lufu \nkeine Signifikanz   Gut, aber \u00e4l-\nter (von \n2007) und \nhat daher \nwichtige \nStudien \nnicht erfasst   Aktuelle RCT nicht in Me-\ntaanalyse erfasst  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  158 \n      \n \nErster  \nAutor  Titel (gek\u00fcrzt)  EG Studientyp  Intervention  N Effekt AE Qualit\u00e4t  Finanzie-\nrung  Kommentar  \nQua-\nlit\u00e4t \nCarpenter \nMJ, 2007  Does genetic \ntesting result in \nbehavioral \nhealth change? \nChanges in \nsmoking behav-\nior following \ntesting for alpha-\n1 antitrypsin de-\nficiency.  2b Nicht random-\nisierte prospek-\ntive Intervention  Testen auf alpha AT mangel bei \nRauchern n=19\n9 \n Smokers who tested severely \nAAT deficient were significantly \nmore likely to report a 24- hr quit \natte \n   Alpha 1 foun-\ndation Besprechung der Lufu war \nhier nicht die Intervention.  \nTaylor KL, \n2007 Lung cancer \nscreening as a \nteachable mo-\nment for smok-\ning cessation.  \n 3b Lung cancer \nscreening wohl \nretrospectiv aus-\ngewertet   two \nsam\nples: \nn=14\n4 \nn=16\n9 At 1-month follow -up, more \nready to stop smoking (p < .05). \nOther sample: in younger partic-\nipants     Besprechung der Lufu war \nhier nicht die Intervention.  \n \nvan der Aalst, \n2011 The impact of a \nlung cancer \ncomputed to-\nmography \nscreening result \non smoking ab-\nstinence.  1b RCT \n CT screening  \n 990 \n prolonged abstinence rate in \nsmokers receiving a negative \ntest (46 (8.9%) out of 519 sub-\njects)  kein gut \u00f6ffentlich  Besprechung der Lufu war \nhier nicht die Intervention.  \n \nErg\u00e4nzt durch Leitliniengruppe NVL COPD.  \nAnhang 6.4  E-Zigaretten Schadenspotential  \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nCardenas VM, Fisch-\nbach LA, Chowdhury \nP. The use of elec-\ntronic nicotine deliv-\nery systems during Systematic \nReview  INTRODUCTION  Use of electronic nicotine delivery systems (ENDS) among \npregnant women is of great concern. To our knowledge the current literature \nprovides conflicting views regarding the uncertainties of the effects of ENDS \nuse during pregnancy on the health of the fetus.  \nMETHODS  We searched PubMed, CINAHL, and EMBASE, for the period \u2022 electronic nicotine delivery systems = ENDS  \n- In a mailed survey of US providers, 53% reported screening pregnant women \nat intake for use of ENDS and other emerging tobacco product use all or some \nof the time. Of these providers, 14% reported that ENDS use had no adverse \nhealth effect s [England LJ, Anderson BL, Tong VT, et al. Screening practices NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  159 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \npregnancy and the \nreproductive out-\ncomes: A systematic \nreview of the litera-\nture. Tobacco in-\nduced diseases \n2019; 17:52. DOI: \n10.18332/tid/104724. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/31582941 . 2007 to October 2017 for terms to identify publications on ENDS use du ring \npregnancy and the reproductive outcomes. We updated the search for the pe-\nriod November 2017 to November 2018 using Ovid Medline. We obtained full \ntext of articles and present a summary of the contents.  \nRESULTS  We found no studies of pregnant women exp osed to ENDS use and \nits effect on their fetus or neonates. However, there is a growing body of exper-\nimental studies in animals that suggest that nicotine in ENDS alters DNA meth-\nylation, induces birth defects, reduces the birth weight, and affects the devel-\nopment of the heart and lungs of their offspring. A large population- based co-\nhort study in the United States estimated that 5% of pregnant women were cur-\nrent ENDS users in 2014; most of them also smoked cigarettes. Surveys con-\nducted among practitioners indicate that there is a need to screen and counsel \npregnant women. Systematic reviews and meta- analysis of studies of women \nwho used smokeless tobacco during pregnancy suggest that prenatal nicotine \nalone is a risk factor for low birth weight, premature del ivery, and stillbirth.  \nCONCLUSIONS There were no previous studies assessing the reproductive \neffects of ENDS use during pregnancy. However, prenatal exposure to nicotine \nis known to be harmful to the fetus and the pregnancy.  and attitudes of obstetricians -gynecologists toward new and emerging tobacco \nproducts. Am J Obstet Gynecol. 2014;211(6):695.e1- 695.e7. \ndoi:10.1016/j.ajog.2014.05.041]  \n \n- CONCLUSIONS: Since the re are no current studies on the effects that ENDS \nuse has on pregnancy outcomes, one can only hypothesize, based on existing \nstudies on the reproductive effects of smokeless tobacco, that ENDS use by \npregnant women is not safe for their fetuses.  \n \nCarpenter MJ, Heck-\nman BW, Wahlquist \nAE, et al. A Natural-\nistic, Randomized Pi-\nlot Trial of E -Ciga-\nrettes: Uptake, Expo-\nsure, and Behavioral \nEffects. Cancer Epi-\ndemiol Biomarkers \nPrev 2017; \n26(12):1795\u2013 803. \nDOI: 10.1158/1055-\n9965.EPI -17-0460. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/29127080 . Naturalistic, \nRandomized \nPilot Trial  \n Background \u2014Most studies of electronic nicotine delivery systems (ENDS) \ncompare self -selected users vs. non- users. The few randomized studies to \ndate generally support a positive impact on reducing smoking behavior, but \nthese studies are focused on guided ENDS use. This study presents a ran-\ndomized naturalistic trial of ENDS with prospective outcomes of uptake and \nbehavioral changes in s moking.  \nMethods \u2014Adult smokers with minimal ENDS history were randomized in a \n2:1 ratio to receive product for 3 weeks (n=46), or not (n=22). Changes in nico-\ntine delivery (16mg vs. 24mg), midway through the study allowed a compelling \nopportunity to examine two ENDS products compared to control group. Pri-\nmary outcomes, assessed via daily diaries during sampling period and in- per-\nson lab visits over 4 months, included uptake and usage of ENDS, cessation-\nrelated outcomes, and exposure to smoke constituents.  \nResu lts\u2014All ENDS participants tried product at least once, with 48% of 24mg \nand 30% of 16mg using their assigned product for the entire sampling period. \nWithin 24mg ENDs group, 57% made an independent purchase of ENDS, vs. \n28% of 16mg, and 14% of control parti cipants (p=.01). Smokers in both ENDS \ngroups significantly reduced their smoking, whereas control participants did not \n(p=.03). Cessation behaviors (quit attempts, biologically verified abstinence) \nnumerically but not statistically favored ENDS participant s. \nConclusions \u2014Results suggest that cigarette smokers are willing to use \nENDS with trends towards reduced cigarette smoking and positive changes in \ncessation -related behaviors.  Adverse Events  \nDuring the course of the study, 11 24mg ENDS participants (52%) reported a to-\ntal of 21 adverse events, compared with 9 16mg ENDS participants (36%) who \nreported 17 adverse events, and compared with 8 control participants (36%) \nwho reported a total of 29 ev ents. Collapsed across both ENDS groups, the \nmost common side effects reported were cough (32%), nausea (24%) and \nmouth/throat irritation (16%), and in the control group, headache (24%), cough \n(21%) and mouth/throat irritation (17%). None of the adverse events resulted in \nstudy termination, or, amongst ENDS participants, early discontinuation of sam-\npling.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  160 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nD'Ruiz CD, Graff DW, \nYan XS. Nicotine de-\nlivery, tolerability and \nreduction of smoking \nurge in smokers fol-\nlowing short -term use \nof one brand of  elec-\ntronic cigarettes. \nBMC Public Health \n2015; 15:991. DOI: \n10.1186/s12889- 015-\n2349- 2. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/26424091 . randomized, \npartially sin-\ngle-blinded, 6-\nperiod crosso-\nver clinic al \nstudy  \n Background: This randomized, partially single- blinded, 6- period crossover \nclinical study of adult smokers compared the nicotine pharmacokinetics, im-\npacts on smoking urge and tolerability of various formulations of one brand of \ne-cigarettes with t hat of a tobacco cigarette.  \nMethods: Five e -cigarettes with different e- liquid formulations containing 1.6 % \nand 2.4 % nicotine and a conventional tobacco cigarette were randomized \namong 24 subjects under two exposure sessions consisting of a 30- min con-\ntrolled and a one- hour ad lib use period to assess plasma nicotine levels, im-\npacts on smoking urge and adverse events. The 30- min controlled use session \ncomprised an intensive use of the e- cigarettes with a total of 50 puffs taken \nevery 30 s for comparison to a single conventional cigarette having a typical \nmachine- measured nicotine yield (~0.8 mg). Ad lib product use conditions pro-\nvided insight into more naturalistic product use behaviors and their accompa-\nnying smoking urge reductions. Adverse events (AEs) were assessed by the \nPrincipal Investigator.  \nResults: Significant (p < 0.05) increases in plasma nicotine concentrations oc-\ncurred within 10 min of controlled e- cigarette use and significant (p < 0.001) re-\nductions from baseline smoking urge were observed within 5 min. E -cigarette \nand cigarette nicotine plasma levels were comparable for up to one hour of \nuse. After both sessions (90 min), nicotine exposure was the highest for the \ncigarette, with all e- cigarettes showing 23 % to 53 % lower plasma concentra-\ntions.  During controlled use, peak reduction in smoking urge for e cigs oc-\ncurred later than for the cigarette. After completion of both sessions, significant \nsmoking urge reduction persisted for most of the tested e- cigarettes, albeit at \nlevels lower than that provided by the tobacco cigarette. Nicotine content, vehi-\ncle differences, and the presence of menthol did not significantly affect smok-\ning urge reduction by the e- cigarettes.  \nNo subjects were discontinued due to AEs. The most frequently reported AEs \nevents included cough, throat  \nirritation, headache, and dizziness.  \nConclusions: Blood plasma nicotine levels obtained from short -term use of e \ncigarettes containing 1.6 % and 2.4 % nicotine were significant, but lower than \nthose of conventional tobacco cigarettes , yet the reduction in craving symp-\ntoms were broadly comparable. The types of AEs were consistent with other \nresearch studies of longer duration that have reported that use of e- cigarettes \nby adult smokers is well tolerated.  \nTrial Registration: http://Clin icalTrials.gov identifier: NCT02210754. Registered \n8 August 2014.  \u2022 Tolerability and reported adverse events  \nDuring the course of the study, a total of 38 subjects were exposed to one or \nmore of the study products. There were no serious adverse events reported and \nno subjects were discontinued due to AEs. Mild productuse-  emergent AEs were \nreported by 18 of 38 subjects provided a study product (including the lead- in pe-\nriod). The number of subjects reporting AEs was similar among products, rang-\ning from 3 to 10 subjects each, with slightly fewer subjects experiencing AEs fol-\nlowing use of the menthol -flavored product. The m ost frequent AE was cough , \nreported 20 times by 11 subjects (more commonly with use of an e- cigarette \nproduct than the tobacco cigarette), followed by throat irritation (8 reports by 5 \nsubjects) and headache  (6 reports by 5 subjects), and dizziness (5 reports by 4 \nsubjects). All AEs resolved without sequelae. The observed acute effects of the \nstudy products on blood pressure, heart rate and CO levels were previously re-\nported by the authors under a separate publication [24] where it was noted that \nheart rate and systolic and diastolic blood pressure were significantly elevated \nafter the use of the tobacco cigarette, but the elevation was less after use of \nmost of the e- cigarettes. Furthermore, it was also obser ved that the use of the e-\ncigarettes produced no increase the exhaled CO levels, whereas the cigarette \nsignificantly increased the exhaled CO more than eight (8) times above the \nbaseline.  \n \nD'Ruiz CD, Graff DW, \nRobinson E. Reduc-\ntions in biomarkers of randomized \ninto one of six \nstudy groups  Background:  Electronic cigarettes (e -cigarettes) are popular alternatives to \nconventional cigarettes among adult smokers wis hing to reduce their exposure \nto harmful smoke constituents. However, little information exists on the relative \u2022 Tolerability and adverse events  \nOverall, 72 mild product -use adverse events were experienced by 30 % of sub-NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  161 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nexpos ure, impacts on \nsmoking urge and as-\nsessment of product \nuse and tolerability in \nadult smokers follow-\ning partial or com-\nplete substitution of \ncigarettes with elec-\ntronic cigarettes. \nBMC Public Health \n2016; 16:543. DOI: \n10.1186/s12889- 016-\n3236- 1. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/27401980 .  internal exposures resulting from the exclusive or dual use of e -cigarettes.  \nMethods:  Measurements of product use; adverse events; changes in sm oking \nurge; and blood, urine and exhaled breath biomarkers of exposure (BoE) rep-\nresenting toxicants believed to contribute to smoking related diseases were \nmade at baseline and after five days of product use in 105 clinically -confined \nsmokers randomized into groups that partially or completely substituted their \nusual brand combustible cigarette with commercial e- cigarettes, or discontin-\nued all nicotine and tobacco products.  \nResults:  Subjects switching to e- cigarettes had significantly lower levels (29 \n%\u201395 %) of urinary BoEs after 5 days. Nicotine equivalents declined by 25 % \u2013\n40 %. Dual users who substituted half of their self -reported daily cigarette con-\nsumption with e- cigarettes experienced 7 % \u201338 % reductions, but had in-\ncreases (1 % \u201320 %) in nicotine equi valents. Blood nicotine biomarker levels \nwere lower in the cessation (75 % \u201396 %) and e- cigarette use groups (11 % \u201383 \n%); dual users had no significant reductions. All groups experienced significant \ndecreases in exhaled CO (27 % \u201389 %). Exhaled NO increases (46 % \u201363 %) \nwere observed in the cessation and e- cigarette use groups; dual users had \nminimal changes. By Day 5, all groups had greater reductions in smoking urge \ncompared to cessation. However, reductions were larger in the dual use group. \nNo serious adverse events were observed.  \nConclusions : Exposures to harmful smoke toxicants were observed to be \nlower in smokers who completely or partially replaced their cigarettes with e-\ncigarettes over five days. Keywords: Electronic cigarettes, Clinical trial, Bio-\nmarkers of  jects. The number of subjects reporting adverse events ranged from 2 to 7 sub-\njects each across groups receiving study products and only 1 s ubject in the ces-\nsation group. The most frequently reported adverse event was headache, re-\nported 15 times by 12 subjects across study groups. There were no individual \nclinically significant laboratory and post product administration physical examina-\ntion findings and or vital sign adverse events. Moreover, there were no serious \nadverse events and no subjects were discontinued due to adverse events.  \n \nEl Dib R, Suzumura \nEA, Akl EA, et al. \nElectronic nicotine \ndelivery systems \nand/or electronic non-\nnicotine delivery sys-\ntems for tobacco \nsmoking cessation or \nreduction: A system-\natic review and meta-\nanalysis. BMJ open \n2017; 7(2):e012680. \nDOI: \n10.1136/bmjopen-\n2016- 012680. \nhttp://www.ncbi.nlm.nSystematic \nReview  \n Objective: A systematic review and meta -analysis to investigate the impact of \nelectronic nicotine delivery systems (ENDS) and/or electronic non- nicotine de-\nlivery systems (ENNDS) versus no smoking cessation aid, or alternative smok-\ning cessation aids, in cigarette smokers on long- term tobacco use.  \nData sources:  Searches of MEDLINE, EMBASE, PsycInfo, CINAHL, CEN-\nTRAL and Web of Science up to December 2015.  \nStudy s election: Randomised controlled trials (RCTs) and prospective cohort \nstudies.  \nData extraction:  Three pairs of reviewers independently screened potentially \neligible articles, extracted data from included studies on populations, interven-\ntions and outcomes and assessed their risk of bias. We used the Grading of \nRecommendations Assessment, Development and Evaluation approach to rate \noverall certainty of the evidence by outcome.  \nData synthesis: Three randomised trials including 1007 participants and nine \ncohorts including 13 115 participants proved eligible. Results provided by only \ntwo RCTs suggest a possible increase in tobacco smoking cessation with \nENDS in comparison with ENNDS (RR 2.03, 95% CI 0.94 to 4.38; p=0.07; Adverse effects  \nSynthesised results from RCTs The Bullen 2013 study reported serious side ef-\nfects in 27 out of 241 participants in the 16 mg ENDS group and 5 out of 57 for \nthe ENNDS group followed at 6 months; results failed to show a difference be-\ntween these groups with a very wide CI (OR 1.31, 95% CI 0.48 to 3.57; p=0.59). \nResults sugges ted possible increase in side effects in the 21 mg nicotine \npatches group (14 of 215) in comparison with ENDS (OR 1.81, 95% CI 0.92 to \n3.55; p=0.08).  \n- Serious side effects include death (n=1, in nicotine e- cigarettes group), life \nthreatening illness (n=1, in nicotine e- cigarettes group), admission to hospital or \nprolongation of hospital stay (12% of all events in nicotine e- cigarettes group, \n8% in patches group and 11% in placebo e- cigarettes group), persistent or sig-\nnificant disability or incapacity and other medically important events (6% of all \nevents in nicotine e- cigarettes group, 4% in patches group and 3% placebo e-\ncigarettes group).  \n- Adriaens 2014 study reported no serious adverse events in ENDS groups as \nwell as in the e- liquid group at 8 months  of follow -up; however at 1 week from \nstart of intervention there were three cases of non -serious adverse events in the NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  162 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nih.gov/pub-\nmed/28235965 . I2=0%, risk difference (RD) 64/1000 over 6 to 12 months, low -certainty evi-\ndence).  \nResults from cohort studies suggested a possible reduction in quit rates with \nuse of ENDS compared with no use of ENDS (OR 0.74, 95% CI 0.55 to 1.00; \np=0.051; I2=56%, very low certainty).  \nConclusions: T here is very limited evidence regarding the impact of ENDS or \nENNDS on tobacco smoking cessation, reduction or adverse effects: data from \nRCTs are of low certainty and observational studies of very low certainty. The \nlimitations of the cohort studies led us to a rating of very low -certainty evidence \nfrom which no credible inferences can be drawn. Lack of usefulness with re-\ngard to address the question of e- cigarettes\u2019 efficacy on smoking reduction and \ncessation was largely due to poor reporting. This review underlines the need to \nconduct well -designed trials measuring biochemically validated outcomes and \nadverse effects.  \n ENDS groups.  \n- Caponnetto 2013 mentioned that no serious adverse events occurred during \nthe study and authors found a significant reduct ion in frequency of reported \nsymptoms compared with baseline.  \n \nSynthesised results from cohort studies  \n- Manzoli reported no significant differences in selfreported serious side effects, \nbut observed four cases of pneumonia, four COPD exacerbations, three myocar-\ndial infarctions and one angina as possibly related serious side effects: two \namong the ENDS users (both switched to tobacco smoking during follow -up); six \namong tobacco smokers (three quit all smoking) and four among tobacco and \nENDS smokers.  \n- Hajek 2015 reported one leak irritating a participant\u2019s mouth and some reports \nof irritation at the back of the throat and minor coughing. The remaining studies \ndid not report adverse effects.  \nFarsalinos KE, Gill-\nman G. Carbonyl \nEmissions in E -ciga-\nrette Aerosol: A Sys-\ntematic Review and \nMethodological Con-\nsiderations. Front \nPhysiol 2017; 8:1119. \nDOI: \n10.3389/fphys.2017.0\n1119. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/29375395 . Systematic \nReview  \n Carbonyl emissi ons from tobacco cigarettes represent a substantial health risk \ncontributing to smoking- related morbidity and mortality. As expected, this is an \nimportant research topic for tobacco harmreduction products, in an attempt to \ncompare the relative risk of thes e products compared to tobacco cigarettes. In \nthis study, a systematic review of the literature available on PubMed was per-\nformed analyzing the studies evaluating carbonyl emissions from e- cigarettes. \nA total of 32 studies were identified and presented. We  identified a large diver-\nsity of methodologies, with substantial discrepancies in puffing patterns, aero-\nsol collection and analytical methods as well as reported units of measure-\nments. Such discrepancies make comparisons difficult, and in some cases the \naccuracy of the findings cannot be determined. Importantly, control for the gen-\neration of dry puffs was not performed in the vast majority of studies, particu-\nlarly in studies using variable power devices, which could result in testing con-\nditions and reported carbonyl levels that have no clinical relevance or context. \nSome studies have been replicated, verifying the presence of dry puff condi-\ntions. Whenever realistic use conditions were ensured, carbonyl emissions \nfrom e -cigarettes were substantially lower than tobacco cigarette smoke, while \nnewer generation (bottom -coil, cotton wick) atomizers appeared to emit mini-\nmal levels of carbonyls with questionable clinical significance in terms of health \nrisk. However, extremely high levels of carbonyl emissions were r eported in \nsome studies, and all these studies need to be replicated because of poten-\ntially important health implications.  \n The main ingredients in e -cigarette liquids, propylene glycol (PG) and glycerol \n(VG) are known to be oxidized to carbonyls (Bekki et  al., 2014; Spencer and \nLauterbach, 2015). [\u2026]  \n- Some studies produced contradictory results.  \n-- Kosmider et al. (2014) found that VG liquids emitted lower carbonyl emissions \ncompared to PG liquids.  \n-- Geiss et al. (2015) found that VG liquids remitted higher carbonyl levels com-\npared to mixed PG/VG liquids  \n-- Wang et al. (2017) found higher levels of carbonyls in VG compared to PG liq-\nuids. VG has higher viscosity compared to PG and, unless diluted with water, it \nis possible that this might adversely affec t the liquid supply rate to the coil and, \nthus, create overheating conditions.  \n \nIn a study that generated a lot of publicity, Jensen et al. (2015) tested a \u201ctank \nsystem\u201d e -cigarette with a commercial ecigarette liquid (Halo \u201ccaf\u00e9 mocha\u201d fla-\nvor, 6 mg/mL nic otine concentration) for the presence of formaldehyde hemiace-\ntals. [...] Despite mentioning that the behavior of formaldehyde hemiacetals in \nthe respiratory tract are unknown, they assumed that the risk is similar to formal-\ndehyde and reported that the cancer risk of long term vaping  was \u201c5 times as \nhigh. . . or even 15 times as high. . . as the risk associated with long term smok-\ning\u201d when comparing 3mL liquid consumption with 20 tobacco cigarettes.  \nFern\u00e1ndez E, Ballb\u00e8 \nM, Sureda X, et al. \nParticulate Ma tter Systematic \nReview and Objectives  The aim of this study is to review the literature on the composition \nof aerosols from electronic cigarettes (ecigarettes) originated by human vaping \nand to describe the emission of particulate matter \u22642.5 \u03bcm in diameter (PM2.5) emissions from ecigarettes can contain potential toxic compounds such as \nnicotine, carbonyls, metals, and organic volatile compounds, besides par-\nticulate mat ter.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  163 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nfrom Electronic Ciga-\nrettes and Conven-\ntional Cigarettes: A \nSystematic Review \nand Observational \nStudy. Current envi-\nronmental health re-\nports 2015; 2(4):423\u2013\n9. DOI: \n10.1007/s40572- 015-\n0072- x. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/26452675 .Study  Observational \nStudy  \n from conventional and e -cigarettes at home in real -use conditions.  \nMethods We conducted a systematic literature search in PubMed and Web of \nScience. We measured PM2.5 in four different homes: one from a conventional \ncigarette smoker, one from an e- cigarette user, and two from non- smokers.  \nResults The review identified eight previous investigations on the composition \nof aerosols from e- cigarettes originated by human vaping and indicated that \nemissions from ecigarettes can contain potential toxic compounds such as nic-\notine, carbonyls, metals, and organic volatile compounds, besides particulate \nmatter. In the observational study, the PM2.5 median concentration was 9.88 \n\u03bcg/m3 in the e- cigarette user home and 9.53 and 9.36 \u03bcg/m3 in the smoke -free \nhomes, with PM2.5 peaks concurrent with the e-cigarette puffs.  \nConclusion Both the literature review and the observational study indicate that \ne-cigarettes used under real -conditions emit toxicants, including PM2.5. Fur-\nther research is needed to characterize the chemicals emitted by different \ntypes  of ecigarettes and to assess secondhand exposure to e- cigarette aerosol \nusing biological markers.  - In the observational study, the PM2.5 median concentration was 9.88 \u03bcg/m3 in \nthe e- cigarette user home and 9.53 and 9.36 \u03bcg/m3 in the smoke- free homes, \nwith PM2.5 peaks concurrent with the e- cigarette puffs.  \nFerrari M, Zanasi A, \nNardi E, et al. Short -\nterm effects of a nico-\ntine-free e- cigarette \ncompared to a tradi-\ntional cigarette in \nsmokers and non-\nsmokers. BMC Pulm \nMed 2015; 15:120. \nDOI: \n10.1186/s12890- 015-\n0106- z. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/26459355 . laboratory -\nbased study; \nrandomized; \ncross -over de-\nsign \n Background: A few studies have assessed the short -term effects of low -dose \nnicotine e cigarettes, while data about nicotine- free e- cigarettes (NF e -ciga-\nrettes) are scanty. Concerns have been expressed about the use of NF e- ciga-\nrettes, because of the high concentrations of propylene glycol and other com-\npounds in the e- cigarette vapor.  \nMethods: This laboratory -based study was aimed to compare the effects of ad \nlibitum use of a NF e- cigarette or and a traditional cigarette for 5 min in healthy \nadult smokers (n = 10) and non- smokers (n = 10). The main outcome \nmeasures were pulmonary function tests, fraction of exhaled nitric oxide \n(FeNO) and fractional concentration of carbon monoxide (FeCO) in exhaled \nbreath.  \nResults:  The traditional cigarette induced statistically significant increases in \nFeCO in both smokers and non- smokers, while no significant changes were \nobserved in FeNO. In non- smokers, the tr aditional cigarette induced a signifi-\ncant decrease from baseline in FEF75 (81 % \u00b1 35 % vs 70.2 % \u00b1 28.2 %, P = \n0.013), while in smokers significant decreases were observed in FEF25 (101.3 \n% \u00b1 16.4 % vs 93.5 % \u00b1 31.7 %, P = 0.037), FEV1 (102.2 % \u00b1 9.5 % vs 98.3 % \n\u00b1 10 %, P = 0.037) and PEF (109.5 % \u00b1 14.6 % vs 99.2 % \u00b1 17.5 %, P = \n0.009). In contrast, the only statistically significant effects induced by the NF e-\ncigarette in smokers were reductions in FEV1 (102.2 % \u00b1 9.5 % vs 99.5 \u00b1 7.6 \n%, P = 0.041) and FE F25 (103.4 % \u00b1 16.4 % vs 94.2 % \u00b1 16.2 %, P = 0.014).  \nDiscussion: The present study demonstrated that the specific brand of NF e-\ncigarette utilized did not induce any majoracute effects. In contrast, several \nstudies have shown that both traditional cigaret tes and nicotinecontaining e-\ncigarettes have acute effects on lung function. Our study expands on previous \u2022 several studies have shown that both traditional cigarettes and nicotinecontain-\ning e- cigarettes have acute effects on lung function  \n \n\u2022 nicotine- free e- cigarettes (NF e- cigarettes): The short -term use of the specific \nbrand of NF e- cigarette assessed in this study had no immediate adverse effects \non non- smokers and only small effects on FEV1 and FEF25 in smokers. The \nlong term health effects of NF e- cigarette use are unknown but worthy of further \ninvestigations.  \n \n\u2022 Diskussion: One of the concerns of using NF e- cigarettes is that the devices \ncontain high concentrations of glycol, which is a known irritant when inhaled. \nOther potentially dangerous ingredients that may be found in NF e- cigarettes ar e \nsolvents, genotoxins and various other chemicals  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  164 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nobservations on the effects of NF e -cigarettes, but also for the first time de-\nscribes the changes induced by smoking one traditional cigarette in a group of \nnever smokers.  \nConclusions: The short -term use of the specific brand of NF e- cigarette as-\nsessed in this study had no immediate adverse effects on non- smokers and \nonly small effects on FEV1 and FEF25 in smokers. The long term health ef-\nfects of NF e -cigarette use are unknown but worthy of further investigations  \nFlach 2019  \n \nE\u2010cigarettes and \nhead and neck can-\ncers: A systematic re-\nview of the current lit-\nerature \n Systematic \nReview  \n Background: Cigarette smoking is a well \u2010established risk factor for head and \nneck (HN) cancers. Use of electronic cigarettes (e\u2010 cigarettes) is gaining popu-\nlarity, being advertised as benign alternatives to tobacco. A wide variety of po-\ntentially harmful chemical components with variable quantity have been identi-\nfied in e\u2010 liquids and aerosols of e\u2010 cigarettes. However, use of e\u2010 cigarettes re-\nmains controversial due to conflicting evidence.  \nObjectives: We aimed to assess the association between e\u2010 cigarettes and HN \ncancers. We conducted a systematic review to evaluate the literature for evi-\ndence on carcinogenic effects of e \u2010cigarettes in the pathogenesis of HN can-\ncers.  \nType of review: Qualitative systematic review.  \nSearch strategy: A PubMed/MEDLINE, Cochrane, CINAHL Plus, Trip Medical \nDatabase and Web of Science search was done for studies on e\u2010 cigarettes \nand HN cancer.  Evaluation method: Abstract review of all articles, full article \nrevision of included studies, data extraction and quality assessment were per-\nformed by two independent assessors.  \nResults: The literature search result ed in the identification of 359 articles. \nEighteen articles were selected for inclusion into the systematic review. The \nmajority were laboratory \u2010based studies, followed by several cohort and case \nstudies, representing low \u2010level evidence. A few reports suggested DNA dam-\nage following exposure to ecigarettes potentially due to increased oxidative \nstress. Flavoured e\u2010 liquids appear to be more harmful. There is variable evi-\ndence from clinical studies.  \nConclusions: Our review outlines potential dangers associated with the use of \necigarettes and their role in HN cancers. More longitudinal and controlled stud-\nies are needed to assess the possible link between e\u2010 cigarettes and HN can-\ncers.  The current literature on the association between e \u2010cigarettes and HN cancer \npathogenesis is poor. There is limited evidence that e- cigarettes are harmful \nand potentially carcinogenic for the head and neck, with some reports stat-\ning that e\u2010 cigarettes can lead to in vitro damage and that flavoured e\u2010 liquids are \nparticularly damaging. T here is currently no good\u2010 quality evidence to conclude \nthat e\u2010 cigarettes are less harmful than conventional cigarettes.  \n \nGentry S, Forouhi \nNG, Notley C. Are \nElectronic Cigarettes \nan Effective Aid to \nSmoking Cessation Systematic \nReview  \n Introduction: Smoking prevalence remains high in s ome vulnerable groups, \nincluding those who misuse substances, have a mental illness, are homeless, \nor are involved with the criminal justice system. E -cigarette use is increasing \nand may support smoking cessation/reduction.  No serious adverse events were identified.  \nSome side effects were reported, commonly cough, headac he, and throat irri-\ntation . O\u2019Brien et al. compared adverse events/month among e- cigarette users \nwith and without mental illness and found no significant difference (0.05 events/ \nmonth in both groups (p = .592, IRR = 0.89, 95% CI = 0.59 to 1.35)). Adverse NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  165 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nor Reduction Among \nVulnerable Groups? \nA Systematic Review \nof Quantitative and \nQualitative Evidence. \nNicotine & tobacco \nresearch official jour-\nnal of the Society for \nResearch on Nicotine \nand Tobacco 2019; \n21(5):602\u2013 16. DOI: \n10.1093/ntr/nty054. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/29608714 . Methods: Systematic review of qu antitative and qualitative data on the effec-\ntiveness of e- cigarettes for smoking cessation/reduction among vulnerable \ngroups. Databases searched were MEDLINE, EMBASE, PsychINFO, CINAHL, \nASSIA, ProQuest Dissertations and Theses, and Open Grey. Narrative syn the-\nsis of quantitative data and thematic synthesis of qualitative data.  \nResults: 2628 records and 46 full texts were screened; 9 studies were identi-\nfied for inclusion. Due to low quality of evidence, it is uncertain whether e- ciga-\nrettes are effective for s moking cessation in vulnerable populations. A moder-\nate quality study suggested that e- cigarettes were as effective as nicotine re-\nplacement therapy. Four studies suggested significant smoking reduction; \nhowever, three were uncontrolled and had sample sizes below 30. A prospec-\ntive cohort study found no differences between e- cigarette users and nonus-\ners. No significant adverse events and minimal side effects were identified. \nQualitative thematic synthesis revealed barriers and facilitators associated with \neach component of the COM -B (capability, opportunity, motivation, and behav-\nior) model, including practical barriers; perceptions of effectiveness for cessa-\ntion/reduction; design features contributing to automatic and reflective motiva-\ntion; smoking bans facilit ating practical opportunity; and social connectedness \nincreasing social opportunity.  \nConclusion: Further research is needed to identify the most appropriate de-\nvice types for practicality and safety, level of support required in e- cigarette in-\nterventions, and to compare e cigarettes  \nwith current best practice smoking cessation support among vulnerable \ngroups.  \nImplications:  Smoking prevalence among people with mental illness, sub-\nstance misuse, homelessness, or criminal justice system involvement remains \nhigh.  E-cigarettes could support cessation. This systematic review found lim-\nited quantitative evidence assessing effectiveness. No serious adverse events \nwere identified. Qualitative thematic synthesis revealed barriers and facilitators \nmapping to each component of the COM -B (capability, opportunity, motivation, \nand behavior) model, including practical barriers; perceived effectiveness; de-\nsign features contributing  event counts were similar between nicotine e -cigarette, placebo e -cigarette, and \nNRT but small numbers prohibited significance testing. Caponetto et al. reported \nside effects experienced among people with mental illness resolved over time, \nbut no data beyond 52 weeks were available.  \n \nGlasser AM, Collins \nL, Pearson JL, et al. \nOverview of Elec-\ntronic Nicotine Deliv-\nery Systems: A Sys-\ntematic Review. Am J \nPrev Med 2017; \n52(2):e33- e66. DOI: \n10.1016/j.ame-\npre.2016.10.036. Systematic \nReview  \n Context \u2014Rapid developments in e- cigarettes, or electronic nicotine delivery \nsystems (ENDS), and the evolution of the overall tobacco product marketplace \nwarrant frequent evaluation of the published literature. The purpose of this arti-\ncle is to report updated findings from a comprehensive review of the published \nscien tific literature on ENDS.  \nEvidence acquisition \u2014The authors conducted a systematic review of pub-\nlished empirical research literature on ENDS through May 31, 2016, using a \ndetailed search strategy in the PubMed electronic database, expert review, \nand additional targeted searches. Included studies presented empirical find-\nings and were coded to at least one of nine topics: (1) Product Features; (2) There have been 116 articles that examine the impact of vaping on human \nhealth and 13 on animal health. Studies address physiologic and cognitive ef-\nfects of vaping, adverse events associated with vaping, exposure to secondhand \nvapor, and cytotoxicity of ENDS.  \n \n- Human exposure to some potentially harmful chemicals is significantly lower \nfor ENDS than for cigarettes. Laboratory studies (n=20) find modest increases \nin nicotine biomarkers after vaping.  \n- Some studies (n=13) have examined cardiovascular measures associated with \nvaping, with the majority finding an increase in heart rate , but three finding no NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  166 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/27914771 . Health Effects; (3) Consumer Perceptions; (4) Patterns of Use; (5) Potential to \nInduce Dependence; (6) Smoking Ces sation; (7) Marketing and Communica-\ntion; (8) Sales; and (9) Policies; reviews and commentaries were excluded. \nData from included studies were extracted by multiple coders (October 2015 to \nAugust 2016) into a standardized form and synthesized qualitatively by topic.  \nEvidence synthesis\u2014 There were 686 articles included in this systematic re-\nview. The majority of studies assessed patterns of ENDS use and consumer \nperceptions of ENDS, followed by studies examining health effects of vaping \nand product features.  \nConclusions \u2014Studies indicate that ENDS are increasing in use, particularly \namong current smokers, pose substantially less harm to smokers than ciga-\nrettes, are being used to reduce/quit smoking, and are widely available. More \nlongitudinal studies and control led trials are needed to evaluate the impact of \nENDS on population- level tobacco use and determine the health effects of \nlonger -term vaping.  \n chan ge after use.  \n \nAdverse events \n- The Food and Drug Administration received 35 adverse event reports ( respira-\ntory symptoms, eye irritation, headache, nausea, sore throat/irritation, diz-\nziness, racing/irregular heart rate)  of passive vapor exposure between Jan-\nuary 2012 and December 2014.  \n- Other studies report the most common adverse events associated with vaping \nas mouth and throat irritation, nausea, headache, and dry cough . \n- From 2012 to 2015, there were 92 reported overheating/fire/explosion  events \nin the U.S., and about half resulted in injuries ( i.e., thermal burns, lacerations, \nor smoke inhalation ). \nGualano MR, Passi \nS, Bert F, et al. Elec-\ntronic cigarettes: As-\nsessing the efficacy \nand the adverse ef-\nfects through a sys-\ntematic review of \npublished studies. J \nPublic Health (Oxf) \n2015; 37(3):488\u2013 97. \nDOI: 10.1093/pub-\nmed/fdu055. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/25108741 . Systematic \nReview  \n Background To investigate the efficacy and the adverse effects (AEs) of the \nelectronic cigarette, we performed a systematic review of published studies.  \nMethods  We selected experimental and observational studies examining the \nefficacy (as reduction of desire to smoke and/or number of cigarettes smoked \nand/or quitting or as reduction of nicotine withdrawal symptoms) and the safety \nof EC (AEs self -reported or clinical/laboratory). The following search engines \nwere used: PubMed, ISIWeb of Knowledge and Cochrane Controlled Trials \nRegister.  \nResults F inally, six experimental studies and six cohort studies were included. \nIn the prospective 12- month, randomized controlled trial, smoking reduction \nwas documented in 22.3 and 10.3% atWeeks 12 and 52, respectively (P, 0.001 \nversus baseline). Moreover, two cohort studies reported a reduction in the \nnumber of cigarette/day (from 50 to 80%) after the introduction of the EC. \n\u2018Mouth and throat irritation\u2019, \u2018nausea\u2019, \u2018headache\u2019 and \u2018dry cough\u2019 were the \nmost frequently AEs reported.  \nConclusions  The use of the EC can reduce the number of cigarettes smoked \nand withdrawal symptoms, but the AEs reported are mainly related to a short \nperiod of use. Long- term studies are needed to evaluate the effects of the EC \nusage after a chronic exposure.  \n \u2018Mouth and throat irritation\u2019, \u2018nause a\u2019, \u2018headache\u2019 and \u2018dry cough \u2019 were the \nmost frequently AEs reported.  \n \nShort -term adverse effects  \n- Mouth (20.6%) and throat (32.4%) irritation, dry cough (32.4%) and nausea \n(14.4%) were the most frequently AEs reported by the EC smokers and dimin-\nished substantially. (n=3 studies)  \n- The same AEs are reported by smokers enrolled in the trial ECLAT where be-\nfore using e- cigarettes, at baseline, the most frequently reported AEs were dry \ncough (26%; average for all study groups combined), mouth irritation (22%) , \nshortness of breath (20%), throat irritation (17%) and headache (17%). For all \nthe investigated AEs, compared with baseline, a significant reduction in fre-\nquency of reported symptoms was observed at Week 52: dry cough (12% aver-\nage for all study groups combined), mouth irritation (11%), shortness of breath \n(6%), throat irritation (13%) and headache (3%)  \n- Finally, the RCT by Bullen et al. identified no significant differences in adverse \nevents between the three arms, with 137 events in the nicotine e- cigar ettes \ngroup, 119 events in the patches group and 36 events in the placebo e- ciga-\nrettes group.  \nHajek P, Phillips -Wal-\nler A, Przulj D, et al. \nA Randomized Trial \nof E-Cigarettes ver-RCT \n BACKGROUND E-cigarettes are commonly used in attempts to stop smoking, \nbut evidence is limited regarding their effectiveness as compared with that of \nnicotine products approved as smoking- cessation treatments.  \nMETHODS We randomly assigned adults attending U.K. National Health Ser-\nvice stop -smoking services to either nicotine -replacement products of their There were 27 serious adverse events in the e -cigarette group and 22 in the nic-\notine- replacement group. No serious adverse event in either group was classi-\nfied by the trial clinician as being related to product use, but we noted 1 respira-\ntory event in the nicotine- replacement group and 5 in the e- cigarette group (2 in NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  167 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nsus Nicotine -Re-\nplacement Therapy. \nN Engl J Med 2019; \n380(7):629\u2013 37. DOI: \n10.1056/NEJMoa180\n8779. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/30699054.  choice, including product combinations, provided for up to 3 mo nths, or an e -\ncigarette starter pack (a secondgeneration refillable e- cigarette with one bottle \nof nicotine e- liquid [18 mg per milliliter]), with a recommendation to purchase \nfurther e- liquids of the flavor and strength of their choice. Treatment included \nweekly behavioral support for at least 4 weeks. The primary outcome was sus-\ntained abstinence for 1 year, which was validated biochemically at the final \nvisit. Participants who were lost to follow -up or did not provide biochemical vali-\ndation were considered to not be abstinent. Secondary outcomes included par-\nticipant -reported treatment usage and respiratory symptoms.  \nRESULTS A total of 886 participants underwent randomization. The 1- year ab-\nstinence rate was 18.0% in the e- cigarette group, as compared with 9.9% in \nthe nicotine- replacement group (relative risk, 1.83; 95% confidence interval \n[CI], 1.30 to 2.58; P<0.001). Among participants with 1- year abstinence, those \nin the e- cigarette group were more likely than those in the nicotine- replace-\nment group to use their assigned product at 52 weeks (80% [63 of 79 partici-\npants] vs. 9% [4 of 44 participants]). Overall, throat or mouth irritation was re-\nported more frequently in the e- cigarette group (65.3%, vs. 51.2% in the nico-\ntine-replacement group) and nausea more frequently in the nicotine replace-\nment group (37.9%, vs. 31.3% in the e- cigarette group). The e- cigarette group \nreported greater declines in the incidence of cough and phlegm production \nfrom baseline to 52 weeks than did the nicotine- replacement group (rel ative \nrisk for cough, 0.8; 95% CI, 0.6 to 0.9; relative risk for phlegm, 0.7; 95% CI, 0.6 \nto 0.9). There were no significant between- group differences in the incidence \nof wheezing or shortness of breath.  \nCONCLUSIONS E-cigarettes were more effective for smo king cessation than \nnicotine- replacement therapy, when both products were accompanied by be-\nhavioral support.  participants who were smoking and not vaping, 2 in participants who were smok-\ning and vaping, and 1 in a participant whose status with respect to smoking and \nvaping was not known).  \n \nprespecified adverse reactions of interest  \n- nausea was reported more frequently in the nicotine- replacement group \n(37.9%, vs. 31.3% in the e- cigarette group) and \n- throat or mouth irritation  more frequently in the e- cigarette group (65.3%, vs. \n51.2% in the nicotine- replacement group).  \n-  participants reporting  severe nausea (6.6% in the e- cigarette group and 6.5% \nin the nicotine- replacement group) or severe throat or mouth irritation  (5.9% \nand 3.9%, respectively)  \n \nHess I, Lachireddy K, \nCapon A. A system-\natic review of the \nhealth risks from pas-\nsive exposure to \nelectronic cigarette \nvapour. Public health \nresearch & practice \n2016; \n26(2):e2621617. DOI: \n10.17061/phrp26216\n17. \nhttp://www.ncbi.nlm.nSystematic \nReview  \n Objectives:  Electronic cigarettes (ECs) have recently become popular around \nthe world, and their safety is being widely discussed in the scientific literature. \nPrevious studies have examined the chemicals in e- liquids and vapour, and \ndemonstrated that the aerosol fro m ECs can contain toxic chemicals that are \nharmful to health. However, little is known about the potential adverse health \neffects of passive exposure to EC vapour. The aim of this paper is to summa-\nrise and review all studies that have examined potential ad verse health effects \nof passive exposure from inhaling EC vapour. Specifically, our research objec-\ntives were to describe 1) the absolute impact of passive exposure from inhaling \nvapour when compared with background, and 2) the relative impact of passive \nexposure from inhaling vapour when compared with passive exposure from in-\nhaling conventional cigarette smoke.  \nMethods:  A systematic review was conducted to identify articles published \nfrom 1996 to 10 September 2015 from Embase, Ovid MEDLINE and PreMED-\u2022 We reviewed 16 studies, with varying designs, investigating potential adverse \nhealth effects of passive exposure to EC vapours.  \n- Studies  (n=9) examining the composition of EC vapour or some of its aspects \nfound that  ECs are not emission -free. \n- The majority of studies (n=10) concluded that  passive exposure to EC va-\npour may pose a health risk to bystanders.  \n- n=2 studies did not comment on the passive exposure risk and n=4 concluded \nthat their investigation showed no risk to bystanders.  \n \n>> It is noted that those studies undertaken by tobacco employees or funded by \nthe National Vapers Club concluded no apparent risk from ECs to bystanders. \nThose who did not declare a conflict of interest were more likely to draw conclu-\nsions that were more precautionary and/or suggested a potential risk from pas-\nsive exposure to ECs, highlighting potential biases in the current literature.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  168 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nih.gov/pub-\nmed/27734060 . LINE. P apers eligible for inclusion had to be written in English, study health ef-\nfects from passive exposure to EC vapour in animals or humans, test or ana-\nlyse the EC vapour directly or in the ambient air (with an inference made about \npassive or second- hand vapour exposure). The review was conducted using \nthe PRISMA guidelines for reporting on systematic reviews. We identified 312 \nstudies, and 16 were relevant for inclusion in our review.  \nResults:  A variety of study designs were used to investigate potential healt h \nrisks from passive exposure to EC vapour. These included direct exposure \nstudies involving humans and animals, and indirect exposure studies using vol-\nunteer EC users or smoking machines. The majority of studies determined that \npassive exposure to EC vapour may pose a health risk to bystanders. All pa-\npers encountered a number of limitations.  \nConclusion: Our review found that the absolute impact from passive exposure \nto EC vapour has the potential to lead to adverse health effects. The risk from \nbeing passi vely exposed to EC vapour is likely to be less than the risk from \npassive exposure to conventional cigarette smoke.   \nKhoudigian S, Devji  \nT, Lytvyn L, et al. The \nefficacy and short -\nterm effects of elec-\ntronic cigarettes as a \nmethod for smoking \ncessation: A system-\natic review and a \nmeta- analysis. Int J \nPublic Health 2016; \n61(2):257\u2013 67. DOI: \n10.1007/s00038- 016-\n0786- z. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/26825455 . Systematic \nReview  \n Objectives  E-cigarettes are increasingly popular as smoking cessation aids. \nThis review assessed the efficacy of e- cigarettes for smoking cessation as well \nas desire to smoke, withdrawal symptoms, and adverse events in adult smok-\ners. \nMethods  A systematic review was conducted. Studies comparing e- cigarettes \nto other nicotine replacement therapies or placebo were included. Data were \npooled using meta- analysis.  \nResults Of 569 articles, 5 were eligible. Study participants were more likely to \nstop smoking when using nicot ine e -cigarettes (43/489, 9 %) versus placebo e-\ncigarettes (8/173, 5 %); however, this difference was not statistically significant \n(RR 2.02; 95 % CI 0.97, 4.22). The pooled effect estimates for the desire to \nsmoke (RR -0.22; 95 % CI - 0.80, 0.36), irritabi lity (RR - 0.03; 95% CI - 0.38, \n0.31), restlessness (RR - 0.03; 95 % CI - 0.42, 0.35), poor concentration (RR -\n0.01; 95 % CI - 0.35, 0.32), depression (RR - 0.01; 95 % CI - 0.22, 0.20), hunger \n(RR -0.01; 95 % CI - 0.32, 0.30), and average number of non- serious adv erse \nevents (RR -0.09; 95 % CI - 0.28, 0.46) were not statistically significantly differ-\nent. Only one study reported serious adverse events with no apparent associa-\ntion with e- cigarette use.  \nConclusions Limited low -quality evidence of a non- statistically si gnificant \ntrend toward smoking cessation in adults using nicotine e- cigarettes exists \ncompared with other therapies or placebo. Larger, high- quality studies are \nneeded to inform policy decisions.  \n Only one study reported serious adverse events with no appa rent association \nwith e -cigarette use.  \n- Serious adverse events, reported in the Bullen et al. (2013) study, were slightly \nhigher in the nicotine e- cigarette group (27/137, 19.7 %) than in the placebo e-\ncigarette group (5/36, 13.9 %). Serious events by con vention included death (n = \n1, in nicotine e- cigarette group), life- threatening illness (n = 1, in nicotine e- ciga-\nrette group), admission to hospital or prolongation of hospital stay (n = 17 and n \n= 4, in nicotine and placebo e- cigarette groups, respectively), persistent or signif-\nicant disability or incapacity, congenital abnormality (n = 8 and n = 1, in the nico-\ntine and placebo e- cigarette groups, respectively).  \n --> not associated with the use of e- cigarettes.  \n \nLiu X, Lu W, Liao S, \net al. Efficiency and Systematic \nReview  Background: Electronic cigarettes (e -cigarettes) are a prevalent smoking ces-\nsation aid worldwide; however, a consensus regarding their efficacy and safety Adverse events of e -cigarettes.  \n- The dominant adverse events of e -cigarettes were reported as  cough, mouth NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  169 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nadverse events of \nelectronic cigarettes: \nA systematic review \nand meta- analysis \n(PRISMA -compliant \narticle). Medicine \n(Baltimore) 2018; \n97(19):e0324. DOI: \n10.1097/MD.0000000\n000010324. \nhttp://www.ncb i.nlm.n\nih.gov/pub-\nmed/29742683 .  has yet to be reached.  \nMethods: We conducted a systematic review of the literature from related \nstudies written in English or Chinese and published between January 1, 2003, \nand July 30, 2017. Eligible studies reporting the number of smokers who re-\nduced or quit smoking and suffered from adverse events after e- cigarette use \nwere selected according to predefined criteria; pertinent data were then ex-\ntracted for a meta -analysis.  \nResults:  Our search produced 198 articles; of these publications, 14 including \n35,665 participants were analyzed. The pooled efficacy rate of e- cigarettes \nranged from 48.3% to 58.7% for smoking reduction and from 13.2% to 22.9% \nfor smoking cessation. The pooled rate of adverse events associated with e-\ncigarettes ranged from 49.1% to 51.6% based on 11 studies including 16,406 \nparticipants. The most prevalent adverse events were mouth or throat irritation, \nanxiety, depressed mood, nausea, and insomnia. No significant differences in \noverall CO2 exhalation (eCO) levels were observed after e cigarette use ac-\ncording to the data f rom 5 studies.  \nConclusion:  Our findings suggest that e- cigarettes are moderately effective \nwith regard to smoking reduction and smoking cessation. eCO levels are unre-\nliable for evaluating the efficacy of e- cigarettes. E cigarette related adverse \nevents frequently occur, especially due to high- dose nicotine- containing car-\ntridges.  or throat irritation, anxiety, depressed mood, nausea, and insomnia   (n=11 \nstudies;  16,406 participants)  \n- Among them, approximately 12.9% claimed to be anxious or nervous, 6.18% \ncomplained of having a depressed or sad mood, and 4.57% felt hungry or were \nconcerned about weight gain.  \n \n- participants who smoked ecigarettes mor e than 3cartridges/day had a high in-\ncidence of adverse events (pooled rate, 63.8%).  \n- Smokers who used ecigarettes less than 12 months also had a high rate of ad-\nverse events (pooled rate, 55.0%).  \n \nOncken CA, Litt MD, \nMcLaughlin LD, et al. \nNicotine concentra-\ntions with electronic \ncigarette use: Effects \nof sex and flavor. Nic-\notine & tobacco re-\nsearch official journal \nof the Society for Re-\nsearch on Nicotine \nand Tobacco 2015; \n17(4):473\u2013 8. DOI: \n10.1093/ntr/ntu232. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/25762758 . randomized,  \ncrossover  \n Introduction: This study examined overall changes in nicotine concentrations \nwhen using a popular e- cigarette and 18 mg/mL nicotine e- Juice, and it further \nexplored effects of sex and flavorings on these concentrations.  \nMethods:  We recruited nontreatment -seeking smokers who were willing to try \ne cigarettes for 2 weeks and abstain from cigarette smoking. Subjects were \nrandomized to either menthol tobacco or non- menthol  tobacco- flavored e- ciga-\nrette use for 7\u2013 10 days, and the next week they were crossed over to the other \ncondition. On the last day of e- cigarette use of each flavor, subjects completed \na laboratory session in which they used the e- cigarette for 5 min ad libitum. \nNicotine concentrations were obtained 5 min before and 5, 10, 15, 20, and 30 \nmin after the onset of e cigarette use.  \nResults: Twenty subjects completed at least 1 monitoring session. Nicotine \nconcentrations significantly increased from baseline to 5 min by 4 ng/mL at the \nfirst laboratory session (p < .01) and by 5.1 ng/mL at the second laboratory \nsession (p < .01). Combining sessions, there were no main effects of sex or \npreferred flavor (based on smoking history) on changes in nicotine concentra-\ntions . After adding preferred flavor, sex, and visit order to the model, there was \na significant preferred flavor by sex interaction (p < .01), such that women who \nreceived nonpreferred flavors had lower nicotine concentrations and rated their \ne-cigarette as less likeable (p < .01).  \nConclusion: We found nicotine concentrations significantly increase after e -\u2022 27 participants (n=18 completed study):  \n- Moderate ad verse events included cough in 19% (5/27) subjects, \nmouth/throat irritation in 15% (4/27) subjects,  nausea in 4% (1/27) subject, \nheadache in 4% (1/27) subjects, and \u201cother\u201d in 4% (1/27) subjects  (irritability, \nstomach cramps) .  \n- One severe adverse event ( itchy throat and cough ) occurred in one subject. \nThis subject had a history of childhood asthma, but no current history of asthma. \nThe subject was discontinued from e- cigarettes use and symptoms resolved.  \n- No serious adverse events occurred in the study.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  170 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \ncigarette use for 5 min, and flavor may impact nicotine concentrations with e -\ncigarette use in women.  \nRam\u00f4a CP, Hiler \nMM, Spindle TR, et \nal. Electronic ciga-\nrette nicotine delivery \ncan exceed that of \ncombustible ciga-\nrettes: A preliminary \nreport. Tob Control \n2016; 25(e1):e6- 9. \nDOI: 10.1136/tobac-\ncocontrol -2015-\n052447. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/26324250 . controlled trial  \n Introduction \u2014Electronic cigarettes (ECIGs) aerosolize a liquid that usually \ncontains propylene glycol and/or vegetable glycerin, flavorants, and the de-\npendence producing drug nicotine in various concentrations. This laboratory \nstudy examined the relationship between liquid nicotine concentration on \nplasma nicotine concentration and puffing behavior in experienced ECIG us-\ners. \nMethods \u2014Sixteen ECIG -experienced parti cipants used a 3.3- Volt ECIG bat-\ntery attached to a 1.5- Ohm dual -coil \u201ccartomizer\u201d loaded with 1 ml of a flavored \npropylene glycol/vegetable glycerin liquid to complete four sessions, at least 2 \ndays apart, that differed by nicotine concentration (0, 8, 18,  or 36 mg/ml). In \neach session, participants completed two 10- puff ECIG use bouts (30- sec puff \ninterval) separated by 60 minutes. Venous blood was sampled to determine \nplasma nicotine concentration. Puff duration, volume, and average flow rate \nwere measured.  \nResults\u2014Immediately after bout 1, mean plasma nicotine concentration was \n5.5 ng/ml (SD=7.7) for 0 mg/ml liquid, with significantly (p<0.05) higher mean \nconcentrations observed for the 8 (mean=17.8 ng/ml, SD=14.6), 18 \n(mean=25.9 ng/ml, SD=17.5), and 36 mg/ml (mean=30.2 ng/ml; SD=20.0) con-\ncentrations; a similar pattern was observed for bout 2. For bout 1, at 36 mg/ml, \nthe mean post - minus pre- bout difference was 24.1 ng/ml (SD=18.3). Puff to-\npography data were consistent with previous results and revealed few reliable \ndifferences across conditions.  \nDiscussion \u2014This study demonstrates a relationship between ECIG liquid nic-\notine concentration and user plasma nicotine concentration in experienced \nECIG users. Nicotine delivery from some ECIGs may exceed that of a combus-\ntible cigarette. The rationale for this higher level of nicotine delivery is uncer-\ntain. n=16 participants  \n \n[...]Thus, some ECIGs are so efficient at delivering nicotine that they appear ca-\npable of exceeding the nicotine delivery profile of a combus tible tobacco ciga-\nrette. We speculate that this excessive nicotine delivery may be harmful if it \nleads to a greater level of nicotine dependence, which could make ECIG ces-\nsation difficult if users eventually choose to try to quit their ECIG use.  \n \nRiley HE, Berry -\nBibee E, England LJ, \net al. Hormonal con-\ntraception among \nelectronic cigarette \nusers and cardiovas-\ncular risk: A system-\natic review. Contra-\nception 2016; \n93(3):190\u2013 208. DOI: \n10.1016/j.contracep-\ntion.2015.11.003. Systematic \nReview  \n Background: Women who use combined hormonal contraceptives and ciga-\nrettes have an increased risk for cardiovascular (CV) events. We reviewed the \nliterature to determine whether women who use hormonal contraceptives (HC) \nand electronic cigarettes (e- cigarettes) also have an increased risk.  \nStudy Design:  Systematic review.  \nMethods:  We searched for articles reporting myocardial infarction (MI), stroke, \nvenous throm boembolism, peripheral arterial disease or changes to CV mark-\ners in women using e- cigarettes and HC. We also searched for indirect evi-\ndence, such as CV outcomes among e- cigarette users in the general popula-\ntion and among HC users exposed to nicotine, propy lene glycol or glycerol.  \nResults: No articles reported on outcomes among e- cigarette users using HC. We identified no evidence on CV outcomes among e -cigarette users using HC. \nLimited data reporting mostly acute outcomes suggested that CV events are rare \namong e- cigarette users in the general population and that e- cigarettes may af-\nfect heart rate and blood pressure less than conventional cigarettes.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  171 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/26546021 . Among the general population, 13 articles reported on heart rate or blood pres-\nsure after e- cigarette use. These markers generally remained normal, even \nwhen significant changes were observed. In three studies, changes were less \npronounced after e- cigarette use than cigarette use. One MI was reported \namong 1012 people exposed to ecigarettes in these studies. One article on \nnicotine and HC exposure found both exposures to be significantly associated \nwith acute changes to heart rate, though mean heart rate remained normal. No \narticles on propylene glycol or glycerol and HC exposure were identified.  \nConclusion: We identified no evidence on CV outcomes among e- cigarette \nusers using HC. Limited data reporting mostly acute outcomes suggested that \nCV events are rare among e- cigarette users in the general population and that \ne-cigarettes may affect heart rate and blood pressure less than conventional \ncigarettes. There is a need for research assessing joint HC and e- cigarette ex-\nposure on clinical CV outcomes.  \nSkotsimara G, Anto-\nnopoulos AS, \nOikonomou E, et al. \nCardiovascular ef-\nfects of electronic cig-\narettes: A systematic \nreview and meta-\nanalysis. Eur J Prev \nCardiol 2019; \n26(11):1219\u2013 28. DOI: \n10.1177/2047487319\n832975. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/30823865 . Systematic \nReview  \n Aims: The electronic cigarette is ma rketed as a safe alternative to tobacco \nsmoking, but electronic cigarette cardiovascular effects remain largely un-\nknown. We systematically reviewed and meta- analysed published literature to \ninvestigate the cardiovascular effects and associated risk from el ectronic ciga-\nrette use.  \nMethods and results:  We searched PubMed from January 2000 to November \n2017 for published studies assessing the cardiovascular effects of the elec-\ntronic cigarette. Evidence suggests that the electronic cigarette negatively af-\nfects endothelial function, arterial stiffness and t he long- term risk for coronary \nevents, but these findings are from single study reports and have not been \nconfirmed in additional studies. Conflicting evidence exists on the effects of the \nelectronic cigarette on heart rate and blood pressure, which is mai nly based on \nnon-randomized clinical studies of moderate quality. The meta- analysis of 14 \nstudies (N=441 participants) suggested that despite the negative acute effects \nof the electronic cigarette on heart rate (pooled mean difference (MD)=2.27, \n95% confidence interval (CI): 1.64 to 2.89, p<0.001), diastolic (pooled \nMD=2.01 mmHg, 95% CI: 0.62 to 3.39, p=0.004) and systolic blood pressure \n(pooled MD=2.02 mmHg, 95% CI: 0.07 to 3.97, p=0.042), benefits may be ob-\nserved in terms of blood pressure regulation when switching from tobacco \nsmoking to chronic electronic cigarette use (systolic blood pressure pooled \nMD= 7.00, 95% CI:  9.63 to  4.37, p<0.001; diastolic blood pressure pooled \nMD= 3.65, 95% CI:  5.71 to  1.59, p=0.001).  \nConclusions: The existing evidence on the cardiovascular effects of the elec-\ntronic cigarette is  concerning, with several unexplored issues. Unless sup-\nported by stronger evidence, the electronic cigarette should not be labelled as \u2022 Evidence suggests that the  electronic cigarette negatively affects endothe-\nlial function, arterial stiffness and the long -term risk for coro nary events,  \nbut these findings are from single study reports and have not been confirmed in \nadditional studies.  \n\u2022 Conflicting evidence exists on the effects of the electronic cigarette on heart \nrate and blood pressure, which is mainly based on non- random ized clinical stud-\nies of moderate quality.  \n \n\u2022 meta -analysis of 14 studies (N=441 participants) suggested that despite the \nnegative acute effects of the electronic cigarette on  \n- heart rate (pooled mean difference (MD)=2.27, 95% confidence interval (CI): \n1.64 to 2.89, p<0.001),  \n- diastolic blood pressure ( pooled MD=2.01 mmHg, 95% CI: 0.62 to 3.39, \np=0.004) and  \n- systolic blood pressure (pooled MD=2.02 mmHg, 95% CI: 0.07 to 3.97, \np=0.042),  \n- benefits may be observed in terms of blood pressure regulation when switching \nfrom tobacco smoking to chronic electronic cigarette use (systolic blood pres-\nsure pooled MD= 7.00, 95% CI:  9.63 to  4.37, p<0.001; diastolic blood pressure \npooled MD= 3.65, 95% CI:  5.71 to  1.59, p=0.001).  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  172 \n      \n \nAutor/ Titel  Studientyp  Abstract  Schadenspotential  \na cardiovascular safe product. Future studies should delineate  whether elec-\ntronic cigarette use is less hazardous to cardiovascular health than conven-\ntional cigarette smoking.  \n \nTseng T -Y, Ostroff \nJS, Campo A,  et al. A \nRandomized Trial \nComparing the Effect \nof Nicotine Versus \nPlacebo Electronic \nCigarettes on Smok-\ning Reduction Among \nYoung Adult Smok-\ners. Nicotine & to-\nbacco research offi-\ncial journal of the So-\nciety for Research on \nNicotine and Tobacco \n2016; 18(10):1937\u2013\n43. DOI: \n10.1093/ntr/ntw017. \nhttp://www.ncbi.nlm.n\nih.gov/pub-\nmed/26783292 . two-arm; dou-\nble-blind RCT  \n Introduction: Electronic cigarette (EC) use is growing dramatically with use \nhighest among young adults and current smokers. One of the most common \nreasons for using ECs is interest in quitting or reducing cigarettes per day \n(CPD); however there are few randomized controlled trials (RCT) on the effect \nof ECs on smoking abstinence and reduc tion. \nMethods:  We conducted a two- arm; double- blind RCT. Subjects were ran-\ndomized to receive 3- weeks of either disposable 4.5% nicotine EC (interven-\ntion) or placebo EC. The primary outcome was self -reported reduction of at \nleast 50% in the number of CPDs s moked at week 3 (end of treatment) com-\npared to baseline. Study subjects (n = 99) were young adult (21\u2013 35), current \nsmokers (smoked \u2265 10 CPDs) living in NYC.  \nResults: Compared with baseline, a significant reduction in CPDs was ob-\nserved at both study time periods (1 and 3 weeks) for intervention (P < .001) \nand placebo (P < .001) groups. Between- group analyses showed significantly \nfewer CPDs in the intervention group compared to the placebo group at week \n3 (P = .03), but not at any other follow -up periods. The logistic regression anal-\nysis showed that using a greater number of ECs, treatment condition and \nhigher baseline readiness to quit were significantly associated with achieving \nat least 50% reduction in CPDs at the end of treatment.  \nConclusion: A diverse yo ung adult sample of current everyday smokers, who \nwere not ready to quit, was able to reduce smoking with the help of ECs. Fur-\nther study is needed to establish the role of both placebo and nicotine contain-\ning ECs in increasing both reduction and subsequent  cessation.  \nImplications:  Despite the critical need for well -designed clinical trials on the \neffect of ECs on cessation and cigarette reduction, the majority of studies have \nbeen observational or noncomparative intervention designs. Only three RCTs \nstudyin g ECs as a cessation or reduction intervention have been published, \nand none were conducted in the United States. The current study adds \nknowledge to current literature on the feasibility of using ECs to aid smoking \nreduction among young smokers in US urban populations.  \u2022 There was no difference in reported side effects between groups (34.1% for in-\ntervention and 17.5% for placebo group at week 1, P = .09; 22.5% for interven-\ntion and 10.3% for placebo group at week 3, P = .14; chi -square test) or between \nstudy time points in each group (P = .39 for intervention and P = .63 for placebo \ngroup; McNemar test).  \n \n\u2022 Common side effects included  mouth or throat irritation, cough, insomnia \nor difficulty sleeping, abnormal dreams, headache and fatigue.  \n \nAnhang 6.5  Selektiv eingebrachte Literatur  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nOsei AD, Mirbolouk M, \nOrimoloye OA, et al. \u2022 Aim: this study examines the as-\nsociation between e- cigarette use \u2022 Baseline -Patientencharakteristika:  n= 705159 participants (with \ncomplete information on all key variables)  Strobe ( https://www.strobe -state -\nment.org/fileadmin/Strobe/up-Selektiv eingebrachte Literatur  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  173 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nAssociation Between \nE-Cigarette Use and \nChronic Obstructive \nPulmonary Disease by \nSmoking Status: Be-\nhavioral Risk Factor \nSurveillance System \n2016 and 2017. Am J \nPrev Med 2020; \n58(3):336\u2013 42. DOI: \n10.1016/j.ame-\npre.2019.10.014.  \n \nhttp://www.ncbi.nlm.ni\nh.gov/pub-\nmed/31902685 . and self -reported chronic bronchi-\ntis, emphysema, or COPD across \ndiffering combustible cigarette \nsmoking use patter ns in the Be-\nhavioral Risk Factor Surveillance \nSystem (BRFSS) (=public data \nset) \n \n\u2022 Studiendesign: r epresentative, \nannual, cross -sectional, tele-\nphone- based survey  \n \n\u2022 Population:  U.S. adult partici-\npants aged \u226518 years  \n\u2022 Intervention:  Fragestellungen  \n \n\u2022 Studienzeitraum : pooled 2016 \nand 2017 data from the Behavioral \nRisk Factor Surveillance System; \nAll the analyses were conducted in \n2019.  \n\u2022 USA  \n \n \n - 25175 (3,6%) were current e -cigarette users,  \n- 64792 (9,2%) current,combustible cigarette smokers,  \n- 207905 (29,5%) former combustible cigarette smokers,  \n- 432462 (61,3%) never combustible cigarette smokers, and  \n- 14036 (2,0%) dual users of e- cigarettes and combustible ciga-\nrettes.  \n \n- median age group of current e- cigarette users was 30\u221234 years  \n \n\u2022 Ergebnisse:  \nAmong never combustible cigarette smokers, current e- cigarette use \nwas associated with 75% higher odds of chronic bronchitis, emphy-\nsema, or chronic obstructive pulmonary disease compared with \nnever e- cigarette users (OR=1.75, 95% CI=1.25, 2.45), with daily \nusers of e- cigarettes having the highest odds (OR=2.64, 95% \nCI=1.43, 4.89).  \n \nAmong former combustible cigarette smokers, cur rent e- cigarette \nusers had higher odds of COPD compared with never e- cigarette \nusers (OR=2.13, 95% CI=1.82, 2.50).  \n \nIn the additional analysis with never combustible cigarette smokers \nwho never used e- cigarette as the sole reference group, dual users \nof combustible cigarette and e- cigarettes had the highest odds of \nthe outcome of interest (OR=6.89, 95% CI=6.29, 7.55).  \n \n\u2022 authors conclusion:  The results suggest possible e- cigarette\u2212re-\nlated pulmonary toxicity across all the categories of combustible cig-\narette smoking status, including those who had never smoked com-\nbustible cigarettes.  loads/checklists/STROBE_chec-\nklist_v4_cross -sectional.pdf )  \n1. Title and abstract: y  \n2. Background/ rationale: y  \n3. Objectives: y  \n4. Study design: y  \n5. Setting: y  \n6. Participants: y  \n7. Variables: py  \n8. Data sources/Measurement: y  \n9. Bias: n  \n10. S tudy size: y \n11. Quantitative variables: y  \n12. Statistical methods: a) y, b) na, \nc) na, d) na, e) na  \n13. Participants: y  \n14. Descriptive data: na  \n15. Outcome data: y  \n16. Main results: py  \n17. Other analyses: na  \n18. Key results: y  \n19. Limitations: y  \n20. Inte rpretation: y  \n21. Generalisability: n  \n22. Funding: y  \n Zusammenhang zwischen E -Ziga-\nretten und Vorkommen von COPD \n(Odds)  \n \nLimitationen:  [...] In addition, the \nauthors cannot exclude the possi-\nbility that reverse causation may \nhave contributed to the finding of \nthe highest odds of COPD among \ndual users when compared with \nnever combustible cigarette smok-\ners who never use e- cigarettes. \nFor example, current and former \ncombustible cigarette smokers with \nthe outcome of interest are poten-\ntially more likely to report using \necigarette as a smoking- cessation \nstrategy. [...] \n \nMethodische Qualit\u00e4t: angelehnt \nan STROBE (Reporting; nicht f\u00fcr \nqualitative Einsch\u00e4 tzung)  \nBhatta DN, Glantz SA. \nAssociation of E -Ciga-\nrette Use With Respir-\natory Disease Among \nAdults: A Longitudinal \nAnalysis. Am J Prev \nMed 2020; 58(2):182\u2013\n90. DOI: \n10.1016/j.ame-\npre.2019.07.028. \u2022 Aim : This study determines the \nlongitudinal associations between  \ne-cigarette use and respiratory dis-\nease controlling for combustible \ntobacco use.  \n \n\u2022 Studiendesign:  nationally repre-\nsentative, population- based, longi-\ntudinal study  \n \u2022 Baseline -Patientencharakteristika:  \n- adult (aged \u226518 years)  \nWave 1: n = 32320 \n- Respiratory disease: Yes 15.1%, No 84.9%  \n- E-cigarette user: Never 82.3%, Former 12.2%, Current 5.5%  \n- Combustible tobacco smoker: Never 28.6%, Former 45.4%, Cur-\nrent 26.0%  \n- Cigarette smoker: Never 33.2%, Former 45.4%, Current 21.4%  \n \n\u2022 Ergebnisse:  Strobe ( https://www.strobe -state -\nment.org/fileadmin/Strobe/up-\nloads/checklists/STROBE_chec-\nklist_v4_cross -sectional.pdf )  \n1. Title and abstract: y  \n2. Background/ rationale: y  \n3. Objectives: y  \n4. Study design: y  \n5. Setting: y  \n6. Participants: y  Selektiv eingebrachte Literatur  \n \nZusammenhang zwischen E -Ziga-\nretten und Entwicklung einer chro-\nnischen Lungenerkrankung  \n \nMethodische Qualit\u00e4t: L. Tooth_ \nQuality of reporting of observatio-\nnal longitudinal research_2005 NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  174 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nhttp://www .ncbi.nlm.ni\nh.gov/pub-\nmed/31859175 . \n \n \n \n \u2022 Population:  adult Population As-\nsessment of Tobacco and Health \nWaves 1, 2, and 3.  \n\u2022 Intervention : Fragestellungen \n- Wave I: Has a doctor or other \nhealth professional ever told you \nthat you had any of the following \nlung or respiratory conditi ons? \n(yes or no): COPD, chronic bron-\nchitis, emphysema, and asthma.  \n- Wave II + III: In the past 12 \nmonths, has a doctor, nurse, or \nother health professional told you \nthat you had any of the following \nlungor respiratory conditions? (yes \nor no): COPD, chroni c bronchitis, \nemphysema, and asthma.  \n>> +  use of e -cigarettes and/or \nconventional cigarettes asked  \n \n\u2022 Studienzeitraum: Data were \ncollected in 2013\u22122016 and ana-\nlyzed in 2018\u22122019.  \n(Waves 1 (September 2013 to De-\ncember 2014), 2 (October 2014 to \nOctober 2015) , and 3 (October \n2015 to October 2016))  \n\u2022 San Francisco, California Wave 1:   \nThe risk of having had respiratory disease was significantly associ-\nated with former e- cigarette use (AOR=1.34, 95% CI=1.23, 1.46) \nand current e- cigarette use (AOR=1.32, 95% CI=1.17, 1.49).  \nThe risk of having had respiratory disease was also significantly as-\nsociated with former combustible tobacco smoking (AOR=1.29, 95% \nCI=1.14, 1.47) and current combustible tobacco smoking \n(AOR=1.61, 95% CI=1.42, 1.82).  \n \nAmong people who did not report respiratory disease at Wave 1, the \nlongitudinal analysis revealed stati stically significant associations \nbetween former e- cigarette use (AOR=1.31, 95% CI=1.07, 1.60) and \ncurrent e- cigarette use (AOR=1.29, 95% CI=1.03, 1.61) at Wave 1 \nand having incident respiratory disease at Waves 2 or 3 adjusting \nfor combustible tobacco smo king, demographic, and clinical varia-\nbles.  \nCurrent combustible tobacco smoking (AOR=2.56, 95% CI=1.92, \n3.41) was also significantly associated with having respiratory dis-\nease at Waves 2 or 3.  \n \nThe total odds of developing respiratory disease for a current  dual \nuser is (odds of respiratory disease among current combustible to-\nbacco smoker) x (odds of respiratory disease among current e- ciga-\nrette user) = 2.56 x 1.29 = 3.30 compared with a never smoker who \nnever used e- cigarettes  \n \n\u2022 authors conclusion: Use of e -cigarettes is an independent risk \nfactor for respiratory disease in addition to combustible tobacco \nsmoking. Dual use, the most common use pattern, is riskier than us-\ning either product alone.  7. Variables: y  \n8. Data sources/Measurement: y  \n9. Bias: n  \n10. Study size: y  \n11. Quantitative variables: y  \n12. Statistical methods: a) y, b) na, \nc) na, d) na, e) na  \n13. Participants: y  \n14. Descriptive data: na  \n15. Outcome data: y  \n16. Main results: py (adjusted OR \nused)  \n17. Other analyses: y  \n18. Key results: y  \n19. Limitations: y  \n20. Interpretation: y  \n21. Generalisability: y  \n22. Funding: y  \n (https://pub-\nmed.ncbi.nlm.nih.gov/15671260/) \nnicht validiert >> deswegen ange-\nlehnt an STROBE (R eporting; nicht \nf\u00fcr qualitative Einsch\u00e4tzung)  \n \nAnhang 7  Evidenztabellen Nicht -medikament\u00f6se Therapie und Rehablitation  \nAnhang 7.1  Cochrane Reviews Nicht -medikament\u00f6se Therapie \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n27016  \n Zainuldin R. Optimal \nintensity and type of \nleg exercise training \nfor people with \u2022 Body of Evidence:  n=3 bzw. 8  eingeschlossene RCTs \nf\u00fcr Metaanalyse ( n=231 bzw. 367  eingeschlossene Pa-\ntienten)  \n\u2022 Suchzeitraum:  current as of 6/2011  Interval training compared with continuous training  \nFunctional exercise capacity: Six -minute walk distance (m), n= 287 (6 studies); \nGRADE: Low  \n- Continuous: The mean change in 6MWD ranged across continuous training AMSTAR -Score: 9/11  \n \ny-y-y-y-y-y-y-y-y-n-n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  175 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nchronic obstructive \npulmonary disease. \nCochrane Database \nof Systematic Re-\nviews 2011;(11).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD008008.pub2/ab-\nstract  \n \n \u2022 Population: Patient *innen mit COPD  \n\u2022 Einschlusskriterien:   \n- participants were diagnosed with COPD defined by best \npost-bronchodilator forced expiratory volume in one sec-\nond (FEV1)/forced vital capacity (FVC) ratio < 0.7  \n- Trials of lower limb exercise training of 12 sessions or \nmore  \n\u2022 Ausschlusskriterien: studies that compared exercise \ntraining with no exercise training  \n \n\u2022 Interventionen:   \n1. higher training intensity to lower training intensity (n=3, \n231 subjects)  \n2. continuous training to interval training (n=8, 367 sub-\njects)  \n \n\u2022 Prim\u00e4re Endpunkte:  \n1. Peak exercise  \n2. Isowork or isotime  \n3. Endurance time of constant work rate exercise test  \n4. Functional exercise capacity  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n1. Symptom scores: dyspnoea or leg fatigue at end of \npeak exercise, and at isowork or isotime  \n2. Health- related quality of life (HRQoL):  (SGRQ) or  \n(CRQ) or SF -12 or SF -36 \n3. Muscle strength  \n groups from 32 to 46 m  \n- Interval: The mean change in 6MWD in the interval training groups was 4.4m \nlonger (10.1 shorter to 18.9m longer)  \n- 6MWD: MD - 3,10m; 95% CI - 17,88 \u2013 11,69; I\u00b2 =0.0%  \n \nHealth- related Quality of Life: Dyspnoea domain of the CRQ, n=212 (4 stud-\nies), GRADE: Moderate  \n- Continuous: The mean change in the CRQ dyspnoea score ranged across \ncontinuous training groups from 3.7 to 8.4 points  \n- Interval: The mean change in the CRQ dyspnoea score for the interval train-\ning groups was 1. 26 lower (0.01 lower to 2.54 points higher)  \n- Total CRQ: MD 2,51; 95% CI - 1,32 \u2013 6,34; I\u00b2 =0.0%  \n \nDyspnoea:  The SMD for peak dyspnoea was in favour of the interval group, \nbut the effect size was small and not significant (SMD 0.09; 95% CI - 0.18 to \n0.35)  \n \nHigher intensity versus lower intensity \nDyspnoea:  The treatment effect for peak dyspnoea was - 1.40 points in favour \nof the higher -intensity group and was significant (95% CI - 2.30 to -0.50)  \n \nHrQoL: Total CRQ score (MD 2.51; 95% CI - 1.32 to 6.34), Dyspnoea domain \nscore (MD 1.26; 95%CI -0.01 to 2.54), Fatigue domain score(MD -0.27; 95%CI \n-1.72 to 1.18), Emotional domain score (MD 0.59; 95% CI -1.30 to 2.47) and \nMastery domain score (MD - 0.02; 95% CI -1.65 to 1.61) were not significantly \ndifferent between continuous and interval training.  \n \n27035 McKeough ZJ. Up-\nper limb exercise \ntraining for COPD. \nCochrane Database \nof Systematic Re-\nviews 2016;(11)  \n \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.. \n\u2022 Body of Evidence:  n=12  eingeschlossene RCTs f\u00fcr \nMetaanalyse ( n=  eingeschlossene Pat ienten)  \n\u2022 Suchzeitraum:  inception to 9/2016 \n\u2022 Population: Patient *innen mit stabiler COPD  \n\u2022 Einschlusskriterien:  \n- any age or disease severity. Participants\u2019 COPD was sta-\nble (that is optimal and stable respiratory medications with \nno exacerbation or hospi tal admission within the previous \nmonth), although oxygen supplementation during training \ncould have been used.  \n- included inpatient, outpatient, and home -based training \u2022 Baseline -Charakteristika  \n- mean age: ranging from 57 to 72 years  \n- mean FEV1: 27% to 60%predicted, indicating moderate to very severe dis-\nease \n \nUpper limb training vs No upper limb training  \nSymptoms of dyspnoea assessed with: Chronic Respiratory Disease Ques-\ntionnaire Dyspnoea Score., n=129 (4 RCTs), GRADE: Moderate  \nNo upper  limb training: The mean symptoms of dyspnoea was 4.2 points.  \nUpper limb training: The mean symptoms of dyspnoea in the intervention \ngroup was 0.37 points higher  (0.02 to 0. 72 points)  AMSTAR -Score: 11/11  \n \ny-y-y-y-y-y-y-y-y-y-y NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  176 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nCD011434.pub2/ab-\nstract  \n. programmes.  \n \n\u2022 Interventionen:  (at least four weeks\u2019 duration)  \n1. upper limb training only (endurance or resistance train-\ning, or both) versus no training or sham intervention;  \n2. combined upper limb training and lower limb training \nversus lower limb training alone; and  \n3. upper limb t raining versus another type of upper limb \ntraining.  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Dyspnoea  \n- Health- related quality of life  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n1. Peak upper limb exercise capacity  \n2. Endurance upper limb exercise capacity  \n3. Upper limb strength  \n4. Respira tory muscle strength  \n5. Physical activity level  \n6. Activities of Daily Living (ADL)  \n7. Psychological status  \n8. Healthcare utilisation recorded as hospitalisation or \nlength of stay.  \n (Comment: Higher value post -intervention is favourable indicating impro ve-\nment in dyspnoea. The MID for dyspnoea component of the chronic respira-\ntory disease questionnaire is 0.5)  \n- CRQ dyspnoea: MD 0.37; 95% CI 0,02 \u2013  0,72 \n \nHealth- Related Quality of Life  assessed with: Chronic Respiratory Disease \nQuestionnaire Total Score, n= 126 (4 RCTs), GRADE: Moderate  \nNo upper limb training: The mean health- related quality of life was 5.3 points.  \nUpper limb training: The mean health- related quality of life in the intervention \ngroup was  0.05 points higher (0.3 points lower to 0. 36 points hi gher)  \n- CRQ total: SMD 0,05; 95% CI \u22120,31 \u2013  0,40)  \n \nActivities of daily living  \nn=1 study showed no between-  group differences on the duration of a black-\nboard/grocery shelving/dishwashing task (SMD 0.67, 95% CI \u22120.12 to 1.47, \n28 participants)  \n \n>> when arm tr aining was compared to no arm training or a sham intervention \nin people with COPD, there was a small improvement in breathlessness. How-\never, this improvement was not evident when the studies of combined arm \nand leg training were compared to leg training al one. No studies have exam-\nined whether breathlessness improves more with different types of arm train-\ning. Arm training had no effect on quality of life in any of the three compari-\nsons. When endurance arm training was specifically examined, there was an \nimprovement seen in the capacity of the arms to move and lift light weights \ncompared to no training. These effects were not seen with arm strength trai-\nning.  \n \n27025  McNamara RJ. Wa-\nter-based exercise \ntraining for chronic \nobstructive pulmo-\nnary disease. \nCochrane Database \nof Systematic Re-\nviews 2013;(12).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\u2022 Body of Evidence:  n=5  eingeschlossene randomised or \nquasi -randomised controlled trials f\u00fcr Metaanalyse (n=176  \neingeschlossene Patienten)  \n\u2022 Suchzeitraum:  inception to 8/2013 \n\u2022 Population: Patient *innen mit COPD  \n\u2022 Einschlusskriterien: The COPD should be stable (i.e. \noptimal and stable respiratory medications with no exacer-\nbation or hospital admission within the previous month), \nand supplemental oxygen may be used.  \nSwimming interventions were excluded.  \n \n\u2022 Interventionen:   \nwater -based exercise training,  supervised or unsupervised \u2022 Baseline -Charakteristika  \n- mean age: ranged from 57 to 73 years  \n- exercise training programmes lasted from four to 12 weeks  \n \nWater -based exercise training compared with no exercise training  \nExercise capacity -  functional, Six-minute walk t est, n=99 (3 studies), GRADE: \nModerate  \nNo exercise training: Mean change in six -minute walk distance ranged across \ncontrol groups from -39 metres to - 16 metres  \nWater -based exercise training: Mean change in six -minute walk distance in \nthe intervention groups was 62 metres higher  (44 metres to 80 metres \nhigher)  \n-6MWD ( MD 62,1m; 95% CI 44,3 \u2013 79,9m; I\u00b2 =27%  AMSTAR -Score: 10/11  \n \ny-y-y-y-y-y-y-y-n-y-y NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  177 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nCD008290.pub2/ab-\nstract  \n \n vs. no exercise training  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Exercise capacity (functional or maximal)  \n- Quality of life  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- Pulmonary function  \n- Respiratory muscle strength  \n- Upper and lower limb strength  \n- Oxygen saturation  \n- Symptoms  \n- Level of activity  \n- Psychological status  \n- Self management/self efficacy  \n- Healthcare utilisation \n- Cost-effectiveness  \n- Adverse events  \n- Withdrawal  \n- Body composition  \n- Attendance  \n- Exercise training mode preference \n- Arteri al blood gases   \nQuality of life St  George\u2019s Respiratory Questionnaire (total score) (Lower \nvalue post intervention is favourable, indicating improvement in QoL), n=19 (1 \nstudy), GRADE: Low  \nNo exercise training: Mean change in St George\u2019s Respiratory Questionnaire \ntotal score in the control group was +6 points  \nWater -based exercise training: Mean change in St George\u2019s Respiratory \nQuestionnaire total score in the intervention group was 10 points lower  (1 \npoint to 19 points lower)  \n- SMD -0,97; 95% CI - 0,37 \u2013 (-) 1,57; I\u00b2 =0.0%   \n \n>> Two studies reported on adverse events; one minor adverse event was \ndocumented (from 20 people participating in water -based exercise training).  \n \n27085 \n Hill K. Neuromuscu-\nlar electrostimulation \nfor chronic obstruc-\ntive pulmonary dis-\nease. Cochrane Da-\ntabase of Systematic \nReviews 2013;(11).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD010821/abstract  \n \n \u2022 Body of Evidence: n=16 eingeschlossene RCTs f\u00fcr \nMetaanalyse ( n=267 eingeschlossene Patienten)  \n\u2022 Suchzeitraum:  inception - 03/2018 \n\u2022 Population: Erwachsene mit COPD  \n\u2022 Einschlusskriterien: Adults with a diagnosis of COPD \nregardless of their clinical stability  \n\u2022 Ausschluss:  randomised crossover trials  \n \n\u2022 Interventionen:   \n1. Neuromuscular electrostimulat ion (NEMS) vs. Ususal \ncare (n=7) or  \n2. Neuromuscular electrostimulation + conventional exer-\ncise training vs. conventional exercise training alone (n=9)  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Peripheral muscle force  \n- Peripheral muscle endurance/fatigability  \n- Thigh musc le size  \n- Serious adverse events (e.g. mortality; for these muscle -\u2022 Baseline- Charakteristika  \n- mean age: range 56 to 76 years  \n- men=179 (67%)  \n- mean FEV1: range 15% to 50% of the predicted value \n \nNMES vs. Usual care \nExercise capacity  assessed with 6MWD (m): n=72 (2 RCTs); GRADE: Low  \nUsual care: The mean change in 6MWD in the control group ranged from -5. \n70 m to 0.80 m.  \nNMES: MD 39.26 m more (95% CI 16.31 to 62.22)  \n \nFunctional performance:  \nNone of the studies reported on functional performance.  \n \nSymptoms of dyspnoea reported on completion of an exercise test assessed \nwith Borg score: n=32 (3 RCTs), GRADE: Very low  \nUsual care:The mean change in dyspnoea reported on completion of an exer-\ncise test ranged from -  0.50 to 0.40.  \nNMES: MD 1.03  less dyspnoea  (95% CI 2.13 less to 0.06 more)  AMSTAR -Score: 11/11  \n \ny-y-y-y-y-y-y-y-y-y-y NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  178 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nspecific outcomes)  \n\u2022 Sekund\u00e4re Endpunkte:  \n- Exercise capacity  \n- Functional performance  \n- Symptoms of dyspnoea and fatigue \n- Health- related quality of life  \n- Minor adverse events (for secondary outcomes)  \n  \nHealth-  related quality of life assessed with: SGRQ; n=72 (2 RCTs), GRADE: \nVery low  \nUsual care: The mean change in HRQoL ranged  from -2. 00 to 0.07  \nNMES: MD 4.12 better (95% CI 12.60 better to 4.35 worse)  \n \nMinor adverse events assessed: r elated to intervention only (e.g. redness), \nn=139 (5 RCTs), GRADE: Low  \nUsual care: 5970 per 100,000  \nNMES: 0 per 100,000 (95% CI - 418 to 418)  \n \n- quadriceps endurance: SMD 1,36; 95% CI 0,59 \u2013  2,12; Datenqualit\u00e4t niedrig  \n- peripheral muscle force SMD 0,34; 95% CI 0,02 -  0.65; Datenqualit\u00e4t niedrig  \n \nNMES + training vs. training alone  \nExercise capacity  assessed with 6MWD (m), n=138 (6 RCTs), GRADE: Very \nlow \nExercise: The mean change in 6MWD ranged from 10. 30 m to 94.00 m  \nNMES + exercise: MD 25.87 m more (1.06 more to 50.69 more)  \n \nFunctional performance assessed with: time (days) until first sit out of bed, \nn=44 (2 RCTs),  GRADE: Very low  \nExercise: The mean time until first sit out of bed ranged from 12.60 to 14.33 \ndays  \nNMES  + exercise: MD 4.98 fewer days (8.55 to 1.41 fewer)  \n \nSymptoms of dyspnoea reported on completion of an exercise test assessed \nwith: Borg score, n=44 (2 RCTs), GRADE: Very low  \nExercise: The mean change in dyspnoea reported on completion of an exer-\ncise test  ranged from -  0.62 units to 1.00 units  \nNMES + exercise: MD 0.44 less dyspnoea (2.27 less to 1.38 more)  \n \nHealth-  related quality of life assessed with: any validated questionnaire, \nn=122 (5 RCTs), GRADE: Very low  \nExercise: - - - \nNMES + exercise: SMD 0.56 S D better  (1.27 better to 0.15 worse)  \n \nMinor adverse events  assessed: related to intervention only (e.g. redness), \nn=144 (6 RCTs), GRADE: LOW  \nExercise: 0 per 1000 \nNMES + exercise: 0 per 1000 (0 to 0   \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  179 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nDays out of bed  \ncombined with conventional exercise reduced the time taken for participants \nto first sit out of bed (4.98 days; 95% CI - 8,55 \u2013 (-)1,41; I\u00b2 =60%; GRADE: \nVery low, 2 RCT, n = 22  \n \n \n26998  \n Ngai-Shirley PC. Tai \nChi for chronic ob-\nstructive pulmonary \ndisease (COPD). \nCochrane Database \nof Systematic Re-\nviews 2016;(6).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD009953.pub2/ab-\nstract  \n \n \u2022 Body of Evidence:  n=12  eingeschlossene RCTs f\u00fcr \nMetaanalyse ( n=811  eingeschlossene Patienten)  \n\u2022 Suchzeitraum:  from inception to 9/2015  \n\u2022 Population: Patient *innen mit COPD  \n\u2022 Einschlusskriterien: No exclusions were based on age, \ngender, disease severity or smoking history.  \n \n\u2022 Interventionen:   \nTai Chi alone or Tai Chi in addition to another intervention  \nvs.usual care or another intervention identical to that used \nin the Tai Chi group \n \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Level of dyspnoea: All measures related to dyspnoea \nwere considered (e.g. Borg Scale, Modified Medical Re-\nsearch Council (MMRC) Dyspnoea Scale, Dyspnoea Vis-\nual Analogue Scale (DVAS)).  \n- Functional capacity or aerobic capacity  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- Pulmonary function  \n- Quality of life status  \n  \u25e6 Generic health- related quality of life  \n  \u25e6 Disease -specific health- related quality of life  \n- Quadriceps or other muscle strength \n- Balance  \n \u2022 Baseline -Charakteristika  \n- mean age: ranged from 61 to 74 years  \n- Programmes lasted for six weeks to one year  \n \nTai Chi versus usual care  \nLevel of dyspnoea Assessed with Modif ied Borg Scale, n=137 (1 RCT); \nGRADE: Low  \n- Usual care: 2.1 units  \n- Tai Chi: 0.2 unit lower  (95%CI -0.67 to 0.27 unit)  \n \nFunctional capacity A ssessed with 6- minute walk test (metre), n=318 (6 \nRCTs), GRADE: Very  low \n- Usual care: Mean 317.38 metres  \n- Tai Chi: 29.64 metres farther  (95% CI 10.52 to 48.77 metres)  \n- 6MWD (MD 29,64 m; 95% CI 10,52 - 48,77 m; I\u00b2 = 59%;  \n \nFunctional capacity Assessed with endurance shuttle walk test (second), n=38 \n(1 RCT), GRADE: Low  \n- Usual care: Mean 430 seconds  \n- Tai Chi: 373 seconds longer  (95%CI 135.42 to 610.58 seconds)  \n \nQuality of life (SGRQ) , n=233 (3 RCTs), GRADE: Very low  \n- Usual care: Mean 48. 93 units  \n- Tai Chi: 7.85 units lower  (95%CI -16.53 to 0.83 unit)  \n \nQuality of life (CRQ),  n=?48 (2 RCTs), GRADE: Low  \n- Usual care: Mean 4. 75 units  \n- Tai Chi: 0.41 unit higher  (95%CI -0.54 to 1.35 units)  \n \n>> No adverse events were reported, implying that Tai Chi is safe to practise \nin people with COPD.  \n AMSTAR -Score: 9/11  \n \ny-n-y-y-y-y-y-y-y-n-y NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  180 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n27074 \n Gendron LM. Active \nmind- body move-\nment therapies as \nan adjunct to or in \ncomparison to pul-\nmonary rehabilitation \nfor people with \nchronic obstructive \npulmonary disease. \nCochrane Database \nof Systematic Re-\nviews 2018;(10).  \n \nhttps://www.cochran\neli-\nbrary.com/cdsr/doi/1\n0.1002/14651858.C\nD012290.pub2/full  \u2022 Body of Evidence:   n=10  eingeschlossene RCTs f\u00fcr \nMetaanalyse (n=  762 eingeschlossene Patienten)  \n\u2022 Suchzeitraum:  inception to 07/2017; updated 07/2018 \n\u2022 Population: patients with COPD  \n\u2022 Einschlusskriterien:  \n- clinical diagnosis of COPD as defined by GOLD 2018  \n- best recorded FEV /FVC ratio < 0.7 \n- \u2265 18 years of age  \n- RCTs comparing AMBMT vs. PR or AMBMT + PR vs. PR  \n \n\u2022 Interventionen:  \nActive mind- body movement therapies  (AMBMT)  \n- including yoga, tai chi, qigong, pilates, others  \n- i.e. controlled breathing and/or focused m editation/ atten-\ntion interventions for which patients must actively move \ntheir joints and muscles for at least four weeks with no \nminimum intervention frequency)  \n- programmes of at least four weeks\u2019 duration with no mini-\nmum intervention frequency  \nvs. pulm onary rehabilitation (PR) \n- any inpatient or outpatient, community -based or home-\nbased rehabilitation programme lasting at least four \nweeks, with no minimum intervention frequency, that in-\ncluded conventional exercise training with or without edu-\ncation or psychological support  \n- Exercise training: any continuous endurance or interval \nexercise or upper limb or lower limb training in the form of \nwalking (groundbased or on a treadmill) and cycling with or \nwithout resistance/ strength training, flexibility training, or \ninspiratory muscle training  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Disease- specific quality of life (all validated tools w, e.g. \nCRQ, SGRQ, CAT)  \n- Generic health- related quality of life (e.g. Short Form \n(SF)-  36) \n- Dyspnoea (all validated tools, e.g. MRC Scale, B ORG \nScale, TDI, Dyspnoea domain of the CRQ)  \n- Serious adverse events (all types)  \n \n\u2022 Sekund\u00e4re Endpunkte:  8/10 studies considered walking training as equal to PR and used this as con-\nventional exercise training within PR --> limits comparison of AMBMT and PR  \n \nAMBMTs vs PR (mainly unstructured walking training)  \n \ndisease- specific quality of life  \n\u2022 SGRQ total score:  \n- statistically significant improvements;favoured AMBMT  \n- MD -5.83, 95% CI -8.75 to -2.92; 3 trials; 249 participants; low -quality evi-\ndence.  \n\u2022 COPD Assessment Test (CAT)  \n- statistically significant improvements favouring AMBMT over PR, with scores \nexceeding the MCID of three \n- MD 6.58 units (95%CI - 9.16 to - 4.00 units; one trial; 74 participants;  low-\nquality evidence)  \n \nDyspnoe  \n>> no between- group differences with regard to dyspnoea measured by:  \n\u2022 modified Medical Research Council Scale:  \n- MD 0.00 units, 95% CI - 0.37 to 0.37; two trials; 127 participants; very low -\nquality eviden ce  \n\u2022 Borg Scale:  \n- MD 0.44 units, 95% CI - 0.88 to 0.00; one trial; 139 participants; very low -\nquality evidence)  \n\u2022 Chronic Respiratory Questionnaire (CRQ) Dyspnoea Scale: MD -0.21, 95% \nCI -2.81 to 2.38; one trial; 11 participants; very low -quality evidenc e \n \n\u2022 Sicherheit: keine Adverse Events berichtet (n=490, 8 RCTs)  \n \nAMBMT + PR vs. PR alone  (mainly unstructured walking training)  \n\u2022 generic QoL  \n>> significant improvements measured by Short Form (SF) -36 for both the:  \n- SF-36 general health summary score (MD 5.42, 95% CI 3.82 to 7.02;  \none trial; 80 participants; very low -quality evidence)  \n- the SF -36 mental health summary score (MD 3.29, 95% CI 1.45 to 4.95; one \ntrial; 80 participants; very low -quality evidence).  \n\u2022 disease- specific QoL  \n>> no signif icant improvement with addition of AMBMT to PR versus PR alone  \n- SGRQtotal score:MD -2.57, 95%CI -7.76 to 2.62 units; one trial; 192 partici-\npants;  \nmoderate- quality evidence  \n- CRQ Dyspnoea Scale score: MD 0.04, 95% CI -2.18 to 2.26 units; one trial; AMSTAR -Score:  11/11  \n \ny-y-y-y-y-y-y-y-y-y-y \n \n \nAMSTAR II -Score:  \nModerate \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  181 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n- Exercise capacity (Maximal exercise performance,  Func-\ntional exercise capacity)  \n\u2022 Pulmonary function (FEV and FEV predicted, %;  FVC,  \nFEV /FVC ratio ) \n\u2022 Limb muscle function (muscle strength, endurance, and \nfatigue)  \n\u2022 Exacerbations  \n\u2022 Adherence (ratio between participants analysed and  \nparticipants who received intervention)  \n 80 parti cipants;  very low quality evidence ).  \n \n\u2022 Sicherheit: keine Adverse Events berichtet (n=272, 2 RCTs)  \n \n02198  \n Ashworth NL. Home \nversus center based \nphysical activity pro-\ngrams in older \nadults. Cochrane \nDatabase of Sys-\ntematic Reviews \n2005;(1).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD004017.pub2/ab-\nstract  \n \n \u2022 Body of Evidence:  n= 2 (f\u00fcr COPD -Subgruppe, mit 68 \neingeschlossenen Patient *innen)  \n\u2022 Suchzeitraum:  until 09/2002 \n\u2022 Population: older adults (50 years or older); eine Sub-\ngruppe mit COPD  \n\u2022 Einschlusskriterien f\u00fcr COPD -Subgruppe:  Existing \nChronic Obstructive Pulmonary Disease (CO PD) and al-\nlied conditions plus pneumoconiosis and other lung dis-\neases due to external agents  \n \n\u2022 Interventionen:   \n'home based' vs. 'center based' exercise program  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Measures of functional activity (ADLs, walking ability etc)  \n \n\u2022 Sekund \u00e4re Endpunkte:  \n- Long- term maintenance of physical activity (e.g. activity \nlog book, Community healthy activities model program for \nseniors -CHAMPS, etc)  \n- Measures of Quality of Life (SF36, Sickness impact pro \nle, etc)  \n- Cost  \n- Health Service utilization  \n \n\u2022 Sekund\u00e4re Endpunkte COPD related:  \n- Mortality  \n- Lung function tests  \n- Exercise capacity  Physiological measures:  \nTwo trials looked at older adults with COPD. In patients with COPD the evi-\ndence is conflicting. One study showed similar changes in various physiologi-\ncal measures at 3 months that persisted in the home based group up to 18 \nmonths but not in the center based group. The other study showed signifi-\ncantly better improvements in physiological measures in the center based \ngroup after 8 weeks but again the possibility of a training effect is high.  \n \nQuality of life:  \nn=1 Studie: Compared with controls, significantly more participants in the ex-\nercise groups experienced 'better' general well -being at 3 months (80% for \ncenter, 73% for home versus 47 % for control) and 18 months (62% for center, \n64% for home versus 50% for control). There was no significant difference be-\ntween home and center groups however.  \n \nMethodische Qualit\u00e4t:  \nAllocation concealment was 'unclear' in all the studies. None of the part ici-\npants in the included studies were blinded to the interventions (for obvious \nreasons). None of the investigators/assessors appeared to be blinded either \nhowever. Dropouts were well described and reached a maximum of approxi-\nmately 16%. Both studies were 'medium' quality.  AMSTAR -Score: 7/11  \n \nn-n-y-y-y-y-y-n-y-y-n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  182 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n26987 \n Osadnik CR. Airway \nclearance tech-\nniques for chronic \nobstructive pulmo-\nnary disease. \nCochrane Database \nof Systematic Re-\nviews 2012;(3).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD008328.pub2/ab-\nstract  \n \n \u2022 Body of Evidence:  n=28  eingeschlossene RCTs  und \nrandomised cross -over trials ( n= 907 eingeschlossene Pa-\ntient*innen); n= 12 f\u00fcr Metaanalys e  \n\u2022 Suchzeitraum:  inception to 10/ 2011 (PEDro 10/2009)  \n\u2022 Population: individuals with AECOPD and stable COPD  \n \n\u2022 Interventionen:   \n- any techniques applied with the primary purpose of clear-\ning sputum from the airways (This included but was not re-\nstricted to \u2019conventional\u2019 techniques, breathing exercises, \nand PEP or mechanical devices, but excluded suctioning \nand breathing strategies for purposes of relaxation (e.g. re-\nlaxed controlled breathing) or respiratory muscle strength-\nening (e.g. inspiratory/ expiratory muscle training).  \n\u2022 Control: intervention, sham intervention or  \ncoughing alone  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- beneficial effects on exacerbations, hospitalisation and \nHRQoL  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- evectiveness: airway clearance techniques  \n- airway clearance techniques are safe for individuals with \nAECOPD and stable COPD.  \n \u2022 Baseline -Charakteristika  \n- mean age: ranging from 54 to 72  \n- mean FEV1: from 29 to 58 % predicted  \n \n>> Ergebnisse f\u00fcr Patient *innen mit stabiler COPD:  \n \nexacerbations and hospit alisations  \n- 1 PEP -based study (n=30= investigated the short -term effect of ACTs on the \nnumber of AECOPDs, finding no significant differences between groups at \nfour weeks (OR 3.21, 95% CI 0.12 to 85.20).  \n- 1 PEP -based study (n=50) investigated the effect of ACTs on respiratory -re-\nlated hospital admissions, with long- term data revealing a significantly lower \nneed for hospitalisation in favour of the ACT group (OR 0.27, 95% CI 0.08 to \n0.95).  \n \nHRQoL  \n1 study (n=15 participants) investigated the effect of a PEP -based ACT on \nHRQoL, with short -term data revealing significantly lower (better) SGRQ (St. \nGeorge\u2019s Respiratory Questionnaire) total scores following one week of daily \nACTs compared to a sham intervention (MD - 6.10, 95% CI - 8.93 to - 3.27)  \n \nSymptoms  \n- 1 stu dy in quantitative analysis: Borg scores were significantly lower immedi-\nately following a PEP -based ACT plus inhaled bronchodilator therapy than af-\nter a sham ACT plus inhaled bronchodilator therapy (MD -0.30 points, 95% CI \n-0.53 to - 0.07; Analysis 2.12)  \n \nmortality (all -cause)  \nNo data were available for analysis.  \nSafety  \n- 5 Studies clearly reported no negative effects from ACTs  \n- 1 study reported a clinically important adverse event (one participant vomited \nand two others felt uncomfortable during a sequenc e of postural drainage po-\nsitions incorporating a head- down tilt)  \n- Meta- analysis revealed no significant effect of ACTs during an AECOPD on \nmortality in the short term (OR 0.72, 95% CI 0.14 to 3.80) or long term (OR \n0.82, 95% CI 0.26 to 2.63), however this  outcome is likely to be underpow-\nered.  AMSTAR -Score: 10/11  \n \ny-y-y-y-y-y-y-y-y-y-n \n27013  \n Holland AE. Breath-\ning exercises for \nchronic obstructive \u2022 Body of Evidence:  n= 16 eingeschlossene RCTs f\u00fcr \nMetaanalyse ( n= 1233 eingeschlossene P atient *innen)  \n\u2022 Suchzeitraum:  inception to 10/ 2011 \u2022 Baseline -Charakteristika  \n- mean age: ranging from 51 to 73 years  \n- mean FEV1: 30% to 51% predicted AMSTAR -Score: 8/11  \n \ny-y-y-y-y-y-y-y-ca-ca-n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  183 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \npulmonary disease. \nCochrane Database \nof Systematic Re-\nviews 2012;(10).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD008250.pub2/ab-\nstract  \n \n \u2022 Population: Patient *innen mit stabiler COPD  \n\u2022 Einschlusskriterien: Adults with a clinical diagnosis of \nCOPD in a stable condition  \n \n\u2022 Interventionen:   \n1. breathing exercises versus no breathing exercise s; \n2. breathing exercises versus another intervention;  \n3. breathing exercises combined with another intervention  \nversus no breathing exercises.  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Dyspnoea  \n- Functional or maximal exercise capacity  \n- Health- related quality of life  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- Gas exchange (e.g. PaO2, PaCO2).  \n- Ventilation (e.g. minute ventilation, tidal volume).  \n- Energy cost (e.g. oxygen consumption).  \n- Breathing pattern (e.g. respiratory frequency, chest wall  \nkinematics).  \n- Adverse events.  \n  \nPursed lip breathing compared to no breathing exercises \nDyspnoea during exercise;  Modified Borg Dyspnoea score; n=19 (1 RCT); \nGRADE: Low  \nNo breathing exercises: 4 units  \nPursed lip breathing: The mean dyspnoea score during exercise in the inter-\nvention groups was 1 unit lower (2.1 lower to 0.1 higher)  \n \nDyspnoea during daily life; University of California San Diego Shortness of \nBreath Questionnaire, n=19 ( 1 RCT), GRADE: Low  \nNo breathing exercises: 69 units  \nPursed lip breathing: The mean dyspnoea score during daily life in the inter-\nvention groups was 10 units lower (28.89 lower to 8.89 higher)  \n \nWalking capacity; 6-minute walk distance (metres), n=30 (1 RCT),  GRADE: \nLow \nNo breathing exercises: 233 metres  \nPursed lip breathing: The mean walking distance in the intervention groups \nwas 50.1 metres higher (37.21m to 62.99m higher)  \n \nHealth- related quality of life;  Dyspnoea domain of Hiratsuka scale, n=60 (2 \nRCTs), G RADE: Low  \nNo breathing exercises: 46 units  \nPursed lip breathing: The mean quality of -life score in the intervention groups \nwas 12.94 units better (lower) (22.29 lower to 3.6 lower)  \n \nDiaphragmatic breathing compared to no breathing exercises  \nDyspnoea, n=30 (1 RCT),  GRADE: Moderate  \nNo breathing exercises: Decrease of 0.33 units  \nDiaphragmatic breathing: The mean reduction in dyspnoea score in the inter-\nvention groups was 0.27 units greater (0.76 greater to 0.22 smaller)  \nWalking capacity , n=30 (1 RCT), GRADE: Mo derate \nNo breathing exercises: Reduction of 8 metres  \nDiaphragmatic breathing: The mean walking distance in the intervention \ngroups was 34.67 metres greater (4.05 higher to 65.29 higher)  \nHealth- related quality of life (SGRQ): n=30 (1 RCT), GRADE: Moderate  \nNo breathing exercises: Increase of 0.8 units  \nDiaphragmatic breathing: The mean change in quality of life score in the inter-\nvention groups was 10.51 units lower (better)  \n \nYoga compared to no breathing exercises \nDyspnoea intensity;  Modified Borg Scale, n=29 (1 RCT), GRADE: Low  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  184 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nNo breathing exercises: 3.3 units  \nYoga: The mean dyspnoea intensity in the intervention group was 0.5 units \nhigher  (0.99 lower to 1.99 higher)  \nDyspnoea distress; Modified Borg scale, n=29 (1 RCT), GRADE: Low  \nNo breathing exercises: 1.4 units  \nYoga: The mean dyspnoea distress in the intervention group was 0.2 units \nhigher  (0.97 lower to 1.37 higher)  \nWalking capacity, n=74 (2 RCTs), GRADE: Moderate  \nNo breathing exercises: Reduction of 6.38 m  \nYoga: The mean walking distance in the interventi on groups was 44.51 m \nhigher (28.47 higher to 60.55 higher)  \nHealth- related quality of life  (SGRQ), n=45 (1 RCT), GRADE: Moderate  \nNo breathing exercises: Reduction of 1.2 units  \nYoga: The mean quality of life score in the intervention group was  5.3 units \nlower (7.82 lower to 2.78 lower)  \n \n27077  \n McNamara RJ. Sing-\ning for adults with \nchronic obstructive \npulmonary disease \n(COPD). Cochrane \nDatabase of Sys-\ntematic Reviews \n2016;(7).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD012296/abstract  \n \n \u2022 Body of Evidence:  n=3 eingeschlossene RCTs f\u00fcr \nMetaanalyse ( n=112 eingeschlossene Patient *innen) \n\u2022 Suchzeitraum:  inception - 08/2017 \n\u2022 Population:  Patient *innen mit stabiler COPD  \n\u2022 Einschlusskriterien: adults with COPD of any age or \ndisease severity. The COPD was required to be stable. \nWe included participants with COPD who used supple-\nmental oxygen.  \n \n\u2022 Interventionen:   \n1. singing versus no intervention (usual care) or another \ncontrol intervention  \n2. singing plus pulmonary rehabilitation versus pulmonary \nrehabilitation alone \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Health- related quality of life  \n- Dyspnoea  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- Respiratory muscle strength  \n- Pulmonary function  \n- Psychological status  \n- Functional exercise capacity  \n- Peak exercise capacity  \u2022 Baseline -Charakterist ika \n- mean age: range 67 to 72 years  \n- mean FEV1: range from 37% to 64% of predicted values  \n- frequency of the singing intervention: ranged from 1 to 2 times a week over a \n6 to 24 week period.  \n- duration of the singing sessions: 60 minutes (conducted in gr oups led by a \nsinging teacher)  \n \n\u2022 Health-  related quality of life (respiratory specific)  SGRQ, n=58 (2 RCTs), \nGRADE: Low  \nControl: The mean change in SGRQ (total score) ranged across control \ngroups from - 5.0 to -0.4 \nSinging: The mean change in SGRQ (total s core) in the intervention groups \nwas 0.8 units higher  (3. 0 units lower to 4.7 units higher)  \n\u2022 Health-  related quality of life (generic)  SF-36 (Physical Component Summary \n(PCS) score), n=52 (2 RCTs, I\u00b2=0%),  GRADE: Low  \nControl: The mean change in SF -36 (PCS  score) ranged across control \ngroups from - 3.8 to -2.5 \nSinging: The mean change in SF -36 (PCS score) in the intervention groups \nwas 12.6 units higher  (5.5 units higher to 19.8 units higher)  \n \n\u2022 Health-  related quality of life (generic ) SF-36 (Mental Component Sumary \n(MCS) score), n=52 (2 RCTs), GRADE: Low  \nControl: The mean change in SF -36 (MCS score) ranged across control \ngroups from -3.2 to 4.3  AMSTAR -Score: 11/11  \n \ny-y-y-y-y-y-y-y-y-y-y NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  185 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n- Healthcare utilisation  \n- Physical activity level  \n- Adverse events/side effects  \n Singing: The mean change in SF -36 (MCS score) in the intervention groups \nwas 5.4 units higher  (3.9 units lower to 14.7 units higher)  \n \n\u2022 Dyspnoea Basal Dyspnea Index (BDI) (score), n=30 (1 RCT), GRADE: Very \nlow \nControl:The mean change in BDI (score) was 0.3 \nSinging: The mean change in BDI (score) in the intervention groups was  0.4 \nunits highe r (0.7 units lower to 1.5 units higher)  \n \n\u2022 Psychological status, n= 52 (2 RCT)  \nThere was no statistically significant improvement in the HADS anxiety score \n(MD -1.09, 95% CI -  3.02 to 0.83, n = 52) or HADS depression score (MD -\n0.87, 95% CI - 2.16 to 0.42, n = 52).  \n \n\u2022  Physical activi ty level: n=24, (1 RCT)  \nThere were no statistically significant differences between the singing group \nand control group for sedentary time (minutes per day), but the confidence in-\nterval is wide (MD - 8.60, 95%CI - 88.33 to 71.13). There were statistically si g-\nnificant differences in the remaining measures of physical activity favouring \nthe control group (steps (steps per day) MD - 1774.00, 95% CI -2847.73 to -\n700.27; physical activity duration (minutes per day) MD - 142.20, 95% CI -\n262.56 to - 21.84; active ener gy expenditure (kJ per day) MD -373.00, 95% CI \n-625.28 to -120.72).  \n \n- SF-36: MD 12,64; 95% CI 5,50 \u2013  19,77  \n \nNo adverse events/side effects  were reported by any of included studies,  \n27046  \n Ferreira IM. Nutri-\ntional supplementa-\ntion for stable \nchronic obstructive \npulmonary disease. \nCochrane Database \nof Systematic Re-\nviews 2012;(12).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD000998.pub3/ab-\nstract  \u2022 Body of Evidence:  n=17  eingeschlossene RCTs f\u00fcr \nMetaanalyse ( n=  632 eingeschlossene Patient *innen)  \n\u2022 Suchzeitraum:  current to 04/2012 \n\u2022 Population: Patient *innen mit stabiler COPD  \n\u2022 Einschlusskriterien: stable patients with COPD, among  \nwhom at least 75% of participants had a forced expired \nvolume in one second (FEV1) less than 70% predicted, \nand less than 12% reversibility after use of a bronchodila-\ntor \n \n\u2022 Interventionen:   \n- subject s received oral, enteral or parenteral nutritional \nsupport vs.  \n(I) placebo  Anthropometric measures (Illustrative comparative risks* (95% CI)  \n \nWeight (mixed population) kg (Follow -up: 2 to 24 weeks; n=512 participants; \n14 RCTs; GRADE: moderate ) \n- The mean weight (mixed population) in the control groups was 56.43 kg  \n- The mean weight (mixed population) in the intervention groups was 0.69 \nhigher (0.86 low er to 2.24 higher)  \n \nWeight (undernourished) kg (Follow -up: 2 to 24 weeks; n=325 participants; 11 \nRCTs; GRADE: moderate ) \n- The mean weight (undernourished) in the control groups was 60.34 kg  \n- The mean weight (undernourished) in the intervention groups was 1.65 \nhigher (0.14 to 3.16 higher)  \n AMSTAR -Score: 9/11  \n \ny-y-y-y-y-y-y-y-y-n-n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  186 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \n (ii) their usual diet or  \n(iii) other treatment regimens such as anabolic substances  \n \n\u2022 Prim\u00e4re Endpunkte:  \n1. Anthropometric measures (body weight, fat -free mass \nindex, lean body ma ss, mid -arm muscle circumference \n(MAMC), skinfold measures).  \n2. Functional exercise (timed walk test).  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n1. Pulmonary mechanics (lung volumes, respiratory mus-\ncle function).  \n2. Peripheral muscle function.  \n3. HRQoL derived from validated scales (e.g. SGRQ, \nCRQ, SF -36). Fat-free mass index  (mixed population) kg/m\u00b2 (Follow -up: 3 to 4 months; \nn=93 participants;  3 RCTs; GRADE: low ) \n- The mean fat -free mass index (mixed population) in the control groups was \n14.8 kg/m\u00b2  \n- The mean fat -free ma ss index (mixed population) in the intervention groups \nwas 0.08 higher (0.51 lower to 0.66 higher)  \n \nFat-free mass index (undernourished patients) kg/m\u00b2 (Follow -up: 3 to 4 \nmonths; n=62 participants; 2 RCTs; GRADE: low ) \n- The mean fat -free mass index (undernourished patients) in the control \ngroups was 14.5 kg/m\u00b2  \n- The mean fat -free mass index (undernourished patients) in the intervention \ngroups was 0.31 higher (0.32 lower to 0.95 higher)  \n \nFunctional exercise  \nThere was low -quality evidence (five RCTs, 142 part icipants) of no significant \ndifference between groups in the six -minute walk distance (MD 14.05 m; 95% \nCI -24.75 to 52.84), 12- minute walk distance or in shuttle walking. However, \nthe pooled change from baseline for the six -minute walk distance was signifi-\ncant (MD 39.96 m; 95% CI 22.66 to 57.26).  \n \nHealth- related quality of life  \nThere was low -quality evidence (4 RCTs, 130 participants) of no significant \ndifference in HRQoL total score (SMD - 0.36; 95% CI - 0.77 to 0.06) when pool-\ning results from both the St George\u2019s Respiratory Questionnaire (SGRQ) and \nthe Chronic Respiratory Questionnaire (CRQ).  \n \nTwo trials (n=67) used the SGRQ to measure individual domains of activity, \nimpact and symptoms. At the end of treatment, the pooled total SGRQ score \nwas both statisti cally and clinically significant (MD  6.55; 95% CI -11.7 to -\n1.41). The 3 RCTs (n=123) that used the CRQ to measure the change in indi-\nvidual domains (dyspnoea, fatigue, emotion, mastery), found no significant dif-\nference between groups.  \n \n>> This review of 17 studies (632 participants) that provided nutritional \nsupplementation for patients with COPD for more than two weeks found \ngrowing evidence that nutritional supplementation improved body \nweight, respiratory muscle strength, walking and quality of life.  \n \n27080  Pollok J. Psychologi-\ncal therapies for the \u2022 Fragestellung: To assess the efectiveness of psycholog-\nical therapies for the treatment of depression in patients \u2022 Baseline -Charakteristika:  \n- depressive symptoms varied from no symptoms to severe depression  AMSTAR -II: \nmoderate  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  187 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \ntreatment of depres-\nsion in chronic ob-\nstructive pulmonary \ndisease. Cochrane \nDatabase of Sys-\ntematic Reviews \n2019;(3).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD012347/abstract  \n \n with chronic obstructive pulmon ary \ndisease.  \n \n\u2022 Suchzeitraum: June 2016 to 26 November 2018  \n\u2022 Population:  patients with COPD whose depressive \nsymptoms were measured before or at baseline assess-\nment.  \n \n\u2022 Interventionen:  \n- psychological therapies  \nvs. \n- either no intervention, education, or  \n \n- psychological therapies combined with a co- intervention  \nvs. \n - the same co -intervention  \n \n\u2022 eingeschlossene Studien: 13 RCTs, 1500 participants  \n  \ndepressive symptoms  \n- small effect showing the effectiveness of psychological therapies in improv-\ning depressive symptoms when compared to  \n-- no intervention (SMD 0.19, 95% CI 0.05 to 0.33; P = 0.009; 6 studies, 764 \nparticipants; GRADE: very low ) \n-- educat ion (SMD 0.23, 95% CI 0.06 to 0.41; P = 0.010; 3 studies, 507 partici-\npants; GRADE: very low ) \n \nChange in Quality of life  \n-- no intervention: standardised mean improvement in QoL from baseline in \nthe psychological therapies group was 0.15 higher (0.09 lower to 0.38 higher) \ncompared to no intervention (3 studies; 348 participants; GRADE: very low ) \n-- education:  \n--- mean change from baseline in QoL, emotional functioning in the psycho-\nlogical therapies group was 2.98 units CRQ higher (9.15 lower to 3.19 lower) \ncompared to education (2 studies; 460 participants; GRADE: very low ) \n--- mean quality of life -  CRQ - dyspnoea in the psychological therapies group \nwas 1.84 units CRQ higher (5.94 lower to 2.26 higher) compared to education \n(2 studies; 458 participants; GRA DE: very low ) \n \npsychological therapy combined with a PR programme  \n- can reduce depressive symptoms more than a PR programme alone (SMD \n0.37, 95% CI - 0.00 to 0.74; P = 0.05; I\u00b2=0%, 2 studies, 112 participants; \nGRADE: very low ) \n \nNone of the included studies  measured adverse events.  \n \n \n  \n \n \n \n \n27054  Usmani ZA. Psycho-\nlogical therapies for \nthe treatment of anx-\niety disorders in \nchronic obstructive \npulmonary disease. \nCochrane Database \nof Systematic Re-\nviews 2017;(3).  \n \u2022 Body of Evidence:  n=3  eingeschlossene RCTs f\u00fcr \nMetaanalyse ( n= 319 eingeschlossene Pat ient*innen) \n\u2022 Suchzeitraum:  to 8/2015 \n\u2022 Population: Patient *innen mit COPD und Angstst\u00f6rung \n\u2022 Einschlusskriterien: > 40 years, with COPD and coex-\nisting anxiety disorders (as confirmed by recognised diag-\nnostic criteria or a validated measurement scale) or anxi-\nety symptom( s)  \n \n\u2022 Interventionen:   \u2022 All three studies assessed psychotherapy (CBT) with a co -intervention, ver-\nsus the co- intervention alone  \n \nAnxiety Becks Anxiety Inventory. Scale f rom: 0 to 63. Follow -up: 3- 12 \nmonths, n=319 (3 RCTs), GRADE: Low; I\u00b2=62%  \n- Control: mean anxiety 15.51 \n- Psyc hological therapies for anxiety: mean anxiety  4.41 lower  (8.28 to 0.53 \nlower)  \n- Comment: Beneficial findings were observed in favour of the psychological AMSTA R-Score: 11/11  \n \ny-y-y-y-y-y-y-y-y-y-y \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  188 \n      \n \nID Referenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD010673.pub2/ab-\nstract  \n \n psychological therapies  \nvs. \nno intervention or education only  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Change in anxiety symptoms  \n- Adverse events  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- Change in quality of life  \n- Difference in exercise toleranc e \n- Change in dyspnoea scores  \n- Change in length of stay or readmission rate  \n- Change in forced expiratory volume in one second \n(FEV1)  \n therapy group (p= 0.03), with levels of anxiety half that of the control popula-\ntion by final follow -up (Gillis 1995)  \n \nQuality of life -  physical composite  (SGRQ and SF36 Follow -up: 6- 12 months), \nn=289 (2 RCTs);  GRADE: Low, I\u00b2=61%  \n- Control: mean QoL physical 45.08 \n- Psychological therapies for anxiety: mean QoL was 0.40 standard devia-\ntions lower (0.88 lower to 0.08 higher)  \n- Comment: Subgroup analyses separating short -term (0 to 3 months; SMD -\n0.22, 95%CI - 0.45 to 0.01; P = 0.06) and long- term follow - up (6 to 12 months; \nSMD -0.30, 95% CI - 0. 53 to -0.06; P = 0.01) resulted in better treatment out-\ncomes longterm  \n \nQuality of life -  emotional composite (SGRQ and SF36 Follow -up: 6- 12 \nmonths), n=289 (2 RCTs),  GRADE: Low, I\u00b2=82%  \n- Control: mean QoL emotional 52.3 \n- Psychological therapies for anxiety: mean QoL emotional was 0 .30 standard \ndeviations lower (1.03 lower to 0.44 higher)  \n- Comment: Subgroup analyses separating short -term (0 to 3 months; (SMD \n0.05, 95% CI - 0.18 to 0.28) and long- term follow -up (6 to 12 months; (SMD -\n0.09, 95% CI - 0.32 to 0.14) resulted in better treatment outcomes long- term \n \nExercise cap acity (6MWD Follow -up: 3- 12 months), n=268 (2 RCTs), \nGRADE: Low; I\u00b2=80%  \nControl: mean 839 \nPsychological therapies for anxiety: mean exercise capacity was 2.78 lower \n(58.49 lower to 52.94 higher)  \n \nAdverse events : No studies reported on adverse events  \n \nAnhang 7.2  Cochrane Reviews Respiratorische Insuffizienz  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nCranston JM. \nDomiciliary oxy-\ngen for chronic \nobstructive pul-\nmonary dis-\nease. Cochrane \u2022 Fragestellung: To determine the effect of domiciliary ox-\nygen therapy on survival and quality of life in patients with \nCOPD.  \n \n\u2022 Suchzeitraum: current as of 1/2007 \n\u2022 Population:  patients with hypoxaemia and COPD  Continuous oxygen therapy versus nocturnal oxygen therapy  \n- Mortality at 12 months:  \nPeto Odds Ratio (OR) 0,53 (95% KI 0,25; 1,11); 1 RCT, n = 203, JADAD 3  \n- Mortality at 24 months:  \nPeto OR 0,45 (95% KI 0,25; 0,81); 1 RCT, n = 203, JADAD 3  \n AMSTAR - I Score: 7/11 \n \ny-n-y-y-y-y-y-y-ca-n-n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  189 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nDatabase of \nSystematic Re-\nviews 2005;(4).  \n \nhttp://onlineli-\nbrary.wiley.com\n/doi/10.1002/14\n651858.CD001\n744.pub2/ab-\nstract  \n \n  \n\u2022 Interventionen: long term domiciliary or home oxygen \ntherapy (all forms  \nof LTOT including provision of oxygen using cylinders, \nconcentrators or liquid oxygen therapy)  \n\u2022 Vergleich:  control treatment (placebo air by the same \nmethod of delivery or no specific intervention)  \n \n\u2022 eingeschlossene Studien: n=6  eingeschlossene RCTs \nf\u00fcr Metaanalyse  \n \n\u2022 RoB der ein geschlossenen Studien (GRADE nicht \ndurchgef\u00fchrt):  \n- methodological quality of the studies was scored as mod-\nerate (Jadad score 3) in five studies (NOTT 1980,MRC \n1981, Fletcher 1992, Gorecka 1997, Chaouat 1999) and \nlow (Jadad score 2) in the remaining trial (Haidl 2004).  \n Long -term oxygen therapy versus no oxygen therapy in severe hypoxaemia  \n- Mortality at 60 months:  \nPeto OR 0,42 (95% KI 0,18; 0,98); 1 RCT, n = 87, JADAD 3  \n \nNocturnal oxygen therapy versus room air with mild to moderate hypoxaemia; \nchange from baseline  \n- Mortality at 36 months:  \nPeto OR 0,97 (95% KI 0,41; 2,31);  I\u00b2:0%, 2 RCT, n = 114, JADAD 3  \n \nLong term oxygen therapy versus no oxygen therapy in mild to moderate hypoxae-\nmia \n- Mortality:  \nPeto OR 1,39 (95% KI 0,74; 2,59);  I\u00b2:0%, 2 RCT, n = 163, JA DAD 2 -3 \n- Mortality between oxygen >15hrs per day and <15hrs per day:  \nPeto OR 1,67 (95% KI 0,62; 4,47); 1 RCT, n = 68, JADAD 3  \n- End exercise dyspnoea score:  \nMean Difference -  1,20 (MD, 95% KI - 2,47; 0,07), 1 RCT, n = 28, JADAD 2  \n- Endurance time:  \nMD 2,20 (95% KI ( -0,73; 5;13), 1 RCT, n = 28, JADAD 2 \n \n>> Long- term home oxygen therapy improved survival in a selected group of  COPD pa-\ntients with severe hypoxaemia (arterial PaO2 less than 55 mm Hg (8.0 kPa)). Home oxy-\ngen therapy did not appear to improve survi val in patients with mild to moderate hypoxae-\nmia or in those with only arterial desaturation at night.  \nAmeer F. Am-\nbulatory oxygen \nfor people with \nchronic obstruc-\ntive pulmonary \ndisease who \nare not hypox-\naemic at rest. \nCochrane Data-\nbase of Sys-\ntematic Re-\nviews 2014;(6).  \n \nhttp://onlineli-\nbrary.wiley.com\n/doi/10.1002/14\n651858.CD000\u2022 Fragestellung: To determine the longer term efficacy of \nambulatory oxygen therapy only in patients with COPD \nwho do not meet the criteria for LTOT, with respect to im-\nprovement in exercise capacity, mortality, quality of life \nand other relevant measures of improvement.  \n \n\u2022 Suchzeitraum: current as of 11/2012 \n\u2022 Population:  \n- Patient*innen mit stabiler COPD  \n- Participants had chronic hypoxaemia (resting PaO 55 to \n59 mmHg) without cor pulmonale (failure of the right side \nof the heart caused by an increase in blood pressure in \nthe pulmonary artery, the vessel that carries blood from \nthe heart to the lungs) or PaO \u2265 60 mmHg, or they devel-\noped hypoxaemia on activity (PaO < 60 mmHg or periph-\neral capillary oxygen de- saturation to < 88% SpO ) with or \nwithout cor pulmonale with sympt oms on exertion.  \n\u2022 Einschlusskriterien:  participants with  \u2022 Baseline -Charakteristika  \n- mean age: 71 years  \n \nMortality ( Follow -up: mean 12 weeks)  \n- RR 4 ,17 (95% KI 0,48; 36,3); I\u00b2: 0%, 2 RCT, n = 179,  GRADE: moderat  \n- Comment: Although deaths occurred only in the intervention arm of the study (n=3), \nthey were not believed to be a direct result of the intervention  \n \nQuality of life (dyspnoea on CRQ, the out put is a number f rom 0 to 7, where higher on \nthe scale is better)  \n- MD 0,28 (95% KI 0,10; 0,45); I\u00b2: 0%, 4 RCT, n = 341,  GRADE: moderat  \n- Control: Baseline risk in control groups ranged from 2.8 to 3.7 points  \n \nDyspnoea  \n- Meta- analysis not possible; 3 RCT,  n = 198, GRADE: not applicable  \n \nAdverse events Follow -up: mean 12 weeks   \n- Ambulatory oxygen: 117/1000 (35 to 325)  AMSTAR - I Score: 11/11  \n \ny-y-y-y-y-y-y-y-y-y-y NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  190 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n238.pub2/ab-\nstract  \n \n COPD who did not meet criteria for LTOT  \n \n\u2022 Interventionen:  ambulatory oxygen therapy provided \nthrough portable oxygen cylinders/batterypowered devices \nor liquid oxygen canisters  \n\u2022 Vergleich: placebo air cylinders, usual medical care or \nco-intervention  \n \n\u2022 eingeschlossene Studien : n=4  eingeschlossene RCTs \nf\u00fcr Metaanalyse ( n=331 eingeschlossene Patient*innen)  - Control:146/1000  \n- OR 0,77 (95% KI 0,21; 2,81); I\u00b2: 1%, 2 RCT, n = 83, GRADE: niedrig  \n \nHospitalisations:  No studies reported data on hospi talisations  \n \n>> In patients with COPD with moderate hypoxia, current evidence on ambulatory oxygen \ntherapy reveals improvements in dyspnoea post exercise and in the dyspnoea and fa-\ntigue domain of quality of life. However, evidence for the clinical utility and effectiveness \nof ambulatory oxygen in improving mortality and exercise capacity was not evident in this \nreview.  \n>> From this review, it is not possible to know whether ambulatory oxygen therapy should \nbe provided during exercise or for day -to-day activities for patients with COPD who are \nnot severely hypoxaemic at rest.  \nBradley JM. \nShort -term am-\nbulatory oxygen \nfor chronic ob-\nstructive pulmo-\nnary disease. \nCochrane Data-\nbase of Sys-\ntematic Re-\nviews 2005;(4).  \n \nhttp://onlineli-\nbrary.wiley.com\n/doi/10.1002/14\n651858.CD004\n356.pub3/ab-\nstract  \n \u2022 Fragestellung: To determine the efficacy of ambulatory \noxygen in patients with COPD using single assessment \nstudies.  \n \n\u2022 Suchzeitraum:  current as of 3/2005 \n\u2022 Population: Patient*innen mit stabiler COPD  \n\u2022 Einschlusskriterien: Studies had to compare oxygen \nand placebo when administered to people with COPD who \nwere undergoing an exercise test \n \n\u2022 Interventionen: ambulatory oxygen therapy (provided \neither via oxygen cylinders or a reservoir system)  \n\u2022 Vergleich: intervention (Placebo) via air cylinders or a \nreservoir system  \n \n\u2022 eingeschlossene Studien:   n=31  eingeschlossene \nRCTs (cross -over  indesign) f\u00fcr Metaanalyse ( n=534  \neingeschlossene Patient*innen)  \n \n\u2022 RoB der eingeschlossenen Studien: Overall, the meth-\nodological quality of the included studies as rated by the \nJadad score was low (16 studies had score of 1; nine \nstudies had a score of  2; 4 studies had a score of 3; and \ntwo studies had a score of 5).  \n \u2022 Baseline -Charakteristika  \n- mean age: ranged from 47 to 73 years  \n- mean PaO2 ranged from 6.9 KPa to 11.3 KPa (52 mmHg to 85 mmHg)  \n \nEndurance test studies: Exercise capacity  \nDistance  \nWith fixed effects modelling oxygen significantly improved exercise distance by 18,86 me-\ntres (95% KI 13,11; 24,61, 10 Studien, n = 238; 6MWT) and 18,61 metres (95% KI 12,83; \n24,39, 10 Studien, n = 238; endurance walk)  \n \nMaximal test studies:  Exercise capacity  \nDistance  \nThere was a significant improvement in distance walked during oxygen versus placebo of \n32 metres (95% KI 20,61; 43,38, 4 Studien, n = 70). There was a moderate level of heter-\nogeneity between the studies. Random Effects modelling widened the confid ence interval \nbut the result remained significant (39,57 metres (95% KI 17,03; 62,11)).  \n \nEndurance test isotimes studies:  \nBreathlessness  \nRandom Effects modelling gave a significant result in favour of oxygen (Somfay 2001 low \ndose: -1,46 (95% KI - 2,30; -0,62); Somfay 2001 high dose: - 1,51 (95% KI -2,41; -0,61); n \n= 44).  \n \nMaximal test isotimes:  \nBreathlessness  \nData from 14 patients showed high dose oxygen significantly reduced breathlessness \ncompared to placebo but no data was provided  \n AMSTAR - I Score: 9/11  \n \ny-n-y-y-y-y-y-y-y-y-n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  191 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n>> This rev iew provides some evidence from small, single assessment studies that am-\nbulatory oxygen improves exercise performance in people with moderate to severe \nCOPD. The results of the review may be affected by publication bias, and the small sam-\nple sizes in the s tudies.  \nNonoyama M. \nOxygen therapy \nduring exercise \ntraining in \nchronic obstruc-\ntive pulmonary \ndisease. \nCochrane Data-\nbase of Sys-\ntematic Re-\nviews 2007;(2).  \n \nhttp://onlineli-\nbrary.wiley.com\n/doi/10.1002/14\n651858.CD005\n372.pub2/ab-\nstract  \n \n \u2022 Fragestellung: To determine how supplemental oxygen \nin comparison to control (compressed air or room air) dur-\ning the exercise- training component of a pulmonary reha-\nbilitation program affects exercise capacity, dyspnea and \nhealth- related quality of life in individuals with COPD.  \n \n\u2022 Suchzeitraum:  last search 6/2009 \n\u2022 Population:  Patient*innen mit COPD  \n\u2022 Einschlusskriterien: > 18 years, diagnosed with COPD \nand did not meet criteria for long- term oxygen therapy. No \nstudies with mixed populations (pulmonary fibrosis, cystic \nfibrosis, etc) were included.  \n \n\u2022 Intervention: supplemental oxyg en during the exercise-\ntraining \n\u2022 Vergleich:  control (compressed air or room air) during \nthe exercise- training  \n \n\u2022 eingeschlossene Studien:   \nn=5  eingeschlossene RCTs f\u00fcr Metaanalyse ( n=31 (oxy-\ngen)/ n=32 (control)  eingeschlossene Patient*innen)  \n Functiona l ex. capacity: 6 MWT distance  (2 studies) n = 22 O\u00b2 + n= 22 control, GRADE: \nLow \nEffect: WMD (95% CI): - 23.87 metres ( -81.55 to 33.82)  \n \nFunctional ex. capacity: 6 MWT end- of-test Borg dyspnea (2 studies) n = 22 O\u00b2 + n = 22 \ncontrol, GRADE: Low  \nEffect: WMD ( 95% CI): 0.06 Borg units ( -0.89 to 1.00)  \n \nCRQ dyspnea (2 studies) n = 26 O\u00b2 + n = 27 control,  GRADE: Low  \nEffect: WMD (95% CI): 0.03 ( -0.54 to 0.59)  \n \n>> This review provides little support for oxygen supplementation during exercise training \nfor individuals with COPD, but the evidence is very limited.  \n AMSTAR - I Score: 9/11  \n \ny-n-y-y-y-y-y-y-y-y-n \nEkstr\u00f6m M. Ox-\nygen for breath-\nlessness in pa-\ntients with \nchronic obstruc-\ntive pulmonary \ndisease who do \nnot qualify for \nhome oxygen \ntherapy. \nCochrane Data-\nbase of Sys-\ntematic Re-\nviews \n2016;(11).  \u2022 Fragestellung: To determine the efficacy of oxygen ver-\nsus air in mildly hypoxaemic or non- hypoxaemic patients \nwith COPD  \n \n\u2022 Suchzeitraum:  to 7/2016 \n\u2022 Population: Patient*innen mit COPD  \n\u2022 Einschlusskriterien : people with COPD and mild or no \nhypoxaemia (partial pressure of  oxygen (PaO2) > 7.3 kPa) \nwho were not already receiving LTOT; > 18 years  \n \n \n\u2022 Intervention : oxygen delivered through a non- invasive \nmethod  \n\u2022 Vergleich:  air delivered through the same non- invasive \nmethod  Breathlessness - all trials  (Lower score indicates improvement in breathlessness), n=865, \n32 RCT, GRADE: Low  \n- Effect: SMD 0.31, SD lower  (95% CI 0.43 lower to 0.2 lower)  \n- Comment: This corresponds to 0. 65 points lower (0.90 lower to 0.42 lower) on a 0- 10 \nNRS.*  \n \nHealth-  related quality of life -  all trials  (Higher scores indicate improved healthrelated \nquality of life), n=267, 5 RCT, GRADE: Low  \n- Effect: SMD 0.12, SD higher (95% CI 0.04 lower to 0.28 higher)  \n- Comment: This corresponds to 0. 25 points higher (0.09 lower to 0.59 higher) on a 0- 10 \nNRS.*  \n \n*Difference on a 0- 10 NRS calculated using the SD of 2.1 for the COPD group in Aber-\nnethy 2010 for individual participant data.  \n AMSTAR - I Score: 9/11 \n \ny-n-y-y-y-y-y-y-y-y-n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  192 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \nhttp://onlineli-\nbrary.wiley.com\n/doi/10.1002/14\n651858.CD006\n429.pub3/ab-\nstract   \n\u2022 eingeschlossene Studien : n=33  eingeschlossene \nRCTs f\u00fcr Metaanalyse (n=901 eingeschlossene Patient*in-\nnen) \n Adverse event s were in sufficiently and inconsistently reported;  \ntherefore, meta- analysis was not possible.  \n \n>> We found that oxygen can modestly reduce breathlessness. To be effective, oxygen \nhas to be given during exercise.Most studies evaluated oxygen given during exercise \ntesting in the laboratory. Oxygen therapy during daily life had uncertain effects on breath-\nlessness and did not clearly change patient quality of life.  \n \nMenadue C. \nNon-invasive \nventilation dur-\ning exercise \ntraining for peo-\nple with chronic \nobstructive pul-\nmonary dis-\nease. Cochrane \nDatabase of \nSystematic Re-\nviews 2014;(5).  \n \nhttp://onlineli-\nbrary.wiley.com\n/doi/10.1002/14\n651858.CD007\n714.pub2/ab-\nstract  \n \n \u2022 Fragestellung : To determine whether NIV during exer-\ncise training (as part of pulmonary rehabilitation) affects \nexercise capacity, HRQL and physical activity in people \nwith COPD compared with exercise training alone or exer-\ncise training with sham NIV.  \n \n\u2022 Suchzeitraum:  1/1987 and 11/ 2013 \n\u2022 Population: Patient*innen mit stabiler COPD  \n\u2022 Einschlusskriterien: no history of an exacerbation was \nreported over the past month  \n\u2022 Ausschlusskriterien:  participants with non- COPD res-\npiratory disease or participants with concomitant neuro-\nmuscular disease, a restrictive thoracic disorder, signifi-\ncant cardiac failure or cardiac disease if data from partici-\npants with COPD could not be analysed separately.  \n \n\u2022 Interventionen: application of NIV (including bilevel, in-\nspiratory pressure support and proportional assist ventila-\ntion) delivered via a mask or mouthpiece during all super-\nvised exercise training sessions  \n \n\u2022 Vergleich: exercise training with or without sham NIV \nduring all supervised exercise training sessions  \n \n\u2022 eingeschlossene Studien : n=6  eingeschlossene RCTs \noder Randomised cross -over trials f\u00fcr Metaanalyse ( \nn=126  eingeschlossene Patient*innen)  \u2022 Baseline -Charakteristika  \n- mean age: ranged from 63 to  71 years  \n- men= n = 93 of 108 (f\u00fcr 5/6 Studien berichtet)  \n- mean FEV1: 26% to 41%predicted \n \nExercise capacity: percentage change in peak work rate Incremental cycle or incremental \ntreadmill test, I\u00b2: 0%, n=60 (3 RCTs), GRADE: Low  \n- Exercise training alone or exercise training with sham non- invasive ventilation: ranged \nfrom a mean of 9% to 38%  \n- Non-invasive ventilation during exercise training: in intervention groups was 17% higher  \n(7% to 27% higher)  \n \nExercise capacity: percentage change constant work rate endurance time Constant work \nrate cycle endurance test, I\u00b2: 0%, n=48 (2 RCTs), GRADE: Low  \n- Exercise training alone or exercise training with sham non- invasive ventilation: ranged \nfrom a mean of 74% to 88%  \n- Non-invasive ventilation during exercise traini ng: in the intervention groups was 59% \nhigher ( 4% to 114% higher)  \n \nHealth- related quality of life, Change in total score (SGRQ), I\u00b2: 0%, n= 48 (2 RCTs), \nGRADE: Moderate  \n- Non-invasive ventilation during exercise training: Mean health- related quality of lif e in \nthe intervention groups was 2.45 points higher  (2.3 lower to 7.2 higher)  \n \n- Physical activity: outcome was not reported in any of the included studies  \n- No information regarding adverse events or cost was reported.  \n AMSTAR - I Score: 11/11  \n \ny-y-y-y-y-y-y-y-y-y-y \nStruik FM. Noc-\nturnal non- inva-\nsive positive \u2022 Fragestellung: To assess the effects of nocturnal -\nNIPPV at home via nasal mask or face mask in people \nwith COPD by using a meta- analysis based on individual  \npatient data (IPD).  \u2022 Baseline -Charakteristika  \n- mean age: 67; men= 77%; mean FEV1: 0.73 L, mean PaCO2: 53 mmHg  \n \n\u2022 NIPPV during the night for 3 and 12 months in people with COPD who had raised levels AMSTAR - I Score: 9/11  \n \ny-y-y-y-y-n-y-y-ca-y-y NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  193 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \npressure venti-\nlation for stable \nchronic obstruc-\ntive pulmonary \ndisease. \nCochrane Data-\nbase of Sys-\ntematic Re-\nviews 2013;(6).  \n \nhttp://onlineli-\nbrary.wiley.com\n/doi/10.1002/14\n651858.CD002\n878.pub2/ab-\nstract   \n\u2022 Suchzeitraum: up to 8/2012  \n\u2022 Population : Patient*innen mit COPD  \n \n\u2022 Interventionen:  nocturnal -NIPPV (applied through a na-\nsal or facemask) at home for at least five hours per night, \nfor at least three consecutive weeks plus standard therapy  \n\u2022 Vergleich:  standard therapy alone \n \n\u2022 eingeschlossene Studien : n=7  eingeschlossene RCTs \nf\u00fcr Meta analyse ( n=245  eingeschlossene Patient*innen)  \n of carbon dioxide had no cl inically or statistically significant effect on gas exchange, six -\nminute walking distance, health- related quality of life, lung function, respiratory muscle \nstrength and sleep efficiency. This means we found little or no difference in the outcomes.  \n \nNoctur nal non- invasive positive pressure ventilation compared with standard treat-\nment  \n6MWD after 3 months,  n=40 (3 RCTs),  GRADE: Low  \nStandard treatment: The mean 6MWD in the control group was 324 m  \nNocturnal -NIPPV: The mean 6WMD in the intervention group was 27, 7 higher (95% KI -\n11,0; 66,3)  \n \nQuality of life: SGQR after 12 months,  n=103 (2 RCTs), GRADE: Low  \nStandard treatment: The mean SGRQ in the control group was 60,15  \nNocturnal -NIPPV: The mean SGRQ Total score in the intervention group was 0,90 \nhigher  (95% KI - 19,21; 21,01)  \nKopsaftis Z, \nCarson-\nChahhoud KV, \nAustin MA, et \nal. Oxygen ther-\napy in the pre-\nhospital setting \nfor acute exac-\nerbations of \nchronic obstruc-\ntive pulmonary \ndisease. \nCochrane Data-\nbase Syst Rev \n2020; \n1:CD005534.  \n \nhttp://www.ncbi.\nnlm.nih.gov/pub\nmed/31934729 . \n \u2022 Fragestellung: To determine the effect of different in-\nspired oxygen concentrations (\"high flow\" compared to \n\"controlled\") in the pre- hospital setting (prior to casu-\nalty/emergency department) on outcomes for people with \nacute exacerbations of COPD (AECOPD).  \n \n\u2022 Suchzeitraum:  16 September 2019 \n\u2022 Population: people with acute exacerbations of COPD \n(AECOPD)  \n\u2022 Ein- und Ausschlusskriterien  \n \n\u2022 Intervention: titrated oxygen therapy  \n\u2022 Vergleich:  high- flow oxygen therapy  \n \n\u2022 eingeschlossene Studien : 1 RCT, n=214 participants  \n \u2022 Baseline -Charakteristika:  mean age 68 years  \n \n\u2022 mortality (respiratory-  related and allcause)  \n- reduction in pre/in- hospital mortality: in favour of the titrated oxygen group (two deaths \nin the titrated oxygen group compared to 11 deaths in the high- flow control arm)  \n- RR 0,22 (95% KI 0,05; 0,97); 1 RCT, n=214; GRADE: low  \n- absolute effect of 94/1000 (high- flow oxygen) vs 21/1000 (titrated oxygen)  \n- number needed to treat for an additional beneficial outcome (NNTB): 14 (95% KI 12;  \n355) with titrated oxygen therapy  \n \n\u2022 Arterial blood gas (pH); 1 RCT, n=214; GRADE: low  \n- titrated oxygen therapy: MD 0.06 pH higher (0.04 lower to 0.16 higher)  \n- high- flow oxygen therapy: mean arterial blood gas (pH) was 7.29  \n \n\u2022 Ventilation of any type  \n- titrated oxygen therapy: 96 per 1000 (41 to 221)  \n- high- flow oxygen therapy:143 per 1000  \n- RR 0.67 (95% KI 0,29; 1,55); 1 RCT, n=189, GRADE: low  \n \n\u2022 Length of hospital stay ; 1 RCT, n=214; GRADE: low  \n- titrated oxygen therapy: MD 0.88 days lower (2.25 lower to 0.49 higher)  \n- high- flow oxygen therapy: mean length of hospital stay was 6.3 days  \n \n>> The one included study found a reduction in pre/in- hospital mortality for the titrated  \noxygen arm compared to the high -flow control arm. However, the paucity of evidence AMSTAR - II \nQualit\u00e4t des Reviews: hoch  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  194 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nsomewhat limits the reliability of these findings and generalisability to other settings. \nThere is a need for robust, well -designed RCTs to further investigate the eIect of oxygen \ntherapies in the pre -hospital setting for people with AECOPD.  \nAnhang 7.3  Ganzk\u00f6rpervibration  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nZhou J. Whole -\nbody vibration \ntraining - better \ncare for COPD pa-\ntients: A system-\natic review and \nmeta- analysis. Int \nJ Chron Obstruct \nPulmon Dis 2018; \n13:3243\u2013 54.  \n \nhttps://www.ncbi.nl\nm.nih.gov/pub-\nmed/30349230 . \n \n \u2022 Metaanalyse, nur RCT  \n\u2022 Herkunft: China  \n\u2022 Suchzeitraum: 04/2018 \n\u2022 Population: Patient*innen mit COPD  \n\u2022 Interventionen:  WBVT vs. conventional training  \n \n\u2022 Einschlusskriterien:  \n1) patients with COPD;  \n2) compare the effects difference between WBVT and \nconventional training;  \n3) be RCTs;  \n4) written in English  \n\u2022 Ausschlusskriterien:  \n1) were reviews, letters, conference abstracts, book \nchapters, animal experiments, and case reports;  \n2) essential information was incomplete;  \n3) WB VT was not conducted for the purpose of improv-\ning patient\u2019s condition.  \n \n\u2022 Endpunkte: functional exercise capacity, pulmonary \nfunction, and quality of life in COPD  \n\u2022 Anzahl eingeschlossener Studien n=8 RCTs (einges-\nchlossene Patient*innen: n=365):  \n- Gloeckl 2012  \n- Pleguezuelos 2013  \n- Greulich 2014  \n- Braz J\u00fanior 2015 \n- Salhi 2015  \n- Spielmanns 2017 (1)  \n- Gloeckl 2017  \n- Spielmanns 2017 (2)  \n Baseline -Charakteristika  \n\u2022 mainly  elderly (average age: 58 to 75 years), com-\nmunity dwelling, and functionally independent  \n\u2022 1 study included people with exacerbated COPD \n(Greulich 2014)  \n\u2022 other trials studied individuals with stable COPD  \n\u2022 Generally, no special intervention was performed in \na control group, but three trials performed physiother-\napy (Greulich 2014), calisthenic s training ( Spiel-\nmanns 2017), and conventional resistance training \n(Salhi 2015)  \n \n\u2022 WBVT increased  \n- 6-minute walking distance (6- MWD) (WMD: 62.14 \nm; 95% CI: 48.12\u2013 76.16; P,0.001),  \n- the change of 6- MWD ( \u03946-MWD) (WMD: 42.33 m; \n95% CI: 15.21\u2013 69.45; P=0.002),  \n- the change of the time to finish five repeated sit -to-\nstand tests (WMD: -2.07 seconds; 95% CI: - 4.00 to -\n0.05; P=0.04),  \n\u2022 WBVT decreased  \n - the change of St George\u2019s Respiratory Question-\nnaire score (WMD: - 6.65 points; 95% CI: - 10.52 to -\n2.78; P,0.001).  \n\u2022 no significant difference was found between the two \ngroups regarding \n- sit-to-stand test, 6 -MWD (% predicated),  \n- change of 6- MWD (% predicated),  \n- St George\u2019s Respiratory Questionnaire score,  \n- COPD Assessment Test score,  \n- and change of COPD Asses sment Test score.  \n \n\u2022 Subgruppenanalyse:  \nSide-alternating vibration  was applied in five trials in AMSTAR -II: Critically \nLow \n \n \n \u2022 Bemerkungen zur H eterogenit\u00e4t \nder in den Review eingeschlosse-\nnen Studien:  \n- differierende Interventionen in \nden Kontrollgruppen; unterschied-\nliche Trainingsprotokolle --> ggf. \nEinfluss auf Vergleichbarkeit der \nErgebnisse \n \n\u2022 Verbesserung von   \n- Mobilit\u00e4t/Funktionalit\u00e4t  \n \n\u2022 Keine Verbesserung der  \n- COPD- Symptomatik  \n- Lebensqualit\u00e4t  \n \n\u2022 der \"type of WBVT\" scheint Ein-\nfluss auf die Trainingseffekte zu \nhaben (siehe Ergebnisse der Sub-\ngruppen- Analyse)  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  195 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nwhich 6 -MWD did not show significant differences be-\ntween two groups (WMD: 38.91, 95% CI: - 1.11 to \n78.92, P=0.11), but the change of 6- MWD (WMD: \n43.73, 95% CI: 14.84\u2013 72.62, P=0.003) increased \nabove the minimal clinically important difference \n(MCID) of 35 m.  \nVertical vibration  was applied in the remaining three \ntrials, but patients enrolled in these trials did not show \nany improvement in their 6- MWD (WMD: 38.66, 95% \nCI: -47.22 to 125.54, P=0.38) and change of 6- MWD \n(WMD: 40.51, 95% CI: - 40.49 to 121.52, P=0.33) sig-\nnificantly.  \n \nConclusion:  WBVT has beneficial effects on func-\ntional exercise capacity for COPD patients.  \nGloeckl R. Whole \nbody vibration \ntraining in patients \nwith COPD: A sys-\ntematic review. \nChron Respir Dis \n2015; 12(3):212\u2013\n21. \nhttps://www.ncbi.nl\nm.nih.gov/pub-\nmed/25904085 . \n \n \u2022 Systematische \u00dcbersicht sarbeit; keine Metaanalyse, \nEinschluss RCT und NRSI  \n\u2022 Suchzeitraum: 09/2014 (updated 02/2015)  \n\u2022 Population: Patient*innen mit COPD  \n\u2022 Einschlusskriterien:  \n- were full papers published as original articles  \n- were written in English  \n\u2022 Ausschlusskriterien:  \n- any kind of chest wall vibration for the purpose of mu-\ncus clearance  \n- Book chapters, letters to the editor, unpublished work, \nand study protocols  \n\u2022 Interventionen:  Trials studied either the effects of \nWBVT - versus an inactive control group,  \n- versus sh am WBVT  \n- during an acute COPD exacerbation or  \n- as a modality on top of conventional endurance and \nstrength training.  \n\u2022 Endpunkte:  functional exercise capacity  \n\u2022 Anzahl eingeschlossener Studien: n=4 RCTs, n=2 \nNRSIs (Non -randomized intervention with cross over to \nsham)  \n- Gloeckl 2012 (RCT)  \n- Furness 2013 (NRSI)  \n- Pleguezuelos 2013 (RCT)  All randomized trials reported a significantly superior \nbenefit on exercise capacity (6- minute walking dis-\ntance) in favor of the WBVT group. Although there \nare only few studies available, there is some prelimi-\nnary evidence that WBVT may be an effective exer-\ncise modality to improve functional exercise capacity \nin patients with COPD.  \n(Details siehe Tabelle 2; alle 4 RCTs: Studienquali-\nt\u00e4t HIGH nach GRADE )) \n AMSTAR -II: Critically \nLow \n \n \n Keine Metaanalyse durchgef\u00fchrt, \nda zu gro\u00dfe Heterogenit\u00e4ten zwi-\nschen den einzelnen Studien (Me-\nthodik, Studienziele, WBVT -Proto-\nkolle) --> daf\u00fcr qualitativ e Auswer-\ntung vorhanden  \n(Up to now, a meta- analysis and \nreliable comparison of these stu-\ndies is not possible due to inhomo-\ngeneous study protocols and set-\ntings (study period, WBV device, \nWBV parameters, exercises per-\nformed on the WBV platform, dise-\nase severi ty, etc.). )  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  196 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n- Furness 2014 (NRSI)  \n- Greulich 2014 (RCT)  \n- Braz J\u00fanior 2015 (RCT)  \n \nAnhang 7.4  H\u00e4usliche Trainingstherapie \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t \n(AMSTAR)  \nAshworth NL. Home \nversus center based \nphysical activity pro-\ngrams in older \nadults. Cochrane \nDatabase of Sys-\ntematic Reviews \n2005;(1).  \n \nhttp://onlineli-\nbrary.wiley.com/ doi/\n10.1002/14651858.\nCD004017.pub2/ab-\nstract  \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD004017.pub2/ab-\nstract  \u2022 Body of Evidence:  n= 2 (f\u00fcr COPD -Subgruppe, mit 68 einges-\nchlossenen Patient*innen)  \n\u2022 Suchzeitraum:  until 09/2002 \n\u2022 Population: older adults (50 years or older); eine Subgruppe mit  \nCOPD \n\u2022 Einschlusskriterien f\u00fcr COPD -Subgruppe:  Existing Chronic \nObstructive Pulmonary Disease (COPD) and allied conditions plus \npneumoconiosis and other lung diseases due to external agents  \n \n\u2022 Interventionen:   \n'home based' vs. 'center based' exercise program  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Measures of functional activity (ADLs, walking ability etc)  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- Long- term maintenance of physical activity (e.g. activity log book, \nCommunity healthy activities model program for seniors -CHAMPS, \netc) \n- Measures of Quality of Life (SF36, Sickness impact pro le, etc)  \n- Cost  \n- Health Service utilization  \n \n\u2022 Sekund\u00e4re Endpunkte COPD related:  \n- Mortality  \n- Lung function tests  \n- Exercise capacity  Physiological measures:  \nTwo trials looked at older adults with COP D. In patients with COPD the evi-\ndence is conflicting. One study showed similar changes in various physio-\nlogical measures at 3 months that persisted in the home based group up to \n18 months but not in the center based group. The other study showed signi-\ncantl y better improvements in physiological measures in the center based \ngroup after 8 weeks but again the possibility of a training effect is high.  \n \nQuality of life:  \nn=1 Studie: Compared with controls, signicantly more participants in the ex-\nercise groups exper ienced 'better' general well -being at 3 months (80% for \ncenter, 73% for home versus 47% for control) and 18 months (62% for cen-\nter, 64% for home versus 50% for control). There was no signicant differ-\nence between home and center groups however.  \n= Strijbos 1996: the home based program consisted of frequent and direct \nsupervision by a qualified physiotherapist, home- care nurse and general \npractitioner and was scored at 10.  \nBaseline: n=30 participants  \nOutcome: Quality of Life (General well -being) after 18 mont h \nHome -based vs. center -based: 8/13 vs. 9/14 better well -being \nOR [95%CI]: 0.89 [ 0.19, 4.24 ]  \n \nMethodische Qualit\u00e4t:  \nAllocation concealment was 'unclear' in all the studies. None of the partici-\npants in the included studies were blinded to the interventions (for obvious \nreasons). None of the investigators/assessors appeared to be blinded either \nhowever. Dropouts were well  described and reached a maximum of approxi-\nmately 16%. Both studies were 'medium' quality.  n-n-y-y-y-y-y-n-y-y-n \n \nMcCarthy B. Pulmo-\nnary rehabilitation \u2022 Body of Evidence:  n= 65 eingeschlossene RCTs f\u00fcr \nMetaanalyse ( n= 3822 eingeschlossene Patient*i nnen)  >> This review highlights that pulmonary rehabilitation improves the health -\nrelated quality of life of people with COPD. Results  y-y-y-y-y-y-y-y-y-y-n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  197 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t \n(AMSTAR)  \nfor chronic obstruc-\ntive pulmonary dis-\nease. Cochrane Da-\ntabase of System-\natic Reviews \n2015;(2).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/\n10.1002/14651858.\nCD003793.pub3/ab-\nstract  \n \n \u2022 Suchzeitraum:  current as of 04/2014  \n\u2022 Population:  \n\u2022 Einschlusskriterien:  \n- participants had COPD  \n- any or all participants were on continuous oxygen \n\u2022 Ausschlusskriterien:   \n- who were mechanically ventilated; or  \n- who had an acute exacerbation wit hin four weeks before com-\nmencement of the intervention  \n\u2022 Interventionen:   \nPulmonary rehabilitation (Any in -patient, out -patient, community -\nbased or home- based rehabilitation programme of at least four \nweeks\u2019 duration that included exercise therapy with or without any \nform of education and/or psychological support delivered to pa-\ntients with exercise lim itation attributable to COPD. We included \nany exercise therapy that included physical activity considered to \nbe aerobically demanding.)  \nvs. Usual Care (without education or additional interventions)  \n \n\u2022 Prim\u00e4re Endpunkte:  \nDisease- specific health- related quality of life (HRQoL)  \n- Chronic Respiratory Disease Questionnaire (CRQ)  \n- St. George\u2019s Respiratory Questionnaire (SGRQ)  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- Functional exercise capacity assessments  \n- \u25e6 Six-minute walk test/distance (6MWT/6MWD)  \n  \u25e6 Incremental shuttle walk test (ISWT)  \n  \u25e6 Endurance shuttle walk test (ESWT)  \n- Maximal exercise tests  \n  \u25e6 Incremental cycle ergometry  strongly suppo rt inclusion of pulmonary rehabilitation as part of the manage-\nment and treatment of patients with COPD.  \n \nQoL - Change in CRQ (dyspnoea)  CRQ Questionnaire.(Higher is better and \n0.5 unit is an important difference), n=1283 (19 RCTs), G RADE: Moderate  \nUsual care: Median change = 0 units  \nRehabilitation versus usual care: Mean QoL - change in CRQ (Dyspnoea) in \nthe intervention groups was 0.79 units higher  (0.56 to 1.03 higher)  \nMD 0.79, 95%CI 0.56 to 1.03; I\u00b2= 63%  \n \nQoL - Change in CRQ (fatique)  \nMD 0.68 (95%CI0.45,  0.92), I\u00b2= 64%, 19 RCT, n = 1291, GRADE:low  \n \nQoL - Change in CRQ (Emotional funtion)  \nMD 0.56 (95%CI 0.34, 0.78), I\u00b2=58% , 19 RCT, n = 1291, GRADE: nicht \nangegeben  \n \nQoL - Change in CRQ (Mastery)  \nMD 0.71 (95%CI 0.47, 0.95), I\u00b2=63%,19 RCT, n = 1212, GRADE:lo w \n \nQoL - Change in SGRQ (total)  (Lower is better and 4 units is an important \ndifference), I\u00b2=59%, n=1146 (19 RCTs), GRADE: Moderate  \nUsual care: Median change = 0.42 units  \nRehabilitation versus usual care: Mean QOL - change in SGRQ (total) in the \ninterventi on groups was  6.89 units lower   (-6.89 (95%CI - 9.26; -4.52)  \n \nChange in maximal exercise ( Incremental Shuttle walk test (ISWT)), n=694 \n(8 RCTs); GRADE: Moderate  \nUsual care: Median change = 1 metre \nRehabilitation versus usual care: Mean maximal exercise (inc remental shut-\ntle walk test) in the intervention groups was 39.77 metres higher ( 22.38 to \n57.15 higher)  \n  \nChange in functional exercise capacity  (6MWT)), n=1879 (38 RCTs), \nGRADE: Very low  \nUsual care: Median change = 3.4 metres  \nRehabilitation versus usual care: Mean functional exercise capacity \n(6MWT)) in the intervention groups was  43.93 metres higher  (32.64 to \n55.21 higher)  \n \nAussagen des Reviews zu Home -based Rehabilitation : NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  198 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t \n(AMSTAR)  \n\u2022 Only six studies reported patient -based programmes, three of which were \ncombined with a home- based follow -up component. Thirty -seven studies \nwere hospital out -patient based; eight of these included a home- based ele-\nment. In all, 21 programmes were community based, 11 of which were en-\ntirely home based, and one programme combined  community - and home-\nbased components.  \nRehabilitation versus usual care (subgroup analysis hospital versus commu-\nnity-based pulmonary rehabilitation)  \n\u2022 In total, 39 included studies were considered to have a hospitalbased PR \nintervention delivered on an in- patient or out -patient basis. A total of 25 stud-\nies focused on programmes that were delivered in the community at com-\nmunity centres or in individuals\u2019 homes. One study had both a community -\nbased and an out -patient - based intervention group, so it was exclu ded from \nthe subgroup analysis (Mendes De Oliveira 2010).  \n\u2022 In the subgroup analysis for the CRQ domain outcomes, the \u2019community\u2019 \nsubgroup included nine studies and the \u2019hospital group\u2019 included 10 studies. \nFor SGRQ outcomes, the community subgroup included nine studies and \nthe hospital subgroup included 10 studies.  \n\u2022 Evidence suggested a significant difference in treatment effect between \nsubgroups for all domains of the CRQ, with higher mean values, on aver-\nage, in the PR group in hospital than in the community - based group (Analy-\nsis 2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4). No subgroup differences \nwere reported for any of the SGRQ domains (Analysis 2.5; Analysis 2.6; \nAnalysis 2.7; Analysis 2.8).  \n>> hier: homebased & community -based Therapien zusammen betrachtet; \nkein direkter Vergleich.  \nAnhang 7.5  Atemtechniken  \nActive chest physiotherapy  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nBasri R. Short -term \neffects of chest \nphysiotherapy in \nacute exacerbation \nof chronic obstruc-\ntive pulmonary dis-\nease. Journal of \u2022 Ziel:  To find out the short -term ef-\nfects of chest physiotherapy in acute \nexacerbation of COPD  \n \n\u2022 Studiendesign: double blinded RCT  \n \n\u2022 Population:  patients with AECOPD; \u2022 Baseline -Patientencharakteristika : leichte Differenzen bez\u00fcglich \nAlter und Exazerbations -Historie  \n- The Mean age of the subjects in group A was 53\u00b13.7 years while in \ngroup B Mean age was 55\u00b13.8 years.  \n- baseline Means of VAS, SaO2 and PEFR of both the groups indi-\ncates that the patients were similar on baseline.  \n Selection bias  \nRandomisierung: gering  \nAllocation concealment: gering  \nVerblindung von Teilnehmern und Personal: gering   \nDetection bias  \nVerblindung der Ergebnisevaluation: gering  \nAttrition b ias NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  199 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nmedical sciences \n(peshawar) 2017; \n25(3):323\u2013 7.  \nwww.jmeds ci.com/in\ndex.php/Jmedsci/ar-\nticle/view/31  \n \n\u2022 Nicht zitiert.  \n. \n n=60  \n \n\u2022 Intervention:  2 weeks  \n- active chest physiotherapy tech-\nniques along with medical treatment  \n> included Breathing control exercise; \nThoracic expansion exercises (incl. \npursed lips), Forced expiration tech-\nnique)  \n\u2022 Vergleich:  \n- only medical treatment  \n \n\u2022 Pakistan  \n\u2022 Messmet hoden: visual analogue \nscale (VAS) for breathlessness  \n \n \n - experimental group showed more improvement on  \n- Peak Expiratory Flow Rates (PEFR) (P<0.05),  \n- SaO2 (P>0.05)   \n- VAS for breathlessness (P<0.05).  \n \nControl group:  Reported Mean difference (paired t -test) for  \n- VAS was 0.40\u00b10.63 with P=0.03  \n- PEFR 2.00\u00b125.89 with P=0.76  \n-  SaO2 -3.7\u00b13.10 with P=0.00 using 95% CI.  \n \nExperimental group:  Reported Mean difference (paired t -test) for  \n- VAS for  breathlessness was 4.78\u00b11.12 with P=0.03  \n- PEFR -5.35\u00b15.35 with P=0.02  \n- SaO2 -3.64\u00b13.20 with P=0.01 with 95% CI.   \n \n- Mean difference (independent t -test) for VAS, SaO2 and for PEFR \nbetween groups (group A and B) using the 95% CI was 1.53, -6.7 \nand -25.65 respectively with statistically significant value (p<0.05).  \n Verlust von Studienteilnehmern/ fehlende Daten: unklar   \nITT-Analyse: nicht durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: unklar   \nAndere Biasursachen  \nBaseline imbalance: unklar   \nInteressenkonflikte/ Sponsoring: angegeben  \n \nManual Chest Physiotherapy  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nCross JL. Evaluation of \nthe effectiveness of \nmanual chest physio-\ntherapy techniques on \nquality of life at six \nmonths post exacerba-\ntion of COPD \n(MATREX): A random-\nised controlled equiva-\nlence trial. BMC Pulm \nMed 2012; 12:33.  \n \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/22748085 . \n \n \u2022 Ziel:  Manual chest physiotherapy: \nassessed its effectiveness on disease-\nspeci fic quality of life.  \n\u2022 Studiendesign: r andomised con-\ntrolled equivalence trial  \n \n\u2022 Population: patients hospitalised \nwith AECOPD; n=526  \n\u2022 Intervention: Manual chest physio-\ntherapy(MCP) + advice on airway \nclearance  \n\u2022 Vergleich:  advice on chest clear-\nance alone  \n \n>active cycle of breathing techniques \n(ACBT) was used in both arms  \n \n\u2022 Follow -up: 6 months  \u2022 Baseline -Patientencharakteristika:  hinsichtlich Alter, Ges-\nchlecht; Rauchstatus; SGRQ Baseline weitestgehend aus-\ngeglichen  \n- All patients were included in the analyses, of which 372 \n(71%) provided evaluable data for the primary outcome.  \n \n- effect size of 0. 3 standard deviations in SGRQ score was \nspecified as the threshold for superiority  \n-  ITT analyses indicated no significant difference at 6 months \npost randomisation in  \n-- total SGRQ score [adjusted effect size (no MCP -  MCP) \n0.03 (95% confidence interval , CI -0.14 to 0.19)],  \n-- SGRQ symptom score  [adjusted effect size 0.04 (95% CI -\n0.15 to 0.23)],  \n-- SGRQ activity score  [adjusted effect size -0.02 (95% CI -\n0.20 to 0.16)] or  \n-- SGRQ impact score [adjusted effect size 0.02 (95% CI - 0.15 \nto 0.18)].  Selection bias  \nRandomisierung: gering   \nAllocation concealment: gering   \nPerformance bias \nVerblindung von Teilnehmern und Personal: hoch  \nKommentar:  \nDetection bias  \nVerblindung der Ergebnisevaluation: unklar   \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: ge ring  \nITT-Analyse: durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: unklar   \nAndere Biasursachen  \nBaseline imbalance: gering \nInteressenkonflikte/ Sponsoring: angegeben  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  200 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \n\u2022 Studienzeitraum: November 21, \n2005, and April 30, 2008 \n\u2022 UK; multicentre  \n\u2022 Messmethoden: SGRQ  \n \n \n \n  \n\u2022 aut hors conclusion:  These data do not lend support to the \nroutine use of MCP in the management of acute exacerbation \nof COPD. However, this does not mean that MCP is of no \ntherapeutic value to COPD patients in specific circumstances.  \n \n \nRocha T. The Manual \nDiaphragm Release \nTechnique improves dia-\nphragmatic mobili ty, in-\nspiratory capacity and \nexercise capacity in \npeople with chronic ob-\nstructive pulmonary dis-\nease: A randomised \ntrial. Journal of physio-\ntherapy 2015; \n61(4):182\u2013 9.  \nhttps://www.ncbi.nlm.nih\n.gov/ pubmed/26386894 . \n \n \u2022 Ziel: Manual Diaphragm Release \nTechnique: Does the technique also \nimprove exercise capacity, maximal \nrespiratory pressures, and kinematics \nof the chest wall and abdomen?  \n\u2022 Studiendesign:  RCT; Single -centre  \n \n\u2022 Population : clinically stable COPD; \nn=20 \n \n\u2022 Intervention:  six treatments with the \nManual Diaphragm Release Tech-\nnique on non- consecutive days within \na 2-week period  \n\u2022 Vergleich:  sham treatments  \n \n\u2022 Italien  \n \n \n \n \n \u2022  Baseline -Patientencharakteristika : weitestgehend aus-\ngeglichen (Alter, Gewicht; Geschlecht)  \n \n- The Manual DiaphragmRelease Technique significantly  \nimproved diaphragmatic mobility over the course of treat-\nments, with a between- group difference in cumulative im-\nprovement of 18 mm (95% CI 8 to 28).  \n- The technique also significantly improved the 6-  minute walk \ndistance over the treatment course, with a between group dif-\nference in improvement of 22 m (95% CI 11 to 32).  \n \n \n \n \n Selection bias  \nRandomisierung: unklar  \nAllocation concealment: gering   \nPerformance bias \nVerbli ndung von Teilnehmern und Personal: gering   \nDetection bias  \nVerblindung der Ergebnisevaluation: unklar  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: gering   \nITT-Analyse: durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: gering   \nAndere Biasursachen  \nBaseline imbalance: gering  \nInteressenkonflikte/ Sponsoring: angegeben  \n \nEngel RM. Medium term \neffects of including man-\nual therapy in a pulmo-\nnary rehabilitation pro-\ngram for chronic ob-\nstructive pulmonary dis-\nease (COPD): A ran-\ndomized controlled pilot \ntrial. J Man Manip Ther \n2016; 24(2):80 \u20139. \u2022 Ziel: To investigate the effect of in-\ncluding manual therapy (MT) in a pul-\nmonary rehabilitation program for pa-\ntients with COPD.  \n\u2022 Studiendesign: RCT  \n \n\u2022 Population : Patient*innen mit \nCOPD; n=33  \n\u2022 Interventionen: MT interven-\ntion:2/week for 8 weeks  \u2022  Baseline -Patientencharakteristika: hinsichtlich Alter und RR \nweitestgehend ausgeglichen, leichte Unterschiede im Baseline \nSGRQ  und 6MWD  \n- p=0.02 Unterschied bez\u00fcglich Geschlecht (Baseline)  \n- aged between 55 and 70 years (mean =65.5\u00b14 years  \n \n \n\u2022 Ergebnisse prim\u00e4rer Endpunkt:  significant difference in FVC \nbetween the three groups at 24 weeks (P=0.04). For the  \nST+SM+PR group versus PR only the increase was 0.40 l (CI: Selection bias  \nRandomisierung: gering Allocation concealment: gering \nPerformance bias \nVerblindung von Teilnehmern und Personal: gering  \nDetection bias  \nVerblindung der Ergebnis evaluation: gering   \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: unklar   \nITT-Analyse: durchgef\u00fchrt  \nReporting bias  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  201 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/27559277 . \n \n  \n- soft tissue therapy (ST) + PR  \n>> ST: gentle Effleurage, friction, and \ncrossfiber friction massage applied to \nthe muscles of the posterior chest wall  \n \n- spinal manipulative  therapy (SM) + \nST + PR  \n>> SM: high velocity low amplitude \n(HVLA) joint manipulation to the tho-\nracic inter -vertebral, costo- vertebral, \nand costo- transverse joints  \n \n\u2022 Vergleich:  pulmonary rehabilitation \n(PR) only  (24-week program)  \n \n\u2022 Australien  \n\u2022 Messmethoden: 6- minute walking \ntest (6MWT), St. George\u2019s  \nrespiratory questionnaire (SGRQ), and \nthe hospital anxiety and depression \n(HAD)  0.02, 0.79; P=0.03).  \n \n\u2022 weitere Ergebnisse  \n- ST+SM+PR group compared to PR only: difference between \ngroups for distance walked (6MWT) at 16 (P=0.01) and 24 \nweeks (P=0.03).  \n- changes in 6MWT  for the ST+PR and ST+ SM+PR groups in-\ndividually compared to PR only were not significant at either \n16 or 24 weeks (P=1.0 and 0.2; P=0.8 and 0.4 respectively).  \n- There were no differences between groups for the SGRQ or \nHAD.  \n \n\u2022 Sicherheit:  No major or moderate adverse events (AE ) were \nreported following the administration of 131 ST and 272 SM \ninterventions.  \n selektive Ergebnisdarstellung: unklar  \nAndere Biasursachen  \nBaseline imbalance: unklar  \nInteressenkonflikte/ Sponsoring: angegeben  \n \nIntrapulmonary percussive ventilation  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nReychler G. In-\ntrapulmonary Per-\ncussive Ventilation \nas an Airway \nClearance Tech-\nnique in Subjects \nWith Chronic Ob-\nstructive Airway \nDiseases. Respir \nCare 2018; \n63(5):620\u2013 31.  \nhttps://www.ncbi.nl\nm.nih. gov/pub-\nmed/29692351 . \n \u2022 Fragestellung:  to summarize the \nphysiological and clinical effects re-\nlated to the use of IPV as an airway \nclearance technique in chronic ob-\nstructive airway diseases  \n \n\u2022 Suchzeitraum:  to May 2017 \n\u2022 Population:  Subjects > 5 y old with \nobstructive disease (cystic fibrosis, \nasthma, COPD , bronchiectasis), sta-\nble or exacerbated  \n \n \n\u2022 Interventionen:  Use of intrapulmo-\nnary percussive ventilation as airway \u2022 systematischer Review ohne Meta -Analyse  \n \n\u2022 Baseline- Charakteristika COPD -Studien:  \n- 3 studies were performed in ICUs during an exacerbation,  \n- 2 studies were performed in stable out -patients.  \n \nCardiorespiratory Parameters, Lung Function, and Lung Mechanics in \nCOPD \n- In subjects with COPD in stabl e conditions and during  \nexacerbation, all cardio- respiratory parameters, lung function,  \nand lung mechanics decreased with IPV. (n=3 studies)  \n[...] \n- After 1 d of treatment in stable subjects, 1 study showed an improvement \nin inspiratory and expiratory musc le strength.  \n AMSTAR -II: \n- critically low  \n \n \n \n Only one of the in cluded stud-\nies had a sample size > 50 \nsubjects.  \n \nSubgruppe f\u00fcr COPD: 6 \nStudien  \n- Antonaglia (RCT)  \n- Ides (Observational)  \n- Nava (RCT)  \n- Testa (controlled)  \n- Vargas RCT  \n- Vargas (Observational)  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  202 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n clearance technique  \n\u2022 Vergleich:  No airway clearance \ntechnique used, placebo or other air-\nway clearance techniques  \n \n\u2022 eingeschlossene Studien : n=12 \nstudies; n= 278 participants  \n- f\u00fcr COPD: n=6 studies (RCTs, con-\ntrolled, observational); n=178 partici-\npants  \n Length of Hospital Stay and Other Clinical Outcomes  \nin COPD  \n- The length of hospital stay was reduced by IPV compared to other airway \nclearance techniques or to a classical medical treatment alone in 2 studies \nin subjects with COPD during exa cerbation.  \n- In 1 study, a decrease in the need for mechanical ventilation was ob-\nserved.  \n \nAdverse Effects and Drop -Outs in COPD.  In subjects with COPD,  \n- 2 studies revealed complications or discomfort.  \n- Even though some subjects were intubated after incl usion in 1 study, it \nwas not related to IPV.  \n- In another study, 2 subjects did not tolerate settings with a higher fre-\nquency of percussions (1.220 cm H2O -350 c/min and 1.840 cm H2O -350 \nc/min). \n \nThe main findings showed that IPV improves gas exchange during exacer-\nbation and could reduce the hospital length of stay for patients with COPD.  \n \n>> CONCLUSIONS: The systematic use of IPV as an airway clearance \ntechnique in chronic obstructive airway diseases is not supported by suffi-\nciently strong evidence to recom mend routine use in this patient popula-\ntion. However, IPV could offer some benefits in patients with COPD during \nexacerbation by improving gas exchange and by possibly reducing the \nlength of hospital stay.  \nChest wall oscillation  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nGoktalay T. Does high -\nfrequency chest wall os-\ncillation therapy have \nany impact on the infec-\ntive exacerbations of \nchronic obstructive pul-\nmonary disease? A ran-\ndomized controlled sin-\ngle-blind study. Clin Re-\nhabil 2013; 27(8):710\u2013 8.  \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/23503735 . \u2022 Ziel:  To investigate the impact of high -fre-\nquency chest wall oscillation in chronic ob-\nstructive pulmonary dis ease patients with in-\nfective exacerbation.  \n \n\u2022 Studiendesign: randomized controlled sin-\ngle-blind study  \n \n\u2022 Population: Stage III -IV COPD patients \nhospitalized with acute infective exacerba-\ntion; n=50 patients randomised \n\u2022 Intervention: group 2: usual exacerbation \u2022  Baseline -Patientencharakteristika:  bez\u00fcglich Alter, \nGewicht; BODE Index baseline, 6MWD weitestgehend aus-\ngeglichen  \n- Mean (SD) age of the 50 participants (one (2%) female and \n49 (98%) male) was 65.06 years (7.39) (range 45\u2013 80). \n- 50 (100%) patients (25 in Group I and 25 in Group II) were \nfollowed up f or five days.  \n \n- Application of high- frequency chest wall oscillation therapy \nresulted in no significant advantage in all outcomes (p > \n0.05).  \n \n- Mean (SD) baseline BODE index v alue in Group I was 7.72 Selection bias  \nRandomisierung: unklar   \nAllocation concealment:  gering   \nPerformance bias \nVerblindung von Teilnehmern und Personal: unklar  \nDetection bias  \nVerblindung der Ergebnisevaluation: unklar   \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: unklar   \nITT-Analyse: nicht durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: unklar  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  203 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \n protocol + received additional high -fre-\nquency chest wall oscillation therapy (20 \nminutes three times a day for 5 days)  \n\u2022 Vergleich: group 1: usual exacerbation \nprotocol  \n \n>> All patients have been treated with bron-\nchodilators, antibiotics, if necessary oxygen \nand patient education, as part of acute \nchronic obstructive pulmonary disease exac-\nerbation protocol.  \n \n\u2022 Follow -up: five-days  \n\u2022 Studienzeitraum: April 2009 to July 2011  \n\u2022 T\u00fcrkei  \n\u2022 BODE; SGRQ  (1.76), in Group II (Intervention) was 7.72(1.89) (p = 0.55).  \n- On the fifth -day assessment, mean (SD) BODE index  value \nin Group I (usual protocol) was 7.24 (1.83), in group II was \n6.44 (2.46) (p = 0.18).  \n \n\u2022 \"authors conclusion \": The application of high- frequency \nchest wall oscillation therapy offers no additional advantages \non infective exacerbations in chronic obstructive pulmonary \ndisease.  \n \n Andere Biasursachen  \nBaseline imbalance: gering  \nInteressenkonflikte / Sponsoring: angegeben  \n \nNicolini A. Safety and ef-\nfectiveness of the high-\nfrequency chest wall os-\ncillation vs intrapulmo-\nnary percussive ventila-\ntion in patients with se-\nvere COPD. Int J Chron \nObstruct Pulmon Dis \n2018; 13:617\u2013 25.  \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/29497290 . \n \n \u2022 Ziel:  adding IPV or HFCWO to the best \npharmacological therapy (PT) may provide \nadditional clinical benefit over chest physio-\ntherapy in patients with severe COPD.  \n\u2022 Studiendesign: 4 -week parallel random-\nized controlled study  \n \n\u2022 Population:  patients with severe CO PD; \nbronchial hypersecretion, and effective \ncough \n \n\u2022 Intervention: treatment for 2 weeks  \n- IPV-group: IPV group (treated with PT and \nIPV; percussive ventilator = IPV Impulsator, \nPercussionaire); n=20  \n- HFCWO -group: PT group with (treated with \nPT and HFCWO;  using a percussive vest; \n20 minutes and was performed twice a day) \nn=20 \n\u2022 Vergleich: control group (treated with PT \nalone) n=20 \n\u2022 Follow -up \n\u2022 ggf. Informationen zu Aufhebung der Ver-\nblindung und Cross -over \n\u2022 relevante Ein-  und Ausschlusskriterien  \n \u2022  Baseline -Patientencharakteristika:  hinsichtlich Alter, \nGeschlecht, Gewicht; Exazerbations -Historie weitestgehend \nausgeglichen  \n \n- Patients in both the IPV group and the HFCWO group \nshowed a significant  improvement in the tests of dyspnea \nand daily life and health status assessment (mMRC, BCSS, \nand CAT) compared to those in the control group.  \n- Moreover, IPV patients showed an improvement in BCSS \n(p,0.001) and CAT (p,0.02) scores in comparison with \nHFCW O. \n \n- authors conclusion: The two techniques improved daily life \nactivities and lung function in patients with severe COPD. \nIPV demonstrated a significantly greater effectiveness in im-\nproving some pulmonary function tests linked to the small \nbronchial airw ays obstruction and respiratory muscle strength \nand scores on health status assessment scales (BCSS and \nCAT) as well as a reduction of sputum inflammatory cells \ncompared with HFCWO.  \n \n \n Selection bias  \nRandomisierung: gering   \nAllocation concealment: gering   \nPerformance bias \nVerblindung von Teilnehmern und Personal:  unklar  \nDetection bias  \nVerblindung der Ergebnisevaluation: gering  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: unklar   \nITT-Analyse: nicht durchgef \u00fchrt \nReporting bias  \nselektive Ergebnisdarstellung: unklar  \nAndere Biasursachen  \nBaseline imbalance: gering \nInteressenkonflikte/ Sponsoring: angegeben  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  204 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n\u2022 Studi enzeitraum  \n\u2022 Italien  \n\u2022 Messmethoden: CAT; BCSS; mMRC  \nPositive expiratory pressure (PEP)  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nVenturelli E. Efficacy of \ntemporary positive expira-\ntory pressure (TPEP) in pa-\ntients with lung diseases \nand chronic mucus hyper-\nsecretion. The UNIKO(R) \nproject: A multicentre ran-\ndomized controlled trial. \nClin Rehabil 2013; \n27(4):336\u2013 46.  \nhttps://www.ncbi.nlm.nih.go\nv/pubmed/22967853 . \u2022 Ziel:  To evaluate whether temporary \npositive expiratory pressure provides \nbenefit in patients with lung diseases \nand chronic hypersecretion.  \n\u2022 Studiendesign:  Single blind multi-\ncentre randomized trial  \n \n\u2022 Population:   patients with COPD \nand/or chronic bronchitis (n=78), or \nbronchiectasis (n=20), with a peak \ncough expiratory flow >150 l/min and \nsputum production >30 ml/day  \n \n\u2022 Intervention: 10 consec utive days:  \n- twice a day 20- minute cycles of man-\nually assisted breathing techniques in \nsequence with the addition of 15 \nminutes of temporary positive expira-\ntory pressure  \n\u2022 Vergleich:  manually assisted breath-\ning techniques alone.  \n \n\u2022 Studienzeitraum: July 2008 to De-\ncember 2010  \n\u2022 Five Italian rehabilitation centres; in-\npatient  \u2022 Baseline -Patientencharakteristika:  signifikant \n(p=0,017) mehr Frauen in der Interventionsgruppe; \nhinsichtlich Alter, Gewicht; Verteilung der \nErkrankungen weitestgehend ausgeglichen  \n- TPEP device (UNIKO)  \n \n- No significant changes were recorded for the oxy-\ngenation index, while dynamic lung volumes and \nrespiratory muscle strength significantly (P <0.05) \nimproved in the active group.  \n- The group comparison analysis of the pre- to-post \nchange showed that inspiratory capacity was sig-\nnificantly higher in the active than in the control \ngroup (+19.5% and +2.2%, P=0.044) at day 10.  \n- A greater improvement in \u0394-visual analog scale \nwas recorded in the active group at day 3 and 8.  \n \n \n \n Selection bia s \nRandomisierung: gering   \nAllocation concealment: gering \nPerformance bias \nVerblindung von Teilnehmern und Personal: un-\nklar  \nDetection bias  \nVerblindung der Ergebnisevaluation: unklar  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: \nhoch  \nITT-Analyse: angewendet  \nReporting bias  \nselektive Ergebnisdarstellung: gering   \nAndere Biasursachen   \nBaseline imbalance: ggf. Gender -Imbalance  \n \nInteressenkonflikte/ Sponsoring: CoI der Auto-\nren nicht angegeben Endpunkte klinisch rele-\nvant?  \n \nNicolini A. Use of positive \nexpiratory pressure during \nsix minute walk test: Re-\nsults in patients with mod-\nerate to severe chronic ob-\u2022 Ziel: investigate if the use of a posi-\ntive expiratory pressure device could \nimprove the distance walked by pa-\ntients with moderate to severe COPD  \n \n\u2022 Studiendesign:  prospective RCT  \u00b4- Baseline- Patientencharakteristika:  hinsichtlich \nAlter, Geschlecht, Lungenfunktionsparameter weit-\nestgehend ausgeglichen  \n- The average age of the participants was 71.9 \u00b1 \n4.0 in the PEP  group and 72.1 \u00b1 4.1 in control \ngroup.  Selection bias  \nRandomisierung: gering \nAllocation concealment: gering \nPerformance bias \nVerblindung von Teilnehmern und Personal: un-\nklar   NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  205 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nstructive pulmonary dis-\nease. Multidiscip Respir \nMed 2013; 8(1):19.  \nhttps://www.ncbi.nlm.nih.go\nv/pubmed/23497658 .  \n\u2022 Population:  patients with moderate \nto severe COPD (in and out - patients): \nn=100 \n \n\u2022 Intervention:  \n- 6 MWT with PEP  \n- PEP device consisted of a PEP valve \n5 cmH2O connected to 1- meter tube \nand a mouthpiece  \n\u2022 Vergleich:  6 MWT without PEP  \n \n\u2022 Studienzeitraum:  April 2012 to Sep-\ntember 2012  \n\u2022 Italien   \nFunctional capacity  assessed by the distance cov-\nered during 6MWT improved in the PEP group \nmore than in the control group.  \n- PEP group showed an increase in meters walked \n(61.66 \u00b1 4.28) versus Control group (3.23 \u00b1  0.59).   \n- The difference was statistically significant (p < \n0.001).  \n \nOxygen saturation improved to a statistically signifi-\ncant level during 6MWT (p < 0.01). Heart rate was \nalso reduced (p < 0.03).  \n \n Detection bias  \nVerblindung der Ergebnisevaluation: gering  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: \ngering  ITT-Analyse: nicht durchgef\u00fchrt/nicht \nnotwendig \nReporting bias  \nselektive Ergebnisdarstellung: unklar   \nAndere Biasursachen   \nBaseline imbalance: gering  \nInteressenkonflikte/ Sponsoring: angegeben  \n \nOsadnik CR. The effect of \npositive expiratory pressure \n(PEP) therapy on symp-\ntoms, quality of life and inci-\ndence of re- exacerbation in \npatients with acute exacer-\nbations of chronic obstruc-\ntive pulmonary disease: A \nmulticentre, randomised \ncontrolled trial. Thorax \n2014; 69(2):137\u2013 43.  \nhttps://www.ncbi.nlm.nih.go\nv/pubmed/24005444 . \n \n \u2022 Ziel: This study sought to determine \nthe effect of PEP therapy on symp-\ntoms, quality of life and future exacer-\nbations in patients with AECOPD  \n \n\u2022 Studiendesign:  multicentre RCT  \n \n\u2022 Population:  patients with AECOPD \nand sputum expectoration or a history \nof chronic sputum production  \n  \n\u2022 Intervention:  PEP therapy  (ia a \nmask (Astra Tech AB,  \nMolndal, Sweden) in an upright posi-\ntion with elbows resting on  \na table.)  \n+ usual care (including physical exer-\ncise)  \n \n\u2022 Vergleich:  usual care (including \nphysical exercise):  \u2022 Baseline- Patientencharakteristika:  hinsichtlich \nAlter, Geeschlecht, Gewicht; Sputumproduktion; \nBaseline SGRQ weitestgehend ausgeglichen  \n- 90 inpatients (58 men; mean age 68.6 years, \nFEV1 40.8% predicted)  \n \nThere were no significant between -group differ-\nences over time for  \n-  BCSS  score [mean (SE) at discharge 5.2 (0.4) vs \n5.0 (0.4) for PEP and control group, respectively; \np=0.978] or  \n- SGRQ total score [41.6 (2.6) vs 40.8 (2.8) at 8 \nweeks, p=0.872].  \n- Dyspnoea  improved more rapidly in the PEP \ngroup over the first 8 weeks ( p=0.006), however  \nthese benefits were not observed at 6 months.  \n- Exacerbations (p=0.986) and hospitalisations \n(p=0.359) did not differ between groups.  \n \nSubgroup analyses  \nThe nature (infective or non- infective) of the initial \nAECOPD  Selection bias  \nRandomisierung: gering   \nAllocation concealment: gering   \nPerformance bias \nVerblindung von Teilnehmern und Personal:  un-\nklar  \nDetection bias  \nVerblindung der Ergebnisevaluation: gering  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: \ngering  \nITT-Analyse: nicht durchgef\u00fchrt  \n \nReporting bias  \nselektive Ergebnisdarstellung: gering  \n  \nAndere Biasursachen   \nBaseline imbalance: gering  \n \nInteressenkonfl ikte/ Sponsoring: angegeben  \n  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  206 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n- medical therapy including bronchodi-\nlators, corticosteroids, antibiotics, sup-\nplemental oxygen,  non- invasive venti-\nlation (NIV) if indicated, prescribed ac-\ncording to hospital protoc ols;  \n- Physiotherapists: standardised physi-\ncal exercise training regime that com-\nmenced as early as possible with the \naim of achieving 30 min/day of walking \nor equivalent lower limb exercise.  \n \n\u2022 Follow -up: 6 Monate  \n \n\u2022 Studienzeitraum: August 2010 -  Ja-\nnuary  2013 \n\u2022 Australien  \n\u2022 Messmethoden: SGRQ; BODE; \nBCSS  (p=0.180) and the need for ventilatory assistance \n(p=0.342)  \ndid not significantly influence the severity of symp-\ntoms over  \ntime.  \n \n \nNicolini A. Comparison of \nintermittent positive pres-\nsure breathing and tempo-\nrary positive expiratory \npressure in patients with \nsevere chronic obstructive \npulmonary disease. Arch \nBronconeumol 2014; \n50(1):18\u2013 24.  \nhttps://www.ncbi.nlm.nih.go\nv/pubmed/24321380 . \n \n \u2022 Ziel:  hypothesis that adding TPEP or \nIPPB to standard pharmacological \ntherapy may provide additional clinical \nbenefit over, pharmacological therapy  \nonly in patients with severe COPD  \n \n\u2022 Studiendesign:  single- blind ran-\ndomised trial  \n \n\u2022 Population: patients with severe \nCOPD \n \n\u2022 Interventionen:  \n- Gruppe 1: Intermittent positive pres-\nsure breathing (IPPB)  \n--> 30- minute session twice a day; \nn=15 participant s \n \n- Gruppe 2: temporary positive expira-\ntory pressure device (TPEP)  \n-->30-minute session twice a day; \u2022 Base line-Patientencharakteristika : hinsichtlich \nAlter, Geschlecht, BCSS, CAT und mMRC at \nBaseline weitestgehend ausgeglichen \n- average age was 73\u00b16 years in the TPEP group, \n70\u00b19 years in the IPPB group and 70\u00b16 years in \nthe control group  \n \nBoth patients in the IPPB group and in the TPEP \ngroup showed a significant, improvement in two of \nthree tests (MRC,CAT) compared to the control, \ngroup. However,in the group comparison analysis \nfor, the same variables between IPPB group and \nTPEP group we observed a, significant  improve-\nment in the IPPB group (P</=.05 for MRC and \nP</=.01 for, CAT).  \n \n>> The two techniques (IPPB and TPEP) improves \nsignificantly dyspnea; quality of; life tools and lung \nfunction in patients with severe COPD. IPPB \ndemonstrated a greater effectiveness t o improve \ndyspnea and quality of life tools (MRC, CAT) than Selection bias  \nRandomisierung: gering  \nAllocation concealment: gering  \nPerformance bias \nVerblindung von Teilnehmern und Personal: un-\nklar  \nDetection bias  \nVerblindung der Ergebnisevaluation:  gering  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: \ngering   \nITT-Analyse: nicht durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: unklar   \n \nAndere Biasursachen   \nBaseline imbalance: gering  \n \nInteressenkonflikte/ Sponsoring: angegeben  \n  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  207 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nn=15 participants  \n \n\u2022 Vergleich: pharmacological therapy \nalone; n=15 participants  \n \n\u2022 Studienzeitraum: between June 2012 \nand November 2012.  \n\u2022 Italien  TPEP.  \n \n \nNicolini A. Comparison of \neffectiveness of temporary \npositive expiratory pressure \nversus oscillatory positive \nexpiratory pressure in se-\nvere COPD patients. Clin \nRespir J 2018; 12(3):1274\u2013\n82.  \nhttps://www.ncbi.nlm.nih.go\nv/pubmed/28665556 . \n \n \u2022 Ziel:  to compare the effectiveness of \n2 devices Temporary PEP (T -PEP) \nand Oscillatory PEP (O -PEP) [...] in re-\nducing COPD exacerbations and im-\nproving respiratory and health status \nassessment parameters.  \n \n\u2022 Stu diendesign: RCT \n \n\u2022 Population: severe to very severe \nCOPD \n\u2022 Interventionen:  ; 12 days long; 30 \nminutes per session; 2x/day; 2 de-\nvices  \n- Temporary PEP (T -PEP) (n=40) and  \n- Oscillatory PEP (O -PEP) (n=40)  \n>> which use PEP applied at a low ex-\npiratory pressur e of 1 cm H2 O which \ncreates oscillations that decrease \nbronchial obstruction  \n\u2022 Vergleich : control (n=40)  \n \n\u2022 Follow Up: 6 Monate  \n\u2022 Studienzeitraum: January 2014 -  \nJune 2015  \n\u2022 Italien  \n\u2022 Messmethoden (CAT, mMRC; \nBCSS)  \u2022 Baseline -Patientencharakteristika:  h insichtlich Al-\nter, Geschlecht, BCSS, CAT und mMRC at Base-\nline weitestgehend ausgeglichen  \n \n- T-PEP statistically reduced the exacerbations af-\nter 1 and 3 months compared to the control group.  \n- Both the 2 devices improved dyspnea scale \n(MMRC), lung function parameters, and health sta-\ntus assessment (CAT) tests compared to the con-\ntrol group.  \n- Both interventions were well -tolerated by our pa-\ntients.  \n \n \nCONCLUSIONS: O -PEP and T -PEP are useful for \nCOPD treatment but only T -PEP reduces exacer-\nbations. Adding tools for airway clearance to medi-\ncal therapy can help the management of COPD.  \n \n Selection bias  \nRandomisierung: gering  \nAllocation concealment: gering   \nPerformance bias \nVerblindung von Teilnehmern und Personal: un-\nklar  \nDetection bias  \nVerblindung der Ergebniseval uation: gering  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: \nunklar   \nITT-Analyse: nicht durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung:  unklar  \nAndere Biasursachen   \nBaseline imbalance: gering  \nInteressenkonflikte/ Sponsoring: angegeben  \n  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  208 \n      \n \nControlled Breathing  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nvan Gestel AJ. The ef-\nfects of controlled breath-\ning during pulmonary re-\nhabilitation in patients \nwith COPD. Respiration \n2012; 83(2):115\u2013 24.  \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/21474911 . \n \n \u2022 Ziel:  To compare the effects of a conventional \n4-week pulmonary rehabilitation program with \nthose of rehabilitation plus controlled breathing \ninterventions.   \n \n\u2022 Studiendesign: RCT; 4 weeks  \n \n\u2022 Population:  Patient*innen mit COPD; clinical \nstable; n=40  \n \n\u2022 Interven tion:  rehabilitation plus controlled \nbreathing (10 supplemental 30- min sessions of \ncontrolled breathing using techniques of respira-\ntory biofeedback training)  \n\u2022 Vergleich:  rehabilitation (Cardiopulmonary Ex-\nercise Training; outpatient clinic 3 times per \nweek  (1.5-hour sessions) for 3\u2013 4 weeks per-\nforming 10 sessions of physical training)  \n \n\u2022 Studienzeitraum: November 2008 and July \n2009 \n\u2022 Deutschland; Schweiz  \n\u2022 Messmethoden: 6- min walking distance \n(6MWD), health related quality of life (chronic \nrespiratory questi onnaire, CRQ) and cardiac au-\ntonomic function (rMSSD)  \n\u2022 to train effortless diaphragmatic breathing tech-\nniques  the biofeedback loop starts at the sensor \nthat measures the patient's breathing rhythm at \nboth umbilical and abdominal level  \u2022 Baseline -Patientencharakteristika: hinsichtlich ALter, \nGr\u00f6\u00dfe, Gewicht; Geschlecht; Lungenfunktionsparameter \nweitestgehend ausgeglichen  \n- Forty COPD patients (23 females) with a mean (SD) age of \n66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted  \n \n \nno statistically significant differences between the two groups \nregarding  \n-change in FEV 1 (MD  \u20130.8% predicted, 95% CI \u2013 4.4 to \n2.9% predicted, p = 0.33),  \n- 6MWD (MD 12.2 m, 95% CI \u2013 37.4 to 12.2 m, p = 0.16),  \n- CRQ (MD in total score 0.2, 95% CI \u2013 0.1 to 0 .4, p = 0.11) \nand  \n- rMSSD (MD 2.2 ms, 95% CI \u2013 20.8 to 25.1 ms, p = 0.51).  \n \n\u2022 authors conclusion: In patients with COPD undergoing a \npulmonary rehabilitation program, controlled breathing using \nrespiratory biofeedback has no effect on exercise capacity, \npulmonary function, quality of life or cardiac autonomic func-\ntion. \n \n Selection bias  \nRandomisierung: unklar  Allocation concealment: unklar  \nPerformance bias \nVerblindung von Teilnehmern und Personal: unklar   \nDetection bias  \nVerblindung der Ergebnisevaluation: u nklar   \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: gering  \nITT-Analyse: nicht durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: gering  \nAndere Biasursachen  \nBaseline imbalance: gering  \nInteressenkonflikte/ Sponsoring: angegeben  \n \nValenza MC. Effective-\nness of controlled breath-\ning techniques on anxiety \nand depression in hospi-\ntalized patients with \nCOPD: A randomized \nclinical Trial. Respir Care \n2014; 59(2):209\u2013 15.  \u2022 Ziel: efficacy of controlled breathing techniques \nin improving  \ndyspnea, sleep disturbance, anxiety, depression, \nand quality of life  \n\u2022 Studiendesign:  RCT \n \n\u2022 Population:  Patients hospitalized with acute \nCOPD exacerbation (non- infectious)  \u2022  Baseline -Patientencharakteristika: hinsichtlich Alter; \nRauchstatus; Hospitalisationen/Jahr weitestgehend ausgegli-\nchen; Unterschiede im Baseline SGRQ: Interventionsgruppe \nann\u00e4hernd 5 Punkte weniger im Total -Score  \n- 46 male subjects, 67\u2013  86 years old \n \nmMRC  \n-dyspnea scores significantly improved in  \nthe intervention group (P =0.004), whereas the control  Selection bias  \nRandomisierung: gering   \nAllocation concealment:  gering   \nPerformance bias \nVerblindung von Teilnehmern und Personal: unklar  \nDetection bias  \nVerblindung der Ergebnisevaluation:  unklar   \nAttrition bias  \nVerlu st von Studienteilnehmern/ fehlende Daten: gering   NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  209 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/23882107 . \n \n \u2022 Intervention: 10-day controlled breathing pro-\ngram; 2x/ day; 30 minutes  \n- included: relaxation exercises, pursed- lips \nbreathing, and active expiration \n \n\u2022 Vergleich:  standard medical treatment  \n \n\u2022 Spanien \n\u2022 Messmethoden: Hospit al Anxiety and Depres-\nsion Scale; SGRQ, mMRC; European Quality of \nLife Questionnaire (EQ -5D) \n \n \n \n \n \n \n group\u2019s dyspnea score increased between baseline and dis-\ncharge.  \n- difference between baseline and discharge: 2,917 \u00b13,21 \n(95% CI - 1,228 tov 0,280)  \n \nHospital Anxiety and Depression scale  \n- anxiety and depression subscores showed better improve-\nment after the controlled breathing intervention.  \n- Depression: Higher mean change values were found in the \ndepression score (10.56 \u00b1 0.465; 95% CI -9.79 to 1.05 ).  \n- Anxiety:  Difference between Baseline and Discharge: 6.314 \n\u00b1 0.712 (95%CI - 18.36 to 2.014)  \n \nEuropean Quality of Life  \n- All subscales showed better improvement at discharge in \nthe intervention group, with greater improvements in the mo-\nbility score (difference between baseline and discharge: \n0.881 \u00b1 0.789 (95%CI - 0.738 to 0.168) and the anxiety/de-\npression score.  \n \n\u2022 authors conclusion: In hospitalized patients with chronic \nlung disease, controlled breathing techniques improved mo-\nbility and reduced dys pnea, anxiety, and depression scores.  ITT-Analyse: durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: unklar  \nAndere Biasursachen  \nBaseline imbalance: unklar  \nInteressenkonflikte/ Sponsoring: no CoI  \n \nLiu F. Effects of an ani-\nmated diagram and \nvideo- based online \nbreathing program for \ndyspnea in patients with \nstable COPD. Patient \nPrefer Adherence 2013; \n7:905\u2013 13.  \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/24049441 . \n \u2022 Ziel: to evaluate the effectiveness of an online \nbreathing program which included an animated \ndiagram and video- guided instruction on pulmo-\nnary function, exercise capacity, and health- re-\nlated quality of life in patients with COPD.  \n \n\u2022 Studiendesign:  RCT \n \n\u2022 Population: patients with stable COPD; n=60  \n \u2022 Baseline -Patientencharakteristika:  hinsichtlich Alter, \nGeschlecht; Gewicht; Rauchstat us weitestgehend ausgegli-\nchen \n \n6MWD  \n- increased by 74.6 m in the dyspnea breathing group and \ndecreased by 5.8 m in the control group; this difference was \nstatistically significant (P , 0.05).  \n \nSGRQ  \n- two groups were comparable at baseline on the measures Selection bias  \nRandomisierung: unklar  \nAllocation concealment: gering  \nPerformance bias \nVerblindung von Teilnehmern und Personal: unklar  \nDetection bias  \nVerblindung der Ergebnisevaluation: unklar   \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: gering   \nITT-Analyse: nicht durchgef\u00fchrt; Poweranalyse vorhanden  \nReporting bias  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  210 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \u2022 Intervention: web-based home breathing pro-\ngrams;  trained for 4 months using an online pro-\ngram which included an animated diagram and \nvideo- guided instruction  \n- included: pursed lips breathing, Deep inspira-\ntion-slow blowing, Deep inhale- holding- slow ex-\nhale, Global exercise  \n \n\u2022 Vergleich:  conventional patient education on \ndischarge from hospital  \n \n\u2022 China of this questionnaire, ie, impact, activity, symptoms, and total \nscore.  \n- statistically significant change in these measures in the \ndyspnea breathing program group (SGRQ total after 4 \nmonth: - 18,6; P < 0.05) and no change in the control group \n(P > 0.05).  \n selektive Ergebnisdarstellung: unklar   \nAndere Biasursachen  \nBaseline imbalance: gering  \nInteressenkonflikte/ Sponsoring: no CoI  \n \nBorge CR. Effects of \nguided deep breathing on \nbreathlessness and the \nbreathing pattern in \nchronic obstructive pul-\nmonary disease: A dou-\nble-blind randomized \ncontrol study. Patient \nEduc Couns 2015; \n98(2):182\u2013 90.  \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/25468399 . \n \n \u2022 Ziel:  to investigate whether guided deep \nbreathing using a device improves breathless-\nness, quality of life, and breathing pattern in \nmoderate and severe stage of COPD  \n\u2022 Studiendesign:  double- blind RCT; parallel \ngroup  \n \n\u2022 Population:  moderate/severe COPD  \n\u2022 Interv entionen : 4 weeks; all listened to the \nsame music  \n- guided deep breathing group (GDBG); (Re-\nspeRate Device)  \n> first time at the hospital for 15 min used and \nlater at home, twice a day (i.e. morning and \nevening) for four weeks  \n- music listening group (MLG)  \n> were not given any instructions to breathe \nslowly  \n- sitting still group ( SSG)  \n> sit down and listen to the same music for 1- 2 \nmin, but without any instructions about breathing \nor music during the at the rest of the session  \n \n\u2022 Follow -up: 4 months  \n \n\u2022 Studi enzeitraum: between July 2011 and Sep-\ntember 2013  \n\u2022 Norwegen; muticentre  \u2022  Baseline -Patientencharakteristika:  \n- Predicted lung function is significantly higher in the SSG \ncompared to GDBG and MLG (p < 0.05)  \n- number of comorbidities was significantly lower in the MLG \ncompared to  \nGDBG and SSG at Tl (p < 0,05)  \n- n=150 Teilnehmer  \n \nGRC Scale  \nPositive effects of the GDBG were detected in GRC scale in \nbreathlessness at four weeks (p=0.03) with remaining ef fect \ncompared to MLG (p=0.04), but not to SSG at four months \nfollow -up.  \nGDBG showed positive effect for respiratory rate (p<0.001) \nat four weeks follow -up, n=49,  \n-Respiratory rate (RR) am Anfang der Session: baseline 16 \n(SD 5,1); nach 4 Wochen: 13,4 (5,6) = - 2,6 \n- Respiratory rate (RR) am Ende der \u00dcbung: baseline: 11,8 \n(5,1); RR nach 4 Wochen: 9 (5) = -2,8 \n \nSGRQ  \nA positive significant change (p<0.05- 0.01) was found in all \ngroups of SGRQ symptom score.  Selection bias  \nRandomisierung: gering   \nAllocation concealment: gering   \nPerformance bias \nVerblindung von Teilnehmern und Personal: gering   \nDetection bias  \nVerblindung der Ergebnisevaluation: gering  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: gering   \nITT-Analyse: durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: unkla r  \nAndere Biasursachen  \nBaseline imbalance: hoch  \nInteressenkonflikte/ Sponsoring: angegeben  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  211 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n\u2022 Messmethoden: SGRQ; Global Rating Change \nscale (GRC)  \n  \nauthors conclusion : GDBG had a beneficial effect on res-\npiratory pattern and breathlessness. MLG and SSG also yiel-\nded significant improvements.  \nTorres -Sanchez I. Effects \nof different physical ther-\napy programs on per-\nceived health status in \nacute exacerbation of \nchronic obstructive pul-\nmonary disease patient s: \nA randomized clinical \ntrial. Disabil Rehabil \n2018; 40(17):2025\u2013 31.  \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/28478693 . \n \n \u2022 Ziel:  To evaluate the repercussion of different \nphysical therapy interventions on the perceived \nhealth status of chronic obstructive pulmonary \ndisease (COPD) patients during acute exacerba-\ntion \n\u2022 Studiendesign:  RCT \n \n \u2022 Population: patients hospitalized due to \nAECOPD;  n=90  \n \u2022 Interventionen:  \n- controlled breathing (relaxation exercises, \npursed lips breathing and active expiration) + \nrange of motion exercises group + standard \nmedical treatment ; daily during 30 \u201340 min  \nor \n- Resistance exercises group (included dail y \nlower limb) + standard medical treatment  \n \n \u2022 Vergleich:  Control group = standard medical \ntreatment  \n \n \u2022 Studienzeitraum: September 2015 to June \n2016 \n \u2022 Spanien  \n \u2022 Messmethoden: EuroQol -5D (EQ -5D) ques-\ntionnaire \n \n \n \n \u2022 Baseline -Patientencharakteristika: hinsichtlich Alter und \nGewicht; Lungenfunktionsparameter weitestgehend ausgegli-\nchen \n- Baseline Dyspnea shows differences between control and \ncontrolled breathing+range of motion exercises group \n(p<0.05).  \n- Mean age of the patients was 71.70 \u00b1 9.79 years  \n \n- Perceived health status improved significantly in all groups.  \n- Significant differences in: mobility, self -care and usual activ-\nities subscales of EQ -5D and Visual Analogue Scale be-\ntween control and controlled breathing + range of motion ex-\nercises group. (favorisiert Intervention)  \n \n- Significant differences were found in all variables except \npain between control group and Resistance exercises group. \n(favorisiert Intervention)  \n \n- usual care and anxiety/depression subscales of EQ -5D \nshowed significant differences  between controlled breathing \n+ range of motion exercises group and Resistance exercises \ngroup, the improvements being greater in Resistance exer-\ncises group.  \n \n- Dyspnea improved in higher measure in Resistance exer-\ncises GROUP when compared with control and controlled \nbreathing + range of motion exercises GROUP (mean \nchange 4.09 vs. 2.73 and 2.09 for dyspnea, respectively, and \n7.21 vs. 4.79 and 7.27 for FEV1, respectively).  \n \n>> In conclusion, short duration physical therapy programs in \naddition to the standard care appear to be helpful in the man-\nagement of acute exacerbated COPD patients.  \n \nTabelle 3  Selection bias  \nRandomisierung: gering  \nAllocation concealment: gering   \nPerformance bias \nVerblindung von Teilnehmern und Personal: unklar  \nDetection bias  \nVerblindung der Ergebnisevaluation: unklar  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: unklar  \nITT-Analyse: nicht durchgef\u00fchrt; Poweranalyse erfolgt  \nReporting bias  \nselektive Ergebnisdarstellung: gering   \nAndere Biasursachen  \nBaseline imbalance: hoch  \nInteressenkonflikte/ Sponsoring: angegeben  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  212 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nDie erste Interventionsgruppe konnte im Vergleich zur Kon-\ntrollgruppe signifikante Ver\u00e4nderungen in den Subskalen des \nEuroQol -5D unter anderem hinsichtlich Mobili t\u00e4t (MD 0,67 \n(95% KI 0,40; 0.93) vs. MD Kontrollgruppe 0,28 (95%KI 0,10; \n0,47)) und allt\u00e4glicher Aktivit\u00e4ten (MD 0,53 (95%KI 0,06; \n1,01) vs. MD Kontrollgruppe 0,28 (95%KI 0,05; 0,51)) errei-\nchen. Auch die Krafttrainings -Gruppe konnte in fast allen Be-\nreichen des Testes (Ausnahme Schmerzskala) signifikante \nVerbesserungen erzielen. Sowohl die Atemnot (Borg- Skala: \nMD Krafttraining 4,09 (95%KI 2,50; 5,68); MD Ateminterven-\ntion 2,09 (95%KI 0,63; 3,55); MD Kontrollgruppe 2,73 (95%KI \n1,99;3,47), als auch die Einsch\u00e4t zung von Angst und De-\npression(MD 1,65 (95% KI 1,04; 1,75) vs. MD 0,04 (95%KI \n0,06; 0,32) vs. MD 0,04 (95%KI 0,06; 0,32)) verbesserte sich \nin h\u00f6herem Ma\u00dfe in der Krafttrainings -Gruppe, es konnten \njedoch auch Verbesserungen in den anderen beiden Grup-\npen aufgezeigt werden.  \nYoga, Tai Chi, Singing  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nNgai SP. Tai Chi for \nchronic obstructive pul-\nmonary disease (COPD). \nCochrane Database Syst \nRev 2016; \n6(6):CD009953.  \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/27272131 . \n \n \u2022 Body of Evidence:  n=12  einge schlossene \nRCTs f\u00fcr Metaanalyse ( n=811  einges-\nchlossene Patient*innen)  \n\u2022 Suchzeitraum : from inception to 9/2015  \n\u2022 Population: Patient*innen mit COPD  \n\u2022 Einschlusskriterien: No exclusions were \nbased on age, gender, disease severity or \nsmoking history.  \n \n\u2022 Interventionen:   \nTai Chi alone or Tai Chi in addition to an- other \nintervention  \nvs.usual care or another intervention identi -cal \nto that used in the Tai Chi group \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Level of dyspnoea: All measures related to \ndyspnoea were considered (e. g. Borg Scale, \nModified Medical Research Council (MMRC) \nDyspnoea Scale, Dyspnoea Visual Analogue \nScale (DVAS)).  \u2022 Baseline -Charakteristika  \n- mean age: ranged from 61 to 74 years  \n- Programmes lasted for six weeks to one year  \n \nTai Chi versus usual care  \nLevel of dyspnoea Assessed with Modif ied Borg Scale, n=137 (1 RCT); GRADE: \nLow \n- Usual care: 2.1 units  \n- Tai Chi: 0.2 unit lower (95%CI - 0.67 to 0.27 unit)  \n \nFunctional capacity Assessed with 6- minute walk test (metre), n=318 (6 RCTs), \nGRADE: Very low  \n- Usual care: Mean 317.38 metres  \n- Tai Chi: 29.64 metres farther (95% CI 10.52 to 48.77 metres)  \n \nFunctional capacity  Assessed with endurance shuttle walk test (second), n=38 (1 \nRCT), GRADE: Low \n- Usual care: Mean 430 seconds  \n- Tai Chi: 373 seconds longer (95%C I 135.42 to 610.58 seconds)  \n \nQuality of life (SGRQ),  n=233 (3 RCTs), GRADE: Very low  AMSTAR -Score: 9/11  \n \ny-n-y-y-y-y-y-y-y-n-y \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  213 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n- Functional capacity or aerobic capacity  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- Pulmonary function  \n- Quality of life status  \n  \u25e6 Generic health- related quali ty of life  \n  \u25e6 Disease -specific health- related quality of life  \n- Quadriceps or other muscle strength \n- Balance  \n - Usual care: Mean 48. 93 units  \n- Tai Chi: 7.85 units lower (95%CI -16.53 to 0.83 unit)  \n \nQuality of life (CRQ),  n=?48 (2 RCTs), GRADE: Low  \n- Usual care: Mean 4. 75 units  \n- Tai Chi: 0.41 unit higher (95%CI -0.54 to 1.35 units)  \n \n>> No adverse events were reported, implying that Tai Chi is safe to practise in \npeople with COPD.  \nMcNamara RJ. Singing \nfor adults with chronic ob-\nstructive pulmonary dis-\nease (COPD). Cochrane \nDatabase Syst Rev 2017; \n12(12):CD012296.  \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/29253921 . \n \n\u2022 Nicht zitier t. \n \n \u2022 Body of Evidence: n=3 eingeschlossene \nRCTs f\u00fcr Metaanalyse ( n=112 einges-\nchlossene Patient*innen)  \n\u2022 Suchzeitraum: inception - 08/2017 \n\u2022 Population : Patient*innen mit stabiler COPD  \n\u2022 Einschlusskriterien:  adults with COPD of \nany age or disease severity. The COPD was \nrequired to be stable. We included partici -pants \nwith COPD who used sup- plemental oxygen.  \n \n\u2022 Interventionen:   \n1. singing versus no intervention (usual care) or \nanother control intervention  \n2. singing plus pulmonary rehabilitation versus \npulmonary rehabili -tation alone \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Health- related quality of life  \n- Dyspnoea  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- Respiratory muscle strength  \n- Pulmonary function  \n- Psychological status  \n- Functional ex ercise capacity  \n- Peak exercise capacity  \n- Healthcare utilisation \n- Physical activity level  \n- Adverse events/side effects  \n Baseline -Charakteristika  \n- mean age: range 67 to 72 years  \n- mean FEV1: range from 37% to 64% of predicted values  \n- frequency of the s inging intervention: ranged from 1 to 2 times a week over a 6 \nto 24 week period.  \n- duration of the singing sessions: 60 minutes (conducted in groups led by a sing-\ning teacher)  \n \n\u2022 Health-  related quality of lif e (respiratory specific) SGRQ, n=58 (2 RCTs), \nGRADE: Low  \nControl: The mean change in SGRQ (total score) ranged across control groups \nfrom -5.0 to - 0.4 \nSinging: The mean change in SGRQ (total score) in the intervention groups was \n0.8 units higher (3. 0 units lower to 4.7 units higher)  \n\u2022 Health-  related quality of life (generic) SF -36 (Physical Component Summary \n(PCS) score), n=52 (2 RCTs), GRADE: Low  \nControl: The mean change in SF -36 (PCS score) ranged across control groups \nfrom -3.8 to - 2.5 \nSinging: The mean change in SF -36 (PCS score) in the intervention groups was \n12.6 units higher (5.5 units higher to 19.8 units higher)  \n \n\u2022 Health-  related quality of life (generic) SF -36 (Mental Component Sumary (MCS) \nscore), n=52 (2 RCTs), GRADE: Low  \nControl: The mean change in SF -36 (MCS score) ranged across control groups \nfrom -3.2 to 4.3  \nSinging: The mean change in SF -36 (MCS score) in the intervention groups was \n5.4 units higher (3.9 units lower to 14.7 units higher)  \n \n\u2022 Dyspnoea Basal Dyspnea Index (BDI) (score),n=30 (1 RCT), GRADE: Very low  \nControl:The mean change in BDI (score) was 0.3  \nSinging: The mean change in BDI (score) in the intervention groups was 0.4 units AMSTAR -Score: 11/11  \n \ny-y-y-y-y-y-y-y-y-y-y \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  214 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nhigher (0.7 units lower to 1.5 units higher)  \n \n\u2022 Psychological status , n= 52 (2 RCT)  \nThere was no statistically significant improvement in the HADS anxie ty score (MD \n-1.09, 95% CI -  3.02 to 0.83, n = 52) or HADS depression score (MD - 0.87, 95% \nCI -2.16 to 0.42, n = 52).  \n \n\u2022  Physical activity level: n=24, (1 RCT)  \nThere were no statistically significant differences between the singing group and \ncontrol group for sedentary time (minutes per day), but the confidence interval is \nwide (MD - 8.60, 95%CI - 88.33 to 71.13). There were statistically significant differ-\nences in the remaining measures of physical activity favouring the control group \n(steps (steps per day)  MD -1774.00, 95% CI - 2847.73 to - 700.27; physical activity \nduration (minutes per day) MD - 142.20, 95% CI - 262.56 to - 21.84; active energy \nexpendi -ture (kJ per day) MD - 373.00, 95% CI - 625.28 to -120.72).  \n \nNo a dverse events/side effects  were reported by any of included studies  \n \nCramer 2019. The risks \nand benefits of yoga for \npatients with chronic ob-\nstructive pulmonary dis-\nease: a systematic review \nand meta- analysis  \n \n\u2022 Nicht zitiert.  \n \u2022 Deutschland; UK; Australien  \n\u2022 Fragestellung:  To determine the effective-\nness and safety of yoga interventions on dis-\nease symptoms, quality of life and function in \npatients diagnosed with chronic obstructive pul-\nmonary disease (COPD).  \n \n\u2022 Suchzeitraum:  through 6 June 2019 \n\u2022 Population:  Patient*innen mit COPD  \n \n\u2022 Interventionen:  \n1. Interventions including yoga breathing only \n(based on yoga theory and/or traditional yoga \npractices), without physical postures, medita-\ntion, or lifestyle advice.  \n2. Complex yoga interventions including yoga \nbreathing and at least 1 of the following: physi-\ncal postures, meditation, and/or lifestyle advice \n(based on yoga theory and/or practices).  \n \n\u2022 Vergleich:  \nno treatment, sham yoga, or any active control \nintervention  \u2022 Baseline -Charakteristika:  \n- median age of included patients: 57.6 years; the studies included a median of \n16.7% female patients.  \n- median duration of  yoga interventions: 12 weeks, with a median frequency of \nfive yoga sessions per week.  \n \n\u2022 effects of yoga compared to no treatment on  \n- quality of life on  the COPD Assessment Test (MD = 3.81; 95% CI = 0.97 to 6.65; \nP = 0.009, I2 = 70%; n=3 studies; n=115 participants)  \n- exercise capacity assessed by the 6- minute walk test (MD = 25.53 m; 95% CI = \n12.16 m to 38.90 m; P = 0.001, I2 = 0%; n=7 studies; n=288 participants),  \n- pulmonary function assessed by FEV1 predicted (MD = 3.95%; 95% CI = 2.74% \nto 5.17%; P < 0.001, I2 = 0%; n=3 studies; n=118 participants).  \n \n\u2022 Subgruppe:  \nIn subgroup analyses, when limiting the analysis to studies using breathing- based \nyoga interventions, we found positive effects compared to no treatment on  \n- dyspnea (standardized MD= \u20130.43 (95% CI \u20130.81, \u20130.05; p=0.03; I\u00b2= 0%; n=2 \nstudies; n=11 participants)  \n- exercise capacity  (MD= 22.74 m (7.01 m, 38.48 m); p=0.003; I\u00b2=0%; n=4 studies; \nn= 146 participants)  \n- predicted forced expiratory volume in one second (MD 3.97% (2.79%, 5.15%); \np< 0,001; I\u00b2=0%; n=3 studies; n=138 parti cipants)  AMSTAR -II: \n- critica lly low  \n \n \n \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  215 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \n\u2022 eingeschlossene Studien: n=11 RC Ts \n(n=586 participants)  \n   \nWhen limiting the analysis to complex yoga interventions, we only found effects on \nexercise capacity.  \n \n\u2022 Sicherheit:  \n- 2/ 11 studies reported safety -related outcomes. (a case of cancer; hospitaliza-\ntions - no reasons reported)  \n- None of these st udies reported whether the adverse events were intervention-  \nrelated or not.  \n \n>> Effects were only present in breathing- focused yoga interventions but not in in-\nterventions including yoga postures.  \n>> Yoga may be an effective option for improving physical c apacity and breathing \nparameters in chronic obstructive pulmonary disease rehabilitation.  \n>> The safety of yoga in chronic obstructive pulmonary disease is inconclusive \ndue to insufficient safety reporting in clinical trials to date.  \n \n \nDiaphragmatic breathing  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nYamaguti WP. Dia-\nphragmatic breathing \ntraining program im-\nproves abdominal mo-\ntion during natural \nbreathing in patients \nwith chronic obstructive \npulmonary disease: A \nrandomized controlled \ntrial. Arch Phys Med Re-\nhabil 2012; 93(4):571\u2013 7.  \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/22464088 . \u2022 Ziel: To investigate the ef-\nfects of a diaphragmatic \nbreathing training program \n(DBTP) on thoracoabdominal \nmotion and functional capacity \nin patients with chronic ob-\nstructive pulmonary disease.  \n\u2022 Studiendesign: prospective \nRCT \n\u2022 Population: patients with \nCOPD ((N 30; FEV 1, 42% \u00b1 \n13% predicted)  \n \n\u2022 Intervention:  Subjects in the \nTraining group (TG) completed \na 4-week supervised Dia-\nphragmatic breathing training \u2022 Baseline -Patientench arakteristika:  hinsichtlich Alter, \nGewicht, Geschlecht, Schwere der Ekrankung, 6MWD, \nSGRQ, Bode- Index weitestgehend ausgeglichen  \n \n- TG showed a greater abdominal motion during natural \nbreathing quantified by a reduction in the RC/ABD ratio \nwhen compared wi th the CG (F=8.66; P<.001).  \n- Abdominal motion during voluntary diaphragmatic breath-\ning after the intervention was also greater in the TG than in \nthe CG (F=4.11; P<.05).  \n- The TG showed greater diaphragmatic mobility after the 4-\nweek DBTP than did the CG (F=15.08; P<.001).  \n- An improvement in the 6- minute walk test and in health- re-\nlated quality of life was also observed in the TG.  \n \nConclusions:  DBTP for patients with chronic obstructive  \npulmonary disease induced increased diaphragm participa-\ntion Selection bias  \nRandomisierung: gering   \nAllocation concealment: unklar   \nPerformance bias \nVerblindung von Teilnehmern und Personal: \ngering  \nDetection bias  \nVerblindung der Ergebnisevaluat ion: unklar  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende \nDaten: gering  \nITT-Analyse: durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: unklar  \nAndere Biasursachen  \nBaseline imbalance: gering  \nInteressenkonflikte/ Sponsoring: CoI nicht \nbeschrieben  Endpunkte klinisch relevant?  \n \nn= 30 Teilnehmer  \n \nkeine Langzeitwirkung untersucht  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  216 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nprogram  (DBTP;3 individual-\nized weekly sessions)  \n\u2022 Vergleich: Controlgroup \n(CG) received usual care  \n \n\u2022  Brasilien  \n \n\u2022 Endpunkte:  \n-rib cage to abdominal motion \nratio (RC/ABD ratio) (primary \noutcome)  \n- diaphragmatic mobility (sec-\nondary outcome)  during n atural breathing, resulting in an improvement in \nfunctional  \ncapacity.  \n \n  \nPursed lips breathing (PLB)  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nMayer AF, Karloh M, \nDos Santos K, de \nAraujo CLP, Gulart AA. \nEffects of acute use of \npursed- lips breathing \nduring exercise in pa-\ntients with COPD: a \nsystematic review and \nmeta- analysis. Physio-\ntherapy. 2018 \nMar;104(1):9- 17 \n \u2022 Fragestellung:  To investigate the  effects of acute use of PLB in \nexercise performance, dyspnoea, ventilatory parameters and oxy-\ngen saturation during exercise in patients with COPD.  \n \n\u2022 Suchzeitraum:   up to May 2016.  \n\u2022 Population:  Patient*innen mit COPD  \n\u2022 Einschlusskriterien:  \n- >40 years of  age; clinical diagnosed COPD confirmed wit spirom-\netry; absence of: pulmonary desases other than COPD, heart dis-\nease and/or neuromuscular disease.  \n \n\u2022 Interventionen:   PLB as a ventilatory strategy during exercise \nconditions  \n\u2022 Vergleich:  non-exposed to the PLB group \n \n\u2022 eingeschlossene Studien:  n=8 ; 197 patients (cross -over stud-\nies) \u2022 Meta -analysis of PLB acute effect on exercise performance \n(six minute walk test)  \nMean Difference (MD): 6.14 (95% CI - 35-03, 47.30), n= 2 Stud-\nies; 78 participants; I\u00b2=33%  \n \n\u2022 Meta-analysis of PLB acute effect on dyspnoea evaluated by:  \n(A) Visual Analogue Scale \nMD: -0-11 (95% CI - 1.05- 0.83); n=2 studies; 44 participants; \ni\u00b2=0%  \n(B) BORG dyspnea scale  \nMD: -0.15 (95% CI - 0,45-0.15); n= 5 studies; 372 participants; \nI\u00b2=0%  \n \n >> PLB is effective in reducing minute ventilation and respira-\ntory rate during exercise in patients with COPD. It is still unclear \nwho responds to PLB and how these responders benefit from its \nuse. Further studies with better methodological quality are nec-\nessary to understand the implications of its acute use on the \nfunctional capacity and symptoms of patients with COPD.  AMSTAR -II: \ncritically low  \n \n \n \n \nSakhaei S. The Impact \nof Pursed- lips Breath-\u2022 Ziel:  to evaluate the effect of PLB on cardiac, pulmonary and ox-\nygenation level in patients with Chronic Obstructive Pulmonary \nDisease (COPD).  \u2022 Baseline -Patientencharakteristika:  hinsichtlich Gewicht und \nGr\u00f6\u00dfe ausgeglichen; Unterschied hinsichtlich Alter (p= 0.001)  \n- PLB intervention group: patients with mild to  moderate disease Selection bias  \nRandomisierung: niedrig  \nAllocation concealment: niedrig   NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  217 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \ning Maneuver on Car-\ndiac, Respiratory, and \nOxygenation Parame-\nters in COPD Patients. \nOpen Access Maced J \nMed Sci 2018; \n6(10):1851\u2013 6.  \nhttps://www.ncbi.nlm .ni\nh.gov/pub-\nmed/30455761 . \n \n \n\u2022 Nicht zitiert.   \n\u2022 Studiendesign: three- group clinical RCT  \n \n\u2022 Population:  Patient* innen mit COPD (n=40) + n=20 healthy sub-\njects \n \n\u2022 Intervention: patients were trained to perform the PLB  \n- Gruppe 1: n=20 Patienten mit COPD  \n- Gruppe 2: n=20 gesunde Teilnehmer  \n\u2022 Vergleich:  received just routine cares and drug treatments.  \n- Kontrollgruppe: n=20 Patienten mit COPD  \n \n\u2022 Einschlusskriterien:  \n- age over 40, diagnosis of COPD, stability in clinical condition, un-\nused rehabilitation programs other than PLB, the absence of un-\nderlying chronic illnesses (hypertension, cardiomyopathy, or dia-\nbetes) and the patient's willingness to participate in the study.  \n \n\u2022 Studienzeitraum: 2017  \n\u2022 Iran  were selected  \n \nOn evaluation within the COPD patient intervention group in Sat-\nuration of Peripheral Oxygen (SPO2) index with the mean differ-\nence of 2.05 percent, Respiratory Rate(RR) -0.65 minute and \nPulse Rate(PR) -1.6 bpm was significant (p \u2264 0.05), and systolic \nblood pressure index in healthy subjects was increased (3.35 \nmmHg).  \n \n \n \n Performance bias  \nVerblindung von Teilnehmern und Perso-\nnal: unklar  \nDetection bias  \nVerblindung der Ergebnisevaluation: un-\nklar \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende \nDaten: hoch   \nITT-Analyse: nicht durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: unklar  \nAndere Biasursachen  \nBaseline imbalance: unklar  \nInteressenkonflikte/ Sponsoring:  An-\ngabe: keine  \n \nCollins EG. The Effect \nof Breathing Retraining \nUsing Metronome-\nBased Acoustic Feed-\nback on Exercise En-\ndurance in COPD: A \nRandomized Trial. Lung \n2019.  \nhttps://www.ncbi.nlm.ni\nh.gov/pub-\nmed/30739217 . \n \n\u2022 Nicht zitiert.  \u2022 Ziel:  to assess the impact of exercise- training plus breathing- re-\ntraining using a metronome- based acoustic feedback on exercise \nduration, dynamic hyperinflation, and quality of life in patients with \nmoderate- to-severe COPD.  \n \n\u2022 Studiendesign: prospective RCT  \n \n\u2022 Population: Patient*innen mit COPD; n=119  \n \n\u2022 Intervention: exercise training (training on the treadmill for 25 \nmin and progressed as tolerated up to 45 min of exercise)  \nplus breathing- retraining using acoustic feedback (n= 58)  \n>>patients were instructed to inhale through the nose and exhale \nthrough the mouth with their lips pursed  \n \n\u2022 Vergleich:  or exercise -training alone (n= 61)  \n \n\u2022 USA  \u2022 Baseline- Patientencharakteristika (relevante): hinsichtlich \nAlter, Gewicht, Lungenfunktionsparameter weitestgehend aus-\ngeglichen  \n- exercised on a treadmill thrice- weekly for 12 weeks  \n \nAt completion of training, improvements in exercise duration  in \nthe breathing- retraining plus exercise- training and exercise-\ntraining alone groups were similar (p = 0.35).  \nAt isotime, inspiratory capacity increased (less exercise- induced \ndynamic hyperinflation) by 3% (p = 0.001) in the breathing- re-\ntraining plus exercise- training group and remained unchanged in \nthe exercise- alone group. The between- group change in inspira-\ntory capacity, however, was not significant (p = 0.08).  \n \nQoL \nAt the conclusion of training, dyspnea during activities  \nof daily living, fatigue, emotional function and mastery  \nimproved in both groups of patients. Improvements  \nin mastery were greater in the breathing- retraining group \nthan in the exercise- alone group (p= 0.042).  Selection bias  \nRandomisierung: unklar  \nAllocation concealment:  unklar  \nPerformance bias \nVerblindung von Teilnehmern und Perso-\nnal: Verblindung aufgrund Studienaufbau \nnicht m\u00f6glich  \nDetection bias  \nVerblindung der Ergebnisevaluation: un-\nklar  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende \nDaten: niedrig  \nITT-Analyse: nicht durchgef\u00fchrt  \nReporting bias  \nselektiv e Ergebnisdarstellung: unklar  \nAndere Biasursachen  \nBaseline imbalance:  niedrig \nInteressenkonflikte/ Sponsoring:  an-\ngegeben  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  218 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \n\u2022 authors conclusion : In patients with COPD, breathing- retrain-\ning using a metronome- based acoustic feedback did not result in \nimproved exercise endurance or decreased dynamic hyperinfla-\ntion when compared to exercise- training alone.   \nUbolsakka -Jones C. \nPositive expiratory \npressure breathing \nspeeds recovery of \npostexercise dyspnea \nin chronic obstructive \npulmonary disease. \nPhysiother Res Int \n2019; 24(1):e1750.  \nhttps://www.ncbi.nlm.ni\nh.gov/pub-\nmed/30251299 . Studiendesign: prospective randomized cross \u2010over trial  \n \nPopulation:  n=13 male COPD patients (GOLD II & III)  \nIntervention: at the end of exercise (marching): six breaths \nagainst a 5\u2010 cm H2O expiratory load (positive expiratory pressure \n[PEP]) , with 3 \u2010hr rest between interventions  \nVergleich:  at the end of exercise: six breaths against no load \n(Sham)  \n-Recovery was followed for the next 10 min.  \n \nEinschlusskriterien  \n- clinically stable and free of exacerbations  \nAusschlusskriterien  \n- age over 70 years, cardiovascular disease, any musculoskeletal \nproblems that limited exercise, neurological or cognitive impair-\nment, or psychiatric illness  \n \nThailand  `- None of t he patients used supplemental oxygen or reported \ndyspnea at rest.  \n \n- Dyspnea recovered significantly faster after the PEP interven-\ntion in all patients, taking 2.8 \u00b1 0.4 min to return to baseline \ncompared with 5.1 \u00b1 0.6 min for Sham (p < 0.01).  \n \n- PEP was e qually effective in reducing dyspnea in all patients \nirrespective of the degree of dynamic hyperinflation  \n \n- Changes in oxygen saturation, end\u2010 tidal CO2, heart rate, and \nbreathing frequency were similar in PEP and Sham.  \n Selection bias  \nRandomisierung: unk lar \nAllocation concealment: unklar  \nPerformance bias \nVerblindung von Teilnehmern und Perso-\nnal: hoch  \nDetection bias  \nVerblindung der Ergebnisevaluation: \nhoch \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende \nDaten: unklar  \nITT-Analyse: nein  \nReporting bias  \nselektive Ergebnisdarstellung: unklar  \nAndere Biasursachen  \nBaseline imbalance: unklar  \nInteressenkonflikte/ Sponsoring:  Dr \nUbolsakka\u2010 Jones is academic advisor to \nthe company distributing BreatheMAX (= \neingesetztes PEP -Ger\u00e4t)  \n \nPhysiotherapien (verschiedene)  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nZhang C. Effectiveness \nof physiotherapy tech-\nniques for rehabilitation \nafter acute chronic ob-\nstructive pulmonary dis-\nease exacerbation: A \nmeta- analysis. Int J \nClin Exp Med 2018; \n11(8):7572 \u201382. \u2022 Fragestellung: to investigate the \neffect of all potential physiotherapy \ntechniques on motor function in \nCOPD exacerbation patients.  \n \n \u2022 Suchzeitraum:  until August 30, \n2017,  \n \u2022 Population:  Patients with severe \nCOPD/after exacerbation  ELTGOL  is a bronchial de- obstruction technique.  \n- no different effect between ELTGOL and the control group in \nexercise distance (WMD - 2.74, 95% CI= -9.76 to 4.29, subgroup \nI2=0%, P=0.44; n=5 studies: 162 participants)  \n- or endurance time (SMD - 3.15, 95% CI= -9.58 to 4.05, sub-\ngroup I2=0%; P=0. 83; n=3 studies; 118 Participants)  \n- Thus, the test of overall effect of  ELTGOL is undoubtedly in-\nsignificant (overall I2=0%; P=0.43).  AMSTAR -II: \n- critically low  \n \n \n \u00b4- keine verl\u00e4ssliche Metaanalyse: \nPooling trotz sehr hoher Heter oge-\nnit\u00e4ten und Verwendung eines fixed \neffects models  \n- keine methodische Bewertung der \neingeschlossenen Studien  \n- keine Aussage zu excluded stu-\ndies \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  219 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \npdfs.seman-\nticscholar.org/2884/726\nf7d57818c6e9103a926\n364a2372c48cc7.pdf.  \n \n\u2022 Nicht zitiert.   \n \u2022 Interventionen:  verschiedene \nPhysiotherapie- Verfahren  \n- High freqeuncy Chest wall oscilla-\ntion \n- ELTGOL  \n- TENS  \n \n \u2022 eingeschlossene Studien: n=13 \nRCTs  HFCWO  \n-> studies containing application of HF CWO in COPD exacer-\nbation:  \n- increased exercise distance (WMD 23.14, 95% CI=10.93 to \n35.36, subgroup I2=50%; P=0.0002; n=4 studies; 143 partici-\npants))  \n- and relatively long motor tolerance duration (SMD 60.85, 95% \nCI=32.81 to 88.89, subgroup I2=35%; P<0.00001; n=4 studies; \n175 participants)  \n- Motor function improvement of HFCWO in COPD exacerba-\ntion was significantly higher than that in control group \n(P<0.00001).  \nUbolnuar N. Effects of \nBreathing Exercises in \nPatients With Chronic \nObstructive Pulmonary \nDisease: Systematic \nReview and Meta- Anal-\nysis. Ann Rehabil Med \n2019;43(4):509- 523 \n \n\u2022 Nicht zitiert.  \n \u2022 Fragestellung: evidence on the ef-\nfects of breathing exercises (BEs) on \nventilation, exercise capacity, dysp-\nnea, and quality of life (QoL) in \nCOPD patients  \n \n\u2022 Suchzeitraum:  through May 2018 \n\u2022 Population:  Patient*innen mit \nCOPD (any stage)  \n \n\u2022 Ausschlusskriterien (Auswahl)  \n- unstable COPD, on ventilator, or \nwith other diseases, not English,  BE \nwas less than 50% of total treatment \nin the experimental group  \n \n\u2022 Interventionen:  breathing exer-\ncises (BE):  \n- PLB (pursed- lip breathing),  \n- VF (ventilatory feedback) training,  \n- VF plus exercise,  \n- singing,  \n- DBE (d iaphragmatic breathing),  \n- and combined BEs (combination of \nDBE with other BEs)  \n\u2022 Vergleich:  any, except BE  \n \n\u2022 eingeschlossene Studien: n=19 \nRCTs teilweise cross -over; n=745 Pursed -lip breathing  \nThere was no significant between- group difference [\u2026], dysp-\nnea (p=0.15), and 6MWD (p=0.85).  \n \nVentilatory feedback training alone \nNo significant differences in [...], dyspnea (p=0.15)  \n \nVentilatory feedback training plus exercise  \nThere was no significant between- group difference in [...], dysp-\nnea (p=0.83), exercise capacity (p=0.68\u2013 0.90), and QoL \n(p=0.97).  \n \nSinging exercise  \nThere was moderate quality evidence of significant difference \nin the physical component summary of SF -36, between the \nsinging group and the control group (MD 12.64 (95% CI 5.50 ; \n19.77, n=2 studies; p=0.0005)  \nHowever, there was no statistically significant difference in \nother QoL related measures (p=0.07\u2013 0.52) or exercise capacity \n(p=0.44)  \n \nDiaphragmatic breathing  \nThere was no statistically significant difference in dyspnea \n(p=0.47) and SGRQ score (p=0.58), between the DBE group \nand the control group.  \n AMSTAR -II: \ncritically low  \n \n \n ventilatory related outcomes nicht \nextrahiert; da bisher nicht in PICO -\nFrage formuliert  \n \nnach Recherche ver\u00f6ffentlic ht \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  220 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nparticipants  \n\u2022 Quality of evidence: low to moder-\nate. \n \nAnhang 7.6  Patientenschulung  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nWittmann M. Patient \neducation in COPD \nduring inpatient rehabil-\nitation improves quality \nof life and morbidity. \nPneumologie 2007; \n61(10):636\u2013 42.  \nhttps://www.ncbi.nlm.ni\nh.gov/pub-\nmed/17886195 . \n \n \u2022 Studiendesign: prospektiv, randomisiert  \n\u2022 Follow -up /Assessments:  w\u00e4hrend der Rehabilitation; \nnach 12 Monaten  \n \n\u2022 Population: Patient*innen mit COPD  (n=212 )  \n \n \n\u2022 Einschlusskriterien:  \n- Patient*innen mit der Rehabilitations - Indikation chro-\nnisch obstruktive B ronchitis  \n-manifeste Obstruktion (FEV1/VC < 70%)  \n- Alter:18-  70 Jahre \n \n\u2022 Ausschlusskriterien:  \n- Asthma bronchiale/Allergie der Atemwege, \u2206FEV1 nach \nBronchospasmolyse> 15 %, Notwendigkeit einer intermit-\ntierenden Selbstbeatmung, dekompensiertes Cor pulmo-\nnale, FEV1/VC < 0,25, maligner Tumor, Herzerkrankung \nNYHA III -IV, andere schwere Organerkrankungen \n- unzureichende deutsche Sprachkenntnisse,Schulung \n\u00fcber Atemwegskrankheiten in den letzten 2 Jahren, man-\ngelnde Kooperationsf\u00e4higkeit.  \n \n\u2022 Endpunkte:  \n- Sozialmedizinische Parameter  \n- Lebensqualit\u00e4t (SGRQ)  \n \n\u2022 Studienzeitraum: 06/1999 - 03/2001 \n\u2022 Deutschland  \nSchulung + Aktionsplan + multidisziplin\u00e4re, station\u00e4re \nRehabilitation  \nvs. \u2022 Baseline -Patientencharakteristika: hinsichtlich ALter, Ge-\nschlecht, Rauchstatus; Lungenfunktionsparameter wei-\ntestgehend ausgeglichen  \n- Kontrollgruppe (KG): n=90, Alter 54,4 \u00b1 6,1 Jahre, FEV1 \n1,83 \u00b1 0,61  \n- Schulungsgruppe (SG): n=94, Alter 53, 5 \u00b1 7,6 Jahre, \nFEV1 1,81 \u00b1 0,61  \n \n- R\u00fccklaufquote der Fragebogen nach 1 Jahr: 98%  \n- Drop -Out: n= 28 mit Angabe von Gr\u00fcnden \n \nResultate 1 Jahr nach der Rehabilitation:  \nIn beiden Gruppen reduzierte sich im Jahr nach der Reha-\nbilitation  \n- die Zahl der Krankenhausaufnahmen (KG: 24,7% auf \n11,5%, p=0,02; SG: 30,8% auf 9,9%, p = 0,001)  \n  \n- Der Anteil der Raucher*innen in beiden Gruppen war ge-\nring unterschiedlich, er blieb bis ein Jahr nach der Rehabi-\nlitation unver\u00e4ndert: Kontrollgruppe (n = 88) 41 % Rau-\ncher*innen, S chulungsgruppe (n=92) 48%.  \n \n \nnur in der SG reduzierte sich:  \n-  die Zahl der Intensivbehandlungstage (11,8 auf 2,2 p = \n0,02)  \n- die Inanspruchnahme \u00e4rztlicher Notdienste (18,3 auf 5,5 \n%, p = 0,01)  \n- die Zahl der Notfalleinweisungen (19,6% auf 8,7%, \np=0,03)  \n \nrelevante Besserung der Lebensqualit\u00e4t:  \n- SG: OR = 2,5; CI 1,07 -5,84; p = 0,03  Selection bias  \nRandomisierung: gering   \nAllocation concealment: un-\nklar  \nPerformance bias \nVerblindung von Teilneh-\nmern und Personal:  nicht \nm\u00f6glich  \nDetection bias  \nVerblindung der Ergebnise-\nvaluation: unklar  \nAttrition bias  \nVerlust von Studienteilneh-\nmern/ fehlende Daten:  ge-\nring \nITT-Analyse: nicht durchge-\nf\u00fchrt \nReporting bias  \nselektive Ergebnisdarstel-\nlung: unklar  \nAndere Biasursachen  \nBaseline imbalance: gering \nInteressenkonflikte/ Sponso-\nring: Projekt B4 des Rehabi-\nlitationswissenschaftlichen \nForschungsverbundes Bay-\nern[...] gef\u00f6rder t von VdR \nund BMBF.  \nKeine Angaben zu CoI der \nAutoren \n \u2022 methodische Qualit\u00e4t, \nkeine Angaben zu Interes-\nsenkonflikten  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  221 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nmultidisziplin\u00e4re, station\u00e4re Rehabilitation  \n \n\u2022 Rehabilitation inkludiert: Fa ch\u00e4rztliche Optimierung \nder medikament\u00f6sen Therapie, Erlernen der korrekten \nInhalationstechniken, k\u00f6rperliches Training, Atemphysio-\ntherapie mit dem Erlernen von Selbstkontroll - und Selbst-\nhilfetechniken, im Bedarfsfall Hilfen zur Tabakentw\u00f6h-\nnung, psychologi sche Unterst\u00fctzung, Sozialberatung und \nErn\u00e4hrungsberatung.  \n \n\u2022 Schulung:  \n1. Doppelstunde:  \n\u2022 Aufbau und Funktion der Atemwege \n\u2022 Chronische Bronchitis und Lungenemphysem: Ursa-\nchen,  \nEntstehung, Verlauf  \n\u2022 M\u00f6glichkeiten der Terti\u00e4rpr\u00e4vention \n2. Doppelstunde:  \n\u2022 Grundlagen der Inhalation  \n\u2022 Die Medikamente anhand des Stufenplans  \n3. Doppelstunde:  \n\u2022 Bedeutung der nichtmedikament\u00f6sen Therapiema\u00dfnah-\nmen:  \nPhysiotherapie, Bronchusdrainage, k\u00f6rperliches Training  \n\u2022 Vermeiden von Verschlechterungen, Infektprophylaxe \n\u2022 Fr\u00fchzei tiges Erkennen von Verschlechterungen und \nrichtiges Reagieren  \n4. Doppelstunde:  \n\u2022 Wiederholung und \u00dcbung des Erlernten \n\u2022 Steigerung von Krankheitsakzeptanz und Bew\u00e4ltigung \nim \npsychosozialen Umfeld \n5. Nachbesprechung in der Kleingruppe:  \n\u2022 Aush\u00e4ndigung des Ak tionsplans  \n  \n- Die geschulten Patient*innen absolvierten nach 1 Jahr \nvermehrt k\u00f6rperliches Training (Wochentrainingszeit mehr \nals 1 Stunde: SG n = 58, KG n = 34, p< 0,01).  \nBosch D. COPD outpa-\ntient education pro-\ngramme (ATEM) and \nBODE index. Pneumol-\nogie 2007; 61(10):629\u2013\n35.  \u2022 Studiendesign:  prospektiv, randomisiert  \n\u2022 Follow up/ Assessments : bei Eintritt in die Studie; \nnach 12 Monaten  \n \n\u2022 Population: Patient*innen mit leichter bis sehr schwe-\nrer COPD (n=50 eingeschlossen)  \n\u2022 Einschlusskriterien:  \u2022 Baseline- Patientencharakteristika: hinsichtlich Alter, Ge-\nwicht, BODE -Index weitestgehend ausgeglichen  \n- aktiver Rauchstatus Intervention: 13%; Kontrollgruppe: \n27% --> statistisch nicht signifikant  \n> deutlich mehr Teilnehmer in der Interventionsgruppe \n(30/38), als in der Kontrollgruppe (11/12)  \n Selection bias  \nRandomisierung: unklar  \n \nAllocation concealment : un-\nklar \n \nPerformance bias  \u2022 methodische Qualit\u00e4t, \nkeine Angaben zu Interes-\nsenkonflikten  \n\u2022 Inbalance in Verteilung \nder Studienteil nehmer zu \nden Gruppen (30 vs. 11)  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  222 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nhttps://www.ncbi.nlm.ni\nh.gov/pub-\nmed/17661240 . \n \n - Diagnose einer COPD; spirometrisch gesicherte Ob-\nstruktion; FEV1/VC max <70%  \n\u2022 Ausschlusskriterien:  \n- Komorbidit\u00e4t mit ma\u00dfgeblicher Beeinflussung von Lun-\ngenfunk tion, Symptomatik oder Leistungsf\u00e4higkeit (symp-\ntomatische kardiopulmonale Zweiterkrankung)  \n\u2022 Endpunkte (keine Unterteilung in prim\u00e4r und sekund\u00e4r)  \n- BODE -Index (BMI, FEV1; mMRC; 6MWD)  \n- Morbidit\u00e4tsmarker (Hospitalisationsrate; Antibiotikabe-\ndarf) \n \n\u2022 Studienzeitraum:  01/2005 - 01/2006 \n\u2022 Deutschland, multicenter study  \n\u2022 statistische Auswertung: deskriptiv  \n \nSchulungsprogramm (ATEM)  \nvs. \nStandardtherapie (mit sp\u00e4terer M\u00f6glichkeit der Schulung)  \n \nATEM  \n- ambulantes, strukturiertes, zielgruppenspezifisches Pa-\ntientens chulungsprogramm  \n- Anleitung zur Lebensstilmodifikation \n- Kleingruppen; 3 Schulungstermine \u00e1 120 min; 1 Nach-\nschulungstermin 6 Wochen sp\u00e4ter (\u00e1 120 min)  \n- Schulung von ausgebildeten Krankenschwestern durch-\ngef\u00fchrt + fach\u00e4rztliche Supervision \n \n \u2022 Drop Out n=9 (ohne Angabe von Gr\u00fcnden)  \nIntervention n=8 (21%)  \nKontrolle: n=1 (8%)  \n \n\u2022 Interventionsgruppe (I) (n=30); Kontrollgruppe (K) \n(n=11)  (Mittelwert \u00b1 SD):  \nBODE -Index gesamt  \n- I: Start: 3,0 \u00b1 2,0 --> nach 12 Monaten: 2,5 \u00b1 1,6; \np=0,047  \n=> statistisch signifikanter Abfall; Verbesserung von \n16,7%  \n- K: Start: 2,6 \u00b1 1,6 --> nach 12 Monaten: 3,6 \u00b1 1,8; \np=0,012 \n=> stat. signifikanter Anstieg \nmMRC  \n- I:  Start: 1,6 \u00b1 0,9 --> nach 12 Mon. : 1,1 \u00b1 0,8; p=0,005 \n=> sig. Verbesserung \n- K: Start: 1,6 \u00b1 0,8 --> nach 12 Mon.: 2,4 \u00b1 0,7; p=0,02 \n=> sig. Verschlechterung \n6-MWD  \n- I: Start: 406 \u00b1 92 --> nach 12 Mon.: 436 \u00b1 94; p=0,001 \n=> sig. Verbesserung (7,4%)  \n- K: Start: 396 \u00b1 79 --> nach 12 Mon.: 386 \u00b1 99; p=0,3  \n=> nicht signifikante Verringerung \nsportliche Bet\u00e4tigung (Befragung)  \n- I: Start: 27% --> nach 12 Mon.: 60%  \n- K: Start: 27% --> nach 12 Mon.: 45%  \nBeeintr\u00e4chtigung der Lebensf\u00fchrung (Befragung)  \n- I: Start: 84% --> nach 12 Mon.: 60%  \n- K: Start:  63% --> nach 12 Mon.: 82%  \nCOPD- bedingte Krankenhausbehandlungen in den letzten \n12 Monaten (Befragung)  \n- I: Start: 1,1 \u00b1 1,0 --> nach 12 Mon.: 0,3 \u00b1 0,6; p<0,0001 \n- K: Start + ebenso nach 12 Mon.: 0,6 \u00b1 0,7 \nWissenszuwachs (Ursache der COPD; atemphysikali-\nscher M\u00f6glichkeiten; Ern\u00e4hrungszustand, k\u00f6rperliches \ntraining; Notfallmedikation)  \nI: Start: 2,3 \u00b1 1,1 --> nach 12 Mon.: 4,2 \u00b1 1,1 (p<0,001)  \nK: Start: 2,1 \u00b1 1,5 --> nach 12 Mon.: 2,4 \u00b1 1,4 (p=0,4)  \n Verblindung von Teilneh-\nmern und Personal: nicht \nanwendbar  \n \nDetection bias  \nVerblindung der Ergebnise-\nvaluation:unklar  \n \nAttrition bias  \nVerlust von Studienteilneh-\nmern/ fehlende Daten: hoch  \n \nITT-Analyse: keine ITT -Ana-\nlyse durchgef\u00fchrt  \n \nReporting bias  \nselektive Ergebnisdarstel-\nlung: unklar  \n \nAndere Biasursachen  \nBaseline imbalance: unklar  \n \nInteressenkonflikte/ Sponso-\nring: keine Angaben  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  223 \n      \n \nAnhang 7.7  Ern\u00e4hrung  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nFerreira IM. Nutritional \nsupplementation for \nstable chronic obstruc-\ntive pulmonary disease. \nCochrane Database \nSyst Rev 2012; \n12:CD000998. \nhttps://www.ncbi.nlm.ni\nh.gov/pub-\nmed/23235577 . \n \n \u2022 Body of Evidence:  n=17  \neingeschlossene RCTs f\u00fcr \nMetaanalyse ( n=  632 einges-\nchlossene Patient*innen)  \n\u2022 Suchzeitraum:  current to \n04/2012 \n\u2022 Population: Patient*innen \nmit stabiler COPD  \n\u2022 Einschlusskriterien: stable \npatients with COPD, among \nwhom at least 75% of part ici-\npants had a forced expired \nvolume in one second (FEV1) \nless than 70% predicted, and \nless than 12% reversibility af-\nter use of a bronchodilator  \n \n\u2022 Interventionen:   \n- subjects received oral, en-\nteral or parenteral nutritional \nsupport vs.  \n(I) placebo  \n(ii) their usual diet or  \n(iii) other treatment regimens \nsuch as anabolic substances  \n \n\u2022 Prim\u00e4re Endpunkte:  \n1. Anthropometric measures \n(body weight, fat -free mass in-\ndex, lean body mass, mid- arm \nmuscle circumference \n(MAMC), skinfold measures).  \n2. Functional exerci se (timed \nwalk test).  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n1. Pulmonary mechanics (lung \nvolumes, respiratory muscle \nfunction).  \n2. Peripheral muscle function.  Anthropometric measures (Illustrative comparative risks* (95% CI)  \n \nWeight (mixed population) kg (Follow -up: 2 to 24 weeks; n=512 participants; 14 RCTs; GRADE: moder-\nate) \n- The mean weight (mixed population) in the control groups was 56.43 kg  \n- The mean weight (mixed population) in the intervention groups was 0.69 higher (0.86 low er to 2.24 \nhigher)  \n \nWeight (undernourished) kg (Follow -up: 2 to 24 weeks; n=325 participants; 11 RCTs; GRADE: moder-\nate) \n- The mean weight (undernourished) in the control groups was 60.34 kg  \n- The mean weight (undernourished) in the intervention groups was 1.65 higher (0.14 to 3.16 higher)  \n \nFat-free mass index (mixed population) kg/m\u00b2 (Follow -up: 3 to 4 months; n=93 participants;  3 RCTs; \nGRADE: low ) \n- The mean fat -free mass index (mixed population) in the control groups was 14.8 kg/m\u00b2  \n- The mean fat -free ma ss index (mixed population) in the intervention groups was 0.08 higher (0.51 lower \nto 0.66 higher)  \n \nFat-free mass index (undernourished patients) kg/m\u00b2 (Follow -up: 3 to 4 months; n=62 participants; 2 \nRCTs; GRADE: low ) \n- The mean fat -free mass index (undernourished patients) in the control groups was 14.5 kg/m\u00b2  \n- The mean fat -free mass index (undernourished patients) in the intervention groups was 0.31 higher \n(0.32 lower to 0.95 higher)  \n \nFunctional exercise  \nThere was low -quality evidence (five RCTs, 142 part icipants) of no significant difference between groups \nin the six -minute walk distance (MD 14.05 m; 95% CI - 24.75 to 52.84), 12- minute walk distance or in \nshuttle walking. However, the pooled change from baseline for the six -minute walk distance was signifi-\ncant (MD 39.96 m; 95% CI 22.66 to 57.26).  \n \nHealth- related quality of life  \nThere was low -quality evidence (4 RCTs, 130 participants) of no significant difference in HRQoL total \nscore (SMD - 0.36; 95% CI - 0.77 to 0.06) when pooling results from both the St George\u2019s Respiratory \nQuestionnaire (SGRQ) and the Chronic Respiratory Questionnaire (CRQ).  \n \nTwo trials (n=67) used the SGRQ to measure individual domains of activity, impact and symptoms. At the \nend of treatment, the pooled total SGRQ score was both statisti cally and clinically significant (MD  6.55; \n95% CI -11.7 to -1.41). The 3 RCTs (n=123) that used the CRQ to measure the change in individual do-\nmains (dyspnoea, fatigue, emotion, mastery), found no significant difference between groups.  AMSTAR:  \ny-y-y-y-y-y-y-y-y-n-n \n \nScore: 9/11  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  224 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n3. HRQoL derived from vali-\ndated scales (e.g. St. \nGeorge\u2019s Respiratory Ques-\ntionnaire (SGRQ), Chronic \nRespiratory  Questionnaire \n(CRQ), Short -Form -36 (SF -\n36)). \n  \n>> This review of 17 studies (632 participants) that provided nutritional supplementation for pa-\ntients with COPD for more than two weeks found growing evidence that nutritional supplementa-\ntion improved body weight, respiratory muscle strength, walking and quality of life.  \n \nAnhang 7.8  Selektiv eingebrachte Literatur  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nWiles L, Cafarella P, \nWilliams MT. Exercise \ntraining combined with \npsychological interven-\ntions for people with \nchronic obstructive pul-\nmonary disease. Respi-\nrology (Carlton, Vic.) \n2015; 20(1):46\u2013 55. \nDOI: \n10.1111/resp.12419. \nhttp://www.ncbi.nlm.nih.\ngov/pubmed/25339508 . \u2022 Fragestellung: to examine \nthe effect of interventions  \nwhich combine exercise train-\ning and psychological inter-\nventions for a range of health \noutcomes in people with \nCOPD \n \n\u2022 Suchzeitraum: 08/2013 \n\u2022 Population:  Patient*innen \nmit COPD oder COPD/ \nAsthma overlap  \n \n\u2022 Interventionen:  All forms of \npsychological interventions de-\nlivered to individuals or groups \nin conjunction with exercise \ntraining or standard compre-\nhensive pulmonary rehabilita-\ntion (CPR), of greater than 2 \nweeks duration in any setting  \n\u2022 Vergleich:  All comparators \nwhich did not include a combi-\nnation of exercise training and \npsychological intervention  \n keine Metaanalyse aufgrund Heterogenit\u00e4t durchgef\u00fchrt:Range der SMD \nbeschrieben  \n \nCompared with control conditions (e.g. wait listing list for active intervention, \nusual care), SMD consistently favoured interventions which included both exer-\ncise + psychological components;  \nSMD range:  \n-  dyspnoea \u22121.63 to \u22120.25;  \n- anxiety \u22120.50 to \u22120.20;  \n- depression \u22120.46 to \u22120.18;  \n- QOL 0.09 to 1.16;  \n- functional exercise capacity 0.22 to 1.23 ) (siehe Fig. 2a,b).  \n \nWhen compared with active comparators (e.g. education/lecture series, ex ercise/ \npsychotherapy alone), SMD consistently favoured interventions that included ex-\nercise training and a psychological component for  \n- dyspnoea (SMD range \u22120.35 to \u22120.97),  \n- anxiety (SMD range \u22120.13 to \u22121.00) and  \n- exercise capacity (SMD range 0.64 to 0.71),  \n- but were inconsistent for depression (\u22120.11 to 1.27) and QOL (0.02 to \u22122.00) \n(siehe Fig 3a,b)  \n AMSTAR -II: \ncritically low  \n \n \n \n \n \n \n selektiv eingebrachte Lite-\nratur \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  225 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n\u2022 eingeschlossene Studien:  \n12 RCT  \n \nAnhang 8  Evidenztabellen Medikament\u00f6se Therapie  \nAnhang 8.1  Cochrane Reviews Medikament\u00f6se Therapie \nSAMA or SAMA/SABA vs. SABA  \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nAppleton S. \nIpratropium bro-\nmide versus short \nacting beta- 2 ag-\nonists for stable \nchronic obstruc-\ntive pulmonary \ndisease. \nCochrane Data-\nbase of System-\natic Reviews \n2006;(2).  \n Suchzeitraum:  07/2008  \nFragestellung: relative efficacy and safety of regular long term use (at least \nfour weeks) of ipratropium bromide and short - acting beta-  2 agonist therapy \nin patients with stable COPD  \nSetting: outpatient  \n \nInterventionen und Vergleiche:  at least 4 weeks of treatment with  \n1) Ipratropium bromide vs. SABA  (metaproterenol, fenoterol or salbutamol \n(albuterol)); delivered via nebuliser or MDI (metered dose inhaler)  \n2) Ipratropium bromide + SABA versus SABA alone (salbutamol or metapro-\nterenol);  delivered via nebuliser or MDI  \n \nStudientyp:  RCT \nEingeschlossene Studien:  11 (n=3912 Studienteilnehmer)  Population:  Non-asthmatic adults with stable COPD  \n \n\u2022 \u2019Stable\u2019  was defined as no recent infections, exacerbations, hos-\npitalisation in the past month + no severe, concurrent other dis-\neases (including cardiac, liver and renal disease)  \n\u2022  COPD definition (BTS 1997):  tobacco smoking related, chronic, \nslowly progressive disorder characterised by airways obstruction \n(FEV1 <80% predicted and FEV1/FVC ratio <70%) which does not \nchange markedly over several months  \n\u2022 mean age 64 y. (group 1); mean age 65 y. (group 2)  \n y-n-y-y-y-y-y-n-ca-y-n \n \nScore: 7  \nStudienergebnisse  \nIpratropium bromide vs. SABA (n=8 studies)  \n1) Health status [health related quality of life scores (HRQL)]  \n\u2022 Meta -analysis of \u201cbetween treatment group\u201d differences showed small, statistically significant differences in CRQ domain scores be tween treatments.These favoured IpB treat-\nment and were found in all four domains of the CRQ (n=1529; studies=5, RoB in 5/5 s tudies: low):   \n- Dyspnoea: MD: 0.16 units (95% CI: 0.09, 0.23), I\u00b2 = 49%;  \n- Fatigue: MD: 0.13 units (95% CI: 0.02, 0.23),  I\u00b2 = 38%;  \n- Emotion: MD: 0.17 units (95% CI: 0.04, 0.29), I\u00b2 = 50%;  \n- Mastery: MD: 0.18 units (95% CI: 0.06, 0.30), I\u00b2 = 30%.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  226 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \n \n2) Dyspnoea scores ( measured directly, at rest or during exercise, or indirectly by self -report in symptom diaries)  \n\u2022 Symptoms scores did not change significantly over time within any treatment group (studies=3) and metaanalysis showed no st atistically signif icant differences between treat-\nments (n=1533, studies=5) for:  \n- Wheezing: MD: - 0.04 (95% CI: - 0.13, 0.04);  \n- Shortness of Breath: MD: 0.00 (95% CI: -0.09, 0.09);  \n- Tightness of Chest:MD: 0.01 (95%CI: - 0.06, 0.09).  \nSABA treatment however, was associated with a small reduction in the scores for Coughing: MD: - 0.08 (95% CI: - 0.13, -0.03).  \n \n3) Exercise capacity - six minute walk distance (6MWD), shuttle walk test  \n>> keine eindeutige Aussage m\u00f6glich:  \n\u2022 n=1 study (small unblinded) found that ipratropium treat ment was associated with a significant increase from baseline in the distance walked in the six minute walk test. Another \nstudy reported no significant difference in the distance walked in a six minute walk test between the IpB and salbutamol treated groups during the parallel phase (day 43- 84) of the \ntrial \n(n=423; studies=2: MD 62.60 [ -15.65, 140.85]), I\u00b2 = not applicable, RoB 1 study: low; 1 study unclear  \n \n4) Adverse and haemodynamic effects -  blood pressure and pulse rate effects from the medication \n\u2022 regardless of delivery method (MDI, nebulised), fewer subjects receiving IpB experienced medication- related adverse events compared with subjects receiving SABA, either \nsalbutamol or metaproterenol (n=1858; studies=6; Peto OR = 0.71, 95% CI:0.53, 0.97; I\u00b2 =63% with either fixed or random effects models, RoB 5/6 studies low; 1/6 study unclear)  \n\u2022 Subgroup analysis based on type of beta- 2 agonist showed that there was no benefit of IpB treatment, when compared with salbutamol, delivered via MDI or nebuliser (P eto OR: \n0.94, 95% CI: 0.64, 1.39). However, IpB treatment was associated with significantly less adverse events compared to metaproterenol (Peto OR: 0.47, 95% CI:0.29, 0.76; I\u00b2 =72%), \nhowever the I\u00b2 was high.  \n \nKommentar:  \n\u2022 Review von 2006 >> 4 July 2008: New search has been performed: no new studies found \n\u2022 Applikationen siehe S. 5 Review  \n\u2022 Differente Angaben bez\u00fcglich Anzahl eingeschlossener Studien verschiedener Analysen im Text vs. zusammenfassende Auswertetabellen \n\u2022 teilweise hohe Heterogenit\u00e4t der vergl ichenen Studien  \n \nLAMA vs. SAMA  \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nCheyne L. Tiotropium \nversus ipratropium bro-\nmide for chronic ob-\nstructive pulmonary dis-\nease. Cochrane Data-\nbase of Systematic Re-\nviews 2015;(9).  Suchzeitraum:  08/2015  \nFragestellung:  relative effects of tiotropium to ipratropium bromide on \nmarkers of quality o f life, exacerbations, symptoms, lung  \nfunction and serious adverse events in patients with COPD  \n \nInterventionen und Vergleiche:  tiotropium vs. ipratropium  \nStudientyp:  RCT \nEingeschlossene Studien:  2 (n=1073)  Population: stable (moderate to severe) COPD in adults  \n>> a diagnosis of COPD as defined by an external set of diagnostic \ncriteria (eg. from  GOLD, ATS, BTS and TSANZ.  \n- mean age: 65 y.  \n \nVincken 2002:  clinical diagnosis of COPD according to ATS guid-\nance \nVoshaar 2008: spirometric criteria were specified  y-n-y-y-y-y-y-y-ca-n-y \n \nScore: 8  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  227 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \n  \n \nTheophylline, inhaled steroids and oral steroid s (prednisolone) up to and \nincluding a  dose of 10 mg (if the dose was stable for at least six weeks) \nwere allowed in both studies.  \n  \nStudienergebnisse  \nPrim\u00e4re Endpunkte  \nSAEs  \n\u2022 fewer people experiencing one or more non- fatal SAEs on tiotropium compared to ipratropium (OR 0.5; 95% CI 0.34 to 0.73, high quality evidence; n=1073; studies=2)  \n>> absolute reduction in risk from 176 to 97 per 1000 people over three to 12 months  \nDisease specific adverse events  \n\u2022 the tiotropium group were less likely to experience a COPD -related serious adverse event when compared to ipratropium bromide (OR 0.59; 95% CI 0.41 to 0.85, moderate \nquality evidence)  \n \nSekund\u00e4re Endpunkte  \nHospital admissions  \n\u2022 fewer hospital admissions in the tiotropium group (OR 0.34; 95% CI 0.15 to 0.70, moderate quality evidence; n=538; study=1)  \npatients experiencing one or more exacerbations leading to hospitalisation  \n\u2022 fewer patients on tiotropium (OR 0.56; 95% CI 0.31 to 0.99, moderate quality evidence)  \nMortality  \n\u2022 no significant difference between the treatments (OR 1.39; 95% CI 0.44 to 4.39, moderate quality evidence; n=1073; studies= 2) \nSGRQ  \n\u2022 the mean SGRQ score at 52 weeks was lower in the tiotropi um group than the ipratropium group (lower on the scale is favourable) (MD - 3.30; 95% CI - 5.63 to - 0.97, moder-\nate quality evidence; n=535; study=1).  \nExazerbations  \n\u2022 fewer participants suffering one of more exacerbations in the tiotropium arm (OR 0.71; 95%  CI 0.52 to 0.95, high quality evidence; n=1073; studies=2) and there was also a \nreported difference in the mean number of exacerbations per person per year which reached statistical significance (MD - 0.23; 95% CI -0.39 to - 0.07, P = 0.006, moderate \nqualit y evidence)  \nWithdrawals  \n\u2022 significantly fewer withdrawals from the tiotropium group (OR 0.58; 95% CI 0.41 to 0.83, high quality evidence; n=1073; studies=2)  \n \nKommentar:  \nOne study used tiotropium via the HandiHaler (18 \u03bcg) for 12 months and the other via the Respimat device (5 \u03bcg and 10 \u03bc g) for 12 weeks.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  228 \n      \n \nSAMA or SAMA/LABA vs. LABA  \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nAppleton S. Ipratro-\npium bromide ver-\nsus long- acting \nbeta- 2 agonists for \nstable chronic ob-\nstructive pulmonary \ndisease. Cochrane \nDatabase of Sys-\ntematic Reviews \n2006;(3).  \n Suchzeitraum:  07/2008  \nFragestellung:  relative efficacy and safety of regular long term use (at least \nfour weeks) of ipratropium bromide and LABA in patients with stable COPD  \nSetting: outpatient  \nInterventionen und Vergleiche:   \n1) Ipratropium bromide vs. LABA.  \n2) Ipratropium bromide + LABA vs. LABA alone  \nStudientyp:  RCT \nEingeschlossene Studien:  7 (n= 2652)  \n Population:  Non-asthmatic adults with stable COPD as defined by \nBTS 1997 \n \n\u2019Stable\u2019 was defined as no recent infections, exacerbations, hospi-\ntalisation in the past month.  \n- mean age: 63- 65 y.  \n y-n-y-y-y-y-y-y-y-n-n \n \nScore: 8  \nStudienergebnisse  \n1) Ipratropium bromide vs. LABA (n=6 studies)  \n\u2022 no significant differences in quality of life, exacerbations, or symptoms  \n\u2022 Formoterol appeared to confer some benefits over ipratropium treatment in terms of morning peak flow  \n \n2) Ipratropium bromide + LABA vs. LABA alone (n=3 studies)  \n\u2022 significant improvement in  \n- supplemental short -acting betaagonist use and  \n- HRQL in favour of combination therapy compared with salmeterol alone \n \nLAMA vs. LABA  \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nChong J. Tiotropium \nversus long- acting \nbeta- agonists for \nstable chronic ob-\nstructive pulmonary \ndisease. Cochrane \nDatabase of Sys-\ntematic Reviews \n2012;(9).  \n Suchzeitraum:  02/2012  \nFragestellung:  relative clinical effects of tiotropium bromide alone versus \nLABA  alone, upon measures of quality of life, exacerbations, lung function \nand serious adverse events, in people with stable COPD  \n \nSetting: Community  \n \nInterventionen und Vergleiche:   \n1) tiotropium (delivered by HandiHaler) alone vs. LABAs alone  \n \nLABA: salmeterol (four studies, 8936 participants), formoterol (one study, \n431 participants) or indacaterol (two studies,  \n2856 participants)  \n>> All participants were instructed to discontinue anticholinergic or LABAs Population: people with stable (moderate to severe) COPD (as \njudged by a set of criteria equivalent to e.g. GOLD, ATS, BTS,  \nTSANZ)  \n \n \ndescribed COPD severity  \n\u2022 severe (mean % predicted FEV1 between 35% to 40%; n=2 stud-\nies),  \n\u2022 moderate to severe (mean % predicted FEV1 between 49% to \n57%, n=4 studies), \u2022 not described in n=1 study  \n \n\u2022 mean age of between 60 and 65 years and wer e predominately \nmale \n y-n-y-y-y-y-y-y-y-y-y \n \nScore: 10  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  229 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nduring treatment, but could receive ICS at a stable  dose.  \nStudientyp:  RCT and full economic evaluations  \nEingeschlossene Studien:  7 (n=12.223; extracted data for 11,223 partici-\npants)  \n \nStudienergebnisse  \nPrim\u00e4re Endpunkte  \nSGRQ  \n\u2022 did not pool data because of a high level of heterogeneity  \n\u2022 Subgroup analyses based on the type of LABA found statistically significant differences among effects on quality of life depending on whether tiotropium was compared with \nsalmeterol, formoterol or indacaterol  \nExacerbations  \n\u2022 Tiotropium reduced the number of participants experiencing one or more exacerbations compared with LABA (OR  0.86; 95%CI 0.79 to 0.93; n=12,123; studies=6; moderate \nquality evidence)  \n\u2022 no difference seen among the different types of LABA  \nMortality  \n\u2022 no statistical difference in mortality observed between the treatment groups (OR 0.82; 95% CI 0.60 to 1.13; n=12,123; studies=6; very low quality evidence)  \n \nSekund\u00e4re Endpunkte  \nExacerbations leading to hospitalisation  \n\u2022 tiotropium was associated with a reduction compared with LABA treatment (OR 0.87; 95% 0.77 to 0.99)  \nHospitalisation all -cause  \n\u2022 no difference  \nSymptom score  \n\u2022 no statistically significant difference  \nNon-fatal SAEs  \n\u2022 lower rate of recorded SAEs recorded with tiotropium compared with LABA (OR 0.88; 95% CI 0.78 to 0.99)  \nStudy withdrawals  \n\u2022 lower rate in tiotropium group (OR 0.89; 95% CI 0.81 to 0.99).  \n \nKommentar:  \n\u2022 \u00e4lterer Review von 2012  \n\u2022 hohe Dropout -Raten in den Studien NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  230 \n      \n \nLAMA vs. Placebo or LABA or LAMA  \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nNi H. Aclidinium \nbromide for stable \nchronic obstructive \npulmonary disease. \nCochrane Data-\nbase of Systematic \nReviews 2014;(9).  \n Suchzeitraum:  04/2014  \n \nFragestellung:  efficacy and safety of aclidinium bromide in stable COPD  \n \nSetting: Community  \n \nInterventionen und Vergleiche:   \n1. Aclidinium bromide vs. placebo  \n2. Aclidinium bromide vs.long- acting beta2- agonist (LABA)  \n3. Aclidinium bromide vs. long- acting muscarinic antagonist (LAMA)  \nStudientyp:  RCT \nEingeschlossene Studien:  12 (n= 9547)  \n Population:  adults with stable COPD  \n- mean age: 61,7 - 65,6 y.  \n- moderate to severe symptoms at randomisation  \n y-y-y-y-y-y-y-y-y-y-y \n \nScore: 11  \nStudienergebnisse  \n1. Aclidinium bromide vs. placebo  \nAll-cause mortality \n\u2022 no difference between aclidinium and placebo (OR 0.92; 95% CI 0.43 to 1.94; n=5252; studies=9; low quality)  \nexacerbations  \n\u2022 number of patients requiring a short course of oral steroids or antibiotics, or both: no difference (OR 0.88; 95% CI 0.74 to 1.04; n=5624; studies=10; moderate quality)  \nSGRQ  \n\u2022 Aclidinium improved: mean difference of - 2.34 (95% CI -3.18 to -1.51; I\u00b2 = 48%, 7 trials, 4442 participants)  \n>> More patients on aclidinium achieved a clinic ally meaningful improvement of at least four units decrease in SGRQ total score (OR 1.49; 95% CI 1.31 to 1.70; I\u00b2 = 34%; \nn= 4420; Studies=7; NNT = 10, 95% CI 8 to 15, high quality evidence) over 12 to 52 weeks than on placebo \nExacerbations requiring hospit alisation  \n\u2022 Aclidinium reduced the number of patients by 4 to 20 fewer per 1000 over 4 to 52 weeks (OR 0.64; 95% CI 0.46 to 0.88; I\u00b2 = 0%, studies=10, n=5624; NNT = 77, 95% \nCI 51 to 233, high quality evidence) compared to placebo  \nSAEs  \n\u2022 no difference in non -fatal serious adverse events (OR 0.89; 95% CI 0.7 to 1.14; n=5651; studies=10;  moderate quality evidence) between aclidinium  and placebo.  \n \n2. Aclidinium bromide vs.long- acting beta2- agonist (LABA)  \nInadequate data prevented the comparison of aclidinium t o formoterol or other LABAs.  \n \n3. Aclidinium bromide vs. long- acting muscarinic antagonist (LAMA)  \nCompared to tiotropium, aclidinium did not demonstrate significant differences for  \n\u2022 exacerbations requiring oral steroids or antibiotics, or both (OR 2.64; 95% CI 0.31 to 22.18; n=729; studies= 2; very low quality evidence),  \n\u2022 exacerbation- related hospitalisations (OR 0.54; 95% CI 0.07 to 4.11; n=729; studies=2; very low quality evidence) and  \n\u2022 non- fatal serious adverse events (OR 0.67, 95% CI 0.17 to 2.65; n=729; studies=2; very low quality evidence).   \n \nKommentar:  All studies were industry sponsored  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  231 \n      \n \nLAMA/LABA vs. LAMA or LABA  \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nNi H. Combined \naclidinium bromide and \nlong- acting beta2- ago-\nnist for COPD. \nCochrane Database of \nSystematic Reviews \n2018 \n Suchzeitraum:  10/2018  \nFragestellung: efficacy and safety of combined aclidinium bromide and \nlong\u2010 acting beta2\u2010 agonists in stable COPD  \n \nSetting: outpatient  \nInterventionen und Vergleiche:  \n1) aclidinium/formoterol FDC (fixed- dose combination) vs. aclidinium  \n2) aclidinium/formoterol FDC vs.formoterol  \n3) aclidinium/formoterol FDC vs. placebo  \n \nincluded the following cointerventions provided they are not part of the \nrandomised treatment: salbu tamol or albuterol as rescue medication, \noral sustained- release theophylline, ICSs or systemic corticosteroids \n(oral or parenteral) at stable doses and oxygen therapy of less than 15 \nhours/day  \n \nStudientyp: RCT \nEingeschlossene Studien:  7 (n=5921 Studienteil nehmer*innen)  \n Population: people with stable COPD  \n\u2022 >18 years of age  \n\u2022 diagnosis of COPD (according to GOLD 2018, ATS/ERS 2011, \nTSANZ 2018, NICE 2010, or WHO).  \n\u2022 diagnosed with stable moderateto-  severe airway obstruction ac-\ncording to GOLD criteria (postbronchodilator FEV1/FVC ratio less \nthan 70%and FEV1 30% or greater but less than 80% of pre-\ndicted normal value).  \n \n\u2022 Participants had evidence of airway obstruction (postbronchodi-\nlator FEV1/ FVC ratio less than 70%) with symptoms of dysp-\nnoea, chronic cough or sputum production with or without a his-\ntory of smoking.  \n\u2022 excluded studies that enrolled participants with bronchial \nasthma, bronchiectasis, cystic fibrosis or other chronic lung dis-\neases.  \n \n\u2022 mean postbronchodilator FEV1: between 50.5% and 61% of \npredicted normal and the baseline mean FEV1 of 1.23 L to 1.43 L  \n\u2022 mean age ranged from 60.7 to 64.7 years  \n\u2022 mostly men with a mean smoking pack \u2010years of 46.4 to 61.3 of \nwhich 43.9% to 63.4% were current smokers  \n y-y-y-y-y-y-y-y-y-y-y \n \nScore: 11  \nStudienergebnisse   \nCombination therapy significantly improved trough FEV1 compared to aclidinium, formoterol or placebo.  \n \nFDC versus aclidinium  \nThere was no evidence of a difference between FDC and aclidinium for  \n\u2022 exacerbations requiring steroids or antibiotics, or both  (OR 0.95, 95%CI 0.71 to 1.27; 2 trials, 2156 participants; moderate- certainty evidence);  \n\u2022 quality of life measured by SGRQ tot al score (MD -0.92, 95% CI -2.15 to 0.30);  \n\u2022 participants with significant improvement in SGRQ  score (OR 1.17, 95% CI 0.97 to 1.41; 2 trials, 2002 participants; moderate- certainty evidence);  \n\u2022 non-fatal SAE  (OR 1.19, 95% CI 0.79 to 1.80; 3 trials, 2473 participants; moderate- certainty evidence);  \n\u2022 hospital admissions due to severe exacerbations  (OR 0.62, 95%CI 0.29 to 1.29; 2 trials, 2156 participants; moderate- certainty evidence) or  \n\u2022 adverse events (OR 0.95, 95% CI 0.76 to 1.18; 3 trials, 2473 participants; moderate- certainty evidence).  \n \nCompared with aclidinium, FDC   \n\u2022 improved symptoms TDI focal score: MD 0.37, 95%CI 0.07 to 0.68; 2 trials, 2013 participants) with a higher chance of achieving a minimal clinically  important difference \n(MCID) of at le ast one unit improvement (OR 1.34, 95% CI 1.11 to 1.62; high certainty evidence);  \n>> the number needed to treat for an additional beneficial outcome (NNTB) being 14 (95% CI 9 to 39).  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  232 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \n \nFDC versus formoterol  \ncompared to formoterol, combination therapy  \n\u2022 reduced exacerbations  requiring steroids or antibiotics, or both (OR 0.78, 95% CI 0.62 to 0.99; 3 trials, 2694 participants; high- certainty evidence);  \n\u2022 may decrease SGRQ  total score (MD -1.88, 95% CI - 3.10 to -  0.65; 2 trials, 2002 participants; low -certai nty evidence; MCID for SGRQ is 4 units);  \n\u2022 increased TDI focal score (MD 0.42, 95% CI 0.11 to 0.72; 2 trials, 2010 participants) with more participants attaining an MCID (OR 1.30, 95% CI 1.07 to 1.56; high- certainty \nevidence) and an NNTB of 16 (95% CI 10 to 60).   \n\u2022 lowered the risk of adverse events  compared to formoterol (OR 0.78, 95% CI 0.65 to 0.93; 5 trials, 3140 participants; high- certainty evidence; NNTB 22)  \n \n\u2022 no difference between FDC and formoterol for hospital admissions , all-cause mortality  and non-fatal SAEs.  \n \nFDC versus placebo  \nCompared with placebo, FDC demonstrated no evidence of a difference in  \n\u2022 exacerbations  requiring steroids or antibiotics, or both (OR 0.82, 95% CI 0.60 to 1.12; 2 trials, 1960 participants; moderate- certainty evidence) or  \n\u2022 hospital admissions  due to severe exacerbations (OR 0.55, 95% CI 0.25 to 1.18; 2 trials, 1960 participants; moderate- certainty evidence), although estimates were uncertain \n \n\u2022 SGRQ total  score was significantly better with FDC compared to placebo (MD - 2.91, 95% CI - 4.33 to -1.50; 2 trials, 1823 participants) resulting in a corresponding increase in \nSGRQ responders who achieved at least four units decrease in SGRQ total score (OR 1.72, 95% CI 1.39 to 2.13; high- certainty evidence) with an NNTB of 7 (95% CI 5 to 12).  \n\u2022 FDC also improved symptoms measured by TDI  focal score (MD1.32, 95%CI 0.96 to 1.69; 2 studies, 1832 partic ipants) with more participants attaining at least one unit \nimprovement in TDI focal score (OR 2.51, 95% CI 2.02 to 3.11; high- certainty evidence; NNTB 4).  \n \n\u2022 no differences  in non-fatal SAEs , adverse events and all-cause mortality  between FDC and placebo.  \n \nKommentar:  \nAll studies were sponsored by Almirall (SA, Barcelona, Spain) and Forest Laboratories, Inc (New York, USA) or Menarini Group through its affiliate Berlin- Chemie and Astra-\nZeneca.  \n \nFarne HA. Long -acting \nbeta2- agonist in addition \nto tiotropium v ersus ei-\nther tiotropium or long-\nacting beta2- agonist \nalone for chronic ob-\nstructive pulmonary dis-\nease. Cochrane Data-\nbase of Systematic Re-\nviews 2015;(10).  \n Suchzeitraum:  07/2015  \n \nFragestellung:  relative effects on markers of quality of life, exacerba-\ntions, s ymptoms, lung function and serious adverse events in people \nwith COPD randomised to LABA plus tiotropium versus tiotropium alone; \nor LABA plus tiotropium versus LABA alone \nSetting: community  \n \nInterventionen und Vergleiche:   \n1) LABA plus tiotropium vs. tiot ropium alone  \n2) LABA plus tiotropium vs. LABA alone \n \nLABA: n=4 studies olodaterol (1x/d); n=3 studies indacaterol (1x/d); n=2 \nstudies formoterol (2x/d); n=1 study salmeterol (2x/d)  Population:  diagnosis of moderate or severe COPD (included \nstudies that used an external set of criteria to screen participants \nfor this condition (e.g. GOLD, ATS, BTS, TSANZ)  \n\u2022 4 studies included also participants with very severe COPD \n(FEV1 less than 30%  predicted))  \n \n\u2022 mean age: 63 to 73 years  \n\u2022 gender distribution varied from 50% to 93% men  \n\u2022 mean baseline FEV1 varied between 38% and 67% predicted  \n y-n-y-y-y-y-y-y-ca-n-y \n \nScore: 8  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  233 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \n \nStudientyp:  RCT \nEingeschlossene Studien:  10 (n=10894)  \n \nCo-Treatments erlau bt: \n\u2022 10/10 studies: rescue medication, when necessary, to relieve symp-\ntoms (inhaled salbutamol/ albuterol)  \n\u2022 8/10 studies permitted continued use of regimens of ICS  \n\u2022 1/10 studies: respiratory medications such as oxygen, anti -leukotri-\nenes, and methylxanthines were continued \n\u2022 2/10 studies permitted temporary increases in the dose or addition of \noral corticosteroids andmethylxanthines  \n\u2022 1/10 studies: Participants were either newly diagnosed or discontinued \nthe use of any COPD medications  \n \nStudienergebnisse  \n1) LABA + tiotropium vs. tiotropium alone  \ntreatment with tiotropium plus LABA resulted in  \nSGRQ  \n\u2022 slightly larger improvement (MD -1.34, 95% CI - 1.87 to - 0.80; n=6709 participants; 5 studies; moderate quality evidence). The MD was smaller than the four units that is \nconsidered clinically importan t, but a responder analysis indicated that 7% more participants receiving tiotropium plus LABA had a noticeable benefit (greater than four units) \nfrom treatment in comparison to tiotropium alone. (Most data from oldetarol -studies)  \nHospital admission  \n\u2022 no s ignificant differences  \n> all-cause OR 1.01; 95% CI 0.86 to 1.19, n=4856; studies=4; moderate quality evidence  \n>exacerbation OR 1.02; 95% CI 0.80 to 1.28; n=4856; studies=4, low quality evidence  \nMortality  \n\u2022 no significant differences (all -cause OR 1.24; 95% CI 0.81 to 1.90; n=9633; studies=8)  \n \nSekund\u00e4re Endpunkte  \nExacerbations  (moderate heterogeneity; I\u00b2 = 43%)  \n\u2022 no statistically significant differences between the groups  \nSymptom scores  \n\u2022 no statistically significant differences between the group \nSerious ad verse events  \n\u2022 no statistically significant differences between the group \nWithdrawals (moderate heterogeneity; I\u00b2 = 54%)  \n\u2022 no statistically significant differences between the group \n \n2) LABA plus tiotropium vs. LABA alone  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  234 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nSGRQ  \n\u2022 small but significant impro vement (MD - 1.25, 95% CI - 2.14 to - 0.37; n=3378 participants; 4 studies; most data from oldetarol -studies)  \n>> difference was smaller than four units, this still represented an increase of 10 people with a clinically important improv ement for 100 treated.  \nExazerbation rates \n\u2022 improvement (OR) 0.80, 95% CI 0.69 to 0.93; n=3514 participants; 3 studies).  \nHospital admission  \n> all-cause OR 0.93; 95% CI 0.76 to 1.14; n=3514; studies=3, moderate quality evidence  \n>exacerbation OR 0.90; 95%CI 0.66 to 1.22; n=3514; s tudies=3, low quality evidence  \nMortality  \n\u2022 uncertainty to the true impact on mortality (all -cause OR 1.15; 95%CI 0.62 to 2.13; n=3514; studies=3; low quality evidence)  \nSerious adverse events (non -fatal) \n\u2022 n=4 studies (3552 participants) reported the number  of participants experiencing serious, but non- fatal, adverse events during the study period (n=1 study: none SAEs)  \n\u2022 no statistically significant difference between the treatment groups (OR 0.94, 95% CI 0.77 to 1.14)  \n \nKommentar:  \nAppl. S. 15 des Reviews  \nLAMA/LABA vs. LABA/ICS  \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nHorita N. Long -acting \nmuscarinic antagonist \n(LAMA) plus long- acting \nbeta- agonist (LABA) \nversus LABA plus in-\nhaled corticosteroid \n(ICS) for stable chronic \nobstructive pulmonary \ndisease (COPD). \nCochrane Database of \nSystematic Reviews \n2017;(2).  \n Suchzeitraum:  06/2016  \nFragestellung:  benefits and harms of LAMA+LABA versus LABA+ICS \nfor treatment of people with stable COPD  \n \nSetting: outpatient  \n \nInterventionen und Vergleiche:   \n1) LAMA+LABA vs. LABA+ICS  \n \nLABA+ICS:   \n\u2022 salmeterol/fluticasone propionate (10/11 studies combined; n=1 study \nuncombined)  \nLAMA+LABA:  \n\u2022 indacaterol/glycopyrronium (n=3 studies)  \n\u2022 umeclidinium/vilanterol (n=3 studies)  \n\u2022 tiotropium/olodaterol (n=1 study)  \n\u2022 tiotropium/indacaterol (n=1 study)  \n\u2022 tiotropium/salmeterol (n=1 study)  \n\u2022 tiotropium/formoter ol (n=1 study)  \n\u2022 aclidinium/formoterol (n=1 study)  \n Population:  adults with a diagnosis of [stable] COPD according to \nGOLD 2016  \n\u2022 most studies: people with moderate to severe COPD, without re-\ncent exacerbations.  \n\u2022 1 gro\u00dfe Studie (37% der Studienteilnehmer) :  included only peo-\nple with recent exacerbations  \n- mean age: 61 -  71 (median; 63 y.)  \n \nRekrutierung nach GOLD -Kategorien (A -D): \n\u2022 GOLD B: n=5 studies  \n\u2022 GOLD D: n=1 study  \n\u2022 GOLD A/B: n=2 studies  \n\u2022 regardless of Category: n=3 studies  \n y-y-y-y-y-y-y-y-y-y-y \n \nScore: 11  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  235 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \n(treatments administered via a single combined device or via two sepa-\nrate devices; duration ranged from 6 to 52 weeks)  \n \nStudientyp:  RCT, teilweise parallel -group design und cross -over design  \nEingeschlossene Studien:  11 (n= 9839)  \n \nStudienergebnisse  \nCompared to the LABA+ICS arm, the results for the pooled primary outcomes  for the LAMA+LABA arm were as follows:  \nExazerbations  \n\u2022 significant decrease in the number of people experiencing one or more exacerbations with LAMA+LABA (OR 0.82, 95% CI 0.70 to 0.9 6; P = 0.01; I\u00b2 = 17%;  low quality \nevidence; n=8932; studies=9)  \nSubgruppen:  \n\u2022 treated with indacaterol/ glycopyrronium had fewer exacerbations (OR 0.72, 95% CI 0.63 to 0.83; P < 0.001; I\u00b2 = 0%) compared to participants treated with LABA+ICS. In \ncontrast,  LAMA+LABA was not related to reduced risk of exacerbation in umeclidinium/vilanterol and other LAMA+LABA subgroups.  \nSAEs  \n\u2022 non- significant decrease (OR 0.91, 95% CI 0.79 to 1.05, P = 0.18, I\u00b2 = 0, moderate quality evidencen=9793; studies=10)  \nSGRQ total sc ore change from the baseline  \n\u2022 non- significant decrease (MD - 1.22; 95% CI - 2.52 to 0.07, P = 0.06, I\u00b2 = 71%, low quality evidence; n=5858; studies=6)  \nSubgruppen:  \n\u2022 significant decrease in scores in participants treated with indacaterol/ glycopyrronium and \u2019other LAMA/LABA inhalers\u2019 compared to participants treated with LABA+ICS \n(indacaterol/glycopyrronium: MD - 1.29, 95% CI - 2.08 to - 0.50; P = 0.001; I\u00b2 = 0%; other LAMA/ LABA inhalers: MD - 5.00, 95% CI -7.35 to -2.65, P < 0.0001).  \n \nsekund\u00e4re Endpunkte  \nPneumo nia \n\u2022 significant reduction in the number of participants experiencing one or more episodes of pneumonia with LAMA+LABA (OR 0.57;  95% CI 0.42 to 0.79, P = 0.0006, I\u00b2 = 0%, \nlow quality evidence; n=8540; studies=8)  \nAll-cause death  \n\u2022  similar risk (OR 1.01; 95% CI 0.61 to 1.67, P = 0.88, I\u00b2 = 0%, low quality evidence; n=8200; studies=8)  \nSGRQ otal score change from the baseline (4 points or greater)  \n\u2022  more frequent change (OR 1.25; 95% CI 1.09 to 1.44, P = 0.002, I2 = 0%, moderate quality evidence; n=3192; studies=2)  \n \nKommentar:  \n10/11 studies: sponsored by pharmaceutical companies -->  \nrated high risk of \u2019other bias\u2019  \n1/11 studies:unsponsored --> rated at high risk of performance and detection bias, and possible selective reporting  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  236 \n      \n \nLABA/ICS vs LAMA  \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nSliwka A. Once daily \nLong- acting beta2- ago-\nnists/Inhaled corticoster-\noids combined inhalers \nversus inhaled long- act-\ning muscarinic antago-\nnists for people with \nchronic obstructive pul-\nmonary disease. \nCochrane Database of \nSystematic Reviews 2018  \n Suchzeitraum: 05/2018  \n \nFragestellung:  compare a once- daily combination of ICS/LABA ver-\nsus inhaled LAMA alone for people with COPD  \n \nSetting: studies were conducted at 102 medical centres in 11 coun-\ntries (Canada, Czech Republic, Germany, Poland, Romania, USA, Ar-\ngentina, France, Italy, Norway, Russian Federation, Ukraine)  \n \nInterventionen und Vergleiche:  \n1) inhaled ICS/LABA (fluticasone furoate and vilanterol 100/25 mcg \nonce daily; FF/VI) versus LAMA (18 mcg tiotropium; TIO).  \n \nStudientyp: RCT  \nEingeschlossene Studien:  n=2 (880 participants)  \n \u2022 included adults (over 21 years old) with a diagnosis of COPD con-\nfirmed by an external set of criteria for this condition, eg GOLD \n2018, ATS, BTS, or TSANZ.  \n \n\u2022 Participants were men and women aged 40 or older who had \nCOPD with various degr ees of severity.  \n \n\u2022 studies enrolled participants with both partially reversible and non-\nreversible COPD and baseline mean %pred FEV1 of 43.4 to 49.6.  \n y-y-y-y-y-y-y-y-y-y-y \n \nScore: 11  \nStudienergebnisse  \nFF/VI vs TIO (ICS/LABA vs LAMA):  \n\u2022 mortality:  OR 0.20, 95% CI 0.02 to 1.73, 880 participants (deaths reported only in the TIO arm), very low -quality evidence \n --> risk with LAMA: 9 per 1000;  \n\u2022 COPD exacerbation (requiring short -burst oral corticosteroids  or antibiotics, or both): OR 0.72, 95% Cl 0.35 to 1.50, 880 participants, very low -quality evidence \n --> risk with LAMA: 41 per 1000; risk with LABA/ICS: 30 (15 to 60) per 1000;  \n\u2022 pneumonia: reported in both studies only during treatment with FF/VI:OR 6. 12, 95%Cl 0.73 to 51.24, 880 participants, very low -quality evidence; and  \n\u2022 total serious adverse events: OR 0.96, 95% Cl 0.50 to 1.83, 880 participants, very low -quality evidence.  \n \n>> no statistically significant difference for pooled secondary outcomes , including  \n\u2022 SGRQ mean total score change;  \n\u2022 hospital admissions (all -cause);  \n\u2022 disease- specific adverse events;  \n\u2022 mean weekly rescue medication use (results available from only one of the studies);  \n\u2022 mean weekly percentage of rescue- free days for FF /VI.  \n \n>>no statistically significant differences between ICS/LABA and LAMA for improvement in symptoms measured by CAT score nor for FEV (change from baseline trough in \n24-hour weighted mean on treatment day 84).  \n \nMany pooled estimates lacked precision. D ata for other endpoints such as exacerbations leading to intubation and physical activity measures were not available in incl uded \ntrials.  \n \nKommentar:  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  237 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nFallzahlen ausreichend?  \n \nevidence presented in this review = of very low quality, review authors have ver y little confidence in the findings  \n \nWelsh EJ. Combination \ninhaled steroid and long-\nacting beta2- agonist ver-\nsus tiotropium for chronic \nobstructive pulmonary \ndisease. Cochrane Data-\nbase of Systematic Re-\nviews 2013;(5).  \n Suchzeitraum:  11/2012  \n \nFragestellung:  relative effects of inhaled combination therapy \n(LABA/ICS) and tiotropium on markers of exacerbations, symptoms, \nquality of life, lung function, pneumonia and serious adverse events in \npatients with COPD  \n \nInterventionen und Vergleiche:   \n1) ICS + LABA (such  as fluticasone/salmeterol, budesonide/for-\nmoterol, beclomethasone/ formoterol) vs. inhaled tiotropium bromide.  \nStudientyp:  RCT \nEingeschlossene Studien:  3 (n=1528)  \n Population:  Populations with a diagnosis of COPD; only included \nstudies where an external set of criteria had been used to screen \nparticipants for this condition (e.g. GOLD, ATS, BTS, TSANZ).  \n- mean age: n.a.  \n \nINSPIRE:  \nGOLD stage III (FEV1 30% to <50% pred)  \n\u2022 n=540 on fluticasone/ salmeterol with a mean FEV1 of 1.09  \n\u2022 n=537 with a mean FEV1 of 1.11 L on tiotropium  \nGOLD stage IV (FEV1 < 30% pred)  \n\u2022 n=100 patients on fluticasone/ salmeterol with a mean FEV1 of \n0.73 L  \n\u2022 n=101 patient with a mean FEV1 of 0.71 L on tiotropium  \n\u202248% of participants in the fluticasone/ salmeterol arm and 51% in \nthe tiotropium armstopped taking ICS at baseline \n y-y-y-y-y-y-y-y-y-n-n \n \nScore: 9  \nStudienergebnisse  \n\u2022 The results from these trials were not pooled (because of disparity in the trial lengths and because the primary focus of the review was on long -term outcomes)  \n \n\u2022 Gr\u00f6\u00dfte der 3 Studien ist INSPIRE (n=1323)  \n \n\u2022 INSPIRE had a high and unbalanced withdrawal rate. The proportion of missing outcome data compared to the observed outcome data is enough to induce a clinically \nrelevant bias in the intervention effect. The relative efficacy and safety of combined inhalers and tiotropium remains uncert ain. \n \nKommentar:  \npairwise metaanalysis zum Vergleich LABA/ICS vs. LAMA in neuerem Review (Oba- Network -meta -analysis 2018; Ref ID 27070) durchgef\u00fchrt.  \n \nLAMA/LABA vs. LABA/ICS vs. LABA vs. LAMA  \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nOba Y. Dual combination \ntherapy versus long- act-\ning bronchodilators alone \nfor chronic obstructive Suchzeitraum: 04/2018  \nFragestellung: efficacy and safety of available formulations from f our \ndifferent groups of inhalers (i.e. LABA/LAMA combination, LABA/ICS \ncombination, LAMA and LABA) in people with moderate to severe Population:  people aged 35 years or older with a diagnosis of \nCOPD and a baseline FEV1 of less than 80% of predicted \n \n\u2022 moderate to severe COPD  y-y-y-y-y-y-y-y-y-n-y \n \nScore: 10  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  238 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \npulmonary disease \n(COPD): a systematic re-\nview and network meta-\nanalysis.). Cochrane Da-\ntabase of Systematic Re-\nviews 2018 \n COPD  \n \nSetting: outpatient  \nInterventionen und Vergleiche: >> studies comparing at least two of \nthe following therapies:  \n1. LAMA monotherapy  \n2. LABA monotherapy  \n3. Fixed- dose or free combination of LABA/ICS  \n4. Fixed- dose or free combination of LABA/LAMA  \n \n>> allowed the use of a short -acting bronchodilator, such as salbuta-\nmol( also known as albuterol), and ipratropium as rescue treatment.  \n \nStudientyp:  RCT \nEingeschlossene Studien:  99 (n=101.311 participants  \n\u2022 high- risk group: 26 studies (n=32.265 participants)  \n\u2022 low -risk group: 73 studies )n=69,046 participants)  \n \u2022 in accordance with ATS/ERS 2004, GOLD 2018, or equivalent cri-\nteria \n\u2022 excluded studies that enrolled participants with a history of asthma \nor other respiratory disease \n \n\u2022 high- risk group: one or more exacerbations in the previous 12 \nmonths  \n \nStudienergebnisse  \nLABA/LAMA vs. LABA/ICS  \n\u2022 Moderate to severe exacerbation:  high- risk population  \nOR 0.87; 95%CI 0.76 to 1.00 (n=3372; studies=1; moderate quality evidence)  \n\u2022 Moderate to severe exacerbation:  low-risk population  \nOR 0.86; 95%CI 0.65 to 1.14 (n=4315; studies=6; moderate quality evidence)  \n\u2022 Severe exacerbations: high- risk population \nOR 0.88; 95% CI 0.74 to 1.06 (n=3354; studies=s; moder ate quality evidence)  \n\u2022 Severe exacerbations:  low-risk population \nOR 0.66; 95% CI 0.27 to 1.63 (n=2860; studies=4; moderate quality evidence)  \n\u2022 Pneumonia:  high- risk population  \nOR 0.62; 95% CI 0.40 to 0 .96 (n=3358; studies=1; moderate quality evidence)  \n\u2022 Pneumonia:  low-risk population  \nOR 0.43; 95% CI 0.19 to 0.97 (n=5395; studies=7; moderate quality evidence)  \n \nLABA/LAMA vs. LAMA \n\u2022 Moderate to severe exacerbation:  high- risk population  \nOR 1.06; 95%CI 0.89 to 1.27 (n=2206; studies 1; moderate quality evidence)  \n\u2022 Moderate to severe exacerbation: l ow-risk population  \nOR 0.93; 95% CI 0.66 to 1.30 )n=5192; studies=8; low quality evidence)  \n\u2022 Severe exacerbations : high- risk population \nOR 0.73; 95% CI 0.45 to 1.16 (n=304; studies=1; moderate quality evidence)  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  239 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \n\u2022 Severe exacerbations:  low-risk population  \nOR 0.99; 95%CI 0.57 to 1.72 (n=4937; studies=7; moderate quality evidence)  \n\u2022 Pneumonia:  high- risk population  \nOR 0.98; 95%CI 0.59 to 1.61(n=2510; studies=2; moderate quality evidence)  \n\u2022 Pneumonia:  low-risk populat ion \nOR 1.23; 95%CI 0.84 to 1.81(n=18538; studies=22; moderate quality evidence)  \n \nLABA/LAMA vs. LABA  \n\u2022 Moderate to severe exacerbation: low -risk population  \nOR 0.77; 95%CI 0.62 to 0.97 (n=2488; studies=5; moderate quality evidence)  \n\u2022 Severe exacerbations:  low-risk population \nOR 0.78; 95%CI 0.55 to 1.12 (n=2898; studies=6; moderate quality evidence)  \n\u2022 Pneumonia: low -risk population  \nOR 1.54; 95%CI 0.95 to 2.49 (n=8252; studies=10; moderate quality evidence)  \n \nLABA/ICS vs. LAMA  \n\u2022 Moderate to severe exacerbation:  high- risk population  \nOR 1.12; 95%CI 0.90 to 1.39 (n=1580; studies=2; moderate quality evidence)  \n\u2022 Moderate to severe exacerbation:  low-risk population  \nOR 0.63; 95%CI 0.24 to 1.66 (n=623; studies=1; low quality evidence)  \n\u2022 Severe exacerbations: high- risk po pulation \nOR 1.28; 95%CI 0.95 to 1.73 (n=1580; studies=2; moderate quality evidence)  \n\u2022 Severe exacerbations : low-risk population \nOR 3.05; 95%CI 0.32 to 29.47 (n=623; studies=1; low quality evidence)  \n\u2022 Pneumonia:  high- risk population  \nOR 1.80; 95%CI 1.06 to 3.06 (n=1580; studies=2; moderate quality evidence)  \n\u2022 Pneumonia:  low-risk population  \nOR 5.82; 95%CI 0.70 to 48.80 (n=885; studies=2; low quality evidence)  \n \nLAMA vs. LABA  \n\u2022 Moderate to severe exacerbation: high- risk population  \nOR 0.84; 95%CI 0.76 to 0.92 (n= 7376; studies=1; high quality evidence)  \n\u2022 Moderate to severe exacerbation: low -risk population  \nOR 0.92; 95%CI 0.79 to 1.07 (n=4567; studies=5; moderate quality evidence)  \n\u2022 Severe exacerbations: high- risk population \nOR 0.88; 95%CI 0.78 to 1.01 (n=7376; studies=1; moderate quality evidence)  \n\u2022 Severe exacerbations: low -risk population \nOR 0.64; 95%CI 0.36 to 1.13 (n=3320; studies=4; low quality evidence)  \n\u2022 Pneumonia: high- risk population  \nOR 0.83; 95%CI 0.61 to 1.13 (n=10815; studies=2; moderate quality evidence)  \n\u2022 Pneumonia: low -risk population  \nOR 1.01; 95%CI 0.61 to 1.69 (n=11338; studies=10; moderate quality evidence)  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  240 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nKommentar:  \nNetwork -Metaanalyse >> es wurden nur die paarweisen direkten Metaanalysen in unsere Darstellung aufgenommen  \nLAMA/LABA/ICS  \nZitat Stud iencharakteristika  Population Methodische Qualit\u00e4t  \nTan DJ. Inhaled \ncorticosteroids with \ncombination in-\nhaled long- acting \nbeta2- agonists and \nlong- acting musca-\nrinic antagonists for \nchronic obstructive \npulmonary disease. \nCochrane Data-\nbase of Systematic \nReviews 2016;(11).  \n Suchzeitraum:   \n09/2016 (Cochrane Airways Group Specialised Register of Trials),  \n12/2015 (Cochrane Library + MEDLINE)  \n01/2016 (ClinicalTrials.gov + WHO trials portal + pharmaceutical company \nclinical trials\u2019 databases)  \n \nInter ventionen und Vergleiche:   \n1) ICS + LABA/LAMA vs. LABA/LAMA alone  \nStudientyp:  RCT \nEingeschlossene Studien:  0 \n Population: stable COPD  \n keine AMSTAR -Bewertung \nm\u00f6glich, da keine Studien \neingeschlossen werden \nkonnten  \n \nStudienergebnisse  \nGeplante Endpunkte  \nPrimary outcomes  \n1) Acute exacerbation of COPD (AECOPD): defined as needing treatment with oral steroids, antibiotics or hospital attendance for a COPD exacerbation, or a combination of these \ntreatments. Exacerbation events based on standardised patientreported outcome tools for measuring changes in symptoms were also accepted.  \n2) Respiratory health- related quality of life (HRQoL): measured by the Chronic Respiratory Questionnaire (CRQ) or St. George\u2019s Respiratory Questionnaire (SGRQ).  \n3) Pneumonia and other serious adverse events:  defined as requiring treatment or hospital admission for pneumonia or other serious adverse events.  \n \nSecondary outcomes  \n4) Symptom score:  measures of breathlessness, cough, wheeze and sputum production, preferabl y using validated scales.  \n5) Lung function: pre -bronchodilator (BD) and post -BD measure including FEV and FVC.  \n6) Physical capacity:  measures including timed walking tests, endurance tests.  \n7) Mortality  \n \nICS Pneumonie  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nKew KM. Inhaled \nsteroids and risk of \npneumonia for \nchronic obstructive \u2022 Fragestellung: To assess the \nrisk of pneumonia associated with \nthe use of fluticasone and \nbudesonide for COPD.  \u2022 Baseline -Charakteristika:  \n- often male with a mean age of around 63, mean pack -years smoked \nover 40  \nand mean predicted forced expiratory volume of one second (FEV1) AMSTAR:  \ny-y-y-y-y-y-y-y-y-ca-y \n \u2022 finding should be interpreted with \ncaution because of possible differ-\nences in the assignment of pneu-\nmonia diagnosis, and because no NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  241 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \npulmonary disease. \nCochrane Data-\nbase of Systematic \nReviews 2014;(3).  \n  \n\u2022 Suchzeitraum: September 2013 \n\u2022 Population:  people with COPD  \n\u2022 Ein - und Ausschlusskriterien:  \n- RCTs of at least 12 weeks\u2019 dura-\ntion \n \n\u2022 Vergleiche:    \n- ICS (budesonide or fluticasone)  \nvs. placebo  \nor \n- ICS + LABA vs. the same LABA  \n \n\u2022 eingeschlossene Studien:  \n- fluticasone (26 studies; n = \n21,247)  \n- budesonide (17 studies; n = \n10,150)  \n \n\u2022 RoB der eingeschlossenen Stu-\ndien (wenn GRADE nicht durchge-\nf\u00fchrt wurde)  \n less than 50%  \n \n\u2022 Fluticasone  \n- increased non- fatal serious adverse pneumonia events (requi ring \nhospital admission) (43/1000 vs. 25/1000; OR 1.78, 95% CI 1.50 to \n2.12; 18 more per 1000 treated over 18 months; I\u00b2 = 0%, 17 RCT, n = \n19504; GRADE : high quality)  \n- no evidence suggested that this outcome was reduced by delivering \nit in combination wit h salmeterol or vilanterol (subgroup differences: I\u00b2 \n= 0%, P = 0.51), or that different doses, trial duration or baseline se-\nverity significantly affected the estimate  \n \n\u2022 Budesonide  \n- also increased non- fatal serious adverse pneumonia events com-\npared with placebo, but the effect was less precise and was based on \nshorter trials (15/1000 vs. 9/1000; OR 1.62, 95% CI 1.00 to 2.62; six \nmore per 1000 treated over nine months; I\u00b2 = 28%, 7 RCT, n = 6472, \nGRADE:  moderate quality).  \n \n\u2022 indirect comparison of budesoni de versus fluticasone monotherapy   \n- revealed no significant differences with respect to serious adverse \nevents (pneumonia- related or all -cause) or mortality  \n- risk of any pneumonia event (i.e. less serious cases treated in the \ncommunity) was higher with f luticasone than with budesonide (OR \n1.86, 95% CI 1.04 to 3.34); this was the only significant difference re-\nported between the two drugs  Score: 10  trials directly compared the two \ndrugs. . \n \nOCS  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nWalters -Julia AE. \nOral corticoster-\noids for stable \nchronic obstruc-\ntive pulmonary \ndisease. \nCochrane Data-\nbase of Systema-\ntic Reviews \n2005;(3).  \u2022 Fragestellung: To assess the effects of oral \ncorticosteroids on the health status of patients \nwith stable COPD.  \n \n\u2022 Suchzeitraum:  December 2003 and 2004 \n\u2022 Population: patients with stable COPD  \n\u2022 Ein - und Ausschlusskriterien:  RCT in adults \nwith stable COPD, a history of smoking, exclud-\ning known asthmatics  \n FEV1  \n- significant difference in FEV1 after two weeks treatment, WMD 53.30 ml; 95% CI 22.21 to \n84.39 favouring oral steroid use compared to placebo (14 RCT, n=396, no significant heteroge-\nneity).  \n- significant increase in odds for individual patient FEV1 response greater than 20% from base-\nline with high dose oral steroid treatment compared to placebo, OR 2.71; 95% CI 1.84 to 4.01 \n(10 studies, n = 259; I\u00b2 = 0%)  \n \nQoL \n- All differences in health -related quality of life were less than t he minimum clinically important AMSTAR: y -y-y-ca-y-y-y-n-ca-n-n \n \nScore: 6  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  242 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n \u2022 Interventionen : oral steroids  \n\u2022 Vergleich: Placebo \n \n\u2022 eingesch lossene Studien: 24 RCT  \n difference.  \n \nAuthors\u2019 conclusions  \nThere is no evidence to support the long- term use of oral steroids at doses less than 10- 15 mg \nprednisolone though some evidence that higher doses (30 mg prednisolone) improve lung \nfunction over a short period. Potentially harmful adverse effects e.g. diabetes, hypertension, \nosteoporosis would prevent recommending long- term use at these high doses in most patients.  \nProphylaktische Antibiose  \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nHerath SC. Prophylactic an-\ntibiotic therapy for chronic \nobstructive pulmonary dis-\nease (COPD). Cochrane \nDatabase of Systematic Re-\nviews 2018 \n Suchzeitraum: 07/2018  \nFragestellung: determine whether or not regular (continuous, inter-\nmittent or pulsed) treatment of COPD patients with prophylactic anti-\nbiotics reduces exacerbations or affects quality of life.  \nSettings: Outpatients presenting to hospital clinics  \n \nInterventionen und Vergleiche:  \n1) antibiotic vs placebo  \n\u2022 included studies of oral antibiotics, including  \n- penicillin (amoxycillin, amoxicillin, clavulanic acid),  \n- tetracycline (doxycycline, tetracycline),  \n- quinolones (ciprofloxacin, moxifloxacin),  \n- macrolides (clarithromycin, eryt hromycin, roxithromycin, azithromy-\ncin) and  \n- sulphonamides (co- trimoxazole),  \n>>administered in appropriate doses for a period of at least three \nmonths  \nStudientyp:  RCT \neingeschlossene Studien:  n=16; f\u00fcr Analyse: n=14 (3932 \nTeilnehmer*innen)  \n Population:  \n\u2022 adults (> 18 years of age) with a diagnosis of COPD, as defined \nby ATS, ERS or GOLD, with airflow obstruction evident by spi-\nrometry (post -bronchodilator FEV1 of less than 80% of the pre-\ndicted value and an FEV1/FVC of 0.7 or less)  \n\u2022 included studies only if they confirmed diagnosis with lung func-\ntion testing (spirometry).  \n\u2022 excluded: participants with bronchiectasis, asthma, or genetic \ndiseases, such as cystic fibrosis or primary ciliary dyskinesia  \n y-n-y-y-y-y-y-y-y-n-y \n \nScore: 9  \nStudienergebnisse  \nAntibiotics versus placebo (data from pulsed and continuous courses of antibiotics  \nNumber of people with one or more exacerbations  \n\u2022 OR 0.57; 95%CI 0.42 to 0.78 (n=2716; studies=8; moderate quality evidence, I\u00b2 = 42%)  \n\u2022 Subgroup analysi s of continuous versus intermittent versus pulsed antibiotics suggested that pulsed antibiotics were less effective at reduci ng exacerbations (P = 0.01 \nfor subgroup difference; I\u00b2 = 77.3%)  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  243 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \n\u2022 Definitions: continuous prophylactic antibiotics (every day), or antibiotics that were used intermittently (three times per week) or pulsed (e.g. for five days every eight \nweeks)  \n \nRate of exacerbation per patient/ year  \n\u2022 Rate ratio 0.67; 95%CI 0.54 to 0.83 (n=1384; studies=5; moderate quality evidence, I\u00b2 = 52% ) \n\u2022 Test for subgroup difference between continuous and intermittent antibiotics not significant (P = 0.38; I\u00b2 = 0%)  \n \nHRQoL, SGRQ (total score)  \n\u2022 The mean HRQoL (SGRQ total score) in the intervention group was 1.94 lower (3.13 lower to 0.75 lower); n=2237; studies= 7; high quality evidence  \n\u2022 Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0. 35; I\u00b2 = 5.2% ) \nAll-cause mortality \n\u2022 OR 0.87; 95%CI 0.66 to 1.15; n=3309; studies=6; moderate quality evidence)  \n\u2022 Test for subgroup differences between continuous, intermittent and pulsed antibiotics not significant (P = 0. 60; I\u00b2 = 0%)  \nSerious adverse events  \n\u2022 OR 0.88; 95%CI 0.74 to 1.05 (n=2978; studies=9; moderate quality evidence, I\u00b2 = 0%)  \n\u2022 Test for subgroup differenc es between continuous, intermittent and pulsed antibiotics not significant (P = 0. 60; I\u00b2 = 0%)  \n\u2022 most frequently recorded: gastrointestinal in origin (OR 1.16, 95% CI 0.43 to 3.11; participants = 2522; studies = 6; I\u00b2 = 72%) >> significant heterogeneity among these \nstudies which suggested differences among the antibiotics and their adverse events for each study  \nAny adverse event  \n\u2022 OR 1.07 95%CI 0.69 to 1.67 (n=512; studies=4; moderate quality evidence)  \n\u2022 Test for subgroup differences between continuous, i ntermittent and pulsed antibiotics not significant (P = 0. 28), I\u00b2 = 21.9%)  \n \nKommentar:  \nAufschl\u00fcsselung spezifischer adverse events: S. 23 Review  \nPDE4 -Inhibitoren vs. Placebo  \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nChong J. Phosphodiester-\nase 4 inhibitors for chronic \nobstructive pulmonary dis-\nease. Cochrane Database of \nSystematic Reviews 2017  \n Suchzeitraum:  10/2016  \nFragestellung:  ef\ufb01cacy and safety of oral PDE 4 inhibitors in the \nmanagement of stable COPD.  \nInterventionen und Vergleiche:   \n1) PDE4 inhibitors vs. Placebo  \n(co-administration of standard COPD therapy allowed)  \nStudientyp:  RCT \nEingeschlossene Studien:  34  \n\u2022 20 roflumilast, n=17.627;  \n\u2022 14 cilomilast, n=6457  \n \n Population: Adults (>18 years of age) wi th COPD, as defined by \nATS, ERS or GOLD  \n\u2022 moderate to very severe COPD (GOLD grades II IV), with a \nmean age of 64 years  \n \n\u2022 excluded participants requiring mechanical ventilation on \npresentation  \n y-n-y-y-y-y-y-y-n-y-y \n \nScore: 9  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  244 \n      \n \nZitat Studiencharakteristika  Population Methodische Qualit\u00e4t  \nStudienergebnisse  \nPDE 4 vs. Placebo  \nSGRQ  \n\u2022 small improvements (MD - 1.06 units, 95%CI - 1.68 to -0.43, n=7645; studies=11, moderate- quality evidence due to moderate levels of heterogeneity and risk of report-\ning bias)  \n\u2022 notable: n=2 trials with a duration of one year --> no signi \ufb01cant change in QoL (MD0.26, 95%CI - 1.18 to 1.69)  \nCOPD- related symptoms  \n\u2022 one trial of cilomilast: for breathlessness scored using a Borg scale (MD -0.19, 95% CI 0.33 to - 0.05) --> small absolute difference so is of doubtful clinical relevance  \nExercise tolerance  \n\u2022 no signi \ufb01cant change  \nCOPD exacerbation  \n\u2022 reduced likelihood  (OR 0.78, 95% CI 0.73 to 0.83; n=19,948 ; studies=23, high- quality evidence)  \n\u2022 number needed to treat for an additional bene \ufb01cial outcome (NNTB) 20, 95% CI 16 to 26)  \n\u2022 Ein Vergleich von Roflumilast 500\u00b5g gegen Placebo ergab eine Reduktion an Teilnehmern, die eine oder mehr Exazerbationen hatten (OR 0,0.79 [95% CI 0.73, 0.86]; \nI\u00b2= 0%,13 RCT, n= 14420)  \n\u2022 Wenn Roflumilast zusammen mit einem langwirksamen Bronchodilatator verabreicht wurde, zeigte sich ebenfal ls eine Reduktion an Teilnehmern mit stattgehabten \nExazerbationen (OR 0,69; 95% CI 0,54 -  0,88; I\u00b2=32%, 2 RCT. n = 1676). Wurde Roflumilast zusammen mit Corticosteroiden gegeben, ergab sich eine OR von 0,81 \n(95% CI 0,70 -  0,95), 1 RCT, n = 2686)  \n \nAdverse events (any)  \n\u2022 OR 1.29; 95%CI 1.22 to 1.37 (n=20988; studies=27; moderate quality evidence)  \nNon-serious adverse events  \n\u2022 More participants in the treatment groups experienced non- serious AEs compared with controls, particularly a range of gastrointestinal symptoms such as  \n- diarrhoea ( OR 3.13; 95%CI 2.76 to 3.54; n=20181; studies=25; high quality evidence),  \n- nausea (OR 3.78, 95% CI 3.23 to 4.43; n=20627; studies=25)  \n- headache (OR 1.69, 95% CI 1.47 to 1.95; n=18977; studies=22)  \n- vomiting (OR 4.01, 95% CI 2.80 to 5.74; n=5828; studies=11)  \n- dyspepsia (OR 3.17, 95% CI 2.33 to 4.30; n=6216; studies=13)  \n- abdominal pain (OR 2.04, (95% CI 1.63 to 2.55; n=8165; studies=13)  \n\u2022 number needed to treat for an additional harmful outcome (NNTH) 15, 95% CI 13 to 17)  \n\u2022 Ro\ufb02umilast in particular was associated with weight loss during the trial period and an increase in insomnia and depressive mood symptoms  \n(Psychiatric adverse events (roflumilast 500\u00b5g): OR 2.13; 95%CI 1.79 to 2.54, n=11168; studies=14; moderate quali ty evidence; Pooled data from FDA website, not \nindividual trial reports)  \nNon-fatal serious adverse events  \n\u2022 no signi \ufb01cant effect of treatment on non- fatal serious adverse events (OR 0.99, 95% CI 0.91 to 1.07)  \nMortality  \n\u2022 no signi \ufb01cant effect (OR 0.97, 9 5% CI 0.76 to 1.23; n=19344; studies=23; moderate quality evidence), although mortality was a rare event during the trials.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  245 \n      \n \nMukolytika  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nPoole P, Sathananthan \nK, Fortescue R. Muco-\nlytic agents versus pla-\ncebo for chronic bron-\nchitis or chronic obstruc-\ntive pulmonary disease. \nCochrane Database \nSyst Rev 2019; (5).  \n \nhttp://www.ncbi.nlm.nih.\ngov/pubmed/31107966.  \n \u2022 prim\u00e4re Fragestellung: To \ndetermine whether treatment \nwith m ucolytics reduces exac-\nerbations and/or days of disa-\nbility in patients with chronic \nbronchitis or COPD  \n\u2022 sekund\u00e4re Fragestel-\nlungen:   \nTo assess whether mucolytics \nlead to improvement in lung \nfunction or quality of life +   \nTo determine frequency of ad-\nverse effects associated with \nuse of mucolytics  \n \n\u2022 Suchzeitraum: most re-\ncently on 23.April 2019  \n\u2022 Population: adults with \nchronic bronchitis or COPD  \n \n\u2022 Einschlusskriterien  \n- RCT \n- adults with chronic bronchitis \nas defined by the British Medi-\ncal Research Council or \nCOPD as defined by the crite-\nria of ATS, GOLD, ERS, or \nWHO  \n- must have received regular \ntreatment with oral mucolytics \nor placebo for at least two \nmonths  \n \n\u2022 Ausschlusskriterien:  \n- people with asthma and \ncystic fibrosis; children  \n- studies of inhaled mucolytics \nand combinations of muco-\nlytics with antibiotics and mu-\ncolytics with bronchodilators , Baseline -Charakteristika  \n- mean age of participants  ranged from 40 to 71 years  \n- All but five studies reported the percentage of current smokers or ex -smokers, \nwhich ranged from 55% to 100%  \n- verschiedene Mukolytika in Studien betrachtet; verschiedene Dosierungen  \n \nParticipants with no exacerbations in stud y period (Follow -up: 8.8 months):  \nRisk with placebo: 386 per 1000 \nRisk with mucolytic: 521 per 1000 (495 to 545)  \nPeto OR 1.73, 95% CI 1.56 to 1.91; 28 RCTs, 6723 participants; moderate \ncertainty evidence  \n>> Generally larger effects in earlier studies of mucolytics in chronic bronchitis \nand smaller effects in more recent studies in COPD  \n>>  The overall number needed to treat with mucolytics for an average of nine \nmonths to keep an additional participant free from exacerbations was eight \n(NNTB 8, 95% CI 7 to 10).  \n>> High heterogeneity was noted for this outcome (I\u00b2 = 62%)  \n>>The type or dose of mucolytic did not seem to alter the effect size, nor did \nthe severity of COPD, including exacerbation history.  \n>>Longer studies showed smaller effects of mucolytics than were reported in \nshorter studies.  \n \nDays of disability per participant per month (Follow -up: 8.3 months):  \nRisk with placebo: Mean days of disability per participant per month was 1.57 \ndays  \nRisk with mucolytic: MD 0.43 days lower (0.56 lower to 0.30 lower ) \n9 RCTs, 2259 participants;  I\u00b2 = 61%; moderate certainty evidence  \n \nHealth-  related quality of life (total score SGRQ) Scale f rom 1 to 100; lower \nscores indicate better quality of life (Follow -up: 14.1 months):  \nRisk with placebo: Mean SGRQ total score was 39.02 points  \nRisk with mucolytic: MD 1.37 lower (2.85 lower to 0.11 higher)  \n7 RCTs; 2721 participants; I\u00b2 = 64%;  moderate certainty evidence  \n \nHospitalisation during study period (Follow -up: 16.6 months):  \nRisk with placebo: 188 per 1000 \nRisk with mucolyti c: 136 per 1000 (107 to 171)  \nPeto OR 0.68 (0.52 to 0.89); 1833 participants; 5 RCTs; I\u00b2 = 58%;  moderate \ncertainty evidence  \n \nAdverse effects (Follow -up: 8.2 months):  AMSTAR II:  \nlow \n \n teilweise gro\u00dfe Heterogenit\u00e4t be-\nachten; meist fixed effects model \nangewendet  \n \nteilweise unterschiedliche Anga-\nben zu Studien/Teilnehmern in \nder Darstellung von ein und dem \nselben Ergebnis (Summary of \nfindings table vs. Ergebnisse im \nAbstract; Bsp. Hospitalisierung)  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  246 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nas well as studies of deoxyri-\nbonuclease or proteases such \nas trypsin . \n \n\u2022 Interventionen : oral muco-\nlytic therapy for at least two \nmonths  \n \n\u2022 Vergleich : Placebo  \n \n\u2022 eingeschlossene Studien:  \nrandomised, placebo- con-\ntrolled trials; n=38 (10,377 par-\nticipants)  \n--> betrachtete Mukolytika im \nReview:  \nN-acetylcysteine (NAC) (n=21 \nstudies)  \ncarbocysteine (n = 3)  \nambroxol (n = 3)  \nerdosteine (n = 2)  \nsobrerol (n = 1)  \ncarbocysteinesobrerol (n = 1)  \ncarbocysteine- lysine (n = 1)  \nletosteine (n = 1),  \ncithiolone (n = 1)  \niodinated glycerol (n = 1)  \nN-isobutyrylcysteine (NIC) (n = \n1) \nmyrtol (n = 1) \ncineole and lysozyme (n = 1)  \n Risk with placebo: 235 per 1000  \nRisk with mucolytic: 205 per 1000 (185 to 224)  \nPeto OR 0.84  (0.74 to 0.94); 7264 participants; 24 RCTs; I\u00b2 = 46%; moderate \ncertainty evidence  \n>>  pooled effect includes no difference if a random -effects model is used.  \n \nDeath during study period (Follow -up: 13.3 months):  \nRisk with placebo: 11 per 1000 \nRisk with mu colytic:10 per 1000 (5 to 20)  \nPeto OR 0.98 (0.51 to 1.87); 3527 participants; 11 RCTs;  I\u00b2 = 0%; moderate \ncertainty evidence  \n>> 18 deaths on mucolytics and 19 on placebo  \n \nBetablocker  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nSalpeter SR. Cardiose-\nlective beta- blockers for \nchronic obstructive pul-\nmonary disease. \nCochrane Database of \u2022 Fragestellung:  To assess the \neffect of cardioselective  beta-\nblockers on respiratory function of \npatients with COPD.  \n Cardioselective beta- blockers (s ingle dose (n=131) or longer duration (n=185))  \n- no change in FEV1 compared to placebo  \n-- single dose: MD - 2.08 [ -5.25, 1.09], 4 RCT, n=108 \n-- longer duration: MD -4.00 [ -8.09, 0.08], 5 RCT, n=121  \n AMSTAR: y -n-y-n-y-y-y-n-y-n-n \n \nScore: 6  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  247 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nSystematic Reviews \n2005;(4).  \n \u2022 Suchzeitraum: from 1966 to Au-\ngust 2010  \n\u2022 Population:  patients with COPD  \n\u2022 Ein - und Ausschlusskriterien:  \nRCTs (blinded) of single dose or \nlonger duration, studied the effects \nof  cardioselect ive beta- blockers \non FEV1 or symptoms in patients \nwith COPD.  \n \n\u2022 Interventionen: cardioselective \nbeta- blockers  \n\u2022 Vergleich:  Placebo \n \n\u2022 eingeschlossene Studien:  11 \nRCTs (single dose, n=131), 11 \nRCTs (longer duration, n=185)  \n - no Change in respiratory symptoms compared to placebo  \n-- single dose: Risk difference 0.0 [ -0.04, 0.04], 9 RCT, n=301  \n-- longer duration: Risk difference -0.01 [ -0.06, 0.04], 10 RCT, n=273  \n \n- did not affect the FEV1 treatment response to beta2 agonists  \n-- Single- dose Beta- agonist treatment effect: MD - 1.21 [ -10.97, 8.56], 2 RCT. n=50  \n-- Longer duration Beta- agonist treatment effect: MD - 0.70 [ -5.02, 3.63], 3 RCT, n=89  \n \nSubgroup analyses  \n- no significant change in results for those participants with severe chronic airways ob-\nstruction, those with a reversible obstructive component, or those with concomitant cardi-\novascular disease.  \n \nAuthors\u2019 conclusions  \nCardioselective beta- blockers, given to patients with COPD in the identified studies did \nnot produce adverse respiratory effects. Given their demonstrated benefit  in conditions \nsuch as heart failure, coronary artery disease and hypertens on, cardioselective beta-\nblockers should not be routinely withheld from patients with COPD.  \nImpfungen  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nWalters -Julia AE. Pneu-\nmococcal vaccines for \npreventing pneumonia in \nchronic obstructive pul-\nmonary disease. \nCochrane Database of \nSystematic Reviews \n2017;(1).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/10.1\n002/14651858.CD00139\n0.pub4/abstract  \n \u2022 Fragestellung:  \nTo determine the efficacy of injectable pneumococcal \nvaccination for prev enting pneumonia in persons with \nCOPD.  \n \n\u2022 Suchzeitraum: up to 25 Nov. 2016 \n \n\u2022 Population: Patient*innen mit COPD  \n \n\u2022 Einschlusskriterien:  RCTs using injectable pneu-\nmococcal vaccines  \n \n\u2022 Interventionen:  injectable pneumococcal polysac-\ncharide vaccine (PPV) or pneumococcal conjugated \nvaccine (PCV)  \n \n\u2022 Vergleich:   \ncontrol or alternative vaccine type  \n \u2022 Baseline -Charakteristika  \n- average age of participants was 66 years, 67% were male and participants had re-\nceived a diagnosis of moderate to severe COPD  \n \n\u2022 Ergebnisse: pneumococcal vaccine vs. control  \nPneumonia, community acquired  (at least 1 episode Follow -up: range 6 to 36 \nmonths): O R 0.62 (95% CI 0.43 to 0.89) (n=1372 participants; 6 RCTs;  \nGRADE: Moderate ) \n--> 21 people with COPD (95% CI 15 to 74) would have to be vaccinated to prevent \none episode of pneumonia  \n \nPneumococcal pneumonia  (at least 1 episode Follow -up: range 6 to 36 mont hs):  \nOR 0.26 (95% CI 0.05 to 1.31) (n=1158 participants; 3 RCTs; GRADE: Low ; Very \nfew confirmed episodes of pneumococcal pneumonia.)  \n \nDeath from cardiorespiratory causes (Follow -up: range 24 to 48 months):  \nOR 1.07 (95% CI 0.69 to 1.66) (n=888 participant s; 3 RCTs;  \nGRADE: Moderate ) \n AMSTAR -Score: 10/11  \n \ny-y-y-y-y-y-y-y-y-ca-y NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  248 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n1. Comparison:  pneumococcal polysaccharide vac-\ncine, 23-  valent (PPSV -23) OR 14- valent (PPV -14), \nversus contr ol. \n2. Comparison:  23-valent pneumococcal polysaccha-\nride vaccine (PPV -23) versus 7- valent diphtheria- con-\njugated pneumococcal polysaccharide vaccine (PCV -\n7). \n \n\u2022 eingeschlossene Studien:   \n12 RCTs( 2171 participants with COPD)  \n Death from all causes  (Follow -up: range 12 to 48 months): OR 1.00 (95% CI (0.72 to \n1.40) (n=1053 participants; 5 RCTs; GRADE: Moderate ) \n \nHospital admission (any cause, at least 1 episode; Follow -up: range 6 to 12 months): \nOR 0 .74 ( 95% CI 0.32 to 1.74) (n=391 participants; 3 RCTs; GRADE: Moderate ) \n \nCOPD exacerbation  (at least 1 episode; Follow -up: range 6 to 24 months):  \nOR 0.60 (95% CI 0.39 to 0.93) (n=446 participants; 4 RCTs; GRADE: Moderate ) \n--> 8 people with COPD (95% CI 5 to 58) would have to be vaccinated to prevent one \nperson from having an acute exacerbation \n \n- one study (n =181) compared the efficacy of different  vaccine types -  23-valent PPV \nversus 7 -valent PCV - and reported no differences for  CAP, all -cause mortality, hos-\npital admission or likelihood of a COPD exacerbation, but investigators described a \ngreater likelihood of some mild adverse effects of vaccination with PPV -23. \n \nAuthors\u2019 conclusions  \nInjectable polyvalent pneumococcal vaccination provides significant protection \nagainst community -acquired pneumonia, although no evidence indicates that vaccina-\ntion reduced the risk of confirmed pneumococcal pneumonia, which was a relatively \nrare event. Vaccination reduced the likelihood of a COPD exacerbation, and moder-\nate-quality evidence suggests the benefits of pneumococcal vaccination in people \nwith COPD. Evidence was insufficient for comparison of different pne umococcal vac-\ncine types.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  249 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nKopsaftis Z, Wood-\nBaker R, Poole P.  \nInfluenza vaccine for \nchronic obstructive pul-\nmonary disease \n(COPD).  \nCochrane Database of \nSystematic Reviews \n2018, Issue 6. Art. No.: \nCD002733.  \nDOI: \n10.1002/14651858.CD0\n02733.pub3.  \n \nhttps://www.cochraneli-\nbrary.com/cdsr/doi/10.1\n002/14651858.CD00273\n3.pub3/full  \n \u2022 Fragestellung:  \nTo determine whether influenza vaccination in people \nwith COPD reduces respiratory illness, reduces mor-\ntality, is associated with excess adverse events, and is \ncost effe tive.  \n \n\u2022 Suchzeitraum: 12/2017 \n \n\u2022 Population: Patient*innen mit COPD  \n \n\u2022 Einschlusskriteri en:  \n- RCT, included adults with COPD,  \n-receive at least one annual influenza vaccination. In-\nfluenza vaccination may have been one of the follow-\ning types: live attenuated whole virus, inactivated, or a \nsplit-virus type vaccine, and may have been a minis-\ntered by either intramuscular injection or intranasal \nspray.  \n \n\u2022 Interventionen:  live or inactivated virus vaccines, ei-\nther alone or with another vaccine  \n \n\u2022 Vergleich:  placebo  \n \n \n\u2022 eingeschlossene Studien:  6/11 eingeschlossenen \nRCT betrachten Patient*innen mit  COPD (2469 partici-\npants).  \n \u2022 Baseline -Charakteristika  \n- \u00c4ltere Studien eingeschlossen (alle vor 2004 publiziert)  \n \nErgebnisse:  \n\u2022 Inaktivierter Impfstoff reduzierte die Gesamtzahl der Exazerbationen pro geimpf-\ntem/r Teilnehmer/in im Vergleich zu denen, die Placebo erhielten:  \nMD -0.37 (95% KI -0,64; -0.11); I\u00b2 = 8%, 2 RCT, n = 180, Datenqualit\u00e4t niedrig  \n.  \n\u2022 Hospitalisierungsrate in der Interventionsgruppe im Vergleich zur Kontrollgruppe \nverringert : 23/1000 vs. 76/1000, OR 0,33 (95% KI 0,09; 1,24), I\u00b2 = 0%, 2 RCT, n = \n180, Datenqualit\u00e4t niedrig ). \n \n\u2022 Mortalit\u00e4t: 67/1000 vs. 76/1000, OR 0,87 (95% KI 0,28; 2,70); I\u00b2=0% , 2 RCT, n = \n180, Datenqualit\u00e4t niedrig.  \n \n\u2022 Sicherheit:  Two studies evaluating mortality for influenza vaccine versus placebo \nwere too small to have detected any effect on mortality.  \nHowever, a large study (N=2215) noted that there was no difference in mortality when \nadding live attenuated virus to inactivated virus vaccination.  AMSTAR -II \n \nmoderat  \nAnhang 8.2  Triple -Therapie \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nLee S -D. Efficacy and \ntolerability of \nbudesonide/formoterol \nadded to tiotropium \ncompared with tiotro-\npium alone in patients \u2022 Studientyp: randomized, parallel -group, open -\nlabel Phase IV study  \n\u2022 Population:  patients with severe or very se-\nvere COPD (n= 578)  \n\u2022 Studienzeitraum:  07/2011 - 06/2013;  12 week \ntrial \n \u2022 Baseline -Patientencharakteristika: hinsichtliche Alter, \ngeschlecht, Dauer der Erkrankung weitestgehend ausgegli-\nchen; leichte Unterschiede in der Schwere der Erkrankung  \n \n-ITT comprised 287 patients in the triple therapy group and \n290 patients in the tiotropium alone group \n Selection bias  \nRandomisierung: unclear  \nAllocation concealment: unclear  \n \nPerformance bias \nVerblindung von Teilnehmern und \nPersonal: high kein Protokoll zur Ver-\nf\u00fcgung; keine Anga-\nben zur Methodik auf \nclinicaltrials.gov  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  250 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nwith severe or very se-\nvere COPD: A random-\nized, multicentre study \nin East Asia. Respiro-\nlogy 2016; 21(1):119\u2013\n27. \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/26394882 . \n \n \u2022 Intervention:  \n- 14-day run- in period: tiotropium 18 \u03bcg once \ndaily \n-- Budesonide/Formoterol (Symbicort\u00ae Turbuha-\nler\u00ae 160/4.5 \u03bcg/Inhalation, 2 Inhalations Twice \nDaily) Added to Tiotropium (SpirivaTM 18 \u03bcg/In-\nhalation, 1 Inhalation Once Daily)  \nvs. \n-- Tiotropium (SpirivaTM18 \u03bcg/Inhalation, 1 Inha-\nlation Once Daily) Alone  \n \n\u2022 Einschlusskriterien:  \n- \u226540 years of age; diagnosis of COPD with \nsymptoms > 2 years; a history of at least one \nCOPD exacerbation requiring a course of oral \nsteroids and/or antibiotics within 1- 12 months \nbefore Visit 2  \n- FEV1 \u226450% of predicted normal value,  FEV1 / \nFVC < 70%  \n- Total symptom score of 2 or more per day for \nat least half of run- in period (breathing, cough \nand sputum scores from the diary card)  \n\u2022 Ausschlusskriterien ( Auswahl):  \n- Asthma, exacerbations within 4 weeks prior to \nVisit 2 or during run in; relevant cardiovascular \ndisorder  \n \n\u2022 prim\u00e4rer Endpunkt  \n- Pre-dose FEV1 \n\u2022 sekund\u00e4re Endpunkte (Auswahl)  \n- Change in COPD Symptoms -  Breathing, \ncough, sputum, exacerbations  \n- change in SGRQ  \n \n\u2022 East Asia; multicenter (41 study centres in \nChina, Hong Kong, Indonesia, South Korea and \nThailand)  \n \u2022 sekund\u00e4re Endpunkte:  \nExazerbationen  \nnumber of patients with \u22651 COPD exacerbation  \n- triple therapy group:n= 40 (13.9%)  \n- tiotropium: n= 61 (21.0%)   \nrate of COPD exacerbations  \nThe rate of COPD exacerbations per 12weeks was reduced \nby 40.7% (95% CI: \u221216.1, \u221258.1; P = 0.0032) with triple \ntherapy (0.18 (95% CI: 0.14, 0.24)) versus tiotropium alone \n(0.31 (95% CI: 0.25, 0.38)).  \n \nTriple therapy significantly prolonged the time to first exacer-\nbation compared with tiotropium alone (38.6% risk reduction \n(95% CI: \u22128.4, \u221258.8), P = 0.017)  \n \nSGRQ -C total score  \n- triple therapy mean change from baseline: \u221210.00 units \n(95% CI: \u221212.26, \u22127.74)  \n- tiotropium mean change from baseline: \u22124.80 units (95% \nCI: \u22127.03, \u22122.56)  \n>> LS mean difference: \u22125.20 units (95% CI: \u22128.03, \u22122.38; \nP = 0.0003)  \nA higher proportion of patients in the triple therapy group \nachieved a clinically meaningful improvement in the SGRQ -\nC total score (i.e. a change of \u22654 units) versus the tiotropium \nalone group (59.6 vs 46.2%, respectively; P = 0.0015).  \n \nCOPD symptoms  \nTriple therapy significantly improved COPD symptoms com-\npared with tiotropium alone, with significant reductions in \nbreathing difficulty, cough and sputum scores  \nBreathing  \nTriple: n=284 \u22120.37 (\u22120.45, \u22120.29); Tio: n= 286 \u22120.11 \n(\u22120.19, \u22120.03); treatment difference: \u22120.26 (\u22120.36, \u22120.16); p \n<0.0001 \nCough \nTriple: n=283 \u22120.31 (\u22120.39, \u22120.23); Tio: n=  286 \u22120.17 \n(\u22120.25, \u22120.09); treatment difference: \u22120.14 (\u22120.25, \u22120.04); \np= 0.0067  \nSputum  \nTriple: n=284 \u22120.22 (\u22120.30, \u22120.14); Tio: n=  286 \u22120.09 \n(\u22120.17, \u22120.01); treatment difference: \u22120.12 (\u22120.22, \u22120.02);  \nDetection bias  \nVerblindung der Ergebnisevaluation: \nunclear  \n \nAttrition bias  \nVerlust von Studienteilnehmern/ feh-\nlende Daten: unclear  \n \nITT-Analyse: durchgef\u00fchrt (siehe \nKommentar)  \n \nReporting bias  \nselektive Ergebnisdarstellung: un-\nclear  \n \nAndere Biasursachen  \nBaseline imbalance: unclear  \n \nInteressenkonflikte/ Sponsoring: \nAstra Zeneca \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  251 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \np= 0.0171  \n \n\u2022 Sicherheit:   \n- Incid ence of adverse events was 26% for both groups.  \n- All six deaths were judged by an investigator as unrelated \nto treatment.  \n \nVestbo J. Single inhaler \nextrafine triple therapy \nversus long- acting mus-\ncarinic antagonist ther-\napy for chronic obstruc-\ntive pulmonary disease \n(TRINITY): A double-\nblind, parallel group, \nrandomised controlled \ntrial. Lancet 2017; \n389(10082):1919\u2013 29. \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/28385353 . \n \n TRINITY  \n\u2022 Studientyp:  double- blind, parallel group,dou-\nble-dummy, active- controlled, randomised con-\ntrolled trial  \n\u2022 Population:  n= 2691 patients (fixed triple \n(n=1078), tiotropium (n=1075), open triple \n(n=538))  \n\u2022 Studienzeitraum:  01/2014 - 03-2016; 52 week \ntrial \n \n\u2022 Intervention:  \n- 2-week run- in period: one inhalation per day via \nsingle- dose dry -powder inhaler of open- label 18 \n\u03bcg tiotropium  \n- patients were randomised (2:2:1) to tiotropium, \nfixed triple, or open triple  \n--tiotropium 18 \u03bcg \n-- extrafine beclometasone dipropionate, for-\nmoterol fumarate, and glycopyrronium bromide \n(100 \u03bcg BDP/6 \u03bcg FF/12,5 \u03bc g GB; fixed triple)  \n-- 100 \u03bcg BDP/6 \u03bc g FF plus tiotropium 18 \u03bcg \n(open triple)  \n \n\u2022 Einschlusskriterien:  \n- had COPD, 40 years of age or older; current or \nex-smokers; postbronchodilator FEV1 of less \nthan 50%, at least one moderate- to-severe \nCOPD exacerbation in the previous 12 months, \nand a COPD Assessment Test total score of at \nleast 10 \n- used ICS/LABA, ICS/LAMA; LAMA/LABA or \u2022 Baseline -Patientencharakteristika: hinsichtlich Alter, Ges-\nchlecht; Rauchstatus; Blueosinophilen, Lungenfunktion, \nBegleiterkrankungen weitestgehend ausgeglichen \n\u2022 sites were a mixture of primary care (17), secondary care \n(121), tertiary care (48), and specialist investigation units \n(38) \n\u2022 Statistik : prespecified hierarchical order  \n\u2022 completed study:  \n- fixed triple: 986/1078 \n- tiotropium: 914/1075 \n- open triple: 496/538  \n \n\u2022 prim\u00e4rer Endpunkt: moderate -to-severe exacerbation \nrates \n-  fixed triple: 0,46 (95% CI 0,41\u2013 0,51)  \n- tiotropium: 0,57 (95% CI 0,52\u2013 0,63)  \n- open triple: 0,45 (95% CI 0,39\u2013 0,52)  \n>> fixed triple was superior to tiotropium (rate ratio 0,80 \n[95% CI 0,69\u2013 0,92]; p=0\u00b70025)  \n \n\u2022 Subgruppe: Eosinophile  \n- compared with tiotropium monotherapy the effect of the \ntwo triple therapies on exacerbation rate was greater in the \nsubgroups with higher eosinophil concentrations  \neosinophil count of at least 2%  \nthe triple therapies also reduced exacerbation rates versus \ntiotropium (RR 0,70 [95% CI 0,58\u2013 0,85] f or fixed and 0,69 \n[0,55\u2013 0,87] for open triple)  \neosinophil count of <2% subgroup  \ncorresponding reductions in the <2% subgroup were smaller \n(0,3 [0,75\u2013 1,17] for fixed triple and 0,91 [0,69\u2013 1,20] for open \ntriple).  Selection bias  \nRandomisierung: low \nAllocation concealment:  low \n \nPerformance bias \nVerblindung von Teilnehmern und \nPersonal: low \n \nDetection bias  \nVerblindung der Ergebnisevaluation:  \nlow \n \nAttrition bias  \nVerlust von Studienteilnehmern/ feh-\nlende Daten: unclear  \n \nITT-Analyse: durchgef\u00fchrt  \n \nReporting bias  \nselektive Ergebnisdarstellung: low \n \nAndere Biasursachen  \nBaseline imbalance:  low \n \nInteressenkonflikte/ Sponsoring: \nChiesi Farmaceutici SpA.The funder \nwas responsible for the design and \nanalysis of the study, oversaw its \nconduct and was responsible for pre-\nparing the study report.  \n Appendix abruf bar \n \nBDP/FF/GB: Superior-\nity over Tiotropium  \n \nopen vs. fixed triple: \nnon- inferiority  \n \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  252 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nLAMA mono for at least 2 month before screen-\ning \n\u2022 Ausschlusskriter ien (relevante )  \n- receiving triple therapy of inhaled \nLABA/LAMA/ICS \n- diagnosis of asthma, or history of allergic rhini-\ntis or atopy; COPD exacerbation in the 4 weeks \nbefore screening or during the run -in period; clin-\nically significant cardiovascular condi tions or la-\nboratory abnormalities (including persistent, \nlong- standing, or permanent atrial fibrillation); or \nunstable concurrent disease; requiring LTOT, re-\nquiring antibiotics or systemic steroids or PDE -4 \ninhibitors in the4 weeks prior to screening \n\u2022 prim\u00e4rer Endpunkt  \n- moderate- to-severe COPD exacerbation rate  \n\u2022 sekund\u00e4re Endpunkte  (Auswahl)  \n- key secondary endpoint was change from \nbaseline in pre- dose FEV1 at week 52  \n- time to first moderate to severe COPD exacer-\nbation, and to first severe COPD exacerbation; \nrate of severe and of moderate COPD exacerba-\ntions throughout 52 weeks of treatment; SGRQ \nresponse at weeks 26 and 52; SGRQ total score \nat all clinic visits; percentage of days without res-\ncue medication use  \n \n\u2022 multicenter: at 224 sites across 15 count ries \n  \npatients with more than one exacerbation in the previous 12 \nmonths  \nAdditionally, compared with open triple, fixed triple signifi-\ncantly reduced the rate of moderate- to-severe exacerbations \nin the subgroup of patients with more than one exacerbation \nin the previous 12 months (0,71 [0,51\u2013 1,00]).  \n \n\u2022 Sic herheit:  Adverse events were reported by 594 (55%) \npatients with fixed triple, 622 (58%) with tiotropium, and 309 \n(58%) with open triple.  \n \nChapman KR. Long-\nTerm Triple Therapy De-\nescalation to In-\ndacaterol/Glycopyrro-\nnium in Patients with \nChronic Obstructive Pul-\nmonary Disease (SUN-\nSET): A Randomized, \nDouble- Blind, Triple -\nDummy Clinical Trial. \nAm J Respir Crit Care SUNSET  \n\u2022 Objective: direct  de-escalation  from long- term \ntriple therapy to indacaterol/glycopyrronium  \n\u2022 Studientyp: randomized, double -blind, triple-\ndummy clinical trial; parallel group; Nicht -Unter-\nlegenheitsstudie  \n\u2022 Population : n=1053 (nach Run- In Phase)  \n\u2022 Studienzeitraum:  11/2015 - 07/2017; 26- week \ntrial \n \n\u2022 Intervention:  \u2022 Baseline -Patientencharakteristika:   hinsichtlich Ge-\nschlecht, Alter, Gewicht, Lungenfunktion, Dauer der Erkran-\nkung weitestgehend ausgeglichen.  \n- no differences in the distri bution of patients according to \ntheir exacerbation history and the baseline blood eosinophil \ncounts  \n- nach Randomisierung: n=456/527 completed in Ind/Gly -\ngroup; n=472/526 in triple therapy group  \n. \n\u2022 Ergebnisse sekund\u00e4rer Endpunkt: Exazerbationen  \nPatients i n the two groups experienced similar annualized Selection bias  \nRandomisierung: low \nAllocation concealment:  low \n \nPerformance bias \nVerblindung von Teilnehmern und \nPersonal: low \n \nDetection bias  \nVerblindung der Ergebnisevaluatio n: \nlow prim\u00e4rer Endpunkt: kli-\nnische Relevanz? \n(nicht durch Leitlinien-\ngruppe priorisiert)  \n \nAusschluss  von Pati-\nenten mit eosinophils  \n> 600 cells/\u00b5l  \n \nAusschluss von Pati-NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  253 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nMed 2018; 198(3):329 \u2013\n39. \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/29779416 . \n \n - 4-week run -in period on standard triple therapy \n(tiotropium 18 \u03bcg once daily + combination of \nsalmeterol/fluticasone propionate 50/500 \u03bcg \ntwice daily) -->  \n- Nach Run- In: Randomisierung (1:1) to  \n-- indacaterol/glycopyrronium (110/50 \u03bcg) once \ndaily (+ Placebo: triple- Therapy)  \nor  \n-- triple therapy ( tiotropium plus salmet-\nerol/fluticasone) (+ Placebo: duale Therapie)  \n\u2022 Follow -up: 30 d nach Studien- Ende  \n \n\u2022 Einschlusskriterien:  \n- nonfrequently exacerbating patients with mod-\nerate- to-severe COPD (stable)  \n- patients > 40 years of age  \n- with a postbronchodilator FEV 1 of at least 40% \nto less than 80% predicted, a post -bronchodila-\ntor ratio of FEV1 to FVC of less than 0.70, and a \nsmoking history of at least 10 pack -years.  \n- Patients wer e not frequent exacerbators (i.e., \nthey had a history of no more than one moderate \nor severe exacerbation in the previous year)  \n- must have received long- term triple therapy (for \nat least 6 mo) before enrollment  \n\u2022 Ausschlusskriterien:  \n- a history of asthm a  \n- with a blood eosinophil count greater than 600 \ncells/ \u03bcl during screening  \n \n\u2022 prim\u00e4rer Endpunkt:  noninferiority on change \nfrom baseline in trough FEV1  \n\u2022 sekund\u00e4re Endpunkte:   \n- Moderate or severe exacerbations (predefined)  \n- TDI, SGRQ, effect of baseline eosinophil blood \nlevel/abslolute eosinophil counts  \n \n\u2022multicenter study  \n rates of  \n- moderate or severe COPD exacerbations  (indacaterol/gly-\ncopyrronium vs. tiotropium plus salmeterol/ fluticasone, 0.52 \nvs. 0.48; rate ratio, 1.08; 95% CI, 0.83 to 1.40)  \n- all (mild, moderate, and sev ere) exacerbations  (4.11 vs. \n3.86; rate ratio, 1.07; 95% CI, 0.93 to 1.22).  \n- no difference between treatments in the time to first moder-\nate or severe COPD exacerbation (hazard ratio, 1.11; 95% \nCI, 0.85 to 1.46)  \n \n\u2022 weitere ausgew\u00e4hlte Ergebnisse:  \nExazerb ationen und Eosinophile  \n- The rate of moderate or severe exacerbations according to \nbaseline blood eosinophils subgroups did not differ between \nthe two treatment arms, with the exception of patients with \nbaseline blood eosinophil counts \u2265300 cells/ \u03bcl who w ere at \nincreased risk of exacerbations (rate ratio, 1.86; 95% CI, \n1.06 to 3.29)   \n- There was no difference in the time to first exacerbation \nbetween the two arms in patients with <300 cells/ \u03bcl (hazard \nratio, 0.95; 95% CI, 0.70 to 1.29)  \n- whereas a differ ence in favor of tiotropium plus salmet-\nerol/fluticasone was observed in patients with \u2265300 cells/ \u03bcl \n(hazard ratio, 1.80; 95% CI, 0.98 to 3.28)  \n \nQualitiy of Life (SGRQ)  \nThe change from baseline in SGRQ -C score at Week 12 \nwas -0.7 and - 2.5 units for indacat erol/glycopyrronium and \ntiotropium plus salmeterol/fluticasone, respectively (\u2206 = 1.8 \nunits; 95% CI, 0.7 to 3.0); similar changes were observed at \nWeek 26 ( - 1.0 and - 2.5 units with indacaterol/glycopyrro-\nnium and tiotropium plus salmeterol/fluticasone, res pec-\ntively; \u2206  = 1.4 units; 95% CI, 0.2 to 2.6 units).  \n \n\u2022 Sicherheit:  \n- The incidence of adverse events and serious adverse \nevents were similar across both treatment arms  \n- Adverse events leading to permanent discontinuation of \nstudy drug were similar (indacaterol/ glycopyrronium 3.6% \nand tiotropium plus salmeterol/fluticasone 3.4%)  \n  \nAttrition bias  \nVerlust von Studienteilnehmern/ feh-\nlende Daten:  unclear  \n \nITT-Analyse: die sekund\u00e4ren End-\npunkte wurden f\u00fcr die Gruppe aus-\ngewertet, die mind. 1 Behandlung er-\nhalten hat, nicht nach Randomisie-\nrung \nReporting bias  \nselektive Ergebnisdarstellung: low \n \nAndere Biasursachen  \nBaseline imbalance: low  \n \nInteressenkonflikte/ Sponsoring: No-\nvartis (via clinicaltrials.gov NCT \n02603393)  \n enten, welche > 1 mo-\nderate oder schwere \nExazerbation im letz-\nten Jahr hatten  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  254 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nPapi A. Extrafine inhaled \ntriple therapy versus \ndual bronchodilator ther-\napy in chronic obstruc-\ntive pulmonary di sease \n(TRIBUTE): A double-\nblind, parallel group, \nrandomised controlled \ntrial. Lancet 2018; \n391(10125):1076\u2013 84. \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/29429593 . \n \n TRIBUTE  \n\u2022 Studientyp:  double- blind, parallel group, dou-\nble-dummy randomised controlled trial  \n\u2022 Population:  n= 1532 (BDP/FF/G: n=764; \nIND/GLY: n=768)  \n\u2022 Studienzeitraum:  05/2015 - 07/2017; 52 \nweeks trials  \n \n\u2022 Intervention:  \n- 2 week run in period with one inhalation per \nday of IND /GLY (85 \u03bcg/43 \u03bcg) \n- randomly assigned (1:1) to  \n-- two inhalations of extrafine beclometasone di-\npropionate, formoterol fumarate, and glycopyrro-\nnium (BDP/FF/G)  (87 \u03bcg/5 \u03bcg/9 \u03bcg) twice per \nday  (single- inhaler) or  \n-- one inhalation of  indacaterol plus gly copyrro-\nnium (IND/GLY) (85 \u03bcg/43 \u03bcg) per day (single- in-\nhaler)  \n \n\u2022 Einschlusskriterien  \n- >40 years of age; symptomatic COPD, severe \nor very severe airflow limitation, at least one \nmoderate or severe exacerbation in the previous \nyear, and were receiving inhal ed maintenance \nmedication  \n\u2022 Ausschlusskriterien (Auswahl)  \n- Asthma with ICS or OCS therapy  \n- requiring use systemic steroids, antibiotics, \nPDE4 inhibitors in the 4 weeks prior to screening  \n- treated with non- cardioselective \u03b2-blockers for \nat least 10 days  before randomization \n- requiring LTOT  \n- clinically significant cardiovascular conditions; \natrial fibrillation  \n\u2022 prim\u00e4rer Endpunkt  \n- rate of moderate- to-severe COPD exacerba-\ntions over 52 week treatment  \n\u2022 sekund\u00e4re Endpunkte:  \n- Time and rate of COPD exacerb ation  \n- Change from baseline pre- dose morning FEV1, \nFVC and FEV1 response  \u2022 Baseline -Patientencharakteristika:  hinsichtlich Alter, \nGeschlecht, Gewicht, Rauchstatus, Blut -Eosinophilen, \nDauer der Erkrankung, Begleiterkrankungen weitestgehend \nausgeglichen  \n \n\u2022 multicenter: mixture of primary (n=37), secondary (n=104) \nand tertiary care centres (n=1), and specialised investig ation \nunits (n=45)  \n- The study was completed by 666 (87%) of 764 patients as-\nsigned to the BDP/FF/G group and 648 (84%) of 768 pa-\ntients in the IND/GLY group  \n \n\u2022 prim\u00e4rer Endpunkt: Exazerbationensraten (moderate-\nto-severe)  \n- BDP/FF/G: 0,50 per patient per year (95% CI 0,45\u2013 0,57)  \n- IND/GLY: 0,59 per patient per year (0,53\u2013 0,67)  \n--> ITT rate ratio of 0,848 (0,723\u2013 0,995, p=0,043) in favour \nof BDP/FF/G (indicating a 15% reduction in the exacerbation \nrate) \n \n\u2022 Subgruppen:  \npatients with chronic bronchitis  \n- BDP/FF/G  had a significantly reduced exacerbation rate \ncompared with IND/GLY (rate ratio 0,752, 0,605\u2013 0,935, \np=0,010)  \npatients with emphysema  \n-adjusted rate ratio 0,995 (0,754\u2013 1,314, p=0,974)  \nmixed bronchitis and emphysema  \n- adjusted rate ratio 0,939 (0,605\u2013 1,459, p=0,781)  \npatients with eosinophils of at least 2%  \n- BDP/FF/G also significantly reduced the exacerbation rate \ncompared with IND/GLY: rate ratio 0\u00b7806, 0\u00b7664\u2013 0\u00b7978; \np=0\u00b7029  \npatients with eosinophils less than 2%  \n- adjusted rate ratio of 0,943 (0,711\u2013 1,251, p=0,685)  \n \n- In a second eosinophil subgroup analysis, the adjusted \nrate ratio was 0,806 (0,646\u2013 1,007; p=0,057) in patients with \nat least 200 cells per \u03bcL and 0,872 (0,692\u2013 1,098, p=0,244) \nfor patients with <200 cells/ \u03bcL. \n Selection bias  \nRandomisierung: low \nAllocation concealment:  low \n \nPerformance bias \nVerblindung von Teilnehmern und \nPersonal: low \n \nDetection bias  \nVerblindung der Ergebnisevaluation:  \nlow \n \nAttrition bias  \nVerlust von Studienteilnehmern/ feh-\nlende Daten: unclear  \n \nITT-Analyse: durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: un-\nclear  \n \nAndere Biasursachen  \nBaseline imbalance:  low \n \nInteressenkonflikte/ Sponsoring: \nChiesi Farmaceutici.  \n Appendix einsehbar  \n \n \nProtokolldaten (Zu-\nsammenfassungen) \nlediglich \u00fcber clini-\ncaltrialsregister und \nclinicaltrials.gov --> \nkein extra Protokoll \naufgefunden \n--> Methodische Be-\nwertung teilweise mit \nHilfe dieser Online- In-\nhalte bewertet)  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  255 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n- Change in SGRQ, CAT, EXACT -PRO score  \n- Use of rescue medication and nocturnal symp-\ntoms  \n \n\u2022 multicenter (187 sites across 17 countries)  \n Quality of life (SGRQ  total score defined as \u22654 units de-\ncrease from baseline)  \n- Improvement in mean SGRQ total score was significantly \nbetter with BDP/FF/G than with IND/GLY both overall and at \nall visits  \nWeek 26 BDP/FF/G: n=310/764 (41%)  \nWeek 26 IND/GLY: n=292/768 (38%) --> OR 1,13 (95% CI \n0,92\u2013 1,40) p=0,255  \nWeek 52 BDP/FF/G: n=311/764 (41%)  \nWeek 52 IND/GLY: n=279/768 (36%) --> OR 1,22 (0,99\u2013\n1,51); p= 0,068  \n \n\u2022 Sicherheit: Adverse events were reported by 490 (64%) of \n764 patients receiving BDP/FF/G and 516 (67%) of 768 pa-\ntients receiving IND/GLY. Pneumonia occurred in 28 (4%) \npatients receiving BDP/FF/G versus 27 (4%) patients receiv-\ning IND/GLY. One treatment -related serious adverse event \noccurred in each group: dysuria in a patient receiving \nBDP/FF/G and atrial fibrillation in  a patient receiving \nIND/GLY.  \nFerguson GT. Triple \ntherapy with \nbudesonide/glyco-\npyrrolate/formoterol \nfumarate with co- sus-\npension delivery tech-\nnology versus dual ther-\napies in chronic obstruc-\ntive pulmonary disease \n(KRONOS): A double-\nblind, parallel -group, \nmulticentre, phase 3 \nrandomised c ontrolled \ntrial. Lancet Respir Med \n2018; 6(10):747\u2013 58. \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/30232048 . \n \n KRONOS  \n\u2022 Studientyp:  randomized, double- blind, paral-\nlel-group, Phase III, multicenter trial  \n\u2022 Population : n=1902 \n\u2022 Studienzeitraum:  08/2015 - 01/2018 \n\u2022 Intervention:  \n- budesonide/glycopyrrolate/formoterol fumarate \nmetered- dose inhaler 320/18/9.6 \u03bcg (BGF MDI) \n(n=640)  \n- glycopyrrolate/ formoterol fumarate metered-\ndose inhaler 18/9.6 \u03bcg (GFF MDI) (n =627)  \n- budesonide/formoterol fumarate metered- dose \ninhaler 320/9.6 \u03bcg (BFF MDI) (n=316)  \n- open- label budesonide/formoterol fumarate \ndry-powder inhaler 400/12 \u03bcg (BUD/ FORM DPI) \n(n=319)  \n \n>> before screening: discontinued prohibited \nmedication  \n>> all patien ts  received  ipratropium  bromide  \u2022 Baseline- Patientencharakteristika:  hinsichtlich Ge-\nschlecht weitestgehend ausgeglichen \n>> leichte Differenzen in der Verteilung der Ethnizit\u00e4ten, \nstattgehabter Exazerbationen im letzten Jahr; median Eo-\nsinophilenzahl und der Geschlechter auf die Gruppen (GFF \nMDI-Gruppe vs. alle anderen Gruppen)  \n \n\u2022 Ergebnisse prim\u00e4rer Endpunkt  \nOver 24 weeks, BGF MDI significantly improved FEV1 \nAUC0 -4 versus BFF MDI (least squares mean difference \n104 mL, 95% CI 77 to 131; p<0.0001) and BUD/FORM DPI \n(91 mL, 64 to 117; p<0.0001). BGF MDI also significantly \nimprov ed pre- dose trough FEV1 versus GFF MDI (22 mL, 4 \nto 39; p=0.0139) and was non- inferior to BUD/FORM DPI ( -\n10 mL, - 36 to 16; p=0.4390). At week 24, patients in the \nBGF MDI group had a significantly improved FEV1 AUC0- 4 \ncompared with patients receiving BFF MD I (116 mL, 95% CI \n80 to 152; p<0.0001); there was a non- significant improve-\nment in the change from baseline in morning pre- dose \ntrough FEV1 at week 24 versus GFF MDI (13 mL, -9 to 36 Selection bias  \nRandomisierung: low \nAllocation concealment: unclear  \n \nPerformance bias \nVerblindung von Teilnehmern und \nPersonal: low \n \nDetection bias  \nVerblindung der Ergebnisevaluation: \nunclear  \n \nAttrition bias  \nVerlust von Studienteilnehmern/ feh-\nlende Daten: unclear  \n \nITT-Analyse:modifizierte ITT  \n \nReporting bias  Aussagekraft der pri-\nm\u00e4ren Endpunkte? \nKlinischer Nutzen?  \n \nVerschiedene prim\u00e4re \nund sekund\u00e4re End-\npunkte je nach Land \ngew\u00e4hlt  \n \nBaseline inbalance? \nErgebnisse des Ver-\ngleichs BGF MDI vs. \nGFF MDI aus klini-\nscher Sicht dennoch \nvertrauensw\u00fcrdig?  \n \nAppendix nicht zur \nVerf\u00fcgung \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  256 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n(34 \u00b5g ex -actuator) 4x/d  for  maintenance  of  \nCOPD,  and  were permitted to continue using \nICS during  screening  \n>> Ipratropium   and   ICS  were   stopped be-\nfore  randomisation.  \n \n\u2022 Einschlusskriterien:  \n- 40-80 years of age, current or former smokers \n(with smoking history of >/=10 pack -years), had \nan established clinical history of COPD (mild to \nvery severe: defined post -BD FEV1 less than \n80% and 25% or more), and were symptomatic \nfor COPD , despite receiving two or more inhaled \nmaintenance therapies for at least 6 weeks be-\nfore screening.  \n-  without a requirement for a history of exacer-\nbations in the preceding year  \n\u2022 Ausschlusskriterien:  \n- Asthma or any other respiratory disease or \ncondition other than COPD  \n- acute worsening of COPD that required treat-\nment with OCS or antibiotics less than 6 weeks \nbefore screening, with less than a 4- week wash-\nout of corticosteroids or antibiotics before visit 1, \nor during screening \n- hospitalised because of COPD within 3 month \nbefore or during screening  \n- requiring a spacer devider  \n- unable to perform acceptable spirometry  \n- change in smoking status within 6 weeks be-\nfore or during screening  \n- need for a long- term oxygen therapy \n(<15h/day)  \n \n\u2022 prim\u00e4rer Endpunkt  \n- FEV1 AUC 0 -4 h (for BFG MDI v s. BFF MDI \nand BFG MDI vs. BUD/FORM DPI over 24 \nweeks)  \n- and change from baseline in morning pre- dose \ntrough FEV1 for BGF MDI versus GFF MDI and \nnon-inferiority of BFF MDI versus BUD/FORM \nDPI (margin of -50 mL from lower bound of 95% mL; p=0.2375).  \n \n\u2022 sekund\u00e4rer Endpunkt: Exazerbation  \nThe model -estimated rates of moderate or severe exacerba-\ntions were  \n- 0,46 per year for BGF MDI  \n- 0,95 per year for GFF MDI, rate ratio 0,48 (95%CI 0,37 to \n0,64), n=625  \n- 0,56 per year for BFF MDI, rate ratio 0,82 (95%CI 0,58 to \n1,17), n=314, and  \n- 0,55 per year for BUD/FORM  DPI, rate ratio 0,83 (95%CI \n0,59 to 1,18), n=318  \n \nThe rate of moderate or severe exacerbations was signifi-\ncantly lower during treatment with BGF MDI versus GFF \nMDI \nBGF MDI  reduced the rate of moderate or severe exacerba-\ntions compared with BFF MDI and BU D/FORM DPI, but \nthese reductions were not significant   \n \n\u2022 Subgruppe: Eosinophile  \nThe rates of moderate or severe exacerbations with BGF \nMDI were lower than with GFF MDI for patients in both eo-\nsinophil  subgroups (<150 cells/mm3 and \u2265150 cells/mm3), \nwith l ocally weighted scatter -plot smoothing showing that \ntreatment differences increased with baseline  blood  eosin-\nophil concentrations; beginning at approximately 75- 100 \ncells/mm3, a level exceeded by more than 75% of patients. \nNo apparent differences were seen between BGF MDI and \nGFF MDI below these concentration thresholds. Differences \nbetween BGF MDI and BFF MDI in the rate of moderate or \nsevere exacerbations were similar across most eosinophil \ncounts  \n \n\u2022 Sicherheit  \nmost common treatment -emergent adverse ev ents were  \n- nasopharyngitis (n=49 [8%] in the BGF MDI group; n=41 \n[7%] in the GFF MDI group; n=26 [8%] in the BFF MDI \ngroup; and n=30 [9%] in the BUD/FORM DPI group) and  \n- upper respiratory tract infection (n=65 [10%]; n=38 [6%]; \nn=18 [6%]; and n=22 [7%] ). \n- Pneumonia incidence was low (<2%) and similar across selektive Ergebnisdarstellung: un-\nclear   \nAndere Biasursachen  \nBaseline imbalance: unclear  \n \nInteressenkonflikte/ Sponsoring: \nPearl (AstraZeneca Group)  \nThe funder of the study had a role in \nstudy design, data collection, data \nanalysis, data  interpretation, and \nwriting of the report. The corre-\nsponding  author had full access to \nall the  data in the study and had fi-\nnal responsibility for the decision to \nsubmit for publication.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  257 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nCI) over 24 weeks  \n\u2022 sekund\u00e4re Endpunkte ( Auswahl f\u00fcr Europa \nund Kanada)  \n- change from  baseline in  morning  pre- dose  \ntrough  FEV,   (BGF  MDI  vs  BFF MDI), peak \nchange from baseline in FEV, within 4 h after \ndosing, rate of  moderate or severe COPD exac-\nerbations, TDI  focal  score  (Europe  statistical  \nanalysis  approach  only), change  from  base-\nline  in  daily  rescue  medication use,  change  \nfrom  baseline  in  SGRQ   total  score,  E -RS: \nCOPD total score (RS -Total score), and time to \nclinically important     deteriora tion    (BGF   MDI    \nvs   GFF    MDI, vs BFF MDI, and vs \nBUD/FORM  DPI), all over  24weeks  \n \n\u2022 Canada, China, Japan, and the USA  \n\u2022 SGRQ f\u00fcr QoL -Erhebung verwendet  \n treatments  \n- two treatment -related deaths, both in the GFF MDI group.  \n \n \n \n \nLipson DA. Once -Daily \nSingle- Inhaler Triple ver-\nsus Dual Therapy in Pa-\ntients with COPD. N \nEngl J Med 2018; \n378(18):1671\u2013 80. \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/29668352 . \n \n IMPACT  \n\u2022 Studientyp: randomized, double- blind, paral-\nlel-group, Phase III, multicenter trial  \n\u2022 Population:  n=10.335  \n\u2022 Studienzeitraum:  June 2014 through July \n2017 \n \n\u2022 Intervention: 52 weeks of a once- daily combi-\nnation of  \n- fluticasone furoate 100 \u03bcg, \n- umeclidinium 62.5 \u03bcg, \n- vilanterol 25 \u03bcg (triple therapy)  \nvs. \n- fluticasone furoate\u2013  vilanterol (100 \u03bcg and 25 \n\u03bcg)  \nor \n- umeclidinium \u2013vilanterol (62.5 \u03bcg and 25 \u03bcg) \n \n>> Each regimen was administered in a single \nEllipta inhaler  \n>> 2-week run- in period before randomization: \ncontin ued to take their own medication, which \u2022 Baseline -Patientencharakteristika:  hinsichtlich Ges-\nchlecht, Alter, ehemaliger Raucherstatus; stattgehabte \nExzerbationen unterschiedlicher Schwere und Anzahl im \nletzten Jahr weitestgehend ausgeglichen; in Umeclidini um-\nVilanterol -Gruppe halb so viele Teilnehmer (n=2070), wie in \nden anderen beiden Gruppen \n \n\u2022 Ergebnisse prim\u00e4rer Endpunkt:  \n- rate of moderate or severe exacerbations  in the triple -ther-\napy group was 0.91 per year, as compared with 1.07 per \nyear in the flut icasone furoate\u2013 vilanterol group (rate ratio \nwith triple therapy, 0.85; 95% CI, 0.80 to 0.90; 15% differ-\nence; P<0.001) and 1.21 per year in the umeclidinium \u2013vilan-\nterol group (rate ratio with triple therapy, 0.75; 95% CI, 0.70 \nto 0.81; 25% difference; P<0.001)  \n- annual rate of severe exacerbations resulting in hospitali-\nzation  in the triple- therapy group was 0.13, as compared \nwith 0.19 in the umeclidinium \u2013vilanterol group (rate ratio, \n0.66; 95% CI, 0.56 to 0.78; 34% difference; P<0.001).  \n \n\u2022 weitere ausgew\u00e4hlt e Ergebnisse: Eosinophile  (nicht in \nhierarchisches statistisches Modell aufgenommen)  Selection bias  \nRandomisierung: unclear  \n \nAllocation concealment: unclear  \n \nPerformance bias \nVerblindung von Teilnehmern und \nPersonal: unclear  \n \nDetection bias  \nVerblindung der Ergebnisevaluation:  \nunclear  \n \nAttrition bias  \nVerlust von Studienteilnehmern/ feh-\nlende Daten: low \n \nITT-Analyse: durchgef\u00fchrt  \n \nReporting bias  \nselektive Ergebnisdarstellung: Un-\nclear  Drop out -Rate 18; 25; \n27% \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  258 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \ncould include a LAMA, a LABA, or an inhaled \nglucocorticoid alone or in combination  \n \n\u2022 Follow -up Zwischen -Assessment:  \n- Electrocardiographic (ECG) measurements and \nvital signs were assessed at screening and after \n4, 28, and 52 weeks of treatment.  \n- Clinical (chemical and hematologic) assess-\nments were performed at screening and at 16, \n28, and 52 weeks.  \n \n\u2022 Einschlusskriterien  \n- > 40 years of age; symptomatic COPD (CAT \nscore \u226510; range 0 - 40) and  \n- either: FEV1 predict ed <50% + history of at \nleast one moderate or severe exacerbation in \nthe previous year  \n- or: FEV1 of 50 to 80% of the predicted normal \nvalue and at least two moderate exacerbations \nor one severe exacerbation in the previous year  \n \n\u2022 prim\u00e4rer Endpunkt:  \n- the annual rate of moderate or severe COPD \nexacerbations during treatment  \n\u2022 sekund\u00e4re Endpunkte:  hierarchisch \n1) FEV1 + change in SGRQ  \n2) time to the first moderate or severe COPD ex-\nacerbation during treatment  \n>> Prespecified protocol -defined secondary out-\ncomes that were not in the hierarchy included \nthe annual rate of moderate or severe exacerba-\ntions and the time to the first moderate or severe \nexacerbation among patients with a blood eosin-\nophil count of at least 150 cells per microliter at \nbaseline, and the annual rate of severe exacer-\nbations.  \n \n \n - annual rate of moderate or severe exacerbations was \nlower with triple therapy than with either dual -therapy combi-\nnation, regardless of eosinophil level, although a great er re-\nduction in the exacerbation rate was observed in patients \nwith eosinophil levels of at least 150 cells per microliter  \n- patients with eosinophil levels < 150 cells/ \u03bcl, the annual \nrate of moderate or severe exacerbations was 0.85 (95% CI, \n0.80 to 0.91) with triple therapy, 1.06 (95% CI, 0.99 to 1.14) \nwith fluticasone furoate\u2013  vilanterol, and 0.97 (95% CI, 0.88 \nto 1.07) with umeclidinium \u2013vilanterol  \n- patients with eosinophil levels of \u2265 150 cells/ \u03bcl, the annual \nrate was 0.95 (95% CI, 0.90 to 1.01) with triple therapy, 1.08 \n(95% CI, 1.02 to 1.14) with fluticasone furoate\u2013 vilanterol, \nand 1.39 (95% CI, 1.29 to 1.51) with umeclidinium \u2013 vilan-\nterol.  \n \n\u2022 Sicherheit: (ausf\u00fchrlich i m Appendix)  \n- There was a higher incidence of pneumonia in the inhaled-\nglucocorticoid groups than in the umeclidinium \u2013vilanterol \ngroup, and the risk of clinician- diagnosed pneumonia was \nsignificantly higher with triple therapy than with umec-\nlidinium \u2013vilant erol, as assessed in a time- to-first event anal-\nysis (hazard ratio, 1.53; 95% CI, 1.22 to 1.92; P<0.001).  \n- The incidence of adverse events during treatment that led \nto discontinuation of trial treatment or withdrawal from the \ntrial was 6% for triple therapy, 8% for fluticasone furoate\u2013  vi-\nlanterol, and 9% for umeclidinium \u2013vilanterol; the incidence \nof discontinuation or withdrawal due to an adverse event of \nCOPD was 2%, 2%, and 3%, respectively. Serious adverse \nevents during treatment occurred in 895 patients  (22%) re-\nceiving triple therapy, 850 (21%) receiving fluticasone fu-\nroate\u2013 vilanterol, and 470 (23%) receiving umeclidinium \u2013vi-\nlanterol.  \n- A serious adverse event of pneumonia occurred in 184 pa-\ntients (4%), 152 patients (4%), and 54 patients (3%), re-\nspectivel y. \n \n\u2022 Mortalit\u00e4t: \nDeath during treatment occurred in 50 patients (1%) in the \ntriple -therapy group, 49 patients (1%) in the fluticasone fu-\nroate \u2013vilanterol group, and 39 patients (2%) in the umec- \nAndere Biasursachen  \nBaseline imbalance:  low \n \nInteressenkonflikte/ Sponsoring: \nFunded by GlaxoSmithKline; the \nlead author is an  \nemployee of the sponsor.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  259 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nlidinium \u2013vilanterol group. All -cause mortality was signifi-\ncantl y lower with the regimens that included the inhaled glu-\ncocorticoid fluticasone furoate (triple therapy and fluticasone \nfuroate\u2013 vilanterol) than with umeclidinium \u2013vilanterol. The \nhazard ratio for triple therapy versus umeclidinium \u2013vilanterol \nwas 0.58 (95% C I, 0.38 to 0.88; 42% difference; unadjusted \nP = 0.01), and the hazard ratio for fluticasone furoate\u2013 vilan-\nterol versus umeclidinium \u2013 vilanterol was 0.61 (95% CI, 0.40 \nto 0.93; 39% difference; unadjusted P = 0.02).  \n \nLipson DA. FULFIL \nTrial: Once -Daily Triple \nTherapy for Patients \nwith Chronic Obstructive \nPulmonary Disease. Am \nJ Respir Crit Care Med \n2017; 196(4):438\u2013 46. \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/28375647 . \n \n FULFIL  \n\u2022 Studientyp:  Phase 3, randomized, double-\nblind, double- dummy, parallel group multicenter  \nstudy  \n\u2022 Population:  n=1810  \n\u2022 Studienzeitraum:  01/2015 - 04/2016; 24 \nweeks trial; patient subgroup remained on \nblinded treatment for up to 52 weeks  \n \n\u2022 Intervention:  \n- continue maintenance medications unchanged \nduring the 2- week run- in period; randomised \n(1:1) \n \n-- once- daily triple therapy (fluticasone fu-\nroate/umeclidinium/vilanterol 100 \u03bcg/ 62.5 \u03bcg/ 25 \n\u03bcg) \nvs. \n-- twice -daily ICS/LABA therapy (budesonide/for-\nmoterol 400 \u03bcg/ 12 \u03bcg) \n \n\u2022 Einschlusskriterien :  \n- aged 40 years or older who were defined as \nbeing in GOLD group D:  \n(1) FEV1 less than 50% and COPD  Assessment \nTest score greater than or equal to 10, or  \n(2) patients with FEV1 less than or equal to 50% \nto less than 80% and COPD Assessment Test \nscore greater than or equal to 10, and either at \nleast two moderate exacerbations or at least one \nsevere exac erbation in the past year.  \u2022 Baseline -Patientencharakteristika: hinsichtliche Alter, Ges-\nchlecht; Rauchstatus; Lungenfunktion; Exazerbationshistorie \nweitestgehend ausgeglichen  \n \n\u2022 In the intent -to-treat population (n = 1,810) at Week 24:  \n\u2022 mean changes from baseline in SGRQ scores  \n- for triple t herapy (n = 911): 26.6 units (95% CI, 27.4 to \n25.7)  \n- ICS/LABA therapy (n = 899): 24.3 units (95% CI, 25.2 to \n23.4)  \n>> between- group differences in improvement in SGRQ to-\ntal score was statistically significant for FF/UMEC/VI (22.2 \nunits; 95% CI, 23.5 to 21.0; P<0,001)  \n \nmoderate/severe exacerbation rate \n- The mean annualized rates of moderate/severe exacerba-\ntions were 0.22 and 0.34 for FF/UMEC/VI and BUD/FOR, \nrespectively, and the reduction in the annualized rate was \nstatistically significant (35%; 95% CI, 1 4\u201351%; P = 0.002) \nbased on data up to 24 weeks in the ITT  \n- The incidence rates of moderate/severe COPD exacerba-\ntions over the 24- week treatment period were 10% (n = 95) \nfor FF/UMEC/VI and 14% (n = 126)  and BUD/FOR  \n \n\u2022 Sicherheit: The safety profile of tri ple therapy reflected the \nknown profiles of the components.  \n>> (SAes und AEs im Supplement dargestellt)  \n- The incidence rates of on- treatment AEs in the ITT popula-\ntion up to Week 24 were 38.9% in the FF/UMEC/VI group \nand 37.7% in the BUD/FOR group.  Selection bias  \nRandomisierung: low \nAllocation concealment: unclear  \n \nPerformance bias \nVerblindung von Teilnehmern und \nPersonal:  low \n \nDetection bias  \nVerblindung der Ergebnisevaluation: \nunclear  \n \nAttrition bias  \nVerlust von Studienteilnehmern/ feh-\nlende Daten: unclear  \n \nITT-Analyse: durchgef\u00fchrt  \n \nReporting bias  \nselektive Ergebnisdarstellung:  un-\nclear  \n \nAndere Biasursachen  \nBaseline imbalance: low  \n \nInteressenkonflikte/ Sponsoring: Gla-\nxoSmithKline  \n Supplement abrufbar: \nhttps://www.atsjour-\nnals.org/doi/suppl/10.1\n164/rccm.201703-\n0449OC/suppl_file/lip-\nson_data_supple-\nment.pdf  \n \nProtokoll vorhanden \nhttps ://s3.amazo-\nnaws.com/ctr -gsk-\n7381/116853/6290c5e\n2-7f0d- 4536- 84b9-\nc08ce4adf390/f90aca\n32-1e4c -47ff-8f93-\n3a48b17b7bd9/gsk -\n116853- protocol -re-\ndact-v1.pdf  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  260 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n- Subject must be receiving daily maintenance \ntreatment for their COPD for at least 3 months \nprior to Screening  \n \n\u2022 Ausschlusskriterien (Auswahl):  \n- current diagnosis of asthma causing their \nsymptoms or if they had unresolved pneumonia \nor severe COPD exacerbation  \n \n\u2022 prim\u00e4re Co -Endpunkte:  \n- change from baseline in trough FEV1  \n- change in St. George\u2019s Respiratory Question-\nnaire (SGRQ) total score at Week 24 \n \n\u2022 sekund\u00e4re Endpunkte (Auswahl)  \n- TDI, SAEs, AEs  \n \n\u2022 multicenter  - For F F/UMEC/VI and BUD/FOR, respectively, the inci-\ndence rates of ontreatment SAEs in the ITT population up to \nWeek 24 were 5.4% and 5.7%, and the most common on-\ntreatment SAEs were COPD exacerbation (1.3% and 2.3%) \nand pneumonia (1.0% and 0.3%).  \n \n\u2022 Mortalit\u00e4t: \nThere were 12 on- treatment deaths in this study (6 in each \ntreatment group), which was in line with expectations for pa-\ntients with advanced COPD and multiple comorbidities  \n \nSingh D. Single inhaler \ntriple therapy versus in-\nhaled corticosteroid plus \nlong- acting beta2- ago-\nnist therapy for chronic \nobstructive pulmonary \ndisease (TRILOGY): A \ndouble- blind, parallel \ngroup, randomised con-\ntrolled trial. Lancet 2016; \n388(10048):963\u2013 73. \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/27598678 . \n \n TRILOGY  \n\u2022 Studientyp:  randomised, parallel group, dou-\nble-blind, active- controlled study  \n\u2022 Population:  n= 1368 (BDP/FF/GB n=687; \nBDP/FF n=681)  \n\u2022 Studienzeitraum: 03/2014 - 01/2016; 52 week \ntrial \n \n\u2022 Intervention  \n-  2-week open- label run- in period: beclometa-\nsone dipropionate (100 \u03bcg) and formoterol \nfumarate (6 \u03bcg) in two actuations twice daily  \n- then randomly assigned (1:1) to  \n-- continue BDP (100 \u03bcg) and FF (6 \u03bc g) or  \n-- step- up to BDP (100 \u03bcg), FF (6 \u03bcg), and GB \n(glycopyrronium bromide) (12,5 \u03bcg) in two actua-\ntions twice daily via pressurised metered- dose \ninhaler  \n \n\u2022 Follow -up (gesamt und Zwischen -Assess-\nments)  \u2022 Baseline -Patientencharakteristika: hinsichtlich Alter, Ges-\nchlecht, Gewicht, Rauchstatus, Blut -Eosinophilen, Dauer der \nErkrankung, CAT -Score, Exazerbationsrate im letzten Jahr, \nBegleiterkrankungen weitestgehend ausgeglichen \n \n- Statistik: hierachical order --> (1) pre -dose FEV 1 ; (2) 2- h \npost-dose FEV ; (3) TDI focal score \n- No association between blood eosinophil concentration \nand treatment e \ufb00ect was observed  \n \n\u2022 prim\u00e4rer Endpunkt: TDI  \n- Mean TDI focal scores at week 26 were 1,71 for \nBDP/FF/GB and 1,50 for B DP/FF, with a di \ufb00erence of 0,21 \n(95% CI \u2013 0,08 to 0,51; p=0,160); not statistically significant  \n- Increases in TDI focal score were observed in both groups \nat all visits, with a statistically signi \ufb01cant difference between \ntreatments favouring BDP/FF/GB at t he two earliest visits \n(weeks 4 and 12). More than 50% of patients in each group \nreported clinically relevant improvements (\u22651 unit) in TDI fo-\ncal score at weeks 26 and 52; at week 26, patients were \nsigni\ufb01cantly more likely to respond to BDP/FF/GB than \nBDP/ FF; jedoch nicht nach 52 Wochen (s.u.)  Selection bias  \nRandomisierung:  low \nAllocation concealment: low  \n \nPerformance bias \nVerblindung von Teilnehmern und \nPersonal:  low \n \nDetection bias  \nVerblindung der Ergebni sevaluation:  \nlow \n \nAttrition bias  \nVerlust von Studienteilnehmern/ feh-\nlende Daten: unclear  \n \nITT-Analyse: durchgef\u00fchrt  \n \nReporting bias  \nselektive Ergebnisdarstellung: low  \n \nAndere Biasursachen  Protokolldaten (Zu-\nsammenfassungen) \nlediglich \u00fcber clini-\ncaltrialsregister und \nclinicaltrials.gov --> \nkein extra Protokoll \naufgefunden \n--> Methodische Be-\nwertung teilweise mit \nHilfe dieser Online- In-\nhalte bewertet)  \n \nAppendix nicht zur \nVerf\u00fcgung \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  261 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n\u2022 ggf. Informationen zu Aufhebung der Ver-\nblindung und Cross -over \n \n\u2022 Einschlusskriterien:  \n- patients with C OPD had post -bronchodilator \nFEV1 < 50%, one or more moderate- to-severe \nCOPD exacerbation in the previous 12 months, \nCOPD Assessment Test total score of 10 or \nmore, and a Baseline Dyspnea Index focal score \nof 10 or less  \n- used ICS/LABA, ICS/LAMA; LAMA/LABA or \nLAMA mono for at least 2 month before screen-\ning \n\u2022 Ausschlusskriterien  \n- patients received LAMA/LABA/ICS  \n- diagnosis of asthma, or history of allergic rhini-\ntis or atopy; a COPD exacerbation in the 4 \nweeks before screening or during the run- in pe-\nriod; cli nically signi \ufb01cant cardiovascular condi-\ntions or laboratory abnormalities; or unstable \nconcurrent disease  \n\u2022 prim\u00e4re Co -Endpunkte:  \n-  pre-dose FEV1,  \n- 2-h post -dose FEV,  \n- Transition Dyspnea Index (TDI) focal score af-\nter 26 weeks  \n\u2022 sekund\u00e4re Endpunkte (Ausw ahl) \n- moderate- to-severe COPD exacerbation rate  \n- SGRQ  \n \n\u2022 multicenter: 159 sites (mixture of primary, sec-\nondary, and tertiary care providers, and special-\nist investigation units) across 14 countries  \n \n  \nWeek 26 BDP/FF/GB: n=394/687 (57%)  \nWeek 26 BDP/FF: n=352/680 (52%) --> OR 1,28 (95% CI \n1,03\u2013 1,59);  p=0,027  \nWeek 52 BDP/FF/GB: n=370/687 (54%)  \nWeek 52 BDP/FF: n=354/680 (52%) --> OR 1,09 (95% CI \n0,88\u2013 1,36); p=0,430 \n \n\u2022 sekund\u00e4rer Endpunkt: Exazerbationen  \nAdjusted annual moderate- to-severe exacerbation frequen-\ncies were 0,41 for BDP/FF/GB and 0,53 for BDP/FF (rate ra-\ntio 0,77 [95% CI 0,65\u2013 0,92]; p=0,005), corresponding to a \n23% reduction in exacerbations with BDP/FF/GB compared \nwith BDP/FF -->indicating a signi \ufb01cant 23% reduction in the \nrate with BDP/FF/GB  \n\u2022 Subgruppe Exazerbationshistorie:  \nhistory of more than one exacerbation  \n- signi\ufb01cant 33% reduction in the rate of moderate- to-severe \nexacerbations with BDP/FF/GB compared with BDP/FF  \n(rate ratio 0,67 [95% CI 0,48\u2013 0,94]; p=0,019)  \n- adjusted exacerbation frequency: 0,65 and 0,97 in the \nBDP/FF/GB and BDP/FF group  \nhistory of one exacerbation \n- treatment reduction appeared to be slightly lower (0,83 \n[0,67\u2013 1,02]; p=0,074)  \n- adjusted exacerbation frequency in patients was 0,37 and \n0,44 in the BDP/FF/GB and BDP/FF groups  \n \nThe frequency of both moderate and severe exacerbations \nwas lower in the BDP/FF/GB group than the BDP/FF group. \nFurthermore, BDP/FF/GB signi \ufb01 cantly prolonged the time to \n\ufb01 rst moderate- to-severe exacerbation compared with \nBDP/FF (hazard ratio 0,80 [95% CI 0,67\u2013 0,97]; p=0,020)  \n \n\u2022 sekund\u00e4rer Endpunkt: SGRQ:  \nWeek 26 BDP/FF/GB: n=321/687 (47%)  \nWeek 26 BDP/FF: n= 246/680 (36%) --> OR 1,52 (95% CI \n1,21\u20131,91); p<0\u00b7001  \nWeek 52 BDP/FF/GB: n=297/687 (43%)  \nWeek 52 BDP/FF: n= 244/680 (36%) -->  OR 1,33 (95% CI \n1,06\u2013 1,66); p=0\u00b7014  \n Baseline imbalance:  low \n \nInteressenkonflikte/ Sponsoring: \nChiesi F armaceutici SpA: The funder \nof the study was responsible for the \ndesign and analysis of the study, \noversaw its conduct, and was re-\nsponsible for the study report prepa-\nration.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  262 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n\u2022 Sicherheit  \nAdverse events were reported by 368 (54%) patients with \nBDP/FF/GB and 379 (56%) with BDP/FF. One serious treat-\nment -related adverse event occurred (atrial \ufb01brillation) in a \npatient in the BDP/FF/GB group.  \n \nAnhang 8.3  Kardiale Nebenwirkungen LABA oder LAMA  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nJara M. A new user \ncohort study com-\nparing the safety of \nlong- acting inhaled \nbronchodilators in \nCOPD. BMJ Open \n2012; 2(3).  \n \nhttps://www.ncbi.nlm\n.nih.gov/pub-\nmed/22619266 . \n \n\u2022 nicht zitiert  \u2022 UK \n\u2022 Studiendesign:  retrospektive \nKohortenstudie (Registerdaten; \nUK healthcare system general \npractitioner electronic medical rec-\nord database)  \n \n\u2022 Fragestellung: To investigate a \npossible increased risks of stroke \nand other adverse events, includ-\ning angina and my ocardial infarc-\ntion, with tiotropium use in chronic \nobstructive pulmonary disease \n \n\u2022 Population:  \n- Patient*innen mit COPD oder \nCOPD/Asthma  \n- n=10 840 patients  \n \n\u2022 Vergleich  \n- New users of LAMA therapy (tio-\ntropium HandiHaler powder formu-\nlation) were compar ed with new \nusers of LABA monotherapy (Sal-\nmeterol oder Formoterol)  \n \nEinschlusskriterien:   \n- at least 40 years old, and not \u2022 Baseline -Patientencharakteristika  \n- hinsichtli ch Alter, Geschlecht, Gewicht weitestgehend ausgeglichen  \n- diagnosis of COPD and asthma: 38% of tiotropium patients and 55% \nof LABA patients  \n- diagnosis of COPD only: 51% of tiotropium patients and 32% of \nLABA patients  \n- More LABA patients than tiotropium patients had an asthma codiag-\nnosis (42% vs 63%)  \n \n- newly prescribed tiotropium (n=4767) or  \n- single- ingredient LABA (n=6073); 95% salmeterol  \n- Mean duration of exposure was 212 days for tiotropium patients and \n139 days for LABA patients  \n \nErgebnisse:  \n\u2022 Tiotropium was associated with increased rates of  \n- stroke (HR=1.49, 95% CI 0.91 to 2.45)  \n- angina (HR=1.38, 95% CI 0.88 to 2.16)  \n- myocardial infarction (HR=1.26, 95% CI 0.72 to 2.21)  \n \n\u2022 There were similar rates between treatment groups of  \n- aneurysm (HR=0.96, 95% CI 0.44 to 2.05)  \n- atrial fibrillation or flutter (HR=0.99, 95% CI 0.71 to 1.38)  \n- coronary artery disease (HR=1.11, 95% CI 0.84 to 1.47)  \n- hypertension (HR=1.03, 95% CI 0.81 to 1.29)  \n- syncope (HR=0.94, 95% CI 0.57 to 1.55)  \n- tachycardia (HR=1.08, 95% CI 0.48 to 2.41)  \n \n\u2022 There was a decrease in the tiotropium group in the rate of  (In Anlehnung an NOS)  \nI. Selektion der Studienteilnehmer  \n1. exponierte Kohorte repr\u00e4senta-\ntiv f\u00fcr die zu untersuchende Inter-\nvention/Exposition: ja  \n2. nicht -exponierte Kohorte repr\u00e4-\nsentativ, ad\u00e4quat ausgew\u00e4hlt: ja  \n3. valide Erfassung der Exposition: \nja (Registerdaten)  \n4. wahrscheinlich, dass der ge-\nmessene Endpunkt nicht zu Stu-\ndienbeginn vorhanden w ar: \nunklar  \nII. Vergleichbarkeit  \n1.Vergleichbarkeit der exponierten \nund nicht -exponierten Kohorte ge-\ngeben: ja  \nIII. Endpunkterfassung  \n1. valide Erfassung der End-\npunkte: ja  \n2. Konnte in der Beobachtungszeit \nder Endpunkt auftreten: ja  \n3. fehlende Daten ad\u00e4quat  ber\u00fcck-\nsichtigt: k.A.  \nIV. CoI/ Funding  \nFunding: Boehringer Ingelheim \nPharmaceuticals.  \nTwo of the authors were employ-\nees of Boehringer Ingelheim.  Patienten mit e rstmaliger Nut-\nzung von LABA oder LAMA  \n \nEinige nutzten jedoch bereits \nvorab:  \n- LAMAs  \n- LABAs  \n- ICS \n- OCS  \n- Theophyllines  \n-Cromoglycates  \n \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  263 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nhaving asthma as their only respir-\natory illness.  \n- Patients had to have at least one \nprescription for tiotropium or LABA  \nfrom Novem ber 2002 (the earliest \nuse of tiotropium) until January \n2007.  \n \n\u2022 Studienzeitraum:  from 11/ 2002 \nuntil 01/ 2007  \n \n\u2022 Statistik: propensity scores were \nused to control confounding  \n \n\u2022 Endpunkte:  \n- included various cardiovascular  \nadverse events (aneurysm, atrial \nfibrillation, cardiac arrest, coronary \nartery disease, angina, MI, heart \nfailure, hypertension, stroke, syn-\ncope, tachycardia and ventricular \ntachycardia)  \n- respiratory events and other AEs  - heart failure (HR=0.85, 95% CI 0.63 to 1.14)   \n- allcause mortality (HR=0.70, 95% CI 0.56 to 0.89)   \n \n\u2022 receiving long- acting bronchodilator  therapy for at least 6 month s, \neffect estimates increased for  \n- stroke (HR=1.63, 95% CI 0.83 to 3.17)  \n- angina (HR=1.42, 95% CI 0.78 to 2.59)  \n- MI (HR=1.65, 95% CI 0.63 to 4.27)  \n\u2022 The difference between groups in rates of total mortality diminished \n(HR=0.90, 95% CI 0.58 to 1.38).  \n\u2022 Associations for other cardiovascular events were weaker, including  \n- aneurysm (HR=0.82, 95% CI 0.27 to 2.45)  \n- atrial fibrillation/ flutter (HR=1.17, 95% CI 0.70 to 1.94)  \n- heart failure (HR=0.77, 95% CI 0.47 to 1.24)  \n- hypertension (HR=1.07, 95% CI 0.79 to 1.45)  \n- syncope (HR=0.79, 95% CI 0.36 to 1.70) and  \n- tachycardia (HR=0.98, 95% CI 0.32 to 3.04).  \n \nWith regard to concomitant asthma diagnosis, the association with an-\ngina was stronger in patients with asthma and COPD (HR=1.91, 95% \nCI 1.00 to 3.63) than patients with only COPD (HR=0.93, 95% CI 0.49 \nto 1.77), while the association with MI was stronger in patients who \nhad only COPD (HR=1.94, 95% CI 0.77 to 4.94).  Data sets for this study are the \nproperty of Boehringer Ingelheim \nand not currently available.  \nVogelmeier C. Effect \nof tiotropium vs. \nsalmetero l on exac-\nerbations: GOLD II \nand maintenance \ntherapy na\u00efve pa-\ntients. Respir Med \n2013; 107(1):75\u2013 83. \nhttps://www.ncbi.nlm\n.nih.gov/pub-\nmed/23102611.  \n \n\u2022 nicht zitiert  \u2022 Deutschland, Italien  \n\u2022 Fragestellung:  To explore the \nrelative effects of therapy with tio-\ntropium or salmeterol on exacer-\nbation outcomes further, we con-\nducted prespecified subgroup \nanalyses  of the POET -COPD \nstudy cohort in patients with mod-\nerate (GOLD stage II) disease, \nand those who were maintenance \nnaive.  \n \n\u2022 Studiendesign:  Subgrup-\npenanalyse eines randomized, \ndouble blind, doubledummy, 1-\nyear trial  \n \n\u2022 Population:  Patient*innen mit siehe Tabelle 2: Incidence for Cardiac disorders (nicht n\u00e4her beschrie-\nben)  \n>> Subgruppe: Maintenance therapy naive patients:  \nTiotropium (n=672): 1,8%  \nSalmeterol (n=671): 1,5%  \n \n Selection bias  \nRandomisierung: gering  \n \nAllocation concealment: gering  \n \nPerformance bias  \nVerblindung von Teilnehmern und \nPersonal: ja  \n  \nDetection bias  \nVerblindung der Ergebnisevalua-\ntion: unklar  \nAttrition bias  \nVerlust von Studienteilnehmern/ \nfehlende Daten: hoch  \nITT-Analys e: nein  \nReporting bias  Patients were considered \n\u201cmaintenance naive\u201d if they were \nexclusively using short -acting b2-\nagonists, or none o f the following \nmaintenance medications at \nbaseline: ICS, systemic cortico-\nsteroids, xanthines, anticholiner-\ngics (shortor long- acting), and \nLABAs.  \n \nF\u00fcr die methodische Bewertung \nwurden die Referenzen  \n9 Vogelmeier C, Hederer B, \nGlaab T, et al. Tiotropiu  versus \nsalmeterol for the prevention of \nexacerbations of COPD. N Engl \nJ Med 2011;364:1093e103.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  264 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nCOPD  \n\u2022 Interventionen:  tiotropium 18 \u00b5g \nonce daily (via HandiHaler ) plus \nplacebo twice daily (via HFA -\npMDI),  \nor salmeterol 50  \u00b5g twice daily \n(via HFA -pMDI) plus pla cebo once \ndaily (via HandiHaler).  \n \n\u2022 relevante Einschlusskriterien  \n- history of at least 1 COPD exac-\nerbation within the past year re-\nquiring treatment with antibiotics \nand/or systemic steroids and/or re-\nquiring hospitalization  \n \n\u2022 Endpunkt sekund\u00e4r:  serious \nadverse events  \n \n\u2022 Studienzeitraum:  01/2008  \n \n \n \n selektive Ergebnisdarstellung: ge-\nring \nBaseline imbalance: gering \nInteressenkonflikte/ Sponsoring:  \nBoehringer Ingelheim.  \n 10 Beeh KM, Hedere  B, Glaab \nT, et al. Study design considera-\ntions in a large COPD trial com-\nparing effect  of tiotropium with \nsalmeterol on exacerbations. Int \nJ Chron Obstruct Pulmon Dis \n2009;4:119e25.   \n \ninklusive Supplements herange-\nzogen \nGershon A. Cardio-\nvascular safety of in-\nhaled long- acting \nbronchodilators in \nindividuals with \nchronic obstructive \npulmonary disease. \nJAMA Intern Med \n2013; \n173(13):1175\u2013 85. \nhttps:/ /www.ncbi.nlm\n.nih.gov/pub-\nmed/23689820.  \n \n\u2022 nicht zitiert  \u2022 Kanada  \n\u2022 Studiendesign:  population-\nbased, nested case- control analy-\nsis of a retrospective cohort study \n(Health care databases from On-\ntario)  \n \n\u2022 Fragestellung:  to clarify the rel-\native cardiovascular r isk of LABA \ncompared with LAA in older pa-\ntients with COPD.  \n \n\u2022 Population: \u00e4ltere Patient*innen \nmit COPD  \n \n\u2022 Vergleich:  New use of an in-\nhaled long- acting beta- agonist or \u2022 Baseline -Charakteristika  zwischen Cases und Controls: ausgegli-\nchen \n \n\u2022 n=191.005 eligible patients  \n\u2022 n= 53.532 (28.0%) with hospitalization or an emergency department \nvisit for a cardiovascular event  \n\u2022 n=26.628 (49,7%) were matched to a control  \n \n- Cases were more likely than cont rols to have a history of diabetes \nmellitus and hypertension, to be taking some medications, and to have \nhad a recent hospitalization and/or emergency department visit  \n \n\u2022 Newly prescribed long- acting inhaled beta- agonists and anticholiner-\ngics were associat ed with a higher risk of an event compared with \nnonuse of those medications:  \n- LABA: adjusted OR 1.31 [95% CI, 1.12- 1.52; p < .001] and  \n- LA[M]A: adjusted OR 1.14 [1.01- 1.28; p = 0.03]).  \n (In Anlehnung an NOS)  \nI. Selektion der Studienteilnehmer  \n1. exponierte Kohorte repr\u00e4senta-\ntiv f\u00fcr die zu untersuchende Inter-\nvention/Exposition: ja  \n2. nicht -exponierte Kohorte repr\u00e4-\nsentativ, ad\u00e4quat ausgew\u00e4hlt: ja  \n3. valide Erfassung der Exposition: \nja (Registerdaten)  \n4. wahrscheinlich, dass der ge-\nmessene Endpunkt nicht zu Stu-\ndienbeginn vorhanden war: unklar  \nII. Vergleichbarkeit  \n1.Vergleichbarkeit der e xponierten \nund nicht -exponierten Kohorte ge-\ngeben: ja  \nIII. Endpunkterfassung  Definitionen:  \n \n\u2022 cardiovascular event defined as   \n- acute coronary syndrome (in-\ncluding acute myocardial infarc-\ntation)  \n- heart failure \n- ischemic stroke  \n- or cardiac arrhythmia  \n \n\u2022 New use of LABA or LAMA \nconstituted the primary expo-\nsure.  \n --> defined as receiving a pre-\nscription within 90 days of the in-\ndex date and not having received NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  265 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nlong-acting anticholinergic (dry tio-\ntropium inhalation powder).  \n \n\u2022 relevante Ein - und \nAusschlusskriterien:  \n- All individuals 66 years or older \nmeeting a validated case definition \nof COPD, based on health admin-\nistrative data, and treated for \nCOPD \n- were entered into study once \nthey received at least 1 prescrip-\ntion a SABA, LABA, LA[M]A, ICS \nor Methylxanthine  \n \n\u2022 Studienzeitraum: 01/2003 - \n03/2009 \n \n\u2022 Endpunkte:  \n- Emergency department visit or a \nhospitalization for a cardiovascular \nevent.  \n \n \n \u2022 We found no significant difference in events between the 2 medica-\ntions:  \n- adjusted OR of LABAs compared with anticholinergics: OR 1.15 \n[95% CI, 0.95- 1.38; p = 0.16]).  \n \n\u2022 Cardiovascular events in cases newly taking LABAs or LA[M]As ap-\npeared to be highest in the first 2 to 3 weeks after medication was pre-\nscribed.  \n\u2022 Card iovascular risk associated with new use of LA[M]A relative to \nLABA did not appear to differ by sex, preexisting cardiovascular dis-\nease, or COPD severity.  \n \nSeparate cardiovascular outcome s \nCompared with nonuse of either medication, LABA and LA[M]A use \nwere associated with an increased risk of acute coronary syndrome \nand heart failure but not cardiac arrhythmias or stroke.  \n\u2022 ACS including acute MI:  \n- New use of LAMA: OR 1.30 [95% CI, 1.04- 1.62; p = 0.02]  \n- New use of LABA: OR 1.43 [95% CI, 1.08- 1.89; p = 0.01 ] \n \n\u2022 Heart failure:  \n- New use of LAMA: OR 1.31 [95% CI, 1.08- 1.60; p = 0.006]  \n- New use of LABA: OR 1.42 [95% CI, 1.10- 1.83; p = 0.008]  \n \n\u2022 Arrhythmias  \n- New use of LAMA: OR 1.26 [95% CI, 0.91- 1.75; p = 0.17]  \n- New use of LABA: OR 1.17 [95% CI, 0.74- 1.83; p = 0.50]  \n \n\u2022 Ischemic stroke  \n- New use of LAMA: OR 0.68 [95% CI, 0.50- 0.91; p = 0.01]  \n- New use of LABA: OR 1.17 [95% CI, 0.78- 1.74; p = 0.58]  \n  \nA protective effect for ischemic strokes were observed with new \nLA[M]A but not new LABA use, resulting in 73% increased risk of \nstroke in new users of LABAs compared with new users of LA[M]As.  \n 1. valide Erfassung der End-\npunkte: ja  \n2. Konnte in der Beobachtungszeit \nder Endpunkt auftreten: ja  \n3. fehlende Daten ad\u00e4quat ber\u00fcck-\nsichtigt: ja  \nIV. CoI/ Funding  \nGovernment of Ontar io; Institute \nfor Clinical Evaluative Sciences; \nMinistry of Health and Longterm \nCare, Canadian Institute of Health \nResearch; Institute of Nutrition  \n any prescriptions for the s ame \nmedication in the previous year  \n \n \n \nDong Y -H. Compar-\native Cardiovascular \nand Cerebrovascu-\nlar Safety of Inhaled \nLong- Acting Bron-\u2022 Taiwan  \n \n\u2022 Studiendesign: Retrospective \ncohort study, population- based \n(Taiwan National Health Insurance \nResearch Database)  \u2022 Baseline -Patientencharakteristika   \n- mean age 70.2 years; 80% male  \n- initiators of  LABA alone: waren j\u00fcnger, mehr Frauen, hatten mehr \nambulante Besuche und erhielten mehr SABAs, ICS, OCS oder orale \nB2 Agonisten \n (In Anlehnung an NOS)  \nI. Selektion der Studienteilnehmer  \n1. exponierte Kohorte repr\u00e4senta-\ntiv f\u00fcr die zu untersuchende Inter-\nvention/Exposition: ja  Selbe Datenbank wie RefID \n29331; teilweise \u00fcberlappender \nUnte rsuchungszeitraum: 1997 -  \n2008 vs. 2001 -  2010  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  266 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nchodilators in Pa-\ntients with Chronic \nObstructive Pulmo-\nnary Disease: A \nPopulation- Based \nCohort Study. Phar-\nmacotherapy 2016; \n36(1):26 \u201337. \nhttps://www.ncbi.nlm\n.nih.gov/pub-\nmed/26799347.  \n \n\u2022 nicht zitiert   \n\u2022 Fragestellung:  to compare the \ncardiovascular and cerebrovascu-\nlar risks of LAMA alone, LABA \nalone, and LABA/LAMA combina-\ntion \n \n\u2022 Population:  Patient*innen mit \nCOPD > 40 years of age  \n \n\u2022 Vergleich:  \n- LAMA (Tiotropium; dry powder)  \n- LABA \n- LABA/LAMA  \n \n\u2022 Einschlusskriterien:  \n- Individuals with COPD who initi-\nated LAMAs alone, LABA alone, \nand LABA and LAMA in combina-\ntion \n \n\u2022 Ausschlusskriterien:  \n- patients who received LABA or \nLAMA within 1 year before index \ndate from the analysis  \n- older 100 years  \n- lack of  continous insurance c ov-\nerage the year before drug initia-\ntion \n- patients with asthma co- diagno-\nsis \n \n\u2022 Studienzeitraum: 2001 - 2010  \n \n\u2022 Follow up: mean duration of 3.1 \nyears (1 day to 10.0 years)  \n composite cardiovascular outcome  (hospitalization for acute myocar-\ndial infarction, congestive heart failure, and cerebrovascul ar diseases)  \n>> LABA alone (n=2363) and LAMA alone (n=1004) were associated \nwith similar risks of the composite outcome (adjusted HR 1.09; 95% CI \n0.87- 1.37; crude HR 0.94; 95% CI 0.76 -  1.16)  \n \nSubgroup analyses  (Table4) for risk of composite cardiovascular \nevents comparing LABA alone with LAMA as reference:  \n- Age \u2265 65 yrs (n=2432): adjusted HR 1.08 (95% CI 0.85 - 1.38)  \n- Age < 65 yrs (n=1138): aHR 1.07 (95% CI 0.52 -  2.2.0)  \n- male (n=2834): aHR 1.08 (95% CI 0.84 -  1.38)  \n- female (n=736): aHR 0.77 (95% CI 0.40 - 1.46)  \n- with preexisting cardiovascular histories (n=2176): aHR 1.08 (95% \nCI 0.83 -  1.39)  \n- without preexisting cardiovascular histories (n=1138): aHR 1.12 \n(95% CI 0.66 -  1.90)  \n \n 2. nicht -exponierte Kohorte repr\u00e4-\nsentativ, ad\u00e4quat ausgew\u00e4hlt: ja  \n3. valide Erfassung der Exposition: \nja (Registerdaten)  \n4. wahrscheinlich, dass der ge-\nmessene Endpunkt nicht zu Stu-\ndienbeginn vorhanden war: unklar  \nII. Vergleichbarkeit  \n1.Vergleichbarkeit der exponierten \nund nicht -exponierten Kohorte ge-\ngeben: ja  \nIII. Endpunkterfassung  \n1. valide Erfassung der End-\npunkte: ja (Registerdaten)  \n2. Konnte in der Beobachtungszeit \nder Endpunkt auftreten: ja  \n3. fehlende Daten ad\u00e4quat ber\u00fcck-\nsichtigt: ja  \nIV. CoI/ Funding  \n- partly supported by the Taiwan \nDepartment of Health Grant  \n- 1 author: grant Novartis  \n  \n \nSuissa S. Long -Act-\ning Bronchodilator \nInitiation in COPD \nand the Risk of Ad-\u2022 Kanada (Daten aus  UK) \n \n\u2022 Studiendesign:  population-\nbased comparative Safety Study; \nretrospektive Kohortenstudie `- base cohort: n=463.899 patients  \n- Study cohort of incident users of LABA (n = 88.955) or tiotropium (n \n= 26.442) (For analysis of AMI, CHF and stroke)  \n- Study sub- cohort of incident users of LABA (n = 55,123) or tiotro-\npium (n = 15,427 ) (For analysis of arrhythmia and pneumonia)  (In Anlehnung an NOS)  \nI. Selektion der Studienteilnehmer  \n1. exponierte Kohorte repr\u00e4senta-\ntiv f\u00fcr die zu untersuchende Inter-\nvention/Exposition: ja   NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  267 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nverse Cardiopulmo-\nnary Events: A Pop-\nulation- Based Com-\nparative Safety \nStudy. Chest 2017; \n151(1):60\u2013 7. \nhttps://www.ncbi.nlm\n.nih.gov/pub-\nmed/27554300.  \n \n\u2022 nicht zitiert  (United Kingdom's Clinical Prac-\ntice Research Datalink = primary \ncara database)  \n \n\u2022 Fragestellung: assessed the \ncomparative safety of COPD treat-\nment initiation wit h tiotropium rela-\ntive to a LABA on the incidence of \nacute myocardial infarction (MI), \nstroke, heart failure, and arrhyth-\nmia as well as pneumonia  \n \n\u2022 Population :  \n- cohort of new users of long- act-\ning bronchodilators  \n- Patient*innen mit COPD  \n- age 55 or older  \n \n\u2022 Ausschlusskriterien:  \n- Patients initiating treatment with \nboth bronchodilators on the same \ndate \n \n\u2022 Vergleich:  tiotropium vs. LABA  \n \n\u2022 Follow -up: 1 year from cohort \nentry, with follow -up ending, for \neach studied outcome, at the earli-\nest of the date of the cardiovascu-\nlar or pneumonia outcome, 1 year \nafter cohort entry, date of death  \n \n\u2022 Studienzeitraum: 2002 - 2012  \n >> wurde n jeweils gematcht  \n \n \nTiotropium initiation relative to LABA initiation:  \n- acute myocardial infarction: HR 1.10 (95% CI, 0.88- 1.38),  \n- stroke HR: 1.02 (95% CI, 0.78- 1.34)  \n- arrhythmia 0.81 (95% CI, 0.60- 1.09)  \n- heart failure 0.90 (95% CI, 0.79- 1.02).  \n \n\u2022 initiation of COPD treatment with tiotropium or with a LABA is associ-\nated with similar rates of cardiovascular events in the first year of use.  \n 2. nicht -exponierte Kohorte repr\u00e4-\nsentativ, ad\u00e4quat ausgew\u00e4hlt: ja  \n3. valide Erfassung der Exposition: \nja (Registerdaten)  \n4. wahrscheinlich, dass der ge-\nmessene Endpunkt nicht zu Stu-\ndienbeginn vorhanden war: unklar  \nII. Vergleichbarkeit  \n1.Vergleichbarkeit der exponierten \nund nicht -exponierten Kohorte ge-\ngeben: ja  \nIII. Endpunkterfassung  \n1. valide Erfassung der End-\npunkte: ja (Registerdaten)  \n2. Konnte in der Beobachtungszeit \nder Endpunkt auftreten: ja  \n3. fehlende Daten ad\u00e4quat ber\u00fcck-\nsichtigt: k.A.  \nIV. CoI/ Funding  \nCanadian Institutes of Health Re-\nsearch, Canadian Foundation for \nInnovation, and Boehringer -Ingel-\nheim  \n \nWang M -T. Associa-\ntion of Cardiovascu-\nlar Risk With Inhaled \nLong- Acting Bron-\nchodilators in Pa-\ntients With Chronic \nObstructive Pulmo-\nnary Disease: A \u2022 China  \n\u2022 Studiendesign:  Nested Case -\nControl Study; retrospektive Ko-\nhortenstudie (Taiwan National \nHealth Insurance Research Data-\nbase for health care claims)  \n Baseline -Patientencharakteristika: hinsichtlich Alter und Geschlecht \nausgeglichen; leichte Unterschiede bei Vorerkrankungen \n- mean age, 71.4 years; 68.9% men \n- 37 719 patients with CVD (mean age, 75.6 years; 71.6% men) and \n146 139 matched controls (mean age, 75.2 years; 70.1% men) were \nidentified  \n \n>> New LABA and LAMA use in COPD was associated with a 1.50 -(In Anlehnung an NOS)  \nI. Selektion der Studienteilnehmer  \n1. exponierte Kohorte repr\u00e4senta-\ntiv f\u00fcr die zu untersuchende Inter-\nvention/Exposition: ja  \n2. nicht -exponierte Kohorte repr\u00e4-\nsentativ, ad\u00e4quat ausgew\u00e4hlt: ja  \n3. valide Erfassung der Exposition: vermutlich selbe Datenbank wie \nRefID 29331 und 29329 teilweise \n\u00fcberlappender Untersuchungs-\nzeitraum: 1997 -  2008 vs. 2001 - \n2010 vs. 2007 -  2011  \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  268 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nNested Case -Con-\ntrol Study. JAMA In-\ntern Med 2018; \n178(2):229\u2013 38. \nhttps://www.ncbi.nlm\n.nih.gov/pub-\nmed/29297057.  \n \n\u2022 nicht zitiert  \u2022 Fragestellung:  Does the dura-\ntion since initial use and new use \nof inhaled LABAs or LAMAs for \nthe treatment of COPD act as im-\nportant determinants of the risk of \ncardiovascular disease?  \n \n\u2022 Population: 280 000 patients \nwith COPD; LABA -LAMA \u2013na\u00efve; \nat least 40 years old  \n \n\u2022 Ausschlusskriterien:  received \nany LABA -LAMA therapy or who \nlacked co ntinuous healt  insurance \ncoverage for 1 year preceding co-\nhort entry.  \n \n\u2022 Follow -up: mean  2.0 years  \n \n\u2022 Studienzeitraum:  from 2007 to \n2011 \n \n\u2022 Matching:  Cases with inpatient \nor emergency care visits for coro-\nnary artery disease, heart failure, \nischemic stroke , or arrhythmia  \nwere identified and individually \nmatched to 4 randomly selected \ncontrols.  \n fold (95% CI, 1.35 1.67; P < .001) and a 1.52 -fold (95% CI, 1. 28-1.80; \nP < .001) increased cardiovascular risk within 30 days of initiation , re-\nspectively, whereas the risk was absent, or even reduced with preva-\nlent use [of these medications; siehe Tabelle 2].  \n \n>> Individual LABA agents, LAMA dosage forms, and concom itant \nCOPD regimens did not differ in the CVD risks.  \n \n>> new LABA use vs new LAMA use yielded no difference in the risk \nof CVDs (P = .93)  \n \nAuszug: e- Table 2: Cardiovascular events//subtypes  \nCoronary artery disease  \nLABA new use vs nonuse: adjusted OR 2.01 (95% CI 1.71- 2.38) ; \np<0.001 \nLAMA new use vs nonuse: aOR 1.89 (95% CI1.45- 2.46); p <0.001  \nBoth new use vs nonuse: aOR 3.25 (95% CI 1.97- 5.36); p <0.001  \nNew LAMA vs New LABA: aOR 0.95 (95% CI 0.70- 1.29); p= 0.74  \n \nHeart failure  \nLABA new use vs nonuse: aOR 1. 42 (95% CI 1.16- 1.75); p= 0.001  \nLAMA new use vs nonuse: aOR 1.56 (95% CI 1.14- 2.14)p= 0.006  \nBoth new use vs nonuse: aOR 1.72 (95% CI 0.79- 3.75); p= 0.17  \nNew LAMA vs New LABA: aOR 1.09 (95% CI 0.75- 1.59); p= 0.64  \n \nIschemic stroke  \nLABA new use vs nonuse: aOR  1.06 (95% CI 0.81- 1.37); p= 0.69  \nLAMA new use vs nonuse: aOR 0.93 (95% CI 0.58- 1.51); p= 0.78  \nBoth new use vs nonuse: aOR 0.38 (95% CI 0.09- 1.67); p= 0.20  \nNew LAMA vs New LABA: aOR 0.87 (95% CI 0.50- 1.50); p= 0.61  \n \nCardiac arrhythmia  \nLABA new use vs nonus e: aOR 1.27 (95% CI 0.94- 1.72); p= 0.12  \nLAMA new use vs nonuse: aOR 1.67 (95% CI 1.02- 2.76); p= 0.042  \nBoth new use vs nonuse: aOR 1.87 (95% CI 0.68- 5.13); p= 0.23  \nNew LAMA vs New LABA: aOR 1.31 (95% CI 0.73 -2.33); p= 0.36  ja (Registerdaten)  \n4. wahrscheinl ich, dass der ge-\nmessene Endpunkt nicht zu Stu-\ndienbeginn vorhanden war: unklar \n(teilweise kardiovaskul\u00e4re Anam-\nnese; siehe Tabelle 1)  \nII. Vergleichbarkeit  \n1.Vergleichbarkeit der exponierten \nund nicht -exponierten Kohorte ge-\ngeben: ja  \nIII. Endpunkterfassung  \n1. valide Erfassung der End-\npunkte: ja (Registerdaten)  \n2. Konnte in der Beobachtungszeit \nder Endpunkt auftreten: ja  \n3. fehlende Daten ad\u00e4quat ber\u00fcck-\nsichtigt: k.A.  \nIV. CoI/ Funding  \nThis study was supported by \ngrants from the Ministry of Science \nand Technology, ROC;  \nCoI: non reported  \n  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  269 \n      \n \nAnhang 8.4  Eosinophile  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kom mentar zur Methodik  \nBafadhel M. Blood \neosinophils to di-\nrect corticosteroid \ntreatment of exac-\nerbations of chronic \nobstructive pulmo-\nnary disease: A \nrandomized pla-\ncebo- controlled \ntrial. Am J Respir \nCrit Care Med \n2012; 186(1):48\u2013\n55. \n \nhttps://www.ncbi.nl\nm.nih.gov/pub-\nmed/22447964  \n \n \u2022 Ort: UK \n\u2022Studiendesign: diagnostischer  RCT, \nNichtunterlegenheitsstudie  \n\u2022 Intervention : biomarkergesteuerte \nTherapie \n- \u2264 2% Eosinophile im Blut: Plac ebo \n(14d) + amoxicillin or doxycycline (7d)  \n- > 2% Eosinophile im Blut: 30 mg \nPrednisolon (14d) + Antibiotika (7d)  \nVergleich: biomarkerunabh\u00e4ngige \nTherapie \n- \u2264 2% Eosinophile im Blut:  30 mg \nPrednisolon (14d) + Antibiotika (7d)  \n- > 2% Eosinophile im Blut: 30 mg \nPrednisolon (14d) + Antibiotika (7d)  \n\u2022 Follow -up: 2 (posttherapy) and 6 (re-\ncovery) weeks after exacerbation  \n\u2022 Cross -over:  ja \nEinschlusskriterien:  \n- COPD  \n\u2022 Studienzeitraum:  k.A. \n \n\u2022 Definitionen und Messmethoden:  \n- pre- and post -bronchodilator spirome-\ntry;  \n- health quality questionnaires using \nthe Chronic Respiratory Disease Inter-\nviewer -Administered Standardized \nQuestionnaire (CRQ)  \n- symptom assessment of cough, \nbreathlessness, sputum production \n- sputum purulence using the visual an-\nalog scale (VAS)  \n- cell differential and C -reactive protein; \nand sputum for analysis of bacteria, \ncolony -forming units (CFU), virus, and \nsputum cell differential  \n\u2022 Prim\u00e4rer Endpunkt:  \n(1) noninferiority in the health status \nscore after treatment between the Baseline -Patientencharakteristika:  ausgeglichen, n= \n109 \n \n\u2022 prim\u00e4rer Endpunkt:  \n- noninferiority of health status in the standard therapy  \nand biomarker -directed groups after 2 weeks of treat-\nment was achieved (CRQ mean score change, 0.8 vs. \n1.1; mean difference, 0.3; 95% CI, 0.0; 0.6; p = 0.05  \n- similar reduction in the CRQ score from baseline to ex-\nacerbation in the biomarker -directed and st andard ther-\napy arms (0.9 vs. 0.9; MD 0.0; 95% CI, 20.3; 0.3; p = \n0.97).  \n\u2022 ausgew\u00e4hlte weitere Ergebnisse \n- treatment failures associated with worsening symp-\ntoms of COPD after treatment: 14 (standard: 10 vs. bi-\nomarker -directed  4)  \n- demonstrating at least equivalence with a trend favor-\ning the biomarker -directed arm as there were fewer \ntreatment failures (13 vs. 5%; 95% CI, 21; 16; P = 0.07).  \n \n \n Selection bias:  \nRandomisierung: low; Allocation con-\ncealment: unclear  \n \nPerformance bias:  \nVerblindung von Teilnehm ern und \nPersonal: low  \n \nDetection bias:  \nVerblindung der Ergebnisevaluation: \nunclear  \n \nAttrition bias:  \nVerlust von Studienteilnehmern/ feh-\nlende Daten: unclear  \n \nITT-Analyse: high  \n \nReporting bias:   \nselektive Ergebnisdarstellung: unklar  \n \nAndere Biasursachen:   \nBaseline imbalance: low  \n \nInteressenkonflikte/ Sponsoring: Medi-\ncal Research Council (UK) and Astra-\nZeneca, CoI -Erkl\u00e4rungen der Autoren \nliegen vor  \n - einige Limitationen im RoB -Tool  \n- positiv hervorzuheben ist das RCT -De-\nsign in einer diagnostischen Studie \n- am ehesten Strategiedesign  \n- die Ergebnisbewertung wird dadurch \ngemindert, dass nicht hinsichtlich der \nPatientenzahl sondern der Exazerbatio-\nnen ausgewertet wurde \n \n \n \nFehlende Definition der Ein-  und Aus-\nschlusskriterien  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  270 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kom mentar zur Methodik  \nstandard therapy and biomarker -di-\nrected therapy  \n\u2022 Weitere Endpunkte:  \n(2) equivalence in the proportions of \nexacerbations associated with  treat-\nment failure (defined as need to start or \nrepeat treatment within 30 days of ran-\ndomization, hospitalization for any \ncause, or deat h \n(3) demonstration of a reduction in cor-\nticosteroid therapy prescription in the \nbiomarker -directed therapy study \ngroup.  \nBrightling CE. Spu-\ntum eosinophilia \nand the short term \nresponse to inhaled \nmometasone in \nchronic obstructive \npulmonary disease. \nThorax 2005; \n60(3):193\u2013 8. \n \nhttps://www.ncbi.nlm\n.nih.gov/pub-\nmed/15741434  \n \u2022 UK \n\u2022 Studientyp:  RCT mit Cross -over \n\u2022 Intervention:  ICS Mometasone fu-\nroate (800 \u00b5g/day)  \n\u2022 Vergleich:  Placebo \n\u2022 Design:  \n- 4-week run- in period; treatment peri-\nods separated by a 4- week washout  \n \n\u2022 Population: n=60  \n\u2022 Einschlusskriterien:  \n- symptoms of chronic airflow obstruc-\ntion, postbronchodilator FEV1 < 70% \npredicted, FEV1/FVC ratio < 70%.  \n- no significant improvement in FEV1 \nafter 200 \u00b5g inhaled salbutamol  \n\u2022 Ausschlusskriterien:  \n- asthma, a history of childhood respira-\ntory disorders, variability in s ymptoms \nnot associated with infections, history \nof acute wheeze, breathlessness, or \ndeterioration associated with allergens, \nexacerbation within 6 weeks of trial en-\ntry.  \n- taking regular OCS  \u2022 Baseline- Patientencharakteristika:  hinsichtlich Ges-\nchlecht, Alter weites tgehend ausgeglichen; \nRauchstatus: in mittlerer Terzile doppelt so viele \nRaucher*innen, wie in den anderen beiden Terzilen  \n\u2022 Einteilung nach Baseline eosinophil count tertiles:  \n- <1,0 (n=20)  \n- 1,0\u20133,9 (n=20)  \n- >3,9 (n=20)  \n \n\u2022 prim\u00e4re Endpunkte  \nThe mean pair ed difference between mometasone and \nplacebo treatment for the change in primary outcomes \nfor the whole group were:  \n- post-bronchodilator FEV1 0.04 l (95% CI 20.03 to 0.11; \np=0.24)  \n- CRQ total 20.025 (95% CI 20.23 to 0.18; p=0.8).  \n \nThe group geometric mean sputum eosinophil count de-\ncreased after mometasone from 2.20% to 1.58%, but \nthis change was not significantly different from the \nchange after placebo (2.32% to 1.96%; 1.17- fold de-\ncrease after mometasone compared with placebo (95% \nCI 0.7 to 1.4), p=0.38)  \n \nAuswertung entsprechend der Baseline Eosinophilen im Selection bias:  \nRandomisierung: unclear; Allocation \nconcealment: unclear  \n \nPerformance bias:  \nVerblindung von Teilnehmern und \nPersonal: low  \n \nDetection bias:   \nVerblindung der Ergebnisevaluation: \nunclear  \n \nAttrition bias:  \nVerlust von Studienteilnehmern/ feh-\nlende Daten: low  \n \nITT-Analyse: low  \n \nReporting bias:  \nselektive Ergebnisdarstellung: unclear  \n \nAndere Biasursachen:   \nBaseline imbalance: unclear bis high \n - Endpunkte klinisch relevant?  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  271 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kom mentar zur Methodik  \n- taking ICS: drugs discontinued for at \nleast 1 month before randomisation.  \n- withdrew patients from the study if \nthey had a moderate exacerbation  \nrequiring ICS or antibiotics, a severe \nexacerbation needing OCS, or a severe \nintercurrent illness  \n Sputum:  \n- peripheral blood eosinophil count and total IgE concen-\ntration was higher in the most eosinophilic tertile \n(p<0.05)  \n- There was a progressive increase in the mean differ-\nence between mometasone and placebo from the least \nto the most eosinophilic tertiles for change in post -bron-\nchodilator FEV1 and total CRQ  \n- ITT: The mean change in post -bronchodilator FEV1 \nwith mometasone compared with placebo in the highest \ntertile  was 0.11 l (95% CI 0.03 to 0.19; p=0.02). Simi-\nlarly, an improvement in pre- bronchodilator FEV1 was \nonly observed in those subjects in the highest tertile \n(0.096 l (95% CI 0.00 to 0.19); p=0.05).  \n- posthoc: re- analysed the data including n= 49 subjects \nwho completed the study --> The fi ndings were very \nsimilar to the intention- to-treat analysis with a mean im-\nprovement in post -bronchodilator FEV1 after mometa-\nsone compared with placebo of 0.11 l (95% CI 0.002 to \n0.21; p=0.046).  \n \nausgew\u00e4hlte weitere Ergebnisse:  \n- no significant reduction in the sputum eosinophil count \nin the two tertiles with the highest baseline eosinophil \ncount and in the lowest tertile the sputum eosinophilic \ncount increased after mometasone compared with pla-\ncebo, although this represented a very small change in \nthe absol ute sputum eosinophil count in this group  \n \n\u2022 Sicherheit: nicht betrachtet  \n \n>> An increased sputum eosinophil count is related to \nan improvement in post -bronchodilator FEV(1) following \ntreatment with inhaled mometasone in COPD, but the \nimprovement is not as sociated with a reduction in the \nsputum eosinophil count.  Interessenkonflikte/ Sponsoring: ange-\ngeben: Funded by an unrestricted \ngrant from Schering- Plough, UK  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  272 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kom mentar zur Methodik  \nBrightling CE. Spu-\ntum eosinophilia and \nshort -term response \nto prednisolone in \nchronic obstructive \npulmonary disease: \nA randomised con-\ntrolled trial. Lancet \n2000; \n356(9240):1480\u2013 5. \n \nhttps://www.ncbi.nlm\n.nih.gov/pub-\nmed/11081531  \n \u2022 Studientyp:  RCT mit Cross -over \n\u2022 Intervention:  Prednisolon  \n\u2022 Vergleich:  Placebo \n\u2022 Design : \n- 4-week run- in period; treatment peri-\nods separated by a 4- week washout  \n\u2022 Population : n=67 \n\u2022 Einschlusskriterien:  \n- symptoms of chronic airflow obstruc-\ntion, postbronchodilator FEV1 < 70% \npredicted, FEV1/FVC ratio < 70%.  \n- no substantial improvement in FE V1 \nafter 2,5 mg nebulised albutamol  \n\u2022 Ausschlusskriterien:  \n- asthma, a history of childhood respira-\ntory disorders, variability in symptoms \nnot associated with infections, history \nof acute wheeze, breathlessness, or \ndeterioration associated with allergens, \nexacerbation within 6 weeks of trial en-\ntry.  \n- taking regular OCS  \n- taking ICS: drugs discontinued for at \nleast 1 month before randomisation.  \n- withdrew patients from the study if \nthey had a moderate exacerbation  \nrequiring ICS or antibiotics, a severe \nexacerbation needing OCS, or a severe \nintercurrent illness  \n \u2022 Baseline- Patientencharakteristika:  hinsichtlich Ges-\nchlecht, Alter, Rauchstatus weitestgehend ausgeglichen  \n\u2022 Einteilung nach Baseline eosinophil count tertiles:  \n- <1,3 (n=22)  \n- 1,3\u20134,5 (n=23)  \n- >4,5 (n=22)  \n \n\u2022 Prim\u00e4re Endpunkte:  \nmean paired difference between prednisolone and pla-\ncebo treatment for the change in primary outcomes for \nthe whole group were:  \n- postbronchodilator FEV1 0,07 L (95% CI 0,01\u2013 0,14)  \n- total score on CRQ 0,32 (0,17\u2013 0,47)  \n- shuttle walk distance 12 m (3\u2013 21) \n \nAuswertung entsprechend der Baseline Eosinophilen im \nSputum:  \n- Mean difference between prednisolone and placebo in-\ncreased progressively from the lowest to the highest eo-\nsinophilic tertile for FEV1 and CRQ  \n- in the highest t ertile : mean change in postbronchodi-\nlator FEV1 0,19 L (0,06\u2013 0,32), CRQ scores0,62 (0,31\u2013\n0,93), and shuttle walk distance 20 m (5\u2013 35) with pred-\nnisolone compared with placebo \n\u2022 ausgew\u00e4hlte weitere Ergebnisse:  \n- mean sputum eosinophil count: significantly dec reased \nafter treatment with prednisolone from 2,4% to 0,4% \n[95% CI 3,1 \u201311,4], p<0,0001)  \n- 29 (43%) patients had a baseline eosinophil differential \ncount higher than the normal range in our laboratory \n(>3%).  \n \n\u2022 Sicherheit:  nicht betrachtet  Selection bias:  \nRandomisierung: unclear; Allocation \nconcealment: low  \n \nPerformance bias:  \nVerblindung von Teilnehmern und \nPersonal: low  \n \nDetection bias:   \nVerblindung der Ergebnisevaluation: \nunclear  \n \nAttrition bias:  \nVerlust von Studienteilnehmern/ feh-\nlende Daten: unclear.  \nITT-Analyse: unclear  \n \nReporting bias:  \nselektive Ergebnisdarstellung: unclear  \n \nAndere Biasursachen:   \nBaseline imbalance: unclear bis high \n \nInteressenkonflikte/ Sponsoring: ja, \ngrant from Trent Regional Research \nScheme; Astra- Zeneca;  \n - Endpunkte klinisch  relevant?  \n \n- f\u00fchren die Ein-  und Ausschlusskrite-\nrien zu einem Verzerrungsrisiko? (z.B. \nRun-in-Phase: Absetzen von ICS, dann \nAusschluss bei Exazerbation)  \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  273 \n      \n \nAnhang 8.5  Roflumilast  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nDevi M K. A \nclinical study on \nsafety and effi-\ncacy of for-\nmoterol and tio-\ntropium combi-\nnation com-\npared to for-\nmoterol and tio-\ntropium with \nroflumilast com-\nbination in \ntreatment of \nmoderate to se-\nvere chronic \nobstructive pul-\nmonary disease \npatients. Asian \nJ Pharm Clin \nRes 2018; \n11(3):184. inno-\nvareacadem-\nics.in/jour-\nnals/in-\ndex.php/aj-\npcr/arti-\ncle/view/21871.  \n \n\u2022 Nicht zitiert  \u2022 Fragestellung:  to assess the safety and effi-\ncacy of formoterol and tiotropium combination \ncompared to formoterol and tiotropium with \nroflumilast combination in treatment of moder-\nate-to-severe chronic obstructive pulmonary dis-\nease (COPD) patients on inhaled combination \ntherapy.  \n \n\u2022 Studiendesign: comparative randomized con-\ntrol study  \n \n\u2022 Population : moderate- to-severe COPD; n=61 \npatients  \n\u2022 Intervention:  formoterol and tiotropium combi-\nnation (group A)  \n\u2022 Vergleich: formoterol and tiotropium with \nroflumilast (group B)  \n \n\u2022 12 weeks  \n\u2022 Einschlusskriterien:  genders aged more than \n40 years, moderate- to-severe COPD patient, \ncurrent or ex -smokers, with a smoking history, \npatient with other comorbid conditions  \n \n\u2022 Studienzeitraum: October 2016 to March \n2017 \n\u2022 Indien (single center)  \u2022 Base line-Patientencharakteristika:  \n- average age: 57.63\u00b18.3 years.  \n- Differenzen hinsichtlich Alter und Komorbidit\u00e4ten \nzwischen den Gruppen (aufgrund geringer Fallzahlen)  \n \n\u2022 Comparison of spirometry reports before and after \ndrug administration in both groups w as done. FEV1 \nand FVC were found to be statistically significant be-\ntween the study group (0.001, p<0.05).The average \nmean change of FEV1 before and after treatment in \nGroup B was found to be improved as compared to \nGroup B (0.66).  \n \n\u2022 Sicherheit: adverse dr ug reaction: diarrhea in 10% \nof patients, weight loss (23.3%), headache (3.3%), \nback pain (3.3%), insomnia (10%), and decreased ap-\npetite (13.3%) were observed in Group B patients \ntreated with roflumilast.  \n \n \n \n \n Selection bias  \nRandomisierung: unklar  \n \nAllocat ion concealment: unklar  \n \nPerformance bias \nVerblindung von Teilnehmern und Perso-\nnal: unklar  \n \nDetection bias  \nVerblindung der Ergebnisevaluation: un-\nklar \n \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende \nDaten: gering  \n \nITT-Analyse: nicht durchgef\u00fchrt  \nReporting bias  \nselektive Ergebnisdarstellung: unklar  \n \nAndere Biasursachen  \nBaseline imbalance: hoch  \n  \nInteressenkonflikte/ Sponsoring: nicht \nangegeben  \u2022 keine durch die Leitliniengruppe \nNVL COPD priorisierten End-\npunkte beschrieben  \n\u2022 Methodik in Publikation kaum \nbeschrieben  \n\u2022 geringe Fallzahl: n=61  \n \n \n \nAnhang 8.6  Wirksamkeit von Instruktionen in Inhalationssysteme (NVL Asthma)  \nZitat AMSTAR  Studiencharakteristika (Patienten, Intervention, Verglich, \nStudientypen)  Ergebnisse (inklusive Datenqualit\u00e4t)  \n27137 \nNormansell R. In-\nterventions to im-11 Suchzeitraum: 11/2016  \nZiel: assess impact of interventions to improve inhaler tech-\nnique [\u2026]  enhanced inhaler technique education vs control or usua l care:  \n1. Inhaler technique:  \nErwachsene: correct in intervention group (69/100) vs. control group (31/100) (OR 5.00, 95% CI 1.83 to \n13.65; n=258; 3 studies; I\u00b2 = 57%; moderate quality)  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  274 \n      \n \nZitat AMSTAR  Studiencharakteristika (Patienten, Intervention, Verglich, \nStudientypen)  Ergebnisse (inklusive Datenqualit\u00e4t)  \nprove inhaler tech-\nnique for people \nwith asthma. \nCochrane Data-\nbase Syst Rev \n2017;3:CD012286\n. \nhttp://www.ncbi.nl\nm.nih.gov/pub-\nmed/28288272  P: adults and children with asthma, diagnosed according to na-\ntional or international guidelines or by a healthcare profes-\nsional.  \nI: primarily aimed at improving inhaler technique  \nC:  \n1. Usual care/ No additional intervention \n2. intervention that did not primarily aim to improve inhaler \ntechnique (e.g. asthma education only vs asthma education \nplus an inhaler technique demonstration).  \n3. intervention of different type or intensity, also aimed at im-\nproving inhaler technique (e.g. written instructions only vs writ-\nten instructions plus physical demonstration).  \nS: parallel and cluster - (RCTs); any duration; in any setting  Kinder: no significant differences between groups, with CI including both potential harm and benefit of \nthe intervention (OR 1.29, 95% CI 0.70 to 2.36; n=175; 2 studies; I\u00b2 = 0%; low -quality).  \n2. Asthmakontrolle: benefit in favour of educational intervention but with a lower CI, including no differ-\nence (SMD 0.48, 95%CI -0.29; 1.24; n= 247; 2 studies; I\u00b2 = 88%; very low -quality)  \n3. Exazerbationen: similar number of participants (adults) in each group experienced an exacerbation \nrequiring at least OCS treatment (10 vs 8), Datenqualit\u00e4t: very low  \n4. QoL:  SMD 0.52, 95% CI -0.04 to 1.09; n= 247; 2 studies; I2 = 78%; low -quality, zu Gunsten In-\nstruktion  \nmulti- media training vs control or usual care:  \n1. Inhaler technique: benefit in favour of multi -media intervention when compared with a patient infor-\nmation leaflet and a ver bal explanation, but the lower CI does not rule out benefit for the control group \n(OR 2.15, 95%CI 0.84 to 5.50; n= 164; 2 studies; I\u00b2 = 49%; moderate -quality)  \n2. Asthmakontrolle:  one study in children using the ACT, as endpoint score and as change from bas eline \nand found no significant between group differences, with confidence intervals excluding the established \nminimal clinically important difference (MCID) of 3 (low quality).  \nfeedback device vs control or usual care:  \n1. Inhaler technique:  \n- benefit in favour of the feedback device, but the effect was very imprecise (OR 18.26, 95% CI 2.22 to \n150.13; n = 71; 1 study; low -quality)  \n- Use of an inhaler feedback device in addition to verbal training (pharmacists) increased the odds of \nachieving the correct technique (OR 4.80, 95% CI 1.87 to 12.33; n= 97; 1 study; low -quality). 51/ 100 \nin control vs 83/ 100 in intervention (95% CI 66 to 93).  \n2. Asthmakontrolle:  \n- Erwachsene: found no differences between groups and confidence intervals, excluding the MCID of \n0.5 (MD -0.10, 95% CI -  0.46 to 0.26; 97 participants; one study; low -quality).  \n- Kinder: no between- group differences, with confidence intervals again excluding theMCID of 0.5 (MD \n-0.02, 95% CI - 0.35 to 0.32; n= 98; 2 studies; I\u00b2 = 0%; moderate- quality).  \n3. QoL:  \n- Erwachsene: analysis suggests benefit of device feedback over usual care; below the MCID of 0.5, \nlower CI includes no difference (MD 0.38, 95%CI - 0.01 to 0.77; n= 100; 2 studies; I\u00b2 = 0%; low quality).  \n27138 \nGillette C. Inhaler \nTechnique in Chil-\ndren With Asthma: \nA Systematic Re-\nview. Acad Pediatr \n2016;16(7):605-\n15. 6 Suchzeitraum: 2015/08  \nFragestellung:  \n1) the prevalence of correct inhaler  \ntechnique among children with asthma \n2) are educational interventions associated with improved rates \nof correct inhalation technique Ergebnisse zur Frage 1 nicht Inhalt der von uns gestellten Frage  \nFragestellung 2 : \n- Overall, teaching how to correctly use an inhaler: associated with improved inhaler technique, regard-\nless of who did the coaching  \n- All but 1 study: communication was associated with improved inhaler technique and the more often \nthe child received instruction, the better the  technique.  \n- technique should be continuously assessed even in children who have previously demonstrated cor-\nrect technique  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  275 \n      \n \nZitat AMSTAR  Studiencharakteristika (Patienten, Intervention, Verglich, \nStudientypen)  Ergebnisse (inklusive Datenqualit\u00e4t)  \nhttp://www.ncbi.nl\nm.nih.gov/pub-\nmed/27130811  \n \n- nicht einge-\nschlossen  3) is improved inhaler technique associated with improved \nasthma outcomes  \nP: 6 through 18 years of age  \nI und C: nicht definiert  \nS: experimental and observational studies  \n>> narrative Synthese und tabellarische Darstellung erfolgt  - 2 studies: repeated instruction about inhaler technique is associated with improved technique over \ntime.  \n-  2 studies reported: children demonstrate correct use of the inhaler was also associated with correct \ninhaler technique.  \n- more intensive training in which each child\u2019s technique was checked and rechecked until the educator \nwas satisfied were also more likely to use their inhaler correctly.  \n- 4 studies: examined effects of telemedicine by pharmacists: improved technique in children  \n- prerecorded video (3 minutes): the improvement in technique was not sustained 1 month later  \nFragestellung 3:  \nin 8 Prim\u00e4rstudien untersucht; 3 directly examined how inhaler technique was associated with asthma \noutcomes: heterogene Ergebnisse \nSelbstmanagement: in 7 Studien untersucht; All studies reported increases in asthma knowledge,  \nquality of life, and self -efficacy  \n \nAnhang 8.7  Mukolytika  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nZeng Z. Ef-\nfect of car-\nbocisteine on \npatients with \nCOPD: A sys-\ntematic re-\nview and \nmeta- analy-\nsis. 2017.  \n \u2022 Fragestellung:  we investigated the effi-\ncacy of carbocisteine on stable COPD.  \n \n\u2022 Suchzeitraum:  up to September 1, \n2016 \n\u2022 Population: stable COPD  \n\u2022 Einschlusskriterien:  \n- RCT \n- oral carbocisteine for a period of at least \n3 months  \n- adults with COPD  \n \n\u2022 Interventionen:  oral carbocisteine \n1.500 mg daily  \n- (1 study: carbocisteine lysine 2,700 mg \ndaily = equivalent to carbocisteine 1,500 \nmg daily)  \n\u2022 Vergleich:  placebo  \n \u2022 Exacerbation rates (total number)  \n- significant decrease in the rate of exacerbations in the carbocisteine \ngroup compared with the placebo group (3 studies: n=1,215; MD -\n0.43; 95% c onfidence interval [CI] -0.57, -0.29, I\u00b2=60%, P,0.00001)  \n\u2022 Number of patients with at least one exacerbation  \n- 3 three studies reported the outcome of the number of patients with \nat least one exacerbation.  \n- One study showed no difference in the risk of t he outcome.  \n- significant difference in  number of patients with at least one exacer-\nbation compared with placebo (3 studies: n=1,215; relative risk [RR] \n0.86; 95% CI 0.78, 0.95, I\u00b2=84%, P=0.002).  \n- NNT = 12  \n\u2022 Quality of life (SGRQ)  \n- significant decrease was seen in the rate of exacerbations in the car-\nbocisteine group compared with the placebo group (2 studies: n=849; \nMD -6.29; 95% CI -9.30, -3.27, I\u00b2=61%,  P<0.0001; tota SGRQ)  \n\u2022 Adverse effects \n- most common adverse events reported were gastrointestinal prob-\nlems  \n- No significant difference was seen with carbocisteine compared with \nplacebo (3 studies: n=1,201; RR 1.02; 95% CI 0.73, 1.43, I\u00b2=61%, AMSTAR -II: \n low \n >> geringe Studienanzahl  \n>> RoB der eingeschlossenen \nStudien: wurde durchgef\u00fchrt, \nkann jedoch nicht dargestellt \nwerden, da \"supplemental mate-\nrial\" auf einer asiatischen Inter-\nnetseite hinterlegt ist  \n \n>> substantial heterogeneity \nwas detected in some outco-\nmes. The conclusion needs to \nbe used with caution  \n>> Publication bias may be \nseen in this review. It may \ncause overestimate outcomes  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  276 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n\u2022 eingeschlossene Studien:  4 RCTs; \n1357 Participants  \n P=0.75)  \n- no significant difference  in the adverse effects of gastrointestinal \nproblems (3 studies: n=1,201; RR 1.38; 95% CI 0.71, 2.66, I\u00b2=77%, \nP=0.34).  \n- No fatal adverse effects were found in the four studies.  \n\u2022 Rates of hospitalization  \n- No significant difference was seen in it (1 study: n=352; RR 9.52; \n95% CI 0.52, 175.57, P=0.13).  \n\u2022 Rates of mortality  \n- 2 stu dies: no one died  \n \n\u2022 Subgruppen- Analysen: rate of exacerbations  \n- subgroup with the population of non- Chinese showed a large reduc-\ntion in the carbocisteine group (2 studies: n=508, MD = -0.34; 95% CI -\n0.90, -0.40, I\u00b2=2%, P,0.00001) compared to placebo.  \n- subgroup with the population of Chinese showed no difference in the \nrisk of the outcome (1: n=707, MD = -0.34; 95% CI - 0.51, -0.17, \nP,0.0001)  \nCazzola M. \nThe thera-\npeutic effi-\ncacy of er-\ndosteine in \nthe treatment \nof chronic ob-\nstructive \nbronchitis: A \nmeta- analysis \nof individual \npatient data. \nPulm Phar-\nmacol Ther \n2010; \n23(2):135\u2013 44. \nhttps://www.n\ncbi.nlm.nih.go\nv/pub-\nmed/1985428\n5. \n \n\u2022 Nicht zitiert.  \u2022 Fragestellung: to test the available evi-\ndence for the efficacy of erdosteine in \nadults with stable or exacerbated \nCB/COPD.  \n \n\u2022 Suchzeitraum: nicht angegeben (Indi-\nvidual patient data from the published \nand unpublished studies in patients with \nCB submitted for European marketing \napproval in 2005 were considered.)  \n \n\u2022 Population: Patient*innen mit chro-\nnischer Bronchitis/COPD  \n- either at occurrence of an acute exacer-\nbation or during the stable phase of the \ndisease  \n \n\u2022 Interventionen:   \n- Erdosteine (300 mg capsule) vs. pla-\ncebo or mucolytics (ambroxol, N -acetyl-\ncysteine, carbocysteine, sobrerol)  \n- 7-10 days of treatment  \n- 2-3x/day on top of background therapy  \n \u2022 Baseline -Charakteristika  \n- individual data from 1046 pat ients from 15 RCTs (12 on exacerbated \nand 3 on stable CB/COPD) were obtained.  \n \n\u2022 Ergebnisse (Erdosteine vs. Mucolytics  \n- cGEI: erdosteine induced a significant reduction of cGEI versus \ncomparators ( -1.02; 95% CI: from -1.60 to - 0.44; p = 0.0006; n= 1046 \npatients).  \n \n- cough intensity:  the effect of erdosteine was significant vs. muco-\nlytics ( - 0.26; 95% CI: from - 0.43 to - 0.10; p = 0.002; n=496 Partici-\npants).  \n \n- expectoration difficulty  ( 13 RCTs involving 992 patients): Erdosteine \nsignificantly improv ed this symptom vs. mucolytics ( -0.19; 95% CI: \nfrom -0.34 to  0.03; p = 0.02)  \n \n- Dyspnoe:  keine signifikanten Effekte hinsichtlich Dyspnoe (Erdoste-\nine vs. mucolytics)  \n \n\u2022 Sicherheit:  Erdosteine (n=295) versus Placebo (n=292)  \nNo. Patients reporting AEs (n Er dosteine/ n Placebo):  \nGastrointestinal: 21/24  \nTaste Loss: 1/0  AMSTAR -II: \n- critically low  \n \n  - Individual patient data were \nprovided by the manufacturer of \nerdosteine, Edmond Pharma \n(Milano, Italy)  \n>> Furthermore, the manufac-\nturer of erdosteine (Edmond \nPharma s.r.l., Italy) was con-\ntacted and asked for any addi-\ntional non- indexed publications \nand relevant unpublished stud-\nies. Individual patient data from \nthe published and unpublished \nstudies in patients with CB sub-\nmitted for European marketing \napproval in 2005 were consid-\nered.  \n \n- gemischte Population einge-\nschlos sen: COPD und chron. \nBronchitis  (Patients with stable \nCOPD disease accounted for \n26.3% of the study population)  \n \n- Ergebnisse werden f\u00fcr den NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  277 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n \u2022 eingeschlossene Studien:  n=15 RCTs \n(n=1046 participants)  \n \n\u2022 RoB der eingeschlossenen Studien:  \nn= 6 RCTS JADAD 1 -2; n=9 RCTs \nJADAD 3 -5 Score  \n \n\u2022 cumulative global efficacy index = cGEI \n(the sum of all assessed respiratory \nsymptom scores)  \n Allergic reactions: 2/3  \nMiscellaneous: 11/5  \nTotal: 35 (11.9%)/32 (11.0%)  \n \n\u2022 Sicherheit:  Erdosteine (n=234) versus Mucolytics (n=225)  \nNo. Patients reporting AEs (n Erdosteine/ n Mucolytics):  \nGast rointestinal: 11/19  \nTaste Loss: 0/0  \nAllergic reactions: 1/0  \nMiscellaneous: 7/6  \nTotal: 19 (8.1%)/25 (11.1%)  \n Vergleich Erdos tein vs. Mukolyt-\nika dargestellt. F\u00fcr den Ver-\ngleich Erdostein vs. Placebo \nwurde ein Review identifiziert, \nwelche die hier eingeschlosse-\nnen Studien um drei weitere er-\ng\u00e4nzt und metaanalysiert hat \n(Ref ID 29801)  \n \nCazzola M. \nImpact of er-\ndosteine on \nchronic bron-\nchitis and \nCOPD: A \nmeta- analy-\nsis. Pulm \nPharmacol \nTher 2018; \n48:185\u2013 94. \nhttps://www.n\ncbi.nlm.nih.go\nv/pub-\nmed/2923365\n0. \n \n\u2022 Nicht zitiert.  \n \u2022 Fragestellung:  To clarify the real im-\npact of erdosteine in improving the clini-\ncal score of patients with chronic bronchi-\ntis and/or COPD, and the use of this drug \nin preventing chronic bronchitis/COPD \nexacerbations.  \n \n\u2022 Suchzeitraum:  up to July 31, 2017 \n\u2022 Population:  patients with chronic bron-\nchitis and/or COPD  \n \n \n\u2022 Interventionen:  - Erdosteine vs. pla-\ncebo  \n- maximale Tagesdosis zwischen 600mg \nund 900 mg  \n- 2-3x/Tag  \n \n \n\u2022 eingeschlossene Studien:  10 clinical \nstudies (n=8 RCTs) involving 1278 pati-\nents \n\u2022 RoB der eingeschlossenen Studien: n= \n8 studies JADAD \u22653; n=2 studies JADAD \n<3 \u2022 Baseline -Charakteristika  \n-   6 studies on chronic bronchitis; 3 studies on COPD and 1 study on \npatients suffering from both cronic bronchitis and COPD  \n \n\u2022 Effektivit\u00e4t:Treatment with erdosteine:  \nclinical score (studies mixed: patients with CB or COPD)  \n- significantly (p<0.001) improved clinical score of patient with no dif-\nferences (p>0.05) to subanalysis (only high quality studies included)  \n- only high quality studies included: SMD - 0.44; 95% CI - 0.70 to - 0.18; \nI\u00b2 80%; p<0.001; GRADE: MODERATE  \n \nclinical condition (only studies on COPD ) \n- significantly improved clinical condition  \n- SMD all studies -0.56; 95%Ci - 0.94 to - 0.17; I\u00b2 85%; p<0.001; \nGRADE: HIGH  \n- SMD high quality studies - 0.28; 95%Ci - 0.50 to - 0.06; I\u00b2 53%; p=0.12  \n \nCOPD exacerbation  \n- significantly (P < .01 to P < .001) reduced overall risk of CB/COPD \nexacerbations and risk of experiencing at least one exacerbation vs. \ncontrol  \n- risk of COPD exacerbation: RR 0.74 95% CI 0.61 - 0.89, I\u00b2 31%, P = \n.24; GRADE: HIGH  \n- risk of experiencing at least one COPD exacerbation: RR 0.78, \n95%CI 0.64 -  0.96, I\u00b2 6%, P=0.35; GRADE: HIGH  \n AMSTAR -II: \n- critically low  \n \n Update des Cazzola Reviews \nvon 2010 ( ID 29809); hier aus-\nschlie\u00dflich Studien: Erdostein \nvs. Placebo inkludiert  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  278 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nCazzola M. \nInfluence of \nN-acetylcys-\nteine on \nchronic bron-\nchitis or \nCOPD exac-\nerbations: A \nmeta- analy-\nsis. Eur \nRespir Rev \n2015; \n24(137):451\u2013\n61. \nhttps://www.n\ncbi.nlm.nih.go\nv/pub-\nmed/2632480\n7. \n \u2022 Fragestellung:  whether NAC is effec-\ntive in preventing COPD exacerbations, \nand whether the effects are dose related \n \n\u2022 Suchzeitraum: up to July 31, 2014 \n\u2022 Population:  Patient*innen mit COPD  \n \n\u2022 Interventionen:   \n- oral administration of NAC  \n\u2022 Vergleich:   \n- Placebo or control subjects  \n \n\u2022 eingeschlossene Studien : n=13 stud-\nies (RCTs & observational studies)  \n- 4155 COPD patients  \n(NAC n=1933; placebo or controls \nn=2222)  \n \n\u2022 RoB der eingeschlossenen Studien: f\u00fcr \n12 RCTs: 8/12 Studien > 3 JADAD score \n \u2022 Baseline -Charakteristika  \n- NAC treatment ranged from 4 to 36 months.  \n- 10 trials were double- blind, randomised placebo- controlled, one trial \nwas single- blind, randomised placebo- controlled, one trial was open, \nrandomised and controlled and one study was a retrospective cohort \ninvestigation \n \n\u2022 Exazerbationen  \n- relative risk 0.75, 95% CI 0.66- 0.84; p < 0.01 (n=13 studies): at pa-\ntients treated with NAC had significantly and consistently fewer exac-\nerbations of chronic bronchitis or COPD , although this prot ective ef-\nfect was more apparent in patients without evidence of airway ob-\nstruction.  \n \n\u2022 subgroup with Jadad score \u2a7d3  \n- decrease in the risk of exacerbation (six studies: treated n=986, pla-\ncebo n=1267; relative risk 0.64, 95% CI 0.56\u2013 0.74; p=0.07),  \n\u2022 subgr oup with Jadad score >3  \n- significant reduction in the risk of exacerbation was detected in the \nsubgroup of RCTs with Jadad score >3 (seven studies: treated \nn=957, placebo n=955; relative risk 0.85, 95% CI 0.74\u2013 0.98; p<0.01).  \n \n\u2022 Low Doses of NAC  \n- NAC adm inistered at low doses (patients from 10 studies: treated \nn=1298, placebo or controls n=1614) significantly protected against \nCOPD exacerbations (relative risk 0.76, 95% CI 0.65\u2013 0.89; p<0.01)  \n- the reduction of exacerbation risk was less extensive (relativ e risk \n0.90, 95% CI 0.84\u2013 0.96; p<0.01) in the analysis of those RCTs where \nCOPD was diagnosed using PFT (patients from five studies: treated \nn=444,  \nplacebo n=433)  \n \n\u2022 High Doses NAC \n- NAC at high doses included patients from four studies (treated \nn=635, placebo or controls n=1362) and \nshowed a significant reduction of COPD exacerbation rate (relative \nrisk 0.65, 95% CI 0.49\u2013 0.88; p=0.03)  \n- confirmed by the results of the subgroup of RCTs enrolling COPD \npatients using PFT according to ATS/ERS or GOLD guidelines (two \nstudies: treated n=534, placebo n=538; relative risk 0.75, 95% CI \n0.68\u2013 0.82; p=0.04)  \n AMSTAR -II: \n- critically low  \n \u2022 random effects model genutzt, \njedoch keinerlei Untersuchun-\ngen bez\u00fcglich m\u00f6glicher Hete-\nrogenit\u00e4t zwischen den einzel-\nnen Studien durchgef\u00fchrt  \n \n\u2022 sehr schwache methodische \nQualit\u00e4t  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  279 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n\u2022 Sicherheit  \n- NAC was well tolerated and the risk of adverse reactions was not \ndose- dependent  \n-- low doses relative risk 0.93, 95% CI 0.89- 0.97; p = 0.40  \n-- high doses relative risk 1.11, 95% CI 0.89- 1.39; p = 0.58  \n \nFowdar K. \nThe effect of \nN-acetylcys-\nteine on ex-\nacerbations \nof chronic ob-\nstructive pul-\nmonary dis-\nease: A meta-\nanalysis and \nsystematic re-\nview. 2017 \nMar - Apr. \n \u2022 Fragestellung:  To investigate the ef-\nfects of NAC on COPD exacerbation and \nchanges in lung function parameters in \npatients with COPD.  \n \n\u2022 Suchzeitraum:  09/2015 \n\u2022 Population:  patients with stable COPD  \n \n\u2022 Interventionen:   orally administered N -\nacetylcysteine (NAC) for>4 weeks in ad-\ndition to standard therapy  \n\u2022 Vergleich:  Placebo or standard therapy \n(e.g. \u00df2- agonists, anticholinergics,  \nand theophylline)  \n \n\u2022 eingeschlossene Studien:  12 RCTs \n(n=2691 participants: NAC n=1339; con-\ntrol group n=1352)  \n \n\u2022 RoB der eingeschlossenen Studi en: \n11/12 Studien > 3 JADAD score  \u2022 Baseline -Charakteristika:  \n- NAC doses ranged from 257 mg/daly to 1800 mg/day  \n- NAC treatment durations ranged from 3 months to 36 months  \n \n\u2022 Exacerbation prevalence \n- High-dose (RR  = 0.90, 95% CI  = 0.82- 0.996, P  = 0.041, 3 RCTs, \nn=1237) and low -dose (RR  = 0.83, 95% CI  = 0.69- 0.99, P  = 0.043, 6 \nRCTs, n=805) NAC reduced COPD exacerbation prevalence.  \n- Long- term (\u22656 months), but not short -term, NAC reduced exacerba-\ntion prevalence (RR  = 0.85, 95% CI  = 0.74-0.98, P  = 0.024, 7 RCTs, \nn=1741).  \n \n\u2022 Hospital admission  (n=3 Studien; nicht gepoolt aufgrund Hetero-\ngenit\u00e4t)  \n- one study: significantly lower in NAC group (37/50 participants) than \nin control group (55/50 participants)  \n- two other studies: similar but not significant result s (NAC 26/52 vs. \nplacebo 45/56;  and NAC 33/482 vs. placebo 36/482).  \n \n\u2022 NAC did not affect exacerbation rate, forced expiratory volume in 1  s \n(FEV1), forced vital capacity (FVC), or inspiratory capacity (IC). Long-\nterm NAC therapy may reduce risk of COPD e xacerbation.  \n \n\u2022 Sicherheit  (n=6 Studien; nicht gepoolt aufgrund Heterogenit\u00e4t)  \n- mentioned in six studies involving 1777 participants (NAC n=857; \ncontrol n=872)  \n- No significant difference in adverse drug effects was observed be-\ntween NAC -treated patients and controls (RR = 1.13, 95% Cl = 0.86 -\n1.48, P= 0.384)  \n- No significant differences in adverse effects were obtained in our \ndose and treatment duration subgroup analyses (fixed effects models)  \n \n- Participants who received NAC therapy reported gastrointest inal dis-\norders ( e.g., nausea and vomiting, abdominal pain and diarrhea, in-\ncligestion ancl epigastric discomfort) 5/6 studies: average frequency AMSTAR -II: \n- critically low  \n \n  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  280 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n6%  in NAC group vs, 5% in control group).  \n- Skin disorders were reported in two studies: average frequncy 1,3 % \nin NAC group vs. 0.6% in control group.  \n- Central nervous system disorders, dry mouth, joint pain, and muscle \npain were reported in a few patients  \nCazzola M. \nImpact of Mu-\ncolytic Agents \non COPD Ex-\nacerbations: \nA Pair -wise \nand Network \nMeta- analy-\nsis. COPD \n2017; \n14(5):552\u2013 63. \nhttps://www.n\ncbi.nlm.nih.go\nv/pub-\nmed/2875307\n0. \n \u2022 Fragestellung:  To investigate the im-\npact of mucoactive agents on the risk of \nCOPD exacerbations  \n \n\u2022 Suchzeitraum:  03/2017 \n\u2022 Population:  Patient*innen mit COPD \n(not chronic bronchitis)  \n\u2022 Einschlusskriterien:  \n- RCTs  lasting at least 3  months  \n- und Ausschlusskriterien  \n \n\u2022 Interventionen :  oral  \n- ambroxol (150gm) or  \n- carbocysteine (1500mg) or  \n- erdosteine (600mg) or  \n- iodinated glycerol and N -acetylcysteine \n(600 mg/1200mg)  \n\u2022 Vergleich:  Placebo \n \n\u2022 eingeschlossene Studien:  n=11 RCTs \n(n=3.164 patients: n=1.587 treated with a \nmucolytic agent, n=1.577 treated with \nplacebo)  \n \u2022 6 RCT on NAC , 3 on carbocysteine, 1 on erdosteine, and 1 on am-\nbroxol  \n \n\u2022  Mucolytics significantly reduced the odds of exacerbation vs. pla-\ncebo (11 studies analyzed: odds ratio (OR) 0.51, 95% confidence in-\nterval (CI) 0.39 -0.67; p < 0.001).  \n\u2022 Only N -acetylcysteine 1,200  mg/day significantly protected against \nexacerbations vs. placebo (2 studies analyzed: OR 0.56, 95% CI \n0.35- 0.92; p < 0.05; high quality of evidence).  \n\u2022 NAC at lower dose (600 mg/day) did not s ignilicantly improve the \nodds of COPD exacerbations vs. placebo (2 high- quality studies ana-\nlyzed: OR 0.95, 95% Cl 0.85- 1.07; p\u2265 0.05)  \n \n\u2022 A signal of effectiveness was detected for carbocysteine (2 studies \nanalyzed: OR 0.45, 95% CI 0.20- 1.01; p \u2265 0.05; moderate quality of \nevidence; no significant reduction).  \n \n- After adjusting for the significant confounders detected in the meta-\nregression model, therapy with mucolytic agents remained as a statis-\ntically significant treatment against COPD exacerbations (nonad justed \np < 0.001; adjusted for Jadad score p < 0.01; adjusted for studies du-\nration p < 0.05; adjusted for history of exacerbation rate p < 0.001).  \n- The sensitivity analysis identified greater effectiveness of mucolytics \nagents in studies lasting\u2265 1 year v s. shorter RCTs (OR 0.61, 95% Cl \n0.47 - 0.79 vs. OR 0.29, 95%Ci 0.14 -  0.60).  \n \n\u2022 Qualit\u00e4t der Evidenz (GRADE); mucolytic agents and COPD ex-\nacerbations, Anticipated absolute effects  \n- overall (all studies):  MODERATE  \n-- Risk with placebo 317 per 1000  \n-- Risk difference with mucolytic agents 125 fewer per 1000 (164 \nfewer to 80 fewer)  \n \n- N-acetylcysteine, high- dose  (high -quality studies with Jaded score \u2265 \n3): HIGH  \n-- Risk with placebo 256 per 1000  \n-- Risk difference with mucolytic agents 94 fewer per 1000 (178 fewer AMSTAR -II: \n low \n 2 weitere Studien (2x Car-\nbocysteine) eingeschlossen, \ndie nicht im Poole- Review von \n2019 inkludiert wurden \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  281 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nto 16 fewer)  \n \n- N-acetylcysteine, low -dose (high- quality studies with Jaded score \u2265 \n3): HIGH  \n-- Risk with placebo 281 per 1000  \n-- Risk difference with mucolytic agents 10 fewer per 1000 (34 fewer \nto 14 more)  \n \n- Carbocysteine  (high- quality studies wit h Jaded score \u2265 3): MODER-\nATE \n-- Risk with placebo 317 per 1000  \n-- Risk difference with mucolytic agents 144 fewer per 1000 (231 \nfewer to 1 more)  \n \n- Erdosteine (high- quality studies with Jaded score \u2265 3): VERY LOW  \n-- Risk with placebo 515 per 1000  \n-- Risk d ifference with mucolytic agents 164 fewer per 1000 (from 59 \nfewer to 256 fewer)  \n \n- Ambroxo l (high- quality studies with Jaded score \u2265 3): VERY LOW  \n-- Risk with placebo 118 per 1000  \n-- Risk difference with mucolytic agents 6 fewer per 1000 (from 41 \nfewer to 40 more)  \nPoole P. Mu-\ncolytic agents \nversus pla-\ncebo for \nchronic bron-\nchitis or \nchronic ob-\nstructive pul-\nmonary dis-\nease. 2019 \nMay 20.  \n \u2022 prim\u00e4re Fragestellung: To determine \nwhether treatment with mucolytics re-\nduces exacerbations and/or days of disa-\nbility in patients with chronic bronchitis or \nCOPD \n\u2022 sekund\u00e4re Fragestellungen:   \nTo assess whether mucolytics lead to im-\nprovement in lung function or quality of \nlife +   \nTo determine frequency of adverse ef-\nfects associated with use of mucolytics  \n \n\u2022 Suchzeitraum: most recently on  \n23.April 2019  \n\u2022 Population: adults with chronic bron-\nchitis or COPD  \n Baseline -Charakteristika  \n- mean age of participants ranged from 40 to 71 years  \n- All but five studies reported the percentage of current smokers or ex -\nsmokers, which ranged from 55% to 100%  \n- verschiedene Mukolytika in Studien betrachtet; verschiedene Dosier-\nungen \n \nParticipants with no exacerbations in study period (Follow -up: 8.8 \nmonths):  \nRisk with placebo: 386 per 1000 \nRisk with mucolytic: 521 per 1000 (495 to 545)  \nPeto OR 1.73, 95% CI 1.56 to 1.91; 28 RCTs, 6723 participants; \nmoderate certainty evidence  \n>> Generally larger effects in earlier studies of mucolytics in chronic \nbronchitis and sma ller effects in more recent studies in COPD  \n>>  The overall number needed to treat with mucolytics for an aver-AMSTAR -II: \n- low \n \u2022 Ausschlusskriterien irref\u00fch-\nrend:  \nWe excluded studies of in-\nhaled mucolytics and combina-\ntions of mucolytics with antibi-\notics and mucolytics with \nbronchodilators , as well as \nstudies of deoxyribonuclease \nor proteases such as trypsin.  \n \n>> irref\u00fchrende Formulierung: \nes wurden doch Studien einge-\nschlossen, welche Einnahme \nvon langwirksamen Bronchodi-\nlatatoren erlauben (Bsp. Bachh \n2007; Tabelle 2) --> deshalb NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  282 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n\u2022 Einschlusskriterien  \n- RCT \n- adults with chronic bronchitis as defined \nby the British Medical Research Council \nor COPD as defined by the criteria of \nATS, GOLD, ERS, or WHO  \n- must have re ceived regular treatment \nwith oral mucolytics or placebo for at \nleast two months  \n \n\u2022 Ausschlusskriterien:  \n- people with asthma and cystic fibrosis; \nchildren  \n- studies of inhaled mucolytics and com-\nbinations of mucolytics with antibiotics \nand mucolytics with bronchodilators , as \nwell as studies of deoxyribonuclease or \nproteases such as trypsin.  \n \n\u2022 Interventionen : oral mucolytic therapy \nfor at least two months  \n \n\u2022 Vergleich : Placebo  \n \n\u2022 eingeschlossene Studien:  random-\nised, placebo- controlled trials; n=38 \n(10,377 participants)  \n--> betrachtete Mukolytika im Review:  \nN-acetylcysteine (NAC) (n=21 studies)  \ncarbocysteine (n = 3)  \nambroxol (n = 3)  \nerdosteine (n = 2)  \nsobrerol (n = 1)  \ncarbocysteinesobrerol (n = 1)  \ncarbocy steine- lysine (n = 1)  \nletosteine (n = 1),  \ncithiolone (n = 1)  \niodinated glycerol (n = 1)  \nN-isobutyrylcysteine (NIC) (n = 1)  \nmyrtol (n = 1) \ncineole and lysozyme (n = 1)  age of nine months to keep an additional participant free from exacer-\nbations was eight (NNTB 8, 95% CI 7 to 10).  \n>> High heterogeneity was noted for this outcome (I\u00b2 = 62%)  \n>>The type or dose of mucolytic did not seem to alter the effect size, \nnor did the severity of COPD, including exacerbation history.  \n>>Longer studies showed smaller effects of mucolytics than were re-\nported in shorter studies.  \n \nDays of disability per participant per month (Follow -up: 8.3 months):  \nRisk with placebo: Mean days of disability per participant per month \nwas 1.57 days  \nRisk with mucolytic: MD 0.43 days lower (0.56 lower to 0.30 lower)  \n9 RCTs, 2259 participants;  I\u00b2 = 61% ; moderate certainty evidence  \n \nHealth-  related quality of life (total score SGRQ) Scale f rom 1 to 100; \nlower scores indicate better quality of life (Follow -up: 14.1 months):  \nRisk with placebo: Mean SGRQ total score was 39.02 points  \nRisk with mucolytic: MD  1.37 lower (2.85 lower to 0.11 higher)  \n7 RCTs; 2721 participants; I\u00b2 = 64%;  moderate certainty evidence  \n \nHospitalisation during study period (Follow -up: 16.6 months):  \nRisk with placebo: 188 per 1000 \nRisk with mucolytic: 136 per 1000 (107 to 171)  \nPeto OR 0.68 (0.52 to 0.89); 1833 participants; 5 RCTs; I\u00b2 = 58%;  \nmoderate certainty evidence  \n \nAdverse effects (Follow -up: 8.2 months):  \nRisk with placebo: 235 per 1000 \nRisk with mucolytic: 205 per 1000 (185 to 224)  \nPeto OR 0.84 (0.74 to 0.94); 7264 participants; 24 RCTs; I\u00b2 = 46%; \nmoderate certainty evidence  \n>>  pooled effect includes no difference if a random -effects model is \nused.  \n \nDeath during study period (Follow -up: 13.3 months):  \nRisk with placebo: 11 per 1000 \nRisk with mucolytic:10 per 1000 (5 to 20)  \nPeto OR 0.98 (0.51 to 1.87); 3527 participants; 11 RCTs;  I\u00b2 = 0%; \nmoderate certainty evidence  \n>> 18 deaths on mucolytics and 19 on placebo  doch E und Abgleich mit ande-\nren Reviews (Einschluss Pri-\nm\u00e4rstudien), welche E sind  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  283 \n      \n \nAnhang 8.8  Selektiv eingebrachte Literatur  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nDransfield \nMT. Metopro-\nlol for the \nPrevention of \nAcute Exac-\nerbations of \nCOPD. N \nEngl J Med \n2019; \n381(24):2304\n-14. \nhttp://www .nc\nbi.nlm.nih.gov\n/pub-\nmed/3163389\n6 \u2022 Studiendesign: prospective, random-\nized trial, multicenter, placebo- con-\ntrolled \n \n\u2022 Population:  patients with COPD, n = \n532 \n\u2022 Intervention:  Metoprolol (Metoprolol \nsuccinate extended release tablets (50 \nmg) starting dose fol lowed by a dose ti-\ntration procedure (resulting in a final \ndose of 25mg (1/2 of one tablet daily), \n50 mg, or 100 mg (two tablets daily))  \n\u2022 Vergleich:  matching Placebo \n\u2022 Follow -up: 1 year  \n\u2022 ggf. Informationen zu Aufhebung der \nVerblindung und Cross -over \n\u2022 Ein schlusskriterien:  \n- age 40- 85, clinical history of COPD, \nmoderate airflow limitation and an in-\ncreased risk of exacerbations (evi-\ndenced by a history of exacerbations \nduring the previous year or the pre-\nscribed use of supplemental oxygen)  \n \n\u2022 Ausschlusskriteri en: \n- already taking a beta- blocker or who \nhad an established indication for the \nuse of such drugs  \n \n\u2022 Studienzeitraum: 5/2016 - 03/2019 \n\u2022 multicenter: 26 center United States  \n \n \n \n \n \u2022 Baseline -Patientencharakteristika: hinsichtlich Alter, Geschlecht, \nLungenfunktion, COPD -Medikation, Rauchstatus, HF und RR weit-\nestgehend ausgeglichen  \n- mean age: 65.0\u00b17.8 years;  \n \n\u2022 Effektivit\u00e4t / Sicherheit: \n- trial was stopped early because of futility with respect to the primary \nend point and safety concerns .  \n \n- no significant betweengroup difference in the median time until the \nfirst exacerbation (202 days in the metoprolol group and 222 days in \nthe placebo group; hazard ratio for metoprolol vs. placebo, 1.05; 95% \nCI, 0.84 to 1.32; P = 0.66)  \n- Metoprolol wa s associated with a higher risk of exacerbation leading \nto hospitalization (hazard ratio, 1.91; 95% CI, 1.29 to 2.83)  \n- frequency of side effects that were possibly related to metoprolol \nwas similar in the two groups, as was the overall rate of nonrespira-\ntory serious adverse events.  \n \n- during treatment period: 11 deaths in the metoprolol group and 5 in \nthe placebo group, with unadjusted and adjusted hazard ratios for \ndeath of 2.18 (95% CI, 0.76 to 6.29) and 2.13 (95% CI, 0.69 to 6.42)  \n- The majority of deat hs in the metoprolol group were attributed to \nCOPD (7, vs. 1 in the placebo group)  \n- after treatment period: 3 additional deaths in the metoprolol group \n(at 10 to 277 days after the last dose) and 4 additional deaths in the \nplacebo group (at 10 to 26 days after the last dose)  \n \nCAT (COPD assessment test):  \nThe patients in the metoprolol group had a greater increase (indicat-\ning worse control) from baseline in the score on the COPD Assess-\nment Test than those in the placebo group, with a difference of 1.13 \npoint s (95% CI, 0.06 to 2.20) at day 112 and a difference of 1.47 \npoints (95% CI, 0.32 to 2.62) at day 336  \n \nSOBQ (San Diego Shortness of Breath Questionnaire):   \nThe metoprolol group had a greater increase in SOBQ scores from \nbaseline, indicating a worsening in shortness of breath. The between-\ngroup difference in the change from baseline was 3.47 points (95% Selection bias  \nRandomisierung: gering  \n \nAllocation concealment: gering  \n \nPerfor mance bias \nVerblindung von Teilnehmern und \nPersonal: gering \n \nDetection bias  \nVerblindung der Ergebnisevalua-\ntion: unklar  \n \nAttrition bias  \nVerlust von Studienteilnehmern/ \nfehlende Daten: gering  \n \nITT-Analyse: alle Analysen ITT -\nbasiert  \n \nReporting bias  \nselektive Ergebnisdarstellung: un-\nklar \n \nAndere Biasursachen  \nBaseline imbalance: gering \n \nInteressenkonflikte/ Sponsoring: \nFunded by the Department of De-\nfense/ Sponsor: University of Min-\nnesota  Studie vorzeitig abgebro-\nchen u.a. aufgrund von Si-\ncherheitsbedenken  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  284 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nCI, 0.42 to 6.52) at day 112 and 4.80 points (95% CI, 1.52 to 8.07) at \nday 336  \nRabe KF, \nMartinez FJ, \nFerguson GT, \net al. Triple \nInhaled Ther-\napy at Two \nGlucocorti-\ncoid Doses in \nModerate- to-\nVery-Severe \nCOPD. N \nEngl J Med \n2020; \n383(1):35\u2013 48. \nDOI: \n10.1056/NEJ\nMoa1916046.  \n \nhttp://www.nc\nbi.nlm.nih.gov\n/pub-\nmed/3257980\n7. ETHOS  \n\u2022 Studientyp:  randomized, double-\nblind, multi -center, parallel -group study  \n\u2022 Population : moderate- to very -severe \nCOPD and at least one exacerbation in \nthe past year; n=8509 (n=8588 random-\nisiert)  \n\u2022 Studienzeitraum:  2015 - 2019  \n \n\u2022 Interventionen: 1:1:1:1 ratio  \n- twice -daily inhaled doses of triple ther-\napy \n-- inhaled glucocorticoid ( 320 \u03bcg or 160 \n\u03bcg of budesonide), a LAMA (18 \u03bcg of \nglycopyrrolate), and a LABA (9.6 \u03bcg of \nformoterol)  \nor  \n- one of two dual therapies:  \n-- 18 \u03bcg of glycopyrrolate plus 9.6 \u03bcg of \nformoterol or  \n-- 320 \u03bcg of budesonide plus 9.6 \u03bc g of \nformoterol  \n \n\u2022 prim\u00e4rer Endpunkt: annual rate (the \nestimated mean number per patient per \nyear) of moderate or severe COPD ex-\nacerbations  \n \n\u2022 sekund\u00e4re Endpunkte:  time to the \nfirst moderate or severe COPD exacer-\nbation, the change from baseline in av-\nerage daily use of rescue medication \nover 24 weeks, the percentage of pa-\ntients who had a St. George\u2019s Respira-\ntory Questionnaire (SGRQ) response \n(defined as a decrease from baseline in \nthe total score on the SGRQ of \u22654 \npoints at week 24),  the annual rate of \u2022 Baseline -Patientencharakteristika:  hinsichtlich Alter, G eschlecht, \nRauchstatus, stattgehabte Exazerbationen weitestgehend ausgegli-\nchen; etwas weniger Patienten mit Baseline \u2265300 cells/mm3 Eosino-\nphilen in LAMA/LABA -Gruppe (13,8% vs. 14,5%; 15,0%; und 15,6%)  \n \n\u2022 Ergebnisse prim\u00e4rer Endpunkt:   \nannual rates of moder ate or severe exacerbations  \n \n- 320-\u03bcg\u2013budesonide triple- therapy group (n=2137 patients): 1.08  \n- 160 \u03bcg\u2013budesonide triple- therapy group (n=2121 patients): 1.07  \n- glycopyrrolate\u2013 formoterol group (n=2120 patients): 1.42  \n- budesonide\u2013 formoterol group (n=2131 patients): 1.24  \n \nThe rate was significantly lower with 320- \u03bcg\u2013budesonide triple ther-\napy than with glycopyrrolate\u2013  formoterol (24% lower: rate ratio, 0.76; \n95% confidence interval [CI], 0.69 to 0.83; P<0.001) or budesonide\u2013\nformoterol (13% lower: rate rati o, 0.87; 95% CI, 0.79 to 0.95; P = \n0.003). Similarly, the rate was significantly lower with 160 \u03bcg\u2013bude-\nsonide triple therapy than with glycopyrrolate\u2013 formoterol (25% lower: \nrate ratio, 0.75; 95% CI, 0.69 to 0.83; P<0.001) or budesonide\u2013 for-\nmoterol (14% lowe r: rate ratio, 0.86; 95% CI, 0.79 to 0.95; P = 0.002).  \n \n\u2022 Eosinophile: (siehe Figure 4 Supplement)  \n \n\u2022 Sicherheit: (siehe Supplement)  \n- The incidence of any adverse event was similar across the treat-\nment groups (range, 61.7 to 64.5%); the incidence of conf irmed \npneumonia ranged from 3.5 to 4.5% in the groups that included in-\nhaled glucocorticoid use and was 2.3% in the glycopyrrolate\u2013 for-\nmoterol group.  \n- The most frequently reported adverse events overall were naso-\npharyngitis (10.5%), COPD (10.4%), and upper respiratory tract in-\nfection (5.6%)  \n \n\u2022 risk of death from any cause (sekund\u00e4rer Endpunkt):  \n- in 320- \u03bcg\u2013budesonide tripletherapy group was 46% lower than that \nin the glycopyrrolate\u2013 formoterol group (28 vs. 49 deaths; hazard ra-\ntio, 0.54; 95% CI, 0.34 to 0.87)  and 22% lower than that in the Selection bias  \nRandomisierung: low \nAllocation concealment: low  \n \nPerformance bias \nVerblindung von Teilnehmern und \nPersonal: low \n \nDetection bias  \nVerblindung der Ergebnisevalua-\ntion: unclear  \n \nAttrition bias  \nVerlust von Studienteilnehmern/ \nfehlende Daten:  low \n \nITT-Analyse:modifizierte ITT (with \nthe use of on- treatment data only)  \n \nReporting bias  \nselektive Ergebnisdarstellung: \nunclear  \n \nAndere Biasursachen  \nBaseline imbalance: low  \n \nInteressenkonflikte/ Sponsoring: \nFunded by AstraZeneca \n Selektiv eingebrachte Lite-\nratur \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  285 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nsevere COPD exacerbations, and time \nto death from any cause.  \n \n\u2022 26 countries  \n\u2022 52-week, phase 3  budesonide \u2013formoterol group (28 vs. 34 deaths; hazard ratio, 0.78; \n95% CI, 0.47 to 1.30). The risk of death from any cause in the 160-\n\u03bcg\u2013budesonide triple- therapy group was lower than that in the glyco-\npyrrolate\u2013  formoterol group (39 vs. 49 deaths; hazard ratio, 0.79; \n95% CI, 0.52 to 1.20) but higher than that in the budesonide\u2013 for-\nmoterol group (39 vs. 34 deaths; hazard ratio, 1.13; 95% CI, 0.72 to \n1.80)  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  286 \n      \n \nAnhang 9  Evidenztabellen Medizinische Rehabilitation  \nAnhang 9.1  Cochrane Reviews Rehabilitation \nReferenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nMcCarthy B. Pulmonary re-\nhabilitation for chronic ob-\nstructive pulmonary disease. \nCochrane Database of Sys-\ntematic Reviews 2015;(2).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/10.1002/\n14651858.CD003793.pub3/\nabstract  \n \u2022 Body of Evidence:  n= 65 eingeschlossene \nRCTs f\u00fcr Metaanalyse ( n= 3822 einges-\nchlossene Patient*innen)  \n\u2022 Suchzeitraum:  current as of 04/2014 \n\u2022 Population:  \n\u2022 Einschlusskriterien:  \n- participants had COPD  \n- any or all participants were on continuous oxy-\ngen \n\u2022 Ausschlusskriterien:   \n- who were mechanically ventilated; or  \n- who had an acute exacerbation within four \nweeks before commencement of the intervention  \n\u2022 Interventionen:   \nPulmonary rehabilitation (Any in -patient, out -pa-\ntient, community -based or home- based rehabili-\ntation programme of at least four weeks\u2019 dura-\ntion that included ex ercise therapy with or with-\nout any form of education and/or psychological \nsupport delivered to patients with exercise limita-\ntion attributable to COPD. We included any ex-\nercise therapy that included physical activity \nconsidered to be aerobically demanding.)  \nvs. Usual Care (without education or additional \ninterventions)  \n \n\u2022 Prim\u00e4re Endpunkte:  \nDisease- specific health- related quality of life \n(HRQoL)  \n- Chronic Respiratory Disease Questionnaire \n(CRQ)  \n- St. George\u2019s Respiratory Questionnaire \n(SGRQ)  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- Functional exercise capacity assessments  \n- \u25e6 Six-minute walk test/distance (6MWT/6MWD)  \n  \u25e6 Incremental shuttle walk test (ISWT)  >> This review highli ghts that pulmonary rehabilitation improves the health -re-\nlated quality of life of people with COPD. Results  \nstrongly support inclusion of pulmonary rehabilitation as part of the management \nand treatment of patients with COPD.  \n \nQoL - Change in CRQ (dyspnoea)  CRQ Questionnaire.(Higher is better and 0.5 \nunit is an important difference), n=1283 (19 RCTs), G RADE: Moderate  \nUsual care: Median change = 0 units  \nRehabilitation versus usual care: Mean QoL -  change in CRQ (Dyspnoea) in the \nintervention groups was 0.79 units higher  (0.56 to 1.03 higher)  \nMD 0.79, 95%CI 0.56 to 1.03; I\u00b2= 63%  \n \nQoL - Change in CRQ (fatique)  \nMD 0.68 (95%CI0.45, 0.92), I\u00b2= 64%, 19 RCT, n =  1291, GRADE:low  \n \nQoL - Change in CRQ (Emotional funtion)  \nMD 0.56 (95%CI 0.34, 0.78), I\u00b2=58% , 19 RCT, n = 1291, GRADE: nicht an-\ngegeben  \n \nQoL - Change in CRQ (Mastery)  \nMD 0.71 (95%CI 0.47, 0.95), I\u00b2=63%,19 RCT, n = 1212, GRADE:low  \n \nQoL - Change in SGRQ (tot al) (Lower is better and 4 units is an important differ-\nence), I\u00b2=59%, n=1146 (19 RCTs), GRADE: Moderate  \nUsual care: Median change = 0.42 units  \nRehabilitation versus usual care: Mean QOL - change in SGRQ (total) in the in-\ntervention groups was  6.89 units low er  (-6.89 (95%CI - 9.26; -4.52)  \n \nChange in maximal exercise ( Incremental Shuttle walk test (ISWT)), n=694 (8 \nRCTs); GRADE: Moderate  \nUsual care: Median change = 1 metre \nRehabilitation versus usual care: Mean maximal exercise (incremental shuttle \nwalk test) in the intervention groups was 39.77 metres higher ( 22.38 to 57.15 \nhigher)  \n  \nChange in functional exercise capacity  (6MWT)), n=1879 (38 RCTs), GRADE: \nVery low  \nUsual care: Median change = 3.4 metres  AMSTAR -Score: 10/11  \n \ny-y-y-y-y-y-y-y-y-y-n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  287 \n      \n \nReferenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n  \u25e6 Endurance shuttle walk test (ESWT)  \n- Maximal exercise tests  \n  \u25e6 Incremental cycle ergometry  \n Rehabilitation versus usual care: Mean functional exercise  capacity (6MWT)) in \nthe intervention groups was  43.93 metres higher  (32.64 to 55.21 higher)  \n \nAussagen des Reviews zu Home- based Rehabilitation:  \n\u2022 Only six studies reported patient -based programmes, three of which were com-\nbined with a home- based follow -up component. Thirty -seven studies were hospi-\ntal out -patient based; eight of these included a home- based element. In all, 21 \nprogrammes were community based, 11 of which were entirely home based, \nand one programme combined community - and home- based components . \nRehabilitation versus usual care (subgroup analysis hospital versus community -\nbased pulmonary rehabilitation)  \n\u2022 In total, 39 included studies were considered to have a hospitalbased PR inter-\nvention delivered on an in- patient or out -patient basis. A total of 25 studies fo-\ncused on programmes that were delivered in the community at community cen-\ntres or in individuals\u2019 homes. One study had both a community -based and an \nout-patient - based intervention group, so it was excluded from the subgroup \nanalysis ( Mendes De Oliveira 2010).  \n\u2022 In the subgroup analysis for the CRQ domain outcomes, the \u2019community\u2019 sub-\ngroup included nine studies and the \u2019hospital group\u2019 included 10 studies. For \nSGRQ outcomes, the community subgroup included nine studies and the hospi-\ntal subgroup included 10 studies.  \n\u2022 Evidence suggested a significant difference in treatment effect between sub-\ngroups for all domains of the CRQ, with higher mean values, on average, in the \nPR group in hospital than in the community - based group (Analysis 2.1;  Analysis \n2.2; Analysis 2.3; Analysis 2.4). No subgroup differences were reported for any \nof the SGRQ domains (Analysis 2.5; Analysis 2.6; Analysis 2.7; Analysis 2.8).  \n>> hier: homebased & community -based Therapien zusammen betrachtet; kein \ndirekter Vergleich.  \nPuhan MA. Pulmonary reha-\nbilitation following exacerba-\ntions of chronic obstructive \npulmonary disease. \nCochrane Database of Sys-\ntematic Reviews 2016;(12).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/10.1002/\n14651858.CD005305.pub4/\nabstract  \n \u2022 Body of Evidence:  n=20 eingeschlossene \nRCTs f\u00fcr Metaanalyse ( n=  1477 einges-\nchlossene Patient*innen)  \n\u2022 Suchzeitraum:  current as of 10/2015; \nhandsearches up to 4/016  \n\u2022 Population: Patient*innen mit COPD nach Ex-\nazerbation  \n\u2022 Einschlusskriterien:  \n- Participants with COPD after inpatient or out-\npatient care for acute exacerbation. This review \nrequired that more than 90% of study partici-\npants were patients with COPD.  \n- The rehabilitation programme must commence Hospital readmission (to end of follow -up, median 9 months), high r isk for 1 -year \nreadmission, n=810 (8 RCTs), GRADE: Moderate  \nControl: 500 per 1000  \nRehabilitation: 306 per 1000 (174 to 476)  \n-reduced hospital readmissions (OR 0.44, 95% CI 0.21 to 0.91; I2 = 77%).  \n \nMortality (to end of follow -up, median 12 months), High ri sk for 1 -year mortality, \nn=670 (6 RCTs), GRADE: Low  \nControl: 150 per 1000  \nRehabilitation: 107 per 1000 (47 to 228)  \n(Comment: None of the trials used mortality as a primary outcome, and none of \nthe trials was powered to detect a meaningful ef fect of rehabi litation on mortal-\nity) AMSTAR -Score: 11/11  \n \ny-y-y-y-y-y-y-y-y-y-y NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  288 \n      \n \nReferenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n immediately after initiation of exacerbation treat-\nment orwithin three weeks of initiation of exacer-\nbation treatment.  \n \n\u2022 Interventionen:  Any inpatient and/ or outpa-\ntient pulmonary rehabilitation programme, in-\ncluding at least physical exercise (endurance or \nstrength exercise, or both), delivered to patients \nwho have received acute care for an exacerba-\ntion of COPD vs. usual care control groups  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Hospital admissions (at least one hospital ad-\nmission during follow -up) \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- HRQL (SF -36, CRQ, SGRQ)  \n- Exacerbation rates (after discharge)  \n- Number of outpatient visits  \n- Length of readmissions  \n- Mortality  \n- Functional exercise capacity as measured by \ntwo-, three- , \nfour-, six- or 12- minute- walk test, or by a shuttle \nwalk test  \n- Maximal exercise capacity  \n- Exercise endurance  \n- Withdrawals  \n- Adverse events  \n- Costs  \n - OR 0.68, 95% CI 0.28 to 1.67), I2 = 59%.  \n \nhealth- related quality of life (SGRQ), n=1003 (8 RCTs), GRADE: High  \nControl: SGRQ score at beginning of rehabilitation was typically around 65 \nRehabilitation: Mean change from baseline in S GRQ Total score in the interven-\ntion group was 7.80 units lower  (95%CI -12. 12 to -3.47)  \n- SGRQ total score (MD) -7.80, 95% CI - 12.12 to -3.47; I2 = 64%).  \n \nChange from baseline in 6- minute walking test  (to end of follow -up, median 3 \nmonths). n=819 (13 RCTs) , GRADE: High  \nControl: 6- Minute walking distance at beginning of rehabilitation was typically \naround 300 metres  \nRehabilitation: Mean change from baseline in 6- minute walking test in the inter-\nvention group was 62. 38 metres more (95%CI 38.45 to 86.31)  \n \nAdverse events  \nFive studies involving 278 participants explicitly recorded adverse events, four \nstudies reported no adverse events during rehabilitation  \nprogrammes and one study reported one serious event.  \n \n \n>> Quality of life and exercise capacity were improved by rehabilitation, \nand the effect was substantially larger than the minimal important differ-\nence. Results for hospital readmissions and mortality were diverse, with \nsome studies showing that pulmonary rehabilitation reduced hospital ad-\nmissions and mortality compared with usual community care (no rehabili-\ntation), and other studies not showing such effects.  \n \nMcCabe C. Computer and \nmobile technology interven-\ntions for self -management in \nchronic obstructive pulmo-\nnary disease. Cochrane Da-\ntabase of Systematic Re-\nviews 2017;(5).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/10.1002/\u2022 Body  of Evidence:  n=3  eingeschlossene \nRCTs f\u00fcr Metaanalyse ( n=557  einges-\nchlossene Patient*innen)  \n\u2022 Suchzeitraum:  11/2016 \n\u2022 Population: Patient*innen mit COPD (alle \nSchweregrade)  \n\u2022 Einschlusskriterien: adult > 18y  \n- We included participants who live at home or in \na non- healthcare residential setting (sheltered \u2022 Baseline -Charakteristika  \n- mean age: 64 years;  \n- men=307 (64.9%)  \n- n= 319 received smart technology to support self -management, and n=238 \nreceived face- to-face verbal/written or digital information and education about \nself-management  \n \nHospital admission, n=239 (1 RCt), GRADE: Low  \n- Hospital admission not reported at 4 months. At 12 months. smart technology \ndid not signif icantly impact the number of hospital admissions  AMSTAR -Score: 9/11  \n \ny-n-y-y-y-y-y-y-y-y-n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  289 \n      \n \nReferenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n14651858.CD011425.pub2/\nabstract  \n \n housing) and who use, or have access to, tech-\nnology, for example, personal computer, tablet, \nor smart phone, to help them manage their ill-\nness.  \n \n\u2022 Interventionen:   \n- remote and Web 2.0- based interventi ons deliv-\nered via technologies that give patients access \nto ehealth information to change behaviours to-\nwards self -management of COPD. These tech-\nnologies include personal computers (PCs) and \napplications  (apps) for mobile technology such \nas iPad, Android t ablets, smart phones, and \nSkype.  \nvs. \n- face- to-face and/or hard copy/digital documen-\ntary educational/self management support  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Hospital admissions  \n- Acute exacerbations requiring general practi-\ntioner (GP)  \nvisit or additional treatment, or both \n- Health- related quality of life (HRQoL)  \n \n\u2022 Sekund\u00e4re Endpunkte:  \n- Self-efficacy  \n- Cost-effectiveness  \n- Functional capacity  \n- Lung function  \n- Anxiety and depression  \n- Sustained behaviour change (smoking cessa-\ntion and  \nincreased phys ical activity)   \nAcute exacerbations requiring general practitioner (GP) visit and/ or additional \ntreatment, n= 239 (1 RCT), GRADE: Low  \n- Acute exacerbations were not reported at 4 months. At 12 months, smart tech-\nnology did not signif icantly impact the number of acute exacerbations  \n \nHealth- related quality of life  (HRQoL) assessed with SGRQ and CCQ, n=472 (3 \nRCTs), GRADE: Low  \n- Risk with face - to- face/ digital and/or written support: Mean HRQoL ranged \nacross control groups from 0.08 to 1.686  \n- Risk with smart technology: SMD in HRQoL in the intervention group was 0.22 \nlower  (0.44 to 0.03 low er) (Lower scores on both SGRQ and CCQ indicate bet-\nter HRQoL.)  \n \nSelf-efficacy  was not measured in any of the included studies  \nFunctional capacity  (6- minute walking test or similar): None of the included \nstudies measured this outcome  \n \n>> People who received smart technology showed greater improvement in self \nmanagement and quality of life and increased physical activity compared with \npeople who received face- to-face/digital and/or written support over a four -week \nto six -month period. Also, hospital admissions and exacerbations of COPD did \nnot differ between those who used smart technology and those who did not. \nOnly one study provided information about people who stopped smoking and re-\nported no differences between groups.  \n \nMcLean S. Telehealthcare \nfor chronic obstructive pul-\nmonary disease. Cochrane \nDatabase of Systematic Re-\nviews 2011;(7).  \n \u2022 Body of Evidence:  n=10 RCTs einges-\nchlossen (n=1004 patients)  \n\u2022 Suchzeitraum:  up to January 2010 \n\u2022 Population: participants with COPD  \n\u2022 Einschlusskriterien:  \n- COPD, as diagnosed by a clinician \n- with no exclusions on the basis of age, gender, \nethnicity or language spoken  Total exacerbations (2 studies)  \n- Bourbeau 2003 (telephone system used): 362 acute exa cerbations of COPD in \nthe control group (n = 95) and 299 exacerbations in the intervention group (n =  \n96) over a 12 month period.  (p = 0.06)  \n- Vitacca 2009 (used Internet; n=240 participants,n=101 with COPD): mean \nnumber of exacerbations per month was significantly higher in controls than in \nthe telehealthcare group (0.78\u00b10.77 and 0.23\u00b10.38; p<0.0001).  \n AMSTAR -Score: 9/11  \n \ny-n-y-y-y-y-y-y-y-y-ca NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  290 \n      \n \nReferenz  Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n\u2022 Ausschlusskriterien:  \n- people with asthma only  \n \n\u2022 Interventionen:  telehealthcare vs. usual f ace-\nto-face care   \n1. Video or telephone links with healthcare pro-\nfessionals in real time or using store and forward \ntechnlogies.  \n2. Systems of care using Internet -based tele-\ncommunication with healthcare profes -sionals.  \n3. Systems of care using both wired and wire-\nless telemetry for telemonitoring of spirometry \n(FEV1/FVC), respiratory rate, blood pressure \nand oxygen saturations involving feedback to \nthe patient, which has been processed or a \nthorised by a healthcare professional.  \n4. Other systems of remote healthcare.  \n5. Complex intervention studies if it is pos -sible \nto tease out the individual tele- healthcare ele-\nments.  \n6. Interventions in all settings and from all types \nof healthcare provider.  \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Total exacerbations  \n- Quality of life (e .g. SGRQ)  \n- Emergency Department visits  \n- Hospitalisations  \n- Deaths  \n\u2022 Sekund\u00e4re Endpunkte:  \n- FEV1; FVC; Patient satisfaction; Study with-\ndrawal; Costs; Cost effectiveness  Quality of life (SGRQ)  \n- Telehealthcare was associated with a clinically significant increase in quality of \nlife \n--> mean difference - 6.57 (95%CI -13.62 to 0.48; n=2 studies, 253 participants ; \nminimum clinically significant difference is a change of -4.0) (Wide CI)  \n- QoL with CRQ assessed: Nguyen 2008 dyspnoea management(face to face \nvs.  electronic web- networked interface) --> minimal clinically important differ-\nence is 0.5 (CRQ used)  \n \nEmergency department visits  \n- Telehealthcare showed a significant reduction in the number of patients with \none or more emergency department attendances over 12 months;  \n--> OR 0.27 (95% CI 0.11 to 0.66; n=3 trials, n=449 parti cipants)  \n \nHospitalisations  \n- having one or more admissions to hospital over 12 months:  \n--> OR 0.46 (95% CI 0.33 to 0.65, n=4 trials with 604 participants)  \n \nDeath  \nThere was no significant difference in the OR for deaths over 12 months for the \ntelehealthcare group as compared to the usual care group:  \n--> OR 1.05 (95% CI 0.63 to 1.75), n=3 trials, 503 participants  \n \n>> verschiedene Arten von Telehealthcare in den verschiedenen Studien, \njedoch dennoch gepoolt!  \n \nAnhang 9.2  Ger\u00e4tebasiertes Training \nZitat Studiencharakteristika  Interventionen  Studienergebnisse  \nDuruturk N. A \ncomparison of \ncalisthenic and \ncycle exercise \ntraining in \u2022 Studientyp: RCT  \n \n\u2022 6-Wochen Programm; Assesment at \nbaseline + after intervention  \n \u2022 Setting: evtl. Rehabilitation; in a physical therapy clinic un-\nder supervision of a physiotherapist  \n \n\u2022 formal education session was provided to all participants \nbefore starting the interventions  \u2022 Baseline -Patientencharakteristika: hinsichtlich Alter,Gewicht, Lungenfunk-\ntion weitestgehend ausgeglichen; Geschlecht: etwas mehr Frauen in Cycle \nexercise group (4/11), als in den anderen Gruppen (calisthenic 1/13; control \n2/11)  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  291 \n      \n \nZitat Studiencharakteristika  Interventionen  Studienergebnisse  \nchronic obstruc-\ntive pulmonary \ndisease pa-\ntients: A ran-\ndomized con-\ntrolled trial. Ex-\npert Rev Respir \nMed 2016; \n10(1):99\u2013 108. \nhttps://www.ncbi\n.nlm.nih.gov/pub\nmed/26616764 . \n \u2022 Population: n= 47 patients with COPD; \nStudienende n=42  \n \n\u2022 Einschlusskriterien:  \n- diagnosis of stage II or II COPD accord-\ning to GOLD  \n- clinical stable patient  \n\u2022 Ausschlusskriterien  \n- patients clinically unstable  \n- CVD or malignent disorders  \n- non-complient with treatment or unabel \nto perform l ung function testing, cardio-\npulmonary exercise testing, or exercise \ntraining \n\u2022 prim\u00e4rer Endpunkt  \nQuality of life (Saint George Respiratory \nQuestionnaire)  \n\u2022 sekund\u00e4re Endpunkte  \npulmonary functions, cardiopulmonary \nexercise testing, Fitness Testing, and \nHosp ital Anxiety -Depression, Modified \nMedical Research Council Dyspnea, Fa-\ntigue Severity, Fatigue Impact Scale \n \n\u2022 Studienzeitraum: keine Angaben \n\u2022 T\u00fcrkei  \n  \n\u2022 6-week intervention period  \n \n3 randomisierte Gruppen:  \n- Calisthenic (3x/Woche f\u00fcr 6 Wochen)  \n--> included strengthening and stretching of lower and upper \nextremity muscles (siehe S. 2 [100] der Publikation); 20- 45 \nMinuten; kontinuierliche Steigerung der Wiederholungen \n- Cycle ergometer exercise (3x/Woche f\u00fcr 6 Wochen)  \n--> 50- 70% of VO2max obtained from cycle ergometer test-\ning; 20- 30 Minuten; kontinuierliche Steigerung der Intensit\u00e4t  \n- Control group: no exercise (nur Schulung und Weiterf\u00fchren \nihrer medikament\u00f6sen Behandlung)  \n \u2022 Ergebnisse prim\u00e4rer Endpunkt: SGRQ (total) (mean  \u00b1 SD)  \nCycle exercise group:  \nbaseline: 49,3 \u00b1 19,6 \n6 weeks: 28,7 \u00b1 12,9  \ndifference: -20,7 \u00b1 11,4  \n \nCalisthenic  exercise group:  \nbaseline: 49,9 \u00b1 19,6 \n6 week: 26,7 \u00b1 15,9  \ndifference: -22,6 \u00b1 10,4  \n \n\u2022 ausgew\u00e4hlte weitere Ergebnisse: 6MWDT (m) (mean  \u00b1 SD)  \nCycle exercise group:  \nbaseline: 448,7 \u00b1 60,9  \n6 weeks: 514,2 \u00b1 59,3  \ndifference: 65,4 \u00b1 21,7  \n \nCalisthenic exercise group:  \nbaseline: 395,6 \u00b1 98,2  \n6 week: 482,3 \u00b1 65,4 \ndifference: 86,7 \u00b1 44,5  \n \n- Physical fitness, QoL, anxiety -depression, dyspnea and fagtigue changed \nsignificantly in exercise groups  \n- no between- group differences; p=0,66 f\u00fcr SRGQ total; p=0,31 f\u00fcr 6MWDT  \n- no significant improvements in control group \n \n>>> main finding: cycle ergometer and calisthenic exercise training were \nsimilarly effective in improving quality of life, exercise capacity, physical fit-\nness psychosocial status and reducing respiratory symptoms in patients with \nCOPD \n \nSelection bias  \nRandomisierung: gering  \nAllocation concealment: gering  \nPerformance bias \nVerblindung von Teilnehmern und Personal: nicht anwendbar  \nDetection bias  \nVerblindung der Ergebnisevaluation: unklar  \nAttrition bias  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  292 \n      \n \nZitat Studiencharakteristika  Interventionen  Studienergebnisse  \nVerlust von Studienteilnehmern/ fehlende Daten: gering  \nITT-Analyse: keine ITT -Analyse durchgef\u00fchrt;  \nReporting bias  \nselektive Ergebnisdarstellung: unklar  \nAndere Biasursachen   \nKommentar: Vertrauensw\u00fcrdigkeit der Ergebnisdarstellung: Baseline- Daten f\u00fcr SGRQ (total) sind f\u00fcr beide Interventionsgruppen exakt gleich.  \nInteressenkonflikte/ Sponsoring: funded by Baskent University; writing assistance by EDANZ editing service  \nBaseline -Daten f\u00fcr SGRQ (total) sind f\u00fcr beide Interventionsgruppen exakt gleich.  \nFrage: ist dies eher unwahrscheinlich? Vertrauensw\u00fcrdig?  \n \nZitat Studiencharakteristika  Interventionen  Studienergebnisse  \nGreulich T. A random-\nized clinical trial to as-\nsess the influence of a \nthree months training \nprogram (gym -based \nindividualized vs. cal-\nisthenics -based non-\ninvidualized) in \nCOPD- patients. Re-\nspir Res 2014; 15:36. \nhttps://www.ncbi.nlm.n\nih.gov/pub-\nmed/24666558 . \n \n \u2022 Studientyp: RCT \n\u2022 Assessments:  At the begin-\nning and after three months  \n \n\u2022 Population: patients with mild \nto very severe COPD (n=61 ran-\ndomisiert; n=34 patients com-\npleted the study)   \n\u2022 Einschlusskriterien:  stable \nCOPD; diagnostic criteria pub-\nlished by GOLD  \n\u2022 Endpunkte (keine Unterschei-\ndung zwischen prim\u00e4r und \nsekund\u00e4r)  \n- 6-minute walking tes t (6-MWT)  \n- health- related quality of life us-\ning SGRQ and CAT  \n- ultrasound measurement of M. \nrectus femoris cross -sectional \narea (M. rect. fem.)  \n- serum level measurements of \nmyokines and inflammatory \nmarkers  \n \n\u2022 Studienzeitraum: 01/2009 -  \n12/2012 \n\u2022 Deutsch land Setting: outpatient  \n \n\u2022 Individualisiertes Ger\u00e4tetraining vs. nicht -individualisierte Calisthenics  \n\u2022 3 - 4 months ambulatory training program ; both low -intensity training ap-\nproaches  \n\u2022 jeweils 1x/Woche 1 Stunde; at least 12 trainings sessions  \n \n\u201cIndivi dualized Training\u201d (IT):  \n- patients participated in a weekly individualized gym -based outpatient exer-\ncise training.  \n- included all components of exercise training suggested by ACCP/AACVPR \nclinical practice guidelines.  \n- Each patient received an individual training schedule at the beginning of the \ntraining period based on his maximal force and endurance time in different ap-\nproaches  \n- special focus on the following muscle groups: thigh muscles (especially the \nquadriceps femoris), lateral hip and trunk stabi lizers, anterior shoulder mus-\ncles, rotator cuff muscles, different muscles of the upper extremities and dor-\nsal trunk and scapular stabilizers  \n- Endurance training was done on the ergometer  \n \n\u201cNon -individualized Training\u201d (NT):  \n- patients participated once weekly as part of a group in different forms of ex-\nercise (calisthenics).  \n- training unit was divided into three parts: warm -up (free movements, stretch-\ning) for ten minutes; the main part was a forty minute training which included \ncollectively performed e xercises like ball games, stepping, thera -band training \u2022 Baseline -Patienten charakteristika: hinsichtlich Geschlecht, \nAlter,Gewicht, Schwere der COPD weitestgehend ausgegli-\nchen (no statistical significant differences)  \n- Comorbidities: Patients in all groups reported a high number \nof comorbidities; no statistical significant differ ences between \ngroups  \n \nexercise capacity (6- MWT)  \n- IT group: significant change of the walking distance (M1 = \n407 \u00b1 105.44 m, M2 = 439.37 \u00b1 122.89 m; p = 0.012)  \n- NT group: no significant change was observed (M1 = 411.79 \n\u00b1 64.74 m, M2 = 427.5 \u00b1 84.57 m; p = 0.116)  \n- No significant between group differences could be observed.  \n \nQuality of life  \nWe were not able to detect significant differences of SGRQ \nand CAT between measurement 1 and 2 in any of the groups. \n(keine weiteren Daten hierzu angegeben)  \n \nWhen consi dering only patients that entered the training period \nwe observed a differential dropout, with significantly more sub-\njects stopping NT than IT (13/27 vs. 5/25; p = 0.04). Assessing \npossible reasons for this phenomenon, the main causes were \nnot significantl y different between both groups [...] In summary, \npatients with a worse baseline condition had a higher probabil-\nity to drop out.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  293 \n      \n \nZitat Studiencharakteristika  Interventionen  Studienergebnisse  \n and dumbbells. The training period was finalized by a ten minute relaxing ex-\nercises period.  \n- Disease- specific techniques (body positions, different breath and cough tech-\nniques, like the pursed lips breathing) were communicated to the group.  \n \n\u2022 in both group: same physiotherapist  \n\u2022 All patients were encouraged to perform domestic workout. However, it was \nnot systematically assessed, to which extent this recommendation was fol-\nlowed \n  \n \n \nSelection bias  \nRandomisierung:  gering  \nAllocation concealment: gering.  \nPerformance bias \nVerblindung von Teilnehmern und Personal: nicht anwendbar  \nDetection bias  \nVerblindung der Ergebnisevaluation: gering  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: hoch  \nITT-Analyse: : keine ITT -Analyse durchgef\u00fchrt;  \nReporting bias  \nselektive Ergebnisdarstel lung: unklar  \nAndere Biasursachen  \nBaseline imbalance:  gering \nInteressenkonflikte/ Sponsoring:  Teilweise durch pharmakol. Unternehmen gesponsert (The project was supported by the German Centre for Lung Research (DZL). The study has been funded par tially \nby GSK. No further conflict of interest has to be acknowledged.)  \nSetting: outpatient training program (3 months ambulatory training program)  \n \nZitat Studiencharakteristika  Interventionen  Studienergebnisse  \nNormandin EA. \nAn evaluation of \ntwo approaches \nto exercise con-\nditioning in pul-\nmonary rehabili-\ntation. Chest \n2002; \n121(4):1085 \u201391. \u2022 Studientyp: prospective, randomized, unblinded, \n8-week -trial \n \n\u2022 Assessments: before/during the first week of PR \n+ immediately after the 8- week program  \n \n\u2022 Population: n=40 patients with COPD referred for \npulmonary rehabilitation  \n\u2022 Ein- und Ausschlusskriteri en: Setting: hospital -based outpatient pulmonary \nrehabilitation program  \n \n\u2022 compared the short -term effectiveness of a \nhigh- intensity, lower extremity endurance pro-\ngram  \nvs. \na low -intensity, multicomponent calisthenics \nprogra m \u2022 Baseline -Patientencharakteristika: hinsichtlich Geschlecht, Alter,Gewicht weit-\nestgehend ausgeglichen  \nLungenfunktion + CRQ at baseline: Baseline FEV1 was significantly lower in the \nhigh- intensity group (p=0,03), and the CRQ total score tended to be higher in this \ngroup (p=0,16)  \n \nPatients in the high- intensity group showed greater increases in treadmill endur-\nance and greater reductions in exertional dyspnea, whereas those in the low -inten-\nsity group showed greater increases in arm -endurance testing. Both groups had NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  294 \n      \n \nZitat Studiencharakteristika  Interventionen  Studienergebnisse  \nhttps://www.ncbi\n.nlm.nih.gov/pub\nmed/11948036 . \n \n 1) symptomatic COPD  \n2) ability tp perform aerobic treadmill and station-\nary bicycle training and peripheal muscle training  \n3) absence of a significant comorbid disease  \n4) no formal PR within the past 12 month  \n\u2022 prim\u00e4rer Endpunkt: health status (measured us-\ning Chronic Respiratory Disease Questionnaire; \nCRQ)  \n\u2022 sekund\u00e4re Endpunkte (Auswahl):  \nexertional dyspnea, treadmill endurance time, \nnumber of sit -to-stand repetitions and arm lifts in 1 \nminute, overall dyspnea, questionnaire- rated func-\ntional status  \n\u2022 Stu dienzeitraum: nicht angegeben \n\u2022 USA  \n  \n\u2022 before exercising: all patients received \neduaction  \n\u2022 high- intensity group trained predominantly on \nthe stationary bicycle and treadmill, with a  \ngoal of exercising at \u2265 80% of maximal level \ndetermined from incremental testing for 30 \nminutes per session  \n\u2022 low -intensity group performed predominantly \nclassroom exercises for approximately 30 \nminutes per session  \n\u2022 beide Gruppen trainierten 2x/Woche f\u00fcr \ninsgesamt 8 Wochen \n similar improvements in overall dyspnea, functional pe rformance, and health sta-\ntus. \n \nhealth status  \nboth groups showed significant inmprovements in CRQ scores after rehabilitation \n(no significant group differences in change)  \n- high- intensity group increased 11,5 \u00b1 2,9U (p<0,001 vs. baseline)  \n- low-intensity gr oup increased 18,8  \u00b1 2,9U (p<0,001 vs. baseline)  \n- 8/20 patients (40%) in high- intensity group had clinically meaningful changes in \nCRQ vs 14/20 patients (70%) in the low -intensity group  \n \nfunctional performance (questionnaire)  \nPFSS function and emotion sc ores both showed significant improvements from \nbaseline (no significant group differences in change)  \n- high- intensity group: PFSS function 2,8 \u00b1 0,7 U ; p<0,001  \nPFSS emotion: 3,1  \u00b1  1,2; p=0,01  \n- low-intensity group: PFSS function: 3,9  \u00b1 0,7; p<0,001 \nPFSS emotion: 5,8  \u00b1  1,2; p<0,001 \n \nOverall dyspnea (TDI)  \n- high- intensity group: 2,9 \u00b1  0,5; p<0,001 \n- low-intensity group: 3,2\u00b1  0,5; p<0,001 \nSelection bias  \nRandomisierung: unklar  \nAllocation concealment: unklar  \nPerformance bias \nVerblindung von Teilnehmern und Personal: nicht anwendbar  \nDetection bias  \nVerblindung der Ergebnisevaluation: gering (f\u00fcr prim\u00e4ren Endpunkt)  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: unklar  \nITT-Analyse: keine ITT -Analyse durchgef\u00fchrt;  \nReporting bias  \nselektive Ergebnisdarstellung: unklar  \nAndere Biasursachen   \nBaseline imbalance: unklar  \nInteressenkonflikte/ Sponsoring: Funding beschrieben (funded in part by [..] Hoffman foundation \nSetting: hospital -based outpatient pulmonary rehabilitation program  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  295 \n      \n \nZitat Studiencharakteristika  Interventionen  Studienergebnisse  \nProbst VS. Effects of 2 \nexercise training pro-\ngrams on physical activ-\nity in daily life in patients \nwith COPD. Respir Care \n2011; 56(11):1799\u2013 807. \nhttps://www.ncbi.nlm.nih\n.gov/pubmed/22035826 . \n \u2022 Studientyp: prospective randomized \ntrial \n \n\u2022 Studiendesign: keine Angaben zur \nRandomisierung  \n\u2022 Population: n=40 Patient*innen mit \nCOPD; (n=63 consecutive patients ini-\ntially included)  \n\u2022 Einschlusskriteri en:  \n- COPD diagnosis according GOLD \ncriteria;  \n- stable condition (no exacerbations or \ninfections in the preceding 3 months);  \n- no severe/unstable cardiac disease \n(eg, left -ventricular failure or atrial fi-\nbrillation);  \n- no comorbidities that might influence \nthe execution of the tests and/or the \nexercise training programs;  \n- had not attended a pulmonary reha-\nbilitation program in the last year;  \n- able to attend the out -patient clinic 3 \ntimes per week.  \n>> Pharmacologic treatment was not \nchanged during the  course \nof the study  \n\u2022 prim\u00e4rer Endpunkt: effects on physi-\ncal activity in daily life  \n\u2022 sekund\u00e4re Endpunkte: exercise ca-\npacity, (respiratory and peripheral) \nmuscle force, health- related quality of \nlife, functional status  \n\u2022 Studienzeitraum: July 2006 to July \n2009 \n\u2022 Brasilien \n \n \n \u2022 Setting:  out-patient clinic  \n \nhigh- intensity whole- body endurance and- strength pro-\ngram  \nvs. \nlow-intensity calisthenics -and-breathing- exercises pro-\ngram  \n \n>> Both groups: 3 sessions per week for 12 weeks  \n>> Activity monitoring in dail y life was performed with 2 \nbrands of motion sensor: DynaPort Activity Monitor and \nSenseWear multisensor  \n>> Assement 1x before and 1x after exercise programs  \n \nThe low -intensity calisthenics -and-breathing program  \nconsists of 5 sets of exercises:  \n- breathing exercises (diaphragmatic breathing and \npursed- lips breathing)  \n- strengthening of the abdominal muscles (crunches)  \n- calisthenics (trunk rotation and flexion, associated with \npursed lips breathing and prolonged expiration)  \n>> Exercises were performed in v arious body positions: \nsupine, side- lying, sitting, kneeling, and standing. Each \nset consisted of 12 different exercises, repeated 15 \ntimes each.  \n \nThe high- intensity whole- body endurance and strength \nexercise training included:  \n- cycling ergometry: traini ng intensity was initially set at \n60% of the initial maximum work rate \n- treadmill walking: training intensity was initially set at \n75% of the average walking speed during the baseline \n6-min walk test  \n- strength training for the quadriceps, biceps, and tri ceps \nmuscle groups: training intensity was initially set at 70% \nof the baseline one- repetition maximum test  \n \u2022 hinsichtlich Geschlecht, Alter,Gewicht, Lungenfunktion, Rauchstatus weit-\nestgehend ausgeglichen  \n \n\u2022 Ergebnisse prim\u00e4rer Endpunkt (effects on physic al activity in daily life)  \nTime spent standing, sitting, and lying and energy expenditure  in daily \nlife were not significantly altered in either group.  \nTime spent standing (min)  \nniedrige Intensit\u00e4t: 270 \u00b1139  \nhohe Intensit\u00e4t: 248 \u00b1 95  \nTime spent sitting (m in) \nniedrige Intensit\u00e4t: 283 \u00b1 121  \nhohe Intensit\u00e4t: 296 \u00b1 91  \nTime spent lying (min)  \nniedrige Intensit\u00e4t: 108 \u00b1 100  \nhohe Intensit\u00e4t: 113 \u00b1 101 \nenergy expenditure (kcal)  \nniedrige Intensit\u00e4t: 1,331 \u00b1 596  \nhohe Intensit\u00e4t: 1,295 \u00b1 635  \n \nIn time spent walking,  the endurance- and-strength group had no significant \nchange, whereas a reduction was observed in the calisthenics -and-breathing \ngroup.  \n \nweitere Ergebnisse  \n- Exercise capacity and muscle force significantly improved only in the en-\ndurance- and-strength group. (p=0.02 )  \n- The change in the endurance- and-strength- training group was significantly \nlarger than that in the calisthenics -and-breathing- exercises group (p=0.04) \nfor: Maximum work load; One- Repetition Maximum Strength Tests (Table 3)  \n \n- Health -related qualit y of life and functional status  improved significantly \nin both groups.  \n- functional status assessed with  \n> London Chest Activity of Daily Living Scale total score: only the endur-\nance- and-strength group showed significant improvement  \n> Pulmonary Functional Scale and Dyspnea Questionnaire: (dyspnea and fa-\ntigue domains) showed significant improvements only in the calisthenics -and \nbreathing group (Table 4)  \n \n\u2022 Subgruppenanalysen  \nIn both groups, the subgroups of patients who dropped- out were not signifi-\ncantly dif ferent from the subgroups that completed the exercise programs, NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  296 \n      \n \nZitat Studiencharakteristika  Interventionen  Studienergebnisse  \nexcept in the 6 -min walk test in the calisthenics -and-breathing group. 6 -min \nwalk distance was greater in the drop- out group (median 496 m, IQR 460\u2013\n560 m, vs 420 m, IQR 351\u2013  468 m, P = 0.006).  \n \n\u2022 Sicherheit:  No patients had hypoxemia at rest, but 10 patients used oxygen \nduring exercise throughout the endurance- and strength program, due to de-\nsaturation during exertion, whereas no patients in the calisthenics -and-\nbreathing group needed supplement al oxygen during the training.  \nSelection bias  \nRandomisierung: unklar  \nAllocation concealment: unklar  \nPerformance bias \nVerblindung von Teilnehmern und Personal: nicht anwendbar  \nDetection bias  \nVerblindung der Ergebnisevaluation: unklar  \nAttrition bias  \nVerlust von Studienteilnehmern/ fehlende Daten: gering  \nITT-Analyse:unklar  \nReporting bias  \nselektive Ergebnisdarstellung: unklar  \nAndere Biasursachen   \nBaseline imbalance: gering \nInteressenkonflikte/ Sponsoring: CoI wurden beschrieben \nSetting: out -patient cli nic \n \nAnhang 9.3  Telemedizin \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nHong Y. Effectiveness of \ntele-monitoring by patient \nseverity and intervention \ntype in chronic obstruc-\ntive pulmonary disease \npatients: A systematic re-\nview and meta- analysis. \nInt J Nurs Stud 2019; \u2022 Fragestellung: to analyze the effect of tele -mon-\nitoring on chronic obstructive pulmonary disease \npatients and performed subgroup analysis by pa-\ntient severity and intervention type.  \n \n\u2022 Suchzeitraum: up to April 2017 \n\u2022 Population:  Patient*innen mit COPD  \n\u2022 Einschlusskriterien:  `- 15 studies used tele -monitoring only  \n- 4 stu dies used integrated tele- monitoring (pure control = exer-\ncise or education was not applied to control group)  \n- 8 studies used integrated tele- monitoring (not pure control=re-\nceived some degree of chronic obstructive pulmonary disease \neclucation or exercise additionally)  \n \n\u2022 Emergency room visits (n=11 studies)  AMSTAR -II: \n- critically low  \n \n \n \n  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  297 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n92:1\u201315. \nhttps://www.ncbi.nlm.nih.\ngov/pubmed/30690162.  \n \n -  COPD; RCT; Intervention: telemonitoring; out-\ncome measures: QoL, hospitalization; emergecy \nroom visits, mortality, lenght of stay, radmission, \nexacerbations, outpatient visits  \n \n- n=27 RCTs eingeschlossen  \n \n\u2022 Interventionen:    \n- tele-monitoring only  \n- integrated tele- monitoring: such as the delivery of \nself-management education or teleconsultation by \nphone in addition to tele- monitoring of vital sign \nand systems  \n\u2022 Vergleich:  usual care  \n \n \n tele-monitoring (alle) reduced the emergency room visits (risk ra-\ntio 0.63, 95% confidence interval 0.55- 0.72; I\u00b2=69%;))  \n- subgroup analysis of patient severity showed that tele- monitor-\ning more effectively reduced emergency room visits in patients \nwith severe (risk ratio 0.48, 95% confidence interval 0.31- 0.74) \nvs. moderate disease (risk ratio 1.28, 95% confidence interval \n0.61- 2.69)  \n- Tele- monitoring only (p < 0.01, RR=0.65, 95% Cl 0.55-  0.76, \nI2=72%) and integrated tele- monitoring (p < 0.01, RR =0.42, 95% \nCl 0.28- 0.62, I2= 65%) significantly reduced emergency room vis-\nits. \n \n\u2022 Hospitalization (n=12 studies)  \ntele-monitoring (alle) reduced hospitalizations (risk ratio 0.88, \n95% confidence interval 0.80- 0.97)  \n- subgroup analysis of patient severity (severe vs. moderate) \nshowed that tele- monitoring more effectively reduced hospitaliza-\ntions (risk ratio 0.92, 95% confidence interval 0.82- 1.02; risk ratio \n1.24, 95% confidence interval 0.57 -2.70, retrospectively)  \n- Tele- monitoring only reduced hospitalizations but this was not \nstatistically significant (p=0.13, RR=0.92, 95% CI 0.82- 1.03, \nI\u00b2=36%). On the other hand, integrated tele- monitoring did signifi-\ncantly reduce hospitalizations (p=0.03, RR -0.79, 95% CI 0.64 to \n0.98, I\u00b2=26%)  \n\u2022 Qol (n=4 studies)  \nThe mental health quality of life score (mean difference 3.06, \n95% confidence interval 2.15- 3.98) showed more improved qual-\nity of life than the physical health quality of life score (mean differ-\nence -0.11, 95% confidence i nterval -0.83- 0.61)  \n \n\u2022 Mortality (n=8 studies)  \nThere was a slight reduction in mortality between the tele- moni-\ntoring group and the control group, but it was not statistically sig-\nnificant (p =0.25, RR = 0.85, 95% Cl 0.64- 1.13). No heterogeneity \nwas found ( p=0.66, I\u00b2=O)  \n \n\u2022 Our results showed that tele- monitoring reduced emergency \nroom visits, hospitalizations, and the mental health quality of life, \nwhile there were no differences in mortality, outpatient visits, or \nlength of stay.  \n\u2022 Tele -monitoring has prov ed to be more useful in reducing the \nnumber of Emergency room visits and hospitalization of patients NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  298 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nwith (very) severe chronic obstructive pulmonary disease than \nthose with moderate diseases,  \n\u2022 Active integrated tele- monitoring, which includes the act of deliv-\nering skills and education to cope with disease and online pulmo-\nnary rehabilitation, produced more improvement than tele- moni-\ntoring only intervention when it comes to emergency room visits \nand hospitalization.  \n \nLundell S. Telehealthcare \nin COPD: A systematic \nreview and meta- analysis \non physical outcomes \nand dyspnea. 2015 Jan.  \n \u2022 Fragestellung:  to investigate the effects of tele-\nhealthcare on physical activity level, physical ca-\npacity and dyspnea in patients with C OPD, and to \ndescribe the interventions used  \n \n\u2022 eingeschlossene Studien : n=9 RCTs; 982 pa-\ntients  \n\u2022 Suchzeitraum: inception to August 30/ 2013  \n\u2022 Population : Patienten mit COPD > 40 Jahre alt  \n\u2022 Einschlusskriterien  (Auswahl)  \n- Interventions: The major part (in length of time or \nnumber of contacts) could be classified as home \nbased telehealthcare. Some kind of feedback, mo-\ntivational element, or counseling had to be pro-\nvided to the patient through telehealthcare at least \nthree times during the first three months.  \n \n\u2022 Interventionen:  Telehealthcare (phone calls, \nwebsites or mobile phones, often combined with \neducation and/or exercise training)   \n\u2022 Vergleich : ordinary care, exercise training and/or \neducation  \n \n\u2022 telehealthcare = \u201cthe use of electronic infor-\nmation and c ommunications technologies to pro-\nvide and support health care when distance sepa-\nrates the participants\u201d  \n\u2022 telehealthcare criteria:  \n- information (delivery of health services) is trans-\nmitted electronically over a distance \n- information can be, for example , voice, sounds, \nvideo, pictures or text  \n- transmission can be asynchronous (store -and `- total of 982 patients (34% women)  \n- moderate to severe COPD  \n \nFor physical activity level,  there was a significant effect favoring \ntelehealthcare (MD, 64.7 min; 95% CI, 54.4 -74.9).  \nNo difference between groups was found for physical capacity \n(MD, -1.3 m; 95% CI, - 8.1-5.5) and dyspnea (SMD, 0.088; 95% \nCI, -0.056- 0.233; n=7 studies).  \n\u2022 authors conclusion:  \nThe use of telehealthcare may lead to improvements in physical \nactivity level, although the results should be interpreted with cau-\ntion given the heterogeneity  in studies. This is an i mportant area \nof research and further studies of the effect of telehealthcare for \npatients with COPD would be beneficial.  \n AMSTAR -II: \n- low \n \n \n \n \n n=9 Studien RCTs ein-\ngeschlossen \n- Bourbeau, 2003  \n- Carrieri - Kohlman, \n1996 \n- Garcia -Aymerich, 2007  \n- Maltais, 2008  \n- Nguyen, 2009  \n- Nguyen, 2013  \n- Nield, 2012  \n- Oh, 2003  \n- Waterhouse, 2010 \n \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  299 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nforward applications) or synchronous (e.g. two -\nway video consultations)  \n \nAnhang 9.4  Selektiv eingebrachte Literatur  \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \nSchultz K, Jelusic \nD, Wittmann M, et \nal. Inspiratory mus-\ncle training does \nnot improve clinical \noutcomes in 3-\nweek COPD reha-\nbilitation: Results \nfrom a randomised \ncontrolled trial. Eur \nRespir J 2018; \n51(1). DOI: \n10.1183/13993003.\n02000- 2017. \nhttp://www.ncbi.nlm\n.nih.gov/pub-\nmed/29371382 . RIMTCORE (Routine Inspiratory Muscle \nTraining within COPD Rehabilitation)  \n \n\u2022 Studiendesign:  RCT, parallel -group \n \n\u2022 Population: patients with COPD (GOLD II \n- IV); n=602  \n\u2022 Intervention:  highly intensive IMT + 3-\nweek inpatient pulmonary rehabilitation \n\u2022 Vergleich:  sham IMT+3 - week inpatient \npulmonary rehabilitation  \n \nintensive pulmonary rehabilitation pro-\ngramme:  \n- Obligatory components (mostly 30 - to 60-\nmin sessions): physical training (endurance \ntraining: four or five sessions per week; \nstrength training: three sessions per week; \nwhole- body vibration muscle training: seven \nsessions per week), patient education  \n(seven or more session s) and respiratory \nphysiotherapy in groups (two to four ses-\nsions per week).  \n- Optional components: smoking cessation \n(eight sessions), mucolytic physiotherapy, \nsaline inhalation, psychological interven-\ntions, social counselling, nutritional counsel-\nling and occupational therapy.  \n \n\u2022 Studienzeitraum: 02/2013  - 07/2014 \n\u2022 Ort: Bad Reichenhall, Germany  \n \u2022 Baseline -Patientencharakteristika : 64.6% of the patients were \nmale, mean\u00b1SD age was 57.8\u00b17.4 years; most frequent comorbidities: \nCardiovascular (63.5%), musculoskeletal (58.1%) and metabolic disor-\nders (54.7%)  \n-  hinsichtlich Alter, Geschlecht, Erkrankungsstadium, Rauchstatus \nweitestgehend ausgeglichen  \n\u2022 n=602 ITT; n=611 gesamt randomisiert  \n \n\u2022 Outcomes were assessed pre-  and post -pulmonary rehabilitation  \n\u2022 secondary outcomes: 6 -min walk distance, dyspnoea, quality of life \nand lung function --> outcomes in both study groups improved signifi-\ncantly, but without further betweengroup differences. Sex and pulmo-\nnary rehabilitation admission shortly after hospitalisation modified qual-\nity of life effects.  \n \nChange after 3 wee ks rehabilitation \n6MWD (m)  \nControl: 83.99\u00b165.74  \nIntervention: 85.30\u00b162.80  \naMD: 1.59 (\u22127.94\u2013 11.12)  \n \nSGRQ -Total  \nControl: \u221210.50\u00b113.22  \nIntervention: \u22129.42\u00b113.44 \naMD: 1.57 (\u22120.44\u2013 3.59)  \n \nCAT \nControl: \u22123.42\u00b15.85  \nIntervention: \u22123.76\u00b15.76  \naMD: \u22120.09 (\u22120.94\u2013 0.76)  \n \nCCQ -Total  \nControl: \u22120.58\u00b10.90  Selection bias  \nRandomis ierung: gering  \nAllocation concealment: gering  \n \nPerformance bias \nVerblindung von Teilnehmern \nund Personal: unklar  \n \nDetection bias  \nVerblindung der Ergebnisevalu-\nation: gering  \n \nAttrition bias  \nVerlust von Studienteilnehmern/ \nfehlende Daten: gering \n \nITT-Analyse: durchgef\u00fchrt  \n \nReporting bias  \nselektive Ergebnisdarstellung: \nunklar  \n \nAndere Biasursachen  \nBaseline imbalance: gering \nInteressenkonflikte/ Sponsoring: \nonline verf\u00fcgbar (f\u00fcr Autoren); \nThis study was supported by \nDeutsche Rentenversicherung \nBayer n S\u00fcd.  \n selektiv eingebrachte Lite-\nratur \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  300 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  Kommentar  \n\u2022 Frageb\u00f6gen QoL:  St George\u2019s Respira-\ntory Questionnaire (SGRQ), COPD Assess-\nment Test (CAT), Clinical COPD Question-\nnaire (CCQ)  \n\u2022 Erfassung Dyspnoe:  Baseline and t ransi-\ntion dyspnoea indexes (BDI and TDI)  \n Intervention: \u22120.63\u00b10.98  \naMD: 0.01 (\u22120.12\u2013 0.15)  \n \nTDI \ncontrol (n=268): 4.60\u00b13.01  \nIntervention (n=275): 4.57\u00b13.17  \naMD: \u22120.09 (\u22120.61\u2013 0.42)  \n \n\u2022 authors conclusion:  IMT as an add- on to a 3- week pulmonary reha-\nbilitation improves inspiratory muscle strength, but does not provide \nadditional benefits in terms of exercise capacity, quality of life or dysp-\nnoea. A general recommendation for COPD patients to add IMT to a 3-\nweek pulmonary rehabilitation cannot be made.  \nAnhang 10  Evidenztabellen Versorgungskoordination  \nAnhang 10.1  Cochrane Reviews Versorgungskoordination \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nKruis AL. Integrated dis-\nease management inter-\nventions for patients with \nchronic obstructive pul-\nmonary disease. \nCochrane Database of \nSystematic Reviews \n2013;(10).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/10.10\n02/14651858.CD009437.\npub2/abstract  \n \n \u2022 Fragestellung:  To evaluate the effects of integrated disease man-\nagement (IDM) programs or interventions in people with COPD on \nhealth- related QoL, exercise tolerance and number of exacerbations.  \n \n \u2022 Suchzeitraum: 12 April 2012  \n \u2022 Population:  Patient*innen mit COPD  \n \n \u2022 Interventionen:  IDM programs for COPD  \n- consisted of multidisciplinary (two or more health care providers) and  \n- multi -treatment (two or more components) IDMprograms with  \n- duration of at least three months.  \n \n- m\u00f6gliche Komponenten:   \n1. Education/self management:  i.e. education, selfmanagement, per-\nsonal goals and/or action plan, exacerbation management  \n2. Exercise:  i.e. (home) exercise training and/or strength and/ or en-\ndurance traini ng \n3. Psychosocial: cognitive behavioral therapy, stress management, \nother psychological assessment and/or treatment  \n4. Smoking cessation  \u2022 Baseline -Charakteristika:  \n- mean age: 68 years, 68% male; mean FEV1% predicted value \nwas 44.3% (range 28% to 66%)  \n- Participants were treated in all types of healthcare settings: pri-\nmary (n = 8), secondary (n = 12), tertiary care (n = 1), and in both \nprimary and secondary care (n = 5).  \n \nQuality of life measured on the CRQ (Chronic Respiratory \nQuestionnaire) (GRADE: Moderate ) \nCompared with controls, IDM showed a statistically and clinically \nsignificant improvement in disease -specific QoL on all domains of \nthe Chronic Respiratory Questionnaire after 12 months:  \n\u2022 dyspnea MD 1.02; 95% CI 0.67 to 1.36 (n=4 studies; 160 partici-\npants; GRADE moderate)  \n\u2022 fatigue MD 0.82; 95% CI 0.46 to 1.17 \n\u2022 emotional MD 0.61; 95% CI 0.26 to 0.95  \n\u2022 mastery MD 0.75; 95% CI 0.38 to 1.12  \n \n AMSTAR Score: 9/11  \n \ny-y-y-y-y-y-y-y-y-n-n \n \n \n \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  301 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n5. Medication:  optimal medication/prescription of medication adher-\nence \n6. Nutrition:  dietary intervention  \n7. Follow -up and/or communication: structural follow -up and/or \ncommunication, case management by nurses, optimal diagnosis  \n8. Multidisciplinary team: active participation and formation of teams \nof professional caregivers from different disciplines, revision of profes-\nsional roles, integration of services, local team meetings  \n9. Financial intervention:  fees/payment/grants for providing IDM.  \n \n \u2022 Vergleich: controls  (varying from usual care or no treatment to sin-\ngle interventions, mono- disciplinary interventions)  \n \n \u2022 eing eschlossene Studien:  26 RCTs; involving 2997 people  \n \u2022 Follow -up: from 3 to 24 months  \n \u2022 Overall: studies were of high to moderate methodological quality  \n Quality of life measured on the SGRQ (St. George\u2019s Respira-\ntory Questionnaire) (GRADE: High)  \n\u2022 total score: MD -3.71 ( -5.83 to - 1.59) (n=13 studies; 1425 partic-\nipants; GRADE high)  \n\u2022 impact domain:  clinically relevant difference of four units: (MD -\n4.04; 95% CI - 5.96 to -2.11, P < 0.0001).  \n\u2022 activity domain:  significantly improved disease specifi c QoL \n(MD -2.70 (95% CI -4.84 to -0.55, P = 0.01)  \n\u2022 symptom domain:  no significant difference (MD -2.39 (95% CI -\n5.31 to 0.53, P = 0.11)  \n \nFunctional exercise capacity (6- minute Walking Distance) \n(GRADE: Moderate)  \n\u2022 clinically relevant improvement: MD 43.86 meters compared with \ncontrols after 12months (95%CI 21.83 to 65.89; P < 0.001, n=14 \nstudies; 838 participants)  \n \nRespiratory- related hospital admissions (GRADE: High)  \n\u2022 reduction in the number of participants with one or more hospital \nadmissions over three to 12 months from 27 per 100 participants in \nthe control group to 20 (95% CI 15 to 27) per 100 participants in \nthe IDM group  \n\u2022 OR 0.68; 95% CI 0.47 to 0.99, P = 0.04; number needed to treat \n= 15; n=7 studies; 1470 participants)  \n \nHospital days per patient  (all causes) (GRADE: High)  \n\u2022 significantly lower in the IDM group compared with controls after \n12 months  \n\u2022 MD - 3.78 days; 95% CI - 5.90 to - 1.67, P < 0.001  \n \nAdverse events \nNo adverse effects were reported in the intervention group.  \n \nMortality  \nNo difference between groups was found on mortality (OR 0.96; \n95%CI 0.52 to 1.74).  \n \nLong term effects  \nThere was insufficient evidence to refute or confirm the long term \neffectiveness of IDM.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  302 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nGon\u00e7alves -Bradley DC. \nEarly discharge hospital \nat home. Cochrane Data-\nbase of Systematic Re-\nviews 2017;(6).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/10.10\n02/14651858.CD000356.\npub4/abstract  \n \n \u2022 Fragestellung:  To determine the effectiveness and cost of managing \npatients with early discharge hospital at home compared with inpatient \nhospital care.  \n \n \u2022 Suchzeitraum:  9 January 2017  \n \u2022 Population : 1 Subgruppe= Patient*innen mit COP D \n \n \u2022 Ausschlusskriterien: services providing long- term care, services \nprovided in outpatient settings or post -discharge from hospital, end- of-\nlife care at home and selfcare by the patient in their home, such as \nself-administration of an intravenous infusion.  \n \n \u2022 Interventionen:  early discharge hospital at home  \n- service that provides active treatment by healthcare professionals in \nthe patient\u2019s home for a condition that otherwise would require acute \nhospital inpatient care, and always for a limited time period.  \n- has to offer a specific service to patients in their home requiring \nhealthcare professionals to take an active part in the patients\u2019 care  \n- If not available then the patient would not be discharged early from \nhospital and would remain on an acute hospital ward  \n \n \u2022 Vergleich: acute hospital inpatient care  \n \n \u2022 eingeschlossene Studien:  n=5 RCTs (f\u00fcr Patient*innen mit COPD)  \u2022 insgesamt 32 RCT (4746 participants)  \n \n\u20221 Subgruppe=COPD  \n \nMortality  \n- In people with COPD there was insufficient information to deter-\nmine the effect of early discharge hospital at home vs. acute hospi-\ntal inpatient care on mortality  \n- RR 0.53, 95% CI 0.25 to 1.12, N = 496, 5 trials, GRADE: low \ncertainty evidence  \n \nHospital readmission  \n- Early discharge hospital at home may decrease the risk of read-\nmission for people with COPD  \n- RR 0.86, 95% CI 0.66 to 1.13, N = 496, 5 trials; GRADE: low -\ncertainty evidence  \n  \nAMSTAR Score 8/11  \n \ny-y-y-y-y-y-y-y-ca-n-n \n \n \n \n \nJeppesen E. Hospital at \nhome for acute exacerba-\ntions of chronic obstruc-\ntive pulmonary disease. \nCochrane Database of \nSystematic Reviews \n2012;(5).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/10.10\n02/14651858.CD003573.\npub2/abstract  \n \n \u2022 Fragestellung: To evaluate the efficacy of hospital at home com-\npared to hospital inpatient care in acute exacerbations of COPD.  \n \n \u2022 Suchzeitraum:  October 2010  \n \u2022 Population:  patients presented to the emergency department with \nan exacerbation of COPD  \n \n \u2022 Einschlusskriterien:  Studies must not have recruited patients for \nwhom treatment at home is usually not viewed as an responsible op-\ntion (e.g. patients with an impaired level of consciousness, acute con-\nfusion, acute changes on the radiograph or electrocardi ogram, arterial \npH less than 7.35, concomitant medical conditions)  \n \n \u2022 Interventionen : hospital at home \n- under the care of a specialist respiratory nurse (under guidance of \nthe hospital medical team)  Readmission to hospital (inpatient)  \n- significant reduction in readmission rates for hospital at home \ncompared with hospital inpatient care of acute exacerbations of \nCOPD  \n- RR 0.76; 95% CI from 0.59 to 0.99; P=0.04; n=8 studies; 870 \nparticipants; GRADE: moderate  \n \nMortality  \n- trend towards l ower mortality in the hospital at home group, but \nthe pooled effect estimate did not reach statistical significance  \n- RR 0.65, 95% CI 0.40 to 1.04, P = 0.07; n=7 studies; 845 partici-\npants; GRADE: moderate  \n \nPatient satisfaction  (follow -up: 0 to 2 weeks aft er discharge)  \n- RR 1.06 (95% CI 0.96 to 1.17); n=2 studies; 158 participants; \nGRADE: low  \n AMSTAR Score: 8/11  \n \ny-n-y-y-y-y-y-y-y-n-n \n \n \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  303 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \n- provided with the treatment as deemed appropriate at the time of ini-\ntial assessment on presentation to the emergency department  \n- would have regular scheduled visits by the nurse as well as additional \nvisits as requested by the patient or deemed appropriate by the nurse \nor the medical team  \n- should be visited by the respiratory nurse until discharged from care \n \n \u2022 Vergleich:  hospital inpatient care (treated as usual)  \n \n \u2022 eingeschlossene Studien:  8 RCTs (870 participants)  Carer satisfaction (follow -up: 2 weeks after discharge)  \n- RR 0.97 (95% CI 0.79 to 1.19); n=1 study; 34 participants; \nGRADE: very low  \n \n\u2022 For health- related quality of life, lung function (FEV1) and direct \ncosts, the quality of the available evidence is in general too weak \nto make firm conclusions.  \n \nAuthors\u2019 conclusions  \nSelected patients presenting to hospital emergency departments \nwith acute exacerbations of COPD can be  safely and successfully \ntreated at home with support from respiratory nurses .[...] \n \nWong C, X. Home care \nby outreach nursing for \nchronic obstructive pul-\nmonary disease. \nCochrane Database of \nSystematic Reviews \n2012;(4).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/10.10\n02/14651858.CD000994.\npub3/abstract  \n \n \u2022 Fragestellung: To evaluate the effectiveness of outreach respiratory \nhealth care worker  programmes for COPD patients in terms of improv-\ning lung function, exercise tolerance and health related quality of life \n(HRQL) of patient and carer, and reducing mortality and medical ser-\nvice utilisation.  \n \n \u2022 Suchzeitraum:  November 2011 \n \u2022 Population:  Patient*innen mit COPD  \n \n \u2022 Ausschlusskriterien: Studies in which the therapeutic intervention \nunder test was physical training were not included.  \n \n \u2022 Interventionen:  outreach nurse visiting patients in their homes  \n- providing social support, education, monitoring health and liaising \nwith physicians.  \n- identify respiratory deteriorations promptly and reinforce correct tech-\nnique with inhaler therapy  \n \n \u2022 Vergleich:  routine care (without respiratory nurse/health worker in-\nput) \n \n \u2022 eingeschlossene Studien:  9 RCTs (1498 participants)  \n Mortality  \n- OR 0.72, 95%  CI 0.45 to, 1.15, n=5 studies; 711 participants; \nGRADE: low  \n \nDisease- specific heath -related quality of life (SGRQ total)  \n- statistically significant improvement in HRQL  \n- MD -2.61, 95% CI -4.82 to -0.40; n=4 studies; 587 participants; \nGRADE: low  \n \nHospital isation  \n- no statistically significant difference in the number of hospitalisa-\ntions  \n- OR 1.01, 95%CI 0.71 to 1.44; n=5 studies; 686 participants; \nGRADE: low  \n- there was significant heterogeneity  \n \nAuthors\u2019 conclusions  \nOutreach nursing programmes for COPD im proved disease- spe-\ncific HRQL. However the effect on hospitalisations was heteroge-\nneous, reducing admissions in one study, but increasing them in \nothers, therefore we could not draw firm conclusions for this out-\ncome.  \n AMSTAR Score: 7/11  \n \ny-n-y-y-y-y-y-y-ca-n-n \n \n \n \n \nLenferink A. Self -man-\nagement interventions in-\ncluding action plans for \u2022 Body of Evidence:  n=22 eingeschlossene RCTs f\u00fcr Metaanalyse ( \nn=3854  eingeschlossene Patienten)  Health -related quality of life  (HRQoL) assessed with: SGRQ: \nn=1582 (10 RCTs), GRADE: High  \n- usual care: mean HRQoL ranged f rom 37.7 to 70. 4 points  AMSTAR Score 10/11  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  304 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nexacerbations versus \nusual care in patients \nwith chronic obstructive \npulmonary disease. \nCochrane Database of \nSystematic Reviews \n2017;(8).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/10.10\n02/14651858.CD011682.\npub2/abstract  \n \n  \n\u2022 Suchzeitraum:  1995- 05/2016  \n\u2022 Population: Patient*innen mit COPD  \n \n\u2022 Einschlusskriterien: self-management intervention included a writ-\nten action plan for AECOPD and an iterati ve process between partici-\npant and healthcare provider(s) in which feedback was provided  \n\u2022 Ausschlusskriterien:  disease management programmes classified \nas pulmonary rehabilitation or exercise classes offered in a hospital, at \na rehabilitation centre, or i n a community -based setting;  \nParticipants with primary diagnoses of asthma  \n \n\u2022 Interventionen:   \nself-management interventions that included a written action plan for \nacute exacerbations of COPD(AECOPD  \nvs. \nUsual care \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Health- related quality of life (HRQoL)  \n- Respiratory -related hospital admissions  \n \n - self-management interventions including action plans for exacer-\nbations: MD 2.69 points lower (4.49 lower to 0.9 lower) (Lower \nscore indicates better health- related quality of life.)  \n \nRespiratory -related hospital admissions  assessed with: number of \npatients with at least one respiratory -related hospital admission, \nn=3157 (14 RCTs), G RADE: Moderate  \n- usual care: 312 per 1,000  \n- self-management interventions including action plans for exacer-\nbations: 238 per 1,000 (188 to 298)  \n- OR 0.69 (0.51 to 0.94)  \n \nRespir atory -related mortality  assessed with: num - ber of respira-\ntory-re- lated deaths, n=1219 (7 RCTs),  GRADE: Very low  \n- usual care: 48 per 1000  \n- self-management interventions including action plans for exacer-\nbations: 89 per 1,000 (57 to 136)  \n- OR 1.94 (1.20 t o 3.13)  \n \nDyspnoea a ssessed with: (modified) Medical Research Council \nDyspnoea Scale, n=217 (3 RCTs),  GRADE: Low  \n- usual care: mean dyspnoea ranged f rom 2.4 to 2.6  \n- self-management interventions including action plans for exacer-\nbations: MD 0.63 lower  (1.44 lower to 0.18 higher)  \n \nCOPD exacerbations  assessed with: number of COPD exacerba-\ntions per patient, n=740 (4 RCTs), GRADE: Moderate  \n- usual care: mean COPD exacerbations ranged f rom 1.13 to 4.3  \n- self-management interventions including action plans for exacer-\nbations: MD 0.01 higher (0.28 lower to 0.29 higher)  \n \n- usual care:  \n- self-management interventions including action plans for exacer-\nbations:  \n \n>> Self -management interventions including an action plan for \nworsening COPD symptoms improved health- related quality of life \ncompared with usual care (high- quality evidence). The number of \npeople who had at least one hospital admission related to lung dis-\nease was reduced among those who participated in a self -man-\nagement intervention (moderate- quality evidence).  There was a \nvery small but significant increase in respiratory -related deaths for y-y-y-y-y-y-y-y-y-y-n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  305 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nself-management interventions (very low -quality evidence). [...] Alt-\nhough we were unable to identify the most effective components, \nwe found that including a smoking cessati on programme seemed \nto be effective to further improve health- related quality of life.  \n \nZwerink M. Self manage-\nment for patients with \nchronic obstructive pul-\nmonary disease. \nCochrane Database of \nSystematic Reviews \n2014;(3).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/10.10\n02/14651858.CD002990.\npub3/abstract  \n \n \u2022 Body of Evidence:  n=23  eingeschlossene Controlled trials (ran-\ndomised and non- randomised) f\u00fcr Metaanalyse  \n \n\u2022 Suchzeitraum:  1994 - 11/2011  \n\u2022 Population: Patient*innen mit COPD  \n \n\u2022 Einschlusskriterien: interventions required at least an iterative pro-\ncess of interaction between participant and healthcare provider, and \nideally also included formulation of goals and provision of feedback  \n\u2022 Ausschlusskriterien: i nterventions with fewer than two contact mo-\nments between study participants and healthcare providers; Education \nonly \n \n\u2022 Interventionen:   \nSelf management interventions (structured)  \nvs. \nUsual care \n \n\u2022 Prim\u00e4re Endpunkte:  \n1. Health- related quality of life (HRQoL) scores.  \n2. Number of hospital admissions.  \n \n HRQoL:  SGRQ total score, n=1413 (10 studies); GRADE: Moder-\nate \n- Control: mean SGRQ total scores from 34.7 to 65.3 points  \n- Self management: Mean SGRQ total score was 3.51 lower  (5.37 \nto 1.65 lower)  \n \nRespiratory -related hospital admissions: , n=1749 (9 studies),  \nGRADE: Moderate  \n- Control: 293 per 1000 \n- Self management: 190 per 1000 (151 to 237)  \n- OR 0.57 (0.43 to 0.75 )  \n \nDyspnoea:  (m)MRC score, n= 119 (3 studies), GRADE: Low  \n- Control: mean (m)MRC scores varied from 2.4 to 3.6 points  \n- Self management: Mean (m)MRC total score was 0.83 lower \n(1.36 to 0.3 lower)  \n \nExercise capacity: 6MWD, n= 570 (6 studies), GRADE: Low  \n- Control: Range of mean 6MWD varied from 68.6 to 440.9 m  \n- Self management: Mean 6MWD was 33.69 higher (9.12 lower to \n76.50 higher)  \n \nMortality,  n=2134 (8 studies), GRADE: Very low  \n- Control: 97 per 1000 \n- Self management: 79 per 1000 (59 to 103)  \n- OR 0.79 (0.58 to 1.07 )  \n \n>> The studies assessed in this review were diverse. Self manage-\nment programmes differed in content and duration. Also, types of \nparticipants differed across studies. Therefore, no clear reco m-\nmendations on the most effective content of self management \ntraining can be made at this time.  AMSTAR Score 8/11  \n \nca-n-y-y-y-y-y-n-y-y-y \nHowcroft M. Action plans \nwith brief patient educa-\ntion for exacerbations in \u2022 Body of Evidence:  n=7  ei ngeschlossene parallel -group RCTs f\u00fcr \nMetaanalyse ( n= 1550 eingeschlossene Patient*innen)  \u2022 Baseline -Charakteristika  \n- mean age: 68 years  \n- men=66%  AMSTAR Score 11/11  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  306 \n      \n \nZitat Studiencharakteristika  Studienergebnisse  Methodische Qualit\u00e4t  \nchronic obstructive pul-\nmonary disease. \nCochrane Database of \nSystematic Reviews \n2016;(12).  \n \nhttp://onlineli-\nbrary.wiley.com/doi/10.10\n02/14651858.CD005074.\npub4/abstract  \n \n \u2022 Suchzeitraum:  current to 11/2015  \n\u2022 Population: Patient*innen mit COPD  \n \n\u2022 Einschlusskriterien: Participants with a clinical diagnosis of COPD \nbased on spirometric criteria  \n\u2022 Ausschlusskriterien: participants who had received a primary diag-\nnosis of asthma; cross -over trials  \n \n\u2022 Interventionen:   \naction plan for COPD exacerbations provided with a single short pa-\ntient education component and without a comprehensive self -manage-\nment programme  \nvs. \nusual care \n \n\u2022 Prim\u00e4re Endpunkte:  \n- Healthcare utilisation, including respiratory -related hospital admis-\nsion, treatment in an emergency department (ED) and GP visits for \nCOPD \n- Mortality: respiratory -related and all -cause \n- Use of medication: time to initiation of therapy after  \nsymptom onset; courses/duration of antibiotic or  corticosteroid use, or \nboth; participant initiation of antibiotic or steroid use, or both  \n \n \n  \nHospitalisations for COPD/ 100 patient - years (action plan + phone \nfollow -up), n=743 (1 RCT), GRADE: Moderate  \n- Rate ratio 0.69 (0.47 to 1.01)  \n \nHospitalisations and emergency visits for COPD / 100 patient - \nyears (action plan + phone follow -up), n= 743 (1 RCT), GRADE: \nHigh  \n- Rate ratio 0.59 (0.44 to 0.79)  \n \nAt least 1 hospital admission , n=897 ( 2 RCTs), GRADE: Moder-\nate \n- Usual care: 209 per 1000  \n- Action plan: 154 per 1000 (114 to 204)  \n- Odds r atio 0.69 (0.49 to 0.97)  \n \nMortality (all -cause), n= 1134 (4 RCTs), GRADE: Moderate  \n- Usual care: 103 per 1000  \n- Action plan: 91 per 1000 (63 to 130)  \n- Odds ratio 0.88 (0.59 to 1.31)  \n \nRespiratory - related quality of lif e: SGRQ, n=1009 (3RCTs), \nGRADE: Modera te \n- Usual care: Mean SGRQ overall score ranged f rom -2 to +6 \nunits  \n- Action plan: Mean SGRQ overall score in the intervention group \nwas 2.82 units lower (0. 83 lower to 4.81 lower)  \n \nDepression score assessed with HADS Scale f rom 0 to 21 \n(worst), n=154 ( 1 RCT), GRADE: Low  \n- Usual care: Mean depression score was - 0.04 \n- Action plan: Mean depression score was 0.25 lower ( 1.14 lower \nto 0.64 higher)  \n \n>> People with COPD should be given an individualised action \nplan with a short educational component so they c an benefit from \nfewer and shorter hospital stays, better understanding of the need \nto self -start treatment and appropriate use of medication for exac-\nerbations.  y-y-y-y-y-y-y-y-y-y-y NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  307 \n      \n \nAnhang 10.2  Auswirkungen des Wechsels von Inhalationssystemen ohne erneute Instruktion (NVL Asthma)  \nZitat Studiencharakteristika  Ergebnisse  Methodische Bewertung  \n26961 \nThomas M. Inhaled \ncorticosteroids for \nasthma: impact of \npractice level de-\nvice switching on \nasthma control. \nBMC Pulm Med \n2009;9:1.  \nhttp://www.ncbi.nlm\n.nih.gov/pub-\nmed/19121204  \n Retrospektive Kohortenstudie,  \n- 2 Jahre, Registerdaten  \n- Indexdatum: Wechsel des Inhalationssystem s ohne Konsulta-\ntion, 1 Jahr Vor - u. Nachbetrachtung \nn= 1648 (1:1)  \nFragestellung:  \n- evaluate the impact on asthma control of inhaler device switching \nwithout an accompanying consultation in general practice in the \nUnited Kingdom  \nEinschlusskriterien:  \n- Alter: 6-65 J., dokumentierte Diagnose Asthma  \n- switches to inhaler devices that require training to use  \nAusschlusskriterien:  \n- COPD  \n- changed to a device recorded as 'generic'  \nDefinition des prim\u00e4ren EP:  \nSuccessful treatment: \u22640.5 dose/day SABA, keine OCS, unver\u00e4n-\nderte Langzeittherapie, keine Hospitalisierung \nPartially successful treatment: 0.5 bis \u22642 dose/day SABA, \u22642 OCS, \nunver\u00e4nderte Langzeittherapie, keine Hospitalisierung \nUnsuccessful treatment: > 2 dose/day SABA, \u22653 OCS, ver\u00e4nderte \nLangzeittherapie, \u22651  Hospitalisierung \nStatistik: \n- logistische Regression f\u00fcr Korrektur von Baseline- Confoundern Baseline- Charakteristika:  \nausgeglichen bis auf Sozio\u00f6konomischer Status, t\u00e4gliche SABA -\nDosis, Konsultationsh\u00e4ufigkeit  \nh\u00e4ufigster Wechsel : DPI to MDI (53%)  \nPrim\u00e4re r EP:  Asthmakontrolle (Composit -Endpunkt):  \n- switched having significantly lower odds of success than control \npatients (OR, 0.30; 95% CI, 0.20 to 0.45; p < 0.001)  \n- likelihood of unsuccessful treatment among switched patients \n(50,7%) and control patients (37,9%)  \n- not substantially different when the ICS dose was included in the \nanalysis (OR, 1.89; 95% CI, 1.48 to 2.40; p < 0.001)  \nSekund\u00e4re EP  \n- number of patient per year analyzed for inhaled SABA: switched \ncohort used 0.38 extra doses/day of SAB A, compared with baseline \nuse, than the control cohort (95% CI, 0.22 to 0.53; p < 0.001)  \n- number of patient per year analyzed for inhaled OCS: no significant \ndifferences  \n- number of general practice consultations for asthma : no significant \ndifference  \n- number of hospital admissions for asthma: k.A.  \n- number of hospital admissions for possible asthma  (defined as non-\nspecific hospitalization code and asthma- related code within a 1-\nweek window): no significant difference (In Anlehnung an NOS)  \nI. Selektion der Studienteilnehmer  \n1. exponierte Kohorte repr\u00e4sentativ \nf\u00fcr die zu untersuchende Interven-\ntion/Exposition: ja \n2. nicht -exponierte Kohorte repr\u00e4sen-\ntativ, ad\u00e4quat ausgew\u00e4hlt: ja  \n3. valide Erfassung der Exposition: ja \n(Registerdaten)  \n4. wahrscheinl ich, dass der gemes-\nsene Endpunkt nicht zu Studienbe-\nginn vorhanden war: ja (1 Jahr Vorbe-\nobachtung)  \nII. Vergleichbarkeit  \n1.Vergleichbarkeit der exponierten \nund nicht -exponierten Kohorte gege-\nben: ja  \nIII. Endpunkterfassung  \n1. valide Erfassung der Endpunkte: ja  \n2. Konnte in der Beobachtungszeit der \nEndpunkt auftreten: ja  \n3. fehlende Daten ad\u00e4quat ber\u00fcck-\nsichtigt: ja (Ausschluss)  \nIV. CoI/ Funding  \n- unrestricted grant from Glax-\noSmithKline, from Schering- Plough \n \n26959 \nDoyle S. What hap-\npens to patients \nwho have their \nasthma device \nswitched without \ntheir consent? Prim Qualitative Studie  \nn = 19  \nFragestellung:  \n- describe patients\u2019 experiences of non- consented switching of \nmedication  Baseline- Charakteristika:  \n- Weiblich: n=14  \n- Raucher *innen: ja:3, nein: 10, ehemals: 6  \n- Ergebnisse des ACT: well controlled: n=12 (63%)  \nErgebnisse:  \nPatient views on the circumstances of the NCS:  (In Anlehnung an McMaster)  \n1. Ziel/ Fragestellung : ja \n2. Literatur:  \n2.1 relevante Literatur gesichtet: ja  \n3. study design  \n3.1. Studiendesign: dargestellt: ja  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  308 \n      \n \nZitat Studiencharakteristika  Ergebnisse  Methodische Bewertung  \nCare Respir J \n2010;19(2):131- 9. \nhttp://www.ncbi.nlm\n.nih.gov/pub-\nmed/20174771  \n - investigate the potential range of circumstances in which \nswitches happened \n- investigate the perception of the impact of the switch  \nEinschlusskriterien:  \n- reported diagnosis of asthma and currently using an inhaler de-\nvice \n- experience of having an asthma inhaler device changed/switched \nwithout their knowledge or consent  \n- \u2265 18 J  \nAusschlusskriterien:  \n- no inhaler device or no switch in inhaler device  \n- presence of acute illness or other impai rment  \nStudiendesign:  \n- Rekrutierung: Normalbev\u00f6lkerung (lokale Medien)  \n- in-depth exploratory interviews  \n- Semi -structured face- to-face interviews  \n- demographic questionnaire, a clinical questionnaire, and ACT  \n - Most participants: identified doctor being responsible for instigating \nthe switch, a couple identified the pharmacist.  \n- one case: pharmacist identified as source of the nonconsented \nswitch (NCS), doctor unaware of switch  \n- two cases, source of the NCS unclear  \n- vermutete Gr\u00fcnde der Patienten f\u00fcr Wechsel: cost issues, many \nbelieved the decision was not made in their best interests  \nDevice use post -switch:  \n- nine preventer, nine rescue inhalers, one both  \n- most: not shown how to operate new device.  \n- Many: struggled to actuate new device as effectively as their previ-\nous \n- some: admitted not using the new device; unable to operate.  \n- L\u00f6sungsans\u00e4tze: resorted to use of old inhalers, returned to their \ndoctor, went without asthma therapy until someone explai ned how \nto use device.  \n- p. indicated overuse of medication due to lack of confidence in new \nmedication or inability to actuate new device effectively  \nChanges in perception of asthma control:  \n- most: more asthma symptoms and worse asthma control  \n- some: no  change in their asthma  \n- two: reported improvements in symptom relief.  \nRelationship with health professionals:  \n- levels of relationship with doctors, ranging from, \u201cI am completely \nsatisfied\u201d, to, \u201cI don\u2019t think they know who I am\u201d.  \n- inhaler switches had a clear impact on the doctor -patient relation-\nship \n- Almost all said: switch impacted on their relationship wit h doctor, \nirrespective of whether their previous relationship had been good or \nnot. Participants talked of being \u2018angry\u2019 and \u2018upset\u2019 or \u2018shocked\u2019 that \nthey had not been told anything about the NCS.  \n- while participants mainly experienced a deterioration i n their phys-\nical functioning (though not always), the participants indicated that \nthe surreptitious nature of the switch was to blame for the impairment \nin their doctor -patient relationship, not the decline in symptom control  3.2. theoretische Perspektive darge-\nstellt: ja  \n3.3. Methoden dargestellt: ja  \n4. Sampling  \n4.1. Selektion beschrieben: ja  \n4.2. Auswahl durchgef\u00fchrt bis Redun-\ndanz erreicht: unklar  \n4.3. informed concent: ja  \n5. Data collection  \n5.1. Beschreibung von Teilnehmern \nund Situation: ja  \n5.2. Beschreibung der Rolle des For-\nschers: unklar  \n5.3. Annahmen der Forscher  und \nBiasrisiko beschrieben:  \n6. Procedural Rigour: ja \n7. Datenanalyse:  \n7.1. analytische Stringenz: ja  \n8. Nachvollziehbarkeit: ja  \n9. Theoretische Zusammenh\u00e4nge: \nja \n10. Gesamtstringenz: unklar  \n11. Zusammenfassung: ja \nFunding:  unrestricted grant from Gla-\nxoSmithKline  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  309 \n      \n \nZitat Studiencharakteristika  Ergebnisse  Methodische Bewertung  \n26956 \nEkberg- Jansson A. \nBudesonide inhaler \ndevice switch pat-\nterns in an asthma \npopulation in Swe-\ndish clinical prac-\ntice (ASSURE). Int \nJ Clin Pract \n2015;69(10):1171-\n8. \nhttp://www.ncbi.nlm\n.nih.gov/pub-\nmed/26234385  \n Retrospektive Kohortenstudie  \n- 2005- 2013, Registerdaten, Schweden \n- Indexdatum: Erste Verschreibung BDP DPI  \n- Ursache f\u00fcr Wechsel nicht ermittelbar  \nUntersuchte Populationen:  \n- switch population: P. mit erfasstem Wechsel des Systems  \n- non-switch population: P. ohne Wechsel des Systems  \n- valid switch population: P. mit verf\u00fcgbaren Daten 12 Monate vor \nund nach Wechsel: n= 463  \n- nested case- control population: P. mit verf\u00fcgbaren Daten 12 \nMonate vor Wechsel: n = 960  \n>> Subgruppenanalysen stratifiziert nach MPR (Medication pos-\nsession ratio = prozentualer Anteil der Tage im Jahr, an denen \nMedikation vorliegt)  \nFragestellung:  \n- provide scientific insights on inhaler device switching on asth-\nmatic patients treated with BUD DPI  \nEinschlusskriterien:  \n- \u2265 6 Jahre,  \n- Diagnose: Asthma  \nAusschlusskriterien:  \n- COPD  \n- Ipratropium, Tiotropium  \nDefinition der Asthmakontrolle (bezogen auf das letzte Jahr):  \n- kontrolliert: keine OCS, \u2264 1 SABA -Verschreibung \n- teilweise kontrolliert: 1 OCS - und/ oder 1 SABA -Verschreibung \n- unkontrolliert: > 1 OCS - und/ oder > 1 SABA -Verschreibung Baseline- Charakteristika: ausgeglichen  \nErgebnisse der valid -switch -population [n= 926 (1:1)]  \nEvents pro Patient und Jahr [switch vs. non- switch]  \n- Exazerbationsrate: 0,4 vs. 0,32  \n- Konsultationsrate: 2,57 vs. 2,26  \n- SABA- Verschreibung: 1,32 vs. 1,21 \n- LABA -Verschreibung: 0,56 vs. 0,60 \nErgebnisse der nested case- control population [n = 1920 (1:1)]  \n- Evaluation m\u00f6glicher pr\u00e4diktiver Faktoren f\u00fcr Wechsel  \n- switch -Population: 4,5 Jahre j\u00fcnger, niedrigere MPR, LABA -Nut-\nzung seltener  \nRelevante Subgruppenanalyse:  \nEndpunkt in Abh\u00e4ngigkeit von Kontakt zum Gesundheitswe-\nsen am Tag des Wechsels  \nWechsler mit Arzt - oder Pflegepersonalk ontakt (n=214) Wechsler \nohne Kontakt (n= 116):  \n- ambulanter Krankenhauskontakt: 0,81 vs. 2,01 (p<0,001)  \n- Konsultationen: 4,29 vs. 4,96 \n- Exazerbationen: 0,77 vs. 0,90  \n  (In Anlehnung an NOS)  \nI. Selektion der Studienteilnehmer  \n1. exponierte Kohorte repr\u00e4s entativ \nf\u00fcr die zu untersuchende Interven-\ntion/Exposition: ja \n2. nicht -exponierte Kohorte repr\u00e4sen-\ntativ, ad\u00e4quat ausgew\u00e4hlt: ja  \n3. valide Erfassung der Exposition: ja \n(Registerdaten)  \n4. wahrscheinlich, dass der gemes-\nsene Endpunkt nicht zu Studienbe-\nginn vorhanden war: ja \nII. Vergleichbarkeit  \n1.Vergleichbarkeit der exponierten \nund nicht -exponierten Kohorte gege-\nben: ja  \nIII. Endpunkterfassung  \n1. valide Erfassung der Endpunkte: ja  \n2. Konnte in der Beobachtungszeit der \nEndpunkt auftreten: ja  \n3. fehlende Daten ad\u00e4quat ber\u00fcck-\nsichtigt: k.A.  \nIV. CoI/ Funding  \n- study sponsor: AstraZeneca  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  310 \n      \n \nAnhang 11  Kommentare aus der \u00f6ffentlichen Konsultation \nAnhang 11.1  Inhaltliche Kommentare  \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n2 Diagnostik und Monitoring  \nAbbildung 1; S. 14  R\u00f6 Thorax nicht als obligate Untersuchung abbilden Im Algorithmus werden sowohl Spirometrie als \nauch R\u00f6 Thorax als obligate Untersuchungen ab-\ngebildet. Die begr\u00fcndende Evidenz w\u00fcrde mich \ninteressieren. Aus Screening- Untersuchungen an \nrauchenden Menschen wei\u00df man, dass ein gene-\nrelles R\u00f6ntgen eher zu vermehrten Krebserkran-\nkungen f\u00fchrt, als durch Fr\u00fcherkennung Leben zu \nretten. Warum soll es im Einzelfall nicht m\u00f6glich \nsein, bei spirometrischer Diagnose einer COPD \nsymptomorientiert zu behandeln und nur bei aus-\nbleibender Symptomkontrolle zu r\u00f6ntgen? Algorithmus so belassen.  \n \nKeine \u00c4nderung.  \n \n \n4 \n(vorab)  Diagnostik und Monitoring  \nTabelle 5 Risikofaktoren; S. 17  E-Zigaretten aufnehmen?  \n [...] Eigentlich m\u00fcssten wir daher E -Zigaretten in \ndie Tabelle schreiben. Langzeitdaten haben wir \nnat\u00fcrlich nicht, sondern nur Tier -Daten. Als Kom-\npromiss k\u00f6nnen Sie \u201eGasen und Partikel / Fein-\nstaub\u201c schreiben. Unten im Text k\u00f6nnen Sie dann \nbei den EZ auf die Tabelle Bezug nehmen und \ndarstellen das bei Rauchen von EZ Gase und...  \nfreigesetzt werden.  \n Der Punkt:  \n\u2022 \u201eInhalativer Konsum alternativer Tabak-\nprodukte (wie Wasserpfeife, Tabakerhit-\nzer, E -Zigaretten)\u201c  \n \nwird in die Tabelle 5 Risikofaktoren aufge-\nnommen. Im Hint ergrundtext wird ein \nAnalogismus zu den breiter vorhandenen \nDaten zu Gasen und Feinstaub herge-\nstellt.  \n \n5 Diagnostik und Monitoring  \n2.4.2 Spirometrie  \n \nEmpfehlung 2- 3; S. 18  \nBei Patient*innen mit nachgewiesener \nAtemwegsobstruktion soll zur Best\u00e4ti-\ngung der Diagnose zun\u00e4chst ein Re-\nversibilit\u00e4tstest mit kurzwirkenden \nBeta- 2-Sympa -thomimetika (SABA) \ndurchgef\u00fchrt werden.  Eine COPD ist aber nur bei einer Normalisierung der \nObstruktion ausgeschlossen. Auch ein negativer Re-\nversibilit\u00e4tstest schlie\u00dft  ein Asthma bronchiale nicht si-\ncher aus.  Leitlinie 020- 017, Spirometrie, Seite 24 \n Die Empfehlung zum Reversibilit\u00e4tstest \nwird angepasst; der Grund f\u00fcr einen Re-\nversibilit\u00e4tstest wird gestrichen (zur Best\u00e4-\ntigung der Diagnose).  \n \nSomit lautet die Empfehlung 2 -3: \nBei Patient*innen mit nachgewiesener \nAtemwegsobstruktion soll zun\u00e4chst ein \nReversibilit\u00e4tstest mit kurzwirkenden \nBeta- 2-Sympathomimetika (SABA) durch-\ngef\u00fchrt werden.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  311 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nDer Hintergrundtext wird dahingehend an-\ngepasst und der Sachverhalt n\u00e4her erl\u00e4u-\ntert. \n \n6 Diagnostik und Monitoring  \n2.4.3 Ganzk\u00f6rperplethysmographie; \nS. 20  \n \nDie Ganzk\u00f6rperplethysmographie ist \neine in Deutschland fl\u00e4chendeckend \nverf\u00fcgbare Untersuchungsmethode \nund fester Bestandteil der ambulan-\nten Versorgung. Sie stellt eine ann\u00e4-\nhernd mitarbeitsunabh\u00e4ngige objek-\ntive Messmethode der Obstruktion \ndar und ist sinnvoll bei Patient*innen, \ndie nicht in der Lage sind, auswert-\nbare maximale und/oder forcierte \nAtemman\u00f6ver zus\u00e4tzlich zur Spiro-\nmetrie durchzuf\u00fchren [11]. Die Druck-\nflusskurve gibt Informationen \u00fcber \nden Elastizit\u00e4tsverlust der Lunge (ex-\nspiratorische Keule) und kann zur Ab-\nsch\u00e4tzung der \u00dcberbl\u00e4hung herange-\nzogen werden.  \n Die Ganzk\u00f6rperplethysmographie ist eine in Deutsch-\nland fl\u00e4chendeckend verf\u00fcgbare Untersuchungsme-\nthode und fester Bestandteil der ambulanten Versor-\ngung. Sie stellt eine ann\u00e4hernd mitarbeitsunabh\u00e4ngige \nobjektive Mess -methode der Obstruktion dar und misst \nim Gegensatz zur Spirometrie s\u00e4mtliche Volumina; \ngibt somit wichtige Informationen \u00fcber eine \u00dcberbl\u00e4-\nhung der Lunge und ist auch sinnvoll bei Patient*in-\nnen, die nicht in der Lage sind, auswertbare maximale \nund/oder forcierte Atemman\u00f6ver zus\u00e4tzlich zur Spiro-\nmetrie durchzuf\u00fchren [11]. Die Druckflusskurve gibt In-\nformationen \u00fcber den Elastizit\u00e4tsverlust der Lunge \n(exspiratorische K eule) und kann zur Absch\u00e4tzung der \n\u00dcberbl\u00e4hung herangezogen werden.  \n N\u00e4here Erl\u00e4uterungen zu Methode auch in Ab-\ngrenzung zur Spirometr ie \n \nCrie\u00e9 et al.  Body plethysmography e Its principles \nand clinical use. Respir Med. 2011 Jul;105(7):959-\n71. \ndoi: 10.1016/j .rmed.2011.02.006.  \n Der erg\u00e4nzende Textvorschlag wird ein-\ngef\u00fcgt.  \nUm den Stellenwert der Bodyplethysmo-\ngraphie nicht \u00fcber den der Spirometrie zu \nstellen, wird die Formulierung \u201eim Gegen-\nsatz zur\u201c ge\u00e4ndert in \u201eerg\u00e4nzend zur\u201c. So-\nmit lautet der Textabschnitt:  \n \nDie Ganzk\u00f6rperplethysmographie ist eine \nin Deutschland fl\u00e4chendeckend verf\u00fcg-\nbare Untersuchungsmethode und fester \nBestandteil der ambulanten Versorgung. \nSie stellt eine ann\u00e4hernd mitarbeitsunab-\nh\u00e4ngige objektive Messmethode der Ob-\nstruktion dar und misst erg\u00e4nzend zur \nSpirometrie s\u00e4mtliche Volumina; gibt so-\nmit wichtige Informationen \u00fcber eine \n\u00dcberbl\u00e4hung der Lunge und ist auch sinn-\nvoll bei Patient*innen, die nicht in der \nLage sind, auswertbare maximale \nund/oder forcierte Atemman\u00f6ver zus\u00e4tz-\nlich zur Spirometrie durchzuf\u00fchren [11]. \nDie Druckflusskurve gibt Informationen \n\u00fcber den Elastizit\u00e4tsverlust der Lunge (ex-\nspiratorische Keule) und kann zur Ab-\nsch\u00e4tzung der \u00dcberbl\u00e4hung herangezo-\ngen werden.  \n7 Diagnostik und Monitoring  \n2.5 Diagnostik von Komorbidit\u00e4ten; S. \n22 Neuer Abschnitt 2.5.3, einzuf\u00fcgen nach 2.5.2 (Angst \nund Depression)  \nVorgeschlagene Erg\u00e4nzung: Patienten, die die Ein-\nschlusskriterien f\u00fcr ein Screening auf Lungenkrebs er-\nf\u00fcllen (Siehe S3- Leitlinie \u201ePr\u00e4vention, Diagnostik, The-\nrapie und Nachsorge des Lungenkarzinoms), sollte die \nTeilnahme an einem entsprechenden, qualit\u00e4tsgesi-\ncherten Screeningprogramm angeboten werden. Da-Lungenkarzinom und COPD haben \u00e4hnliche Risi-\nkofaktoren, die Risikopopulation ist gr\u00f6\u00dftenteils \nidentisch, zudem ist das Lungenemphysem ein \nunabh\u00e4ngiger Risikofaktor f\u00fcr Lungenkrebs (de \nTorres, J. P., et  al. (2007). \"Assessing the rela-\ntionship between lung cancer risk and emphy-\nsema detected on low -dose CT of the chest.\" \nChest 132(6): 1932- 1938.). Lungenkrebsscree-\nning ist eine geeignete Ma\u00dfnahme, die Mortalit\u00e4t \nvon Lungenkrebs in der Risikogruppe zu senken  \u2013 Die Schritte des G -BA werden abgewartet \n(IqWIG -Bericht zum Thema \nwurde10/2020 fertiggestellt).  \nNach der Definition der Risikogruppe (G -\nBA) wird die Leitliniengruppe absch\u00e4tzen, \nob auch Patient*innen mit COPD entspre-\nchend abgebildet wurden - oder ob eine \nzus\u00e4tzliche systematische Recherche not-\nwendig wird.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  312 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nbei sollte der Schweregrad der COPD und die indivi-\nduelle M\u00f6glichkeit f\u00fcr den Patienten, von einer fr\u00fchen \nTherapie eines  Lungenkarzinoms zu profitieren, be-\nr\u00fccksichtigt werden.  dies wurde in zahlreichen Studien und Pilotprojek-\nten nachgewiesen (Beispiele f\u00fcr Studien: The Na-\ntional Lung Screening Trial Research Team \n(2011). \"Reduced Lung- Cancer Mortality with \nLow-Dose Computed Tomographic Screening.\" \nNew England Journal of Medici ne 365(5): 395-\n409.; de Koning, H. J., et al. (2020). \"Reduced \nLung- Cancer Mortality with Volume CT Screening \nin a Randomized Trial.\" New England Journal of \nMedicine.) und auch in der Bewertung des IQWiG \nf\u00fcr Deutschland best\u00e4tigt (Projekt S19- 02). \nDa beim Lungenkarzinom in fr\u00fchen Stadien zu-\nnehmend minimal -invasive Therapien m\u00f6glich \nsind, die auch bei Patienten mit eingeschr\u00e4nkter \nLungenfunktion sehr gute Ergebnisse zeigen, \nsollte die Chance genutzt werden, diese Patienten \nin Screeningprogramme aufzunehmen. Dabei \nsollte nat\u00fcrlich der individuelle Gesundheitszu-\nstand und die Lebenserwartung des Patienten so-\nwie seine M\u00f6glichkeiten, von m\u00f6glichen kurativen \nTherapien eines fr\u00fchen Lungenkarzinoms zu pro-\nfitieren, Ber\u00fccksichtigung finden.  Das Thema wird in der 3. Auflage der \nNVL COPD thematisiert.  \n \n8 Diagnostik und Monitoring  \n2.5.1 Tabakabh\u00e4ngigkeit  \n \nEmpfehlung 2- 7; S. 22  \n \nBei rauchenden Patient*innen mit \nCOPD soll der Fagerstr\u00f6mtest \n(FTCD ) zur weiterf\u00fchrenden Diagnos-\ntik eingesetzt werden, um die St\u00e4rke \nder Zigarettenabh\u00e4ngigkeit einzu-\nsch\u00e4tzen.  Bei rauchenden Patient*innen mit COPD soll der Fa-\ngerstr\u00f6mtest (FTCD) eingesetzt werden, wenn es f\u00fcr \ndie Therapie relevant ist, die St\u00e4rke der Zigarettenab-\nh\u00e4ngigkeit einzusch\u00e4tzen.  \n Die Empfehlung in der urspr\u00fcnglichen Variante ig-\nnoriert die Empfehlungen des motivational inter-\nviewing: nur wenn die entsprechende Ver\u00e4nde-\nrungsbereitschaft vorhanden ist, hat es Sinn, das \nAusma\u00df des Rauchens zu quantifizier en. Gerade \nin der Hausarztpraxis kann das \u201e\u00dcberziehen der \nPatient*innen\u201c mit Fragebogen- Instrumenten die \ntherapeutische Beziehung empfindlich st\u00f6ren, \nwenn sie nicht als angemessen empfunden wer-\nden. Die Empfehlung w\u00fcrde mit Sicherheit auch in \n99% der F\u00e4lle nicht befolgt werden.  Zustimmung zur neuen Formulierung.  \n \nEs wird darauf hingewiesen, dass die \nneue Formulierung somit etwas von der \nS3-Leitlinie \u201eScreening, Diagnostik und \nBehandlung des sch\u00e4dlichen und abh\u00e4n-\ngigen Tabakkonsums\u201d abweicht.  \n \nEmpfehlung 2- 7: \nBei rauchenden Patient*innen mit COPD \nsoll der Fagerstr\u00f6mtest (FTCD) eingesetzt \nwerden, wenn es f\u00fcr die Therapie relevant \nist, die St\u00e4rke der Zigarettenabh\u00e4ngigkeit \neinzusch\u00e4tzen.  \n9 Diagnostik und Monitoring  \n2.5.1 Tabakabh\u00e4ngigkeit  \n \"Wenn die St\u00e4rke der Zigarettenabh\u00e4ngigkeit abge-\nsch\u00e4tzt werden soll, soll der Fagerstr\u00f6m -Test zur Ziga-\nrettenabh\u00e4ngigkeit verwendet werden.\"  \n Die generelle SOLL- Empfehlung erscheint uns f\u00fcr \ndie Umsetzung in der Hausarztpraxis nicht realis-\ntisch zu sein. Au\u00dferdem leitet sich kein direktes siehe Nr. 8  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  313 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nEmpfeh lung 2 -7; S. 22:  \nBei rauchenden Patient*innen mit \nCOPD soll der Fagerstr\u00f6mtest \n(FTCD) zur weiterf\u00fchrenden Diagnos-\ntik eingesetzt werden, um die St\u00e4rke \nder Zigarettenabh\u00e4ngigkeit einzu-\nsch\u00e4tzen  Patientenmanagement daraus ab. Wir  bef\u00fcrwor-\nten daher an dieser Stelle einen KANN -Hinweis.  \n \nDie Empfehlung orientiert sich allerdings an der \nS3-Leitlinie Screening, Diagnostik und Behand-\nlung des sch\u00e4dlichen und Abh\u00e4ngigen Tabakkon-\nsums\u201c (die an dieser Stelle auf einem Expert*in-\nnenkonsens ber uht). Insofern muss die NVL \nCOPD an dieser Stelle wohl mitgehen.  \n \n10 Diagnostik und Monitoring  \n2.5.1.1 Objektive Messung des Ta-\nbakkonsums; S. 23  \n \nObjektive Messverfahren stellen eine \nHandlungsoption dar, wenn Zweifel \nan den Selbstausk\u00fcnften des/der Pa-\ntient*in hinsichtlich des Rauchverhal-\ntens  bzw. einer Tabakabstinenz nach \nTabakentw\u00f6hnungsversuch beste-\nhen. Jegliche Tests bed\u00fcrfen der akti-\nven Zustimm ung der Patienten*innen.   Zusatz:  \nDie CO Bestimmung zusammen mit der kapill\u00e4ren \nBGA kann ohne Aufkl\u00e4rung durchgef\u00fchrt werden.  Die Forderung ist im Alltag einer Praxis, bei der \nbei sehr vielen Patienten vor Arztkontakt eine ka-\npill\u00e4re BGA durchgef\u00fchrt wird , nicht umzusetzen.  \n \nDie Forderung wird dazu f\u00fchren, dass dieser \nwichtige Wert nicht mehr erhoben wird.  \n Anpassung im Hintergrundtext:  \nObjektive Messverfahren stellen eine \nHandlungsoption dar, wenn Zweifel an \nden Selbstausk\u00fcnften des/der Patient*in \nhinsic htlich des Rauchverhaltens  bzw. ei-\nner Tabakabstinenz nach Tabakentw\u00f6h-\nnungsversuch bestehen. Entsprechende \nTests bed\u00fcrfen der aktiven Zustimmung \nder Patienten*innen.   \n \n11 \n(vorab)  Diagnostik und Monitoring  \n2.5.1.1 Objektive Messung des Ta-\nbakkonsums; S. 23  \n \nObjektive Messverfahren stellen eine \nHandlungsoption dar, wenn Zweifel \nan den Selbstausk\u00fcnften des/der Pa-\ntient*in hinsichtlich des Rauchverhal-\ntens bzw. einer Tabakabstinenz nach \nTabakentw\u00f6hnungsversuch beste-\nhen. Jegliche Tests bed\u00fcrfen der akti-\nven Zustimm ung der Patienten*innen.    Eine aktive Zustimmung bei der Bestimmung der \nBGA ist im Alltag schwer umzusetzen. Ich hatte \ndies bei einer vorigen Version in einer E -Mail mit-\ngeteilt und hierbei auf andere Verfahren in der \nMedizin verwiesen, die ebenfalls relevante Be-\nfunde abkl\u00e4ren ohne dass eine aktive Zustim-\nmung eingeholt wird. Z:B Ultraschall Abdomen \netc. \n Siehe Nr. 10 \n \n12 Diagnostik und Monitoring  \n2.7 Strukturierte Symptomerfassung \n \nTabelle 10; S. 25   Mir ist es nicht ersichtlich, warum hier  nicht der \nCAT zum Abfragen der Symptome abgebildet ist. \nSeine einzelnen Items werden Punkt f\u00fcr Punkt im \nDMP abgefragt  \n Keine \u00c4nderung.  \n \nDie Gruppe hat sich bewusst f\u00fcr ein eige-\nnes k\u00fcrzeres Instrument entschieden. Zu-\ndem w\u00fcrde die Verwendung des CAT zu NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  314 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n einer anderen (strengeren) Symptomein-\nsch\u00e4tzung f\u00fchren im Vergleich zum \nmMRC.  \n \n13 Diagnostik und Monitoring  \n2.7.1 Erfassung von Exazerbationen \n \nTabelle 11; S. 27  \n \nHatten Sie wegen Ihrer COPD seit \ndem letzten Besuch in der Praxis ei-\nnen station\u00e4ren Krankenhausaufent-\nhalt?  Exazerbationen sind im allgemeinen der Grund f\u00fcr \neinen Krankenhausaufenthalt wegen COPD.  \nWarum muss ein weiteres Kriterium erf\u00fcllt sein, \num auf eine Exazerbation zu schlie\u00dfen? \n Keine \u00c4nderung.  \n \nAbbildung der Fragen entsprechend dem \nsystemati sch entwickelten Patient*innen-\nQuestionnaire \u201eMonitoring of Exacerbation \nProbability (MEP).  \n \n14 Diagnostik und Monitoring  \n2.2.1 Zus\u00e4tzliche Anamnese f\u00fcr rau-\nchende Patient*innen mit COPD  \n \n- Abb. 2: Raucheranamnesebogen \n(\u201eVorschlag\u201c f\u00fcr ausf\u00fchrliche Anam-\nnese zum aktuellen Rauchverhalten, \nzur Empf. 2- 1 und Abb. 1, Diagnostik -\nAlgorithmus), S. 14, S. 16  \n \nEmpfehlung 2- 1 \nBei der Diagnose der COPD soll ent-\nsprechend dem Algorithmus (siehe \nAbbildung 1) vorgegangen werden.  In der aktuellen Fassung werden f\u00fcr COPD -Patienten \ninsgesamt vier (!) Frageb\u00f6gen empfohlen. Das er-\nscheint uns f\u00fcr die Gesamtheit der COPD -Patienten in \nHausarztpraxen nicht realisierbar zu sein.  [\u00c4ZQ: Kom-\nmentar gilt f\u00fcr Nr. 14- 17 zusammen]  \n \n \nF\u00fcr eine strukturierte Erfassung von T abakabh\u00e4ngig-\nkeit, Symptomschwere und Exazerbationen wird die \nVerwendung von Frageb\u00f6gen allerdings lediglich emp-\nfohlen (KANN) und nur die konkreten Frageb\u00f6gen sind \ndann mit einer SOLLTE -Empfehlung versehen. [\u00c4ZQ: \nKommentar gilt f\u00fcr Nr. 14- 17 zusammen]   Keine \u00c4nderung.  \n \nKein konkreter \u00c4nderungsvorschlag, \ndurch den Hinweis auf den offenen Emp-\nfehlungsgrad (\u201eKANN\u201c).  \n \n \n15 Diagnostik und Monitoring  \n2.5.1 Tabakabh\u00e4ngigkeit  \n \nEmpf. 2 -7: Fagerstr\u00f6mtest (Objekti-\nvierung der Tabakabh\u00e4ngigkeit); S. \n22 \n \nEmpfehlung 2- 7 \nBei rauchenden Patient*innen mit \nCOPD soll der Fagerstr\u00f6mtest Siehe weiteres Vorgehen Nr. 8  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  315 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n(FTCD) zur weiterf\u00fchrenden Diagnos-\ntik eingesetzt werden, um die St\u00e4rke \nder Zigarettenabh\u00e4ngigkeit einzu-\nsch\u00e4tzen.  \n16 Diagnostik und Monitoring  \n2.7 Strukturierte Symptomerfassung \n \n- Empf. 2 -8/2-9: Strukturierte Doku-\nmentation, z.B. anhand Tab. 10 \n(neues Instrument anstelle CAT -\n/MRC- Fragebogen); S. 24  \n \nEmpfehlung 2- 8 \nDie Schwere der Symptomatik einer \nCOPD soll strukturiert erfasst und be-\nurteilt werden.  \n \nEmpfehlung 2- 9 \nF\u00fcr die strukturierte Erfassung und \nBeurteilung kann Tabelle 10 genutzt \nwerden.  Keine \u00c4nderung.  \n \n17 Diagnostik und Monitoring  \n2.7.1 Erfassung von Exazerbationen \n \nEmpfehlung 2- 10; S. 26 \nDie Exazerbationen sollen strukturiert \nerfasst und dokumentiert werden.  \n \nEmpfehlung 2- 11 \nF\u00fcr die Erfassung der Exazerbationen \nkann der (validierte) MEP -Fragebo-\ngen (Monitoring of Exacerbation Pro-\nbability) genutzt werden.  Keine \u00c4nderung.  \n \n18 Tabakentw\u00f6hnung  \n \nEmpfehlung 3- 4; S. 31 Bei entw\u00f6hnungsbereiten Patient*innen mit COPD soll \neine Verhaltenstherapie und bei entsprechendem Be-\ndarf eine medikament\u00f6se Entzugssyndrombehandlung \nnachdr\u00fccklich empfohlen und angeboten werden Keineswegs alle ben\u00f6tigen oder w\u00fcnschen eine \nEntzugssyndrombehandlung. In den Studien zur \nmedikament\u00f6sen Begleittherapie w aren nur Pati-\nenten eingeschlossen, die nach entsprechender Empfehlung nicht \u00e4ndern.  \n \nDiese wurde ausf\u00fchrlich i n der Arbeits-\ngruppe diskutiert und auch aufgrund der NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  316 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nBei entw\u00f6hnungsbereiten Patient*in-\nnen mit COPD soll eine kombinierte \nTherapie mit Verhaltenstherapie und \nmedikament\u00f6ser Entzugssyndrombe-\nhandlung nachdr\u00fccklich empfohlen \nund angeboten werden.   intensiver Aufkl\u00e4rung einer potentiellen Behand-\nlung mit Psychopharmaka zugestimmt haben-  \nmeist solche mit vorherigen frustranen Absetzver-\nsuchen  \n vorhandenen Evidenz so formuliert.  \nDer identifizierte Cochrane Review (van \nEerd 2016) zeigt deutlich den Vorteil einer \nKombinationsbehandlung (bzw. einer \npharmakologischen Behandlung als Add \non zur Verhaltenstherapie) auf (siehe S. \n31). \n \nZudem wurde im Cochrane Review kein \ndirekter Vergleich zwischen Verhaltens-\ntherapie und medikament\u00f6ser Therapie \n(entweder/oder) durchgef\u00fchrt -  somit kann \nentsprechend der vorliegenden Evidenz \ndie Verhaltenstherapie nicht direkt \u00fcber \ndie medikament\u00f6se Therapie gestellt wer-\nden. \nAuch wird im Hintergrundtext die medika-\nment\u00f6se Therapie nicht konkretisiert; be-\nzieht sich also nicht zwangsl\u00e4ufig nur auf \nPsychopharmaka.(S. 32)  \n \n20 \n(vorab)  Tabakentw\u00f6hnung  \n \nEmpfehlung 3- 7; S. 34  \nAls M\u00f6glichkeit des Biomonitorings \nkann eine CO -Messung durchgef\u00fchrt \nwerden.  Was soll gemessen werden? Hb- CO? \n  Kurze Erl\u00e4uterung im Hintergrundtext.  \n \nIm Kapitel 2.5.1.1 wird bereits auf die ver-\nschiedenen M\u00f6glichkeiten der CO -Mes-\nsung eingegangen: Verlinkun g darauf wird \neingef\u00fcgt  \n21 Tabakentw\u00f6hnung  \n3.4 Strukturierte Entw\u00f6hnung im \nAkutkrankenhaus/im Rahmen der Re-\nhabilitation  \n \nEmpfehlung 3- 8; S. 36  \nBei rauchenden Patient*innen mit \nCOPD soll bereits w\u00e4hrend eines \n(akut)station\u00e4ren Aufenthaltes im \nKrankenhaus eine Tabakentw\u00f6hnung Bei entw\u00f6hnungsbereiten Patient*innen mit COPD soll \neine Verhaltenstherapie und bei entsprechendem Be-\ndarf eine medikament\u00f6se Entzugssyndrom -behand-\nlung nachdr\u00fccklich empfohlen und angeboten werden.  \n Die Empfehlung k\u00f6nnte etwas zur\u00fcckhaltender \nformuliert werden.  \nKeineswegs ben\u00f6tigen oder w\u00fcnschen alle eine \nEntzugssyndrombehandlung.  \nIn den Studien zur medikament\u00f6sen Begleitthera-\npie waren nur Patienten eingeschlossen, die nach \nentsprechender intensiver Aufkl\u00e4rung einer poten-\ntiellen Behandlung mit Psychopharmaka zuge-\nstimmt haben-  meist solche mit vorherigen frustra-\nnen Absetzversuchen  \n Empfehlung nicht \u00e4ndern.  \n \nSiehe Nr. 18 \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  317 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \ninitiiert und eine anschlie\u00dfende am-\nbulante Entw\u00f6hnungsbehandlung or-\nganisiert werden.  \n22 Tabakentw\u00f6hnung  \n \nEmpfehlung 3- 9; S. 36  \nRauchenden Patient*innen mit \nCOPD, die eine Rehabilitationsma\u00df-\nnahme wahrnehmen, soll im Rahmen \nder Rehabilitation ein strukturiertes \nEntw\u00f6hnungsprogramm (kognitive \nVerhaltenstherapie und medikamen-\nt\u00f6se Therapie) angeboten werden.  Rauc henden Patient*innen mit COPD, die eine Reha-\nbilitationsma\u00dfnahme wahrnehmen, soll im Rahmen \nder Rehabilitation ein strukturiertes Entw\u00f6hnungspro-\ngramm (kognitive Verhaltenstherapie und bei entspre-\nchendem Bedarf medikament\u00f6se Therapie) angeboten \nwerden.  \n Analog zu 3- 4 [Keineswegs alle ben\u00f6tigen oder \nw\u00fcnschen eine Entzugssyndrombehandlung. In \nden Studien zur medikament\u00f6sen Begleittherapie \nwaren nur Patienten eingeschlossen, die nach \nentsprechender intensiver Aufkl\u00e4rung einer poten-\ntiellen Behandlung mit Psychopharmaka zuge-\nstimmt haben-  meist solche mit vorherigen frustra-\nnen Absetzversuchen]  \n Empfehlung nicht \u00e4ndern.  \n \nSiehe Nr. 18 \n \n69 Tabakentw\u00f6hnung  \n \nEmpfehlung 3- 9; S. 36  \nRauchenden Patient*innen mit \nCOPD, die eine Rehabilitationsma\u00df-\nnahme wahrnehmen, soll im Rahmen \nder Rehabilitation ein strukturiertes \nEntw\u00f6hnungsprogramm (kognitive \nVerhaltenstherapie und medikamen-\nt\u00f6se Therapie) angeboten werden.  Rauchenden Patient*innen mit COPD, die eine Reha-\nbilitationsma\u00dfnahme wahrnehmen, soll im Rahmen \nder Rehabilitation ein strukturiertes Entw\u00f6hnungspro-\ngramm (kognitive Verhaltenstherapie und bei entspre-\nchendem Bedarf medikament\u00f6se Therapie) angeboten \nwerden.  \n Keineswegs ben\u00f6tigen oder w\u00fcnschen alle eine \nEntzugssyndrombehandlung.  \n \nIn den Studien zur medikament\u00f6sen Begleitt hera-\npie waren nur Patienten eingeschlossen, die nach \nentsprechender intensiver Aufkl\u00e4rung einer poten-\ntiellen Behandlung mit Psychopharmaka zuge-\nstimmt haben-  meist solche mit vorherigen frustra-\nnen Absetzversuchen  Dopplung.  \nUmgang siehe Nr. 22  \n24 Tabakentw\u00f6hnung  \n3.3. E -Zigaretten; S. 35  \n \nStellenwert  \n[\u2026]. Andererseits h\u00e4lt sie m\u00f6gliche \nVorz\u00fcge einer harm reduction Thera-\npie mittels E -Zigarette bei solchen \nPatient*innen f\u00fcr plausibel, die entwe-\nder trotz mehrerer Entw\u00f6hnungsver-\nsuche weiterhin rauchen oder die \neine Therapie der Tabakabh\u00e4ngigkeit \nkategorisch ablehnen. Idealerweise \nbedarf die Therapie mittels E -Ziga-\nrette einer verhaltenstherapeutischen \nBeratung Der Passus sollte gestrichen werden.   \nAlternativ: Stattdessen in Anlehnung an die S3 LL Ta-\nbak: G leichwohl ist der Leitliniengruppe bewusst, dass \nmanche Raucher dieses Produkt nutzen, um ihren Ta-\nbakkonsum zu beenden. Sollte der Einsatz der E -Ziga-\nrette zur Unterst\u00fctzung der Tabakabstinenz erwogen \nwerden, dann nur nach dokumentierten Versagen \noder Ablehnung anderer evidenzbasierter Ma\u00dfnah-\nmen sowie Aufkl\u00e4rung \u00fcber bekannte Risiken bei \ngleichzeitiger Beendigung des Tabakkonsums und ab-\ngestimmter Folgetermine.  \n Wegen der hohen Wahrscheinlichkeit von dual \nuse mit hohem Sch\u00e4digungspotential ist eine \nharm reduc tion hier nicht plausibel.  \n \nAnfang September wurde dem \u00c4ZQ bereits die \nArgumentation der DGP und das ERS Positions-\npapier sowie weitere Dokumente zugeleitet.  \n \nDie DGP vertritt mit allen bekannten pneumologi-\nschen Gesellschaften diese Meinung. Die DGP \nhat hierzu klar Stellung bezogen und dies zB auf \nder Homepage deutlich gemacht.  \nhttps://pneumologie.de/fileadmin/user_upload/Ak-\ntuelles/2020- 11-02_DGP_Stellungnahme_Tabak-\nentwoehnung_mit_E -Zigarette.pdf  \n Der vorgeschlagene Text aus der \u00f6ffentli-\nchen Konsultation wird \u00fcbernommen; der \nurspr\u00fcngliche Passus zur harm reduction \n(siehe 2. Spalte NVL) wird damit ersetzt:  \nGleichwohl ist der Leitliniengruppe be-\nwusst, dass manche Raucher dieses Pro-\ndukt nutzen, um ihren Tabakkonsum zu \nbeenden. Sollte der Einsatz der E -Ziga-\nrette zur Unterst\u00fctzung der Tabakabsti-\nnenz erwogen werden, dann nur nach do-\nkumentierten Versagen oder Ablehnung \nanderer evidenzbasierter Ma\u00dfnahmen so-\nwie Aufkl\u00e4rung \u00fcber bekannte Risiken bei \ngleichzeitiger Beendigung des Tabakkon-\nsums und abgestimmter Folgeter mine.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  318 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n- Der Hinweis \u00fcber die verhaltensthera-\npeutische Beratung aus der urspr\u00fcngli-\nchen Textversion wird mit aufgenommen.  \n- Die Formulierung \u201eund abgestimmter \nFolgetermine\u201c wird redaktionell ange-\npasst.  \n25 Tabakentw\u00f6hnung  \n3.3. E -Zigaretten; S. 35  \n \n\u201eAufgrund der aktuell unzureichenden \nDatenlage, und auch wegen der noch \nnicht absch\u00e4tzbaren gesundheitlichen \nLangzeitfolgen f\u00fcr Patient*innen mit \nCOPD, sieht die Leitliniengruppe in \nder E -Zigarette keine Option f\u00fcr einen \nprim\u00e4ren Entw\u00f6hnungsversuch. An-\ndererseits h\u00e4lt sie m\u00f6gliche Vorz\u00fcge \neiner harm reduction Therapie mittels \nE-Zigarette bei solchen Patient*innen \nf\u00fcr plausibel, die entweder trotz meh-\nrerer Entw\u00f6hnungsversuche weiterhin \nrauchen oder die eine Therapie der \nTabakabh\u00e4ngigkeit kategorisch ab-\nlehnen. \u201c Neue Empfehlung \n Evtl. k\u00f6nnte hier eine zus\u00e4tzliche Empfehlung ein-\ngef\u00fcgt werden \n Nicht ber\u00fccksichtigen.  \n \nIn den Diskussionen: bewusste Entschei-\ndung der Gruppe, keine Empfehlung zu \nformulieren.  \n \n26 Tabakentw\u00f6hnung  \n3.3. E -Zigaretten; S. 35  \n \n\u201eAufgrund der aktuell unzureichenden \nDatenlage, und auch wegen der noch \nnicht absch\u00e4tzbaren gesundheitlichen \nLangzeitfolgen f\u00fcr Patient*innen mit \nCOPD, sieht die Leitliniengruppe in \nder E -Zigarette keine Option f\u00fcr einen \nprim\u00e4ren Entw\u00f6hnungsversuch. An-\ndererseits h\u00e4lt sie m\u00f6gliche Vorz\u00fcge \neiner harm reduction Therapie mittels \nE-Zigarette bei solchen Patient*innen \nf\u00fcr plausibel, die entweder trotz meh-\nrerer Entw\u00f6hnungsversuche weiterhin \nrauchen oder die eine Therapie der Die Befundlage hinsichtlich Wirkung und Risiken der \nE-Zigarette in der Tabakentw\u00f6hnung ist uneinheitlich \nmit Hinweisen auf ein Entw\u00f6hnungspotential und auf \nlangfristige Risiken dieser neuen Produkte. E -Zigaret-\nten sollten zur Reduktion des Zigarettenkonsums nicht \nangeboten werden.  \n [...] sind die pneumologischen Fachgesellschaften \nsich einig, dass die E -Zigarette nicht empfohlen \nwird. In der Anlage ein Dokument der Deutschen \nGesellschaft f\u00fcr Pneumologie, welches eine \u00dcber-\nsetzung der europ\u00e4ischen Fachgesell schaften ist. \nWeiter eine Empfehlung aus Australien. Positive \nEmpfehlungen pneumologischer Fachgesellschaf-\nten zur EC sind nicht bekannt. Aus Sicht der DGP, \nmit der ich das Vorgehen abgestimmt habe, sollte \ndaher der letzte Satz ge\u00e4ndert werden. Wir w\u00fcr-\nden v orschlagen \u201eDie Befundlage hinsichtlich Wir-\nkung und Risiken der E -Zigarette in der Tabakent-\nw\u00f6hnung ist uneinheitlich mit Hinweisen auf ein \nEntw\u00f6hnungspotential und auf langfristige Risiken \ndieser neuen Produkte\u201c.  Und \u201eE -Zigaretten soll-\nten zur Reduktion des Zigarettenkonsums nicht Siehe Umgang zu Nr. 24.  \nNach Einarbeitung des neuen Passus \nwird der Textabschnitt nochmals in G\u00e4nze \nauf Plausibilit\u00e4t gepr\u00fcft.  \nEs wird darauf geachtet, dass eine even-\ntuelle \u201esprachliche Verwirrung von harm \nreduction und Reduktion des Tabakkon-\nsums\u201c vermieden wird.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  319 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nTabakabh\u00e4ngigkeit kategorisch ab-\nlehnen. \u201c angeboten werden\u201c. Dies entspricht der bisher \nkonsentierten Fassung der Tabakleitlinie, die al-\nlerdings nicht COPD -spezifisch ist.  \n27 Nicht -medikament\u00f6se Therapie  \n \nTabelle 12, S. 38  Erg\u00e4nzungspunkt f\u00fcr Barrieren.  \nNeu auf nehmen: Ansteckungsgefahr  Wichtiger Punkt in Pandemiezeiten \n Zus\u00e4tzlichen Punkt in Tabelle 12 aufneh-\nmen:  \n\u2022 Angst vor Ansteckung  \n70 Nicht -medikament\u00f6se Therapie  \n \nTabelle 12, S. 38  Erg\u00e4nzungspunkt f\u00fcr Barrieren.  \nNeu aufnehmen: Ansteckungsgefahr  Wichtiger Punkt in Pandemiezeiten \n Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr. 27  \n28 Nicht -medikament\u00f6se Therapie  \n \nEmpfehlung 4- 11; S. 48 \nNachschulungen sollen nach sp\u00e4tes-\ntens zwei Jahren angeboten werden \n Nachschulungen sollten nach sp\u00e4testens zwei Jahren \nangeboten werden \n Aufgrund fehlender solider Evidenz nur sollte, zu-\nmal dies mit erheblichem Ressourcenverbrauch \nverbunden ist  \n Nach Diskussion der aktuellen Datenlage \nzum Thema wird beschlossen, die Emp-\nfehlungsformulierung der NVL Asthma an-\nstelle der urspr\u00fcnglichen Empfehlung zu \n\u00fcbernehmen. Somit lautet die Empfeh-\nlung:  \nNachschulungen sollen bei Bedarf ange-\nboten werden.  \n \nIm Hintergrundtext wird der Begriff Nach-\nschulung entsprechend dem jeweiligen \nBedarf der  Patient*innen spezifizierter \ndargestellt (wann komplette Schulungen \nbzw. Teile wiederholt werden; Gruppen-\nsetting oder individuell; regelm\u00e4\u00dfige Erhe-\nbung des Bedarfes).  \n \nEin Patientenblatt zum Thema wird er-\nstellt.  \n71 Nicht -medikament\u00f6se Therapie  \n \nEmpfehlung 4 -11; S. 48 \nNachschulungen sollen nach sp\u00e4tes-\ntens zwei Jahren angeboten werden Nachschulungen sollten nach sp\u00e4testens zwei Jahren \nangeboten werden \n Aufgrund fehlender solider Evidenz nur sollte, zu-\nmal dies mit erheblichem Ressourcenverbrauch \nverbunden ist  \n Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr. 28  \n \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  320 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n29 Nicht -medikament\u00f6se Therapie  \n4.2. Atemphysiotherapie; ab S. 41  \n \n Bitte eingehen auf Hustentechniken.  \n Bei ca. 30% ist Husten das dominante Symptom. \nEs wird aber dominant auf Techniken zur Linde-\nrung der Dyspnoe bzw. der Sekretelimination ein-\ngegangen.  \n Nicht ber\u00fccksichtigen.  \n \n- Verweis wird eingef\u00fcgt: S. Weise, Peter \nKardos,  \nD. Pfeiffer -Kascha, H. Worth. Empfehlun-\ngen zur Atemphysiotherapie. Dustri Ver-\nlag, 3. Au flage,2019  \n \n- Hustentechniken sind auf Seite 47 er-\nw\u00e4hnt (Vertiefende Informationen, Punkt \n4).  \nDie Sekretretention ist meist die Ursache \ndes Hustens bei COPD. Eine besonders \nh\u00e4ufige Reizhustenproblematik, die noch \ngemeint sein k\u00f6nnte, wird f\u00fcr Patient*in-\nnen mit COPD nicht gesehen.  \n72 Nicht -medikament\u00f6se Therapie  \n4.2. Atemphysiotherapie; ab S. 41  \n Bitte eingehen auf Hustentechniken.  \n Bei ca. 30% ist Husten das dominante Symptom. \nEs wird aber dominant auf Techniken zur Linde-\nrung der Dyspnoe bzw. der Sekretel imination ein-\ngegangen.  Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr. 29  \n \n30 \n(vorab)  Nicht -medikament\u00f6se Therapie  \n4.2 Atemphysiotherapie  \n \nTabelle 14; S. 45/46  \n\u2022 Hypertonus und Druckdolenz der \nAtemmuskeln  \n Wo und f\u00fcr welche Muskeln soll man eine Druckdo-\nlenz versp\u00fcren?  \n  Muskelgruppen im Text benennen.  \nErfahrungsgem\u00e4\u00df h\u00e4ufig betroffen und \nleicht zu palpieren sind der z. B. M. trape-\nzius, die autochtonen R\u00fcckenmuskeln, die \nMm. pectorales, die Mm. scaleni und der \nM. sternocleidomastoideus. Der Hyperto-\nnus wird durch Druck im Bereich des \nMuskelbauches erfasst. Die Druckdolen-\nzen finden sich in Muskelbauch oder - an-\ns\u00e4tzen.  \n31 Nicht -medikament\u00f6se Therapie  \n4.3 4.3 Patientenschulung und \nSelbstmanagement; S. 49  \n \n\u201eDie Schulung wird in 6x60 Minuten \ndurchgef\u00fchrt und kann in der Praxis \nsowohl durch die behandelnden Die Schulung kann von in einem Trainerseminar quali-\nfizierten Team aus \u00c4rztin und Helferin in der Praxis \ndurchgef\u00fchrt werden \n Missverst\u00e4ndlicher Text, da beide Personen in der \nSchulung notwendig sind.  \n Hintergrundtext wird angepasst:  \n \nVertiefende Informationen  \nAuch COBRA (Chronisch obstruktive \nBronchitis mit und ohne Emphysem) ist ei-\nnes der ambulanten Schulungspro-\ngramme f\u00fcr Patient*innen mit COPD und \nz\u00e4hlt zu den evaluierten und strukturierten \nMa\u00dfnahmen in diesem Kontext [130]. NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  321 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n\u00c4rzt*innen, als auch durch qualifi-\nzierte Mitarbeiter*innen vermittelt wer-\nden.\u201c  \n Wichtige Inhalte sind u.a. die Selbstkon-\ntrolle der Erkrankung sowie das Erlernen \ngeeigneter Selbsthilfema\u00dfnahmen. Die \nSchulung wird in 6x60 Minuten durchge-\nf\u00fchrt und kann in der Praxis durch ein \nqualifiziertes Team aus einem Arzt/ einer \n\u00c4rztin und einem/r Mitarbeiter*in vermittelt \nwerden. Voraussetzung f\u00fcr die Durchf\u00fch-\nrung ist das erfolgreiche Absolvieren ei-\nnes zertifizierten Trainer -Seminares . \n73 Nicht -medikament\u00f6se Therapie  \n4.3 4.3 Patientenschulung und \nSelbstmanagement; S. 49  \n \n\u201eDie Schulung wird in 6x60 Minuten \ndurchgef\u00fchrt und kann in der Praxis \nsowohl durch die behandelnden \n\u00c4rzt*innen, als auch durch qualifi-\nzierte Mitarbeiter*innen vermittelt wer-\nden.\u201c  Die Schulung kann von in einem Trainerseminar quali-\nfizierten Team aus \u00c4rztin und Helferin in der Praxis \ndurchgef\u00fchrt werden \n Missverst\u00e4ndlicher Text, da beide Personen in der \nSchulung notwendig sind.  \n Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr. 31  \n \n32 Nicht -medikament\u00f6se Therapie  \n4.4 Ern\u00e4hrung \n \nEmpfehlung 4- 13; S. 49 \nUntergewichtige oder adip\u00f6se Pati-\nent*innen mit COPD sollen eine Er-\nn\u00e4hrungsberatung erhalten.  Untergewichtige oder adip\u00f6se Patient*innen mit  COPD \nsollen eine Ern\u00e4hrungsberatung angeboten bekom-\nmen.  \n Auch hier: die Empfehlung muss zu den Bed\u00fcrf-\nnissen der Patient*innen passen. Eine starke \nEmpfehlung zur Gewichtsreduktion bei Adip\u00f6sen \nignoriert die Tatsache, dass die meisten Betroffe-\nnen sich mit i hrem Gewicht in irgendeiner Weise \narrangiert haben. Zudem ist \u2013 zumindest bei Adi-\npositas \u2013 die Evidenz f\u00fcr die Effizienz solcher Be-\nratungen sehr relativ.  Redaktionelle \u00c4nderung Empfehlung 4- 13 \n(entspricht Empfehlungsduktus der NVL):  \nUntergewichtigen oder adip\u00f6sen Pati-\nent*innen mit COPD soll eine Ern\u00e4hrungs-\nberatung angeboten werden.  \n \n33 Nicht -medikament\u00f6se Therapie  \n4.4 Ern\u00e4hrung \n \nEmpfehlung 4- 12; S. 49 \nKrankheitsbedingt untergewichtigen \nPatient*innen mit COPD soll eine \nausgewogene hoc hkalorische Nah-\nrungserg\u00e4nzung zur Erh\u00f6hung des \nK\u00f6rpergewichtes empfohlen werden.  Krankheitsbedingt untergewichtigen Patient*innen mit \nCOPD und normalgewichtigen Patient*innen mit \nCOPD und krankheitsbedingter (Risiko f\u00fcr) Mangeler-\nn\u00e4hrung/Sarkopenie soll \u2013 im Rahmen einer individu-\nellen, bedarfsgerechten Ern\u00e4hrungstherapie durch \nden daf\u00fcr qualifizierten Gesundheitsfachberuf (Di\u00e4tas-\nsistenten) \u2013 eine supportive, ggf. krankheitsspezifi-\nsche, orale bilanzierte Erg\u00e4nzungsnahrung wie \nTrinknahrung zur Erh\u00f6hung bzw. zum Erhalt des K\u00f6r-\npergewichtes empfohlen werden.  \n Neben krankheitsbedingt untergewichtigen Pati-\nent*innen mit COPD sollen auch normalgewichti-\ngen Patient*innen mit COPD und krankheitsbe-\ndingter (Risiko f\u00fcr) Mangelern\u00e4hrung/Sarkopenie \n[1-6], m\u00f6glichst im Rahmen einer individuellen, \nbedarfsgerechten Ern\u00e4hrungstherapie [3,7- 11], \neine supportive, ggf. krankheitsspezifische, orale \nbilanzierte Erg\u00e4nzungsnahrung wie Trinknahrung \nzur Erh\u00f6hung bzw. zum Erhalt des K\u00f6rpergewich-\ntes empfohlen werden [3,5- 6,8-16]. Im Sinne ei ner \npatientensicheren, prozessgeleiteten Durchf\u00fch-\nrung von Ern\u00e4hrungstherapie muss der daf\u00fcr per Empfehlung nicht \u00e4ndern.  \n \nDie Empfehlung beruht auf einer systema-\ntisch durchgef\u00fchrten Recherche zum \nThema. Es konnte 1 Cochrane Review \nidentifiziert werden (Ferreira 2012; siehe \nHintergrundtext S. 50). Hier zeigten die \ngepoolten Daten aus 11 RCTs mit insge-\nsamt 325 unterern\u00e4hrten Patient*innen \neine st atistisch signifikante Gewichtszu-\nnahme (MD 1.65 kg (95% KI 0,14; 3,16); \nI\u00b2 = 17%, 11 RCTs, n = 325; Datenqualit\u00e4t NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  322 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nBerufsgesetz (Di\u00e4tAssG \u00a73) [17] qualifizierte Ge-\nsundheitsfachberuf der Di\u00e4tassistenten ausdr\u00fcck-\nlich genannt werden. Zur Initiierung der Ern\u00e4h-\nrungstherapie bedar f es der \u00e4rztlichen An-  oder \nVerordnung. \u00c4rzte selbst (Approbationsordnung \nf\u00fcr \u00c4rzte \u00a7 27 ) [18] oder gar Medizinische Fach-\nangestellte (Verordnung \u00fcber die Berufsausbil-\ndung zum Medizinischen Fachangestellten / zur \nMedizinischen Fachangestellten vom 26. Apr il \n2006) [19] sind per Approbationsordnung bzw. per \nBerufsausbildung in diesem Arbeitsgebiet nicht \nausgebildet und k\u00f6nnten im Arbeitsalltag einen \nsolch aufwendigen Prozess nicht durchf\u00fchren. \nWenn eine orale bilanzierte Erg\u00e4nzungsnahrung, \ndie es in verschiedenen Zusammensetzungen, \nKonsistenzen, Energiedichten und ml -Mengen pro \nPackungseinheit gibt [6,13], verschrieben wird, \nsollte sie, unter Ber\u00fccksichtigung m\u00f6glicher vorlie-\ngender Komorbidit\u00e4t, optimal im personbezoge-\nnen Ern\u00e4hrungs - [7-11] und Gesamtrehabili tati-\nonskonzept passen [14- 16], eine zu hohe zus\u00e4tzli-\nche Energiezufuhr durch Trinknahrung kann sich \nnachteilig auswirken [20].  \n1. Cederholm T, Jensen GL, Correia MITD, Gon-\nzalez MC, Fukushima R, Higashiguchi T, et al. \nGLIM criteria for the diagnosis of malnutrition - A \nconsensus report from the global clinical nutrition \ncommunity. Clin Nutr 2019;38(1):1 -9. DOI: \n10.1016/j.clnu.2018.08.002  \n2. Cruz -Jentoft AJ, Bahat G, Bauer J, Boirie Y, \nBruyere O, Cederholm T, et al. Sarcopenia: re-\nvised European consensus on definition and diag-\nnosis. Age Ageing 2019;48(1):16- 31. DOI: \n10.1093/ageing/afy169  \n3. Hauner H, Beyer -Reiners E, Bischoff G, Brei-\ndenassel C, Ferschke M, Gebhardt A, et al.  \nLeitfaden Ern\u00e4hrungstherapie in Klinik und Praxis \n(LEKuP). Manual of Nutritional Therapy in Patient \nCare. Aktuel Ernahrungsmed 2019;44(6):384- 419. \nDOI: 10.1055/a- 1030- 5207 \n4. Jensen GL, Cederholm T. The malnutrition \noverlap syndromes of cachexia and sarcopenia: a \nmalnutrition conundrum. Am J Clin Nutr moderat) zugunsten der Nahrungserg\u00e4n-\nzung. Wurden RCTs gepoolt, welche so-\nwohl normalgewichtige, als auch unterge-\nwichtige Patient*innen mit COPD  unter-\nsuchten, so konnte jedoch kein signifikan-\nter Unterschied zwischen den Gruppen \nidentifiziert werden (MD -1.28 kg (95% KI -\n6,27; 3,72); I\u00b2 = 56%, 3 RCTs, n=116).  \n \nDie selektiv eingebrachte Literatur wurde \ngesichtet. Eine systematische \u00dcbersichts-\narbeit ( Nr. 15: Aldhahir AM) konnte hierbei \nidentifiziert werden. Es gab keinen Hin-\nweis auf relevante klinische Verbesserun-\ngen.  \nDa Aussagen zur Wirksamkeit m\u00f6glichst \nauf RCT -Basis getroffen werden, wurden \ndie angef\u00fchrten Kohortenstudien nicht be-\ntrachtet.  \n \nEs ist  nicht definiert, was unter einem Ri-\nsiko f\u00fcr Mangelern\u00e4hrung oder Sarkope-\nnie zu verstehen ist. Die erweiterte For-\nmulierung kann zu einer Ausweitung der \nIndikation f\u00fchren.  \n \nZudem war die Formulierung eine be-\nwusste Entscheidung der Gruppe, die \nEmpfehlung ni cht weiter zu spezifizieren.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  323 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n2018;108(6):1157 -8. DOI: 10.1093/ajcn /nqy314  \n5. Barazzoni R, Bischoff SC, Breda J, Wickra-\nmasinghe K, Krznaric Z, Nitzan D, et al. ESPEN \nexpert statements and practical guidance for nutri-\ntional management of individuals with SARS -CoV-\n2 infection. Clin Nutr 2020;39(6):1631- 8. DOI: \n10.1016/j.cl nu.2020.03.022.  \n6. Volkert D, Beck AM, Cederholm T, Cruz -Jentoft \nA, Goisser S, Hooper L, et al. ESPEN guideline \non clinical nutrition and hydration in geriatrics. Clin \nNutr 2019;38(1):10- 47. DOI: \n10.1016/j.clnu.2018.05.024  \n7. Rondanelli M, Faliva MA, Per oni G, Infantino V, \nGasparri C, Iannello G, et al. Food Pyramid for \nSubjects with Chronic Obstructive Pulmonary Dis-\neases. Int J Chron Obstruct Pulmon Dis \n2020;15:1435- 48. DOI: 10.2147/COPD.S240561.  \nassessment and therapy in COPD: a European \nRespiratory So ciety statement. Eur Respir J \n2014;44(6):1504- 20. DOI: \n10.1183/09031936.00070914.  \n8.Schols AM, Ferreira IM, Franssen FM, Gosker \nHR, Janssens W, Muscaritoli M, et al. Nutritional  \n9. Sch\u00e4fer C. Ern\u00e4hrungstherapie bei COPD. Er-\nn\u00e4hrung im Fokus 2013;13(03- 04):128-33. \n10. Collins PF, Yang IA, Chang YC, Vaughan A. \nNutritional support in chronic obstructive pulmo-\nnary disease (COPD): an evidence update. J Tho-\nrac Dis 2019;11(Suppl 17):S2230- S7. DOI: \n10.21037/jtd.2019.10.41.  \n11. Meteling- Eeken M, Schilling- Ma\u00dfmann B . Die \nBestimmung des Energie-  und Eiwei\u00dfbedarfs in \nder Ern\u00e4hrungstherapie. Beispiel COPD: Ma\u00dfar-\nbeit ist gefragt. Ern\u00e4hrungs Umschau \n2012;59(12):690- 4.  \n12. Ferreira IM, Brooks D, White J, Goldstein R. \nNutritional supplementation for stable chronic ob-\nstruct ive pulmonary disease. Cochrane Database \nSyst Rev 2012;12:CD000998. DOI: \n10.1002/14651858.  \n13. Kalde S. E&P: Orale Supplemente im klini-\nschen Alltag. Ern\u00e4hrungs Umschau \n2015;62(11):S43 -S6.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  324 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n14. Korkmaz C, Demirbas S, Vatansev H, Yildirim \nE, Teke T, Zamani A. Effects of comprehensive \nand intensive pulmonary rehabilitation and nutri-\ntional support on quality of life and functional sta-\ntus in patients with chronic obstructive pulmonary  \ndisease. J Int Med Res \n2020;48(4):300060520919567. DOI: \n10.1177/0300060520919567.  \n15. Aldhahir AM, Rajeh AMA, Aldabayan YS, \nDrammeh S, Subbu V, Alqahtani JS, et al. Nutri-\ntional supplementation during pulmonary rehabili-\ntation in COPD: A systematic review. Chron \nRespir Dis 2020;17:1479973120904953. DOI: \n10.1177/1479973120904953, wit h Editorial:  \n16. van den Borst B. Nutritional supplementation \nduring pulmonary rehabilitation in COPD: Do not \nexpect an elixir of life but keep the hunger for \nmore robust evidence. Chron Respir Dis \n2020;17:1479973120904954. DOI: \n10.1177/1479973120904954.  \n17. Bundestag, Bundesrat. Gesetz \u00fcber den Beruf \nder Di\u00e4tassistentin und des Di\u00e4tassistenten (Arti-\nkel 1 des Gesetzes \u00fcber den Beruf der Di\u00e4tassis-\ntentin und des Di\u00e4tassistenten und zur \u00c4nderung \nverschiedener Gesetze \u00fcber den Zugang zu an-\nderen Heilberufen) ( Di\u00e4tassistentengesetz - Di\u00e4t-\nAssG). Di\u00e4tassistentengesetz vom 8. M\u00e4rz 1994 \n(BGBI. I S. 446), das zuletzt durch Artikel 38 des \nGesetzes vom 15. August 2019 (BGBI. I S. 1307) \nge\u00e4ndert worden ist. 2019. http://www.gesetze- im-\ninternet.de/di_tassg_1994/Di\u00e4tAssG. pdf  \n18. Bundesministerium f\u00fcr Gesundheit. Approba-\ntionsordnung f\u00fcr \u00c4rzte (\u00c4ApprO 2002) Approba-\ntionsordnung f\u00fcr \u00c4rzte vom 27. Juni 2002 (BGBl. I \nS. 2405), die zuletzt durch Artikel 3 des Gesetzes \nvom 16. M\u00e4rz 2020 (BGBl. I S. 497) ge\u00e4ndert wor-\nden ist. Berli n: Bundesministerium f\u00fcr Gesundheit; \n2020.  \n19. Bundesministerium f\u00fcr Gesundheit. Verord-\nnung \u00fcber die Berufsausbildung zum Medizini-\nschen Fachangestellten/zur Medizinischen Fach-\nangestellten vom 26. April 2006. Bundesgesetz-\nblatt 2006;2006(22):1097 -108.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  325 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n20. Broekhuizen R, Creutzberg EC, Weling -\nScheepers CA, Wouters EF, Schols AM. Optimiz-\ning oral nutritional drink supplementation in pa-\ntients with chronic obstructive pulmonary disease. \nBr J Nutr 2005;93(6):965- 71.  \n34 Nicht -medikament\u00f6se Therapie  \n4.4 Ern\u00e4hrung \n \nEmpfehlung 4- 13; S. 49 \nUntergewichtige oder adip\u00f6se Pati-\nent*innen mit COPD sollen eine Er-\nn\u00e4hrungsberatung erhalten.  Untergewichtige oder adip\u00f6se Patient*innen mit COPD \nsowie normal - oder \u00fcbergewichtigen Patient*innen mit \nCOPD und einer krankheitsbedingten (Risiko f\u00fcr) Man-\ngelern\u00e4hrung/ Sarkopenie sollen eine Ern\u00e4hrungsthe-\nrapie zur Ern\u00e4hrungsoptimierung und Verbesserung \ndes Ern\u00e4hrungszustandes durch den daf\u00fcr qualifizier-\nten Gesundheitsfachberuf (Di\u00e4tassistenten) erhalten.  \n Neben untergewichtigen und adip\u00f6sen Patient*in-\nnen mit COPD sollen auch normal - und \u00fcberge-\nwichtigen Patient*innen mit COPD und einer \nkrankheitsbedingten (Risiko f\u00fcr) Mangelern\u00e4h-\nrung/Sarkopenie eine Ern\u00e4hrungstherapie zur Er-\nn\u00e4hrungsoptimierung [21] und Verbesserung des \nErn\u00e4hrungszustandes erhalten [1- 11,14]. Im \nSinne einer patientensicheren, prozessgeleiteten \nDurchf\u00fchrung von Ern\u00e4hrungstherapie muss der \ndaf\u00fcr per Berufsgesetz (Di\u00e4tAssG \u00a73) [17] qualifi-\nzierte Gesundheitsfachberuf der Di\u00e4tassistenten \nausdr\u00fccklich genannt werden. Zur Initiierung der \nErn\u00e4hrungstherapie bedarf es der \u00e4rztlichen An-  \noder Verordnung. \u00c4rzte selbst (Approbationsord-\nnung f\u00fcr \u00c4rzte \u00a7 27) [18] oder gar Medizinische \nFachangestellte (Verordnung \u00fcber die Berufsaus-\nbildung zum Medizinischen Fachangestellten / zur \nMedizinischen Fachangestellten vom 26. April \n2006) [19] sind per Approbationsordnung bzw. per \nBerufsausbildung in diesem Arbeitsgebiet nicht \nausgebildet und k\u00f6nnten im Arbeitsalltag einen \nsolch aufwendigen Prozess nicht durchf\u00fchren. 21. \nvan de Bool C, Mattijssen- Verdonschot C, van \nMelick PP, Spruit MA, Franssen FM, Wouters EF, \net al. Quality of dietary intake in relation to body \ncomposition in patients with chronic obstructive \npulmonary disease eligible for pulmonary rehabili-\ntation. Eur J Clin Nutr 2014;68(2):159- 65. DOI: \n10.1038/ejcn.2013.257. Ern\u00e4hrungsberatung ist \neine der m\u00f6glichen Interventionsformen in der Er-\nn\u00e4hrungstherapie und wird aus leistungsrechtli-\ncher Perspektive als Beratung gesunder Men-\nschen bezeichnet. Bei der Ern\u00e4hrungstherapie \nhandelt es sich um eine Ern\u00e4hrungsintervention \nmit therapeutischer Ausrichtung, die sich folglich \nrichtet an Menschen mit einer Erkrankung wie Pa-\ntienten mit COPD und die Ern\u00e4hrungsberatung Empfehlungsformulierung siehe Nr. 32  \nBewusste Entscheidung der Gruppe, nicht \nn\u00e4her auf die Therapie einzugehen bzw. \ndazu Stellung zu nehmen, was thematisch \n\u00fcber eine Beratung hinausgeht.  \nDarstellung der Evidenz siehe Nr.33 \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  326 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nbeinhalten kan n [3,9,22].  \n22. Buchholz D, Lang C. Entstehung und Definiti-\nonen. In: VDD -Leitlinie f\u00fcr die Ern\u00e4hrungstherapie \nund das prozessgeleitete Handeln in der Di\u00e4tetik. \nBand 1. Manual f\u00fcr den German- Nutrition Care \nProcess (G -NCP). Ein Standardwerk f\u00fcr die \nDurchf\u00fchr ung, Weiterentwicklung, \u00dcberpr\u00fcfung \nund Qualit\u00e4tssicherung der Di\u00e4tetik in Deutsch-\nland. Hrsg: Verband der Di\u00e4tassistenten \u2013  Deut-\nscher Bundesverband e. V (VDD). Lengerich: \nPabst Science Publishers, 2015. ISBN: 978- 3-\n95853- 119-2 \n35 Nicht -medikament\u00f6se Therapie  \n4.4 Ern\u00e4hrung; S. 50  \n \n\u201eGenerell ist eine Abnahme des K\u00f6r-\npergewichts um > 10 % in den letzten \n6 Monaten oder um > 5% im letzten \nMonat als Gewichtsverlust zu wer-\nten.\u201c Laut den Kriterien der Global Leadership Initiative on \nMalnutrition (GLIM) 2019 ist eine ungewollte Abnahme \ndes K \u00f6rpergewichts > 5 % in den letzten 6 Monaten \noder > 10 % in > 6 Monaten als Gewichtsverlust zu \nwerten.  \n Es sollen weltweit die gleichen Konsensus -Diag-\nnosekriterien f\u00fcr Mangelern\u00e4hrung angewendet \nwerden [1], die Leitlinie zur Diagnostik und Thera-\npie von Pat ienten COPD 2018 [23] ist diesbez\u00fcg-\nlich veraltet. 23. Vogelmeier C, Buhl R, Burghuber \nO, Criee CP, Ewig S, Godnic -Cvar J, et al. [Guide-\nline for the Diagnosis and Treatment of COPD Pa-\ntients - Issued by the German Respiratory Society \nand the German Atemwegsl iga in Cooperation \nwith the Austrian Society of Pneumology]. \nPneumologie 2018;72(4):253- 308. DOI: \n10.1055/s -0043- 125031 Hintergrundtext entsprechend vorgeschla-\ngener Text\u00e4nderung anpassen.  \n \n36 Nicht -medikament\u00f6se Therapie  \n4.4 Ern\u00e4hrung; S. 50  \n \n\u201eDie Definitionen f\u00fcr eine krankhaft \nbedingte Gewichtsabnahme werden \nin einer selektiv eingebrachten Studie \n[131] f\u00fcr Patient*innen mit COPD dif-\nferenzierter dargestellt: Die hier for-\nmulierte Konsensusdefinition f\u00fcr \nKachexie beinhaltet einen Gewichts-\nverlust von > 5% in 12 Monaten oder \neinen niedrigen BMI zus\u00e4tzlich zu ei-\nner 3/5 verringerten Muskelkraft, \nM\u00fcdigkeit, Magersucht, niedrigem \nFFMI (fat -free-mass -index) und er-\nh\u00f6hten Entz\u00fcndungswerten.\u201c  Die Definitionen f\u00fcr eine krankhaft bedingte Gewichts-\nabnahme werden i n einer selektiv eingebrachten Stu-\ndie [131] f\u00fcr Patient*innen mit COPD differenzierter \ndargestellt: Die hier formulierte Konsensusdefinition \n2008 f\u00fcr Kachexie beinhaltete einen Gewichtsverlust \nvon > 5% in 12 Monaten oder einen niedrigen BMI (< \n20 kg/m2) zus\u00e4tzlich zu drei von f\u00fcnf der Kriterien ver-\nringerten Muskelkraft, M\u00fcdigkeit, Magersucht, niedri-\ngem FFMI (fat -free-mass -index) und erh\u00f6hten Entz\u00fcn-\ndungswerten.  \n Die Konsensusdefinition f\u00fcr Kachexie wurde 2008 \nformuliert [24], heutzutage sollten allererst die \nGLIM -Kriterien 2019 angewendet werden [1,4].  \n24. Evans WJ, Morley JE, Argiles J, Bales C, Bar-\nacos V, Guttridge D, et al. Cachexia: a new defini-\ntion. Clin Nut r 2008;27(6):793- 9. DOI: \n10.1016/j.clnu.2008.06.013. Was wird hier unter \neine niedrige BMI verstanden? Deshalb Angabe \n\u00fcbereinstimmend mit [24]. \u201eeiner 3/5\u201c war nicht \ndeutlich, deshalb Korrektur in \u00dcbereinstimmung \nmit [24]. \n Hintergrundtext entsprechend vor geschla-\ngener Text\u00e4nderung anpassen.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  327 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n37 Nicht -medikament\u00f6se Therapie  \n4.4 Ern\u00e4hrung; S. 50  \n \n\u201eEin bereits vor Beginn der Erkran-\nkung bzw. Diagnosestellung beste-\nhender niedriger BMI ist keine Indika-\ntion f\u00fcr eine Nahrungssupplementie-\nrung.\u201c  Ein bereits vor Begi nn der Erkrankung bzw. Diagnose-\nstellung bestehender niedriger BMI ist keine Indikation \nf\u00fcr eine Nahrungssupplementierung. Zur fr\u00fchzeitigen \nErkennung einer Mangelern\u00e4hrung oder eines Risikos \nf\u00fcr Mangelern\u00e4hrung ist bei allen COPD -Patient*innen \nein regelm\u00e4\u00dfi ges Screening mit einer validierten, \nschnell durchzuf\u00fchrenden Methode notwendig \n(https://www.dgem.de/screening). Im Krankenhaus soll \ndas Screening standardm\u00e4\u00dfig bei Aufnahme und an-\nschlie\u00dfend w\u00f6chentlich durchgef\u00fchrt werden, in der \nLangzeitpflege soll das S creening mindestens alle 3 \nMonate erfolgen. In Haus - bzw. Facharztpraxen wird \nein zumindest j\u00e4hrliches Screening empfohlen, wobei \nes sich anbietet Follow -Up-Untersuchungen in den \nWochen 1 bis 4 nach Exazerbation und weitere Ree-\nvaluation 12- 16 Wochen nach E xazerbation auch f\u00fcr \nScreening auf Mangelern\u00e4hrung(srisiko) zu nutzen. \nBei positiver Screening soll anschlie\u00dfender Diagnostik \n(GLIM -Kriterien 2019 und ggf. zus\u00e4tzlich f\u00fcr Sarkope-\nnie die Kriterien der European Working Group on Sar-\nkopenia in Older People 2019 (EWGSOP2)) stattfin-\nden. Wenn Mangelern\u00e4hrung vorliegt, ist Ern\u00e4hrungs-\ntherapie notwendig.  \n Durch Screening mit einer validierten, einfach und \nschnell durchzuf\u00fchrenden Methode sollen Patien-\nten mit einem Mangelern\u00e4hrungsrisiko oder be-\nreits vorliegender Mangelern\u00e4hrung fr\u00fchzeitig er-\nkannt werden (https://www.dgem.de/screening). \nIm Krankenhaus soll das Screening routinem\u00e4\u00dfig \nbei Aufnahme und danach in w\u00f6chentlichen Inter-\nvallen erfolgen, in der Langzeitpflege mindestens \nalle 3 Monate. In Haus - bzw. Facharztpraxen wird \ninsbesondere bei \u00e4lteren Patienten in Abh\u00e4ngig-\nkeit vom Gesundheitszustand ein zumindest j\u00e4hrli-\nches Screening empfohlen.\u201c [3, S. 391)] Laut \nCOPD- Leitlinie [23] finden Follow -Up-Untersu-\nchungen in den Wochen 1 bis 4 nach Exazerba-\ntion und ggf. weitere R eevaluation 12- 16 Wochen \nnach Exazerbation statt. Es bietet sich bei der \n\u201eEvaluation der klinischen Situation\u201c an auch auf \nMangelern\u00e4hrung(srisiko) zu screenen. Es sollen \nweltweit die gleichen Konsensus -Diagnosekrite-\nrien f\u00fcr Mangelern\u00e4hrung und Sarkopenie ange-\nwendet werden [1- 4]. Mangelern\u00e4hrung sollte \nrechtzeitig festgestellt und behandelt werden [1,3 \n(S. 391), 5,6,9,25, DGEM -Leitlinien, weitere ES-\nPEN-Leitlinien].  \n25. Cederholm T, Barazzoni R, Austin P, Ballmer \nP, Biolo G, Bischoff SC, et al. ESPEN guidel ines \non definitions and terminology of clinical nutrition. \nClin Nutr 2017;36(1):49- 64. DOI: \n10.1016/j.clnu.2016.09.004.  Keine \u00c4nderung.  \n \nThema ist nicht in der Gruppe diskutiert / \nnicht als Versorgungsproblem wahrge-\nnommen worden.  \nKeine Daten f\u00fcr Nutzen des  Screenings.  \n \n38 Nicht -medikament\u00f6se Therapie  \n4.4 Ern\u00e4hrung; S. 50  \n \nRationale \n\u201eDie Leitliniengruppe sch\u00e4tzt die Evi-\ndenz so ein, dass sie prinzipiell den \nVorteil von gewichtsf\u00f6rdernden Ma\u00df-\nnahmen bei krankheitsbedingt unter-\ngewichtigen Menschen mit COPD be-\nlegt. Gleichwohl empfiehlt sie aus-\ndr\u00fccklich nicht die in einigen Studien \nuntersuchte Gabe von Steroiden oder Erg\u00e4nzung:  hochkalorische Nahrungserg\u00e4nzung und \nden Einsatz vieler kleiner Mahlzeiten am Tage  \n  Um die evidenzbasierte Aussage der Rati-\nonale (hochkalorische Nahrungserg\u00e4n-\nzung) von der praktischen Erfahrung ab-\nzugrenzen, wird ein zus\u00e4tzlicher Satz f\u00fcr \nden Hintergrundtext formuliert. Dieser \nkann dann lauten:  \n \nHinweis:  \nErfahrungsgem\u00e4\u00df kann man den Pati-\nent*innen zur Gewichtsf\u00f6rderung zus\u00e4tz-\nlich auch den Einsatz mehrerer kleiner NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  328 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nWachstumshormonen, sondern \nspricht sich f\u00fcr eine hochkalorische \nNahrungserg\u00e4nzung aus, um Ge-\nwichtszunahme zu f\u00f6rdern. Ange-\nsichts des deutlichen Z usammen-\nhangs zwischen Prognose und Unter-\ngewicht sowie dem prinzipiellen Be-\nnefit der Gewichtsf\u00f6rderung spricht \ndie Leitliniengruppe eine starke Emp-\nfehlung aus\u201c  Mahlzeiten am Tage sowie das Aufneh-\nmen von fester Nahrung vor dem Trinken \nvorschlagen.  \n \n39 Nicht -medikament\u00f6se Therapie  \n4.4 Ern\u00e4hrung; S. 50  \n \nRationale \n\u201eDie Leitliniengruppe geht davon aus, \ndass stark \u00fcber - und untergewichtige \nPatient*innen mit COPD von einer Er-\nn\u00e4hrungsberatung profitieren, um da-\nnach zu pr\u00fcfen, welche Lebensstil-\nma\u00dfnahmen in ihrem individuellen \nFall geeignet sein k\u00f6nnen.\u201c  Die Leitliniengruppe geht davon aus, dass sowohl \nstark \u00fcber - und untergewichtige Patient*innen mit \nCOPD, als auch normal - und leicht bis m\u00e4\u00dfig \u00fcberge-\nwichtige Patient*innen mit COPD und krankheitsbe-\ndingter (Risiko f\u00fcr) Mangelern\u00e4hrung von einer indivi-\nduellen Ern\u00e4hrungstherapie z ur Ern\u00e4hrungsoptimie-\nrung und Verbesserung des Ern\u00e4hrungszustandes \nprofitieren, um danach zu pr\u00fcfen, welche Lebensstil-\nma\u00dfnahmen in ihrem individuellen Fall geeignet sein \nk\u00f6nnen.  \n Laut Konsensuskriterien und Leitlinien sollen auch \nPatient*innen mit krankheit sbedingter (Risiko f\u00fcr) \nMangelern\u00e4hrung eine Ern\u00e4hrungstherapie be-\nkommen [1- 3,6]. Generell: DGEM -Leitlinien: \nhttps://www.dgem.de/leitlinien ESPEN -Guidelines: \nhttps://www.espen.org/guidelines -home/espen-\nguidelines COPD geht h\u00e4ufig mit Begleiterkran-\nkungen ei nher [8,9,23], die durch eine lebens-\nlange Einhaltung ern\u00e4hrungstherapeutischer Ma\u00df-\nnahmen g\u00fcnstig zu beeinflussen sind [3]. Deshalb \nsollten COPD -Patienten eine individuelle Ern\u00e4h-\nrungstherapie [9,19,23] zur Ern\u00e4hrungsoptimie-\nrung [18,26] und Verbesserung des Ern\u00e4hrungs-\nzustandes [1,7- 10,14] im multidisziplin\u00e4ren Rah-\nmen nicht vorenthalten werden. Diesbez\u00fcgliche \ngute Studien, unter anderem unter Ber\u00fccksichti-\ngung der neueren Erkenntnissen zum Qualit\u00e4t der \nMakron\u00e4hrstoffen [3,7,9], sind dringend erforder-\nlich [7,8,1 6].  \n26. McLoughlin RF, McDonald VM, Gibson PG, \nScott HA, Hensley MJ, MacDonald- Wicks L, et al. \nThe Impact of a Weight Loss Intervention on Diet \nQuality and Eating Behaviours in People with \nObesity and COPD. Nutrients 2017;9(10). DOI: \n10.3390/nu9101147. Si ehe f\u00fcr Ern\u00e4hrungsbera-\ntung versus Ern\u00e4hrungstherapie unter Punkt 2.  Keine \u00c4nderung.  \n \nSiehe Nr. 34  \n40 Nicht -medikament\u00f6se Therapie  \n4.6.3  \nTherapie der respiratorischen Insuffi-\nzienz Typ II; S. 54 Diskussion und Erg\u00e4nzung der Literatur  \n Die Literaturstellen [144,145] sind von 2013 und \n2014, also eher alt, w\u00e4hrend es aktuelle Evidenz -\nBewertungen von der ERS gibt.  \nErgan E et al, European Respiratory Society \nguidelines  Keine \u00c4nderung.  \n \nDie Gruppe hat die Daten der Cochrane \nReviews gepr\u00fcft und als g\u00fcltig befunden. \nDie hier vorgeschlagene Literatur ist eine NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  329 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n \n\u201eZudem wurden in der strukturierten \nRecherche nach aggregierter Evidenz \nzwei Cochrane- Reviews identifiziert \n[144,145]\u201c.  on long -term home non -invasive  \nventilation for management of COPD, Eur Respir \nJ 2019; 54: 1901003, \nhttps://doi.org/10.1183/13993003.01003- 2019  \nDiese Literaturstelle soll aufgenommen werden.  \n Leitlinie (nicht aus dem deutschen Kon-\ntext) und keine Evidenz.  \nDie Begr\u00fcndung f\u00fcr die dazugeh\u00f6rige \nEmpfehlung 4- 18 basiert insbesondere \nauf ei nem Expert*innenkonsens inklusive \nAbgleich mit der S2k -Leitlinie Nichtinva-\nsive und invasive Beatmung als Therapie \nder chronischen respiratorischen Insuffizi-\nenz. \n74 Nicht -medikament\u00f6se Therapie  \n4.6.3  \nTherapie der respiratorischen Insuffi-\nzienz Typ II; S. 54  \n \n\u201eZudem wurden in der strukturierten \nRecherche nach aggregierter Evidenz \nzwei Cochrane- Reviews identifiziert \n[144,145]\u201c.  Diskussion und Erg\u00e4nzung der Literatur  \n Die Literaturstellen [144,145] sind von 2013 und \n2014, also eher alt, w\u00e4hrend es aktuelle Evidenz -\nBewertungen von der ERS gibt.  \nErgan E et al, European Respiratory Society \nguidelines  \non long- term home non- invasive  \nventilation for management of COPD, Eur R espir \nJ 2019; 54: 1901003, \nhttps://doi.org/10.1183/13993003.01003- 2019  \nDiese Literaturstelle soll aufgenommen werden.  Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr. 40  \n41 \n(vorab)  Medikament\u00f6se Therapie  \nAb S. 58  W\u00e4re es nicht sinnvoll in diesem Abschnit t eine Excel -\nTabelle mit allen Substanzen der jeweiligen Gruppe \n(LAMA, LABA, ICS, SAMA, SABA) aufzulisten als Hil-\nfestellung f\u00fcr Nutzer der Leitlinie??? \nVielleicht auch an einer anderen Stelle   Keine \u00c4nderung.  \n \nEine fortlaufende Aktualisierung ist nicht \nzu gew\u00e4hrleisten.  \n \n42 Medikament\u00f6se Therapie  \n \nAbbildung 4; S. 58  \nu.a. SAMA zur Symptomkontrolle bei \nleichter bis mittelgradiger Symptoma-\ntik SAMA streichen  \n Es gibt Hinweise auf eine erh\u00f6hte Kardiotoxizit\u00e4t \ndieser Medikamentengruppe \u2013  anders als bei \nLAMA. Singh S, Loke Y, Furberg C. Inhaled anti-\ncholinergics and risk of major adverse cardiovas-\ncular events in patients with chronic obstructive \npulmonary disease: a systematic review and \nmeta- analysis . JAMA  \n2008;300:1439- 50. doi: \n10.1001/jama.300.12.1439  SAMA im Algorithmus belassen. Keine \n\u00c4nderung.  \n \nStudie wird von Experten eher als \nschwach eingesch\u00e4tzt. Betrifft auch SABA \nund sollte nicht prinzipiell dazu f\u00fchren, be-\ndarfsorientiert Medikation bei leichter \nSymptomatik auszuschlie\u00dfen.  \n43 Medikament\u00f6se Therapie  \n5.2.2.2 Triple- Therapie; S. 61/62  \n \nAuszug Evidenz:  \nFerguson et. al (KRONOS, n = 1902, \nVerzerrungsrisiko (RoB): 2x gering/5x Erweiterung des Abschnitts Evidenzbeschreibung \ndurch Text zur ETHOS Studie:  \nRabe et al. (Rabe et al., Triple Inhaled Therapy at Two \nGlucocorticoid Doses in Moderate- to-Very-Severe \nCOPD, N Engl J Med. 2020 Jul 2;383(1):35- 48. doi: \n10.1056/NEJMoa1916046) untersuchten die klinische Wichtige neue Evidenz f\u00fcr die COPD Therapie \nfehlt, Literatur im Text und:  \n1. Rabe et al., Triple Inhaled Therapy at Two Glu-\ncocorticoid Doses in Moderate- to-Very-Severe \nCOPD, N Engl J Med. 2020 Jul 2;383(1):35- 48. \ndoi: 10.1056/NEJMoa1916046 Aufnahme in Hintergrundtext:  \nNach Abschluss der Recherche zum \nThema wurde ein weiterer RCT zum \nThema publiziert, welcher diese Ergeb-\nnisse best\u00e4tigt [Rabe et al. 2020]  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  330 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nunklar) [168] untersuchten die Ef fekte \nder Triple- Therapie( Budesonid/Gly-\nkopyrronium/Formoterol) im Vergleich \nzu LAMA/LABA (Glykopyrro-\nnium/Formoterol) und LABA/ICS (Bu-\ndesonid/Formoterol) bei Patient*innen \nmit symptomatischer COPD \n(n=1902). Stattgehabte Exazerbatio-\nnen im vorausgegangenen J ahr wa-\nren keine Einschlussbedingung. Bei \nBehandlung mit der Triple- Therapie \n(n=640) zeigte sich eine reduzierte \nExazerbationsrate von 0,46 pro Jahr \nim Vergleich zu LAMA/LABA (signifi-\nkant;Exazerbationsrate 0,95 /Jahr; \nn=627) und auch zu LABA/ICS (nicht \nsignifikant; Exazerbationsraten \n0,56/Jahr f\u00fcr MDI, n=316 bzw. \n0,55/Jahr f\u00fcr DPI, n=319). In Sub-\ngruppenanalysen ergaben sich Hin-\nweise auf einen m\u00f6glichen Benefit \nerst ab einer Baseline- Eosinophilen-\nzahl von 75- 100 cells/mm\u00b3, wenn eine \nLAMA/LABA -Behandlung mit IC S es-\nkaliert wird\u2026  Wirksamkeit der Triple -Kombination Budesonid/Glyko-\npyrronium/Formoterolfumarat in zwei verschiedenen \nICS-Dosierungen (160 bzw. 320 \u00b5g) im Vergleich mit \nGlykopyrronium/Formoterolfumarat oder Bude-\nsonid/Formoterolfumarat an Patienten mit moderater \nbis sehr schwerer COPD nach prospektiver Stratifizie-\nrung von eosinophilen Granulozyten (ETHOS, n= \n8572). Prim\u00e4rer Endpunkt der Studie war die Rate mo-\nderater und schwerer Exazerbationen. Weitere End-\npunkte waren COPD -Symptomati k, Lebensqualit\u00e4t, \nGesamtmortalit\u00e4t sowie Sicherheitsparameter. Unter \nbeiden Triple- Therapien zeigte sich eine statistisch \nsignifikante Reduktion an moderaten/schweren \nExazerbationen (320 \u00b5g Budesonid 1,08; 160 \u00b5g Bu-\ndesonid 1,07) gegen\u00fcber LAMA/LABA (1,42;  Rate ra-\ntio Dreifachtherapie 320 \u00b5g Budesonid: 0,76 (95% KI \n0,69; 0,83); relative Risikoreduktion 24%; Rate ratio \nDreifachtherapie 160 \u00b5g Budesonid: 0,75 (95% KI \n0,69; 0,83); relative Risikoreduktion 25% Unterschied) \nund gegen\u00fcber ICS/LABA (1,24; Rate rati o Drei-\nfachtherapie 320 \u00b5g Budesonid: 0,87 (95% KI 0,79; \n0,95); relative Risikoreduktion 13%; Rate ratio Drei-\nfachtherapie 160 \u00b5g Budesonid: 0,86 (95% KI 0,79; \n0,95); relative Risikoreduktion 14%). Die Number -nee-\nded-to-treat zur Vermeidung einer moderaten/sc hwe-\nren Exazerbation war f\u00fcr beide ICS -Tripeldosierungen \n3 gegen\u00fcber der LAMA/LABA und 7 bzw. 6 gegen\u00fcber \nder ICS/LABA Kombination (Rabe et al., COPD exa-\ncerbation benefits relative to pneumonia risk with bu-\ndesonide/glycopyrronium/formoterol metered dose in-\nhaler: analyses from ETHOS, European Respiratory \nJournal 2020 56: 5230; DOI: 10.1183/13993003.con-\ngress -2020.5230). Gegen\u00fcber ICS/LABA zeigte die \n320 \u00b5g ICS -Tripeldosierung au\u00dferdem eine signifi-\nkante Reduktion der Rate an COPD -bedingten Kran-\nkenhauseinweisungen. Die Verringerung der Exazer-\nbationsrate durch die Tripel -Therapie war generell un-\nabh\u00e4ngig davon, ob die Patienten  in der Vorbehand-\nlung ICS erhalten hatten. Das Ausma\u00df der Exazerbati-\nonsrisikoreduzierung stieg mit h\u00f6heren Eosinophilen-\nSpiegel. So nahm der Exazerbationsvorteil bei Patien-\nten mit \u2265150 eosinophilen Granulozyten/\u03bcl Blut unter \nder Dreifachkombination versus der LAMA/LABA 2. Rabe et al., COPD exacerbation benefits rela-\ntive to pneumonia risk with budesonide/glyco-\npyrronium/formoterol metered dose inhaler: anal-\nyses from ETHOS, European Respiratory Journal \n2020 56: 5230; DOI: 10.1183/13993003.congress -\n2020.5230;  \n3. Martinez et al., Budesonide/Glycopyrrolate/For-\nmoterol Fumarate Metered Dose Inhaler (BGF \nMDI) All -Cause Mortality Versus LAMA/LABA in \nCOPD: Sensitivity Analysis of All -Cause Mortality \n(Secondary Endpoint) in the ETHOS Trial with Fi-\nnal Retrieved Vital Status Data; \nhttps://doi.org/10. 1164/ajrccm -confer-\nence.2020.201.1_MeetingAbstracts.A4214, Amer-\nican Journal of Respiratory and Critical Care Med-\nicine 2020;201:A4214  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  331 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nZweifachkombination signifikant zu. Im Studienarm der \n320 \u00b5g ICS Triple- Therapie zeigte sich zudem eine \nsignifikante Reduktion der Gesamtmortalit\u00e4t um 49% \n(nicht adjustierter p- Wert 0,0035) gegen\u00fcber dem \nLAMA/LABA Arm (Martinez et al., Budesonide/Glyco-\npyrrolate/Formoterol Fumarate Metered Dose Inhaler \n(BGF MDI) All -Cause Mortality Versus LAMA/LABA in \nCOPD: Sensitivity Analysis o f All-Cause Mortality (Se-\ncondary Endpoint) in the ETHOS Trial with Final Ret-\nrieved Vital Status Data; \nhttps://doi.org/10.1164/ajrccm -con-\nference.2020.201.1_MeetingAbstracts.A4214, Ameri-\ncan Journal of Respiratory and Critical Care Medicine \n2020;201:A4214).  \n44 Medikament\u00f6se Therapie  \n5.2.2.2 Triple- Therapie; S. 62  \n \nRationale  \nAuf Basis der identifizierten Evidenz \nund klinischer \u00dcberlegungen sieht die \nLeitliniengruppe in der Triple- Thera-\npie eine M\u00f6glichkeit der Therapie-\neskalation f\u00fcr Patient*innen mit \nCOPD, bei welchen \u2013  trotz Therapie \nmit einer LAMA/LABA - Kombination - \nweiterhin Exazerbationen vorrangig \nsind. Bei Patient*innen ohne Exazer-\nbationen hat die Triple- Therapie da-\ngegen keinen Stellenwert , da der Ef-\nfekt auf die Symptomatik kaum unter-\nsucht wurde und nicht plausibel er-\nscheint. Insbesondere bei einer h\u00f6he-\nren Eosinophilenzahl im Differential-\nblutbild sieht die Leitliniengruppe eine \nm\u00f6gliche Indikation f\u00fcr die zus\u00e4tzliche \nGabe eines ICS (siehe d en folgenden \nAbschnitt). Anhalts -punkte f\u00fcr ein \neventuell erh\u00f6htes Ansprechen auf \ndie inhalative Steroidgabe k\u00f6nnen -  \nneben der erh\u00f6hten Eosinophilenzahl \n\u2013 ein diagnostisch gesichertes Erg\u00e4nzung der Rationale durch  \n \nHinzuzuf\u00fcgen ist, dass Studien in den letzten Jahren \neine reduzierte Mortalit\u00e4t mi t Triple -Therapien im Ver-\ngleich zu LAMA, LABA/LAMA oder LABA/ICS gezeigt \nhaben (Lipson et al., Am J Respir Crit Care Med. 2020 \nJun 15;201(12):1508- 1516. doi: \n10.1164/rccm.201911- 2207OC. Reduction in All -\nCause Mortality with Fluticasone Furoate/Umec-\nlidinium /Vilanterol in Patients with Chronic Obstructive \nPulmonary Disease; Fabri et al., Reduction in fatal \nevents with extrafine inhaled corticosteroid (ICS) -con-\ntaining medications: results of stratified safety pooled \nanalysis of the TRILOGY, TRINITY and TRIBUTE  \nstudies, European Respiratory Journal 2018 52: \nOA1659; DOI: 10.1183/13993003.congress -\n2018.OA1659; Rabe et al., Triple Inhaled Therapy at \nTwo Glucocorticoid Doses in Moderate- to-Very-Severe \nCOPD, N Engl J Med. 2020 Jul 2;383(1):35- 48. doi: \n10.1056/NEJMoa1916046; Global strategy for diagno-\nsis, management, and prevention of chronic obstruc-\ntive pulmonary disease 2021 Report. https://gold-\ncopd.org/wp- content/uploads/2020/11/GOLD -RE-\nPORT -2021- v1.0- 16Nov20_WMV.pdf). Im Gegensatz \nzu fr\u00fcheren Studien zielen die j\u00fcngsten Studien auf \nPatientenpopulationen mit st\u00e4rkerer Symptomatik und \nh\u00e4ufigen und/oder schweren Exazerbationen in der \nVorgeschichte.  Wichtige neue Evidenz zur Mortalit\u00e4tsreduktion \nbei der COPD noch nicht erw\u00e4hnt, Literatur im \nText und:  \n1. Lipson et al.,  Am J Respir Crit Care Med. 2020 \nJun 15;201(12):1508- 1516. doi: \n10.1164/rccm.201911- 2207OC. Reduction in All -\nCause Mortality with Fluticasone Furoate/Umec-\nlidinium/Vilanterol in Patients with Chronic Ob-\nstructive Pulmonary Disease;  \n2. Fabri et al., Reduction in fatal events with ex-\ntrafine inhaled corticosteroid (ICS) -containing \nmedications: results of stratified safety pooled \nanalysis of the TRILOGY, TRINITY and TRIBUTE \nstudies, European Respiratory Journal 2018 52: \nOA1659; DOI: 10.1183/13993003.congress -\n2018.OA1659;  \n3. Rabe et al., Triple Inhaled Therapy at Two Glu-\ncocorticoid Doses in Moderate- to-Very-Severe \nCOPD, N Engl J Med. 2020 Jul 2;383(1):35- 48. \ndoi: 10.1056/NEJMoa1916046;  \n4. Global strategy for diagnosis, management, \nand prevention of chronic obstr uctive pulmonary \ndisease 2020 Report. 2020 [cited: 2020- 01-30]. \nhttps://goldcopd.org/wp- content/up -\nloads/2019/12/GOLD -2020- FINAL -ver1.2-\n03Dec19_WMV.pdf).   \n Nicht ber\u00fccksichtigen.  \n \nDarstellung der Effektst\u00e4rke erfolgt in NVL \nCOPD in der Evidenzbeschreibung.  \n \nZitierte Literatur:  \n- Lipton et al.: Reduction in All -Cause \nMortality = Posthoc -Analyse. Dieser End-\npunkt wurde vorab nicht angegeben \n(siehe https://clinicaltri-\nals.gov/ct2/show/study/NCT02164513); in \nPrim\u00e4ranalysen nicht betrachtet.  \n- Fabri et al.: Kongr essbeitrag  \n- Rabe et al.: im Hintergrundtext erw\u00e4hnt \n(siehe Nr. 43)  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  332 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nAsthma oder eine Atopie, erhebliche \nVariationen der FEV1 \u00fcber einen l\u00e4n-\ngeren Zeitraum (mindestens 400ml), \noder eine \u00fcber den Tag erhebliche \nVariation des maximal expiratori-\nschen Flusses (mindestens 20%) sein \n[12].  \n45 Medikament\u00f6se Therapie  \n5.2.2.2 Triple- Therapie; S. 62  \n Erg\u00e4nzung  \nBitte aufnehmen: K.F. Rabe etal. N. Engl. J. \nMed.383:35- 48 (2020)  \nhttps://www.nejm.org/doi/10.1056/NEJMoa1916046 \n Wichtige neue Arbeit zur Triple Therapie \n Aufnahme in Hintergrundtext  \nNach Abschluss der Recherche zum \nThema wurde ein weiterer RCT zum \nThema publiziert, welcher diese Ergeb-\nnisse best\u00e4tigt [Rabe et al. 2020]  \n \nsiehe Nr. 43:  \n75 Medikament\u00f6se Therapie  \n5.2.2.2 Triple- Therapie; S. 62  \n Erg\u00e4nzung  \nBitte aufnehmen: K.F. Rabe etal. N. Engl. J. \nMed.383:35- 48 (2020)  \nhttps://www.nejm.org/doi/10.1056/NEJMoa1916046 Wichtige neue Arbeit zur Triple Therapie \n Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr. 45  \n \n46 Medikament\u00f6se Therapie  \n5.2.2.2  \n \nVertiefende Informationen  \nEosinophilenzahl \u2013 Cut-Off; S. 63  \n\u201eUm einen m\u00f6glichen Cut -Off der Eo-\nsinophilen f\u00fcr oder gegen den Einsatz \nvon ICS zu ermitteln, wurde eine zu-\ns\u00e4tzliche systematische Recherche \ndurchgef\u00fchrt. Es konnten 3 RCTs \nidentifiziert werden [172\u2013 174], die das \nAnspre- chen auf eine Steroidgabe \nabh\u00e4ngig von der Eosinophilenzahl \nim Blut oder Sputum untersuchten. \nDie Fragestellung nach einem Cut -Off \nkonnte mit dieser  Recherche nicht \neindeutig beantwortet werden, jedoch \nzeigten sich auch hier Hinweise f\u00fcr \neine m\u00f6glicherweise erh\u00f6hte Steroid-\nwirkung bei h\u00f6heren Eosinophilen-Um einen m\u00f6glichen Cut -Off der Eosinophilen f\u00fcr oder \ngegen den Einsatz von ICS zu ermitteln, wurde eine \nzus\u00e4tzliche systematische Recherche durchgef\u00fchrt. \nEs konnten 4 RCTs identifiziert werden [172\u2013 174, \nRabe et al., Triple Inhaled Therapy at Two Glucocorti-\ncoid Doses in Moderate- to-Very-Severe COPD, N \nEngl J Med. 2020 Jul 2;383(1):35- 48. doi: \n10.1056/NEJMoa1916046+Supplement to: Rabe KF, \nMartinez FJ, Ferguson GT, et al. Triple inhaled ther-\napy at two glucocorticoid doses in  \nmoderate- to-very-severe COPD. N Eng l J Med \n2020;383:35- 48. DOI: 10.1056/NEJMoa1916046], die \ndas Ansprechen auf eine Steroidgabe abh\u00e4ngig von \nder Eosinophilenzahl im Blut oder Sputum untersuch-\nten. Die Fragestellung nach einem Cut -Off konnte mit \ndieser Recherche nicht eindeutig beantwortet werden, \njedoch zeigten sich auch hier Hinweise f\u00fcr eine m\u00f6g-\nlicherweise erh\u00f6hte Steroidwirkung bei h\u00f6heren Eo-\nsinophilenzahlen. Nach Einsch\u00e4tzung der Leitlinien-\ngruppe handelt es sich dementsprechend um flie-\n\u00dfende \u00dcberg\u00e4nge. Es ergeben sich jedoch Hinweise Wichtige neue Evidenz zum  Eosinophilenzahl \u2013 \nCut-Off f\u00fcr ICS -Therapie- Ansprechen bei der \nCOPD noch nicht erw\u00e4hnt, Literatur im Text und:  \n1. Rabe et al., Triple Inhaled Therapy at Two Glu-\ncocorticoid Doses in Moderate- to-Very-Severe \nCOPD, N Engl J Med. 2020 Jul 2;383(1):35- 48. \ndoi: 10.1056/NEJMoa1916046;  \n2. Supplement to: Rabe KF, Martinez FJ, Fergu-\nson GT, et al. Triple inhaled therapy at two gluco-\ncorticoid doses in  \nmoderate- to-very-severe COPD. N Engl J Med \n2020;383:35- 48. DOI: 10.1056/NEJMoa1916046 \n Nicht annehmen (da nicht systematisch \ngesucht), jedoch Umgang gleich wie vor-\ngeschlagen zur Triple Therapie.  \n \n- Im Hintergrundtext anpassen: Ein nach \nAbschluss der systematischen Recherche \nselektiv eingebrachter RCT [Rabe et. al + \nSupplement] best\u00e4tigt diese Ergebnisse.  \n \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  333 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nzahlen. Nach Einsch\u00e4tzung der Leitli-\nniengruppe handelt es sich dement-\nsprechend um flie\u00dfende \u00dcberg\u00e4nge. \nEs ergeben sich jedoch Hinweise aus \nden Subgruppen-  und Post -hoc-Ana-\nlysen, dass eine Eosinophilenzahl > \n300 cells/\u03bcl im Differentialblut f\u00fcr ein \nm\u00f6glicherweise besseres Ansprechen \nauf inhalative Steroide spricht. Stero-\nidnaive Patient*innen mit gemesse-\nnen Eosinophilen < 100 cells/\u03bcl ha-\nben hingegen wom\u00f6glich keinen zu-\ns\u00e4tzlichen Nutzen von einer ICS -\nGabe.\u201c  aus d er vorliegenden Evidenz, dass eine Eosinophi-\nlenzahl >150 Zellen/\u03bcl im Differentialblut f\u00fcr ein m\u00f6g-\nlicherweise besseres Ansprechen auf inhalative Stero-\nide spricht.  \n \n47 Medikament\u00f6se Therapie  \n5.3 Inhalationssysteme  \n \nVertiefende Informationen; S . 65 \nInhalationssysteme werden in Dosie-\nraerosole, Pulverinhalatoren und \nelektrische Vernebler zur Feuchtinha-\nlation unterschieden Inhalationssysteme werden in Dosieraerosole, Pulve-\nrinhalatoren, Spr\u00fchvernebler und elektrische Verneb-\nler zur Feuchtinhalation unterschieden \n Die Klasse der Spr\u00fchvernebler ist ein etabliertes \nund eigenst\u00e4ndiges Inhalationssystem mit von an-\nderen Devices unterschiedlichen Charakteristika \nund Anforderungen an Patienten. Sowohl das ak-\ntuelle GOLD -Positionspapier, als auch die deut-\nsche A temwegsliga f\u00fchren Spr\u00fchvernebler als ei-\ngene Device- Klasse (Spr\u00fchvernebler/Soft Mist In-\nhalatoren/Respimat). Spr\u00fchvernebler unterschei-\nden sich in ihrer Funktionsweise deutlich von Do-\nsieraerosolen, Trockenpulverinhalatoren und \nelektrischen Verneblern und sol lten als viertes In-\nhalationssystem eingruppiert werden. (Quellen: \nWachtel et al. Respir Drug Deliv 2020;195- 204; \nCiciliani et al. Int J Chron Obstruct Pulmon Dis. \n2017 May 26;12:1565- 1577.; Fachinformation Spi-\nolto Respimat, Stand: Dez. 2018; Fachinformation \nSpiriva Respimat, Stand: Okt. 2018; Fachinforma-\ntion Striverdi Respimat, Stand: Okt. 2018; GOLD \n2020: https://goldcopd.org/wp- content/uplo-\nads/2019/12/GOLD -2020- FINAL -ver1.2-\n03Dec19_WMV.pdf ; Deutsche Atemwegsliga: \nhttps://www.atemwegsliga.de/respimat.html  ) Anpassung im Hintergrundtext.  \n \n \n48 Medikament\u00f6se Therapie  \n5.3 Inhalationssysteme  \n \nVertiefende Informationen; S. 65  Bei der Inspiration unterscheiden sich Dosieraerosole, \nSpr\u00fchvernebler und elektrische Vernebler von Pulve-\nrinhalatoren:  \n Siehe Kommentar Nr. 1 [Nr.47]  \n Hintergrundtext anpassen.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  334 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nBei der Inspiration unterscheiden sich \nDosieraerosole und Vernebler von \nPulverinhalatoren:  \n49 Medikament\u00f6se Therapie  \n5.3 Inhalationssysteme  \n \nVertiefende Informationen; S. 65  \nDosieraerosole und Vernebler erfor-\ndern eine m\u00f6glichst langsame Inspi-\nration, weil eine zu hohe\u2026  Dosieraerosole, Spr\u00fchvernebler und elektrische Ver-\nnebler erfordern eine m\u00f6glichst langsame Inspiration, \nweil eine zu hohe\u2026  \n Siehe Kommentar Nr. 1 [Nr.47]  \n Hintergrundtext anpassen.  \n \n50 Medikament\u00f6se Therapie  \n5.3 Inhalationssysteme  \n \nTabelle 15; S. 66  \nVernebler:  \n\u2022 passive Aerosolerzeugung unab-\nh\u00e4ngig von der Mitarbeit des Patien-\nten/der Patientin  \n\u2022 Funktion auch bei geringen Atem-\nfl\u00fcssen gew\u00e4hrleistet  \n\u2022 Medikamentenapplikation kann \ndurch Aufs\u00e4tze mit einer Stenoseat-\nmung kombiniert werden Spr\u00fchvernebler:  \n\u2022 Passive Aerosolerzeugung durch mechanische Ener-\ngie unabh\u00e4ngig von der Mitarbeit des Patienten/ der \nPatientin.  \n\u2022 Funktion auch bei geringen Atemfl\u00fcssen gew\u00e4hrleis-\ntet \nElektrische Vernebler:  \n\u2022 passive Aerosolerzeugung durch Elektrizit\u00e4t unab-\nh\u00e4ngig von der Mitarbeit des Patienten/der Patientin.  \n\u2022 Funktion auch bei geringen Atemfl\u00fcssen gew\u00e4hrleis-\ntet  \n\u2022 Medikamentenapplikation kann durch Aufs\u00e4tze mit \neiner Stenoseatmung kombiniert werden  \n Siehe Kommentar Nr. 1 [Nr.47]  \n Tabelle 15 wird angepasst: neue Zeile \n\u201eelektrische Vernebler\u201c einf\u00fcgt.  \n \nDie Formulierung: \u201epassive Aerosolerzeu-\ngung durch Elektrizit\u00e4t\u201c ist  redundant und \nwird wie folgt spezifiziert:  \n\u2022 passive Aerosolerzeugung durch Druck-\nluft bzw. Ultraschall.  \n \nDie Darstellung wird angepasst.  \n \n51 Medikament\u00f6se Therapie  \n5.3 Inhalationssysteme  \n \nHinweis; S. 66  \nZur Unterst\u00fctzung der Beratung und \nEinweisung in Inhalationssysteme \nwurde das Patientenblatt \u201eUnter-\nschiede bei Inhalier -Ger\u00e4ten\u201c (siehe \nPatientenbl\u00e4tter) entwickelt.  Erg\u00e4nzung:  \nVideos aller verf\u00fcgbaren Inhalatoren kostenlos auflad-\nbar \u00fcber Deutsche Atemwegsliga  \n Wichtige Hilfe f\u00fcr Patienten, daher bereits an die-\nser Stelle erw\u00e4hnen.  \n Erg\u00e4nzen im Hintergrundtext: S. 66 unter \n\"Hinweis\"  \n \nZur Unterst\u00fctzung der Beratung und Ein-\nweisung in Inhalationssysteme wurde das \nPatientenblatt \u201eUnterschiede bei Inhalier -\nGer\u00e4ten\u201c (siehe Patientenbl\u00e4tter) entwi-\nckelt. Zus\u00e4tzlich stellt die Atemwegsliga \nunter www.atemwegsliga.de/richtig- inha-\nlieren.html verschiedene Videos \u00fcber alle \nzur Zeit verf\u00fcgbaren Inhalatoren kostenlos \nzur Verf\u00fcgung.  \n76 Medikament\u00f6se Therapie  \n5.3 Inhalationssysteme  Erg\u00e4nzung:  Wichtige Hilfe f\u00fcr Patienten, daher bereits an die-\nser Stelle erw\u00e4hnen.  Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr. 51  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  335 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n \nHinweis; S. 66  \nZur Unterst \u00fctzung der Beratung und \nEinweisung in Inhalationssysteme \nwurde das Patientenblatt \u201eUnter-\nschiede bei Inhalier -Ger\u00e4ten\u201c (siehe \nPatientenbl\u00e4tter) entwickelt.  Videos aller verf\u00fcgbaren Inhalatoren kostenlos auflad-\nbar \u00fcber Deutsche Atemwegsliga  \n   \n52 Medikament\u00f6se Therapie  \n5.3 Inhalationssysteme  \n \nEmpfehlung 5- 5; S. 67  \nWenn f\u00fcr die verordneten Substanzen \nverf\u00fcgbar, sollte f\u00fcr  die Langzeitthera-\npie nur ein Inhalationssystem (nur ein \nTyp eines Dosieraerosols oder eines \nPulverinhalators) f\u00fcr die inhalative \nMedikation verordnet werden.  \n (nur ein Typ eines Dosieraerosols, Spr\u00fchverneblers \noder eines Pulverinhalators)  \n Neben dem wiederverwendbaren Respimat sind \nauch nicht -wiederverwendbare Inhalatoren auf-\ngrund von Re- Importen verkehrsf\u00e4hig und im Han-\ndel. \n Redaktionelle \u00c4nderung der Empfehlung \n5-5. \n \nEmpfehlung 5- 5: \nWenn f\u00fcr die verordneten Substanzen \nverf\u00fcgbar, sollte f\u00fcr die Langzeittherapie \nnur ein Inhalationssystem (nur ein Typ ei-\nnes Dosieraerosols, eines Spr\u00fchverneb-\nlers, eines elektrischen Verneblers oder \neines Pulverinhalators) f\u00fcr die inhalative \nMedikation verordnet werden.  \n \nDie Hintergrundtexte werden entspre-\nchend angepasst. \n53 Medikament\u00f6se Therapie  \n5.6 Mukolytika; S. 70  Keine Evidenz zu Mukolytika.  \nStudie H. Worth et al. Concomitant therapy with cine-\nole (eucalyptole) reduces exacerbations in COPD.A \nplacebo controlled double-  blind trial.Respir. Res. \n10:69(2007)  RCT mit  positivem Effekt bei COPD. Kann er-\nw\u00e4hnt und diskutiert werden.  \n Die Fragestellung wird in der 3. Auflage \nder NVL bearbeitet. Es wird eine systema-\ntische Recherche zur Wirkung von Cineol \n(Eucalyptol) bei Patient*innen mit COPD \ndurchgef\u00fchrt.  \n \n77 Medikament\u00f6 se Therapie  \n5.6 Mukolytika; S. 70  Keine Evidenz zu Mukolytika.  \nStudie H. Worth et al. Concomitant therapy with cine-\nole (eucalyptole) reduces exacerbations in COPD.A \nplacebo controlled double-  blind trial.Respir. Res. \n10:69(2007)  RCT mit positivem Effekt bei COPD. Kann er-\nw\u00e4hnt und diskutiert werden.  \n Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr. 53  \n \n54 Medikament\u00f6se Therapie  \n5.9 Impfschutz bei Patient*innen mit \nCOPD \n \nEmpfehlung 5- 9; S. 71  Patient*innen mit COPD soll eine Impfung gegen In-\nfluenza angeboten werden.  \n Die Evidenz f\u00fcr einen Nutzen der Pneumokokken-\nimpfung bei Patient*innen mit COPD ist schlecht. \nIm epidemiologi schen Bulletin 37/2016 schreibt \ndie StIKo selbst auf S. 393: \u201eEs wurden 5 kleine \nRCTs (ausschlie\u00dflich mit PPSV23) mit \u00fcberwie-\ngend unspezifischen klinischen Endpunkten iden-\ntifiziert. Die gepoolte Impfeffektivit\u00e4t gegen CAP Nicht ber\u00fccksichtigen.  \nDer Suchzeitraum des identifizierten \nCochrane Reviews [194] ist etwas aktuel-\nler (schlie\u00dft zus\u00e4tzliche 10 Monate mit \nein); die Datenqualit\u00e4t wird hier als mode-\nrat dargestellt, die Daten sprechen f\u00fcr die \nPneumokokkenimpfung.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  336 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nPatient*innen mit COPD sollen Imp-\nfungen gem\u00e4\u00df den Empfeh lungen der \nSTIKO (aktuell Influenza und \nPneumokokken) angeboten werden jeglicher Ursache lag bei 26 % (95  % KI: -6 \u2013 48 \n%), erreichte aber keine statistische Signifikanz. \nDer spezifischer Endpunkt Pneumokokken- Pneu-\nmonie wurde nur in einem RCT 27 untersucht. In \nder PPSV23- Gruppe traten unter 800 geimpften \nkeine F\u00e4lle, in der Plazebo- Gruppe unter 798 Pro-\nbanden 5 F\u00e4lle auf. Daraus resultiert eine nicht \nsignifikante Impfeffektivit\u00e4t von 91 %  \n(95 % KI: -64 \u2013 99 %).   \n \n55 Medikament\u00f6se Therapie  \n5.9 Impfschutz bei Patient*innen mit \nCOPD \n \nEmpfehlung 5- 9; S. 71  \nPatient*innen mit COPD sollen Imp-\nfungen gem\u00e4\u00df den Empfehlungen der \nSTIKO (aktuell Influenza und \nPneumokokken) angeboten werden \n Patient*innen mit COPD sollen Impfungen gem\u00e4\u00df den \nEmpfehlungen der STIKO (aktuell Influenza und \nPneumokokken) angeboten werden. Der Pertus-\nsisimpfstatus soll \u00fcberpr\u00fcft und ggf. en tsprechend der \noffiziellen Empfehlungen aufgefrischt werden.  \n Eine Pertussisinfektion f\u00fchrt h\u00e4ufig zu Komplikati-\nonen bei Patienten mit COPD und kann eine der \nUrsachen f\u00fcr eine Exazerbation sein.  \nCOPD f\u00fchrt dazu, dass die Atemwege anschwel-\nlen und mit Schlei m blockiert werden, was das At-\nmen erschweren kann. Eine Pertussisinfektion \nkann diese Schwellung der Atemwege und der \nLunge verst\u00e4rken. Die Kombination aus beidem \nf\u00fchrt oftmals zu Lungenentz\u00fcndung und anderen \nschweren Atemwegserkrankungen. Die Pertus-\nsisimp fung ist eine der sichersten M\u00f6glichkeiten \ndie Gesundheit von COPD Patienten zu sch\u00fctzen, \nselbst wenn Sie verschreibungspflichtige Medika-\nmente einnehmen.  \nDaher wurde die Empfehlung zur Pertussisimp-\nfung von COPD -Patienten in die aktuelle Version \nder internationalen GOLD Leitlinie aufgenommen.  \nLiteratur zu diesem Thema finden Sie untenste-\nhend.   \n \nGlobal Initiative for Chronic Obstructive Lung Dis-\nease,  \nGlobal Strategy for the Diagnosis, Management, \nand Prevention of Chronic Obstructive Pulmonary \nDisease  \nRepor t 2020 \nhttps://goldcopd.org/wp- content/up-\nloads/2020/11/GOLD -REPORT -2021- v1.0-\n16Nov20_WMV.pdf  \nBlasi F, Bonanni P, Braido F, Gabutti G, Marchetti \nF, Centanni S. The unmet need for pertussis pre-\nvention in patients with chronic obstructive pulmo-\nnary disease in  the Italian context. Hum Vaccin Nicht ber\u00fccksichtigen. Es wird kein rele-\nvantes Versorgungsproblem gesehen.  \n \n \n- STIKO empfiehlt die Pertussisimpfung \nnicht f\u00fcr chronisch Kranke (wie bspw. \nCOPD; siehe aktuelle STIKO -Empfehlun-\ngen (Epi Bull 2020;34)); aus diesem \nGrund nicht in Empfehlung verorten.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  337 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nImmunother. 2020;16(2):340 -348. doi: \n10.1080/21645515.2019.1652517. Epub 2019 \nSep 6. PMID: 31403385; PMCID: PMC7062424.  \nhttps://www.ncbi.nlm.nih.gov/pmc/arti-\ncles/PMC7062424/  \n \nBuck PO, Meyers JL, Gordon LD, Parikh R, Kuro-\nsky SK, Davis KL. Economic burden of diagnosed \npertussis among individuals with asthma or \nchronic obstructive pulmonary disease in the \nUSA: an analysis of administrative claims. Epi-\ndemiol Infect. 2017 Jul;145(10):2109- 2121. doi: \n10.1017/S0950268817000887. Ep ub 2017 May 2. \nPMID: 28462763; PMCID: PMC5968309.  \nhttps://www.ncbi.nlm.nih.gov/pmc/arti-\ncles/PMC5968309/  \nJenkins VA, Savic M, Kandeil W. Pertussis in \nhigh- risk groups: an overview of the past quarter -\ncentury. Hum Vaccin Immunother. 2020 Apr 16:1-\n9. doi: 10. 1080/21645515.2020.1738168. Epub \nahead of print. PMID: 32298213.  \nhttps://www.tandfonline.com/doi/pdf/10.1080/2164\n5515.2020.1738168 \nEmmanuel Aris, Esse Ifebi Akpo, Amit Bhavsar, \nLauriane Harrington, Evie Merinopoulou, Nicola \nSawalhi -Leckenby, Elisa Turriani , Kinga Mesza-\nros, Dimitra Lambrelli, Piyali Mukherjee European \nRespiratory Journal Sep 2020, 56 (suppl 64) \n2468; DOI: 10.1183/13993003.congress -\n2020.2468 \nhttps://erj.ersjournals.com/con-\ntent/56/suppl_64/2468  \nPesek R, Lockey R. Vaccination of adults with \nasthma and COPD. Allergy. 2011 Jan;66(1):25-\n31. doi: 10.1111/j.1398- 9995.2010.02462.x. Epub \n2010 Aug 17. PMID: 20716316.  \nhttps://onlineli-\nbrary.wiley.com/doi/full/10.1111/j.1398-\n9995.2010.02462.x  \nHashemi SH, Nadi E, Hajilooi M, Seif -Rabiei MA, \nSamaei A. High S eroprevalence of Bordetella per-\ntussis in Patients with Chronic Obstructive Pulmo-\nnary Disease: A Case -Control Study. Tanaffos. NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  338 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n2015;14(3):172 -6. PMID: 26858762; PMCID: \nPMC4745185.  \nhttps://www.ncbi.nlm.nih.gov/pmc/arti-\ncles/PMC4745185/  \nMbayei SA, Faulkner A, Miner C, Edge K, Cruz V, \nPe\u00f1a SA, Kudish K, Coleman J, Pradhan E, \nThomas S, Martin S, Skoff TH. Severe Pertussis \nInfections in the United States, 2011- 2015. Clin \nInfect Dis. 2019 Jul 2;69(2):218- 226. doi: \n10.1093/cid/ciy889. PMID: 30321305; PMCID: \nPMC7108152.Mbayei SA, Faulkner A, Miner C, \nEdge K, Cruz V, Pe\u00f1a SA, Kudish K, Coleman J, \nPradhan E, Thomas S, Martin S, Skoff TH. Severe \nPertussis Infections in the United States, 2011-\n2015. Clin Infect Dis. 2019 Jul 2;69(2):218- 226. \ndoi: 10.1093/cid/ciy889. PMID:  30321305; \nPMCID: PMC7108152.  \nhttps://www.ncbi.nlm.nih.gov/pmc/arti-\ncles/PMC7108152/  \n \nERS- Whitebook:  \nhttps://www.erswhitebook.org/chapters/immunisa-\ntion-against -respiratory -diseases/pertussis/  \n56 Medikament\u00f6se Therapie  \n5.9 Impfschutz bei Patient*innen mit \nCOPD \n \nEmpfehlung 5- 9; S. 71  \nPatient*innen mit COPD sollen Imp-\nfungen gem\u00e4\u00df den Empfehlungen der \nSTIKO (aktuell Influenza und \nPneumokokken) angeboten werden \n Patient*innen mit COPD sollen Impfungen gem\u00e4\u00df den \nEmpfehlungen der STIKO (aktuell Influenza und \nPneumokokken) angeboten werden. Zudem wird von \nder STIKO eine Standardimpfung f\u00fcr Patient*innen ab \n60 Jahren sowie eine Indikationsimpfung f\u00fcr COPD \nPatient*innen ab 50 Jahren gegen Herpes Zoster \nempfohlen. Neue Studiendaten aus Deutschland un-\nterst\u00fctzen, dass bei Patient*innen mit COPD und ins-\nbesondere Patient*innen unter systemischer Korti-\nkosteroid- Therapie eine Impfung gegen Herpes Zoster \nin Abstimmung mit dem Arzt/\u00c4rztin erwogen werden \nsollte.  \n In einer Auswertung repr\u00e4sentativer nationaler \nVersorgungsdaten auf Basis der Versicherten der \nBARMER (7 Millionen Versicherte in 2018, 13 % \naller GKV -Versicherten in Deutschland) konnte \nein erh\u00f6htes Risiko f\u00fcr eine Herpes Zoster (HZ) \nInzidenz beobachtet werden. Untersucht wurden \ndie Jahre 2008 bis 2018, berichtet werden die Er-\ngebnisse f\u00fcr das aktuellste Jahr (2018). Bei einer \nnicht multimorbiden COPD -Kohorte wurde gegen-\n\u00fcber einer gesunden Vergleichspopulation in der \nAltersgruppe ab 18 Jahren ein erh\u00f6htes Risiko f\u00fcr \neine HZ beobachtet (OR=1,2, 95% KI=1, 10-1,30). \nBei Beachtung von Multimorbidit\u00e4t wird f\u00fcr Pati-\nent*innen ab 60 Jahren mit COPD (OR=1,05, 95% \nKI: 1,0 -1,1) ebenfalls ein erh\u00f6htes Risiko beo-\nbachtet. Durch Gabe systemischer Kortikosteriode \nerh\u00f6hte sich das Risiko in derselben Altersgruppe \nnochmals  (OR=1,21, KI:1,12- 1,31). Bei j\u00fcngeren Klammerausdruck weglassen. Zus\u00e4tzlich \nwird \u201ea ktuelle\u201c mit in die Empfehlung auf-\ngenommen. Diese lautet dann wie folgt:  \n \nPatient*innen mit COPD sollen Impfungen \ngem\u00e4\u00df den aktuellen Empfehlungen der \nSTIKO angeboten werden.  \n \nDurch das Weglassen der Klammer (Be-\nzugnahme auf bestimmte Impfungen) \nwerden alle von der STIKO empfohlenen \nImpfungen f\u00fcr Patient*innen mit COPD \nabgebildet.  \n \nEine Verlinkung auf das aktuelle Bulletin \ndes RKI wird eingef\u00fcgt.  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  339 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nCOPD Patient*innen ist unter Steroidgabe das Ri-\nsiko ebenfalls erh\u00f6ht, etwa in der Altersgruppe \nvon 18- 49 Jahren (OR=1,09, 95% KI=0,90- 1,31) \nsowie in der Altersgruppe von 50- 59 Jahren \n(OR=1,02, 95% KI:0,83- 1,26), aller dings nicht sta-\ntistisch signifikant.  \n \nVergleiche:  \nBatram M, Witte J, Schwarz M, Hain J, Ultsch B, \nSteinmann M, Amit B, Wutzler P, Cri\u00e9e CP, Her-\nmann C, Wahle K, F\u00fcchtenbusch M, Greiner W. \nBurden of Herpes Zoster in adult patients with un-\nderlying condition s  \u2013 analysis of German claims \ndata, 2007- 2018. Dermatology and therapy [in \nsubmission].  \nSt\u00e4ndige Impfkommission: Empfehlungen der \nSt\u00e4ndigen Impfkommission (STIKO). Epid Bull \n2020; 34:1- 68 DOI:10.25646/7083.5].  \n57 Medikament\u00f6se Therapie  \n5.9 Impfschutz bei Patient*innen mit \nCOPD; S. 72  \n \n Evidenzbeschreibung \nSeit 2018 empfiehlt die STIKO allgemein f\u00fcr alle Per-\nsonen ab 60 Jahren eine Impfung gegen Herpes Zos-\nter, sowie eine Indikations -Impfung f\u00fcr Personen ab 50 \nJahren. Im Rahmen der Indikationsimpfempfehlung \nwird explizit auf COPD Patient*innen als Personen mit \nerh\u00f6hter gesundheitlicher Gef\u00e4hrdung verwiesen. Zu-\ndem wird im Zuge der Impfempfehlung eine internatio-\nnale systematische \u00dcbersichtsarbeit benannt, die ein \nerh\u00f6htes Herpes Zoster Risiko f\u00fcr COPD Patient*in-\nnen zeigt.  \n \nEine repr\u00e4sentative, nationale Sekund\u00e4rdatenanalyse \nhat \u00fcber einen Zeitraum von 10 Jahren ebenfalls ein \nsignifikant h\u00f6heres Risiko f\u00fcr eine Herpes Zoster -Inzi-\ndenz bei einer nicht multimorbiden COPD -Kohorte ge-\ngen\u00fcber einer gesunden Vergleichspopulation der Al-\ntersgruppe ab 18 Jahren gezeigt (OR=1,2, 95% \nKI=1,10- 1,30). Wird Multimorbidit\u00e4t ber\u00fccksichtigt, \nzeigt sich insbesondere bei Patient*innen ab 60 Jah-\nren ein statistisch signifikant h\u00f6heres Herpes Zoster -\nRisiko (OR=1,05, 95% KI: 1,0- 1,1). Bei Patient*innen \nunter systemischer  Kortikosteroid- Therapie ist das In Anlehnung an die bestehende Impfempfehlung \nder STIKO (siehe Epi.Bull.) bezieht sich die vorge-\nschlagene Text\u00e4nderung lediglich auf die Alters-\ngruppen 50- 59 Jahre sowie die Altersgruppe ab \n60 Jahren, wenngleich die Analysen ebenfalls bei \nPatient*innen ab 18 Jahren ein erh\u00f6htes Risiko \nzeigen. So wurde bei j\u00fcngeren Patient*innen von \n18-49 Jahren das h\u00f6chste Risi ko einer Herpes \nZoster Erkrankung beobachtet, allerdings auf sta-\ntistisch nicht signifikantem Niveau (OR=1,09, 95% \nKI=0,90- 1,31).  \n \nVergleiche:  \nSt\u00e4ndige Impfkommission: Empfehlungen der \nSt\u00e4ndigen Impfkommission (STIKO). Epid Bull \n2020; 34:1- 68 DOI:10.25646/7083.5].  \nSt\u00e4ndige Impfkommission (STIKO): Wissenschaft-\nliche Begr\u00fcndung zur Empfehlung einer Impfung \nmit dem Herpes zoster -subunit -Totimpfstoff. Epid \nBull 2018;50:541 \u2013    567 [DOI 10.17886/EpiBull -\n2017- 059.2].  \nBatram M, Witte J, Schwarz M, Hain J, Ultsch B, \nSteinmann M, Amit B, Wutzler P, Cri\u00e9e CP, Her-\nmann C, Wahle K, F\u00fcchtenbusch M, Greiner W. Nicht ber\u00fcc ksichtigen.  \n \n- Selektiv eingebrachte Sekund\u00e4rdaten-\nanalyse noch nicht publiziert (kein peer \nreview), daher nicht zitiert.  \n- RKI EpidBull wird als Referenz angege-\nben \uf0e0 - siehe Umgang zu Nr. 56  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  340 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \nZoster -Risiko nochmals erh\u00f6ht (ab 60 Jahren \nOR=1,21, KI:1,12- 1,31sowie von 50- 59 Jahren \nOR=1,02, 95% KI= 0,83- 1,26).  Burden of Herpes Zoster in adult patients with un-\nderlying conditions  \u2013 analysis of German claims \ndata, 2007- 2018. Dermatology and therapy [in \nsubmission].  \n58 Medikament\u00f6se Therapie  \n5.9 Impfschutz bei Patient*innen mit \nCOPD; S. 72  \n Vertiefende Informationen:  \nAus aktuellen nationalen Versorgungsdaten kann zu-\ndem gezeigt werden, dass Patient*innen mit mindes-\ntens einer Risikoerkrankung wie bspw. COPD ein er-\nh\u00f6htes Risiko f\u00fcr eine Herpes -Zoster Rekurrenz auf-\nweisen.  \nDies wird auch in internationalen Arbeiten best\u00e4tigt. \nSo zeigten eine taiwanesische Sekund\u00e4rdatenanalyse \nmit rund 8.500 Patient*innen (HR=3,00; 95% KI= 2,40-\n3,75) wie auch eine Auswertung britischer Prim\u00e4rver-\nsorgungsdaten mit rund 145.000 Patient* innen \n(OR=1,82; 95% KI: 1,58- 2,1) bereits ein erh\u00f6htes Ri-\nsiko f\u00fcr eine Herpes Zoster Erkrankung, insbesondere \nbei Patient*innen unter systemischer Kortikosteroid-\nTherapie.  Vergleiche:   \nBatram M, Witte J, Schwarz M, Hain J, Ultsch B, \nSteinmann M, Amit B, Wutzler P, Cri\u00e9e CP, Her-\nmann C, Wahle K, F\u00fcchtenbusch M, Greiner W. \nBurden of Herpes Zoster in adult patients with un-\nderlying conditions  \u2013 analysis of German claims \ndata, 2007- 2018. Dermatology and therapy [in \nsubmission].  \nForbes HJ, Bhaskaran K, Thomas SL, Smeeth L, \nClayton T, Langan SM. Quantification of risk fac -\ntors for herpes zoster: population based case- con-\ntrol study. BMJ 2014; 348: g2911 [DOI \n10.1136/bmj.g2911].  \nYang Y -W, Chen Y -H, Wang K -H, Wang C -Y, Lin \nH-W. Risk of herpes zoster among patients wi th \nchronic obstructive pulmonary disease: a popula-\ntion-based study. CMAJ 2011; 183(5): E275- 80 \n[DOI 10.1503/cmaj.101137].  Nicht ber\u00fccksichtigen \n \nRKI EpidBull wird als Referenz angege-\nben \uf0e0 siehe Umgang zu Nr. 56 \n59 Medizinische Rehabilitation  \n \nVorbemerkung; S. 73  \nWichtige nicht -medikament\u00f6se Thera-\npiekomponenten sind Patientenschu-\nlung, medizinische Trainingstherapie, \nAtemphysiotherapie, Ergotherapie, \nHilfsmittelberatung, psychologische \nHilfen, Ern\u00e4hrungsberatung, Tabak-\nentw\u00f6hnung sowie Sozial - und Be-\nrufsberatung.  Wichtige nicht -medikament\u00f6se Therapiekomponenten \nsind Patientenschulung, medizinische Trainingsthera-\npie, Atemphysiotherapie, Ergotherapie, Hilfsmittelbera-\ntung, psychologische Hilfen, Ern\u00e4hrungstherapie, Ta-\nbakentw\u00f6hnung sowie Sozial - und Ber ufsberatung.  \n Siehe f\u00fcr Ern\u00e4hrungsberatung versus Ern\u00e4h-\nrungstherapie unter Punkt 2.  \n \n[SSc: Nr. 35]  \n Nicht ber\u00fccksichtigen.  \n \nGruppe hat explizit von Beratung gespro-\nchen.  \n \n61 Versorgungskoordination  \n7.2 Ambulante \u00dcberweisungsindikato-\nren \n \nTabelle 19; S. 80  \u2022 bei klinischen Hinweisen auf therapiebed\u00fcrftige \nschlafbezogene At mungsst\u00f6rungen (Abstimmung \nmit/\u00dcberweisung an schlafmedizinisch t\u00e4tigen \nPneumologen oder HNO -Arzt oder einen Schlafmedi-\nziner)  \n Zur weiteren Diagnostik bei Verdacht auf eine \nschlafbezogene Atmungsst\u00f6rung bedarf es einer \nschlafmedizinischen Expertise, die nicht jeder \nPneumologe und HNO -Arzt hat. Nur ein Teil der \nPneumologen und HNO -\u00c4rzte f\u00fchrt die hierf\u00fcr not-\nwendigen Untersuchungen (kardiorespiratorische Keine \u00c4nderung.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  341 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n\u2022 bei klinischen Hinweisen auf thera-\npiebed\u00fcrftige schlafbezogene \nAtmungsst\u00f6rungen (Abstimmung \nmit/\u00dcberweisung an Pneumologie, \nHNO, Schlafmedizin)  Polygraphie und kardiorespiratorische Polysom-\nnographie) durch.  \n \n62 Versorgungskoordination  \n7.2 Ambulante \u00dcberweisungsindikato-\nren \n \nTabelle 19; S. 80  Neue Zeile: Fachgebiet:  Hals-Nasen- Ohrenheilkunde, \nKonstellation : rezidivierende Infekte der Nase und Na-\nsennebenh\u00f6hlen sowie pharyngo- laryngealer Reflux \nals beobachtete Exacerbationstrigger und relevante \nKomorbidit\u00e4ten. Tracheostoma und Z.n. Laryngekto-\nmie als relevante Besonderheiten.  \n In der Anamnese (Seite 15) wird auf HNO -Be-\ngleiterkrankungen abgehoben. Das lange be-\nkannte Ph\u00e4nomen des \u201esinu- bronchialen Syn-\ndroms \u201c, moderner \u201eunited airways\u201c ist eine prak-\ntisch klinische immer wieder beobachtete Tatsa-\nche, die auch in der Literatur bekannt ist. Reflux \nkann Hustensymptomatik verst\u00e4rken und ist eine \ntypische Komorbidit\u00e4t. Bei vorhandenem Tracheo-\nstoma oder Z.n. Laryngek tomie ist u.a. eine HME -\nVersorgung wichtig. Siehe beiliegender Literatur -\nReview.  \n Die Tabelle 19 (7.2 Ambulante \u00dcberwei-\nsungsindikatoren) wird um das Fachge-\nbiet Hals -Nasen- Ohrenheilkunde erg\u00e4nzt.  \nDie entsprechende Konstellation wird wie \nfolgt abgebildet:  \n \nKonstellation:  \n\u2022 chronische Sinusitis als beobachteter \nExazerbationstrigger.  \n\u2022 Tracheostoma und Z.n. Laryngektomie \nals relevante Besonderheiten.  \n \nDer pharyngo- laryngeale Reflux wird nicht \ndargestellt.  \n63 Versorgungskoordination  \n7.4 Kooperation von \u00c4rzt*innen und \nApotheker*innen  \n \nEmpfehlung 7- 9; S. 82  \nDer Arzt oder die \u00c4rztin soll gemein-\nsam mit den Patient*innen \u00fcber das \nInhalationssystem entscheiden. Um \nsicherzugehen, dass die Patientin \noder der Patient das indizierte Sys-\ntem erh\u00e4lt, soll bei \u201eaut -idem\u201c ein  \nKreuz gesetzt werden.  \n \u201eDer Arzt soll gemeinsam mit dem Patienten \u00fcber das \nInhalationssystem entscheiden. Falls sichergestellt \nwerden muss, dass der Patient das gew\u00fcnschte Inha-\nlationssystem erh\u00e4lt, soll bei \u201eaut -idem\u201c ein Kreuz ge-\nsetzt werden.\u201c  \n \n Hierzu hatten wir eine intensive Diskussion (Man-\ndatstr\u00e4ger/Paten). Wir sind uns einig, dass ein \nWechsel des Inhalationssystems vermieden wer-\nden soll. Die aktuelle Formulierung bzgl. aut idem -\nKreuz w\u00fcrde allerdings dazu f\u00fchren, dass auch \nbei Erstverordnung ein aut -idem -Kreuz gesetzt \nwerden m\u00fcsste. Das erscheint uns nicht notwen-\ndig und angemessen zu sein.  \n Redaktionelle \u00c4nderung:  \nDer Arzt oder die \u00c4rztin soll gemeinsam \nmit den Patient*innen \u00fcber das Inhalati-\nonssystem entscheiden. Wenn sicherge-\nstellt werden muss, dass die Patientin \noder der Patient das verordnete Inhalati-\nonssystem erh\u00e4lt, soll bei \u201eaut -idem\u201c ein \nKreuz gesetzt werden.  \n \nDa es wichtig ist, in diesem Zusammen-\nhang zwischen Erst - und Folgeverord-\nnung zu unterscheiden, wird dieser Sach-\nverhalt nochmals deutlich im Hintergrund-\ntext adressiert.  \n \nF\u00fcr die n\u00e4chste Konsensuskonferenz der \nNVL COPD (3. Auflage) wird die Thematik \nnoch einmal zur Besprechung vorgese-\nhen. NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  342 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Entscheidung der Leitliniengruppe  \n64 Versorgungskoordination  \n7.6 Schriftlicher Aktionsplan  \n \nEmpfehlung 7- 16; S. 85 \nPatient*innen mit COPD sollen einen \nschriftlichen Aktionsplan erhalten.  Wenn im Arzt -Patient eine gemeinsame therapeuti-\nsche Entscheidung gefunden wurde, soll diese schrift-\nlich fixiert werden.  \n Die Empfehlung generalisiert zu stark. Wenn ich \nallen Patient*innen in der Hausarztpraxis neben \nMedikations - auch noch \u201eschriftliche Aktionspl\u00e4ne\u201c \nmitgeben m\u00fcsste, w\u00fcrden wir irgendwann in Pa-\npier absaufen. Wenn \u2013  was meist der Fall ist \u2013  die \nPatient*innen klinisch stabil sind \u2013  oder eben \nnichts an ihrem Rauch-  oder Ess -Verhalten \u00e4n-\ndern wollen, wof\u00fcr sollten sie dann einen \u201eAktions-\nplan\u201c bekommen? Wenn wiederum Ver\u00e4nde-\nrungs -Bereitschaft besteht, dann ist es mit Evi-\ndenz belegt, dass eine Verschriftlichung der in der \ngemeinsamen Entscheidungsfindung gefundenen \nAbsprachen hilft, das Besprochene auch umzu-\nsetzen.  Die Empfehlung wird nicht ge\u00e4ndert.  \n \nIm Hintergrundtext wird konsequent die \nFormulierung \u201eAktionsplan\u201c verwendet. Es \nwird darauf hingewiesen, dass der Akti-\nonsplan \u201eeinfach, klar und verst\u00e4ndlich\u201c \naufgebaut sein m\u00fcsse.  \nEin direkter Link zum Aktionsplan der \nAtemwegsliga ist bereits im Hintergrund-\ntext vorhanden. Zus\u00e4tzlich wird gepr\u00fcft, \nob in Zusammenarbeit mit der Atemwegs-\nliga konkrete Praxishilfen hierzu erstellt \nwerden k\u00f6nnen.  \n65 Versorgungkoordination  \n7.6 Schriftlicher Aktionsplan; S. 85  \n \nRationale \nEin schriftlicher Behandlungsplan be-\ninhaltet individuelle\u2026  Rationale \nEin schriftli cher Aktionsplan beinhaltet individuelle\u2026  \n Die Bezeichnung des Plans sollte in der \u00dcber-\nschrift / Empfehlung und im Hintergrundtext gleich \nlauten (Behandlungsplan vs. Aktionsplan).  \n \nEs w\u00e4re hilfreich, wenn eine Vorlage f\u00fcr den Plan \nz.B. \u00fcber die DMP -Dokumentation zug\u00e4nglich ist \nbzw. generiert werden kann als fester Bestandteil \nder verpflichtenden Erhebungsdaten im DMP \nM\u00f6glicherweise analog dem COBRA Schulungs-\nprogramm der Atemwegsliga.  Siehe weiteres Vorgehen Nr. 64.  \n \n \nAnhang 11.2  Redaktionelle Kommentare  \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Redaktionelle Bearbeitung  \n1 Definition und Epidemiologie  \nS. 11  \n[\u2026] Der akuten Exazerbation liegen eine \nentz\u00fcndlich bedingte vermehrte Broncho-\nkonstriktion und/oder Schleimproduktion mit \n\u00dcberbl\u00e4hung zugrunde. [...]  Akut streichen  Exazerbation ist als Akutereignis definiert.  Vorgeschlagene Text\u00e4nderung wurde \u00fcber-\nnommen.  \n66 Definition und Epidemiologie  \nS. 11  Akut streichen  Exazerbation ist als Akutereignis definiert.  Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr. 1  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  343 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Redaktionelle Bearbeitung  \n[\u2026] Der akuten Exazerbation liegen eine \nentz\u00fcndlich bedingte vermehrte Broncho-\nkonstriktion und/oder Schleimproduktion mit \n\u00dcberbl\u00e4hung zugrunde. [...]  \n3 Diagnostik und Monitoring  \nAbbildung 1; S. 14  \n[...]Post BD: post Bronchodilatator, \nFEV1/FVC: Einsekundenkapazit\u00e4t/forcierte \nVitalkapazit\u00e4t (Tiffeneau- Index), LLN: Lower \nLimit of Normal, GLI: Global Lung Initiative, \nGKP: Ganzk\u00f6rperplethysmografie, DLCO: \nDiffusionskapazit\u00e4t f\u00fcr Kohlen stoffmonoxid, \nTLC: totale Lungenkapazit\u00e4t  \n Kohlenmonoxid  Gebr\u00e4uchliche Bezeichnung in der Literatur und im \nSprachgebrauch  Vorgeschlagene Text\u00e4nderung wurde \u00fcber-\nnommen.  \n67 Diagnostik und Monitoring  \nAbbildung 1; S. 14  \n[...]Post BD: post Bronchodilatator, \nFEV1/FVC: Einsekundenkapazit\u00e4t/forcierte \nVitalkapazit\u00e4t (Tiffeneau- Index), LLN: Lower \nLimit of Normal, GLI: Global Lung Initiative, \nGKP: Ganzk\u00f6rperplethysmografie, DLCO: \nDiffusionskapazit\u00e4t f\u00fcr Kohlenstoffmonoxid, \nTLC: totale Lungenkapazi t\u00e4t \n Kohlenmonoxid  Gebr\u00e4uchliche Bezeichnung in der Literatur und im \nSprachgebrauch  Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr. 3  \n19 Tabakentw\u00f6hnung  \nEmpfehlung 3- 6: (S. 34)  \nDie patientengerechte Erkl\u00e4rung individuel-\nler Gesundheitsparameter in Bezug auf das \nRauchen wie z. B. das Besprechen von \nLungenfunktionsparametern und CO kann \neinen positiven Einfluss auf den Erfolg der \nTabakentw\u00f6hnung haben.  CO- Messungen  Verst\u00e4ndlichkeit  Vorgeschlagene Text\u00e4nderung wurde \u00fcber-\nnommen.  \n \nDie Empfehlung lautet somit:  \nDie patientengerechte Erkl\u00e4rung individuel-\nler Gesundheitsparameter in Bezug auf das \nRauchen wie z. B. das Besprechen von \nLungenfunktionsparametern und CO -Mes-\nsungen kann einen positiven Einfluss auf \nden Erfolg der Tabakentw\u00f6hnung haben.  \n68 Tabakentw\u00f6hnung  \nEmpfehlung 3- 6: (S. 34)  CO- Messungen  Verst\u00e4ndlichkeit  Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr.19  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n            \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  344 \n      \n \nNr. NVL Vorgeschlagene Text\u00e4nderung  Begr\u00fcndung (mit Literaturangaben)  Redaktionelle Bearbeitung  \nDie patientengerechte Erkl\u00e4rung individuel-\nler Gesundheitsparameter in Bezug auf das \nRauchen wie z. B. das Besprechen von \nLungenfunktionsparametern und CO kann \neinen positiven Einfluss auf den Erfolg der \nTabakentw\u00f6hnung haben.  \n23 Tabakentw\u00f6hnung  \n3.3 E -Zigaretten; S. 35  \n[\u2026] M\u00f6gliche kardiovaskul\u00e4re Effekte der E -\nZigarette wurden von Skotsimara et. al an-\ngedeutet [\u2026]  [\u2026] M\u00f6gliche kardiovaskul\u00e4re Effekte der \nE-Zigarette wurden von Skotsimara et. al \nbeschrieben. [\u2026]  Auch an anderer Stelle der LL wurde bei vergleich-\nbarer Qualit\u00e4t der Evidenz nicht \u201eangedeutet\u201c ge-\nnutzt.  Vorgeschlagene Text\u00e4nderung wurde \u00fcber-\nnommen.  \n60 Medizinische Rehabilitation  \n6.1.1 Rehabilitationssport; S. 75  \n \nNach den Empfehlungen der Deutschen \nAtemwegsliga und der Arbeitsgemeinschaft \nLungensport in Deutschland zum Sport und \nk\u00f6rperlichen Training bei Patient*innen mit \nobstruktiven Atemwegserkrankungen ist vor \nder Teilnahme an Sport - oder Trainingspro-\ngrammen eine \u00e4rztliche Untersuchung erfor-\nderlich [202].  Austausch der Literaturstelle 202 Neue Sportempfehlung ersetzt die alte (2020)  \n \nH. Worth et al. Amb ulanter Lungensport und k\u00f6rper-\nliches Training bei Patienten mit Atemwegs - und \nLungenkrankheiten. Empfehlungen der Arbeitsge-\nmeinschaft Lungensport und der Deutschen Atem-\nwegsliga. Pneumologie(2020)  Literatur gepr\u00fcft und aktualisiert.  \nInhalte st\u00fctzen die Form ulierung weiterhin.  \n78 Medizinische Rehabilitation  \n6.1.1 Rehabilitationssport; S. 75  \n \nNach den Empfehlungen der Deutschen \nAtemwegsliga und der Arbeitsgemeinschaft \nLungensport in Deutschland zum Sport und \nk\u00f6rperlichen Training bei Patient*innen mit \nobstruktiven Atemwegserkrankungen ist vor \nder Teilnahme an Sport - oder Trainingspro-\ngrammen eine \u00e4rztliche Untersuchung erfor-\nderlich [202].  Austausch der Literaturstelle 202 Neue Sportempfehlung ersetzt die alte (2020)  \n \nH. Worth et al. Amb ulanter Lungensport und k\u00f6rper-\nliches Training bei Patienten mit Atemwegs - und \nLungenkrankheiten. Empfehlungen der Arbeitsge-\nmeinschaft Lungensport und der Deutschen Atem-\nwegsliga. Pneumologie(2020)  Doppelt eingegangenes Kommentar.  \nUmgang siehe Nr. 60  \n NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  345 \n  \n  \n Literatur  \n1. Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Allgemeine Methoden. Version 5.0. K\u00f6ln: \nIQWiG; 2017. http://www.iqwig.de/download/Allgemeine- Methoden_Version- 5-0.pdf . \n2. Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: Toward International Standards for Clinical Practice Guidelines. Ann Intern Med 2012; 156(7):525\u2013 31. http://www.ncbi.nlm.nih.gov/pubmed/22473437.  \n3. Europarat, Verbindung der Schweizer \u00c4rztinnen und \u00c4rzte, \u00c4rztliche Zentralstelle Qualit\u00e4tssicherung (\u00c4ZQ), et al. Ent-\nwicklung einer Methodik f\u00fcr die Ausarbeitung von Leitlinien f\u00fcr optimale medizinische Praxis . Empfehlung Rec (2001)13 \ndes Europarates am 10. Oktober 2001 und Erl\u00e4uterndes Memorandum. Deutschsprachige Ausgabe. Z Arztl. Fortbild. \nQualitatssich. 2002; 96(Suppl III):3 \u201360. \n4. Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV). Beurteilungskriterien f\u00fcr Leitlinien in der medizini-\nschen Versorgung -  Beschl\u00fcsse der Vorst\u00e4nde der Bundes\u00e4rztekammer und Kassen\u00e4rztlicher Bundesvereinigung, Juni \n1997. Dtsch Arztebl 1997; 94(33):A -2154- 5. \n5. \u00c4rztliches Zentrum f\u00fcr Qualit\u00e4t in der Medizin (\u00c4ZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachge-\nsellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien- Bewertung (DELBI). Fassung 2005/2006. Z Arztl \nFortbild Qualitatssich 2005; 99(8):468\u2013 519. \n6. \u00c4rztliches Zentrum f\u00fcr Qualit\u00e4t in der Medizin (\u00c4ZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachge-\nsellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien- Bewertung (DELBI). Fassung 2005/2006 + Do-\nm\u00e4ne 8. 2008 [cited: 2019- 09-05]. http://www.leitlinien.de/mdb/edocs/pdf/literatur/delbi -fassung- 2005- 2006- domaene- 8-\n2008.pdf . \n7. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) -St\u00e4ndige Kommission Leitlinien. \nAWMF -Regelwerk Leitlinien: Version 2.0. 2020 [cited: 2021- 03-22]. http://w ww.awmf.org/leitlinien/awmf -regelwerk.html . \n8. Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Me-\ndizinischen Fachgesellschaften (AWMF). Programm f\u00fcr Nationale VersorgungsLeitlinien - Methodenreport, 5. Auflage. \nVersion 1. 2017 [cited: 2019- 09-05]. DOI: 10.6101/AZQ/000169. http://doi.org/10.6101/AZQ/000169.  \n9. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Das AW MF-Regelwerk Leitli-\nnien. M\u00fcnchen: Zuckschwerdt; 2012.  \n10. Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Me-dizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie COPD -  Leitlinien- Report, 1. Auflage. Version \n3.2. 2006 [cited: 2021- 08-12]. https://www.leitlinien.de/themen/copd/archiv/pdf/copd- vers3 -2-llr-1.pdf . \n11. Brunsmann F, R G von, K R, et al. Patientenbeteiligung -  Diagnosespezifische Erfahrungen einbringen. Dtsch Arztebl \n2004; 101(28- 29):A -2026- 9. \n12. \u00c4rztliches Zentrum f\u00fcr Qualit\u00e4t in der Medizin (\u00c4ZQ). Handbuch Patientenbeteiligung. Beteiligung am Programm f\u00fcr Natio-nale VersorgungsLeitlinien. Neukirchen: Make a Book; 2008 (\u00e4zq Schriftenreihe; 33). http://www.aezq.de/mdb/e-\ndocs/pdf/schriftenreihe/schriftenreihe33.pdf . \n13. Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztl iche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Me-\ndizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma - Langfassung, 4. Auflage. Version 1. \n2020 [cited: 2020- 09-07]. DOI: 10.6101/AZQ/000469. http://doi.org/10.6101/AZQ/000469.  \n14. Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Me-\ndizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie A sthma - Leitlinienreport, 4. Auflage. Version 1. \n2020 [cited: 2020- 09-07]. DOI: 10.6101/AZQ/000470. http://doi.org/10.6101/AZQ/000470.  \n15. van Eerd EA, van der Meer RM, van Schayck OC, et al. Smoking cessat ion for people with chronic obstructive pulmonary \ndisease. Cochrane Database Syst Rev 2016(8):CD010744. DOI: 10.1002/14651858.CD010744.pub2. \nhttp://www.ncbi.nlm.nih.gov/pubmed/27545342.  \n16. Arbeit sgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft f\u00fcr Psy-\nchiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft f\u00fcr Suchtforschung und Suchttherapie (DG-Sucht), et al. S3- Leitlinie Rauc hen und Tabakabh\u00e4ngigkeit: Screening, Diagnostik und Behandlung: Registernummer \n076-006, Version 2021- 01. 2021 [cited: 2021- 03-11]. https://www.awmf.org/leitlinien/detail/ll/076 -006.htm l. \n17. Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin (DGP), Wissenschaftlicher Aktionskreis Tabakentw\u00f6h-\nnung (WAT), Deutsche Gesellschaft f\u00fcr Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), et al. S3- Leitlinie \nTabakentw\u00f6hnung bei COPD:  Registernummer 020- 005, Version 2014- 03. 2013 [cited: 2021- 06-23]. \nhttps://www.awmf.org/leitlinien/detail/ll/020- 005.html . \n18. Steppuhn H, Kuhnert R, Scheidt -Nave C. 12- Monats -Pr\u00e4valenz der bekannten chronisch obstruktiven Lungenerkrankung \n(COPD) in Deutschland. Journal of health monitoring 2017; 2(3):46\u2013 54. DOI: 10.17886/RKI -GBE -2017 -053. \n19. Akmatov MK, Steffen A, Holstiege J, et al. Die chronisch obstruktive Lungenerkrankung (COPD) i n der ambulanten Ver-\nsorgung in Deutschland \u2013  Zeitliche Trends und kleinr\u00e4umige Unterschiede. 2019 (Versorgungsatlas -Bericht; Nr. 19/06) \n[cited: 2019- 09-02]. DOI: 10.20364/VA -19.06. \nhttps://www.versorgungsatlas.de/fileadmin/ziva_docs/99/VA_19- 06_Bericht -\nCOPD_2019- 08-20_V2.pdf . \n20. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: A measurement tool to assess the methodological \nquality of  systematic reviews. BMC Med Res Methodol 2007; 7:10. DOI: 10.1186/1471- 2288- 7-10. \nhttp://www.ncbi.nlm.nih.gov/pubmed/17302989.  \n21. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: A critical apprais al tool for systematic reviews that include randomised \nor non- randomised studies of healthcare interventions, or both. BMJ 2017; 358:j4008. DOI: 10.1136/bmj.j4008. \nhttp://www.ncbi.nlm.nih.gov/pubmed/28935701.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  346 \n  \n  \n 22. Cochrane Deutschland, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften -  Institut f\u00fcr Medi-\nzinisches Wissensmanagement. Bewertung des Biasrisikos (Risiko systematischer Fehler) in k linischen Studien: ein Ma-\nnual f\u00fcr die Leitlinienerstellung. 2016. http://www.cochrane.de/de/rob -manual ; AWMF: \nhttp://www.awmf.org/leitlinien/awmf -regelwerk/ll -entwicklung.html . \n23. Cochrane Deutschland, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften -  Institut f\u00fcr Medi-\nzinisches Wissensmanagement. Bewertung des Biasrisikos (Risiko systematischer F ehler) in klinischen Studien: Ein Ma-\nnual f\u00fcr die Leitlinienerstellung. Version 1.0 vom 04.05.2016. 2016 [cited: 2021- 03-24]. \nhttps://w ww.cochrane.de/de/news/bewertung- des-biasrisikos -risiko -systematischer -fehler -klinischen- studien.  \n24. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS -2: A revised tool for the quality assessment of diagnostic accuracy \nstudies. Ann Intern Med 2011; 155(8) :529\u2013 36. DOI: 10.7326/0003- 4819- 155-8-201110180- 00009. \nhttp://www.ncbi.nlm.nih.gov/pubmed/22007046.  \n25. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J \nClin. Epidemiol. 2011; 64(4):395\u2013 400. http://www.ncbi.nlm.nih.gov/pubmed/21194891.  \n26. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recomm endations. BMJ 2004; \n328(7454):1490\u2013 7. http://www.ncbi.nlm.nih.gov/pubmed/15205295.  \n27. Society for Medical Decision Making. Proposal for clinical algorithm standards. Committee on Standardization  of Clinical \nAlgorithms. Med Decis Making 1992; 12(2):149\u2013 54. http://www.ncbi.nlm.nih.gov/pubmed/1573982.  \n28. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Empfehlungen der AWMF zum \nUmgang mit Interessenkonflikten bei Aktivit\u00e4ten wissenschaftlicher medizinischer Fachgesellschaften: Fassung vom 10. \nNovember 2017. 2017 [cited: 2018 -02-19]. http://www.awmf.org/fileadmin/user_upload/Leitlinien/AWMF -Publika-\ntionen/20171110_AWMF_Empfehlungen_zu_Interessenkonflikten__V2.2_f.pdf . \n29. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) -  Ad hoc Kommission \u201eGemein-\nsam Klug Entscheiden\u201c. Manual Entwicklung von Empfehlungen im Rahmen der Initiative Gemeinsam Klug Entscheiden. \nVersion 1.1. 2016 [cited: 2018- 08-15]. http://www.awmf.org/fileadmin/user_upload/Medizinische_Versorgung/GKE/Man-\nual_GKE_AWMF_V1 -1.pdf . \n30. Deutsches Netzwerk Evidenzbasierte Medizin (DNEbM). Gute Praxis Gesundheitsinfor mation. Ein Positionspapier des \nDeutschen Netzwerks Evidenzbasierte Medizin. Version 2.0. Stand: 21.07.2016. 2016 [cited: 2019- 09-05]. \nhttps://www.ebm -netzwerk.de/de/medien/pdf/gpgi_2_20160721.pdf . \n31. Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin (DGP), Deutsche Atemwegsliga, \u00d6sterreichische Gesell-\nschaft f\u00fcr Pneumologie (\u00d6GP). S2k -Leitlinie Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis \nund Lungenemphysem (COPD): Registernummer 020- 006, Version 2018- 01. 2018 [cited: 2018- 11-13]. \nhttps://www.awmf.org/leitlinien/detail/ll/020- 006.html . \n32. Oelsner EC, Balte PP, Bhatt SP, et al. Lung function decline in former smokers and low -intensity current smokers: A sec-\nondary data analysis of the NHLBI Pooled Cohorts S tudy. Lancet Respir Med 2020; 8(1):34\u2013 44. DOI: 10.1016/S2213-\n2600(19)30276- 0. http://www.ncbi.nlm.nih.gov/pubmed/31606435.  \n33. Simmons MS, Connett JE, Nides MA, et al. Smoking reduction and the rate of decline in FEV(1): Results from the Lung \nHealth Study. Eur Respir J 2005; 25(6):1011\u2013 7. DOI: 10.1183/09031936.05.00086804. http://www.ncbi.nlm.nih.gov/pub-\nmed/15929955.  \n34. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus short acting beta- 2 agonists for stable chronic obstructive \npulmonary disease. Cochrane Database Syst Rev 2006(2):CD001387. DOI: 10.1002/14651858.CD001387.pub2. http://www.ncbi.nlm.nih.gov/pubmed/16625543.  \n35. Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev \n2014(9):CD010509. DOI: 10.1002/14651858.CD010509.pub2. http://www.ncbi.nlm.nih.gov/pubmed/25234126.  \n36. Chong J, Karner C, Poole P. Tiotropium versus long- acting beta- agonists for stable chronic obstructive pulmonary dis-\nease. Cochrane Database Syst Rev 2012(9):CD009157. DOI: 10.1002/14651858.CD009157.pub2. http://www.ncbi.nlm.nih.gov/pubmed/22972134.  \n37. Ni H, Moe S, Soe Z, et al. Combined aclidinium  bromide and long- acting beta2- agonist for chronic obstructive pulmonary \ndisease (COPD). Cochrane Database Syst Rev 2018(12):179. DOI: 10.1002/14651858.CD011594. http://www.ncbi.nlm.nih.gov/pubmed/30536566.  \n38. Farne HA, Cates CJ. Long- acting beta2- agonist in addition to tiotropium versus either tiotropium or long- acting beta2- ago-\nnist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015(10):CD008989. DOI: \n10.1002/14651858.CD008989.pub3. http://www.ncbi.nlm.nih.gov/pubmed/26490945.  \n39. Tan DJ, White CJ, Walters JA, et al. Inhaled corticosteroids with combination inhaled long- acting beta2- agonists and long-\nacting m uscarinic antagonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016; \n11:CD011600. DOI: 10.1002/14651858.CD011600.pub2. \nhttp://www.ncbi.nlm.nih.gov/pubmed/27830584.  \n40. Lee S -D, Xie C -M, Yunus F, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with \ntiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia. Respirology 2016; 21(1):119\u2013 27. DOI: 10.1111/resp.12646. http://www.ncbi.nlm.nih.gov/pubmed/26394882.  \n41. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long- acting muscarinic antagonist therapy \nfor chronic obstructive pulmonary disease (TRINITY): A double- blind, parallel group, randomised controlled trial. Lancet \n2017; 389(10082):1919\u2013 29. DOI: 10.1016/S0140- 6736(17)30188- 5. http://www.ncbi.nlm.nih.gov/pubmed/28385353.  \n42. Chapman KR, Hurst JR, Frent S -M, et al. Long- Term Triple Therapy De- escalation to Indacaterol/Glycopyrronium in Pa-\ntients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double- Blind, Triple -Dummy Clinical Trial. \nAm J Respir Crit Care Med 2018; 198(3):329\u2013 39. DOI: 10.1164/rccm.201803- 0405OC. http://www.ncbi.nlm.nih.gov/pub-\nmed/29779416.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  347 \n  \n  \n 43. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive \npulmonary disease (TRIBUTE): A double- blind, parallel group, randomised controlled trial. Lancet 2018; \n391(10125):1076\u2013 84. DOI: 10.1016/S0140- 6736(18)30206- X. http://www.ncbi.nlm.nih.gov/pubmed/29429593.  \n44. Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co -\nsuspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): A double-\nblind, parallel -group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018; 6(10):747\u2013 58. D OI: \n10.1016/S2213- 2600(18)30327- 8. http://www.ncbi.nlm.nih.gov/pubmed/30232048.  \n45. Lipson DA, Barnhart F, Brealey N, et al. Once- Daily Single- Inhaler Triple versus Dual Therapy in Patients with C OPD. N \nEngl J Med 2018; 378(18):1671\u2013 80. DOI: 10.1056/NEJMoa1713901. http://www.ncbi.nlm.nih.gov/pubmed/29668352.  \n46. Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: Once- Daily Triple Therapy for Patients with Chronic Obstructive Pul-\nmonary Disease. Am J Respir Crit Care Med 2017; 196(4):438\u2013 46. DOI: 10.1164/rccm.201703- 0449OC. \nhttp://www.ncbi.nlm.nih.gov/pubmed/28375647.  \n47. Singh D, P api A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long- acting beta2- agonist \ntherapy for chronic obstructive pulmonary disease (TRILOGY): A double- blind, parallel group, randomised controlled trial. \nLancet 2016; 388(10048):963\u2013 73. DOI: 10.1016/S0140- 6736(16)31354- X. http://www.ncbi.nlm.nih.gov/pub-\nmed/27598678.  \n48. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of ex acerbations of chronic \nobstructive pulmonary disease: A randomized placebo- controlled trial. Am J Respir Crit Care Med 2012; 186(1):48\u2013 55. \nDOI: 10.1164/rccm.201108- 1553OC. http://www.ncbi.nlm.nih. gov/pubmed/22447964.  \n49. Brightling CE, McKenna S, Hargadon B, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 2005; 60(3):193\u2013 8. DOI: 10.1136/thx.2004.032516. \nhttp://www.ncbi.nlm.nih.gov/pubmed/15741434.  \n50. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short -term response to prednisolone in chronic ob-\nstructive pulmonary disease: A randomised controll ed trial. Lancet 2000; 356(9240):1480\u2013 5. \nhttp://www.ncbi.nlm.nih.gov/pubmed/11081531.  \n51. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Data-\nbase Syst Rev 2017; 9(9):CD002309. DOI: 10.1002/14651858.CD002309.pub5. http://www .ncbi.nlm.nih.gov/pub-\nmed/28922692.  \n52. Normansell R, Kew KM, Mathioudakis AG. Interventions to improve inhaler technique for people with asthma. Cochrane \nDatabase Syst Rev 2017; 3:CD012286. DOI: 10.1002/14651858.CD012286.pub2. http://www.ncbi.nlm.nih.gov/pub-\nmed/28288272.  \n53. Doyle S, Lloyd A, Williams A, et al. What happens to patients who have their asthma device switched without their con-\nsent? Prim Care Respir J 2010; 19(2):131\u2013 9. DOI: 10.4104/pc rj.2010.00009. http://www.ncbi.nlm.nih.gov/pub-\nmed/20174771.  \n54. Thomas M, Price D, Chrystyn H, et al. Inhaled corticosteroids for asthma: Impact of practice level device switching on asthma control. BMC Pulm Med 2009; 9:1. DOI: 10.1186/1471- 2466- 9-1. http://www.ncbi.nlm.nih.gov/pubmed/19121204.  \n55. Ekberg- Jansson A, Svenningsson I, Ragdell P, et al. Budesonide inhaler device switch patterns in an asthma population \nin Swedish clinical practice (ASSURE). Int J Clin Pract 2015; 69(10):1171\u2013 8. DOI: 10.1111/ijcp.12685. \nhttp://www.ncbi.nlm.nih.gov/pubmed/26234385.  \n56. McKeough ZJ, Vellos o M, Lima VP, et al. Upper limb exercise training for COPD. Cochrane Database Syst Rev 2016; \n11:CD011434. DOI: 10.1002/14651858.CD011434.pub2. http://www.ncbi.nlm.nih.gov/pubmed/27846347.  \n57. Zainuldin R, Mackey MG, Alison JA. Optimal intensity and type of leg exercise training for people with chronic obstructive \npulmonary disease. Cochrane Database Syst Rev 2011(11):CD008008. DOI: 10.1002/14651858.CD008008.pub2. \nhttp://www.ncbi.nlm.nih.gov/pubmed/22071841.  \n58. McNamara RJ, McKeough ZJ, McKenzie DK, et al. Water -based exercise training for chronic obstructive pulmonary dis-\nease. Cochrane Database Syst Rev 2013(12):CD008290. DOI: 10.1002/14651858.CD008290.pub2. \nhttp://www.ncbi.nlm.nih.gov/pubmed/24353107.  \n59. Hill K, Mathur S, Roig M, et al. Neuromuscular electrostimulation for adults with chronic obstructive pulmonary disease. \nCochrane Database Syst Rev 2018(5):CD010821. DOI: 10.1002/14651858.CD010821.pub2. \nhttp://www.ncbi.nlm.nih.gov/pubmed/29845600.  \n60. Ngai SP, Jones AY, Tam WW. Tai Chi for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev \n2016(6):CD009953. DOI: 10.1002/14651858.CD009953.pub2. http://www.ncbi.nlm.nih.gov/pubmed/27272131.  \n61. Gendron LM, Nyberg A, Maltais F, et al. Active mind- body movement therapies as an adjunct to or in comparison to pul-\nmonary rehabilitation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev \n2018(10):CD012290. DOI: 10.1002/14651858.CD012290.pub2. http://www.ncbi.nlm.nih.gov/pubmed/30306545.  \n62. Gloeckl R, Heinzelmann I, Kenn K. Whole body vibration training in patients with COPD: A systematic review. Chron Respir Dis 2015; 12(3):212\u2013 21. DOI: 10.1177/1479972315583049. http://www.ncbi.nlm.nih.gov/pubmed/25904085.  \n63. Zhou J, Pang L, Chen N, et al. Whole -body vibration training - better care for COPD patients: A systematic review and \nmeta- analysis. Int J Chron Obstruct Pulmon Dis 2018; 13:3243\u2013 54. DOI: 10.2147/COPD.S176229. \nhttp://www.ncbi.nlm.nih.gov/pubmed/30349230.  \n64. Gosselink R, Vos J de, van den Heuvel SP, et al. Impact of inspiratory muscle training in patients with COPD: What is the \nevidence? Eur Respir J 2011; 37(2):416\u2013 25. DOI: 10.1183/09031936.00031810. http://www.ncbi.nlm.nih.gov/pub-\nmed/21282809.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  348 \n  \n  \n 65. Neves LF, Reis MH, Plentz RD, et al. Expiratory and expiratory plus inspiratory muscle training improves respiratory mus-\ncle strength in subjects with COPD: Systematic review. Respir Care 2014; 59(9):1381\u2013 8. DOI: 10.4187/respcare.02793. \nhttp://www.ncbi.nlm.nih.gov/pubmed/24782553.  \n66. Beaumont M, Forget P, Couturaud F, et al. Effects of inspiratory muscle training in COPD patients: A systematic review \nand meta- analysis. Clin Respir J 2018; 12(7):2178\u2013 88. DOI: 10.1111/crj.12905. http://www.ncbi.nlm.nih. gov/pub-\nmed/29665262.  \n67. Ashworth NL, Chad KE, Harrison EL, et al. Home versus center based physical activity programs in older adults. \nCochrane Database Syst Rev 2005(1):CD004017. DOI: 10.1002/14651858.CD004017.pub2. \nhttp://www.ncbi.nlm.nih.gov/pubmed/15674925.  \n68. McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015(2):CD003793. DOI: 10.1002/14651858.CD003793.pub3. http://www.ncbi.nlm.nih.gov/pub-\nmed/25705944.  \n69. Mayer AF, Karloh M, Dos Santos K, et al. Effects of acute use of pursed- lips breathing during exercise in patients with \nCOPD: A systematic revie w and meta- analysis. Physiotherapy 2018; 104(1):9\u2013 17. DOI: 10.1016/j.physio.2017.08.007. \nhttp://www.ncbi.nlm.nih.gov/pubmed/28969859.  \n70. Ubolsakka- Jones C, Pongpanit K, Boonsawat W, et al. Positi ve expiratory pressure breathing speeds recovery of postex-\nercise dyspnea in chronic obstructive pulmonary disease. Physiother Res Int 2019; 24(1):e1750. DOI: 10.1002/pri.1750. \nhttp://www.ncbi.nlm. nih.gov/pubmed/30251299.  \n71. Rocha T, Souza H, Brandao DC, et al. The Manual Diaphragm Release Technique improves diaphragmatic mobility, in-\nspiratory capacity and exercise capacity in people with chronic obstructive pulmonary disease: A randomised trial. J  Phys-\niother 2015; 61(4):182\u2013 9. DOI: 10.1016/j.jphys.2015.08.009. http://www.ncbi.nlm.nih.gov/pubmed/26386894.  \n72. Engel RM, Gonski P, Beath K, et al. Medium term effects of including manual therapy in a pulmonary rehabilitation pro-\ngram for chronic obstructive pulmonary disease (COPD): A randomized controlled pilot trial. J Man Manip Ther 2016; \n24(2):80\u2013 9. DOI: 10.1179/2042618614Y.0000000074. http://www.ncbi.nlm.nih.gov/pubmed/27559277.  \n73. Cross JL, Elender F, Barton G, et al. Evaluation of the effectiveness of manual chest physiotherapy techniques on quality \nof life at six months post exacerbation of COPD (MATREX): A randomised controlled equivalence trial. BMC Pulm Med \n2012; 12:33. DOI: 10.1186/1471- 2466- 12-33. http://www.ncbi.nlm.nih.gov/pubmed/22748085.  \n74. Yamaguti WP, Claudino RC, Neto AP, et al. Diaphragmatic breathing training program improves abdominal motion during \nnatural breathing in patients with chronic obstructive pulmonary disease: A randomized controlled trial. Arch Phys Med \nRehabil 2012; 93(4):571\u2013 7. DOI: 10.1016/j.apmr.2011.11.026. http://www.ncbi.nlm.nih.gov/pubmed/22464088.  \n75. van Gestel AJ, Kohler M, Steier J, et al. The effects of controlled breathing during pulmonary rehabilitation in patients with \nCOPD. Respiration 2012; 83(2):115\u2013 24. DOI: 10.1159/000324449. http://www.ncbi.nlm.nih.gov/pubmed/21474911.  \n76. Valenza MC, Valenza- Pena G, Torres -Sanchez I, et al. Effectiveness of controlled breathing techniques on anxiety and \ndepression in hospitalized patients with COPD: A randomized clinical Trial. Respir Care 2014; 59(2):209\u2013 15. DOI: \n10.4187/respcare.02565. http://www.ncbi.nlm.nih.gov/pubmed/23882107.  \n77. Liu F, Cai H, Tang Q, et al. Effects of an animated diagram and video- based online breathing program for dyspnea in pa-\ntients with stable COPD. Patient Prefer Adherence 2013; 7:905\u2013 13. DOI: 10.2147/PPA.S43305. \nhttp://www.ncbi.nlm.nih.gov/pubmed/24049441.  \n78. Borge CR, Mengshoel AM, Omenaas E, et al. Effects of guided deep breathing on breathlessness and the breathing pat-\ntern in chronic obstructive pulmonary disease: A double- blind randomized control study. Patient Educ Couns 2015; \n98(2):182\u2013 90. DOI: 10.1016/j.pec.2014.10.017. http://www.ncbi.nlm.nih.gov/pubmed/25468399.  \n79. Torres -Sanchez I, Valenza MC, Cebria I Iranzo MD, et al. Effects of different physical therapy programs on perceived \nhealth status in acute exacerbation of chronic obstruct ive pulmonary disease patients: A randomized clinical trial. Disabil \nRehabil 2018; 40(17):2025\u2013 31. DOI: 10.1080/09638288.2017.1323236. http://www.ncbi.nlm.nih.gov/pubmed/28478693.  \n80. Osadnik CR, McDonald CF, Jones AP, et al. Airway clearance techniques for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012(3):CD008328. DOI: 10.1002/14651858.CD008328.pub2. http://www.nc bi.nlm.nih.gov/pubmed/22419331.  \n81. Nicolini A, Grecchi B, Ferrari -Bravo M, et al. Safety and effectiveness of the high- frequency chest wall oscillation vs intrap-\nulmonary percussive ventilation in patients with severe COPD. Int J Chron Obstruct Pulmon Dis 2018; 13:617\u2013 25. DOI: \n10.2147/COPD.S145440. http://www.ncbi.nlm.nih.gov/pubmed/29497290.  \n82. Goktalay T, Akdemir SE, Alpaydin AO, et al. Does high- frequency chest wall oscillation therapy have any  impact on the \ninfective exacerbations of chronic obstructive pulmonary disease? A randomized controlled single- blind study. Clin Re-\nhabil 2013; 27(8):710\u2013 8. DOI: 10.1177/0269215513478226. http://w ww.ncbi.nlm.nih.gov/pubmed/23503735.  \n83. Reychler G, Debier E, Contal O, et al. Intrapulmonary Percussive Ventilation as an Airway Clearance Technique in Sub-\njects With Chronic Obstructive Airway Diseases. Respir Care 2018; 63(5):620\u2013 31. DOI: 10.4187/respcare.05876. \nhttp://www.ncbi.nlm.nih.gov/pubmed/29692351.  \n84. Venturelli E, Crisafulli E, DeBiase A, et al. Efficacy of temporary positive expiratory pressure (TPEP) in patients with lung \ndiseases and chronic mucus hypersecretion. The UNIKO \u00ae project: A multicentre randomized controlled trial. Clin Rehabil \n2013; 27(4):336\u2013 46. DOI: 10.1177/0269215512458940. http://www.ncbi.nlm.nih.gov/pubmed/22967853\n. \n85. Osadnik CR, McDonald CF, Miller BR, et al. The effect of positive expiratory pressure (PEP) therapy on symptoms, quality of life and incidence of re- exacerbation in patients with acute exacerbations of chronic obstructive pulmonary disease: A \nmulticentre, randomised controlled trial. Thorax 2014; 69(2):137\u2013 43. DOI: 10.1136/thoraxjnl -2013- 203425. \nhttp://www.ncbi.nlm.nih.gov/pubmed/24005444.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  349 \n  \n  \n 86. Nicolini A, Mollar E, Grecchi B, et al. Comparison of intermittent positive pressure breathing and temporary positive expir-\natory pressure in patients with severe chronic obstructive pulmonary disease. Arch Bronconeumol 2014; 50(1):18\u2013 24. \nDOI: 10.1016/j.arbres.2013.07.019. http://www.ncbi.nlm.nih.gov/pubmed/24321380.  \n87. Nicolini A, Mascardi V, Grecchi B, et al. Comparison of effectiveness of temporary positive expiratory pressure versus \noscillatory positive expiratory pressure in severe COPD patients. Clin Respir J 2018; 12(3):1274\u2013 82. DOI: \n10.1111/crj.12661. http://www.ncbi.nlm.nih.gov/pubmed/28665556.  \n88. Holland AE, Hill CJ, Jones AY, et al. Breathing exercises for chronic obstructive pulmonary disease. Cochrane Database \nSyst Rev 2012; 10:CD008250. DOI: 10.1002/14651858.CD008250.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23076942.  \n89. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pul-\nmonary disease. Cochrane Database Syst Rev 2019; 5:CD001287. DOI: 10.1002/14651858.CD001287.pub6. \nhttp://www.ncbi.nlm.nih.gov/pubmed/31107966.  \n90. Cazzola M, Rogliani P, Calzetta L, et al. Impact of Mucolytic Agents on COPD Exacerbations: A Pair -wise and Network \nMeta- analysis. COPD 2017; 14(5):552\u2013 63. DOI: 10.1080/15412555.2017.1347918. http://www.ncbi.nlm.nih.gov/pub-\nmed/28753070.  \n91. Fowdar K, Chen H, He Z, et al. The effect of N -acetylcysteine on exacerbations of chronic obstructive pulmonary disease: \nA meta -analysis and systematic review. Heart Lung 2017; 46(2):120\u2013 8. DOI: 10.1016/j.hrtlng.2016.12.004. \nhttp://www.ncbi.nlm.nih.gov/pubmed/28109565.  \n92. Walters JA, Tang JN, Poole P, et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary \ndisease. Cochrane Database Syst Rev 2017; 1:CD001390. DOI: 10.1002/14651858.CD001390.pub4. \nhttp://www.ncbi.nlm.nih.gov/pubmed/28116747.  \n93. Kopsaftis Z, Wood- Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD). Cochrane \nDatabase Syst Rev 2018; 6(6):CD002733. DOI: 10.1002/14651858.CD002733.pub3. http://www.ncbi.nlm.nih.gov/pub-\nmed/29943802.  \n94. St\u00e4ndige Impfkommission am Robert Koch Institut (STIKO). Mitteilung der St\u00e4ndigen Impfkommission (STIKO) beim Ro-\nbert Koch- Institut (RKI) Empfehlungen der St\u00e4ndigen Impfkommission beim Robert Koch- Institut \u2013 2019/2020. Epidemiol \nBull RKI 2019(34):313\u2013 64. DOI: 10.25646/6233.6.  \n95. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane \nDatabase Syst Rev 2014(3):CD010115. DOI: 10.1002/14651858.CD010115.pub2. http://www.ncbi.nlm.nih.gov/pub-\nmed/24615270.  \n96. Horita N, Goto A, Shibata Y, et al. Long- acting muscarinic antagonist (LAMA) plus long- acting beta- agonist (LABA) versus \nLABA plus inhaled corticoster oid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database \nSyst Rev 2017; 2:CD012066. DOI: 10.1002/14651858.CD012066.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28185242.  \n97. Sliwka A, Jankowski M, Gross -Sindej I, et al. Once- daily long- acting beta\u2082 -agonists/inhaled corticosteroids combined in-\nhalers versus inhaled long- acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Cochrane \nDatabase Syst Rev 2018(8):CD012355. DOI: 10.1002/14651858.CD012355.pub2. http://www.ncbi.nlm.nih.gov/pub-\nmed/30141826.  \n98. Oba Y, Fadila M, Keeney E, et al. Dual combination therapy versus long- acting bronchodil ators alone for chronic obstruc-\ntive pulmonary disease (COPD): A systematic review and network meta- analysis. Cochrane Database Syst Rev \n2018(12):CD012620. DOI: 10.1002/14651858.CD012620.pub2. http ://www.ncbi.nlm.nih.gov/pubmed/30521694.  \n99. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and preven-tion of chronic obstructive pulmonary disease 2020 Report. 2020 [cited: 2020- 01-30]. https://goldcopd.org/wp- content/up-\nloads/2019/12/GOLD -2020- FINAL -ver1.2- 03Dec19_WMV.pdf . \n100. Matte DL, Pizzichini MM, Hoepers AT, et al. Prevalence of depression i n COPD: A systematic review and meta- analysis of \ncontrolled studies. Respir Med 2016; 117:154\u2013 61. DOI: 10.1016/j.rmed.2016.06.006. http://www.ncbi.nlm.nih.gov/pub-\nmed/27492526.  \n101. Willgoss TG, Yo hannes AM. Anxiety disorders in patients with COPD: A systematic review. Respir Care 2013; 58(5):858\u2013\n66. DOI: 10.4187/respcare.01862. http://www.ncbi.nlm.nih.gov/pubmed/22906542.  \n102. L\u00f6we B, Wahl  I, Rose M, et al. A 4 -item measure of depression and anxiety: Validation and standardization of the Patient \nHealth Questionnaire- 4 (PHQ -4) in the general population. J Affect. Disord 2010; 122(1- 2):86\u2013 95. DOI: \n10.1016/j.jad.2009.06.019. http://www.ncbi.nlm.nih.gov/pubmed/19616305.  \n103. Kroenke K, Spitzer RL, Williams JB, et al. An ultra- brief screening scale for anxiety and depression: The PHQ -4. Psycho-\nsomatics 2009; 50(6):613\u2013 21. DOI: 10.1176/appi.psy.50.6.613. http://www.ncbi.nlm.nih.gov/pubmed/19996233.  \n104. Pollok J, van Agteren JE, Esterman AJ, et al. Psychological therapies for the treatment of depression in chronic obstruc-tive pulmonary disease. Cochrane Database Syst Rev 2019; 3(3):CD012347. DOI: 10.1002/14651858.CD012347.pub2. \nhttp://www.ncbi.nlm.nih.gov/pubmed/30838649.  \n105. Usmani ZA, Carson KV, Heslop K,  et al. Psychological therapies for the treatment of anxiety disorders in chronic obstruc-\ntive pulmonary disease. Cochrane Database Syst Rev 2017; 3:CD010673. DOI: 10.1002/14651858.CD010673.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28322440.  \n106. Wiles L, Cafarella P, Williams MT. Exercise training combined with psychological interventions for people with chronic \nobstructive pulmonary disease. Respirology 2015; 20(1):46\u2013 55. DOI: 10.1111/resp.12419. \nhttp://www.ncbi.nlm.nih.gov/pubmed/25339508.  \n107. Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild- to-moderate chronic obstructive \npulmonary disease. The Lung H ealth Study. Am J Respir Crit Care Med 2000; 161(2 Pt 1):381\u2013 90. DOI: \n10.1164/ajrccm.161.2.9901044. http://www.ncbi.nlm.nih.gov/pubmed/10673175.  NVL COPD  \nLeitlinienreport \u2013 2. Au flage, Version 1  \n \n     \n \n\u00a9 \u00c4ZQ 2021    \uf8f7   Seite  350 \n  \n  \n 108. Kanner RE, Anthonisen NR, Connett JE. Lower re spiratory illnesses promote FEV(1) decline in current smokers but not \nex-smokers with mild chronic obstructive pulmonary disease: Results from the lung health study. Am J Respir Crit Care \nMed 2001; 164(3):358\u2013 64. DOI: 10.1164/ajrccm.164.3.2010017. http://www.ncbi.nlm.nih.gov/pubmed/11500333.  \n109. Ellerbeck EF, Nollen N, Hutcheson TD, et al. Effect of Long- term Nicotine Replacement Therapy vs Standard Smoking \nCessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial. JAMA network open 2018; \n1(5):e181843. DOI: 10.1001/jamanetworkopen.2018.1843. http://www.ncbi.nlm.nih.gov/pubmed/30646142.  \n110. Wittmann M, Spohn S, Schultz K , et al. Patient education in COPD during inpatient rehabilitation improves quality of life \nand morbidity. Pneumologie 2007; 61(10):636\u2013 42. DOI: 10.1055/s -2007- 980106. http://www.ncbi.nlm.nih.gov/ pub-\nmed/17886195.  \n111. Bosch D, Feierabend M, Becker A. COPD outpatient education programme (ATEM) and BODE index. Pneumologie 2007; \n61(10):629\u2013 35. DOI: 10.1055/s -2007- 980081. http://www.ncbi.nlm.n ih.gov/pubmed/17661240.  \n112. Jones S, Man WD, Gao W, et al. Neuromuscular electrical stimulation for muscle weakness in adults with advanced dise-\nase. Cochrane Database Syst Rev 2016; 10:CD009419. DOI: 10.1002/14651858.CD009419.pub3. http://www.ncbi.nlm.nih.gov/pubmed/27748503.  \n113. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft f\u00fcr Psy-chiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft f\u00fcr Suchtforschung und Suchttherapie \n(DG-Sucht), et al. S3- Leitlinie Screening, Diagnostik und Behandlung des sch\u00e4dlichen und abh\u00e4ngigen Tabakkonsum: \nRegisternummer 076- 006, Version 2015- 02. 2014 [cited: 2021- 06-23]. http://www.awmf.org/leitlinien/detail/ll/076- 006.html . \n114. McLean S, Nurmatov U, Liu JL, et al. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst \nRev 2011(7):CD007718. DOI: 10.1002/14651858.CD007718.pub2. http://www.ncbi.nlm .nih.gov/pubmed/21735417.  \n115. Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Me-dizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma - Leitlinienreport, 3. Auflage. Versi on 1. \n2018 [cited: 2018- 09-21]. DOI: 10.6101/AZQ/000403. https://doi.org/10.6101/AZQ/000403.  \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}